<SEC-DOCUMENT>0001367644-19-000038.txt : 20190802
<SEC-HEADER>0001367644-19-000038.hdr.sgml : 20190802
<ACCEPTANCE-DATETIME>20190801182440
ACCESSION NUMBER:		0001367644-19-000038
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20190630
FILED AS OF DATE:		20190802
DATE AS OF CHANGE:		20190801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emergent BioSolutions Inc.
		CENTRAL INDEX KEY:			0001367644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				141902018
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33137
		FILM NUMBER:		19993953

	BUSINESS ADDRESS:	
		STREET 1:		400 PROFESSIONAL DR, SUITE 400
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-631-3200

	MAIL ADDRESS:	
		STREET 1:		400 PROFESSIONAL DR, SUITE 400
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ebs-20190630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:7b73fc635a3d46b790161cfbe39a7de5,x:3597d88085164fe38f6a8e648e953c11-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2019 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:ebs="http://emergentbiosolutions.com/20190630" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:AmendmentFlag" id="Fact-633500DED1F4BF58F196D849934C811B-wk-Fact-633500DED1F4BF58F196D849934C811B" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-2FA0529C4504CEE71F4ED84993464F39-wk-Fact-2FA0529C4504CEE71F4ED84993464F39">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-8E766C8D6844019AFF6BD849934B8A9B-wk-Fact-8E766C8D6844019AFF6BD849934B8A9B">Q2</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:DocumentFiscalYearFocus" id="Fact-39072BBAD513B04F4BD6D849934431B1-wk-Fact-39072BBAD513B04F4BD6D849934431B1">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:EntityCentralIndexKey" id="Fact-1A34215A6114696E8063D8499340B004-wk-Fact-1A34215A6114696E8063D8499340B004">0001367644</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:EntityRegistrantName" id="Fact-B3F6E151CFE2EED78B58D84993011B2F-wk-Fact-B3F6E151CFE2EED78B58D84993011B2F">Emergent BioSolutions Inc.</ix:nonNumeric><ix:nonNumeric contextRef="D2019Q2Jun01-Jun30" name="ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" id="Fact-2A03403A030216A3E3E321093923D758-wk-Fact-2A03403A030216A3E3E321093923D758">P12M</ix:nonNumeric><ix:nonNumeric contextRef="D2019Q2Jun01-Jun30" name="ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod" id="Fact-8B1EFCC5E5368BAAE96C2108FAB890A7-wk-Fact-8B1EFCC5E5368BAAE96C2108FAB890A7">P12M</ix:nonNumeric><ix:nonNumeric contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" name="ebs:LockUpPeriodForAdjustmentOfFairValue" id="Fact-F260B6C6DD3982B1D7D3D84993208256-wk-Fact-F260B6C6DD3982B1D7D3D84993208256">P2Y</ix:nonNumeric><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FD2019Q2QTD" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact-1A7A89DDE6C999F9E6DF2086FA579DF9-wk-Fact-1A7A89DDE6C999F9E6DF2086FA579DF9">3000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-A342D42E47C998CA0659D849934F5CA4-wk-Fact-A342D42E47C998CA0659D849934F5CA4">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q2" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-28AD6FF06800448FCC97D84992F7AC01-wk-Fact-28AD6FF06800448FCC97D84992F7AC01">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-4ABB77FA5885B84DDEA8D84993465755-wk-Fact-4ABB77FA5885B84DDEA8D84993465755">200000000.0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:CommonStockSharesAuthorized" id="Fact-81771B26A04EC162D8EED849934B3D7A-wk-Fact-81771B26A04EC162D8EED849934B3D7A">200000000.0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-E1E4968E58EEDCAF4EB2D84992FF0291-wk-Fact-E1E4968E58EEDCAF4EB2D84992FF0291">52400000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:CommonStockSharesIssued" id="Fact-C7DB2D25D2DCB25909BED84992FEBBC4-wk-Fact-C7DB2D25D2DCB25909BED84992FEBBC4">52700000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-5072EC13163953EE3D92D84992F784B7-wk-Fact-5072EC13163953EE3D92D84992F784B7">51200000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:CommonStockSharesOutstanding" id="Fact-F0673B56D186B1F9DD00D8499345C94D-wk-Fact-F0673B56D186B1F9DD00D8499345C94D">51600000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2018Q2YTD" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" id="Fact-032708EBC94F8F4DA859211DB81400F6-wk-Fact-032708EBC94F8F4DA859211DB81400F6">3200000</ix:nonFraction><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-4F1A902A54F8D066E7D7D849932EB424-wk-Fact-4F1A902A54F8D066E7D7D849932EB424">P22Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-10FA5BCA54E05A324A68D849932F3022-wk-Fact-10FA5BCA54E05A324A68D849932F3022">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-B1D092BCDB05B3A1547DD849932DFD1D-wk-Fact-B1D092BCDB05B3A1547DD849932DFD1D">P22Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-B9628CE24AEF5E79D891D849932CD1A1-wk-Fact-B9628CE24AEF5E79D891D849932CD1A1">P5Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-166D97F36502E68698B0D849934DFCDD-wk-Fact-166D97F36502E68698B0D849934DFCDD">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q2" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-2A25587A2EA4A9E87B6AD8499300796E-wk-Fact-2A25587A2EA4A9E87B6AD8499300796E">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-23659D7E85AD01EEF88DD84992FA5AB5-wk-Fact-23659D7E85AD01EEF88DD84992FA5AB5">15000000.0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-559FD8D702A8CEEBDFEAD849934EB344-wk-Fact-559FD8D702A8CEEBDFEAD849934EB344">15000000.0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-D470E5B8CC0A026089D0D84992F64C99-wk-Fact-D470E5B8CC0A026089D0D84992F64C99">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:PreferredStockSharesIssued" id="Fact-91427E27D78562DF4FEFD8499345CDDE-wk-Fact-91427E27D78562DF4FEFD8499345CDDE">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-926A78DDB7E4A03F4ABAD849934E47B8-wk-Fact-926A78DDB7E4A03F4ABAD849934E47B8">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-124E9F4D9A287416384CD8499345B615-wk-Fact-124E9F4D9A287416384CD8499345B615">0</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-790EF2D77CD7456B190BD849933598B6-wk-Fact-790EF2D77CD7456B190BD849933598B6">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-2521576F449A80F27EDFD84993328F41-wk-Fact-2521576F449A80F27EDFD84993328F41">P3Y</ix:nonNumeric><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-330109A5D113009A5AF3D8499337534C-wk-Fact-330109A5D113009A5AF3D8499337534C">0.3333</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-57D6C9692EF29E6F36CDD8499336DC5B-wk-Fact-57D6C9692EF29E6F36CDD8499336DC5B">0.3333</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-E6F88B549C357D672F49D84993329813-wk-Fact-E6F88B549C357D672F49D84993329813">0.3333</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-3E7AF7A4FE361AD854CBD84993325550-wk-Fact-3E7AF7A4FE361AD854CBD84993325550">0.3333</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-12C699CA865D16C280D6D8499335F48E-wk-Fact-12C699CA865D16C280D6D8499335F48E">0.3333</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact-1A38FD7962734E4396A7D8499335893A-wk-Fact-1A38FD7962734E4396A7D8499335893A">0.3333</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:TreasuryStockShares" id="Fact-9C2072E5F4FF04FEC05AD8499343C1FC-wk-Fact-9C2072E5F4FF04FEC05AD8499343C1FC">1200000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:TreasuryStockShares" id="Fact-B5EBFBD936C1A40FA8CDD84992F69164-wk-Fact-B5EBFBD936C1A40FA8CDD84992F69164">1200000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="ebs-20190630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul26">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Oct16-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-16</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_VaxchoraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:VaxchoraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-04</xbrli:startDate>
			<xbrli:endDate>2018-10-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-04</xbrli:startDate>
			<xbrli:endDate>2018-10-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_VivotifMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:VivotifMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-04</xbrli:startDate>
			<xbrli:endDate>2018-10-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptAndPaxVaxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptAndPaxVaxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct04-Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-04</xbrli:startDate>
			<xbrli:endDate>2018-10-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Oct05-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-05</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_RaxibacumabMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:RaxibacumabMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-01-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Jun01-Jun30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct15_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_FederalFundsEffectiveSwapRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-15</xbrli:startDate>
			<xbrli:endDate>2018-10-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_LitigationCaseAxis_ebs_ShareholderClassActionLawsuitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:ShareholderClassActionLawsuitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="instrument">
		<xbrli:measure>ebs:instrument</xbrli:measure>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>ebs:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="employee">
		<xbrli:measure>ebs:employee</xbrli:measure>
	</xbrli:unit><xbrli:unit id="acquisition">
		<xbrli:measure>ebs:acquisition</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s8BDCBA43B15C5B1DAE3D7770F56A8CC5"></a></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;color:#00497f;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#00497f;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;color:#00497f;font-weight:bold;">Form </span><span><ix:nonNumeric id="d374411422e600-wk-Fact-CE516FC5B4A898DC9F7BD870EC3DC66A" name="dei:DocumentType" contextRef="FD2019Q2YTD"><span style="color:#00497f;font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;color:#00497f;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:37%;"></td><td style="width:56%;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(Mark One)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d374411422e635-wk-Fact-D5DD5966B88107330E6BD84E72ABC1D1" name="dei:DocumentQuarterlyReport" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td colspan="2" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">For the quarterly period ended</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d374411422e677-wk-Fact-EEDCD96BAB9CA2D7CD222F4D228C6B8C" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q2YTD" format="ixt:datemonthdayyearen">June 30, 2019</ix:nonNumeric></span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-weight:bold;">OR</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d374411422e715-wk-Fact-2E251E1B50C915444822D84EBB192205" name="dei:DocumentTransitionReport" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-weight:bold;">For the transition period from&#160;to</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:24px;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:bold;">Commission file number: </span><span><ix:nonNumeric id="d374411422e762-wk-Fact-BA772165577EB323AF1ED8709A151A9C" name="dei:EntityFileNumber" contextRef="FD2019Q2YTD"><span style="color:#2c2c2c;font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-weight:bold;">001-33137</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:24px;"><img src="emergentlogocmykregistered.jpg" alt="emergentlogocmykregistered.jpg" style="height:88px;width:208px;"></img></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:24px;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;color:#2c2c2c;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:24px;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-style:italic;font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.16091954022988%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:44%;"></td><td style="width:14%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d374411422e793-wk-Fact-9A4BEA10BC73BDA8F014D84F78FC527E" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q2YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d374411422e803-wk-Fact-8E9FB54E32010778E776D84FC2CDF3CE" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q2YTD">14-1902018</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-style:italic;">(State or Other Jurisdiction of</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-style:italic;">Incorporation or Organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-style:italic;">(I.R.S. Employer</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-style:italic;">Identification No.)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d374411422e831-wk-Fact-DBDE0DCD8850005C550D2A8E053DB513" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q2YTD">400 Professional Drive</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d374411422e847-wk-Fact-C2A7FF656B3500EFB4A12A8E4A3061DB" name="dei:EntityAddressAddressLine2" contextRef="FD2019Q2YTD">Suite 400</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d374411422e863-wk-Fact-E34F8434D72E43580BBB2A8E8AD8E6D4" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q2YTD">Gaithersburg</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d374411422e868-wk-Fact-7FB1C4C0A795610424FB2A8EC5CB2937" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q2YTD" format="ixt-sec:stateprovnameen">Maryland</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d374411422e873-wk-Fact-F03A85D27971330A8EFAD85038DD7B4B" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q2YTD">20879</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-style:italic;">(Address of Principal Executive Offices)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-style:italic;">(Zip Code)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:bold;">(</span><span><ix:nonNumeric id="d374411422e895-wk-Fact-D909599260976C428C18D850CAC1A09C" name="dei:CityAreaCode" contextRef="FD2019Q2YTD"><span style="color:#2c2c2c;font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">240</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:bold;">) </span><span><ix:nonNumeric id="d374411422e900-wk-Fact-FF0A615E0F3A41DE53BBD85112C6ECBA" name="dei:LocalPhoneNumber" contextRef="FD2019Q2YTD"><span style="color:#2c2c2c;font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">631-3200</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-style:italic;font-weight:normal;">(Registrant's Telephone Number, Including Area Code)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.85057471264368%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:36%;"></td><td style="width:27%;"></td><td style="width:37%;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonNumeric id="d374411422e953-wk-Fact-2D7F08B785BA5BB823D4D851C9D12584" name="dei:Security12bTitle" contextRef="FD2019Q2YTD">Common Stock, Par Value $0.001 per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonNumeric id="d374411422e958-wk-Fact-86341F3959A8D859B58FD852049AE728" name="dei:TradingSymbol" contextRef="FD2019Q2YTD">EBS</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonNumeric id="d374411422e963-wk-Fact-33B9BBCC4094C42031D1D8524CF36606" name="dei:SecurityExchangeName" contextRef="FD2019Q2YTD" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-family:Arial Unicode MS;font-size:9pt;color:#2c2c2c;font-weight:normal;">&#9746;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;"> </span><span><ix:nonNumeric id="d374411422e972-wk-Fact-895C663B0772AA5AB940D85309A5AA92" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q2YTD"><span style="color:#2c2c2c;font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-weight:normal;">Yes</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;"> </span><span style="font-family:Arial Unicode MS;font-size:7pt;color:#2c2c2c;font-weight:normal;">&#9744;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;">No</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-family:Arial Unicode MS;font-size:9pt;color:#2c2c2c;font-weight:normal;">&#9746;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;"> </span><span><ix:nonNumeric id="d374411422e990-wk-Fact-796FF079E75B04ED201ED85372F0C9A6" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q2YTD"><span style="color:#2c2c2c;font-family:Franklin Gothic Book,sans-serif;font-size:7pt;font-weight:normal;">Yes</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;"> </span><span style="font-family:Arial Unicode MS;font-size:7pt;color:#2c2c2c;font-weight:normal;">&#9744;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;">No</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.55172413793103%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:32%;"></td><td style="width:6%;"></td><td style="width:31%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonNumeric id="d374411422e1020-wk-Fact-4DB970E6D5E5C014E9A82A8FB9697528" name="dei:EntityFilerCategory" contextRef="FD2019Q2YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer </ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9746;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Non-accelerated filer </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Smaller reporting company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;"><span><ix:nonNumeric id="d374411422e1056-wk-Fact-14B4AC70BEC8BC2A0AEA2A9014E74F4E" name="dei:EntitySmallBusiness" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br/></span></div><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial Unicode MS;font-size:9pt;"><span><ix:nonNumeric id="d374411422e1078-wk-Fact-DF1C4F1A77B9921FC2772A905E01ABF2" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. </span><span style="font-family:Arial Unicode MS;font-size:9pt;color:#2c2c2c;font-weight:normal;">&#9744;</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;">Yes </span><span><ix:nonNumeric id="d374411422e1090-wk-Fact-B9C50C21B049F75672FFF6E10694C705" name="dei:EntityShellCompany" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox"><span style="color:#2c2c2c;font-family:Arial Unicode MS;font-size:7pt;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;color:#2c2c2c;font-weight:normal;"> No</span><span style="font-family:Wingdings;font-size:7pt;color:#2c2c2c;font-weight:normal;"> </span><span style="font-family:Arial Unicode MS;font-size:7pt;color:#2c2c2c;font-weight:normal;">&#9746;</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">July&#160;26, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;">, the registrant had approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonFraction id="d374411422e1106-wk-Fact-FED1A04800107DB1A114D849934675DA" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2019Q3Jul26" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">51.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2c2c2c;font-weight:normal;"> shares of common stock outstanding.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">1</span></div></div><hr style="page-break-after:always"></hr><div><a id="sDECB8253D02050E0A9BB741A09DA6400"></a></div><div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Emergent BioSolutions Inc.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Index to Form 10-Q</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:15%;"></td><td style="width:76%;"></td><td style="width:9%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;color:#000000;" href="#s60C87A239282590599960CCD28480A0A"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;color:#000000;">Part I. Financial Information</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Page No.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#sB05FDEF26EDE55E88F7CEC91A927043F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 1.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB05FDEF26EDE55E88F7CEC91A927043F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sB05FDEF26EDE55E88F7CEC91A927043F">5</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s9283725B747051518115E121DDED7E2C"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s9283725B747051518115E121DDED7E2C">5</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB6772F84C2545CE5B4B3A9840E049514"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sB6772F84C2545CE5B4B3A9840E049514">6</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE807CE66694956C19178A83C999B8D6B"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive (Loss) Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sE807CE66694956C19178A83C999B8D6B">7</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA64561CD811B5A0DAC9F5C3DF728D853"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sA64561CD811B5A0DAC9F5C3DF728D853">8</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s2DFC0B488F435290A3A220BA9E6392D1"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Changes in Stockholders' Equity</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s2DFC0B488F435290A3A220BA9E6392D1">9</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE28CD5817F7C54208EF7A6A52B27BC26"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sE28CD5817F7C54208EF7A6A52B27BC26">10</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s0AE4DA2563DC5E1BAD756D538CD84242"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 2.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0AE4DA2563DC5E1BAD756D538CD84242"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s0AE4DA2563DC5E1BAD756D538CD84242">25</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s7A14295A0CE65CC49344617FFBCA2A34"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 3.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s7A14295A0CE65CC49344617FFBCA2A34"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s7A14295A0CE65CC49344617FFBCA2A34">35</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#sCA756891833055978E6B56B621984CA2"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 4.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sCA756891833055978E6B56B621984CA2"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sCA756891833055978E6B56B621984CA2">35</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;color:#000000;" href="#sBD107ABA44A557C394FEF625A1D6B70B"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;color:#000000;">Part II. Other Information</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#sEC0BC65C2D3456358360E4B0EC3A1B70"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 1.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sEC0BC65C2D3456358360E4B0EC3A1B70"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sEC0BC65C2D3456358360E4B0EC3A1B70">36</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s010F7899B30D586BB30E37C214BE9D2B"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 1A.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s010F7899B30D586BB30E37C214BE9D2B"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s010F7899B30D586BB30E37C214BE9D2B">37</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s0479D5786ACF58F2B7BC38D6C73F3B26"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 2.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0479D5786ACF58F2B7BC38D6C73F3B26"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s0479D5786ACF58F2B7BC38D6C73F3B26">68</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s630CF094F0095B6AADD201EFB4F034B5"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 3.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s630CF094F0095B6AADD201EFB4F034B5"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s630CF094F0095B6AADD201EFB4F034B5">68</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s7D07E61462BB55F498673F2F8EC32CC5"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 4.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s7D07E61462BB55F498673F2F8EC32CC5"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s7D07E61462BB55F498673F2F8EC32CC5">68</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s1E13D38B49D852BE806AF01B7C2DA37A"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 5.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1E13D38B49D852BE806AF01B7C2DA37A"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Information</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s1E13D38B49D852BE806AF01B7C2DA37A">68</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;" href="#s41278906D97255EE86CFFF19D42DB3F1"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;">Item 6.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s41278906D97255EE86CFFF19D42DB3F1"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#s41278906D97255EE86CFFF19D42DB3F1">68</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB2EFD6E278B85E858C9EF92158813F0F"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Signatures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:none;" href="#sB2EFD6E278B85E858C9EF92158813F0F">70</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:7pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s60C87A239282590599960CCD28480A0A"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">PART I. FINANCIAL INFORMATION</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">This quarterly report on Form 10-Q and the documents we incorporate by reference include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future earnings and performance of Emergent BioSolutions Inc. or any of our businesses, our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by using words like "will," "believes," "expects," "anticipates," "intends," "plans," "forecasts," "estimates" and similar expressions in conjunction with, among other things, discussions of financial performance or financial condition, growth strategy, product sales, manufacturing capabilities, product development, regulatory approvals or expenditures. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. You should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. You are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">appropriations for the procurement of BioThrax&#174; (Anthrax Vaccine Adsorbed) and our other products addressing public health threats (PHTs);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">the exercise of discretion by the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Biomedical Advanced Research and Development Authority (BARDA)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> to procure AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) in reliance on the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">U.S. Food and Drug Administration (FDA)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> review and acceptance of the company&#8217;s pre-Emergency Use Authorization (pre-EUA) submission;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">our ability to perform under our contracts with the U.S. government (USG) related to BioThrax, our AV7909 </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">product candidate, and our other public health threat products, including the timing of and specifications relating to deliveries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">our ability to commence deliveries based on BARDA&#8217;s procurement of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) for the Strategic National Stockpile (SNS), and to receive eventual licensure of AV7909 from the FDA;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the availa</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">bility of funding for our USG grants and contracts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">our ability to secure follow-on procurement contracts for our PHTs that are under procurement contracts that have expired or will be expiring;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">our ability and the ability of our collaborators to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">defend underlying patents from infringement by generic naloxone entrants</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">our ability to identify and acquire companies, businesses, products or product candidates that satisfy our selection criteria;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">our ability to successfully integrate and realize the benefits of our acquisitions of PaxVax Holding Company Ltd. (PaxVax) and Adapt Pharma Limited (Adapt), both of which were acquired in October 2018;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">our ability to successfully identify and respond to new development contracts with the USG, as well as successfully maintain, through achievement of development milestones, current development contracts with the USG;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">our ability and the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">the results of regulatory inspections;</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">3</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">the operating and financial restrictions placed on us and our subsidiaries under our senior secured credit facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">our ability to obtain and maintain regulatory approvals for our product candidates and the timing of any such approvals</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">the procurement of products by USG entities under regulatory exemptions prior to approval by the FDA and corresponding procurement by government entities outside of the United States under regulatory exemptions prior to approval by the corresponding regulatory authorities in the applicable country;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">the success of our commercialization, marketing and manufacturing capabilities and strategy; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">the accuracy of our estimates regarding future revenues, expenses, capital requirements and needs for additional financing.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. New factors emerge from time to time and it is not possible for management to predict all such factors, nor can it assess the impact of any such factor on the business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. You should consider this cautionary statement, the risk factors identified in the section entitled "Risk Factors" in this quarterly report on Form 10-Q and the risk factors identified in our other periodic reports filed with the Securities and Exchange Commission (SEC) when evaluating our forward-looking statements.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTE REGARDING COMPANY REFERENCES</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">References in this report to &#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Emergent BioSolutions Inc. and its consolidated subsidiaries.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">NOTE REGARDING TRADENAMES</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">BioThrax&#174; (Anthrax Vaccine Adsorbed), RSDL&#174; (Reactive Skin Decontamination Lotion Kit), BAT&#174; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), Anthrasil&#174; (Anthrax Immune Globulin Intravenous (Human)), VIGIV (Vaccinia Immune Globulin Intravenous (Human)), Trobigard&#174; (atropine sulfate, obidoxime chloride), ACAM2000&#174; (Smallpox (Vaccinia) Vaccine, Live), Vivotif&#174; (Typhoid Vaccine Live Oral Ty21a), Vaxchora&#174; (Cholera Vaccine, Live, Oral), NARCAN&#174; (naloxone HCI) Nasal Spray and any and all Emergent brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent or its subsidiaries in the United States or other countries. All other brands, products, services and feature names or trademarks are the property of their respective owners.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB05FDEF26EDE55E88F7CEC91A927043F"></a></div><div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 1. FINANCIAL STATEMENTS</span></div><div><a id="s9283725B747051518115E121DDED7E2C"></a></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">Emergent BioSolutions Inc. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Condensed Consolidated Balance Sheets</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">(unaudited, in millions, except per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e752-wk-Fact-6CA7FDAA9259FA7C68D2D8499320BDDE" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">177.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e771-wk-Fact-5D4E7B3352A75B0F2A05D84992FD64FA" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e786-wk-Fact-B9C41DB0950C2A663727D84993021485" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e805-wk-Fact-44A59C06CCAA8245F02CD849932174C5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e825-wk-Fact-A88953A1A1C03C0062A4D84992F80FB1" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">218.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e844-wk-Fact-5624509D06373D0CA867D84992FD89D0" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">262.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e864-wk-Fact-10DA71DCD649ED36B6D3D84992F794DC" name="us-gaap:InventoryNet" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">232.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e883-wk-Fact-C6A98BDF9041D79AA0CBD84993196BE5" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">205.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e903-wk-Fact-4634D0A8146EC3C727D20ACE35633E63" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e922-wk-Fact-B4560EB1444301088AC6D849930742AC" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e942-wk-Fact-750C9B5A6BEF421975DD0ACE35435A5F" name="us-gaap:AssetsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">692.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e961-wk-Fact-3599C1364ED3CCD717550ACE35248F32" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">620.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1022-wk-Fact-1CEE78D1635C9E8C9F7DD8499312146B" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">520.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1041-wk-Fact-A2A3491175BAC7A69E11D84992FE01C5" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">510.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1062-wk-Fact-FE4ECDD57018F5D60735D8499306CC08" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">742.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1081-wk-Fact-69E40D411BA61D68402FD84993190E23" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">761.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1101-wk-Fact-6F81C8C3571BE73E120CD84993082DA3" name="ebs:InProcessResearchAndDevelopment" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1120-wk-Fact-8B732AAB5AD51B438FD4D84992FC06B9" name="ebs:InProcessResearchAndDevelopment" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1140-wk-Fact-DB909FD2CAB8A2E53C25D84992FF1DFA" name="us-gaap:Goodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">268.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1159-wk-Fact-8DEC0005C0EAFE923857D84993239E34" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">259.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1179-wk-Fact-997D38E6FE71AC07FF840ACE35349412" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1198-wk-Fact-0050FDE657BC3A35F7DDD84993244253" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1223-wk-Fact-BFCA1AE5B25C1940FAE40ACE34F56EC2" name="us-gaap:Assets" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,321.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1242-wk-Fact-4B8732A2A9AE7ABD66990ACE35051DA5" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,229.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1385-wk-Fact-A35825C452EB9BE7AA79D84993238F37" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">124.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1404-wk-Fact-3A5BC904134AE3B47C9BD849930FBF60" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1419-wk-Fact-71002ADA47EFC5B61667D8499323B0B3" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">54.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1438-wk-Fact-EFC9101D85A80C19D87BD8499321E583" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration, current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1458-wk-Fact-F33F9D2812CBF5E99CCAD849930735B7" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">54.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1477-wk-Fact-A8CABA014494591D9ACBD84992F87ED2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1498-wk-Fact-9D7FA89106A10ACF5D96D84992F8F1F0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1517-wk-Fact-5F71788CEFFD4A7A0BF4D849932146FF" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Debt, current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1537-wk-Fact-C06927FD4A5E3D153EA6D84992FA7654" name="us-gaap:LongTermDebtCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1556-wk-Fact-720282BBC8CDC2055C5DD8499301C100" name="us-gaap:LongTermDebtCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1576-wk-Fact-5A16393C4F46E08E9DDD0ACE34E6B7FB" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1595-wk-Fact-5BEC15CD0EECECAC2F61D84993033514" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1615-wk-Fact-1FFE2263889E8673C6E40ACE3553A6E7" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">301.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1634-wk-Fact-533E39F880035C0B5BC70ACE3515323A" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">200.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1654-wk-Fact-2D50EEF0D8061536707FD84992F959B3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1673-wk-Fact-143AF016C4D0C236184BD8499310C013" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">54.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1693-wk-Fact-5684FE71939B0564A1CAD8499314675E" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">830.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1712-wk-Fact-75E6B826C88E6B401542D849930F45CA" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">784.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1732-wk-Fact-F8587F470D18A089A210D849931A07D3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1751-wk-Fact-3DA7ACFDDB3F4939749AD84993130455" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">67.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1771-wk-Fact-588FF4786B98BDA87338D849931A45FB" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">77.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1790-wk-Fact-08ADFF214BCA83FB6FB2D849931F0A04" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1810-wk-Fact-BB34F4626CF61D44F3370ACE356330F3" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1829-wk-Fact-C1C75462575F42DA1303D8499322B6D4" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1854-wk-Fact-730B53D4A98A987E8EEA0ACE35535AAC" name="us-gaap:Liabilities" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,332.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1873-wk-Fact-9A94E1215FD08984AD620ACE356350A9" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,218.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies (Notes 8 &amp; 16)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1888-wk-Fact-D0917CB3AC1DD27240AFD84993201A8C" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q2" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1906-wk-Fact-6E54F817BA4218234B62D84993161809" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stockholders' equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding at both 2019 and 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e1967-wk-Fact-77E0C134362802B1A217D84993003A3A" name="us-gaap:PreferredStockValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e1986-wk-Fact-4EE6146A40839CAA1FE6D8499312E409" name="us-gaap:PreferredStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, $0.001 par value; 200.0 shares authorized, 52.7 shares issued and 51.6 shares outstanding at 2019; 52.4 shares issued and 51.2 shares outstanding at 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e2006-wk-Fact-0208442C2B6D55F7B4E5D84993130D82" name="us-gaap:CommonStockValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e2025-wk-Fact-727F49DBDACE775F3610D84993237E2F" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost, 1.2 common shares at both 2019 and 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374409672e2045-wk-Fact-26396D2B911CD1EC1BACD84993109107" name="us-gaap:TreasuryStockValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374409672e2065-wk-Fact-E7B4820E4E6D7EB9ADACD849931145D4" name="us-gaap:TreasuryStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e2086-wk-Fact-59DA6ED0660CBAA670DCD849931FBE7B" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">701.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e2105-wk-Fact-C56FA79E07A6F6AFB04BD8499317C6B9" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">688.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374409672e2125-wk-Fact-905111246D4FA94C4E21D84992FFB13E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#ededed;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374409672e2145-wk-Fact-AAD4EABBCD043CCAC462D84993105BC2" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e2166-wk-Fact-7BD4E44266377A71871FD84993221A15" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">331.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e2185-wk-Fact-3F36C1EFE3099B33F76CD84992FEE651" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">367.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total stockholders' equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e2205-wk-Fact-3426FA62817349CDE2680ACE3553FBC6" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">988.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e2224-wk-Fact-B4353C2A4F51AFB1781E0ACE3534119C" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,010.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and stockholders' equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409672e2249-wk-Fact-18D607088DEDCAA5943C0ACE3563DDBF" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,321.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ededed;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409672e2268-wk-Fact-BCE723F7CC0C73C8BDBF0ACE35A8F222" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,229.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">See accompanying notes.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB6772F84C2545CE5B4B3A9840E049514"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">Emergent BioSolutions Inc. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Condensed Consolidated Statements of Operations</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">(unaudited, in millions, except per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June&#160;30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e882-wk-Fact-88076C57679DEBBE211ED8499305E222" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">183.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e901-wk-Fact-03C6DD3FE93475379D53D84992F6A572" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">180.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e920-wk-Fact-D3E43AE69523DCD4EE9BD849933CA0FF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">336.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e940-wk-Fact-C239168A4E13BC91AFC1D84993402A50" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">255.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract manufacturing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e955-wk-Fact-6CD0E930F110BBC79097D8499344AE28" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e974-wk-Fact-5F10A1FE3C8C63F7E0FAD849933D6AEA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e993-wk-Fact-25CD4F38EEECA1E915A0D8499300583A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1013-wk-Fact-F4AEB1569AD0C8F57AC8D84993046424" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1033-wk-Fact-6CAE36F4026D53DEBBECD8499307243D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1052-wk-Fact-D368A395B32B7D3E19B2D8499342140F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1071-wk-Fact-8323D54F6C251661152ED849933B4536" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1091-wk-Fact-159F13845B496BD4A6AAD849934CA9C8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1111-wk-Fact-7AE92434260DD4FB2CF8D849934D3C6E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">243.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1130-wk-Fact-EA0211D77CFC99544611D8499308E5C8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1149-wk-Fact-8AF29B1E3DD6C78B7907D849934FCD81" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">433.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1169-wk-Fact-75FE50318A68C4409098D849934304DC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">338.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of product sales and contract manufacturing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1353-wk-Fact-BC9413A8EE13E48DB795D84992FB2BB9" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1372-wk-Fact-CD7467FE4985ABB39350D84992FC83FA" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1391-wk-Fact-836C345479CB7FB8BD11D84993433694" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">192.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1411-wk-Fact-82D63DA99E1978686086D849933B35E5" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">139.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1431-wk-Fact-F91644A6679F4021812AD849934CA920" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1450-wk-Fact-DA635381279112F8A7D4D8499304E143" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1469-wk-Fact-4D3B3459E1B8FF2126E5D84992F802F9" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">110.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1489-wk-Fact-7817EAF32F82F2A1600CD849933E3F48" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">53.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1510-wk-Fact-28FFDE0BF31DADA8B19FD8499301CAFB" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1529-wk-Fact-68B5192079967326094FD849934DA25A" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1548-wk-Fact-8207B37E2BD12B59D6E5D84992FED7C4" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">136.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1568-wk-Fact-CAAF25D22A31CAE05C66D84992F9306D" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">79.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquisition-related intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1588-wk-Fact-38FAEE743CD4490EC338D849930066FB" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1607-wk-Fact-91C07E9A1D86B917DC36D84993429398" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1626-wk-Fact-F2D6BB1B4B9EB2F408EFD84992FE3070" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1646-wk-Fact-D5704BA4F2023D767670D84992F932EB" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1666-wk-Fact-4C627DB7235FEA6A1B5FD84993438ED2" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">250.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1685-wk-Fact-E299E0095131A754D6E2D84993025885" name="us-gaap:OperatingExpenses" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">153.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e1704-wk-Fact-41289C5F0EDC59E69031D84992FB62CE" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">468.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1724-wk-Fact-AEB42FF49DA433FA6C14D84992FA7D02" name="us-gaap:OperatingExpenses" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">280.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e1826-wk-Fact-E1FA88E10CACDEECF57AD84992FF59FB" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1846-wk-Fact-B023BA349C18D956057DD849933DD842" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e1865-wk-Fact-6DC9C2468432039C61EBD8499341D785" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">34.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e1886-wk-Fact-F228648F5E239B2BE170D8499308D1D6" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2070-wk-Fact-C087CCE9758F68C53B9AD84992FCC638" name="us-gaap:InterestExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374415026e2090-wk-Fact-D60803BEA92C84D7E828D84993078F69" name="us-gaap:InterestExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2110-wk-Fact-37BC4CB7E332A044112BD84993460A22" name="us-gaap:InterestExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374415026e2131-wk-Fact-3202B85C26E0464C0F48D849934159A9" name="us-gaap:InterestExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e2152-wk-Fact-6DCDBD4DE0D1D3C27F7CD849933DA0F2" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e2171-wk-Fact-EDF9EB933542A19CC891D84993417ED4" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e2190-wk-Fact-371C4DD2F986DD21488ED84992F6F294" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e2210-wk-Fact-6F7BA23D1D790B6E8F87D849934D7480" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2230-wk-Fact-C350B661BFEAA69EBB3ED849933F71E1" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374415026e2250-wk-Fact-C4AE18B0B41827559EAED84993091084" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2270-wk-Fact-D0296EF7F1B7F7412777D84993068AAA" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">18.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374415026e2291-wk-Fact-D872ACFD2B20499F3358D8499308AD17" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) income before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2395-wk-Fact-5EE662F0B8EF11EBEFBFD849933D8864" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">15.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e2415-wk-Fact-298034CC7080FB1000ABD8499300ADB5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2434-wk-Fact-C993B2D0EAA2F737C3FDD849933ED6B3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">53.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e2455-wk-Fact-8B6C249A640EE6B23D0AD84992F698AA" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2475-wk-Fact-1C0B214C1AC186F572ACD84992FE8A34" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e2495-wk-Fact-D07E37ACA7D991D30539D84992FA4AB9" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2514-wk-Fact-3C8C05A9BD9F0006EED6D84992FEDC0F" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">17.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e2535-wk-Fact-C864500EC8153E8B1CA4D84993419963" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2560-wk-Fact-D743C8D6F80F558CBC290AC7114D7930" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e2580-wk-Fact-6A5AA47224555576B480D849933E5596" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2599-wk-Fact-F8F669F62D331789D59FD84992F9F119" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">35.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e2620-wk-Fact-2EED907790460F1DF430D849934BDBA8" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) income per common share</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2804-wk-Fact-7090664CCD3C5A1ED984D8499303C361" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e2824-wk-Fact-D0A64B8EAE0004E47B12D8499303D192" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2843-wk-Fact-942BAE68901FFA254237D84993449FB1" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e2864-wk-Fact-4C84A2D71E9B4E703742D849933F78FA" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2884-wk-Fact-35C4160347E4E5189413D84992FC2D0C" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e2904-wk-Fact-9C4E901483C9A5C87F06D84993017C7A" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374415026e2923-wk-Fact-5FE71E088EBD1B785B06D849933F0F9D" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e2944-wk-Fact-EE1327C309A8868B9739D849930225C0" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in computing (loss) income per share</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e3041-wk-Fact-604D294840B21CF66CB1D84992F67E5B" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">51.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e3060-wk-Fact-6F53F55F8F03B9782E00D849934F1265" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">49.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e3079-wk-Fact-D473C427EEC3F9B8B9B8D84992FBCF74" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">51.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e3099-wk-Fact-2B2B237C358CCD4D03BAD84993464804" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">49.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e3119-wk-Fact-BEBD441B08D611CB9B81D84992FD4F85" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">51.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e3138-wk-Fact-428DB6DF8872466C8F67D84993452A7C" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">51.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374415026e3157-wk-Fact-82D7F8E323F4CB1ACD59D84992FF590D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">51.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374415026e3177-wk-Fact-6361343FA5C0CEA88D03D849934F771E" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">51.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">See accompanying notes.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE807CE66694956C19178A83C999B8D6B"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">Emergent BioSolutions Inc. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Condensed Consolidated Statements of Comprehensive (Loss) Income</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June&#160;30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374409671e800-wk-Fact-D743C8D6F80F558CBC290AC7114D7930" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409671e820-wk-Fact-6A5AA47224555576B480D849933E5596" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374409671e839-wk-Fact-F8F669F62D331789D59FD84992F9F119" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">35.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409671e860-wk-Fact-2EED907790460F1DF430D849934BDBA8" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive (loss) income, net of tax:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency translations, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409671e953-wk-Fact-DD739EED5B5361CD056FD84993237E35" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374409671e972-wk-Fact-5BFB46AE7E1F05344EDDD849931DE1A1" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409671e992-wk-Fact-DEDC5DF683A2507A69F5D84993211D89" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374409671e1012-wk-Fact-211BEAA3753DF66F74CED849931B7893" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374409671e1033-wk-Fact-EB0834D2D34C0526CD750ACA6E3173B0" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409671e1053-wk-Fact-18078FDCC3D74201AAF40ACA6E2B3145" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374409671e1072-wk-Fact-FE18D26C8ADB4A769B820ACA6E440C26" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409671e1093-wk-Fact-16AB9DF66313E2E3FD110ACA6E3AEFC9" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive (loss) income, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374409671e1113-wk-Fact-0071F5022E8AF89320F2D849931D9ABD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374409671e1133-wk-Fact-2DF3FE6CDC2119F2F7BAD849931E839D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374409671e1153-wk-Fact-1F771DD02ADFBCFFDCE40AC789070A05" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374409671e1173-wk-Fact-3C68A22FA66FBCD106BCD849931E2D0D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive (loss) income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374409671e1199-wk-Fact-95AC380DA86514E6D33ED849931D7121" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409671e1219-wk-Fact-8B23FC4598C1FB5B2EA4D849932105CF" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374409671e1238-wk-Fact-48348395C316A53C3A3ED84993229EE0" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">35.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374409671e1259-wk-Fact-5771ECB6DAD5D327A19DD849931F7ADA" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">See accompanying notes.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA64561CD811B5A0DAC9F5C3DF728D853"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">Emergent BioSolutions Inc. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Condensed Consolidated Statements of Cash Flows</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">(unaudited, in millions)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="7" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows provided by (used in) operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374413382e750-wk-Fact-F8F669F62D331789D59FD84992F9F119" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">35.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e770-wk-Fact-2EED907790460F1DF430D849934BDBA8" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e826-wk-Fact-6C68AB26B84C2F387FD4D849931EB87A" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e845-wk-Fact-4729652EBCBBBCF1ED1FD849931B5C98" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e865-wk-Fact-9B247D9DA9E6DE290D51205CC1A8C2A0" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e884-wk-Fact-146549FB6BC6D3488654D849931C18B9" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of deferred financing costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e904-wk-Fact-33FEE785CA428397506FD84993146283" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e923-wk-Fact-6F670712B3DE770BEEDCD8499311F56C" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374413382e943-wk-Fact-798BB97F971A27773696D849931777EA" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e963-wk-Fact-5B0942CF3423DE657BFDD849931BE8B9" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Change in fair value of contingent consideration, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e983-wk-Fact-EE481DD852320D2A886CD849931E6965" name="ebs:ChangeInFairValueOfContingentConsideration" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1002-wk-Fact-A0E154D44CA3AF539C95D849930F0C4C" name="ebs:ChangeInFairValueOfContingentConsideration" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e1022-wk-Fact-7E1DC485ADE32B53F7D7D84993181055" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1041-wk-Fact-A6871E5C36C55151C07CD849930740A6" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e1103-wk-Fact-F84583569E41C92103CDD84993185CDF" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">44.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374413382e1122-wk-Fact-EF3DB5B1EE8FAE2FAC92D849931664CE" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374413382e1143-wk-Fact-A5D1F4B248D651A2BF38D8499309C6FE" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1163-wk-Fact-0A91AB4EEB98E4473FD7D849931C1A93" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374413382e1183-wk-Fact-2622BA7D4B9DBBA8E2F1205CC1E10238" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374413382e1203-wk-Fact-4C64ACD2FEC767FE68D3205CC18C2248" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e1224-wk-Fact-65DEC97C5335ED0E1780D8499309EFFE" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374413382e1243-wk-Fact-65F6420BA5A3A12EA466D8499310E12A" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e1264-wk-Fact-0BD3AF04A99F2BA5366CD849931ECE55" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1283-wk-Fact-884951A9D6E6FDC0FC4FD8499316645D" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374413382e1303-wk-Fact-A13D8C7726425BD83F2BD849930E2CDF" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">13.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374413382e1323-wk-Fact-EEA1CF7E3D4540870F57D84993112BB5" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e1344-wk-Fact-971FD998A98B9DFD9541D849931A227F" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1363-wk-Fact-711B7BDFEB08F0B89AC0D849931E1B7B" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">Net cash provided by operating activities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"><span><ix:nonFraction id="d374413382e1383-wk-Fact-69C5AF9771FD2CE579BA205CC1D38BB6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1402-wk-Fact-899E9E15C02ACDB8D931205CC1C4ECA2" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows used in investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374413382e1463-wk-Fact-7A1F45131DBD50F50C32D84993159E46" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374413382e1483-wk-Fact-B9C62CDCBFEAFB9552FAD849930802E4" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Milestone payment from prior asset acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374413382e1505-wk-Fact-60EBCBD7116C086793D445FF545396DD" name="us-gaap:PaymentsForPreviousAcquisition" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1525-wk-Fact-9D941AB1105F8880CAC245FF5472E356" name="us-gaap:PaymentsForPreviousAcquisition" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sale of assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e1545-wk-Fact-B5B5335AD4A88472A03F205EC8CD57F1" name="us-gaap:ProceedsFromSaleOfProductiveAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1564-wk-Fact-676CB6C79BC78C4526AE205EC8C62569" name="us-gaap:ProceedsFromSaleOfProductiveAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;">Net cash used in investing activities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374413382e1584-wk-Fact-F74DE832DD9C0266699B205CC19AFFB2" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">45.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374413382e1604-wk-Fact-CAB605F5179A6A462C9B205CC17D67D2" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">22.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Cash flows provided by (used in) financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from revolving credit facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e1666-wk-Fact-F396DF4928EE381FAE72D849931B326F" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">130.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1685-wk-Fact-69B04E6110F50ED96015D84993201D4D" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Principal payments on revolving credit facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374413382e1705-wk-Fact-9C27A50EEE09A8CBB84AD849931FF9F9" name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1725-wk-Fact-F367C67F5C32B344E0F2D84993117442" name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Principal payments on term loan facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374413382e1745-wk-Fact-9BD45498A2B067672263D849931E4079" name="us-gaap:RepaymentsOfMediumTermNotes" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1765-wk-Fact-4A5D6E79036E8F546D6AD849931E7A89" name="us-gaap:RepaymentsOfMediumTermNotes" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuances of stock under share-based benefit plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e1785-wk-Fact-2C16A89326A71BDA5C29D849931388CF" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1804-wk-Fact-33ABDE25371D50B8A8D7D8499318DED8" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes paid on behalf of employees for equity activity</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374413382e1824-wk-Fact-D5458B1D209CEBE42438D8499308BD3F" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374413382e1844-wk-Fact-62A237065735961D385DD8499308973D" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374413382e1865-wk-Fact-4D2877C06F40C4EF7A05D8499309668D" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374413382e1885-wk-Fact-31263A08A121CBE6B6EDD84993205330" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase of treasury stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e1906-wk-Fact-55BC8876E28F54A3C344D849931B9E94" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374413382e1925-wk-Fact-CC0227CB4E083E47711BD849931DFB65" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;">Net cash provided by financing activities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e1947-wk-Fact-BED71B2F9CA4EF83C30A205CC1B6D3E1" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e1966-wk-Fact-81169E2E625AF8EF6075205CC163F2A2" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e1986-wk-Fact-1015F5340F25015F4D3AD8499335C5D7" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374413382e2005-wk-Fact-1B090A66FA10202078B3D8499332692C" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e2026-wk-Fact-ED4C81D13835AA9741A2D8499318C9A3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e2045-wk-Fact-976C2F59E46E5468E9CBD8499313E18B" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e2065-wk-Fact-8DD36C3DCC90E3398706D84993149DCA" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e2084-wk-Fact-E03DD34EEE4AE6C73690D849931B708A" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">179.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">Cash, cash equivalents and restricted cash at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374413382e2109-wk-Fact-9A111BE18CEE889F3286D84993178D44" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">177.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374413382e2128-wk-Fact-0D132E5959EB1358DF80D84993094107" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">191.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">See accompanying notes.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2DFC0B488F435290A3A220BA9E6392D1"></a></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">Emergent BioSolutions Inc. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">Condensed Consolidated Statements of Changes in Stockholders' Equity</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#000000;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="31"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">$0.001 Par Value Common Stock</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Additional Paid-In Capital</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Treasury Stock</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated Other Comprehensive Loss</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Retained Earnings</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Total Stockholders' Equity</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Shares</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Shares</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1127-wk-Fact-DF3F9BFC46AA162061832060B1A929CB" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">52.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1146-wk-Fact-0AA68506EA84EF382B3B2060AD25C79F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1165-wk-Fact-F480243440E5E6780D002060ADB34E8A" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">688.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e1180-wk-Fact-25DAAA90CB7BDAB93FFE2060AFB5FE5D" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e1200-wk-Fact-8384AAFA8E2BA738DAFE2060B1FE57DE" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e1220-wk-Fact-BF912D07EFCD8B1B05482060B2E3A470" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1241-wk-Fact-258F4C55E4A5D30995DC2060AB720E4B" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">367.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1260-wk-Fact-B4353C2A4F51AFB1781E0ACE3534119C" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,010.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee equity plans activity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1280-wk-Fact-DE81B2827C2C5B21915C2060AEAFD6A4" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1313-wk-Fact-2EF44F64E68958AF30172060AD29C2F5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e1347-wk-Fact-DE41F93B77DA26F465562060ABB35B7F" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1406-wk-Fact-9D6E34F8DBA94EFFC8152060B3553BCA" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e1537-wk-Fact-2CA3415AB5BFC93512DF2060AB810F9A" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">35.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e1557-wk-Fact-F8F669F62D331789D59FD84992F9F119" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">35.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1669-wk-Fact-1DB6EE77B0D01CA3E7F62060AD309E17" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1708-wk-Fact-1F771DD02ADFBCFFDCE40AC789070A05" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">Balance at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1733-wk-Fact-2717E9F07256943640B92060B00DA6F7" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">52.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1752-wk-Fact-62221AE53C842ABA34252060AFD476AC" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1771-wk-Fact-DB2714766F53017108B72060B34B477C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">701.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e1786-wk-Fact-9054E5B6AC8EA99821112060B016217B" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e1806-wk-Fact-DA7EA47F43F64B3A97492060B0E38114" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e1826-wk-Fact-7BED963FB6A25CC3D88F2060AFFBA392" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1847-wk-Fact-1A8EACCBD733363A52AA2060AFDD99A7" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">331.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e1866-wk-Fact-3426FA62817349CDE2680ACE3553FBC6" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">988.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">Balance at March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2044-wk-Fact-D3520E0A2616979AB1002060ABDF230F" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">52.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2062-wk-Fact-38E350398C9D9198897C2060B0C874C0" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2080-wk-Fact-8CB43AC6F73E193ABC982060AD834B8F" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">690.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e2094-wk-Fact-CCF2405617361AF64D262060B1762C90" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e2113-wk-Fact-72358FAD7469C8BE5E062060ABD02E2C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e2132-wk-Fact-0EFAF3127A5D8449D04A2060B2F75936" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2152-wk-Fact-3D98EE478D0B34FC531F2060B1491520" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">341.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2170-wk-Fact-C2B1B61974154C70E7472060AFE8B936" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">987.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee equity plans activity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2190-wk-Fact-9292219CB4E96C4746D12060B2D77368" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2221-wk-Fact-DF57480934ECF5574CFA2060AC6CE6EA" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e2253-wk-Fact-FB5FC15B876915FDF86C2060AD43A556" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2308-wk-Fact-5710C04D96CF96C656FC2060AB4ACBD2" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e2440-wk-Fact-129FC81C13FF44BA87B02060B3356D2B" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e2460-wk-Fact-D743C8D6F80F558CBC290AC7114D7930" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e2572-wk-Fact-D38DB35BBE491844CECB2060AE5EFCC3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e2612-wk-Fact-0071F5022E8AF89320F2D849931D9ABD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2638-wk-Fact-2717E9F07256943640B92060B00DA6F7" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">52.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2656-wk-Fact-62221AE53C842ABA34252060AFD476AC" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2674-wk-Fact-DB2714766F53017108B72060B34B477C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">701.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e2688-wk-Fact-9054E5B6AC8EA99821112060B016217B" name="us-gaap:CommonStockSharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e2707-wk-Fact-DA7EA47F43F64B3A97492060B0E38114" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374420172e2726-wk-Fact-7BED963FB6A25CC3D88F2060AFFBA392" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2746-wk-Fact-1A8EACCBD733363A52AA2060AFDD99A7" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">331.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420172e2764-wk-Fact-3426FA62817349CDE2680ACE3553FBC6" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">988.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e2942-wk-Fact-6FA33A0D6C651869BB052060AF1F46F6" name="us-gaap:CommonStockSharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">50.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e2960-wk-Fact-BFFD019483468B140A6E2060B260136B" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e2978-wk-Fact-16EA6A006758778BED612060AF4F7877" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">618.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e2992-wk-Fact-FF6F6756D27CD055A45C2060B272295E" name="us-gaap:CommonStockSharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e3011-wk-Fact-8215D14708821E3C8BD52060B33F429E" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e3030-wk-Fact-A427031C5C45768444FC2060AC103DE9" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e3050-wk-Fact-E1E1171FBFEF8A9D8E782060B35F01AC" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">337.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e3068-wk-Fact-7775F946258B8FAC0C612060AC2FC7B2" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">912.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adoption of new revenue accounting standard (ASC 606), net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e3194-wk-Fact-828CF22DFE1AA732826D206322A45BAC" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">32.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e3214-wk-Fact-CAB2F585A76BD88A3263206322A03858" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1Jan01" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">32.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">Balance at January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonFraction id="d374420172e3240-wk-Fact-080A5FB9DF42A20935F32063EE9D4061" name="us-gaap:CommonStockSharesIssued" contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">50.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonFraction id="d374420172e3254-wk-Fact-6129255B08195147EFE62063F09531AD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonFraction id="d374420172e3273-wk-Fact-1CFD769DCEEAD3F967D02063F2A006DE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">618.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span>(<ix:nonFraction id="d374420172e3293-wk-Fact-46C23BBF213429E675172063F49863A6" name="us-gaap:CommonStockSharesIssued" contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span>(<ix:nonFraction id="d374420172e3308-wk-Fact-0EF30E910D8DAF3F6CD22063F6A0529B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span>(<ix:nonFraction id="d374420172e3328-wk-Fact-60CE32D50E1A74C660102063F87F7756" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonFraction id="d374420172e3349-wk-Fact-EC504C56162E1A616EBA2063FBBC618D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">304.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonFraction id="d374420172e3368-wk-Fact-01798B7F5AE2A741A5452063FDB3EE4A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" contextRef="I2018Q1Jan01" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">879.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee equity plans activity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e3393-wk-Fact-BC18BE16A690E8D81EF62060AFAE2998" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e3424-wk-Fact-06AB402B0E9D6C3405352060B0014B08" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e3456-wk-Fact-03587C926CB40EE9FC832060AD4A0A73" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e3512-wk-Fact-5F8D943B5DDB2255FF872060B3221136" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e3637-wk-Fact-C133E6B004E3700514E02060AD0AAB79" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e3655-wk-Fact-2EED907790460F1DF430D849934BDBA8" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e3761-wk-Fact-DED9A027A706948A40992060AFF1287D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e3799-wk-Fact-3C68A22FA66FBCD106BCD849931E2D0D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">Balance at June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e3825-wk-Fact-420D8E6BFD2786ADE71B2060AC018809" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">51.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e3843-wk-Fact-533B2BF3661F3955825E2060B2EB4C59" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e3861-wk-Fact-FE5E1895F04576FE53002060ACB5EDC0" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">632.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e3875-wk-Fact-273211CECF0B715BA4E62060AD026FAA" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e3894-wk-Fact-39560FDA5BCA8E635D3B2060B32A5287" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e3913-wk-Fact-8CDF1D7CBBA4FA5CA0AB2060B301AAC1" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e3933-wk-Fact-FA3417207E002D6DE6942060AF4831D6" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">349.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e3951-wk-Fact-F4A7C7D211ED420BB1572060AD19696A" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">938.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">Balance at March 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4130-wk-Fact-B39E8F4C42340FD87E9A2060AEBFB905" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">51.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4148-wk-Fact-16C46071F09456CB30E92060B30CD771" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4166-wk-Fact-EF370D03939352A234AD2060AD15EF7B" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">624.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e4180-wk-Fact-3A0435D3CA52C790BBDB2060AFC7A7FF" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e4199-wk-Fact-E4F4DFE5A956E360CD5C2060B0395F6B" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e4218-wk-Fact-D6133E85406578D8DB7D2060B0335C3C" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4238-wk-Fact-AEAE688FE3F05DC0FF372060AC3C97FB" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">299.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4256-wk-Fact-6B8722E80A13159476532060AD56CA24" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">881.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee equity plans activity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4276-wk-Fact-121F2293210B63E896032060B1168E8B" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4307-wk-Fact-13B6F0994DF48D6357BD2060AC1FBCD4" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4394-wk-Fact-9D45128FA0C7E5AA2D572060AFC12F94" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4519-wk-Fact-F4D1C73D4A7C44BD61852060B2CE00C4" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4537-wk-Fact-6A5AA47224555576B480D849933E5596" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e4643-wk-Fact-6DD198419A3D026907272060AD34ABD5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e4681-wk-Fact-2DF3FE6CDC2119F2F7BAD849931E839D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">Balance at June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4707-wk-Fact-420D8E6BFD2786ADE71B2060AC018809" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">51.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4725-wk-Fact-533B2BF3661F3955825E2060B2EB4C59" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4743-wk-Fact-FE5E1895F04576FE53002060ACB5EDC0" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">632.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e4757-wk-Fact-273211CECF0B715BA4E62060AD026FAA" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e4776-wk-Fact-39560FDA5BCA8E635D3B2060B32A5287" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">39.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374420172e4795-wk-Fact-8CDF1D7CBBA4FA5CA0AB2060B301AAC1" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4815-wk-Fact-FA3417207E002D6DE6942060AF4831D6" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">349.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420172e4833-wk-Fact-F4A7C7D211ED420BB1572060AD19696A" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">938.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">See accompanying notes.</span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">9</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE28CD5817F7C54208EF7A6A52B27BC26"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"><br/></span></div><div><a id="s43CFC4A362DE57A8A2920F6BEEDE5392"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="TextSelection-FB7E68EF5FA261F05D63D849935F4815-0-wk-Fact-197B28CE62C5160D2083D849931227D2" continuedAt="TextSelection-FB7E68EF5FA261F05D63D849935F4815-1" escape="true">Business</ix:nonNumeric></span></div><ix:continuation id="TextSelection-FB7E68EF5FA261F05D63D849935F4815-1"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Emergent is a global life sciences company focused on providing specialty products for civilian and military populations that address accidental, deliberate and naturally occurring PHTs. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company is focused on innovative preparedness and response products and solutions addressing the following four distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives (CBRNE); emerging infectious diseases (EID); travelers&#8217; diseases; and opioids. The USG is the Company's largest customer and provides the Company with substantial funding for the development of a number of the Company's product candidates. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The majority of the Company's revenue comes from a product portfolio that includes: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Vaccines and Anti-Infectives</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> - </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">BioThrax&#174; (Anthrax Vaccine Adsorbed), ACAM2000&#174; (Smallpox (Vaccinia) Vaccine, Live), Vaxchora&#174; (Cholera Vaccine, Live, Oral), and Vivotif&#174; (Typhoid Vaccine, Live, Oral Ty21a).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Devices</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> - </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">NARCAN&#174; (naloxone HCl) Nasal Spray for opioid overdose, RSDL&#174; (Reactive Skin Decontamination Lotion Kit), and the Trobigard&#174; (atropine sulfate, obidoxime chloride a nerve agent countermeasure) auto-injector.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Antibody Therapeutics - </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">raxibacumab (Anthrax Monoclonal antibody therapeutic for anthrax),</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Anthrasil&#174;( Anthrax Immune Globulin Intravenous (Human)), BAT&#174;(Botulism Antitoxin Heptavalent), and VIGIV (Vaccinia Immune Globulin Intravenous (Human) therapeutic) for complications from smallpox vaccinations.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company also generates revenue from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">contract development and manufacturing services</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> including </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">pharmaceutical product process development, manufacturing and filling services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, laboratory analytical development support, aseptic filling, lyophilization, final packaging and accelerated and ongoing stability studies, as well as manufacturing of vial and pre-filled syringe formats, bulk drug products and finished units of clinical and commercial drugs. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374415124e656-wk-Fact-5A9CEE1F5ED7B6AAB186D8499312BF92" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q2YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> operating segment.</span></div></ix:continuation><div><a id="sA2F84C487E5B5817AFBCCA865BF9C0E0"></a></div><div style="line-height:120%;padding-bottom:8px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-B5AA59006CB87DA0CA1CD8499360B3BE-0-wk-Fact-010D4421E7C1B3714FB1D849932EE30A" continuedAt="TextSelection-B5AA59006CB87DA0CA1CD8499360B3BE-1" escape="true">Basis of Presentation and Principles of Consolidation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B5AA59006CB87DA0CA1CD8499360B3BE-1" continuedAt="TextSelection-B5AA59006CB87DA0CA1CD8499360B3BE-2"><div style="line-height:120%;padding-bottom:8px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Basis of Presentation </span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-63407DE5606D5987F408D849935FF0F5-0-wk-Fact-66F9FAFE8AC731D81186D849932E15DC" escape="true"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, as filed with the SEC.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Significant Accounting Policies</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, as filed with the SEC, except for recently adopted accounting standards.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Fair Value Measurements</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has interest rate swaps and contingent consideration liabilities that are measured at fair value on a recurring basis (Note 8 and Note 9). The Company also records the assets and liabilities of acquisitions at fair value (Note 3). As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">no</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> other significant assets or liabilities that were measured at fair value on a non-recurring basis. </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">10</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-7832D170B1393697772DD84993604ED0-0-wk-Fact-9BCB39685F4E5105A75ED849932FE289" continuedAt="TextSelection-7832D170B1393697772DD84993604ED0-1" escape="true"><ix:continuation id="TextSelection-B5AA59006CB87DA0CA1CD8499360B3BE-2" continuedAt="TextSelection-B5AA59006CB87DA0CA1CD8499360B3BE-3"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-02, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, which increases transparency and comparability among organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The Company adopted the new standard effective January 1, 2019 using the modified retrospective approach. As of January 1, 2019 total right of use assets increased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;text-align:right;"><span>$<ix:nonFraction id="d374406785e668-wk-Fact-64383CE1B1FAE9A38798D849932F8745" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, while total operating lease liabilities increased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;font-weight:bold;text-align:right;"><span>$<ix:nonFraction id="d374406785e672-wk-Fact-EF9DB71FBFF838338CDFD8499331F0A0" name="us-gaap:OperatingLeaseLiability" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">. There was no adjustment to the opening balance of retained earnings as of January 1, 2019. The standard will not materially affect the Company's consolidated net earnings. The Company continues to apply the legacy guidance from the old lease accounting standard, including its disclosure requirements, in the comparative periods presented. The Company did not reassess existing contracts for lease classification or the classification of existing leases or associated costs. The Company will not reflect leases with an initial term of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> months or less as a right of use asset or liability, but will recognize those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. In addition, the Company will account for non-lease components of the arrangement separate from lease components (see Note 6).</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">SEC Simplification</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In August 2018, the SEC issued Final Rule Release No. 33-10532, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Disclosure Update and Simplification</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, which makes a number of changes meant to simplify interim disclosures. The new rule requires a presentation of changes in stockholders&#8217; equity and noncontrolling interest in the form of a reconciliation, for the current and comparative year-to-date interim periods. The Company adopted the new disclosure requirements beginning in its March 31, 2019 Form 10-Q and included these disclosures in the condensed consolidated statements of changes in stockholders' equity. The additional elements of this release did not have a material impact on the Company's overall condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Tax Effects from Accumulated Other Comprehensive Income</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">In February 2018, the FASB issued ASU 2018-02,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;">&#160;Income Statement&#8212;Reporting Comprehensive Income (Topic 220):&#160;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. ASU 2018-02 provides the option to reclassify certain income tax effects related to the Tax Cuts and Jobs Act passed in December of 2017 between accumulated other comprehensive income and retained earnings and also requires additional disclosures.&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company adopted the new standard effective January 1, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">.&#160;There was no impact for the adoption of ASU 2018-02 on the Company's condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Financial Instruments - Credit Losses</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">In June 2016, the FASB issued&#160;ASU 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;">Financial Instruments - Credit Losses</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. ASU 2016-13 provides&#160;guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking &#8220;expected loss&#8221; model that is likely to result in the earlier recognition of allowances for losses. The guidance was further amended in January 2019 to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">clarify or address stakeholders&#8217; specific issues about certain aspects of the amendments in the update and in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">May 2019 to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">provide an option to irrevocably elect the fair value option for certain financial assets previously measured on an amortized cost basis. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The guidance&#160;is effective for annual periods beginning after December 15, 2019, including interim periods within those years, but early adoption is permitted. The Company is currently evaluating the effect that the pronouncement will have on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">In January 2017, the FASB issued ASU 2017-04,&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. ASU 2017-04 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-04 is effective for annual and interim goodwill tests beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates on or after January 1, 2017. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.</span></div></ix:continuation></ix:nonNumeric><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">11</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-B5AA59006CB87DA0CA1CD8499360B3BE-3"><ix:continuation id="TextSelection-7832D170B1393697772DD84993604ED0-1"><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In August 2018 the FASB issued ASU No. 2018-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">. This new standard modifies certain disclosure requirements on fair value measurements. This new standard will be effective for the Company on January 1, 2020. The Company does not expect that the adoption of this new standard will have a material impact on the Company's disclosures.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Compensation -&#160;Retirement Benefits - Defined Benefit Plans</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In August 2018, the FASB issued ASU 2018-14, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Compensation - Retirement Benefits - Defined Benefit Plans - General</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">. ASU 2018-14 modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. ASU 2018-14 is effective for&#160;all entities for fiscal years ending after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-14 on its consolidated financial statements.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">There are no other recently issued accounting pronouncements that are expected to have a material impact on the Company's financial position, results of operations or cash flows.</span></div></ix:continuation><div><a id="s699B0251AD8A58BD8A1337C496A2A9E3"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="TextSelection-A664ABEE18BF87DD2269D849935F550F-0-wk-Fact-0810F3940BB3C36DEDCED849931D9177" continuedAt="TextSelection-A664ABEE18BF87DD2269D849935F550F-1" escape="true">Acquisitions</ix:nonNumeric></span></div><ix:continuation id="TextSelection-A664ABEE18BF87DD2269D849935F550F-1" continuedAt="TextSelection-A664ABEE18BF87DD2269D849935F550F-2"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Adapt</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">On October 15, 2018, the Company acquired Adapt, a company focused on developing new treatment options and commercializing products addressing opioid overdose and addiction. Adapt's NARCAN&#174; (naloxone HCl) Nasal Spray marketed product is the first needle-free formulation of naloxone approved by the FDA and Health Canada for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. This acquisition includes approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374424724e604-wk-Fact-B3711FC027FFD765F4D7D84993153F85" name="ebs:NumberOfEmployees" contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="employee" decimals="-1" scale="0" format="ixt:numdotdecimal">50</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> employees, located in the U.S., Canada, and Ireland, including those responsible for supply chain management, research and development, government affairs, and commercial operations. The products and product candidates within Adapt's portfolio are consistent with the Company's mission and expands the Company's core business of addressing </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">public health threats</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Under the acquisition method of accounting, the assets and liabilities of Adapt have been recorded as of October 15, 2018, the acquisition date, at their respective fair values, and combined with those of the Company. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">As the Company continues to finalize the fair value of assets acquired and liabilities assumed, purchase price adjustments have been recorded and additional purchase price adjustments may be recorded during the measurement period. The Company reflects measurement period adjustments in the period in which the adjustments occur. The adjustments for the&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> resulted from the receipt of additional financial information </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">associated with certain acquired contract assets and the value of associated contingent purchase consideration</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">. These adjustments did not impact the Company's statements of operations. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, certain fair value estimates relating to</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> intangible assets acquired and income taxes could be</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> subject to further adjustment.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="TextSelection-73412ED114C778BC5A01D849935F5FFA-0-wk-Fact-9F408F5F572315CA550CD849931C64CD" escape="true"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The total purchase price, revised for current period adjustments is summarized below:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">October 15, 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e695-wk-Fact-85270F5C1743B3009B04D84993051A62" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">581.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e715-wk-Fact-97F16201FD7414080B8DD8499306A5A5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of contingent purchase consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e740-wk-Fact-89C7C8797948AFB144A6D8499306A10A" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preliminary purchase consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e765-wk-Fact-CA5E9AA2287FAECDF92FD8499305807F" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2018Q4Oct15-Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">667.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e790-wk-Fact-575B971A7D76E7D28386D84993060CA1" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Updated purchase consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e820-wk-Fact-9B615F6B1FBC23C58772D849930739E3" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">668.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company issued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374424724e832-wk-Fact-F7FF2B633F4C28ABFBC2D849931AA232" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">733,309</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> shares of common stock at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374424724e836-wk-Fact-343C160120E8C8DBF87DD8499315ED71" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">60.44</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> per share, the closing price of Emergent's common stock on October 15, 2018, with a total value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374424724e840-wk-Fact-EE45079896DC2642C2DBD849931EF0B0" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374424724e844-wk-Fact-EE45079896DC2642C2DBD849931EF0B0" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> value of the common shares issued has been adjusted to a fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374424724e848-wk-Fact-97F16201FD7414080B8DD8499306A5A5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.7</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million considering a discount for lack of marketability due&#160;to a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">two</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">-year lock-up period beginning on October 15, 2018. The remaining contingent consideration payable for the acquisition consists of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374424724e857-wk-Fact-B8D6B9134B8B18E9D939D849931E61FB" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="I2018Q4Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> in cash based on the achievement of certain sales milestones through 2022, which the Company has determined had a fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374424724e861-wk-Fact-89C7C8797948AFB144A6D8499306A10A" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.0</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and for the payment of additional consideration based on the collectability of identified acquired contract assets.&#160;The fair value of the contingent purchase consideration is based on management&#8217;s assessment of the potential future realization of the contingent purchase consideration </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">12</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-A664ABEE18BF87DD2269D849935F550F-2" continuedAt="TextSelection-A664ABEE18BF87DD2269D849935F550F-3"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">payments. This assessment is based on inputs that have no observable market inputs (Level 3). The obligation is measured using a discounted cash flow model.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="TextSelection-1E523F6934243B8ED1F8D849935F8F3F-0-wk-Fact-2D8EFA6ABE2504DA9D32D8499319C5D3" continuedAt="TextSelection-B5D8214EF3D176E7C63AD849935F80BD-0" escape="true"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at October 15, 2018 updated for measurement period adjustments recorded through </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">October 15, 2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Measurement Period Adjustments</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Updated  October 15, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Estimated fair value of tangible assets acquired and liabilities assumed:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1039-wk-Fact-B19474CD4680718E2D8FD849934EC32A" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1077-wk-Fact-748233C9E14062C75C0FD849934CC506" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1093-wk-Fact-EB3EE9DDD9002025F669D849934CA257" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1131-wk-Fact-422CEAC8A5EA1AF3AD0FD84992F9235C" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1152-wk-Fact-BD7D6050F6A7AB293FFDD84992FA810B" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1190-wk-Fact-A35549106229FD6322D2D849934EEC67" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1211-wk-Fact-50CE81BECDBC5CFF6CC0D84992F85209" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1230-wk-Fact-16C6934A9EFCCE91C6BFD849934C27A2" name="ebs:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" contextRef="D2019Q2Oct16-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1249-wk-Fact-62886B00918F2C6467F7D849934FFC54" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e1270-wk-Fact-83BFD960099859CB3A07D84992FB4567" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e1309-wk-Fact-FA800A70B4B89D2527F1D84992F8DD34" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e1331-wk-Fact-8A89EBC96E6589A8C25CD84992F794DB" name="ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e1370-wk-Fact-A45B0DC6760D9716E64ED84992F6D6DB" name="ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e1392-wk-Fact-14E70D146E4A317AA5C8D8499304DE2F" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e1412-wk-Fact-69D81EFFAF9EF66900EDD84992F9A2B1" name="ebs:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent" contextRef="D2019Q2Oct16-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e1432-wk-Fact-00434CF33E1D1B60C343D84993021E1D" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total estimated fair value of tangible assets acquired and liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e1454-wk-Fact-BC72454FFA222A041ABDD84992FB9E07" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">56.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1474-wk-Fact-C6A0413D2B1BC7660D1AD84992FB66D8" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod" contextRef="D2019Q2Oct16-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e1493-wk-Fact-61BA540152F4340CD8CCD849934C83CA" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">54.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1578-wk-Fact-ADA71E23AF5C425A7590D84992F95D30" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1616-wk-Fact-504CB8DF796A0AF67A27D849934DFEDA" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1637-wk-Fact-CFBDE830FCA0D30C5C3DD84992FB60D6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">534.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1675-wk-Fact-5A528E8C18A23F1C35C2D84992F777DE" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">534.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1696-wk-Fact-CDA2C1C60532BF1BF876D849934EA25D" name="us-gaap:Goodwill" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">149.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e1715-wk-Fact-DB552347A11C833C2ED6D849934ECC55" name="us-gaap:GoodwillPurchaseAccountingAdjustments" contextRef="D2019Q2Oct16-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1735-wk-Fact-E88DEF3F287FC34BCC5CD84993025599" name="us-gaap:Goodwill" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1761-wk-Fact-CA5E9AA2287FAECDF92FD8499305807F" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2018Q4Oct15-Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">667.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1780-wk-Fact-3AA15105B068070FEDB5D84993016DC4" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" contextRef="D2019Q2Oct16-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e1799-wk-Fact-9B615F6B1FBC23C58772D849930739E3" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">668.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company determined the estimated fair value of the intangible asset using the income approach. The preliminary estimated fair value of the intangible asset acquired for Adapt's marketed product NARCAN&#174; Nasal Spray is valued at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374424724e1812-wk-Fact-CFBDE830FCA0D30C5C3DD84992FB60D6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">534.0</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million. The Company has determined the useful life of the NARCAN&#174; Nasal Spray intangible asset to be </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonNumeric id="d374424724e1816-wk-Fact-A53BC27E2DBE692BF405D8499318BAAD" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> years. The Company estimated the fair value of the NARCAN&#174; Nasal Spray intangible asset using the income approach which is based on the present value of future cash flows with a discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374424724e1820-wk-Fact-A58B1FF87BB549646368D8499316847B" name="ebs:PresentValueDiscountRate" contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Adapt. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value these intangible assets. The projected cash flows from the NARCAN&#174; Nasal Spray intangible asset were based on key assumptions including: estimates of revenues and operating profits, and risks related to the viability of and potential alternative treatments in any future target markets. The fair value measurements are based on significant unobservable inputs that are developed by the Company using estimates and assumptions of the respective market and market penetration of the acquired company's products.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The intangible asset associated with the IPR&amp;D acquired from Adapt is related to a product candidate. Management determined that the estimated acquisition-date fair value of intangible assets related to IPR&amp;D was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374424724e1828-wk-Fact-ADA71E23AF5C425A7590D84992F95D30" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.0</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million. The estimated fair value was determined using the income approach, which discounts expected future cash flows to present value. The Company estimated the fair value using a discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374424724e1832-wk-Fact-A14A528B22870598DE01D849931608D9" name="ebs:PresentValueDiscountRate" contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">11.0</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Adapt and IPR&amp;D assets at a similar stage of development as the product candidate. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value the IPR&amp;D. The projected cash flows for the product candidate were based on key assumptions including: estimates of revenues and operating profits, the stage of development of pipeline programs on the acquisition date; the time and resources needed to complete the development and approval of the product candidate; the life of the potential commercialized product and associated risks, including the inherent difficulties and uncertainties in developing a product candidate, such as obtaining marketing approval from the FDA and other regulatory agencies; and risks related to the viability of and potential for alternative treatments in any future target markets. IPR&amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts (see Note 7).</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">13</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-A664ABEE18BF87DD2269D849935F550F-3" continuedAt="TextSelection-A664ABEE18BF87DD2269D849935F550F-4"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company determined the fair value of inventory using the comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete/dispose of the inventory with a profit on those costs. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company has recorded </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374424724e1842-wk-Fact-E88DEF3F287FC34BCC5CD84993025599" name="us-gaap:Goodwill" contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.0</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million in goodwill related to the Adapt acquisition, which is calculated as the purchase price paid in excess of the fair value of the tangible and intangible assets acquired representing the future economic benefits the Company expects to receive as a result of the acquisition. The goodwill created from the Adapt acquisition is associated with early stage pipeline products. Substantially all of the goodwill generated from the Adapt acquisition is not expected to be deductible for tax purposes due to the legal structure of the transaction.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">PaxVax</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">On October 4, 2018, the Company completed the acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases. This acquisition includes Vivotif&#174; (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever, Vaxchora&#174; (Cholera Vaccine, Live, Oral), the only FDA-licensed vaccine for the prevention of cholera, and clinical-stage vaccine candidates targeting chikungunya and other emerging infectious diseases, European-based current good manufacturing practices (cGMP) biologics manufacturing facilities, and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374424724e1852-wk-Fact-A9241F5B60395BA6CBDAD8499316C537" name="ebs:NumberOfEmployees" contextRef="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="employee" decimals="-1" scale="0" format="ixt:numdotdecimal">250</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> employees including those in research and development, manufacturing, and commercial operations with a specialty vaccines salesforce in the U.S. and in select European countries. The products and product candidates within PaxVax's portfolio are consistent with the Company&#8217;s mission and will expand the Company&#8217;s core business of addressing PHTs. In addition, the acquisition expands the Company's manufacturing infrastructure and related capabilities.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company paid cash consideration of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374424724e1859-wk-Fact-1519335EB80108461268D8499319DD64" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">273.1</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million for PaxVax. As of the date of this filing, the accounting for the PaxVax acquisition is preliminary due to the Company's need to gather data to assess the fair value of property, plant and equipment, intangible assets and accounting for taxes. <ix:continuation id="TextSelection-B5D8214EF3D176E7C63AD849935F80BD-0" continuedAt="TextSelection-B5D8214EF3D176E7C63AD849935F80BD-1">The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at October 4, 2018 updated for measurement period adjustments recorded through </ix:continuation></span><ix:continuation id="TextSelection-B5D8214EF3D176E7C63AD849935F80BD-1" continuedAt="TextSelection-B5D8214EF3D176E7C63AD849935F80BD-2"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">.</span></ix:continuation></div><ix:continuation id="TextSelection-B5D8214EF3D176E7C63AD849935F80BD-2"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">October 4, 2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Measurement Period Adjustments</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Updated October 4, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Estimated fair value of tangible assets acquired and liabilities assumed:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2028-wk-Fact-122C41F2DC3FCB378A36D84992F8B339" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2066-wk-Fact-D76856C69AFB84A34536D849934141E1" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2082-wk-Fact-083E57354FBF8249AAFED84993445455" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2120-wk-Fact-5D1A8C326AAE571683D1D84992FC026B" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2141-wk-Fact-4D42B6F0B1DB695D1973D84993429314" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2179-wk-Fact-2362F8C3D5CCBC448E13D84993457878" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2200-wk-Fact-2E9F1A0905404347ED0AD84992FA46BB" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2238-wk-Fact-434C9092BC1A2045E7E1D849934EDA1C" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2259-wk-Fact-26F7B95B5638A7872F1AD84993425293" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2297-wk-Fact-6ED1C0802D66D2523CF4D84992F74337" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2318-wk-Fact-736BE453D97C8B00C7DFD84992FD5266" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2356-wk-Fact-C10AD37A918472F768DDD849934FD53C" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e2377-wk-Fact-5C28F1B4B4FD22C0A212D84993441189" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e2416-wk-Fact-2356F2333A662EE078E3D849934D7778" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e2438-wk-Fact-EC3D95B7A1D508A36980D849934164AF" name="ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e2458-wk-Fact-7E6A40B0F2CBA2D81D22206FEE9A8A46" name="ebs:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities" contextRef="D2019Q2Oct05-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e2478-wk-Fact-FBC3A0CD94643FCF0098D84993433A87" name="ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total estimated fair value of tangible assets acquired and liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2500-wk-Fact-7E1A8BC7C8C9337DFFFFD8499343E092" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e2519-wk-Fact-783EF8D3D513777D6EB2206D0B58A63A" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod" contextRef="D2019Q2Oct05-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2539-wk-Fact-A2F45F017F8344AE273B206DDAE0C3AD" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2623-wk-Fact-35349A14065AB090293DD84992FFDA26" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374424724e2642-wk-Fact-3B473A645FEF2C6FFD38D84992FCA5C6" name="ebs:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets" contextRef="D2019Q2Oct05-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2662-wk-Fact-D1A027F240154F2ADB24D84993442F59" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2683-wk-Fact-410C4FD19C02A09C3952D849934E30B8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2721-wk-Fact-AE189DD5599DDAE8C2F2D8499316BA55" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2742-wk-Fact-5CC3C3BFC3BF8F54F5CAD84992F93A52" name="us-gaap:Goodwill" contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2761-wk-Fact-36D757AA2BD3951F8663D84992F67D0A" name="us-gaap:GoodwillPurchaseAccountingAdjustments" contextRef="D2019Q2Oct05-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2780-wk-Fact-FCD51E7F089449CE1E52D849931B521E" name="us-gaap:Goodwill" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2806-wk-Fact-9DADD6EE6E7FB1870007D849934E1034" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2018Q4Oct04-Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">273.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2825-wk-Fact-DFB43E02AF53FCF8CB7C4958D376A52A" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374424724e2844-wk-Fact-1519335EB80108461268D8499319DD64" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">273.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The preliminary estimated fair value of the intangible assets acquired for PaxVax's marketed products is a total of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374424724e2857-wk-Fact-AE189DD5599DDAE8C2F2D8499316BA55" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.0</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million. The Company determined the estimated fair value of the intangible assets using the income approach, which is based on the present value of future cash flows. The fair value measurements are based on significant unobservable inputs that are developed by the Company using estimates and assumptions of the respective market and market penetration of the acquired products. The Company has determined that the weighted average useful lives of the intangible assets to be </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonNumeric id="d374424724e2861-wk-Fact-682CF320E3933FDC7F6CD8499317DCEC" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" format="ixt-sec:duryear">19</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> years. The Company estimated the fair value of the Vivotif and Vaxchora intangible assets </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">14</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-A664ABEE18BF87DD2269D849935F550F-4"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">using a present value discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374424724e2868-wk-Fact-E5A2EB7440877457209FD849931ADCC4" name="ebs:PresentValueDiscountRate" contextRef="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_VivotifMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">14.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374424724e2872-wk-Fact-6294EA594EC4DFF846E2D8499319F991" name="ebs:PresentValueDiscountRate" contextRef="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_VaxchoraMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">15.0</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, respectively, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of PaxVax. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value these intangible assets. The projected cash flows from these intangible assets were based on key assumptions, including: estimates of revenues and operating profits, and risks related to the viability of and potential alternative treatments in any future target markets.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The intangible asset associated with the IPR&amp;D </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the measurement of the amounts recognized as of that date. The Company estimates the fair value based on the income approach. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company determined the fair value of the inventory using the comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete/dispose of the inventory with a profit on those costs.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company determined the fair value of the property, plant and equipment utilizing both the cost approach and the sales comparison approach. The cost approach is determined by establishing replacement cost of the asset and then subtracting any value that has been lost due to economic obsolescence, functional obsolescence, or physical deterioration. The sales comparison approach values an asset based on the market price of assets with comparable features such as design, location, size, construction, materials, use, capacity, specification, operational characteristics and other features or descriptions.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company recorded approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374424724e2891-wk-Fact-FCD51E7F089449CE1E52D849931B521E" name="us-gaap:Goodwill" contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.0</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million in goodwill related to the PaxVax acquisition, calculated as the purchase price paid in the acquisition that was in excess of the fair value of the tangible and intangible assets acquired representing the future economic benefits the Company expects to receive as a result of the acquisition. The goodwill created from the PaxVax acquisition is associated with early stage pipeline products along with potential contract manufacturing services. The majority of the goodwill generated from the PaxVax acquisition is expected to be deductible for tax purposes based upon the structure used in the acquisition.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#160;</span><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Impact of Business Acquisitions</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The operations of each of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374424724e2905-wk-Fact-499845D59A16EE98F041D849931DD995" name="ebs:NumberOfBusinessAcquisitions" contextRef="FI2019Q2" unitRef="acquisition" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> business acquisitions discussed above were included in the consolidated financial statements as of each of their respective acquisition dates. <ix:nonNumeric contextRef="FD2019Q2YTD" name="ebs:ImpactOfBusinessAcquisitionsTableTextBlock" id="TextSelection-631FF31A2D52FC9147F1D849935FB776-0-wk-Fact-D261551E39F54995C03ED849931E3807" continuedAt="TextSelection-631FF31A2D52FC9147F1D849935FB776-1" escape="true">The following table presents their revenue and earnings as reported within the consolidated financial statements.</ix:nonNumeric></span></div><ix:continuation id="TextSelection-631FF31A2D52FC9147F1D849935FB776-1"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:694px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:429px;"></td><td style="width:9px;"></td><td style="width:117px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:117px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374424724e3025-wk-Fact-5734024D724714B52A2C206C3A967AC5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374424724e3044-wk-Fact-457746BA4B9820BE2E7AD8499303B809" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">163.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374424724e3059-wk-Fact-85679CF5CF31CC53B83A206C3BF9FE72" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374424724e3078-wk-Fact-5E940714B5074EF05F70D8499304E401" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><a id="s3325C921E7E05CB6BAC299D92CDD12C6"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-4A22B99FE5E90103669FD84993609DD9-0-wk-Fact-0830CFAE9D0A5ED19944D8499333A3BC" continuedAt="TextSelection-4A22B99FE5E90103669FD84993609DD9-1" escape="true">Inventories</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-874F84A90EFB118DE0B3D84993605080-0-wk-Fact-EB0A289AD53A4EC94837D84993345D95" escape="true"><ix:continuation id="TextSelection-4A22B99FE5E90103669FD84993609DD9-1"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The components of inventory are as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420633e684-wk-Fact-E406C21AD50EECE8CAB1D8499323383B" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420633e703-wk-Fact-6180BD0A7996ECF8EF1FD8499310DFCC" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420633e723-wk-Fact-F6EE305F6E87216A5A51D8499317AC35" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">119.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420633e742-wk-Fact-2407BD2436DC1883FDC7D8499323C0F6" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">103.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420633e767-wk-Fact-0CF5E4F8FEC2E25B0535D84993032C9A" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420633e786-wk-Fact-606FF4C6B79B1374B4B2D8499311126F" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374420633e816-wk-Fact-10DA71DCD649ED36B6D3D84992F794DC" name="us-gaap:InventoryNet" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">232.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374420633e835-wk-Fact-C6A98BDF9041D79AA0CBD84993196BE5" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">205.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">15</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD4177E264DD5557F9481A049FAE08231"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-893A98B84763B6FD3419D84993605EB2-0-wk-Fact-11A6AC23A50732D43EAAD849932D5EBB" continuedAt="TextSelection-893A98B84763B6FD3419D84993605EB2-1" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-4F081C3E57117742A4BAD8499360867B-0-wk-Fact-F20DA7B3BE258FDC9EEAD849932F17E3" escape="true"><ix:continuation id="TextSelection-893A98B84763B6FD3419D84993605EB2-1"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Property, plant and equipment consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land and improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374423088e684-wk-Fact-907684047EB19971B1C6D84993244135" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374423088e703-wk-Fact-6750B927B2997FEF0691D8499324D5F8" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings, building improvements and leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374423088e723-wk-Fact-1BA43575A2E8D7F12F04D849931C8944" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">228.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374423088e742-wk-Fact-A39AAEA313BFEB28B682D849930F3195" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">216.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374423088e767-wk-Fact-7A53A1F8751AD833FF5AD8499314EF1C" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">318.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374423088e786-wk-Fact-4688B8115E95E6DC5771D84993136017" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">293.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374423088e811-wk-Fact-C30F358BD068249A02EAD8499320BE4F" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374423088e830-wk-Fact-BC5367AFDB1622C506DED84993115C84" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction-in-progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374423088e855-wk-Fact-5243E5BDEB23C9BECA6BD849932265E2" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374423088e874-wk-Fact-F07D757BD617FA53497BD8499313D736" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374423088e899-wk-Fact-3AAEF2BCCB28FFA4081FD8499312CE46" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">709.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374423088e918-wk-Fact-E9C460827CCF0EE8CB5AD8499326B371" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">681.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374423088e943-wk-Fact-22FD2875F947A67725D9D8499315D9BC" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">189.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374423088e963-wk-Fact-A0A7D8EEBE0BA48461F4D849932C2CB3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">171.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374423088e994-wk-Fact-1CEE78D1635C9E8C9F7DD8499312146B" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">520.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374423088e1013-wk-Fact-A2A3491175BAC7A69E11D84992FE01C5" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">510.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="sF9AB60683876515D9EBD3EDF089A4D00"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-12A83200390F22E2354ED84993609EC0-0-wk-Fact-48FA24CBE4C5E9AEB936D8499322C060" continuedAt="TextSelection-12A83200390F22E2354ED84993609EC0-1" escape="true"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LesseeFinanceLeasesTextBlock" id="TextSelection-3C2C0F01091C718713BD20915C12C5EF-0-wk-Fact-12E1F1468B55CCB54CBC2091A0AB0BCE" continuedAt="TextSelection-3C2C0F01091C718713BD20915C12C5EF-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="TextSelection-12A83200390F22E2354ED84993609EC0-1" continuedAt="TextSelection-12A83200390F22E2354ED84993609EC0-2"><ix:continuation id="TextSelection-3C2C0F01091C718713BD20915C12C5EF-1" continuedAt="TextSelection-3C2C0F01091C718713BD20915C12C5EF-2"><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company has operating leases for corporate offices, research and development facilities and manufacturing facilities. We determine if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately. The Company's leases have remaining lease terms of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonNumeric id="d374421974e608-wk-Fact-15824D6408ACF5B1A765D849931C1770" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:duryear">1</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> year to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonNumeric id="d374421974e612-wk-Fact-9898F224E8A0F01F6FF8D8499321B1FD" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> years, some of which include options to extend the leases for up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonNumeric id="d374421974e616-wk-Fact-F78F2679AFF909EC6B00D84993255038" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2019Q2" format="ixt-sec:duryear">5</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> years, and some of which include options to terminate the leases within </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonNumeric id="d374421974e620-wk-Fact-92BD8E70875102D1988DD8499325A1AA" name="ebs:LesseeOperatingLeaseTerminationPeriod" contextRef="FD2019Q2YTD" format="ixt-sec:duryear">1</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> year.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-1F3C2C4610D8FBD14CA1D8499360BE48-0-wk-Fact-7005115D2DE4841AF71FD84993252C47" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The components of lease expense were as follows:&#160;</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374421974e803-wk-Fact-725D552158279F5467C12F4405946F6F" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374421974e822-wk-Fact-9D6328E6012241854316D84993350133" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest on lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374421974e842-wk-Fact-5767B626DD84076326EC2F44057574F8" name="us-gaap:FinanceLeaseInterestExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374421974e861-wk-Fact-21ACE9167960BF8B39BED84993365237" name="us-gaap:FinanceLeaseInterestExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374421974e891-wk-Fact-9F678F81613521BE2AA32075E9D9C70B" name="us-gaap:LeaseCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374421974e910-wk-Fact-BA60E27E713FA54C25242075E9C0412E" name="us-gaap:LeaseCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">16</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="ebs:ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock" id="TextSelection-2196423E918770EAB0DBD8499360D4AE-0-wk-Fact-8EB49FB3A8CF0DCFFF54D84993228010" escape="true"><ix:continuation id="TextSelection-12A83200390F22E2354ED84993609EC0-2"><ix:continuation id="TextSelection-3C2C0F01091C718713BD20915C12C5EF-2"><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:48%;"></td><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;">(In millions, except lease term and discount rate)</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374421974e994-wk-Fact-93FF9A4DE8197388A9EDD84993013EAC" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374421974e1050-wk-Fact-062FB893FD2CD5E1F57ED84993051A6C" name="ebs:OperatingLeaseOtherLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374421974e1080-wk-Fact-5907FA891CD30FF38B46D84993034707" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374421974e1115-wk-Fact-F1BED82045F3E41AC9CCD84993106DB0" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating leases:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted Average Remaining Lease Term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonNumeric id="d374421974e1200-wk-Fact-6B890051845B6A73677CD849930496B4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q2" format="ixt-sec:duryear">10.3</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted Average Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374421974e1230-wk-Fact-26AB18B31392659E6B51D8499305017B" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q2" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">4.62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">%</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation></ix:nonNumeric><div><a id="sA6731171C4C15DD392D48161061609D0"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="TextSelection-A0F8A54C8AF5430EB91FD84993616E86-0-wk-Fact-47678418347EEEBE9EEDD849932E78D4" continuedAt="TextSelection-A0F8A54C8AF5430EB91FD84993616E86-1" escape="true">Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="TextSelection-A0F8A54C8AF5430EB91FD84993616E86-1"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company's intangible as</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">sets consist of products acquired via business combinations or asset acquisitions. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-E6BDE15025C3F286212ED849936127D0-0-wk-Fact-C82EA5434454CA196B13D849932397CF" continuedAt="TextSelection-E6BDE15025C3F286212ED849936127D0-1" escape="true"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-5BB02749AABD58FD378AD84993611798-0-wk-Fact-6BFFE4810FD968A76701D8499323D0C1" continuedAt="TextSelection-5BB02749AABD58FD378AD84993611798-1" escape="true">The following table summarizes the carrying amount of the Company's intangible assets and goodwill, net of accumulated amortization:</ix:nonNumeric></ix:nonNumeric></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><ix:continuation id="TextSelection-E6BDE15025C3F286212ED849936127D0-1"><ix:continuation id="TextSelection-5BB02749AABD58FD378AD84993611798-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:18%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="24" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Estimated Life (years)</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cost</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Measurement Period Adjustment</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Additions</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Gross Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amortization</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">5-22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374426739e921-wk-Fact-21F1656CB2F2F565B17AD849933C0EAA" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">818.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374426739e960-wk-Fact-37398DD2C1B87FCB227DD849933D11D3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374426739e979-wk-Fact-594F1671C30A84700399D849933E0BB9" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">828.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374426739e998-wk-Fact-96B044CD3BEA5CD564D9D849933E76F3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">86.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374426739e1019-wk-Fact-0C7C73A51E98CE241DE3D849933F6B5F" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">742.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">indefinite</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374426739e1039-wk-Fact-775AB680CDD8596A5FDED849933DF070" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374426739e1058-wk-Fact-FE92E4E2815B27C43FF0D849933EDD71" name="us-gaap:IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments" contextRef="FD2019Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374426739e1098-wk-Fact-D562AB7E7152D961D21CD849933FC030" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374426739e1137-wk-Fact-D562AB7E7152D961D21CD849933FC030" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">indefinite</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374426739e1162-wk-Fact-532AAB61E2D687450027D849933CFCFC" name="us-gaap:GoodwillGross" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">259.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374426739e1181-wk-Fact-7C04505F32C2E5F28A97D84993409574" name="us-gaap:GoodwillPurchaseAccountingAdjustments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374426739e1220-wk-Fact-AF9555A03A8E631ED89FD849933DD1D5" name="us-gaap:GoodwillGross" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">268.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374426739e1259-wk-Fact-DB909FD2CAB8A2E53C25D84992FF1DFA" name="us-gaap:Goodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">268.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation></ix:continuation><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:18%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="24" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Estimated Life (years)</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cost</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Measurement Period Adjustment</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Additions</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Gross Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5-22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374426739e1582-wk-Fact-EF2E5562D3626927B520207B09419698" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">151.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374426739e1621-wk-Fact-80C3B8CE2FC3A1E07DB9207B0C2F890B" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">667.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374426739e1640-wk-Fact-21F1656CB2F2F565B17AD849933C0EAA" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">818.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374426739e1659-wk-Fact-441BEC23B26CD009426B207B0F7080B6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374426739e1680-wk-Fact-6453C4600CA3ACC30F48207B110BD163" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">761.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">indefinite</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374426739e1700-wk-Fact-B00FCC92115D95D80E78207BE6CA3CAF" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374426739e1758-wk-Fact-775AB680CDD8596A5FDED849933DF070" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374426739e1797-wk-Fact-775AB680CDD8596A5FDED849933DF070" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">indefinite</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374426739e1822-wk-Fact-012C4B681D6DF7836508207B730DEE1C" name="us-gaap:GoodwillGross" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374426739e1860-wk-Fact-B50149B40558D008B7B0207D8C8AA6F7" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">210.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374426739e1880-wk-Fact-532AAB61E2D687450027D849933CFCFC" name="us-gaap:GoodwillGross" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">259.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374426739e1919-wk-Fact-8DEC0005C0EAFE923857D84993239E34" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">259.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company recorded amortization expense for intangible assets of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374426739e1947-wk-Fact-F2D6BB1B4B9EB2F408EFD84992FE3070" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.2</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374426739e1951-wk-Fact-D5704BA4F2023D767670D84992F932EB" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, respectively. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company recorded amortization expense for intangible assets of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374426739e1964-wk-Fact-38FAEE743CD4490EC338D849930066FB" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374426739e1968-wk-Fact-91C07E9A1D86B917DC36D84993429398" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million, respectively. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the weighted average amortization period remaining for intangible assets was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span><ix:nonNumeric id="d374426739e1976-wk-Fact-F04F3CFEF96CF746E40ED8499326499F" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="FD2019Q2YTD" format="ixt-sec:duryear">14.0</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> years. IPR&amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts.</span></div></ix:continuation><div><a id="s0AFB4D87B8B854D2BF73787595965F20"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-54F35EFC16A8F19EECB4D84993614552-0-wk-Fact-9C3E53E7311D5E71E9D3D849932C5B36" continuedAt="TextSelection-54F35EFC16A8F19EECB4D84993614552-1" escape="true">Contingent Consideration</ix:nonNumeric></span></div><ix:continuation id="TextSelection-54F35EFC16A8F19EECB4D84993614552-1" continuedAt="TextSelection-54F35EFC16A8F19EECB4D84993614552-2"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Contingent consideration liabilities associated with business combinations are fair value measurement items. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date with the exception of the milestone achievement. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market (Level 3). </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company also has contingent consideration associated with its asset acquisitions. These liabilities are not recorded as level 3 fair value measurements, but rather are accrued when the milestone has been achieved and is payable.  </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">17</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-54F35EFC16A8F19EECB4D84993614552-2"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="TextSelection-9280D05FE31334007B2BD8499361EFA2-0-wk-Fact-5A938659885F6F696CC0D849932C9977" escape="true"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The following table is a reconciliation of the beginning and ending balance of contingent considerations and is based on level 3 significant unobservable inputs, other than the raxibacumb milestone accrual, which is based on achievement of contractual milestones. </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374427024e659-wk-Fact-6A4BA0304E5F8679C1E6D849933F32B4" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Milestone achievement - asset acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374427024e674-wk-Fact-053597C207D81F51A2F5D849933EE98B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Measurement period adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374427024e694-wk-Fact-41D029A1FF713769F640D849933EDD6F" name="ebs:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374427024e714-wk-Fact-FD457FE3CF200D06D71BD84993071BB7" name="ebs:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374427024e734-wk-Fact-E036C77736D926D5B46DD8499341C0B6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;">Balance at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374427024e760-wk-Fact-1AB45EED046D40E7F418D849933E712A" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, a contingent milestone was achieved related to the Company's acquisition of raxibacumab in October 2017. The acquisition of raxibacumab was accounted for as an asset acquisition and therefore the achievement of the $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374427024e776-wk-Fact-C7CBC04D8363447FCC8BD849932C0F4F" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_RaxibacumabMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million milestone resulted in an increase to the contingent consideration liability with a corresponding increase in intangible assets.</span></div></ix:continuation><div><a id="s551f4bb23ef041fa9f9bbb359eb7bfd1"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="TextSelection-6E567451DE879754B60BD84993618334-0-wk-Fact-696256DA45386C5A51FCD849932F658D" continuedAt="TextSelection-6E567451DE879754B60BD84993618334-1" escape="true">Derivative Instruments and Hedging Activities</ix:nonNumeric></span></div><ix:continuation id="TextSelection-6E567451DE879754B60BD84993618334-1" continuedAt="TextSelection-6E567451DE879754B60BD84993618334-2"><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Risk Management Objective of Using Derivatives</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company is exposed to certain risk arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from the Company's senior secured credit agreement's payments of variable interest rate debt.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Accounting Policy for Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company's interest rate swaps qualify for hedge accounting as cash flow hedges. All derivatives are recorded on the balance sheet at fair value.&#160;Hedge accounting provides for the matching of the timing of gain or loss recognition on these interest rate swaps with the recognition of the changes in interest expense on the Company's variable rate debt. For derivatives designated as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#8217;s variable-rate debt. The cash flows from the designated interest rate swaps are classified as a component of operating cash flows, similar to interest expense.&#160;If current fair values of designated interest rate swaps&#160;re</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">mained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374430797e612-wk-Fact-6A6E9AE458921D6C2B7A0B6FCE5AB7AD" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#160;of net deferred gains from&#160;accumulated other comprehensive loss&#160;into income over the next&#160;twelve&#160;months. All outstanding cash flow hedges mature in October 2023.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="TextSelection-D1610045F8B4FD9441370AF5245E9B7C-0-wk-Fact-2EADCC84E01854D48F580AF57CED39C8" escape="true"><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk: </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:61%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Number of Instruments</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Notional</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430797e677-wk-Fact-56E619A1DED7054EA1520AFC3661C0AA" name="us-gaap:NumberOfInterestRateDerivativesHeld" contextRef="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="instrument" decimals="INF" scale="0" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430797e692-wk-Fact-C12CE4B6D12D8F2C4C350AFAF39A1A11" name="invest:DerivativeNotionalAmount" contextRef="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">350.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">18</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-6E567451DE879754B60BD84993618334-2"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="TextSelection-C1A954C929BC9C3D065E20D13DF8D374-0-wk-Fact-2B3525B4FFAF8F4DFCAD20D218386F79" escape="true"><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:11%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Asset Derivatives</span></div></td><td colspan="8" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Liability Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="2" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430797e993-wk-Fact-15C0E1D89399E6C59C070AF03634D335" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430797e1007-wk-Fact-8F1214052823F2E541730AF036248A7C" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430797e1026-wk-Fact-84EFD3E7AD4D663B5BE70AF0C88FAE20" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430797e1046-wk-Fact-D559576FB509C3BA5EBC0AF0C88AA38F" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. To comply with the provisions of ASC 820, Fair Value Measurement, we incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were concluded to not be significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="TextSelection-60D92F6E9D265FD9FF1C20D2DDF5B748-0-wk-Fact-8E22D78D491100E6C5C620D32D0720F6" continuedAt="TextSelection-60D92F6E9D265FD9FF1C20D2DDF5B748-1" escape="true">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income.</ix:nonNumeric></span></div><ix:continuation id="TextSelection-60D92F6E9D265FD9FF1C20D2DDF5B748-1"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Hedging derivatives</span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount of Gain/(Loss) Recognized in OCI on Derivative</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Location of Gain or (Loss) Reclassified from Accumulated OCI into Income </span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:middle;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430797e1241-wk-Fact-246F25FD60CF9902633B0B03DFE71274" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430797e1250-wk-Fact-79BFA566CD15EF8B64E60B03E275EAA3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" unitRef="usd" decimals="-5" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:middle;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430797e1274-wk-Fact-7A9D13DCD4551F6751000B02FBFB6536" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430797e1289-wk-Fact-25E5CC51B6D9716CC4510B02FBFF97BE" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember" unitRef="usd" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><a id="s01e0a9fb6a784d8daec0bc44afffc7ff"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-03E02AEE51C3E416F4CAF6E8EE8E3B64-0-wk-Fact-27A17E9D41333ED2F011F6E9661B51D0" continuedAt="TextSelection-03E02AEE51C3E416F4CAF6E8EE8E3B64-1" escape="true">Debt</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfDebtTableTextBlock" id="TextSelection-925FA57456F4B000E2AEF6EB4EA34672-0-wk-Fact-155A22E4A0BE8A0B6FA4F6EB959AB55B" escape="true"><ix:continuation id="TextSelection-03E02AEE51C3E416F4CAF6E8EE8E3B64-1" continuedAt="TextSelection-03E02AEE51C3E416F4CAF6E8EE8E3B64-2"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The components of debt are as follows:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior secured credit agreement - Term loan due 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374429617e682-wk-Fact-4C9707CB10EBF01153E8F6ECD889B673" name="us-gaap:LongTermDebt" contextRef="FI2019Q2_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">441.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374429617e701-wk-Fact-95B2EF867CD25D8E60D7F6ECDA3625CB" name="us-gaap:LongTermDebt" contextRef="FI2018Q4_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">447.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior secured credit agreement - Revolver loan due 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374429617e721-wk-Fact-C7C71CE8BAF2CA3C52F6F6ECD833C3D1" name="us-gaap:LongTermDebt" contextRef="FI2019Q2_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">398.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374429617e740-wk-Fact-83ADF04A0B2BAC43D849F6ECD9381C9A" name="us-gaap:LongTermDebt" contextRef="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">348.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.875% Convertible Senior Notes due 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374429617e765-wk-Fact-DE0DC91F1975582ACC62F6ECD8413600" name="us-gaap:LongTermDebt" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374429617e784-wk-Fact-DF4B006BF973FACF5B92F6ECD986C876" name="us-gaap:LongTermDebt" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374429617e809-wk-Fact-F03401CE498B2C499FFFF6ECD85CEE77" name="us-gaap:LongTermDebt" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374429617e828-wk-Fact-9D7BF4241D092693944CF6ECD9FDB49E" name="us-gaap:LongTermDebt" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374429617e853-wk-Fact-3B06B24D8397685F5C08F6ECDA17F2D7" name="us-gaap:LongTermDebt" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">853.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374429617e872-wk-Fact-791222ED800E8945B47DF6ECD8D69BED" name="us-gaap:LongTermDebt" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">808.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of long-term debt, net of debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374429617e897-wk-Fact-C06927FD4A5E3D153EA6D84992FA7654" name="us-gaap:LongTermDebtCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374429617e917-wk-Fact-720282BBC8CDC2055C5DD8499301C100" name="us-gaap:LongTermDebtCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unamortized debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374429617e943-wk-Fact-A67148F72E2BC9C306E6F6ED9E39BEBF" name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d374429617e963-wk-Fact-8C3EDE4853D78780C615F6ED9E2F9B0B" name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374429617e994-wk-Fact-5684FE71939B0564A1CAD8499314675E" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">830.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374429617e1013-wk-Fact-75E6B826C88E6B401542D849930F45CA" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">784.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">19</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-03E02AEE51C3E416F4CAF6E8EE8E3B64-2"><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Senior Secured Credit Agreement</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On September 29, 2017, the Company entered into a senior secured credit agreement (the &#8220;2017 Credit Agreement&#8221;) with </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1031-wk-Fact-850CD9B28465B4E8004BF6FF15C1314F" name="ebs:NumberOfLendingInstitutions" contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember" unitRef="number" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> lending financial institutions. On October 15, 2018, the Company entered into an Amended and Restated Credit Agreement (the "Amended Credit Agreement") with multiple lending institutions, which modified the 2017 Credit Agreement. The Amended Credit Agreement (i) increased the revolving credit facility (the "Revolving Credit Facility") from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>$<ix:nonFraction id="d374429617e1035-wk-Fact-4588DA14684479652BA0F7029A54D38B" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="I2018Q4Oct15_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>$<ix:nonFraction id="d374429617e1039-wk-Fact-307D7F235FFA16893593F7031BE1B27D" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="FI2019Q2_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, (ii) extended the maturity of the Revolving Credit Facility from September 29, 2022 to October 13, 2023, (iii) provided for a term loan in the original principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>$<ix:nonFraction id="d374429617e1043-wk-Fact-A399127CB531A8CA0419F7051F84FB89" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="I2018Q4Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">450</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> (the "Term Loan Facility," and together with the Revolving Credit Facility, the "Senior Secured Credit Facilities"). The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") if requirements relating to net leverage ratio will be maintained on a pro forma basis.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Borrowings under the Revolving Credit Facility and the Term Loan Facility will bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1052-wk-Fact-6186A58A4120DEBD92FAF70AE5AA8578" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.25</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1056-wk-Fact-E0CD5CF0F05A3AD627E8F70AE5DEE0E1" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.00</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1060-wk-Fact-61770D59E1AAC5580F5BF70D5BCFB1EF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_FederalFundsEffectiveSwapRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, and a eurocurrency rate for an interest period of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">one month</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> plus </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1068-wk-Fact-F5B741B6D2844B51AACDF7103150074A" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">) plus a margin ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1073-wk-Fact-377699A9BCC560CCABB2F710B9543E42" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1077-wk-Fact-1B1B0B517F042D4483FBF710B6F12A2C" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.00</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, depending on the Company's consolidated net leverage ratio. The Company is required to make quarterly payments under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1081-wk-Fact-F6A16487A1A8AB2C0AE8F711ED8C20A0" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1085-wk-Fact-A944EFE0B0F761DF2066F711ED28B5B5" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.30</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> per annum, depending on the Company's consolidated net leverage ratio, in respect of the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments based on an annual percentage equal to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1089-wk-Fact-EAF605F3D011F0F00CD7F7159844002C" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1093-wk-Fact-7B6C18E87F2DAF3D48C2F716B266E549" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1098-wk-Fact-B2E323244EF0A7CAD227F717E1429265" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature (unless earlier terminated) on October 13, 2023.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Amended Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>$<ix:nonFraction id="d374429617e1107-wk-Fact-87814807083CF30C0D49F71DC05EB669" name="ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> during the term of the Amended Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Amended Credit Agreement contains financial covenants, which were amended in June 2019. The financial covenants require the quarterly presentation of a minimum consolidated 12 month rolling debt service coverage ratio of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1117-wk-Fact-AB1E939355DB85A67C1320EEA097E80C" name="ebs:DebtInstrumentCovenantDebtServiceCoverageRatio" contextRef="D2019Q2Jun01-Jun30" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">2.50</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to 1.00, and an amended maximum consolidated net leverage ratio of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1121-wk-Fact-AA9A929BCC56550E187F20F086CF9AEA" name="ebs:DebtInstrumentCovenantNetLeverageRatioOne" contextRef="D2019Q2Jun01-Jun30" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">4.95</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to 1.00 for the quarter ended June 30, 2019, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1125-wk-Fact-819E252A46F6D32380EB20F0DF8E435F" name="ebs:DebtInstrumentCovenantNetLeverageRatioTwo" contextRef="D2019Q2Jun01-Jun30" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">4.75</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to 1.00 for the quarter ending September 30, 2019, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1129-wk-Fact-FB70CC9B4246DA84FE9B20F12F4B9014" name="ebs:DebtInstrumentCovenantNetLeverageRatioThree" contextRef="D2019Q2Jun01-Jun30" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">3.75</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to 1.00 for the quarterly filing periods from October 1, 2019 through September 29, 2020 and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1133-wk-Fact-E7A5B600BDE207B4787D20F1ACC5272C" name="ebs:DebtInstrumentCovenantNetLeverageRatioFour" contextRef="D2019Q2Jun01-Jun30" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">3.50</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to 1.0 thereafter, which may be adjusted to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1138-wk-Fact-DB63FBCA19C68AA85EB620F4B795FD44" name="ebs:DebtInstrumentCovenantNetLeverageRatioAdjusted" contextRef="D2019Q2Jun01-Jun30" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">4.00</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to 1.00 for a four quarter period in connection with a material permitted acquisition. The Amended Credit Agreement also contains affirmative and negative covenants, which were also amended in June 2019 to limit the amount of restricted payments as defined in the Amended Credit Agreement to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>$<ix:nonFraction id="d374429617e1142-wk-Fact-B4C1AE05A471ACA5E18A21053C2E963E" name="ebs:DebtInstrumentRestrictedPaymentsLimitAmount" contextRef="D2019Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> until the filing of the Company's December 31, 2019 Form 10-K. Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments and enter into certain merger or consolidation transactions. As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">2.875% Convertible Senior Notes due 2021</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On January 29, 2014, the Company issued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1156-wk-Fact-22849E165EB0E18EC19CF71F65C5F910" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.875</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> convertible senior notes due 2021 (the "Notes"). The Notes bear interest at a rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374429617e1160-wk-Fact-22849E165EB0E18EC19CF71F65C5F910" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.875</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> per year, payable semi-annually in arrears on January 15 and July 15 of each year. The Notes mature on January 15, 2021.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">20</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8F65FCA0AC8B547A82C3A39CF8730EEB"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-6CF040923B626EE508A5D84993622CB9-0-wk-Fact-565B3F8BF768B6EC8468D849932E390C" continuedAt="TextSelection-6CF040923B626EE508A5D84993622CB9-1" escape="true">Revenue recognition</ix:nonNumeric></span></div><ix:continuation id="TextSelection-6CF040923B626EE508A5D84993622CB9-1" continuedAt="TextSelection-6CF040923B626EE508A5D84993622CB9-2"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company operates as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374430789e601-wk-Fact-5A9CEE1F5ED7B6AAB186D8499312BF92" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q2YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> operating segment. Therefore, results of its operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="TextSelection-FDA72BCD65523C0AE303D84993616615-0-wk-Fact-115081BD78ED76A476E0D8499308A4DE" continuedAt="TextSelection-FDA72BCD65523C0AE303D84993616615-1" escape="true">The Company's revenues disaggregated by the major sources were as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-FDA72BCD65523C0AE303D84993616615-1"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e915-wk-Fact-2C1B64A05A1B1495D4CAD8499342F2FE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">94.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e934-wk-Fact-16DFAD2B67B7BE3D352FD84993074C17" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e954-wk-Fact-88076C57679DEBBE211ED8499305E222" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">183.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e973-wk-Fact-BA723188CEA5132C171FD8499313B83D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">169.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e992-wk-Fact-1DEBA0CA65229BDCF11ED849933DDFFD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1012-wk-Fact-03C6DD3FE93475379D53D84992F6A572" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">180.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1032-wk-Fact-7215B9863C7B83BC7119D8499318242A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1051-wk-Fact-C730182948DA9595F9DCD84992FE730A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1070-wk-Fact-6CD0E930F110BBC79097D8499344AE28" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1090-wk-Fact-8C2110899BA54F513BA9D8499340C1CE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1109-wk-Fact-7AA32AB27DB747611A88D8499309A6FD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1129-wk-Fact-5F10A1FE3C8C63F7E0FAD849933D6AEA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1154-wk-Fact-41524DBEDCBC420FBD96D84993422E9A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1173-wk-Fact-69A2753E0905296BACF9D8499312C53D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1192-wk-Fact-6CAE36F4026D53DEBBECD8499307243D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1212-wk-Fact-D9E237DD4240C40D66FFD849931134CC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1231-wk-Fact-6321B5B006F414E6C4EFD8499340E28C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1251-wk-Fact-D368A395B32B7D3E19B2D8499342140F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1281-wk-Fact-7E596EE54239BF64C71DD849931455DB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1300-wk-Fact-9E1E272C8731FB73DAF9D849930F6685" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">110.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1320-wk-Fact-7AE92434260DD4FB2CF8D849934D3C6E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">243.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1339-wk-Fact-7E0B17BFA057007FFD02D84993431FF9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">185.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1358-wk-Fact-F081B65075B50FE98893D84993414816" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1378-wk-Fact-EA0211D77CFC99544611D8499308E5C8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1691-wk-Fact-66074840E0A5CAAA19EAD8499306E523" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">167.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1710-wk-Fact-7051ECE89437C0705258D8499330AF4F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">168.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1730-wk-Fact-D3E43AE69523DCD4EE9BD849933CA0FF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">336.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1749-wk-Fact-91D6A5A24AB782C05AB2D8499331DC0B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">235.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1768-wk-Fact-9107ACC563DEA513F8F4D84993059224" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1788-wk-Fact-C239168A4E13BC91AFC1D84993402A50" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">255.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1808-wk-Fact-2C218482470FDB2CEF93D84993332EA3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1827-wk-Fact-E797128F678D70B2632CD849933197AC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1846-wk-Fact-25CD4F38EEECA1E915A0D8499300583A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1866-wk-Fact-DF6DFD06A4FBA9C2C4C7D849932EEA9C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1885-wk-Fact-80BA061FE0B93FEBB555D84993268C29" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1905-wk-Fact-F4AEB1569AD0C8F57AC8D84993046424" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1930-wk-Fact-6BDF87279E2D9F64969CD849932EC8EF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1949-wk-Fact-63F4319ACA5896D3FEC2D8499330AF35" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e1968-wk-Fact-8323D54F6C251661152ED849933B4536" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e1988-wk-Fact-9314FCCE18C5F07B5840D8499305AA15" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e2007-wk-Fact-AE52F28085DFEBABB29DD8499331AD04" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e2027-wk-Fact-159F13845B496BD4A6AAD849934CA9C8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e2057-wk-Fact-AB0B9EB138AC191583C9D849932BF5A1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">226.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e2076-wk-Fact-CD82C827E6E01552AAFFD849933099DF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">207.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e2096-wk-Fact-8AF29B1E3DD6C78B7907D849934FCD81" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">433.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e2115-wk-Fact-4168A530F427F8CD8543D8499330602C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">266.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e2134-wk-Fact-AF339F8CCD6820A3A553D849932D352F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">72.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e2154-wk-Fact-75FE50318A68C4409098D849934304DC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">338.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Contract liabilities </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">When performance obligations are not transferred to a customer at the end of a reporting period, the amount allocated to those performance obligations is reflected as deferred revenue on the consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="TextSelection-8DD02916948ACF01FF2DD8499361CFCD-0-wk-Fact-611C491FEDDCF9D9B80ED849933C076D" continuedAt="TextSelection-8DD02916948ACF01FF2DD8499361CFCD-1" escape="true">The following table presents the rollforward of deferred revenue contract liability balances: </ix:nonNumeric></span></div><ix:continuation id="TextSelection-8DD02916948ACF01FF2DD8499361CFCD-1"><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"><span><ix:nonFraction id="d374430789e2229-wk-Fact-2B1F26CC045FE0825735D8499331A261" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">73.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferral of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e2249-wk-Fact-A7C611749CAC4C976C50D84993314FF5" name="ebs:ContractWithCustomerLiabilityAdditions" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374430789e2274-wk-Fact-16DE932FF380E82AE1EFD8499332D24A" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"><span><ix:nonFraction id="d374430789e2305-wk-Fact-B7D7022A4D3BFD478C07D84993324384" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">89.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Transaction price allocated to remaining performance obligations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, the Company had expected future revenues associated with performance obligations that have not been satisfied of approximately $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374430789e2326-wk-Fact-3C062667E1FD9918BA95D8499319D933" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">533.2</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> million. The Company expects to recognize a majority of these revenues within the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonNumeric id="d374430789e2330-wk-Fact-6B5A843D983E1E609F7BD849931211B1" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="FI2019Q2" format="ixt-sec:durmonth">24</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> months, with the remainder recognized thereafter. However, the amount and timing of revenue recognition for unsatisfied performance obligations can materially change due to timing of funding appropriations from the USG and the overall success of the Company's development activities associated with its PHT product candidates that are then receiving development funding support from the USG under development contracts. In addition, the amount of future revenues associated with unsatisfied performance obligations excludes the value associated with unexercised option periods in the Company's contracts. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Contract assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company considers unbilled accounts receivables and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment, as contract assets. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, the Company had contract assets associated with deferred costs of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374430789e2350-wk-Fact-F47F15BF81F89467CFF7D849932D3680" name="us-gaap:DeferredCostsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.5</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> million and $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374430789e2354-wk-Fact-4B9A37AA1E032D97B611D849932FD486" name="us-gaap:DeferredCostsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> million, respectively, which is reflected as a component of prepaid expenses and other current assets on the Company's consolidated balance sheets. </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">21</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-6CF040923B626EE508A5D84993622CB9-2"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Accounts receivable</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"> </span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="ebs:ScheduleofAccountsReceivableNetTableTextBlock" id="TextSelection-26636B8665F7A186EE72D84993621F07-0-wk-Fact-BF05E96D1327B00AE79AD8499317C93D" escape="true"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Accounts receivable including unbilled accounts receivable contract assets consist of the following: </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Billed, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e2450-wk-Fact-C3063E7AA45E0C8C8133D84993388312" name="us-gaap:BilledContractReceivables" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">179.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e2468-wk-Fact-0ADF81F1BD7895703EB2D8499339BD23" name="us-gaap:BilledContractReceivables" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">234.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unbilled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e2488-wk-Fact-281DBDD5CB140063D293D8499338359E" name="us-gaap:UnbilledContractsReceivable" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e2506-wk-Fact-51C9FBFC507A82E56057D849933876EB" name="us-gaap:UnbilledContractsReceivable" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374430789e2536-wk-Fact-A88953A1A1C03C0062A4D84992F80FB1" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">218.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374430789e2554-wk-Fact-5624509D06373D0CA867D84992FD89D0" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">262.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, allowances for doubtful accounts were de minimis.</span></div></ix:continuation><div><a id="s7F938011D81155B38105C9F86B6F8E4B"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-C1196BB4C415AEC55591D8499362C352-0-wk-Fact-8D909E68E43CFAB9A737D84993389CA4" continuedAt="TextSelection-C1196BB4C415AEC55591D8499362C352-1" escape="true">Income taxes </ix:nonNumeric></span></div><ix:continuation id="TextSelection-C1196BB4C415AEC55591D8499362C352-1"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The estimated effective annual tax rate for the Company, which excludes discrete adjustments, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374430949e601-wk-Fact-9C9164CB9FFAF7237EBAD8499339C9B1" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">27</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374430949e605-wk-Fact-8494FDDFA30C646A1A58D849933812AF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2018Q2YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, respectively. The increase in the estimated effective annual tax rate is primarily due to the impact of foreign and state taxes. For each of the six month periods ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company recorded a discrete tax benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374430949e630-wk-Fact-C350A08FE7588070EED7D8499339EB08" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, primarily due to activity associated with equity awards. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three months ended June 30, 2019</span><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company recorded a discrete tax benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374430949e645-wk-Fact-52900CEA8135C329A029211C88B12EBD" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$<ix:nonFraction id="d374430949e649-wk-Fact-C4E07D4E53F69EE2297E211CBF86DEA3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, respectively, also primarily due to activity associated with equity awards</span><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">. </span></div></ix:continuation><div><a id="sA69B599BD5235C4DB3972A53F9016A7A"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">13.&#160;&#160;&#160;&#160;(Loss) e<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-41D9866491C4D8905542D849936289F4-0-wk-Fact-7E56E3EA6364400FE179D849932F8901" continuedAt="TextSelection-41D9866491C4D8905542D849936289F4-1" escape="true">arnings per share</ix:nonNumeric></span></div><ix:continuation id="TextSelection-41D9866491C4D8905542D849936289F4-1"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-246A0B0492C997A6F682D849936294A3-0-wk-Fact-5030E8CE606F4406F752D84993309151" escape="true"><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The following table presents the calculation of basic and diluted net (loss) income per share:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Numerator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374432199e906-wk-Fact-3DEE1DB2F7CE5FC56F910AD63787861D" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374432199e926-wk-Fact-BD6EEF1FC891BC717D7BF73A591B134F" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374432199e946-wk-Fact-D502B06148AFF8C3996BF73A6CD06CA0" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">35.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374432199e966-wk-Fact-41759653833EDF33A8DAF6DE20D25EEB" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of shares&#8212;basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374432199e1160-wk-Fact-249E34FBEEA91948C2A2D8499337C607" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="0" scale="6" format="ixt:numdotdecimal">51.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374432199e1179-wk-Fact-ED841A50DECF9836B4ABD84993316548" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q2QTD" unitRef="shares" decimals="0" scale="6" format="ixt:numdotdecimal">49.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374432199e1198-wk-Fact-856CB77C93E0A1473181F73A6E773568" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2YTD" unitRef="shares" decimals="0" scale="6" format="ixt:numdotdecimal">51.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374432199e1218-wk-Fact-CD8CBCC1EE178E6E3AA3F6DE20FF501F" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q2YTD" unitRef="shares" decimals="0" scale="6" format="ixt:numdotdecimal">49.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive securities&#8212;equity awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374432199e1243-wk-Fact-7F5E27597B72E3BC1B4CD8499336E640" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2QTD" unitRef="shares" decimals="0" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374432199e1262-wk-Fact-036C603FAE0BC4B44F7AD8499334EE18" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q2QTD" unitRef="shares" decimals="0" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374432199e1281-wk-Fact-AE843246D23137C0A257F73A6F560BFF" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2YTD" unitRef="shares" decimals="0" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374432199e1301-wk-Fact-648B67B027B0AF90AD41F6DE20C61945" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q2YTD" unitRef="shares" decimals="0" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of shares&#8212;diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374432199e1326-wk-Fact-DD6492E03A56A2656BB7D84993341077" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="0" scale="6" format="ixt:numdotdecimal">51.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374432199e1345-wk-Fact-6D20B9CA5221D3C5A871D8499334AC41" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q2QTD" unitRef="shares" decimals="0" scale="6" format="ixt:numdotdecimal">51.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374432199e1364-wk-Fact-04A5DC09FE931F6D409AF73A703168FA" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2YTD" unitRef="shares" decimals="0" scale="6" format="ixt:numdotdecimal">51.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374432199e1384-wk-Fact-9A3CC8B61E79A1F29CB3F6DE20FCD225" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q2YTD" unitRef="shares" decimals="0" scale="6" format="ixt:numdotdecimal">51.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) earnings per share - basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374432199e1501-wk-Fact-7090664CCD3C5A1ED984D8499303C361" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374432199e1521-wk-Fact-D0A64B8EAE0004E47B12D8499303D192" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374432199e1541-wk-Fact-942BAE68901FFA254237D84993449FB1" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374432199e1561-wk-Fact-4C84A2D71E9B4E703742D849933F78FA" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) earnings per share - diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374432199e1587-wk-Fact-35C4160347E4E5189413D84992FC2D0C" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374432199e1607-wk-Fact-9C4E901483C9A5C87F06D84993017C7A" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374432199e1627-wk-Fact-5FE71E088EBD1B785B06D849933F0F9D" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374432199e1647-wk-Fact-EE1327C309A8868B9739D849930225C0" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">For the three and six months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, basic earnings per share is computed by dividing net gain/(loss) by the weighted average number of shares of common stock outstanding during the period.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">For the three and six months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, diluted earnings per share is computed using the treasury method by dividing net loss by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. No adjustment for the potential dilutive effect of dilutive securities is reported as the effect would have been anti-dilutive for the three and six months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> due to the Company's net loss. The s</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">hare-based awards that were excluded from the calculation of diluted loss per share, because they were anti-dilutive, were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span><ix:nonFraction id="d374432199e1684-wk-Fact-D107D657392AAB4531C52086143635B6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> for the three and six months ended June 30, 2019.</span></div></ix:continuation><div><a id="s282DD07B4A925A0B91134946660CA0A5"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-056B27D598271EE74B94D8499362DF67-0-wk-Fact-63DB5029280DFFD6A4F6D849933AA46C" continuedAt="TextSelection-056B27D598271EE74B94D8499362DF67-1" escape="true">Share-based compensation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-056B27D598271EE74B94D8499362DF67-1"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company granted stock options to purchase </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374432743e605-wk-Fact-C1066C0406258632725BD849933AE0B2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> shares of common stock and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374432743e609-wk-Fact-E5979AD010C93E778B42D84993391A81" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> restricted stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. The grants vest over </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> equal annual installments beginning on the day prior to the anniversary of the grant date.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">22</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2B5911BA524F50C0A2556D8F94CE6939"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="TextSelection-58F5A70BB7DF519062B9D84993624CD9-0-wk-Fact-32D14169EAC6A6995C6AD8499334E6A6" continuedAt="TextSelection-58F5A70BB7DF519062B9D84993624CD9-1" escape="true">Defined benefit plan</ix:nonNumeric></span></div><ix:continuation id="TextSelection-58F5A70BB7DF519062B9D84993624CD9-1"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company sponsors a defined benefit pension plan covering eligible employees in Switzerland (the Swiss Plan). Under the Swiss Plan, the Company and certain of its employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. The Swiss Plan assets are comprised of an insurance contract that has a fair value consistent with its contract value based on the practicability exception using level 3 inputs. The entire liability is listed as non-current, because plan assets are greater than the expected benefit payments over the next year. The Company recognizes pension expense as a component of selling, general and administrative expense.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The measurement date used for the Swiss Plan is December 31, annually. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="TextSelection-C7256C9979733087C0ACD8499362BD63-0-wk-Fact-365B776B1D64BB8201FCD84993357958" continuedAt="TextSelection-C7256C9979733087C0ACD8499362BD63-1" escape="true">The expense components of the Swiss Plan consisted of the following:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-C7256C9979733087C0ACD8499362BD63-1"><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374432503e688-wk-Fact-5C13FB1D0B218C088DE0D8499332179F" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374432503e707-wk-Fact-7841B8C095DF40C72D1DD84993345F20" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected return on plan assets, net of expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374432503e727-wk-Fact-D8EC74E71B6160D1A02AD84993379982" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(<ix:nonFraction id="d374432503e747-wk-Fact-697F26574246A0760695D8499337AB9C" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;Total pension expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374432503e778-wk-Fact-D26D1A0F3FEEC0E8AAB0D8499339222B" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374432503e797-wk-Fact-48B9097A72DF98D10251D8499333CB0A" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><a id="sE434E5B412B05EDBA1B11DC6A44B233C"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">16. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="TextSelection-654716BE39FEC6FE3191D8499362B50D-0-wk-Fact-3EA8DFC573AB6E16E208D8499336F7DE" continuedAt="TextSelection-654716BE39FEC6FE3191D8499362B50D-1" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="TextSelection-654716BE39FEC6FE3191D8499362B50D-1" continuedAt="TextSelection-654716BE39FEC6FE3191D8499362B50D-2"><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Perrigo 4mg</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On September 14, 2018, Adapt Pharma Inc., Adapt Pharma Operations Limited and Adapt Pharma Ltd. (collectively, Adapt Pharma), and Opiant Pharmaceuticals, Inc. (Opiant), received notice from Perrigo UK FINCO Limited Partnership (Perrigo) that Perrigo had filed an Abbreviated New Drug Application (ANDA) with the FDA, seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 4mg/spray before the expiration of U.S. Patent Nos. 9,211,253 (the &#8216;253 Patent), 9,468,747 (the &#8216;747 Patent), 9,561,177 (the &#8216;177 Patent), 9,629,965 (the &#8216;965 Patent), and 9,775,838 (the &#8216;838 Patent). On or about October 25, 2018, Perrigo sent a subsequent notice letter relating to U.S. Patent No. 10,085,937 (the &#8216;937 Patent). Perrigo&#8217;s notice letters assert that its generic product will not infringe any valid and enforceable claim of these patents. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On October 25, 2018, Emergent BioSolutions&#8217; Adapt Pharma subsidiaries and Opiant (collectively, Plaintiffs), filed a complaint for patent infringement of the &#8216;253, &#8216;747, &#8216;177, &#8216;965, and the &#8216;838 Patents against Perrigo in the United States District Court for the District of New Jersey arising from Perrigo&#8217;s ANDA filing with the FDA. Plaintiffs filed a second complaint against Perrigo on December 7, 2018, for the infringement of the &#8216;937 Patent. As a result of timely filing the first lawsuit in accordance with the Hatch-Waxman Act, a 30-month stay of approval will be imposed by the FDA on Perrigo&#8217;s ANDA, which is expected to remain in effect until March 2021 absent an earlier judgment, unfavorable to the Plaintiffs, by the Court. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Teva 2mg</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On or about February 27, 2018, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva Pharmaceuticals Industries Ltd. and Teva Pharmaceuticals USA, Inc. (collectively Teva), that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 2 mg/spray before the expiration of U.S. Patent No. 9,480,644 (the &#8216;644 Patent), and U.S. Patent No. 9,707,226 (the '226 Patent). Teva's notice letter asserts that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '644 Patent or the '226 Patent, or that the '644 Patent and '226 Patent are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Teva 4mg</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On or about September 13, 2016, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 4 mg/spray before the expiration of the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received additional notices from Teva relating to the '747, the '177, the '965, the '838, and the &#8216;937 Patents. Teva's notice letters assert that the commercial manufacture, use or sale of </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">23</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, in millions, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-654716BE39FEC6FE3191D8499362B50D-2" continuedAt="TextSelection-654716BE39FEC6FE3191D8499362B50D-3"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">its generic drug product described in its ANDA will not infringe the '253, the '747, the '177, the '965, the '838, or the &#8216;937 Patent, or that the '253, the '747, the '177, the '965, the '838, and the &#8216;937 Patents are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant also filed complaints for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '747, the '177, the '965, and the '838 Patents. All five proceedings have been consolidated. As of the date of this filing, Adapt Pharma Inc., Adapt Pharma Operations Limited, and Opiant, have not filed a complaint related to the &#8216;937 Patent. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In the complaints described in the paragraphs above, the Plaintiffs seek, among other relief, orders that the effective date of FDA approvals of the Teva ANDA products and the Perrigo ANDA product be a date not earlier than the expiration of the patents listed for each product, equitable relief enjoining Teva and Perrigo from making, using, offering to sell, selling, or importing the products that are the subject of Teva and Perrigo&#8217;s respective ANDAs, until after the expiration of the patents listed for each product, and monetary relief or other relief as deemed just and proper by the court.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Shareholder Class Action Lawsuit filed July 19, 2016</span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><ix:continuation id="TextSelection-654716BE39FEC6FE3191D8499362B50D-3" continuedAt="TextSelection-654716BE39FEC6FE3191D8499362B50D-4"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">On July 19, 2016, Plaintiff William Sponn (Sponn), filed a putative class action complaint in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#8217;s common stock between January 11, 2016 and June 21, 2016, inclusive (the Class Period), seeking to pursue remedies under the Exchange Act against the Company and certain of its senior officers and directors (collectively, the Defendants). The complaint alleged, among other things, that the Defendants made materially false and misleading statements about the government&#8217;s demand for BioThrax and expectations that the Company&#8217;s five-year exclusive procurement contract with </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the U.S. Department of Health and Human Services (HHS)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> would be renewed, and omitted certain material facts. Sponn sought unspecified damages, including legal costs. On October 25, 2016, the court added City of Cape Coral Municipal Firefighters&#8217; Retirement Plan and City of Sunrise Police Officers&#8217; Retirement Plan as plaintiffs and appointed them Lead Plaintiffs and Robbins Geller Rudman&#160;&amp; Dowd LLP as Lead Counsel. On December 27, 2016, the plaintiffs filed an amended complaint that cited the same class period, named the same defendants and made similar allegations to the original complaint. The Defendants filed a Motion to Dismiss on February 27, 2017. The plaintiffs filed an opposition brief on April 28, 2017. The Defendants&#8217; Motion to Dismiss was heard and denied on July 6, 2017. The Defendants filed an answer on July 28, 2017. The parties then engaged in the discovery process. The plaintiffs filed an amended motion for class certification and appointment of Lead Plaintiffs, Sponn, and Geoffrey L. Flagstad (Flagstad) as Class Representatives on December 20, 2017. A hearing on that motion was heard on May 2, 2018. On June 8, 2018 the Court granted class certification with a shortened class period, from May 5, 2016 to June 21, 2016. In that same order, the court appointed Flagstad as Class Representative and Robbins Geller Rudman&#160;&amp; Dowd LLP as Class Counsel. The Defendants have denied, and continue to deny, any and all allegations of fault, liability, wrongdoing, or damages. However, recognizing the risk, time, and expense of litigating any case to trial, on August 27, 2018, the Defendants reached an agreement in principle with plaintiffs to settle all of the related claims of any individual plaintiff that purchased or acquired Company stock from January 11, 2016 to June 21, 2016, for $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span><ix:nonFraction id="d374432674e635-wk-Fact-D7D5C808851FF3E9970FD84993366B6F" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="FD2019Q2YTD_srt_LitigationCaseAxis_ebs_ShareholderClassActionLawsuitMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#160;million, an amount that was paid by the Company&#8217;s insurance carrier. The settlement required no payment by any of the Defendants. The Defendants continue to deny any and all liability. The parties executed the settlement agreement on October 16, 2018 and filed the agreement with the court on October 17, 2018. The court granted preliminary approval of the settlement on October 18, 2018. At the time of the approval of the settlement on January 22, 2019, there were no objections to the settlement, but there were two shareholders who had submitted opt-outs so that they could be excluded from the settlement. On January 25, 2019, the court issued an order and final judgment approving the settlement. The time to file a notice of appeal has passed.</span><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;"> </span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><ix:continuation id="TextSelection-654716BE39FEC6FE3191D8499362B50D-4">Defendants continue to believe that the allegations in the complaint are without merit.</ix:continuation> </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><a id="sDD599349D77B5809946E26C2EA94EAD2"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="TextSelection-CCCA959578AFA7A326F3D84993633F05-0-wk-Fact-EAF1C81DEBA93FD99A56D84993114E6D" continuedAt="TextSelection-CCCA959578AFA7A326F3D84993633F05-1" escape="true">Supplemental Information</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="TextSelection-4DED785670F00BF1BD45D8499363B19A-0-wk-Fact-AD059E90F85E0C58ED28D8499315F27B" escape="true"><ix:continuation id="TextSelection-CCCA959578AFA7A326F3D84993633F05-1"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The following table provides a reconciliation of cash, cash equivalents and restricted cash:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374433036e684-wk-Fact-6CA7FDAA9259FA7C68D2D8499320BDDE" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">177.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374433036e703-wk-Fact-5D4E7B3352A75B0F2A05D84992FD64FA" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374433036e723-wk-Fact-D13020F931652E7731E5D849933A39E2" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374433036e742-wk-Fact-DAC97C22E0D2D2261AB8D849933A390F" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span><ix:nonFraction id="d374433036e772-wk-Fact-9A111BE18CEE889F3286D84993178D44" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">177.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d374433036e791-wk-Fact-8DD36C3DCC90E3398706D84993149DCA" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">24</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0AE4DA2563DC5E1BAD756D538CD84242"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and accompanying notes and other financial information included elsewhere in this quarterly report on Form 10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2018. Some of the information contained in this discussion and analysis or set forth elsewhere in this quarterly report on Form 10-Q, includes information with respect to our plans and strategy for our business and financing, as well as forward-looking statements that involve risks and uncertainties. You should carefully review the "Special Note Regarding Forward-Looking Statements" and "Risk Factors" sections of this quarterly report on Form 10-Q for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div><a id="s9C8ED7155D2951BA996B67F02E4DC033"></a></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">We are a global life sciences company focused on providing to civilian and military populations a portfolio of innovative preparedness and response products and solutions that address accidental, deliberate and naturally occurring </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">PHTs</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">We are focused on the following four distinct PHT categories: CBRNE; EID; travelers&#8217; diseases; and opioids. We have a product portfolio of eleven products (vaccines, antibody therapeutics, and drug-device combination products) that generate a majority of our revenue. We also have a development pipeline consisting of a diversified mix of both pre-clinical and clinical stage product candidates (vaccines, antibody therapeutics, and drug-device combination products). Finally, we have a fully-integrated portfolio of contract development and manufacturing services. We continue to pursue acquiring and developing products and solutions that provide an opportunity to serve both government and commercial (non-government) customers.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Our product portfolio includes:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-style:normal;text-decoration:none;">Vaccines and Anti-Infectives </span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">BioThrax&#174; (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">ACAM2000&#174; (Smallpox (Vaccinia) Vaccine, Live), the only smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Vivotif&#174; (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Vaxchora&#174; (Cholera Vaccine, Live, Oral), the only FDA-licensed vaccine for the prevention of cholera.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-style:normal;text-decoration:none;">Devices</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">NARCAN&#174; (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">RSDL&#174; (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Trobigard</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#174;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> (atropine sulfate, obidoxime chloride), an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride, as a nerve agent countermeasure. This product is not currently approved or cleared by the FDA or any similar regulatory body, and is only distributed to authorized government buyers for use outside the United States. This product is not dist</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">ributed in the United States.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-style:normal;text-decoration:none;">Antibody Therapeutics</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">raxibacumab (Anthrax Monoclonal), the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Anthrasil&#174; (Anthrax Immune Globulin Intravenous (Human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">BAT&#174; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antibody therapeutic licensed by the FDA and Health Canada for the treatment of botulism; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">VIGIV (Vaccinia Immune Globulin Intravenous (Human)), the only polyclonal antibody therapeutic licensed by the FDA and Health </span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">25</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:justify;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Canada to address certain complications from smallpox vaccination.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Highlights and Business Accomplishments for 2019</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">On June 3, 2019, we announced a contract award by the&#160;Office of the Assistant Secretary for Preparedness and Response&#160;(ASPR) in the&#160;U.S. Department of Health and Human Services&#160;(HHS) valued at approximately&#160;$535 million&#160;over 10 years for the continued supply of Vaccinia Immune Globulin Intravenous (VIGIV) into the U.S. Strategic National Stockpile (SNS) in support of smallpox preparedness.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">On May 15, 2019, we announced that BARDA informed the company that it will begin procuring AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) for delivery into the Strategic National Stockpile (SNS). Subject to the fulfillment of certain contractual obligations, the company plans to initiate deliveries of AV7909 in the second half of 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">On April 16, 2019, we announced results from an interim analysis of our Phase 2 clinical study evaluating the safety and immunogenicity of the Company&#8217;s chikungunya virus virus-like particle vaccine candidate across a series of dosing regimens. The interim analysis has shown that with a single dose administered, up to 98% of study participants produced a neutralizing antibody response against the chikungunya virus by day 7. Further, the immune response was shown to be persistent through the six-month visit, following the one-dose regimen.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">On March 19, 2019, we announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) following a two-dose schedule administered intramuscularly in healthy adults. AV7909 is being developed for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">On February 28, 2019, we announced that we have signed an indefinite-delivery, indefinite-quantity contract with the U.S. Department of State to establish a long-term, reliable, and stable supply chain for medical countermeasures that address the treatment prosed by chemical warfare agents. The contract is comprised of a five-year base period of performance along with five one-year option periods with a total contract value of a minimum of approximately $7 million to a maximum of $100 million over the contract&#8217;s period of </span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:48px;padding-bottom:5px;padding-top:0px;text-align:justify;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">performance. We will be supplying two of our current medical countermeasures addressing chemical threats; Trobigard&#174; auto-injector and RSDL&#174;kit.</span></div><div><a id="s6AFB948BB9D655C4A4BF2A22EEF1D7D2"></a></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-weight:bold;">Financial Operations Overview</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-style:normal;text-decoration:none;">Revenues</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">We generate revenues from the sale of our eleven marketed products, the performance of contract development and manufacturing services, and our performance of research and development services under contracts and grants that we receive from the USG and others. The USG is the largest purchaser of our CBRNE products and primarily purchases our products for the U.S. Strategic National Stockpile (SNS), a national repository of medical countermeasures including critical antibiotics, vaccines, chemical antidotes, antitoxins, and other critical medical supplies. The USG primarily purchases our products under long-term firm fixed price procurement contracts. The majority of our historical product sales were derived from BioThrax purchases by the USG. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Our opioid overdose treatment, NARCAN&#174; Nasal Spray, is sold commercially through physician-directed or standing order prescriptions at retail pharmacies, as well as to state health departments, local law enforcement agencies, community-based organizations, substance abuse centers, and federal agencies. Our travelers&#8217; disease products, comprising Vivotif and Vaxchora, are sold to wholesalers and distributors, as well as directly to healthcare practitioners. We sell Vivotif and Vaxchora to private travel clinics, retail pharmacies and integrated hospital networks. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">We also generate revenue from the performance of contract development and manufacturing services for third-parties. Our services include fill/finish activities as well as the production of bulk drug substances on behalf of our customers.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">We have received contracts and grants funding from the USG and other non-governmental organizations to perform research and development activities related to programs addressing certain CBRNE threats and emerging infectious disease.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Our revenue, operating results and profitability have varied, and we expect that they will continue to vary on a quarterly basis.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">26</span></div></div><hr style="page-break-after:always"></hr><div><a id="s819C009C99A55028AC19991CB7A4183F"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-weight:bold;">Critical Accounting Policies and Estimates</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, there have been no significant changes to our critical accounting policies and estimates contained in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC, except for the adoption of the new lease standard (see Note 2 and Note 6 to the accompanying condensed consolidated financial statements).</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">27</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF88B3D988EDD5D6185C1091ACC1C0456"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Results of Operations</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="31"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="14" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="14" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Change</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">% Change</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Change</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales net:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NARCAN Nasal Spray</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">73.0</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">138.5</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">138.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ACAM2000</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">6.5</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(50.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(88</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">52.0</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BioThrax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">28.0</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(49.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(64</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">39.6</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">97.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(58.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">76.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">106.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">183.5</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">180.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">336.5</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">255.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">18.7</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">34.6</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">41.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">62.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">94</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">243.2</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.2</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.0</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">433.9</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">338.0</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.9</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of product sales and contract manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">100.8</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">192.7</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">139.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">63.9</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">110.0</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">70.8</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">136.4</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">14.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">29.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">250.2</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">153.4</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">96.8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">468.3</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.7</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">187.6</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) income from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(7.0</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(73.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(34.4</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(91.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(9.5</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(19.0</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">1.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">0.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(8.1</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(18.6</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) income before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(15.1</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(80.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(53.0</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax (benefit) expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(5.6</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(17.4</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(28.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(9.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(35.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(80.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NM</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">NM - Not meaningful</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">28</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Product Sales, net</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="chart-8b90b56754be58a0a19.jpg" alt="chart-8b90b56754be58a0a19.jpg" style="height:388px;width:301px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.47325102880659%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:43%;"></td><td style="width:5%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NARCAN Nasal Spray</span></div></td><td style="vertical-align:bottom;background-color:#abcde5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Product Sales</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ACAM2000</span></div></td><td style="vertical-align:bottom;background-color:#a0a0a0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract Manufacturing</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BioThrax</span></div></td><td style="vertical-align:bottom;background-color:#656565;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and Grants</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">NARCAN Nasal Spray </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">NARCAN Nasal Spray was acquired in October 2018 in connection with the Company's acquisition of Adapt resulting in an increase in product sales in the current quarter and year-to-date periods.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ACAM2000</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The decrease in ACAM2000 sales for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three and six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> was primarily due to the volume of ACAM2000 delivered to the SNS during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three and six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> as compared to the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three and six months ended June 30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. Substantially all of the ACAM2000 product sales revenues during the six months ended June 30, 2019 and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> were made to the USG under a long-term procurement contract at a consistent value per dose. Delivery obligations under this long-term procurement contract were fully satisfied during the quarter ended March 31, 2019.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">BioThrax </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">decrease</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> in BioThrax sales for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three and six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> was primarily due to the number of BioThrax deliveries to the SNS during the period as compared to the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three and six months ended June 30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. The USG purchased fewer units of BioThrax during the three and six months ended June 30, 2019 partially in anticipation of the transition to the Company's next generation anthrax vaccine, AV7909, which we expect to begin delivering to the SNS in the second half of 2019. The decrease in units delivered was slightly offset by contractual per unit pricing increases. Substantially all of the BioThrax product sales revenues are made to the USG under a long-term procurement contract. The fluctuations in BioThrax revenue are largely related to changes in volume depending on when the USG requests delivery. The USG delivery schedule varies based on funding and management of the SNS inventory.   </span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Other Product Sales </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The increase in the Company's other product sales during the three and six months ended June 30, 2019 was primarily due to the contribution of products associated with the PaxVax acquisition as well as increased sales of raxibacumab, which was partially offset by a decrease in Trobigard sales compared to the three and six months ended June 30, 2018.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Contract Manufacturing</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The decrease in contract manufacturing revenue for the three and six months ended June 30, 2019 compared to comparative periods in 2018 is due to Canton contract manufacturing activities in 2018 that did not recur in 2019. The six months ended June 30, 2019 was further impacted by a contract to perform design, construction and validation of manufacturing capability for a third party at our Lansing, Michigan site during the first quarter of 2018 for which no similar services were provided during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Contracts and Grants</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">increase</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> in contracts and grants revenue for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three and six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> primarily reflects research and development activities related to development funding for AV7909 for clinical trial activities and manufacturing. These increases were partially offset by a reduction in development funding for ACAM2000 for stability testing which were recorded during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three and six months ended June 30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> for which no similar services were provided in current period.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">29</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Cost of Product Sales and Contract Manufacturing</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="chart-fc671f5e2a225299909.jpg" alt="chart-fc671f5e2a225299909.jpg" style="height:300px;width:298px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of Product Sales and Contract Manufacturing</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit margin for product sales and contract manufacturing</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Cost of product sales and contract manufacturing </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">increased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three and six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> primarily due to the acquisitions of Adapt and PaxVax, both acquired in October 2018, as well as an increase in facilities related expenses during the three and six months ended June 30, 2019.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Research and Development Expenses (Gross and Net)</span><img src="chart-fc88426c8115514eb1d.jpg" alt="chart-fc88426c8115514eb1d.jpg" style="height:300px;width:298px;"></img><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.5925925925926%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and Development expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and Development expense, net of contracts and grants revenue</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Research and development expenses increased the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">three and six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> primarily due to the acquisitions of Adapt and PaxVax, both acquired in October 2018. Increases also resulted from the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">timing of manufacturing development activities for our AV7909 product candidate. These increases were offset </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">by decreases in technology transfer expenses for raxibacumab. </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">30</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Selling, General and Administrative Expenses</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="chart-c40b459aee255b80b3c.jpg" alt="chart-c40b459aee255b80b3c.jpg" style="height:300px;width:298px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:24px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.76954732510289%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, General and Administrative</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SG&amp;A as a percentage of total revenue</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Selling, general and administrative expenses </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">increased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> for th</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">e </span><span style="font-family:Arial;font-size:10pt;color:#2c2c2c;font-weight:normal;">three and six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> primarily due to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$21.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$42.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> in expenses related to the operations and integration of newly acquired entities during the three and six months ended June 30, 2019, respectively. The newly acquired entities were both acquired in October 2018. The remaining increase is due to an increase in professional services to support our strategic growth initiatives.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Amortization of intangible Assets</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">increase</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> in amortization of intangible assets for the </span><span style="font-family:Arial;font-size:10pt;color:#2c2c2c;font-weight:normal;">three and six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> compared </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">to </span><span style="font-family:Arial;font-size:10pt;color:#2c2c2c;font-weight:normal;text-align:left;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was primarily due to the acquisitions of Adapt and PaxVax.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Total Other Income (Expense), Net</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="chart-03d50f56d7cd54f29ca.jpg" alt="chart-03d50f56d7cd54f29ca.jpg" style="height:300px;width:298px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.36213991769547%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Total other expense, net </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">increased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> by </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$7.1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$17.7</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million for the </span><span style="font-family:Arial;font-size:10pt;color:#2c2c2c;font-weight:normal;">three and six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> due to an increase in</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> borrowings on our senior secured credit facilities established in October 2018 to fund our acquisitions of Adapt and PaxVax.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">31</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Income Tax (Benefit) Expense</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="chart-1352e58451d95236ac3.jpg" alt="chart-1352e58451d95236ac3.jpg" style="height:300px;width:298px;"></img></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:24px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.5925925925926%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax (benefit) expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">l</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The income tax benefit is the result of losses incurred during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three and six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, whereas the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three and six months ended June 30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> had taxable income. These losses were impacted by corresponding increases in the effective foreign and state income tax rates.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">32</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC318E7AD9D6E55C8A7D24BC3DAFF7585"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-weight:bold;">Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:normal;text-decoration:none;">Sources of Liquidity</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We have historically financed our operating and capital expenditures through cash on hand, cash from operations, debt financing and development funding. We also obtain financing from the sale of our common stock upon exercise of stock options. We have operated profitably for each of the last five years for the period ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, we had unrestricted cash and cash equivalents of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$177.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, we believe that we have sufficient liquidity to fund our operations over the next 12 months. </span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">The following table provides information regarding our cash flows for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash provided by (used in):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">69.0</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">(45.5</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">41.7</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Net increase in cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">65.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">33</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Operating Activities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Net cash provided by operating activities of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$69.0</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was primarily due to changes in working capital for accounts receivable and accounts payable. Net operating losses were offset by non cash charges.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Net cash provided by operating activities of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$33.6</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">June&#160;30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was primarily due to net income offset by increases in accounts receivable.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Investing Activities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Net cash used in investing activities of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$45.5</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> reflects software, infrastructure and equipment investments.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Net cash used in investing activities of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">$22.6</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">six months ended June 30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> reflects infrastructure and equipment investments.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Financing Activities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Net cash provided by financing activities of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">41.7</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was primarily due to the net $44.4 million of credit on our debt facility, offset by contingent consideration payments.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Net cash provided by financing activities of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">1.1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> million for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">six months ended June 30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"> was primarily employee equity activity.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Funding Requirements</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We expect to continue to fund our anticipated operating expenses, capital expenditures, debt service requirements and any future repurchase of our common stock from the following sources: </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:42px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-42px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">existing cash and cash equivalents;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:42px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-42px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">net proceeds from the sale of our products and contract manufacturing services;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:42px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-42px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">development contracts and grants funding; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:42px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-42px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">our senior secured credit facilities and any other lines of credit we may establish from time to time.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">There are numerous risks and uncertainties associated with product sales and with the development and commercialization of our product candidates. We may seek additional external financing to provide additional financial flexibility. Our future capital requirements will depend on many factors, including (but not limited to):</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the level, timing and cost of product sales and contract manufacturing services;</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the payment obligations under our indebtedness;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the scope, progress, results and costs of our development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">our ability to obtain funding from collaborative partners, government entities and non-governmental organizations for our development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the extent to which we repurchase additional common stock under our authorized share repurchase program; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">the costs of commercialization activities, including product marketing, sales and distribution.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans or collaboration and licensing arrangements.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">If we raise funds by issuing equity securities, our stockholders may experience dilution. Public or bank debt financing, if available, may involve agreements that include covenants, like those contained in our senior secured credit facilities, which could limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities, buying back shares or declaring dividends. If we raise funds through collaboration and licensing arrangements with third parties, it</span><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">may be necessary to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">We are not restricted under the terms of the indenture governing our 2.875% Convertible Senior Notes due 2021 from incurring additional debt, securing existing or future debt, recapitalizing our debt or taking a number of other actions that could have the effect of diminishing our ability to make payments on our indebtedness. However, our senior secured credit facilities restrict our ability to incur additional indebtedness, including secured indebtedness.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">Economic conditions may make it difficult to obtain financing on attractive terms, or at all. If financing is </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">34</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-weight:normal;">Share Repurchase Program</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">In March 2018, our board of directors authorized our management to repurchase from time to time up to an aggregate of $50 million of our common stock under a board-approved share repurchase program through December 31, 2019. Any repurchased shares will be available for use in connection with our stock plans and for other corporate purposes. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;">, we have not made any repurchases under this program.</span></div><div><a id="s7A14295A0CE65CC49344617FFBCA2A34"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET&#160;RISK</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">For a discussion of additional risks arising from our operations, see &#8220;Item&#160;1A-Risk Factors&#8221; in this&#160;quarterly report.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Market Risk</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">We have interest rate and foreign currency market risk. We manage our interest rate risk in part by entering into interest rate swaps to swap a portion of our indebtedness that is based on variable interest rates to a fixed rate. We currently do not hedge our foreign currency exchange exposure, and the movement of foreign currency exchange rates could have an adverse or positive impact on our results of operations. We have not used derivative financial instruments for speculative purposes. Because of the short-term maturities of our cash and cash equivalents, we believe that an increase in market rates would likely not have a significant impact on the realized</span><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">value of our investments, but any increase in market rates would likely increase the interest expense associated with our debt.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Interest Rate Risk</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">We have debt with a mix of variable and fixed rates of interest. Floating rate debt carries interest based on the eurocurrency, as defined in our Amended Credit Agreement, plus an applicable margin. Increases in interest rates could therefore increase the associated interest payments that we are required to make on this debt. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">We have assessed our exposure to changes in interest rates by analyzing the sensitivity to our operating results assuming various changes in market interest rates. A hypothetical increase of one percentage point in the eurocurrency rate with consideration to outstanding </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">debt and interest rate swap commitments as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, would increase our interest expense by $4.9 million annually.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Foreign Currency Exchange Rate Risk</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">We have exposure to foreign currency exchange rate fluctuations worldwide and primarily with respect to the Euro, Canadian dollar, Swiss franc and British pound. We manage our foreign currency exchange rate risk primarily by incurring, to the extent practicable, operating and financing expenses in the local currency in the countries in which we operate. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><a id="sCA756891833055978E6B56B621984CA2"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act, 1934 (the Exchange Act), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">35</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Changes in Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">There have been no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during the quarter ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Management&#8217;s assessment of and conclusion on the effectiveness of disclosure controls and procedures and internal controls over financial reporting did not include the internal controls related to the operations acquired in the acquisition of PaxVax Holding Company Ltd. and Adapt Pharma Limited, which are included in our unaudited condensed consolidated financial statements for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, and which constituted $1.1 billion and $881.5 million of total assets and net assets, respectively as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and $163.1 million and $4.4 million of revenues and operating income, respectively, for the six months ended June 30, 2019.</span></div><div><a id="sBD107ABA44A557C394FEF625A1D6B70B"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">PART II. OTHER INFORMATION</span></div><div><a id="sEC0BC65C2D3456358360E4B0EC3A1B70"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Perrigo 4mg</span><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On September 14, 2018, Adapt Pharma Inc., Adapt Pharma Operations Limited and Adapt Pharma Ltd. and Opiant Pharmaceuticals, Inc., received notice from Perrigo UK FINCO Limited Partnership that Perrigo had filed an ANDA with the FDA, seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 4mg/spray before the expiration of the &#8216;253 Patent, the &#8216;747 Patent, the &#8216;177 Patent, the &#8216;965 Patent, and the &#8216;838 Patent. On or about October 25, 2018, Perrigo sent a subsequent notice letter relating to the &#8216;937 Patent. Perrigo&#8217;s notice letters assert that its generic product will not infringe any valid and enforceable claim of these patents. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On October 25, 2018, Emergent BioSolutions&#8217; Adapt Pharma subsidiaries and Opiant (collectively, Plaintiffs), filed a complaint for patent infringement of the &#8216;253, &#8216;747, &#8216;177, &#8216;965, and the &#8216;838 Patents against Perrigo in the United States District Court for the District of New Jersey arising from Perrigo&#8217;s ANDA filing with the FDA. Plaintiffs filed a second complaint against Perrigo on December 7, 2018, for the infringement of the &#8216;937 Patent. As a result of timely filing the first lawsuit in accordance with the Hatch-Waxman Act, a 30-month stay of approval will be imposed by the FDA on Perrigo&#8217;s ANDA, which is expected to remain in effect until March 2021 absent an earlier judgment, unfavorable to the Plaintiffs, by the Court.&#160; </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Teva 2mg</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On or about February 27, 2018, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva Pharmaceuticals Industries Ltd. and Teva Pharmaceuticals USA, Inc., that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 2 mg/spray before the expiration of the &#8216;644 Patent, and the '226 Patent. Teva's notice letter asserts that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '644 Patent or the '226 Patent, or that the '644 Patent and '226 Patent are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Teva 4mg</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On or about September 13, 2016, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 4 mg/spray before the expiration of the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received additional notices from Teva relating to the '747, the '177, the '965, the '838, and the &#8216;937 Patents. Teva's notice letters assert that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '253, the '747, the '177, the '965, the '838, or the &#8216;937 Patent, or that the '253, the '747, the '177, the '965, the '838, and the &#8216;937 Patents are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant also filed complaints for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '747, the '177, the '965, and the '838 Patents. All five proceedings have been consolidated. As of the date of this filing, Adapt Pharma Inc., Adapt Pharma Operations Limited, and Opiant, have not filed a complaint related to the &#8216;937 Patent.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In the complaints described in the paragraphs above, the Plaintiffs seek, among other relief, orders that the effective date of FDA approvals of the Teva ANDA products and the Perrigo ANDA product be a date not earlier than the expiration of the patents listed for each product, equitable relief enjoining Teva and Perrigo from making, using, offering to sell, selling, or importing the products that are the subject of Teva and Perrigo&#8217;s respective ANDAs, until after the expiration of the </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">36</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">patents listed for each product, and monetary relief or other relief as deemed just and proper by the court.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:11pt;color:#0094ff;font-weight:normal;">Shareholder Class Action Lawsuit filed July 19, 2016</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">On July 19, 2016, Plaintiff William Sponn (Sponn), filed a putative class action complaint in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#8217;s common stock between January 11, 2016 and June 21, 2016, inclusive, seeking to pursue remedies under the Exchange Act against the Company and certain of its senior officers and directors (collectively, the Defendants). The complaint alleged, among other things, that the Defendants made materially false and misleading statements about the government&#8217;s demand for BioThrax and expectations that the Company&#8217;s five-year exclusive procurement contract with HHS would be renewed, and omitted certain material facts. Sponn sought unspecified damages, including legal costs. On October 25, 2016, the court added City of Cape Coral Municipal Firefighters&#8217; Retirement Plan and City of Sunrise Police Officers&#8217; Retirement Plan as plaintiffs and appointed them Lead Plaintiffs and Robbins Geller Rudman&#160;&amp; Dowd LLP as Lead Counsel. On December 27, 2016, the Lead Plaintiffs filed an amended complaint that cited the same class period, named the same defendants and made similar allegations to the original complaint. The Defendants filed a Motion to Dismiss on February 27, 2017. The Plaintiffs filed an opposition brief on April 28, 2017. The Defendants&#8217; Motion to Dismiss was heard and denied on July 6, 2017. The Defendants filed an answer on July 28, 2017. The parties then engaged in the process of exchanging discovery. The Plaintiffs filed an amended motion for class certification and appointment of Lead Plaintiffs, Sponn, and Geoffrey L. Flagstad as Class Representatives on December 20, 2017. A hearing on that motion was heard on May 2, 2018. On June 8, 2018 the Court granted class certification with a shortened class period, May 5, 2016 to June 21, 2016.&#160;In that same order, the court appointed Flagstad as Class Representative and Robbins Geller Rudman&#160;&amp; Dowd LLP as Class Counsel. The Defendants have denied, and continue to deny, any and all allegations of fault, liability, wrongdoing, or damages. However, recognizing the risk, time, and expense of litigating any case to trial, on August 27, 2018, the Defendants reached an agreement in principle with Plaintiffs to settle all of the related claims of any individual plaintiff that purchased or acquired Company stock from January 11, 2016 to June 21, 2016, for $6.5&#160;million, an amount that was paid by the Company&#8217;s insurance carrier. The settlement required no payment by any of the Defendants. The Defendants continue to deny any and all liability. The parties executed the settlement agreement on October 16, 2018 and filed the agreement with the court on October 17, 2018. The court granted preliminary </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">approval of the settlement on October 18, 2018, issued an amended preliminary approval of the settlement on October 25, 2018, and scheduled a hearing regarding final approval for January 22, 2019. At the time of the final approval hearing on January 22, 2019, there were no objections to the settlement, but there were two shareholders who had submitted opt-outs so that they could be excluded from the settlement. On January 25, 2019, the court issued an order and final judgment approving the settlement. The time to file a notice of appeal has passed.</span><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Defendants continue to believe that the allegations in the complaint are without merit.  </span></div><div><a id="s010F7899B30D586BB30E37C214BE9D2B"></a></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:0px;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">ITEM 1A. RISK FACTORS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">You should carefully consider the following risk factors in addition to the other information in this Quarterly Report on Form 10-Q when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flows.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If any of the risks described below or in subsequent reports we file with the SEC actually occur, they may materially harm our business, financial condition, operating results or cash flows. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results or cash flows. Discussion of these factors is incorporated by reference into and considered an integral part of Part&#160;I,&#160;Item 2, &#8220;Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations.&#8221;</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">GOVERNMENT CONTRACTING RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">   We currently derive a substantial portion of our revenue from sales of BioThrax to our largest customer, the USG. If the USG&#8217;s demand for and/or funding for procurement of BioThrax is substantially reduced, our business, financial condition, operating results and cash flows would be materially harmed.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">     We derive a substantial portion of our current and expected future revenues from sales of BioThrax, our anthrax vaccine licensed by the FDA to the USG. In December 2016, we signed a follow-on procurement contract with the Centers for Disease Control and Prevention (CDC) for the delivery of approximately 29.4 million doses of BioThrax for placement into the SNS over a five-year period ending in September 2021. The potential value of this contract is approximately $911 million if all procurement options are exercised.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">      The procurement of doses of BioThrax by the CDC is subject to the availability of funding. We have no certainty that funding will be made available for the procurement of doses under the CDC contract. If the SNS priorities change, funding to procure doses of BioThrax may be limited or not available, and our business, financial condition and operating results and cash flows would be materially harmed. The </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">37</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">success of our business and our future operating results are significantly dependent on funding for the procurement of BioThrax and the terms of our BioThrax sales to the USG, including the price per dose, the number of doses and the timing of deliveries.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">     Our pre-EUA submission package related to AV7909 may not be accepted and we may not receive EUA and eventual FDA licensure may not be approved by the FDA in a timely manner or at all. Delays in our ability to achieve a favorable outcome from the FDA could prevent us from realizing the full potential value of our BARDA contract for the advanced development and procurement of AV7909.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">      In September 2016, we entered into a contract with HHS, through BARDA for the advanced development and procurement of AV7909, our next generation anthrax vaccine candidate. The contract, as modified in March 2017, is valued at up to approximately $1.5 billion.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">     In collaboration with us, the CDC recently filed with the FDA a pre-EUA submission package related to AV7909, and although there can be no assurances, we currently anticipate that BARDA could begin procuring&#160;AV7909 for delivery into the SNS as early as this year. The FDA may decide that our data are insufficient to accept the pre-EUA submission package and require additional pre-clinical, clinical or other studies. If we are unsuccessful in obtaining acceptance of the pre-EUA submission package for AV7909, and EUA and eventual FDA licensure in a timely manner or at all, we may not be able to realize the full potential value of the contract, which could have a material adverse effect on our future business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">      In addition, if priorities for the SNS change, funding to procure any future doses of AV7909 may be limited or not available, BARDA may never initiate the transition to stockpiling AV7909, and our future business, financial condition, operating results and cash flows could be materially harmed.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our USG procurement and development contracts require ongoing funding decisions by the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">USG. Reduced or discontinued funding of these contracts could cause our</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">business, financial condition, operating results and cash flows to suffer materially.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The USG is the principal customer for our PHT-focused MCMs and is the primary source of funds for the development of our product candidates in our development pipeline, most notably our AV7909 product candidate. We anticipate that the USG will also be a principal customer for those MCMs that we successfully develop within our existing product development pipeline, as well as those we acquire in the future. Additionally, a significant portion of our revenue comes from USG development contracts and grants. Over its lifetime, a USG procurement or </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">development program may be implemented through the award of many different individual contracts and subcontracts. The funding for such government programs is subject to Congressional appropriations, generally made on a fiscal year basis, even for programs designed to continue for several years. For example, sales of BioThrax to be supplied under our procurement contract with the CDC are subject to the availability of funding, mostly from annual appropriations. These appropriations can be subject to political considerations and stringent budgetary constraints.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Additionally, our government-funded development contracts typically give the USG the right, exercisable in its sole discretion, to extend these contracts for successive option periods following a base period of performance. The value of the services to be performed during these option periods may constitute the majority of the total value of the underlying contract. For example, the September 2016 contract award from BARDA for the development and delivery to the SNS of AV7909 for post-exposure prophylaxis of anthrax disease consists of a five-year base period of performance valued at approximately $200 million. The contract award also includes options for the delivery of additional doses of AV7909 to the SNS and options for an additional clinical study and post-marketing commitments which if both were to be exercised in full, would increase the total contract value to up to $1.5 billion. If levels of government expenditures and authorizations for public health countermeasure preparedness decrease or shift to programs in areas where we do not offer products or are not developing product candidates, or if the USG otherwise declines to exercise its options under our existing contracts, our revenues would suffer, as well as our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">There can be no assurance that we will be able to secure follow-on procurement contracts with the USG upon the expiration of any of our current product procurement contracts.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The majority of our revenue is substantially dependent upon product procurement contracts with the USG and foreign governments for our PHT products. Upon the expiration of a procurement contract, we may not be able to negotiate a follow-on procurement contract for the particular product for a similar product volume, period of performance, pricing or other terms, or at all. The inability to secure a similar or increased procurement contract could materially affect our revenues and our business, financial condition, operating results and cash flows could be harmed. For example, the CDC procurement contract for ACAM2000 that we acquired in our acquisition of the ACAM2000 business from Sanofi expired on March 31, 2018. The BARDA procurement contract for </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">38</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">raxibacumab that we acquired in our acquisition of raxibacumab from Human Genome Sciences, Inc. and GlaxoSmithKline LLC, collectively referred to as GSK, will expire in November 2019. Our CDC procurement contract for BioThrax expires in 2021. We intend to negotiate follow-on procurement contracts for each of our PHT products upon the expiration of a related procurement contract, including our procurement contract for ACAM2000, but there can be no assurance that we will be successful obtaining any follow-on contracts. Even if we are successful in negotiating a follow-on procurement contract, it may be for a lower product volume, over a shorter period of performance or be on less favorable pricing or other terms. An inability to secure follow-on procurement contracts for our products could materially and adversely affect our revenues, and our business, financial condition, operating results and cash flows could be harmed.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The government contracting process is typically a competitive bidding process and involves unique risks and requirements.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our business involves government contracts and grants, which may be awarded through competitive bidding. Competitive bidding for government contracts presents many risks and requirements, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the possibility that we may be ineligible to respond to a request for proposal issued by the government;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the commitment of substantial time and attention of management and key employees to the preparation of bids and proposals for contracts that may not be awarded to us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the need to accurately estimate the resources and cost structure that will be required to perform any contract that we might be awarded;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the submission by third parties of protests to our responses to requests for proposal that could result in delays or withdrawals of those requests for proposal; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">in the event our competitors protest or challenge contract or grant awards made to us pursuant to competitive bidding, the potential that we may incur expenses or delays, and that any such protest or challenge could result in the resubmission of bids based on modified specifications, or in the termination, reduction or modification of the awarded contract.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The USG may choose not to award us future contracts for either the development of our new product candidates or for the procurement of our existing products addressing PHTs and may instead </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">award such contracts to our competitors. If we are unable to secure particular contracts, we may not be able to operate in the market for products that are provided under those contracts. Additionally, if we are unable to consistently win new contract awards over an extended period, or if we fail to anticipate all of the costs or resources that we will be required to secure and, if applicable, perform under such contract awards, our growth strategy and our business, financial condition and operating results and cash flows could be materially and adversely affected.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Laws and regulations affecting government contracts make it costlier and more difficult for us to successfully conduct our business. Failure to comply with these laws could result in significant civil and criminal penalties and materially damage our reputation and relationship with the USG, which could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">As a manufacturer and supplier of MCMs to the USG addressing PHTs, we must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts. These laws and regulations govern how we transact business with our government clients and, in some instances, impose additional costs and related obligations on our business operations. Among the most significant government contracting regulations that affect our business are:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the Federal Acquisition Regulation (FAR), and agency-specific regulations supplemental to FAR, which comprehensively regulate the award, formation, administration and performance of government contracts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the Defense Federal Acquisition Regulations (DFARs), and agency-specific regulations supplemental to DFARs, which comprehensively regulate the award, formation, administration and performance of U.S. Department of Defense (DoD) government contracts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the Department of State Acquisition Regulation (DOSAR), which regulates the relationship between a Department of State organization and a contractor or potential contractor;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act, the Procurement Integrity Act, the False Claims Act and the Foreign Corrupt Practices Act;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">39</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">export and import control laws and regulations, including but not limited to International Traffic in Arms Regulations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We may be subject to government investigations of business practices and compliance with government acquisition regulations. USG agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. Even though we take significant precautions to identify, prevent and deter fraud, misconduct and non-compliance, we face the risk that our personnel or outside partners may engage in misconduct, fraud or improper activities. If we are audited or investigated and such audit or investigation were to uncover improper or illegal activities, we could be subject to civil and criminal fines and penalties, administrative sanctions, including suspension or debarment from government contracting, and suffer significant reputational harm. The loss of our status as an eligible government contractor or significant fines or penalties associated with contract non-compliance or resulting from investigations could have a material adverse effect on our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The amount we are paid under our fixed price government procurement contracts is based on estimates we have made of the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">time, resources and expenses required for us to perform under those contracts. If our actual costs exceed our estimates, we may not be able to earn an adequate return or may incur a loss</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">under these contracts, which could harm our operating results and materially reduce our net income.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our current procurement contracts with HHS and the DoD are fixed price contracts. We expect that future procurement contracts we successfully secure with the USG would also be fixed price contracts. Under a fixed price contract, we are required to deliver our products at a fixed price regardless of the actual costs we incur. Estimating costs that are related to performance in accordance with contract specifications is difficult, particularly where the period of performance is over several years. Our failure to anticipate technical problems, estimate costs accurately or control costs during performance of a fixed price contract could reduce the profitability of such a contract or cause a loss, which could harm our operating results and materially reduce our net income.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Unfavorable provisions in government contracts, some of which may be customary, may</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">subject our business to material limitations, restrictions and </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">uncertainties and may have a material adverse impact on our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Government contracts customarily contain provisions that give the USG substantial rights and remedies, many of which are not typically found in commercial contracts, including provisions that allow the USG to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">terminate existing contracts, in whole or in part, for any reason or no reason;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">unilaterally reduce or modify contracts or subcontracts, including by imposing equitable price adjustments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">cancel multi-year contracts and related orders, if funds for contract performance for any subsequent year become unavailable;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">decline, in whole or in part, to exercise an option to purchase product under a procurement contract or to fund additional development under a development contract; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">decline to renew a procurement contract;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">claim rights to facilities or to products, including intellectual property, developed under the contract;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">require repayment of contract funds spent on construction of facilities in the event of contract default;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">take actions that result in a longer development timeline than expected;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">direct the course of a development program in a manner not chosen by the government contractor;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">suspend or debar the contractor from doing business with the government or a specific government agency;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">pursue civil or criminal remedies under acts such as the False Claims Act and False Statements Act; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">control or prohibit the export of products.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Generally, government contracts contain provisions permitting unilateral termination or modification, in whole or in part, at the USG&#8217;s convenience. Under general principles of government contracting law, if the USG terminates a contract for convenience, the government contractor may recover only its incurred or committed costs, settlement expenses and profit on work completed prior to the termination. If the USG terminates a contract for default, the government contractor is entitled to </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">40</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">recover costs incurred and associated profits on accepted items only and may be liable for excess costs incurred by the government in procuring undelivered items from another source. All of our contracts, both development and procurement, with the USG, are terminable at the USG&#8217;s convenience with these potential consequences.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In addition, our USG contracts grant the USG the right to use technologies developed by us under the government contract or the right to share data related to our technologies, for or on behalf of the USG. Under our USG contracts, we might not be able to prohibit third parties, including our competitors, from accessing such technology or data, including intellectual property, in providing products and services to the USG. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">RELIANCE ON THIRD PARTIES</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The loss of any of our non-exclusive, sole-source or single source suppliers or an increase in the price of inventory supplied to us could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We purchase certain supplies used in our manufacturing processes from non-exclusive, or single sources due to quality considerations, costs or constraints resulting from regulatory requirements, including key components for NARCAN&#174; Nasal Spray (Naloxone API, along with the vial, stopper and device). Where a particular single-source supply relationship is terminated, we may not be able to establish additional or replacement suppliers for certain components or materials quickly. This is largely due to the FDA approval system, which mandates validation of materials prior to use in our products, and the complex nature of manufacturing processes. In addition, we may lose a sole-source supplier due to, among other things, the acquisition of such a supplier by a competitor (which may cause the supplier to stop selling its products to us) or the bankruptcy of such a supplier, which may cause the supplier to cease operations. Any reduction or interruption by a sole-source supplier of the supply of materials or key components used in the manufacturing of our products or an increase in the price of those materials or components could adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Additionally, any failure by us to forecast demand for, or our suppliers to maintain an adequate supply of, the raw material and finished product for producing NARCAN&#174; Nasal Spray could result in an interruption in the supply of NARCAN&#174; Nasal Spray and a decline in sales of the product.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to obtain supplies for the manufacture of our products and product candidates in sufficient</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">quantities, at an acceptable cost and in acceptable quality, our ability to manufacture or to </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">develop and commercialize our products and product candidates</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">could be impaired, which could materially harm our revenues, lead to a termination of one or more of our contracts, lead to delays in clinical trials or otherwise materially harm our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We depend on certain single-source suppliers for key materials and services necessary for the manufacture of BioThrax and our other products and product candidates. For example, we rely on a single-source supplier to provide us with Alhydrogel in sufficient quantities to meet our needs to manufacture BioThrax and AV7909, and currently rely on a single-source supplier to manufacture raxibacumab. We also rely on single-source suppliers for the sponge applicator device and the active ingredient used to make RSDL as well as the specialty plasma in our hyperimmune specialty plasma products and certain ingredients for ACAM2000. A disruption in the availability of such materials or services from these suppliers or in the quality of the material provided by such suppliers could require us to qualify and validate alternative suppliers. If we are unable to locate or establish alternative suppliers, our ability to manufacture our products and product candidates could be adversely affected and could harm our revenues, cause us to fail to satisfy contractual commitments, lead to a termination of one or more of our contracts or lead to delays in our clinical trials, any of which could be costly to us and otherwise materially harm our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We depend on third parties to conduct our clinical and non-clinical trials. If these third parties do not perform as contractually</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">required or as we expect, we may not be able to obtain regulatory approval for or</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">commercialize our product candidates and, as a result, our business, financial condition, operating results and cash flows may suffer.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We do not have the ability to independently conduct the clinical and non-clinical trials required to obtain regulatory approval for our product candidates. We depend on third parties, such as independent clinical investigators, contract research organizations and other third-party service providers to conduct the clinical and non-clinical trials of our product candidates and expect to continue to do so. We rely heavily on these third parties for successful execution of our clinical and non-clinical trials, but do not exercise day-to-day control over their activities. Our reliance on these service providers does not relieve us of our regulatory responsibilities, including ensuring that our trials are conducted in accordance with good clinical practice regulations and the plan and protocols contained in the relevant regulatory application. In addition, these organizations may not complete these activities on our anticipated or desired timeframe. We also may experience unexpected cost </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">41</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">increases that are beyond our control. Problems with the timeliness or quality of the work of a contract research organization may lead us to seek to terminate the relationship and use an alternative service provider, which may prove difficult, costly and result in a delay of our trials. Any delay in or inability to complete our trials could delay or prevent the development, approval and commercialization of our product candidates.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In certain cases, government entities and non-government organizations conduct studies of our product candidates, and we may seek to rely on these studies in applying for marketing approval for certain of our product candidates. These government entities and non-government organizations have no obligation or commitment to us to conduct or complete any of these studies or clinical trials and may choose to discontinue these development efforts at any time. Furthermore, government entities depend on annual Congressional appropriations to fund their development efforts, which may not be approved.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">If we are unable to obtain any necessary third-party services on acceptable terms or if these service providers do not successfully carry out their contractual duties or meet expected deadlines, our efforts to obtain regulatory approvals for our product candidates may be delayed or prevented.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">REGULATORY AND COMPLIANCE RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our long-term success depends, in part, upon our ability to develop, receive regulatory approval for and commercialize product candidates we develop or acquire and, if we are not successful, our business, financial condition, operating results and cash flows may suffer.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our product candidates and the activities associated with their development, including testing, manufacture, recordkeeping, storage and approval, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. Except under limited circumstances related to certain government sales, failure to obtain regulatory approval for a product candidate will prevent us from commercializing the product candidate.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In the United States, to obtain approval from the FDA to market any of our future biologic products, we will be required to submit a biologics license application (BLA) to the FDA. Ordinarily, the FDA requires a company to support a BLA with substantial evidence of the product candidate&#8217;s safety, purity and potency in treating the targeted indication based on data derived from adequate and well-controlled clinical trials, including Phase 3 trials conducted in patients with the disease or condition being targeted.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">However, AV7909 and many of our MCM product candidates, for example, may take advantage of a different regulatory approval pathway under the FDA&#8217;s &#8220;Animal Rule.&#8221; The Animal Rule provides a regulatory pathway for drug and biologic products targeting indications for which human efficacy studies are not feasible or would be unethical. Instead, efficacy must be demonstrated, in part, by utilizing animal models rather than testing in humans. We cannot guarantee that the FDA will permit us to proceed with licensure of AV7909 or any of our PHT MCM candidates under the Animal Rule. Even if we are able to proceed pursuant to the Animal Rule, the FDA may decide that our data are insufficient to support approval and require additional preclinical, clinical or other studies, refuse to approve our products, or place restrictions on our ability to commercialize those products. Furthermore, products approved under the Animal Rule are subject to certain additional post-marketing requirements. For example, to the extent feasible and ethical, manufacturers of products approved pursuant to the Animal Rule must conduct post-marketing studies, such as field studies, to verify and describe the product candidate's clinical benefit and to assess its safety when used as indicated. We cannot guarantee that we will be able to meet this regulatory requirement even if one or more of our product candidates are approved under the Animal Rule.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The process of obtaining these regulatory approvals is expensive, often takes many years if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidate involved. Changes in the regulatory approval process during the development period, changes in or the enactment of additional statutes or regulations, or changes in the regulatory review process generally may cause delays in the approval or rejection of an application.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The FDA has substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient to support approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of a product candidate.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Even if we or our collaborators obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we manufacture and market our products, which could materially impair our ability to generate revenue. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation. We and our collaborators must therefore comply with requirements concerning advertising and </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">42</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">promotion for any of our product candidates for which we obtain marketing approval. Promotional communications with respect to prescription products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We and our collaborators and our contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Accordingly, were we to receive marketing approval for one or more of our product candidates, we would continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">If we and our collaborators are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market any products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Any</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> product candidate for which we or our collaborators obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Any product candidate for which we or our collaborators obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine, including the requirement to implement a risk evaluation and mitigation strategy. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The FDA and other agencies, including the Department of Justice (DOJ), closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not market our products for their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">restrictions on such products, manufacturers or manufacturing processes; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">restrictions on the labeling or marketing of a product; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">restrictions on distribution or use of a product; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">requirements to conduct post-marketing studies or clinical trials; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">warning letters or untitled letters; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">withdrawal of the products from the market; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">recall of products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">damage to relationships with collaborators; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">unfavorable press coverage and damage to our reputation; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">fines, restitution or disgorgement of profits or revenues; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">suspension or withdrawal of marketing approvals; </span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">43</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">refusal to permit the import or export of our products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">product seizure; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">injunctions or the imposition of civil or criminal penalties; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">litigation involving patients using our products. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the ACA). Among the provisions of the ACA of potential importance to our business and our product candidates are the following: </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription products and biologic agents; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">a</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for products that are inhaled, infused, instilled, implanted or injected; </span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">expansion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand products to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient products to be covered under Medicare Part D; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">extension of manufacturers&#8217; Medicaid rebate liability to individuals enrolled in Medicaid managed care organizations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">expansion of eligibility criteria for Medicaid programs; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">new requirements to report certain financial arrangements with physicians and teaching hospitals; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">a new requirement to annually report product samples that manufacturers and distributors provide to physicians; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">a new Independent Payment Advisory Board (IPAB), which has authority to recommend certain changes to the Medicare program to reduce expenditures by the program that could result in reduced payments for prescription products; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">established the Center for Medicare and Medicaid Innovation within the Centers for Medicare &amp; Medicaid Services (CMS) to test innovative payment and service delivery models.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">44</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2024 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Since enactment of the ACA, there have been numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by the President on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective on January 1, 2019. According to the Congressional Budget Office, the repeal of the individual mandate will cause 13 million fewer</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Americans to be insured in 2027 and premiums in insurance markets may rise. Further, each chamber of Congress has put forth multiple bills designed to repeal or repeal and replace portions of the ACA. Although none of these measures has been enacted by Congress to date, Congress may consider other legislation to repeal and replace elements of the ACA. Congress will likely consider other legislation to replace elements of the ACA, during the next Congressional session. It is possible that such initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in individuals having insurance coverage with less generous benefits. While the timing and scope of any potential future legislation to amend the ACA is highly uncertain in many respects, it is also possible that some of the ACA provisions that generally are not favorable for the research-based pharmaceutical industry could also be repealed along with an ACA coverage expansion provision. We will continue to evaluate the effect that the ACA and its possible repeal and replacement could have on our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Trump Administration has also taken executive actions to challenge or delay implementation of the ACA. Since January 2017, President Trump has signed two Executive Orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. One Executive Order directs federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. The second Executive Order terminates the cost-sharing subsidies that reimburse insurers under the ACA. Several state Attorneys General filed suit to stop the Trump Administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. In addition, CMS has recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. Further, on June 14, 2018, the U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay more than $12 billion in ACA risk corridor payments to third-party payors who argued were owed to them. The effects of this gap in reimbursement on third-party payors, the viability of the ACA marketplace, providers, and potentially our business, are not yet known.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In addition, the CMS has proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. On November 30, 2018, CMS announced a proposed rule that would amend the Medicare Advantage and Medicare Part D prescription drug benefit regulations to reduce out of pocket costs for plan enrollees and allow Medicare plans to negotiate lower rates for certain drugs. Among other things, the proposed rule changes would allow Medicare Advantage plans to use pre authorization (PA) and step therapy (ST) for six protected classes of drugs, with certain exceptions, permit plans to implement PA and ST in Medicare Part B drugs; and change the definition of &#8220;negotiated prices,&#8221; while providing a definition of &#8220;price concession&#8221; in the regulations. It is unclear whether these proposed changes will be accepted, and if so, what effect such changes will have on our business. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. The Trump administration and CMS have both stated that the ruling will have no immediate effect, and on December 30, 2018 the same judge issued an order staying the judgment pending appeal. The Trump Administration </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">45</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">has recently represented to the Court of Appeals considering this judgment that it does not oppose the lower court&#8217;s ruling. It is unclear how this decision and any subsequent appeals and other efforts to repeal and replace the ACA will impact the ACA and our business. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The costs of prescription pharmaceuticals have also been the subject of considerable discussion in the United States, and members of Congress and the Trump Administration have stated that they will address such costs through new legislative and administrative measures. To date, there have been several recent U.S. congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. While any proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Specifically, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. For example, on May 11, 2018, the Administration issued a plan to lower drug prices. Under this blueprint for action, the </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Administration indicated that HHS will: take steps to end the gaming of regulatory and patent processes by drug makers to unfairly protect monopolies; advance biosimilars and generics to boost price competition; evaluate the inclusion of prices in drug makers&#8217; ads to enhance price competition; speed access to and lower the cost of new drugs by clarifying policies for sharing information between insurers and drug makers; avoid excessive pricing by relying more on value-based pricing by expanding outcome-based payments in Medicare and Medicaid; work to give Part D plan sponsors more negotiation power with drug makers; examine which Medicare Part B drugs could be negotiated for a lower price by Part D plans, and improving the design of the Part B Competitive Acquisition Program; update Medicare&#8217;s drug-pricing dashboard to increase transparency; prohibit Part D contracts that include &#8220;gag rules&#8221; that prevent pharmacists from informing patients when they could pay less out-of-pocket by not using insurance; and require that Part D plan members be provided with an annual statement of plan payments, out-of-pocket spending, and drug price increases. More recently, on January 31, 2019, the HHS Office of Inspector General proposed modifications to the federal Anti-Kickback Statute discount safe harbor for the purpose of reducing the cost of drug products to consumers which, among other things, if finalized, will affect discounts paid by manufacturers to Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these organizations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">If</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> we fail to comply with foreign, federal, state and local healthcare laws, including fraud and abuse and health information privacy and security laws, and </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">46</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">antitrust laws, we could face substantial&#160;penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In the United States, certain of our products are reimbursed under federal and state health care programs such as Medicaid, Medicare, TriCare, and or state pharmaceutical assistance programs. Many foreign countries have similar laws. Federal and state laws designed to prevent fraud and abuse under these programs prohibit pharmaceutical companies from offering valuable items or services to customers or potential customers to induce them to buy, prescribe, or recommend our product (the so-called &#8220;antikickback&#8221; laws). Exceptions are provided for discounts and certain other arrangements if specified requirements are met. Other federal and state laws, and similar foreign laws, not only prohibit us from submitting any false information to government reimbursement programs but also prohibit us and our employees from doing anything to cause, assist, or encourage our customers to submit false claims for payment to these programs. We are also subject to various federal, state and foreign antitrust and competition laws that prohibit certain activities that may have an impact against potential competitors. Violations of the various fraud and abuse and antitrust laws may result in severe penalties against the responsible employees and us, including jail sentences, large fines, and the exclusion of our products from reimbursement under federal and state programs. Some of the laws that may affect our ability to operate include:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the federal Anti-Kickback Statute makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay remuneration, directly or indirectly, overtly or covertly, to induce, or in return for, either the referral of an individual, or the purchase, lease, prescribing or recommendation of an item, good, facility or service reimbursable by a federally funded healthcare program, such as the Medicare or Medicaid program. The term &#8220;remuneration&#8221; has been interpreted broadly and may constrain our marketing practices, educational programs, pricing policies and relationships with healthcare providers or other entities, among other activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material </span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:42px;padding-bottom:12px;text-align:justify;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties, currently set at $10,781 to $21,563 per false claim;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (HITECH), and their respective implementing regulations mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common healthcare transactions, as well as standards relating to the privacy, security and transmission of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA's security standards directly applicable to &#8220;business associates,&#8221; or independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, biologics, medical devices and medical supplies for which payment is available under Medicare, Medicaid or the Centers for Medicare&#160;&amp; Medicaid Services (CMS), certain payments and transfers of value made to physicians and teaching hospitals, and ownership or </span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">47</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:42px;padding-bottom:12px;text-align:justify;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers will also be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives; and</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; state, local and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, obtain pharmaceutical agent licensure, and/or otherwise restrict payments that may be made to healthcare providers and entities; and state, local and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to healthcare providers or entities, or marketing expenditures.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under the U.S. federal Anti-Kickback Statute, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Moreover, recent health care reform legislation has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal health care fraud statutes, so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">If our operations are found to be in violation of any of the laws described above or any governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, individual imprisonment, integrity obligations, exclusion from funded healthcare programs and the curtailment or restructuring of our operations. Any such penalties could adversely affect </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">our financial results. We are developing and implementing a corporate compliance program designed to ensure that we will market and sell any future products that we successfully develop from our product candidates in compliance with all applicable laws and regulations, but we cannot guarantee that this program will protect us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, integrity obligations, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We are committed to conducting the sales and marketing of our applicable products and all our activities in compliance with the healthcare fraud and abuse and antitrust laws, but certain applicable laws may impose liability even in the absence of specific intent to defraud. Furthermore, should there be ambiguity, a governmental authority may take a position contrary to a position we have taken, or should an employee violate these laws without our knowledge, a governmental authority may impose civil and/or criminal sanctions.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:41px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The United States government, state governments and private payors regularly investigate the pricing and competitive practices of pharmaceutical companies and biotechnology companies, and many file actions alleging that inaccurate reporting of prices has improperly inflated reimbursement rates. We may also be subject to investigations related to our pricing practices. Regardless of merit or eventual outcome, these types of investigations and related litigation can result in:</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">48</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Diversion of management time and attention;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Expenditure of large amounts of cash on legal fees, costs and payment of damages or penalties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Limitations on our ability to continue some of our operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Decreased demand for our products; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Injury to our reputation.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:42px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Moreover, an adverse outcome, or the imposition of penalties or sanctions for failing to comply with the fraud and abuse and antitrust laws, could adversely affect us and may have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:42px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we fail to comply with our obligations under U.S. governmental pricing programs, we could&#160;be required to reimburse government programs for underpayments and could pay penalties, sanctions and fines.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The issuance of regulations and coverage expansion by various governmental agencies relating to the Medicaid rebate program will continue to increase our costs and the complexity of compliance and will be time-consuming. Changes to the definition of &#8220;average manufacturer price&#8221; (AMP), and the Medicaid rebate amount under the ACA and CMS and the issuance of final regulations implementing those changes has affected and could further affect our 340B &#8220;ceiling price&#8221; calculations. Because we participate in the Medicaid rebate program, we are required to report &#8220;average sales price&#8221; (ASP), information to CMS for certain categories of drugs that are paid for under Part B of the Medicare program. Future statutory or regulatory changes or CMS binding guidance could affect the ASP calculations for our products and the resulting Medicare payment rate, and could negatively impact our results of operations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Pricing and rebate calculations vary among products and programs, involve complex calculations and are often subject to interpretation by us, governmental or regulatory agencies and the courts. The Medicaid rebate amount is computed each quarter based on our submission to CMS of our current AMP and &#8220;best price&#8221; for the quarter. If we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for a period not to exceed twelve quarters from the quarter in which the data originally were due. Any such revisions could have the impact of increasing or decreasing our rebate liability for prior quarters, depending on the direction of the revision. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid rebate program. Price recalculations also may affect the &#8220;ceiling price&#8221; at which we are required to offer our products to certain covered entities, such as safety-net providers, under the 340B/PHS drug pricing program.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:42px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In addition to retroactive rebate liability and the potential for 340B program refunds, if we are found to have made a misrepresentation in the reporting of ASP, we are subject to civil monetary penalties for each such price misrepresentation and for each day in which such price misrepresentation was applied. If we are found to have knowingly submitted false AMP or &#8220;best price&#8221; information to the government, we may be liable for civil monetary penalties per item of false information. Any refusal of a request for information or knowing provision of false information in connection with an AMP survey verification also would subject us to civil monetary penalties. In addition, our failure to submit monthly/quarterly AMP or &#8220;best price&#8221; information on a timely basis could result in a civil monetary penalty per day for each day the information is late beyond the due date. Such failure also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, no federal payments would be available under Medicaid or Medicare Part B for our covered outpatient drugs. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot assure you that our submissions will not be found by CMS to be incomplete or incorrect.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:42px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In order for our products to be reimbursed by the primary federal governmental programs, we report certain pricing data to the USG. Compliance with reporting and other requirements of these federal programs is a pre-condition to: (i)&#160;the availability of federal funds to pay for our products under Medicaid and Medicare Part B; and (ii)&#160;procurement of our products by the Department of Veterans Affairs (DVA), and by covered entities under the 340B/PHS program. The pricing data reported are used as the basis for establishing Federal Supply Schedule (FSS), and 340B/PHS program contract pricing and payment and rebate rates under the Medicare Part B and Medicaid programs, respectively. Pharmaceutical companies have been prosecuted under federal and state false claims laws for submitting inaccurate and/or incomplete pricing information to the government that resulted in increased payments made by these programs. The rules governing the calculation of certain reported prices are highly complex. Although we maintain and follow strict procedures to ensure the maximum possible integrity for our federal pricing </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">49</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">calculations, the process for making the required calculations involves some subjective judgments and the risk of errors always exists, which creates the potential for exposure under the false claims laws. If we become subject to investigations or other inquiries concerning our compliance with price reporting laws and regulations, and our methodologies for calculating federal prices are found to include flaws or to have been incorrectly applied, we could be required to pay or be subject to additional reimbursements, penalties, sanctions or fines, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">To be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part B programs as well as to be purchased by certain federal agencies and certain federal grantees, we also must participate in the DVA FSS pricing program. To participate, we are required to enter into an&#160;FSS contract with the DVA, under which we must make our innovator &#8220;covered drugs&#8221; available to the &#8220;Big Four&#8221; federal agencies-the DVA, the DoD, the Public Health Service (including the Indian Health Service), and the Coast Guard-at pricing that is capped pursuant to a statutory federal ceiling price (FCP), formula set forth in Section&#160;603 of the Veterans Health Care Act of 1992 (VHCA). The FCP is based on a weighted average wholesale price known as the Non-Federal Average Manufacturer Price (Non-FAMP), which manufacturers are required to report on a quarterly and annual basis to the DVA. Pursuant to the VHCA, knowing provision of false information in connection with a Non-FAMP filing can subject us to significant penalties for each item of false information. If we overcharge the government in connection with our FSS contract or Section&#160;703 Agreement, whether due to a misstated FCP or otherwise, we are required to disclose the error and refund the difference to the government. The failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government&#160;investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We intend to transfer the manufacturing of raxibacumab, which we acquired from GSK, to our bulk and fill finish facilities in Baltimore, Maryland, and this transfer of manufacturing operations requires FDA approval.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Under our arrangements with GSK for our acquisition of the raxibacumab product, we will continue to purchase product from GSK to satisfy deliveries to the SNS under the current BARDA </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">contract, which expires in November 2019. We intend to seek FDA approval to transfer the manufacturing of raxibacumab to our Baltimore, Maryland bulk and fill finish manufacturing facilities and currently anticipate FDA approval of this technology transfer in 2020. Approval of this technology transfer may involve complications or may not be secured on a timely basis or at all. Any delay in the approval of this anticipated technology transfer would delay our expected benefits and synergies from this product acquisition and could materially harm our revenues and our business, financial condition, operating results and cash flows could be harmed. Until approval of this technology transfer, we must rely on GSK to supply product to us to satisfy deliveries to the SNS under the BARDA contract, and GSK may fail to meet delivery obligations, which could result in our inability to satisfy requirements under the BARDA contract.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Even after regulatory approval is received, if we fail to comply with regulatory requirements, or if we experience unanticipated problems with our approved products, they could be subject to restrictions, penalties or withdrawal from the market.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Any vaccine, therapeutic product or medical device for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory bodies. Our approved products are subject to these requirements and ongoing review. These requirements include submissions of safety and other post-marketing information and reports, registration requirements, cGMP, requirements relating to potency and stability, quality control, quality assurance, restrictions on advertising and promotion, import and export restrictions and recordkeeping requirements. In addition, various state laws require that companies that manufacture and/or distribute drug products within the state obtain and maintain a manufacturer or distributor license, as appropriate. Because of the breadth of these laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our regulators enforce cGMP and other requirements through periodic unannounced inspections of manufacturing facilities. The FDA is authorized to inspect domestic manufacturing facilities without prior notice at reasonable times and in a reasonable manner. Health Canada may conduct similar inspections of our facilities where Canadian marketed products are produced, or related formulation and filling operations are conducted. The FDA, Health Canada, and other foreign regulatory agencies conduct periodic inspections of our facilities. Following several of these inspections, regulatory authorities have issued inspectional observations, </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">50</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">some of which were significant, but all of which are being, or have been, addressed through corrective actions. If, in connection with any future inspection, regulatory authorities find that we are not in substantial compliance with all applicable requirements, or if they are not satisfied with the corrective actions we take, our regulators may undertake enforcement action against us, which may include:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">warning letters and other communications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">product seizure or withdrawal of the product from the market;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">restrictions on the marketing or manufacturing of a product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">suspension or withdrawal of regulatory approvals or refusal to approve pending applications or supplements to approved applications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">fines or disgorgement of profits or revenue; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">injunctions or the imposition of civil or criminal penalties.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Similar action may be taken against us should we fail to comply with regulatory requirements, or later discover previously unknown problems with our products or manufacturing processes. For instance, our products are tested regularly to determine if they satisfy potency and stability requirements for their required shelf lives. Even if regulatory approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval. Regulatory approval may also contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. If we experience any of these post-approval events, our business, financial condition, operating results and cash flows could be materially and adversely affected.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Additionally, companies may not promote drugs for &#8220;off-label&#8221; uses (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">i.e.,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> uses that are not described in the product&#8217;s labeling and that differ from those approved by the applicable regulatory agencies). A company that is found to have improperly promoted off-label uses may be subject to significant liability, including civil and administrative remedies (such as entering into corporate integrity agreements with the USG), as well as criminal sanctions. If our employees or agents engage in &#8220;off-label&#8221; marketing of any of our products, we could be subject to civil or criminal investigations and monetary and injunctive penalties, which could adversely impact our ability to conduct business in certain markets, negatively affect our business, financial condition, operating results and cash flows, and damage our reputation.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Failure to obtain or maintain regulatory approval in international jurisdictions could prevent us</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">from marketing our products abroad and could limit the growth of our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We intend to sell certain of our products, outside the United States and received market authorization under the mutual recognition procedure to sell BioThrax, in France, Italy, the Netherlands, Poland, and the U.K. To market our products in foreign jurisdictions under normal circumstances, we may need to obtain separate regulatory approvals and comply with numerous and varying requirements or use alternative &#8220;emergency use&#8221; or other exemptions from general approval and import requirements. Approval by the FDA in the United States or the mutual recognition procedure in the European member states does not ensure approval by all foreign regulatory authorities. The approval procedures in foreign jurisdictions can vary widely and can involve additional clinical trials and data review beyond that required by the FDA or under the mutual recognition procedure. We and our collaborators may not be able to obtain foreign regulatory approvals on a timely basis, if at all, and we may be unable to successfully commercialize our products internationally if no alternate procurement pathway is identified for authorized government customers in a particular jurisdiction. We have limited experience in preparing, filing and prosecuting the applications necessary to gain foreign regulatory approvals and expect to rely on third-party contract research organizations and consultants to assist us in this process.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Additionally, on June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. On March 29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The United Kingdom had a period of a maximum of two years from the date of its formal notification to negotiate the terms of its withdrawal from, and future relationship with, the European Union. If no formal withdrawal agreement can be reached between the United Kingdom and the European Union, then it is expected that the United Kingdom&#8217;s membership of the European Union would automatically terminate on the deadline, which was initially March 29, 2019. That deadline has been extended to October 31, 2019 to allow the parties to negotiate a withdrawal agreement, which has proven to be extremely difficult to date. Discussions between the United Kingdom and the European Union will continue to focus on withdrawal issues and transition agreements. However, limited progress to date in these negotiations and ongoing uncertainty within the government of the United Kingdom sustains the possibility of the United Kingdom leaving the European Union without a withdrawal agreement and associated </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">51</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">transition period in place, which is likely to cause significant market and economic disruption. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, Brexit could materially impact the regulatory regime with respect to the approval of our products or any future product candidate in the United Kingdom or the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for our product candidates, which could significantly and materially harm our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">As we continue to expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The expansion of our international operations increases our risk of exposure to credit losses.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">As we continue to expand our business activities with foreign governments in certain countries that have experienced deterioration in credit and economic conditions or otherwise, our exposure to uncollectible accounts will rise. Global economic conditions and liquidity issues in certain countries have resulted and may continue to result in delays in the collection of accounts receivables and may result in credit losses. Future governmental actions and customer specific actions may require us to re-evaluate the collectability of our accounts receivable and we may potentially incur credit losses that may materially impact our operating results.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">MANUFACTURING RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Disruption at, damage to or destruction of our manufacturing facilities could impede our ability to manufacture BioThrax or our other products, as well as deliver our contract development and manufacturing services, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">An interruption in our manufacturing operations could result in our inability to produce our PHT countermeasures for delivery to satisfy the product demands of our customers in a timely manner, which would reduce our revenues and materially harm our business, financial condition, operating results and cash flows. </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">52</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">A number of factors could cause interruptions, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">equipment malfunctions or failures;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">technology malfunctions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">cyber-attacks;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">work stoppages or slow-downs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">protests, including by animal rights activists;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">injunctions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">damage to or destruction of the facility; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">product contamination or tampering.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Providers of PHT countermeasures could be subject to an increased risk of terrorist activities. The USG has designated both our Lansing, Michigan and our Bayview bulk manufacturing facility in Baltimore, Maryland as facilities requiring additional security. Although we continually evaluate and update security measures, there can be no assurance that any additional security measures would protect these facilities from terrorist efforts determined to disrupt our manufacturing activities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The factors listed above could also cause disruptions at our other facilities, including our manufacturing facilities in Winnipeg, Manitoba, Canada; other Baltimore, Maryland facilities in Camden; facilities in Canton, Massachusetts; Rockville, Maryland, Bern, Switzerland; and Hattiesburg, Mississippi. We do not have any redundant manufacturing facilities for any of our marketed products. Accordingly, any disruption, damage, or destruction of these facilities could impede our ability to manufacture our marketed products, our product candidates and our ability to produce products for external customers, result in losses and delays, including delay in the performance of our contractual obligations or delay in our clinical trials, any of which could be costly to us and materially harm our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may not be able to utilize the full manufacturing capacity of our manufacturing facilities, which could impact our future revenues and materially harm our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Despite our ongoing efforts to optimize the utilization of our manufacturing infrastructure (including bulk, fill/finish, support, aseptic filling, lyophilization, final packaging), we may not be able to realize full utilization, which could adversely affect our future revenues, financial condition, operating results and cash flows.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Problems may arise during the production of our marketed products and product candidates due to the complexity of the processes involved in their manufacturing and shipment. Significant delays in product manufacturing or development could cause delays in revenues, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">BioThrax, raxibacumab, ACAM2000, Anthrasil, BAT, VIGIV, Vivotif, Vaxchora, and many of our current product candidates, including AV7909, are biologics. Manufacturing biologic products, especially in large quantities, is complex. The products must be made consistently and in compliance with a clearly defined manufacturing process. Problems during manufacturing may arise for a variety of reasons, including problems with raw materials, equipment malfunction and failure to follow specific protocols and procedures. In addition, slight deviations anywhere in the manufacturing process, including obtaining materials, maintaining master seed or cell banks and preventing genetic drift, seed or cell growth, fermentation, contamination including from particulates among other things, filtration, filling, labeling, packaging, storage and shipping, potency and stability issues and other quality control testing, may result in lot failures or manufacturing shut-downs, delays in the release of lots, product recalls, spoilage or regulatory action. Such deviations may require us to revise manufacturing processes or change manufacturers. Additionally, as our equipment ages, it will need to be replaced. Replacement of equipment has the potential to introduce variations in the manufacturing process that may result in lot failures or manufacturing shut-downs, delay in the release of lots, product recalls, spoilage or regulatory action. Success rates can also vary dramatically at different stages of the manufacturing process, which can reduce yields and increase costs. From time to time, we may experience deviations in the manufacturing process that may take significant time and resources to resolve and, if unresolved, may affect manufacturing output and could cause us to fail to satisfy customer orders or contractual commitments, lead to a termination of one or more of our contracts, lead to delays in our clinical trials, result in litigation or regulatory action against us, including warning letters and other restrictions on the marketing or manufacturing of a product, or cause the FDA to cease releasing product until the deviations are explained and corrected, any of which could be costly to us, damage our reputation and negatively impact our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We are contractually required to ship our biologic products at a prescribed temperature range and variations from that temperature range could result in loss of product and could significantly and adversely impact our revenues, which would harm our business, financial condition, operating results and cash flows.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">53</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Manufacturing delays, lot failures, shipping deviations, spoilage or other loss during shipping could cause us to fail to satisfy customer orders or contractual commitments, lead to a termination of one or more of our contracts, lead to delays in potential clinical trials or result in litigation or regulatory action against us, any of which could be costly to us and otherwise harm our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are required to obtain FDA approval prior to the release of each lot of raxibacumab and certain other products, which may not be obtained on a timely basis or at all.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">FDA approval is required for the release of each lot of raxibacumab. We are not able to sell any lots that fail to satisfy the FDA release testing specifications. For example, we must provide the FDA with the results of certain tests, including potency tests, before lots are released for sale. Potency testing of each lot of raxibacumab is performed against qualified control lots that we maintain. We continually monitor the status of our reference lots for FDA compliance and periodically produce and qualify a new reference lot to replace the existing reference lot. If we are not able to produce and qualify a new reference lot or otherwise satisfy the FDA&#8217;s requirements for release of raxibacumab, our ability to sell raxibacumab would be impaired until such time as we become able to meet the FDA&#8217;s requirements, which could materially harm our future business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our operations, including our use of hazardous materials, chemicals, bacteria and viruses, require us to comply</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">with regulatory requirements and expose us to significant potential liabilities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our operations involve the use of hazardous materials, including chemicals, bacteria and viruses, and may produce dangerous waste products. Accordingly, we, along with the third parties that conduct clinical trials and manufacture our products and product candidates on our behalf, are subject to federal, state, local and foreign laws and regulations that govern the use, manufacture, distribution, storage, handling, exposure, disposal and recordkeeping with respect to these materials. Under the Federal Select Agent Program, pursuant to the Public Health Security and Bioterrorism Preparedness and Response Act, we are required to register with and be inspected by the CDC and the Animal and Plant Health Inspection Service if we have in our possession, or if we use or transfer, select biological agents or toxins that could pose a threat to public health and safety, to animal or plant health or to animal or plant products. This legislation requires stringent safeguards and security measures for these select agents and toxins, including controlled access and the screening of entities and personnel and establishes a comprehensive national database of registered </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">entities. We are also subject to a variety of environmental and occupational health and safety laws. Compliance with current or future laws and regulations can require significant costs and we could be subject to substantial fines and penalties in the event of noncompliance. In addition, the risk of contamination or injury from these materials cannot be completely eliminated. In such event, we could be held liable for substantial civil damages or costs associated with the cleanup of hazardous materials. From time to time, we have been involved in remediation activities and may be so involved in the future. Any related cost or liability might not be fully covered by insurance, could exceed our resources and could have a material adverse effect on our business, financial condition, operating results and cash flows. In addition to complying with environmental and occupational health and safety laws, we must comply with special regulations relating to biosafety administered by the CDC, HHS, U.S. Department of Agriculture and the DoD, as well as regulatory authorities in Canada.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">RISKS RELATED TO STRATEGIC ACQUISITIONS AND COLLABORATIONS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our strategy of generating growth through acquisitions may not be successful.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our business strategy includes growing our business through acquisition and in-licensing transactions. We may not be successful in identifying, effectively evaluating, structuring, acquiring or in-licensing, and developing and commercializing additional products on favorable terms, or at all. Competition for attractive product opportunities is intense and may require us to devote substantial resources, both managerial and financial, to an acquisition opportunity. A number of more established companies are also pursuing strategies to acquire or in-license products in the biopharmaceutical field. These companies may have a competitive advantage over us due to their size, cash resources, cost of capital, effective tax rate and greater clinical development and commercialization capabilities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Acquisition efforts can consume significant management attention and require substantial expenditures, which could detract from our other programs. In addition, we may devote significant resources to potential acquisitions that are never completed. Even if we are successful in acquiring a company or product, it may not result in a successfully developed or commercialized product or, even if an acquired product is commercialized, competing products or technologies could render a product noncompetitive, uneconomical or obsolete. Moreover, the cost of acquiring other companies or in-licensing products could be substantial, and in order to acquire companies or new products, we may need to incur substantial debt or issue dilutive securities.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">54</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">If we are unsuccessful in our efforts to acquire other companies or in-license and develop additional products, or if we acquire or in-license unproductive assets, it could have a material adverse effect on the growth of our business, and we could be compelled to record significant impairment charges to write-down the carrying value of our acquired intangible assets, which could materially harm our, business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our failure to successfully integrate acquired businesses and/or assets into our operations could adversely affect our ability to realize the benefits of such acquisitions and, therefore, to grow our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We may not be able to integrate any acquired business successfully or operate any acquired business profitably, including our acquisitions of Adapt and PaxVax. In addition, cost synergies, if achieved at all, may be less than we expect, or may take greater time to achieve than we anticipate.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Issues that could delay or prevent successful integration or cost synergies of an acquired business or products include, among others:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">retaining existing customers and attracting new customers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">retaining key employees;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">diversion of management attention and resources;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">conforming internal controls, policies and procedures, business cultures and compensation programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">consolidating corporate and administrative infrastructures;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">successfully executing technology transfers and obtaining required regulatory approvals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">consolidating sales and marketing operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">identifying and eliminating redundant and underperforming operations and assets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">assumption of known and unknown liabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">coordinating geographically dispersed organizations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">managing tax costs or inefficiencies associated with integrating operations.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">If we are unable to successfully integrate pending and future acquisitions with our existing businesses, or operate any acquired business profitably, we may not obtain the advantages that the acquisitions were intended to create, which may materially adversely </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">affect the growth of our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">COMPETITIVE AND POLITICAL RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We face substantial competition, which may result in others developing or</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">commercializing products before or more successfully than we do.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The development and commercialization of new biopharmaceutical and medical technology products is highly competitive and subject to rapid technological advances. We may face future competition from other companies and governments, universities and other non-profit research organizations in respect to our products, any products that we acquire, our current product candidates and any products we may seek to develop or commercialize in the future. Our competitors may develop products that are safer, more effective, more convenient or less costly than any products that we may develop or market. Our competitors may have greater resources to devote to marketing or selling their products, adapt more quickly to new technologies, scientific advances or patient preferences and needs, initiate or withstand substantial price competition more successfully than we can, or more effectively negotiate third-party licensing and collaborative arrangements.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">There are a number of companies with products or product candidates addressing PHT preparedness that are competing with us for both USG procurement and development resources. Many of our competitors have greater financial, technical and marketing resources than we do. Our competitors may receive patent protection that dominates, blocks or adversely affects our products or product candidates.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Any reduction in demand for our products or reduction or loss of development funding for our products or product candidates in favor of a competing product could lead to a loss of market share for our products and cause reduced revenues, margins and levels of profitability for us, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our Biologic Products may face risks of competition from biosimilar manufacturers.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Competition for BioThrax, raxibacumab, ACAM2000, Anthrasil, BAT, VIGIV, Vivotif and Vaxchora otherwise referred to as our &#8220;Biologic Products,&#8221; may be affected by follow-on biologics, or &#8220;biosimilars,&#8221; in the United States and other jurisdictions. Regulatory and legislative activity in the United States and other countries may make it easier for generic drug manufacturers to manufacture and sell biological drugs similar or identical to our Biologic Products, which might affect the profitability or commercial viability of our Biologic Products. Under the Biologics Price Competition and Innovation Act of 2010, the FDA </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">55</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">cannot approve a biosimilar application until the 12-year exclusivity period for the innovator biologic has expired. Regulators in the European Union and in other foreign jurisdictions have already approved biosimilars. The specific regulatory framework for this biosimilar approval path and the extent to which an approved biosimilar would be substituted for the innovator biologic are not yet clear and will depend on many factors. If a biosimilar version of one of our Biologic Products were approved, it could have a material adverse effect on the sales and gross profits of the affected Biologic Product and could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We expect our NARCAN&#174; Nasal Spray marketed product to face future competition from other treatments.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Our marketed product NARCAN&#174; Nasal Spray faces potentially substantial competition from other treatments, including injectable naloxone, auto-injectors, nasal sprays or improvised nasal spray kits. In addition, other entrants may seek approval to market generic versions of NARCAN&#174; Nasal Spray before the underlying patents expire. For example, in 2016 Teva filed, and in 2018 Perrigo filed, ANDAs which seek</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> regulatory approval to market generic versions of NARCAN&#174; Nasal Spray before the expiration of certain underlying patents and in April 2019, Teva received FDA approval to market its generic version of NARCAN&#174; Nasal Spray. Teva may decide to launch its approved generic product although the launch would be at risk since the litigation we instituted against Teva is still ongoing.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Additionally, in January 2019, the FDA released new proposed template Drug Facts Labels to assist sponsors of investigational naloxone nasal sprays and auto-injectors seeking approval from the FDA for over-the-counter naloxone products. Any reduction in demand for NARCAN&#174; Nasal Spray in favor of a competing product, or unsuccessful efforts to defend underlying patents from infringement by generic entrants, could lead to a loss of market share and cause reduced revenues, margins and levels of profitability for us, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Political or social factors may delay or impair our ability to market our products and may require us to spend significant management time and financial resources to address these issues.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Products developed to counter the potential impact of PHTs, whether CBRNE or EID, are subject to changing political and social environments. The political responses and social awareness of the risks of these threats on military personnel or civilians may vary over time. If the threat of terrorism were to decline, </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">then the public perception of the risk on public health and safety may be reduced. This perception, as well as political or social pressures, could delay or cause resistance to bringing our products in development to market or limit pricing or purchases of our products, any of which could negatively affect our revenues and our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In addition, substantial delays or cancellations of purchases could result from protests or challenges from third parties. Lawsuits brought against us by third parties or activists, even if not successful, could require us to spend significant management time and financial resources defending the related litigation and could potentially damage the public's perception of us and our products. Any publicity campaigns or other negative publicity may adversely affect the degree of market acceptance of our PHT countermeasures and thereby limit the demand for our products, which would adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">PRODUCT DEVELOPMENT AND                                                                              COMMERCIALIZATION RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our growth depends on our success in developing and commercializing our product candidates. If we are unable to</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">commercialize these product candidates, or experience significant delays or unanticipated costs in</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">doing so, our business would be materially and adversely affected.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We have invested significant effort and financial resources in the development of our vaccines, therapeutics and medical device product candidates and the acquisition of additional product candidates. In addition to our product sales, our ability to generate revenue is dependent on a number of factors, including the success of our development programs, the USG's interest in providing development funding for or procuring certain of our product candidates, and the commercial viability of our acquired or developed product candidates. The commercial success of our product candidates will depend on many factors, including accomplishing the following in an economical manner:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">successful development, formulation and cGMP scale-up of manufacturing that meets FDA or other foreign regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">successful program partnering;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">successful completion of clinical or non-clinical development, including toxicology studies and studies in approved animal models;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">receipt of marketing approvals from the FDA and equivalent foreign regulatory authorities;</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">56</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">establishment of commercial manufacturing processes and product supply arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">training of a commercial sales force for the product, whether alone or in collaboration with others;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">successful registration and maintenance of relevant patent and/or other proprietary protection; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">acceptance of the product by potential government and other customers.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Under certain circumstances, we might sell unapproved MCMs to government entities. While this is permissible in some cases, the extent to which we may be able to lawfully market and sell unapproved products in many jurisdictions may be unclear or ambiguous. Such sales could subject us to regulatory enforcement action, product liability and reputational risk.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Under certain circumstances, MCMs may be procured by government entities prior to approval by the FDA or other regulatory authorities. In the United States, the Project BioShield Act of 2004 (Project BioShield) permits the Secretary of HHS to contract to purchase MCMs for the SNS prior to FDA approval of the countermeasure in specified circumstances. Project BioShield and the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 also allow the FDA Commissioner to authorize the emergency use of medical products that have not yet been approved by the FDA under an EUA. Absent an applicable exception, our MCM product candidates generally will have to be approved by the FDA or other regulatory authorities through traditional pathways before we can sell those products to governments. Additionally, the laws in certain jurisdictions regarding the ability of government entities to purchase unapproved product candidates are ambiguous, and the permissibility of exporting unapproved products from the United States and importing them to foreign countries may be unclear. Nevertheless, government bodies, such as U.S. federal entities other than HHS, state and local governments within the United States, and foreign governments, may seek to procure our MCM product candidates that are not yet approved. If so, we would expect to assess the permissibility and liability implications of marketing our product candidates to such entities on a case-by-case basis, which presents certain challenges, both in the case of U.S. and foreign governments, and particularly under emergency conditions. In addition, agencies or branches of one country&#8217;s government may take different positions regarding the permissibility of such sales than another country&#8217;s government or even other agencies or branches of the same government. If we determine that we believe such activities are permissible, local enforcement authorities could </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">disagree with our conclusion and take enforcement action against us.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In addition, the sale of unapproved products also could give rise to product liability claims for which we may not be able to obtain indemnification or insurance coverage. For example, liability protections applicable to claims arising under U.S. law and resulting from the use of certain unlicensed products, such as a declaration issued under the Public Readiness and Emergency Preparedness Act (the PREP Act) may not cover claims arising under non-U.S. law.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Regardless of the permissibility and liability risks, in the event a user of one or more of our products suffers an adverse event, we may be subject to additional reputational risk if the product has not been approved by the FDA or the corresponding regulatory authority of another country particularly because we will not have approved labeling regarding the safety or efficacy of those products. In addition, legislatures and other governmental bodies that have oversight responsibility for procuring agencies may raise concerns after the fact even if procurement was permissible at the time, which could result in negative publicity, reputational risk and harm to our business prospects.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Clinical trials of product candidates are expensive and time-consuming, and their outcome is uncertain. We must invest substantial amounts of time and financial resources in these trials, which may not yield viable products. Failure to obtain regulatory approval for product candidates, particularly in the United States, could materially and adversely affect our financial resources, which would adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Before obtaining regulatory approval for the marketing of our product candidates, we and our collaborative partners, where applicable, must conduct preclinical studies and clinical trials to establish proof of concept and demonstrate the safety and efficacy of our product candidates. Preclinical and clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. Success in preclinical testing and early clinical trials does not ensure that later clinical trials or animal efficacy studies will be successful, and interim results of a clinical trial or animal efficacy study do not necessarily predict final results. An unexpected result in one or more of our clinical trials can occur at any stage of testing.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">For certain of our product candidates addressing CBRNE threats, we expect to rely on the Animal Rule to obtain regulatory approval. The Animal Rule permits, in certain limited circumstances, the use of animal efficacy studies, together with human clinical safety and immunogenicity trials, to support an application for marketing approval. For a product </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">57</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">approved under the Animal Rule, certain additional post-marketing requirements apply. For example, to the extent feasible and ethical, applicants must conduct post-marketing studies, such as field studies, to verify and describe the drug's clinical benefit and to assess its safety when used as indicated. We have limited experience in the application of these rules to the product candidates that we are developing. It is possible that results from these animal efficacy studies may not be predictive of the actual efficacy of our product candidates in humans.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Under Project BioShield, the Secretary of HHS can contract to purchase MCMs for the SNS prior to FDA approval of the countermeasure in specified circumstances. Project BioShield also allows the FDA commissioner to authorize the emergency use of medical products that have not yet been approved by the FDA under an EUA. If our product candidates are not selected under this Project BioShield authority, they generally will have to be approved by the FDA through traditional regulatory mechanisms for distribution in the United States.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We may experience unforeseen events or issues during, or as a result of, preclinical testing, clinical trials or animal efficacy studies. These issues and events, which could delay or prevent our ability to receive regulatory approval for a product candidate, include, among others:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">our inability to manufacture sufficient quantities of materials for use in trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the unavailability or variability in the number and types of subjects for each study;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">safety issues or inconclusive or incomplete testing, trial or study results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">drug immunogenicity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">lack of efficacy of product candidates during the trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">government or regulatory restrictions or delays; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">greater than anticipated costs of trials.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We continue to evaluate our product development strategy and, as a result, may modify our strategy in the future. In this regard, we may, from time to time, focus our product development efforts on different product candidates or may delay or halt the development of various product candidates. We may change or refocus our existing product development, commercialization and manufacturing activities based on government funding decisions. This could require </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">changes in our facilities and our personnel. Any product development changes that we implement may not be successful. In particular, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates or choose candidates for which government development funds are not available. Our decisions to allocate our research and development, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources from better business opportunities. Similarly, our decisions to delay or terminate product development programs may also prove to be incorrect and could cause us to miss valuable opportunities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">INTELLECTUAL PROPERTY RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to protect our proprietary rights, our business, financial condition, operating results, and cash flows could be materially harmed.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our success will depend, in large part, on our ability to obtain and maintain protection in the United States and other countries for the intellectual property incorporated into or covering our technology, products, and product candidates. Obtaining and maintaining protection of our intellectual property is very costly. The patentability of technology in the biopharmaceutical field generally is highly uncertain and involves complex legal and scientific questions.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We may not be able to obtain additional issued patents relating to our technology or products. Even if issued, patents may inadvertently lapse or be challenged, narrowed, invalidated, or circumvented, and such happenings could limit our ability to stop competitors from marketing similar products or limit the duration of patent protection we may have for our products. In the past, we have abandoned the prosecution and/or maintenance of patent applications related to patent families in the ordinary course of business. In the future we may choose to abandon such prosecution and/or maintenance in a similar fashion. If these patent rights are later determined to be valuable or necessary to our business, our competitive position may be adversely affected. Changes in patent laws or administrative patent office rules or changes in interpretations of patent laws in the United States and in other countries may diminish the value of our intellectual property, narrow the scope of our patent protection, or result in costly defensive measures. In addition, some countries do not grant patent claims directed to methods of treating humans and, in these countries, patent protection may not be available at all to protect our products or product candidates.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The cost of litigation to uphold the validity of patents to prevent or stop infringement or to otherwise </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">58</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">protect or enforce our proprietary rights could be substantial and, from time to time, our patents may be subjected to opposition proceedings or validity challenges. Some of our competitors may choose to or be better able to sustain the costs of complex patent litigation. Intellectual property lawsuits are expensive and unpredictable and consume management's time and attention and other resources, even if the outcome is successful. In addition, there is a risk that a court could decide that our patents are not valid, are unenforceable, or are not infringed by a competitor product. There is also a risk that, even if the validity of a patent is upheld, a court could refuse to stop the other party from using the invention(s), including on the grounds that its activities do not infringe the patent. If any of these events occur, our business, financial condition, operating results and cash flows could be materially and adversely affected.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our collaborators and licensors may not adequately protect our intellectual property rights. These third parties may have the first right to maintain or defend intellectual property rights in which we have an interest and, although we may have the right to assume the maintenance and defense of such intellectual property rights if these third parties do not do so, our ability to maintain and defend such intellectual property rights may be compromised by the acts or omissions of these third parties. For example, we license from:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Opiant Pharmaceuticals, Inc. formulations of naloxone, for use in our NARCAN&#174; Nasal Spray.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Pharma Consult GmbH autoinjectors, including the autoinjector used for our Trobigard&#174; (atropine sulfate, obidoxime chloride) autoinjector.*</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">*Trobigard&#174; is not currently approved or cleared by the FDA or any similar regulatory body and is only distributed to authorized government buyers for use outside the US. This product is not distributed in the US.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We also will rely on current and future trademarks to establish and maintain recognized brands. If we fail to acquire and protect such trademarks, our ability to market and sell our products, and therefore our business, financial condition, operating results, and cash flows could be materially and adversely affected.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations could be costly, time-consuming, distracting to management, and could materially and adversely affect our business, financial condition, operating results, and cash flows.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be claimed to infringe patents and other intellectual property rights of third parties for which we do not hold sufficient licenses or other rights. Additionally, third parties may be successful in obtaining patent protection for technologies that cover development and commercialization activities in which we are already engaged. Third parties may own or control these patents and intellectual property rights in the United States and abroad. These third parties could bring claims against us that could cause us to incur substantial expenses to defend against these claims and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement or other similar suit is brought against us, we could be forced to stop or delay development, manufacturing, or sales of the product or product candidate that is the subject of the suit. Intellectual property litigation in the biopharmaceutical industry is common, and we expect this trend to continue.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">As a result of patent infringement or other similar claims, or to avoid potential claims, we may choose or be required to seek a license from a third party and be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations. If, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, if at all, or if an injunction is granted against us, these could materially harm our business, financial condition, operating results, and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We are a party to a number of license agreements and expect to enter into additional license agreements in the future. Our existing licenses impose, and we expect future licenses will impose, various diligence, milestone payment, royalty, insurance, and other obligations on us. If we fail to comply with these obligations, the licensor may have the right to terminate the license and/or sue us for breach, which could cause us to not be able to market any product that is covered by the license and subject us to damages, which may be material.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">59</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We also rely upon unpatented proprietary technology, processes, and know-how, particularly as to our proprietary manufacturing processes. Because we do not have patent protection for all of our current products, our only other intellectual property protection for products, other than trademarks, is confidentiality regarding our manufacturing capability and specialty know-how, such as techniques, processes, and unique starting materials. However, these types of confidential information and trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants, and third parties, as well as confidentiality policies and audits, although these may not be successful in protecting our trade secrets and confidential information.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known, including through a potential cyber security breach, or may be independently developed by competitors. If we are unable to protect the confidentiality of our proprietary information and know-how, or if others independently develop our proprietary information or processes, competitors may be able to use this information to develop products that compete with our products, which could materially and adversely impact our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">One or more of our products could be subject to early competition from generic drugs and biosimilars.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">One or more of our products is approved as a drug product under the provisions of the U.S. Food, Drug and Cosmetic Act (FDCA), which renders it susceptible to potential competition from generic manufacturers via the Hatch-Waxman Act and ANDA process. Generic manufacturers pursuing ANDA approval are not required to conduct costly and time-consuming clinical trials to establish the safety and efficacy of their products; rather, they are permitted to rely on the innovator&#8217;s data regarding safety and efficacy. Additionally, generic drug companies generally do not expend significant sums on sales and marketing activities, instead relying on pharmacists or payers to substitute the generic form of a drug for the branded form. Thus, generic manufacturers can sell their products at prices much lower than those charged by the innovative pharmaceutical or biotechnology companies who have incurred substantial expenses associated with the research and development of the drug product and who must spend significant sums marketing a new drug.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The ANDA procedure includes provisions allowing generic manufacturers to challenge the innovator&#8217;s patent protection by submitting &#8220;Paragraph IV&#8221; certifications to the FDA in which the generic manufacturer claims that the innovator&#8217;s patents are </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">invalid, unenforceable, and/or will not be infringed by the manufacture, use, or sale of the generic product. A patent owner who receives a Paragraph IV certification may choose to sue the generic applicant for patent infringement. If the patent owner files suit within 45 days of receiving notice from an ANDA filer, the patent owner is entitled to receive a 30 month stay on the FDA&#8217;s ability to give final approval for the generic product that is the subject of the ANDA.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In recent years, generic manufacturers have used Paragraph IV certifications extensively to challenge the validity of patents listed in the FDA&#8217;s Approved Drug Products List with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, on a wide array of innovative therapeutic products. We expect this trend to continue and to affect drug products with even relatively modest revenues.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Although we intend to vigorously enforce our intellectual property rights, there can be no assurance that we will prevail in our enforcement or defense of our patent rights. Our existing patents could be invalidated, found unenforceable, or found not to cover a generic form of our product.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Further, the 2010 Patient Protection and Affordable Care Act, which was signed into law on March 23, 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA). That Act established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. As of January 1, 2018, the FDA has approved nine biosimilar products for use in the United States. No interchangeable biosimilars, have been approved. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Additional guidances are expected to be finalized by FDA in the near term.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Under the Act, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">60</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">FINANCIAL RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We have incurred significant indebtedness in connection with our acquisitions and servicing our debt requires a significant amount of cash. We may not have sufficient cash flow from our operations to pay our substantial debt.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. We may also seek additional debt financing to support our ongoing activities or to provide additional financial flexibility. Debt financing could have significant adverse consequences for our business, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">requiring us to dedicate a substantial portion of any cash flow from operations to payment on our debt, which would reduce the amounts available to fund other corporate initiatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-48px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">increasing the amount of interest that we have to pay on debt with variable interest rates, if market rates of interest increase;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">subjecting us, as under our senior secured credit facilities, to restrictive covenants that may reduce our ability to take certain corporate actions, acquire companies, products or technology, or obtain further debt financing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">requiring us to pledge our assets as collateral, which could limit our ability to obtain additional debt financing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">limiting our flexibility in planning for, or reacting to, general adverse economic and industry conditions; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">placing us at a competitive disadvantage compared to our competitors that have less </span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-align:justify;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">debt, better debt servicing options or stronger debt servicing capacity.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We may not have sufficient funds or be able to obtain additional financing to pay the amounts due under our indebtedness. In addition, failure to comply with the covenants under our senior secured credit facilities and other debt agreements could result in an event of default under those agreements. An event of default could result in the acceleration of amounts due under a particular debt agreement and a cross default and acceleration under other debt agreements, and we may not have sufficient funds to pay or be able to obtain additional financing to make any accelerated payments. Under these circumstances, our lenders could seek to enforce security interests in our assets securing our indebtedness.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our current indebtedness and any additional debt financing may restrict the operation of our business and limit the cash available for investment in our</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">business operations.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In connection with the acquisition of Adapt, we entered into an amendment and restatement of our 2017 credit agreement to provide for new five-year syndicated senior secured credit facilities that replaced our existing facility. The senior secured credit facilities include a $450 million Term Loan and the ability to borrow up to a $600 million revolver, of which we had outstanding borrowings of $442 million and $398 million, respectively, as of June 30, 2019. We may also seek additional debt financing to support our ongoing activities or to provide additional financial flexibility. Debt financing could have significant adverse consequences for our business, including:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the level, timing and cost of product sales and contract manufacturing services;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the payment obligations under our indebtedness;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the scope, progress, results and costs of our development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">our ability to obtain funding from collaborative partners, government entities and non-governmental organizations for our development programs; </span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">61</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the extent to which we repurchase additional common stock under our authorized share repurchase program; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the costs of commercialization activities, including product marketing, sales and distribution.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We may not have sufficient funds or be able to obtain additional financing to pay the amounts due under our indebtedness. In addition, failure to comply with the covenants under our debt agreements could result in an event of default under those instruments. An event of default could result in the acceleration of amounts due under a particular debt agreement and a cross default and acceleration under other debt agreements, and we may not have sufficient funds or be able to obtain additional financing to make any accelerated payments. Under these circumstances, our lenders could seek to enforce security interests in our assets securing our indebtedness.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our hedging program is subject to counterparty default risk</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We manage our interest rate risk in part by entering into interest rate swaps with a number of counterparties to swap a portion of our indebtedness that is based on variable interest rates to a fixed rate. As a result, we are subject to the risk that the counterparty to one or more of these contracts defaults on its performance under the contract. During an economic downturn, the counterparty's financial condition may deteriorate rapidly and with little notice and we may be unable to take action to protect our exposure. In the event of a counterparty default, we could incur losses, which may harm our business and financial condition. In the event that one or more of our counterparties becomes insolvent or files for bankruptcy, our ability to eventually recover any losses suffered as a result of that counterparty's default may be limited by the liquidity of the counterparty.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may require significant additional funding and may be unable to raise capital when&#160;needed or on acceptable terms, which would harm our ability to grow our business, and our results of operations and financial condition.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans or collaboration and licensing arrangements. In August 2018, we filed an automatic shelf registration statement, which immediately became effective under SEC rules. For so long as we continue to satisfy the requirements to be deemed a &#8220;well-known seasoned issuer&#8221; under SEC rules (which include, among other things, the timely filing of our reports under the Exchange Act and maintenance of </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">at least $700 million of public float or issuing an aggregate amount of $1 billion of non-convertible securities, other than common stock, in registered offerings for cash during the past three years), this shelf registration statement, effective until August 8, 2021, allows us to issue an unrestricted amount of equity, debt and certain other types of securities through one or more future primary or secondary offerings. If we do not file a new shelf registration statement prior to August 8, 2021, the existing shelf registration statement will expire, and we will not be able to publicly raise capital or issue debt until a new registration statement is filed and becomes effective. There can be no assurance that we will be eligible to file an automatically effective shelf registration statement at a future date when we may need to raise funds publicly.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">If we raise funds by issuing equity securities, our stockholders may experience dilution. Public or bank debt financing, if available, may involve agreements that include covenants, like those contained in our senior secured credit facilities, limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities or declaring dividends. If we raise funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us. We are not restricted under the terms of the indenture governing our 2.875% Convertible Senior Notes due 2021 (Senior Convertible Notes) from incurring additional debt, securing existing or future debt, recapitalizing our debt or taking a number of other actions that could have the effect of diminishing our ability to make payments on our indebtedness. However, our senior secured credit facilities restrict our ability to incur additional indebtedness, including secured indebtedness.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Economic conditions may make it difficult to obtain financing on attractive terms, or at all. If financing is unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may not maintain profitability in future periods or on a consistent basis.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Although we have been profitable for each of the last five fiscal years, we have not been profitable for every quarter during that time. Our profitability has been substantially dependent on product sales, which historically have fluctuated significantly from quarter to quarter, and we expect that they will continue to fluctuate significantly based primarily on the timing of our fulfillment of orders from the USG. We may not be able to achieve consistent profitability on a quarterly </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">62</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">basis or sustain or increase profitability on an annual basis.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">SPIN-OFF OF OUR BIOSCIENCES BUSINESS RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If the spin-off distribution on August 1, 2016 of all of the outstanding shares of Aptevo Therapeutics Inc. common stock to our stockholders does not qualify as a tax-free transaction for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">It was our intention that our distribution on August 1, 2016 of all of the outstanding shares of Aptevo common stock to our stockholders (the Distribution), together with certain related transactions, qualify as a tax-free transaction described under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code of 1986, as amended (the Code). In anticipation of the Distribution, we received a favorable private letter ruling from the Internal Revenue Service (the IRS), regarding certain U.S. federal income tax matters relating to the Distribution and certain related transactions and an opinion of counsel substantially to the effect that, for U.S. federal income tax purposes, the Distribution, together with certain related transactions, will qualify as a transaction described under Sections 355 and 368(a)(1)(D) of the Code. A &#8220;private letter ruling,&#8221; is a written statement issued to a taxpayer by an Associate Chief Counsel Office of the Office of Chief Counsel that interprets and applies the tax laws to a specific set of facts. Our private letter ruling is based on certain facts and representations submitted by us to the IRS and the opinion of counsel was based upon and relied on, among other things, the IRS private letter ruling and certain facts and assumptions, as well as certain representations and covenants of us and Aptevo contained in a tax matters agreement and certain representations contained in representation letters provided by us, Aptevo and certain stockholders to such counsel, including representations and covenants relating to the past and future conduct of us, Aptevo and such stockholders. If any of these facts, assumptions, representations, or covenants are, or become, inaccurate or incomplete, the IRS private letter ruling and/or the opinion of counsel may be invalid and the conclusions reached therein could be jeopardized and, as a result, the Distribution, together with certain related transactions, could fail to qualify as a tax-free transaction described under Sections 355 and 368(a)(1)(D) of the Code for U.S. federal income tax purposes.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In addition, the IRS private letter ruling only addresses certain limited matters relevant to determining whether the Distribution, together with certain related transactions, qualifies as a transaction described under Sections 355 and 368(a)(1)(D) of the Code, and the opinion of counsel only represents the </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">judgment of such counsel, which is not binding on the IRS or any court. Accordingly, notwithstanding the IRS private letter ruling and the opinion of counsel, there can be no assurance that the IRS will not assert that the Distribution, together with certain related transactions, should be treated as a taxable transaction for U.S. federal income tax purposes or that a court would not sustain such a challenge.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">If the Distribution, together with certain related transactions, fails to qualify as a tax-free transaction described under Sections 355 and 368(a)(1)(D) of the Code, for U.S. federal income tax purposes, in general, (i) we would recognize taxable gain on the Distribution equal to the amount by which the fair market value of the Aptevo shares distributed to our stockholders exceeded our tax basis in the Aptevo shares and (ii) each of our stockholders who received Aptevo shares in the Distribution would be treated as receiving a taxable distribution equal to the fair market value of the Aptevo shares received by such stockholder.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Under the tax matters agreement that we entered into with Aptevo in connection with the spin-off, Aptevo may be required to indemnify us against any tax liabilities and related expenses resulting from the failure of the Distribution, together with certain related transactions, to qualify as a transaction described under Sections 355 and 368(a)(1)(D) of the Code to the extent that the failure to so qualify is attributable to actions, events or transactions relating to Aptevo&#8217;s stock, assets or business, or a breach of the relevant representations or covenants made by Aptevo in the tax matters agreement or the IRS private letter ruling or in the representation letters provided to our counsel for purposes of their opinion. Any such indemnity obligations could be material, and there can be no assurance that Aptevo will be able to pay any such indemnification.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">To preserve the tax-free treatment of the Distribution, together with certain related transactions, and in addition to Aptevo's indemnity obligation, the tax matters agreement, which expired on August 2, 2018, restricted Aptevo from taking any action that prevents such transactions from being tax-free for U.S. federal income tax purposes. In particular, for the two-year period following the Distribution, Aptevo was restricted from taking certain actions (including restrictions on share issuances, business combinations, sales of assets, amendments to organizational documents and similar transactions) that could cause the Distribution, together with certain related transactions, to fail to qualify as a tax-free transaction for U.S. federal income tax purposes. There can be no assurance that Aptevo adequately complied with these restrictions. If a finding is made by the IRS through a tax audit that Aptevo failed to satisfy its obligations, this could have a substantial </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">63</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">impact on our tax obligations, consolidated financial condition and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">In connection with Aptevo&#8217;s separation from us, Aptevo agreed to indemnify us for certain matters. This indemnity may not be sufficient to hold us harmless from the full amount of losses that we may incur in connection with these matters, and Aptevo may not be able to satisfy its indemnification obligations to us.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Pursuant to the agreements that we entered into with Aptevo at the time of Aptevo&#8217;s separation from us, Aptevo agreed to indemnify us for certain matters, including liabilities related to Aptevo&#8217;s business or for which Aptevo otherwise agreed to be responsible in the separation. This indemnity from Aptevo may not be sufficient to protect us against the full amount of losses that we may incur in connection with these matters, including if third parties assert claims against us for liabilities that were allocated to Aptevo in the separation. Moreover, Aptevo may dispute its indemnification obligation to us or have insufficient resources to satisfy its indemnification obligations to us. Even if we ultimately succeed in recovering from Aptevo the amount of any losses that we incur in connection with these matters, the recovery could take a substantial amount of time and we may be required to bear these losses ourselves while we seek recovery. Each of these risks could negatively affect our business, operating results, financial condition and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">OTHER BUSINESS RISKS</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We face product liability exposure, which could cause us to incur substantial liabilities and</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">negatively affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We face an inherent risk of product liability exposure related to the sale of our products, any other products that we successfully acquire or develop and the testing of our product candidates in clinical trials.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">One measure of protection against such lawsuits is coverage under the PREP Act, which was signed into law in December 2005. The PREP Act creates liability protection for manufacturers of biodefense countermeasures when the Secretary of HHS issues a declaration for their manufacture, administration or use. A PREP Act declaration is meant to provide liability protection from all claims under federal or state law for loss arising out of the administration or use of a covered countermeasure under a government contract. The Secretary of HHS has issued PREP Act declarations identifying certain of our products, namely BioThrax, ACAM2000, raxibacumab, Anthrasil, BAT and VIGIV, as covered countermeasures. These declarations expire in 2022. Manufacturers are not entitled to protection under the PREP Act in cases of willful misconduct. We cannot predict whether the Secretary of HHS will renew the declarations when </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">they expire, whether Congress will fund the relevant PREP Act compensation programs, or whether the necessary prerequisites for immunity would be triggered with respect to our products or product candidates.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Additionally, certain of our products, namely BioThrax and RSDL, are certified anti-terrorism products covered under the protections of the Support Anti-Terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). The SAFETY Act creates product liability limitations for qualifying anti-terrorism technologies for claims arising from or related to an act of terrorism. Although we are entitled to the benefits of the SAFETY Act for BioThrax and RSDL, the SAFETY Act may not provide adequate protection from claims made against us.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">If we cannot successfully defend ourselves against future claims that our products or product candidates caused injuries and if we are not entitled to indemnity by the USG, or the USG does not honor its obligations to us under the PREP Act or SAFETY Act, or if the indemnification under the PREP Act and SAFETY Act is not adequate to cover all claims, we may incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">decreased demand or withdrawal of a product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">injury to our reputation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">withdrawal of clinical trial participants;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">costs to defend the related litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">substantial monetary awards to trial participants or patients;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">loss of revenue; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">an inability to commercialize products that we may develop.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The amount of insurance that we currently hold may not be adequate to cover all liabilities that we may incur. Further product liability insurance may be difficult and expensive to obtain. We may not be able to maintain insurance coverage at a reasonable cost and we may not be able to obtain insurance coverage that will be adequate to satisfy all potential liabilities. For example, we may not have sufficient insurance against potential liabilities associated with a possible large-scale deployment of BioThrax as a countermeasure to a bioterrorism threat. We rely on PREP Act protection for BioThrax, raxibacumab, ACAM2000, Anthrasil, BAT and VIGIV, and SAFETY Act protection for BioThrax and RSDL in addition to our insurance coverage to help mitigate our product </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">64</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">liability exposure for these products. Additionally, potential product liability claims related to our commercial products, including NARCAN&#174; Nasal Spray, Vivotif and Vaxchora, may be made by patients, health care providers or others who sell or consume these products. Such claims may be made even with respect to those products that possess regulatory approval for commercial sale. Claims or losses in excess of our product liability insurance coverage could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The accuracy of our financial reporting depends on the effectiveness of our internal control over financial reporting. A material weakness in our internal control over financial reporting could have an adverse effect on our business and financial results and our ability to meet our reporting obligations could be negatively affected, each of which could negatively affect the trading price of our common stock.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Internal control over financial reporting can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements and may not prevent or detect misstatements. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Failure to maintain effective internal control over financial reporting, or lapses in disclosure controls and procedures, could impact our financial information and disclosures, require significant resources to remediate, and expose us to legal or regulatory proceedings.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We regularly review and update our internal controls and disclosure controls and procedures. In addition, we are required under the Sarbanes-Oxley Act of 2002 to report annually on our internal control over financial reporting. Our system of internal controls, however well-designed, can provide only reasonable, not absolute, assurances that the objectives of the system are met. If we, or our independent registered public accounting firm, determine that our internal controls over financial reporting, or the internal controls of other companies we may acquire, are not effective, or we discover areas that need improvement in the future, these shortcomings could have an adverse effect on our business and financial reporting, and the trading price of our common stock could be negatively affected.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We rely significantly on information technology systems and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm our ability to operate our business effectively or result in data leakage of </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">proprietary and confidential business and employee information.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. The size and complexity of our computer systems make them potentially vulnerable to interruption, invasion, computer viruses, destruction, malicious intrusion and additional related disruptions, which may result in the impairment of production and key business processes.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In addition, our systems are potentially vulnerable to data security breaches-whether by employee error, malfeasance or other disruption-which may expose sensitive data to unauthorized persons. Such data security breaches could lead to the loss of trade secrets or other intellectual property or could lead to the public exposure of personal information, including sensitive personal information, of our employees, clinical trial patients, customers and others.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">A significant business disruption or a breach in security resulting in misappropriation, theft or sabotage with respect to our proprietary and confidential business and employee information could result in financial, legal, business or reputational harm to us, any of which could materially and adversely affect our business, financial condition and operating results.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our success is dependent on our continued ability to attract, motivate and retain key personnel, and any failure to attract or retain key personnel may</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">negatively affect our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Because of the specialized scientific nature of our business, our ability to develop products and to compete with our current and future competitors largely depends upon our ability to attract, retain and motivate highly qualified managerial and key scientific and technical personnel. If we are unable to retain the services of one or more of the principal members of senior management or other key employees, our ability to implement our business strategy could be materially harmed. We face intense competition for qualified employees from biopharmaceutical companies, research organizations and academic institutions. Attracting, retaining or replacing these personnel on acceptable terms may be difficult and time-consuming given the high demand in our industry for similar personnel. We believe part of being able to attract, motivate and retain personnel is our ability to offer a competitive compensation package, including equity incentive awards. </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">65</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">If we cannot offer a competitive compensation package to attract and retain the qualified personnel necessary for the continued development of our business, we may not be able to maintain our operations or grow our business.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Fuad El-Hibri, executive chairman of our Board of Directors, has</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">significant influence over us through his substantial beneficial ownership of our common stock, including an ability to influence the election of</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">the members of our Board of Directors, or delay or prevent a change of</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">control of us.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Mr. El-Hibri has the ability to significantly influence the election of the members of our Board of Directors due to his substantial beneficial ownership of our common stock. As of July 26, 2019, Mr. El-Hibri was the beneficial owner of approximately 11% of our outstanding common stock. As a result, Mr. El-Hibri could exercise substantial influence over all corporate actions requiring board or stockholder approval, including a change of control, or any amendment of our certificate of incorporation or by-laws. The control by Mr. El-Hibri may prevent other stockholders from influencing significant corporate decisions. In addition, Mr. El-Hibri's significant beneficial ownership of our shares could present the potential for a conflict of interest.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Provisions in our certificate of incorporation and by-laws and under Delaware law may discourage acquisition proposals, delay a change in control or prevent transactions that stockholders may consider favorable.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Provisions in our certificate of incorporation and by-laws may discourage, delay or prevent a merger, acquisition or other changes in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">These provisions include:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the classification of our directors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">limitations on changing the number of directors then in office;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">limitations on the removal of directors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">limitations on filling vacancies on the board;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">advance notice requirements for stockholder nominations of candidates for election to the Board of Directors and other proposals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the inability of stockholders to act by written consent;</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the inability of stockholders to call special meetings; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the ability of our Board of Directors to designate the terms of and issue a new series of preferred stock without stockholder approval.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The affirmative vote of holders of our capital stock representing at least 75% of the voting power of all outstanding stock entitled to vote is required to amend or repeal the above provisions of our certificate of incorporation. The affirmative vote of either a majority of the directors present at a meeting of our Board of Directors or holders of our capital stock representing at least 75% of the voting power of all outstanding stock entitled to vote is required to amend or repeal our by-laws.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In addition, we are subject to Section 203 of the Delaware General Corporation Law (Section 203). In general and subject to certain exceptions, Section 203 prohibits a publicly-held corporation from engaging in a business combination with an interested stockholder, generally a person which, together with its affiliates, owns or within the last three years has owned 15% or more of the corporation's voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Accordingly, Section 203 may discourage, delay or prevent a change in control of us.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our Board of Directors may implement a new stockholder rights plan without stockholder approval, which could prevent a change in control of us in instances in</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">which some stockholders may believe a change in control is in their best interests.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our Board of Directors may implement a stockholder rights plan without stockholder approval. We previously implemented a stockholder rights plan, which expired on November 14, 2016. Under our prior stockholder rights plan, we issued to each of our stockholders one preferred stock purchase right for each outstanding share of our common stock. Each right, when exercisable, would have entitled its holder to purchase from us a unit consisting of one one-thousandth of a share of series A junior participating preferred stock at a purchase price of $150 in cash, subject to adjustments. Our stockholder rights plan was intended to protect stockholders in the event of an unfair or coercive offer to acquire us and to provide our Board of Directors with adequate time to evaluate unsolicited offers.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our Board of Directors may implement a new stockholder rights plan, which may have anti-takeover effects, potentially preventing a change in control of us in instances in which some stockholders may </span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">66</span></div></div><hr style="page-break-after:always"></hr><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">believe a change in control is in their best interests. This could cause substantial dilution to a person or group that attempts to acquire us on terms that our Board of Directors does not believe are in our best interests or those of our stockholders and may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our stock price is volatile and purchasers of our common stock could incur</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">substantial losses.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Our stock price has been, and is likely to continue to be, volatile. The market price of our common stock could fluctuate significantly for many reasons, including in response to the risks described in this &#8220;Risk Factors&#8221; section, or for reasons unrelated to our operations, such as reports by industry analysts, investor perceptions or negative announcements by our customers, competitors or suppliers regarding their own performance, as well as industry conditions and general financial, economic and political instability. From November 15, 2006, when our common stock first began trading on the New York Stock Exchange, through July 26, 2019, our common stock has traded as high as $73.89 per share and as low as $4.20 per share. The stock market in general as well as the market for biopharmaceutical companies in particular has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price of our common stock may be influenced by many factors, including, among others:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">contracts, decisions and procurement policies by the USG affecting BioThrax and our other products and product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the success of competitive products or technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">results of clinical and non-clinical trials of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">announcements of acquisitions, financings or other transactions by us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">litigation or legal proceedings;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">public concern as to the safety of our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">termination or delay of a development program;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the recruitment or departure of key personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">variations in our product revenue and profitability; and</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Because we currently do not pay dividends, investors will benefit from an investment in our common stock only if it appreciates in value.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">We currently do not pay dividends on our common stock. Our senior secured credit facilities limit and any future debt agreements that we enter into may limit our ability to pay dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">A significant portion of our shares may be sold into the market at any time. This could cause the market price of our common stock to drop</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">significantly.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales or the perception in the market that the holders of a large number of shares intend to sell shares could reduce the market price of our common stock. Moreover, holders of an aggregate of approximately 6 million shares of our common stock outstanding as of June 30, 2019, have the right to require us to register these shares of common stock under specified circumstances.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">67</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0479D5786ACF58F2B7BC38D6C73F3B26"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Recent Sales of Unregistered Securities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Not applicable.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Use of Proceeds</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Not applicable.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Purchases of Equity Securities</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Not applicable.</span></div><div><a id="s630CF094F0095B6AADD201EFB4F034B5"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Not applicable.</span></div><div><a id="s7D07E61462BB55F498673F2F8EC32CC5"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Not applicable.</span></div><div><a id="s1E13D38B49D852BE806AF01B7C2DA37A"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 5. OTHER INFORMATION</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On June 27, 2019, certain amendments were made to the Amended Credit Agreement which extended the covenant relief period (collectively, the Amendment). The Amendment included, among other things, a change to the maximum consolidated net leverage ratio of 4.95 to 1.00 for the quarter ended June 30, 2019 and 4.75 to 1.00 for the quarter ended September 30, 2019. Covenants in the Amended Credit Agreement were also amended to limit the amount of restricted payments as defined in the Amended Credit Agreement to $25 million until the filing of the Company's December 31, 2019 Form 10-K. This description of the Amendment does not purport to be complete and is qualified in its entirety by the full text of the Amendment, which is filed hereto as Exhibit 10.2.</span></div><div><a id="s41278906D97255EE86CFFF19D42DB3F1"></a></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">ITEM 6. EXHIBITS</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit Index immediately preceding the exhibits hereto.</span></div></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">68</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5B4C8841870A54A2BA714D7084344D77"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:center;-sec-extract:summary;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">EXHIBIT INDEX</span></div><div style="line-height:120%;padding-bottom:12px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit</span></div><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Number</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Description</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></span><span style="font-family:Times New Roman;font-size:12pt;">&#8224;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ebs-20190630xex101.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Modification No. 17, effective June 13, 2019, to the Solicitation/Contract/Order for Commercial Items, effective December 8, 2016, from the Centers for Disease Control and Prevention to Emergent Biodefense Operations Lansing LLC.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ebs-201906030xex102.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">First Amendment, dated June 27, 2019, to Amended and Restated Credit Agreement, dated October 15, 2018, by and among Emergent BioSolutions Inc., the lenders party thereto from time to time, and Wells Fargo Bank, National Association, as the Administrative Agent.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1 </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ebs-20190630xex311.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a).</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2 </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ebs-20190630xex312.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1 </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ebs-20190630xex321.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.2 </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ebs-20190630xex322.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101. INS</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">XBRL Instance Document the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.SCH</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Extension Schema Document.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.CAL</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Calculation Linksbase Document.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.DEF</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Definition Linksbase Document.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.LAB</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Label Linksbase Document.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.PRE</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inline XBRL Taxonomy Presentation Linksbase Document.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Attached as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language):</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">(i)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Condensed Consolidated Statements of Operations for the three and six months ended </span><span style="font-family:Franklin Gothic Book;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">(ii)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended </span><span style="font-family:Franklin Gothic Book;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and 2018;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">(iii)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Condensed Consolidated Balance Sheets at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;color:#2c2c2c;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">(iv)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Condensed Consolidated Statements of Cash Flows for the six months ended </span><span style="font-family:Franklin Gothic Book;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">(v)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Condensed Consolidated Statement of Changes in Stockholders' Equity for the six months ended </span><span style="font-family:Franklin Gothic Book;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">(vi)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Notes to Condensed Consolidated Financial Statements.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:48px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">#</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Filed herewith.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-24px;font-size:12pt;"><span style="font-family:Times New Roman;font-size:12pt;color:#2c2c2c;font-weight:bold;">&#8224;    </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">69</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB2EFD6E278B85E858C9EF92158813F0F"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:11pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:11pt;color:#00497f;font-weight:bold;">EMERGENT BIOSOLUTIONS INC.</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.3515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">EMERGENT BIOSOLUTIONS INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">By: </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/ROBERT G. KRAMER, SR.</span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robert G. Kramer, Sr.</span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">President and Chief Executive Officer</span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Principal Executive Officer)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: August&#160;1, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">By: </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/RICHARD S. LINDAHL</span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Richard S. Lindahl</span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Chief Financial Officer and Treasurer</span></div><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Principal Financial and Accounting Officer)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: August&#160;1, 2019</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">70</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ebs-20190630xex101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9AFE60EA4027E1F40B8A3E69AE39D8BC"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Materials Omitted &#8211; To be filed separately with the</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities and Exchange Commission upon request.  Double asterisks denote omissions.</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;Exhibit 10.1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:9%;"></td><td style="width:19%;"></td><td style="width:6%;"></td><td style="width:15%;"></td><td style="width:12%;"></td><td style="width:4%;"></td><td style="width:12%;"></td><td style="width:7%;"></td><td style="width:6%;"></td><td style="width:10%;"></td></tr><tr><td colspan="5" rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-right:1px solid #000000;border-top:2px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT</font></div></td><td colspan="3" rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:2px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1. CONTRACT ID CODE</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-left:1px solid #000000;border-top:2px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">PAGE OF PAGES</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;">2. AMENDMENT/MODIFICATION NO. </font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:10pt;">P00017</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;">3. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:8pt;">EFFECTIVE DATE</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:inherit;font-size:10pt;">06/13/2019</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;">4. REQUISITION/PURCHASE REQ NO. </font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:10pt;">OS242076</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;">5. PROJECT NO. </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(If applicable)</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">6. ISSUED BY   CODE</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">ASPR-BARDA</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">7. ADMINISTERED BY </font><font style="font-family:Arial;font-size:8pt;font-style:italic;">(</font><font style="font-family:Arial;font-size:7pt;font-style:italic;">If other than Item 6)    </font><font style="font-family:Arial;font-size:8pt;">CODE</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">ASPR-BARDA02</font></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:8px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASPR-BARDA <br>200 Independence Ave., S.W. <br>Room 640-G <br>Washington DC 20201</font></div></td><td colspan="6" style="vertical-align:top;padding-left:2px;padding-top:8px;padding-bottom:4px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US DEPT OF HEALTH &amp; HUMAN SERVICES <br>ASST SEC OF PREPAREDNESS &amp; RESPONSE <br>ACQ MANAGEMENT, CONTRACTS, &amp; GRANTS <br>O&#8217;NEILL HOUSE OFFICE BUILDING <br>Washington DC 20515</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;">8. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:8pt;">NAME AND ADDRESS OF CONTRACTOR </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(No., street, county, State and ZIP Code)</font><font style="font-family:Arial;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">(x)</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">9A. AMENDMENT OF SOLICITATION NO.</font></div></td></tr><tr><td colspan="5" rowspan="6" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">EMERGENT BIODEFENSE OPERATIONS LANSING LLC 330303 <br>Attn:  DIANA <br>EMERGENT BIODEFENSE OPERATIONS LANS <br>3500 N MARTIN LUTHER KING JR BLVD <br>LANSING MI 489062933</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:4px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">9B. DATED </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(SEE ITEM 11)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">x</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">10A. MODIFICATION OF CONTRACT/ORDER NO.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">HHSD200201792634C</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;padding-top:4px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">10B. DATED </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(SEE ITEM 13)</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">CODE    330303</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FACILITY CODE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">12/08/2016</font></div></td></tr><tr><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-top:2px solid #000000;"><div style="padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></div></td></tr><tr><td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;padding-top:4px;text-align:justify;font-size:7pt;"><font style="font-family:Arial;font-size:6pt;">&#160;</font><font style="font-family:Arial;font-size:7pt;">The above numbered solicitation is amended as set forth in Item 14.  The hour and date specified for receipt of Offers  is extended,  is not extended.  Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning _________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or </font></div><div style="padding-bottom:4px;padding-top:4px;text-align:justify;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">&#160;<br>(c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers.  FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER.  If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:4px;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;">12. ACCOUNTING AND APPROPRIATION DATA </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(If required)   </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Net Increase:   $27,927,000.00</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">See Schedule </font></div></td></tr><tr><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.   <br>IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Arial;font-size:6pt;">CHECK ONE</font></div></td><td colspan="9" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-top:4px;padding-left:10px;text-indent:-11px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Specify authority)</font><font style="font-family:Arial;font-size:7pt;">&#160;THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="padding-top:4px;padding-left:10px;text-indent:-11px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES </font><font style="font-family:Arial;font-size:7pt;font-style:italic;">(such as changes in paying office, appropriation date, etc.)</font><font style="font-family:Arial;font-size:7pt;">&#160;SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:4px;padding-left:10px;text-indent:-11px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  </font></div><div style="padding-top:4px;padding-left:10px;text-indent:-11px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FAR 52.217-7 Option for Increased Quantity &#8211; Separately Priced Line Item</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:4px;padding-left:10px;text-indent:-11px;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;">D. OTHER </font><font style="font-family:Arial;font-size:6pt;font-style:italic;">(Specify type of modification and authority)  </font></div></td></tr><tr><td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">E. IMPORTANT:</font><font style="font-family:Arial;font-size:8pt;">&#160;&#160;Contractor    is not,  is required to sign this document and return ____</font><font style="font-family:Arial;font-size:8pt;text-decoration:underline;">1</font><font style="font-family:Arial;font-size:8pt;">____ copies to the issuing office.</font></div></td></tr><tr><td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">14. DESCRIPTION OF AMENDMENT/MODIFICATION</font><font style="font-family:Arial;font-size:6pt;">&#160;</font><font style="font-family:Arial;font-size:6pt;font-style:italic;">(Organized by UCF section headings, including solicitation/contract subject matter where feasible.)</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:8pt;">Tax ID Number: [**]</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:8pt;">DUNS Number: [**]</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:8pt;">The purpose of this modification is to:</font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">1. Order an increased quantity of [**] doses of BioThrax [**] year product at a unit price of $[**] per dose for a total cost of $27,927,000.00.</font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">2. Accordingly, total contract value is hereby increased from $492,321,363.90 by $27,927,000.00 to read $520,248,368.90.</font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">3. This modification supersedes the Authorization to Proceed dated June 13, 2019. Continued&#8230;</font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div></td></tr><tr><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:6pt;"><font style="font-family:Arial;font-size:6pt;">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:8pt;">15A. NAME AND TITLE OF SIGNER </font><font style="font-family:Arial;font-size:8pt;font-style:italic;">(Type or print)</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:8pt;">Michael Mann, Sr. Manager Comm. Ops.</font></div></td><td colspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:8pt;">16A. NAME AND TITLE OF CONTRACTING OFFICER (</font><font style="font-family:Arial;font-size:8pt;font-style:italic;">Type or print</font><font style="font-family:Arial;font-size:8pt;">)</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:8pt;">Natasha Y. Rowland </font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">15B. CONTRACTOR/OFFEROR</font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:7pt;text-decoration:underline;">/s/ J. </font><font style="font-family:Arial;font-size:8pt;text-decoration:underline;">Michael Mann II</font><font style="font-family:Arial;font-size:7pt;text-decoration:underline;">&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Signature of person authorized to sign)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">15C. DATE SIGNED</font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">9 Jul 19</font></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">16B. UNITED STATES OF AMERICA</font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">By</font></div><div style="font-size:7pt;"><font style="font-family:Arial;font-size:7pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;text-decoration:underline;">/s/ Natasha Y. Rowland</font><font style="font-family:Arial;font-size:7pt;text-decoration:underline;">&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Arial;font-size:7pt;font-style:italic;">(Signature of Contracting Officer)</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">16C. DATE SIGNED</font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">7/9/2019</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">NSN 7540-01-152-8070&#160;&#160;&#160;&#160;STANDARD FORM 30 (Rev. 10-83)</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Previous edition unusable&#160;&#160;&#160;&#160;Sponsored by GSA</font></div><div style="line-height:120%;text-align:justify;text-indent:540px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FAR (48 CFR) 53.243</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div><a name="s5F8B0311F02A21A3EBE53E69AE75C245"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:12%;"></td><td style="width:6%;"></td><td style="width:41%;"></td><td style="width:10%;"></td><td style="width:6%;"></td><td style="width:8%;"></td><td style="width:2%;"></td><td style="width:7%;"></td><td style="width:8%;"></td></tr><tr><td colspan="2" rowspan="2" style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">CONTINUATION SHEET</font></div></td><td colspan="4" rowspan="2" style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:4px;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">REFERENCE NO. OF DOCUMENT BEING CONTINUED</font></div><div style="padding-bottom:4px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HHSD200201792634C/P00017</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">PAGE OF</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr><tr><td colspan="9" style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #00000a;"><div style="padding-bottom:4px;padding-top:4px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">NAME OF OFFEROR OR CONTRACTOR</font></div><div style="padding-bottom:4px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EMERGENT BIODEFENSE OPERATIONS LANSING LLC 330303</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">ITEM No.</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:8pt;">(A)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">SUPPLIES/SERVICES</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:8pt;">(B)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">QUANTITY</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:8pt;">(C)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">UNIT</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:8pt;">(D)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">UNIT PRICE</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:8pt;">(E)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">AMOUNT</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:8pt;">(F)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-top:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:8pt;">4. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">No further changes.</font></div><div style="padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delivery Location Code: HHS</font></div><div style="padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">HHS</font></div><div style="padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">200 Independence Avenue, SW</font></div><div style="padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Washington DC 20201 US</font></div><div style="padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">FOB: Origin</font></div><div style="padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Period of Performance: [**] to [**]</font></div><div style="padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Change Item 3 to read as follows (amount shown is the obligated amount):</font></div><div style="padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Optional Line Item 0003</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">BioThrax  [**] product</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Arial;font-size:10pt;">Expiry dating upon date of delivery: </font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No less than [**] Months and no more than [**] months for [**]-year product at a unit price of [**]</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Quantity: [**]</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unit Price: [**]</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total Value: $27,927,000.00</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total dollar value ordered under Item 3 is increased by $27,927,000.00 from $[**] to $[**].</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delivery Address: Contractor&#8217;s Facility</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delivery is estimated to occur by NLT [**]</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amount: $[**]</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Info: </font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">[**] Appr. Yr.: 2019 CAN: [**]</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Object Class: 26402</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Funded: $0.00</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amount: $[**]</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Info:</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">[**] Appr. Yr.: 2019 CAN: [**]</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Object Class: 26402</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Funded: $0.00</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amount: $27,927,000.00</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounting Info: </font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">[**] Appr. Yr.: 2019 CAN: 199SNS1</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Object Class: 26402</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Funded: $27,927,000.00</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$27,927,000.00</font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">NSN 7540-01-152-8067&#160;&#160;&#160;&#160;OPTIONAL FORM 336 (4-86)</font></div><div style="line-height:120%;text-align:left;padding-left:576px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Sponsored by GSA</font></div><div style="line-height:120%;text-align:left;padding-left:576px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">FAR (48 CFR) 53.110</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10..2
<SEQUENCE>3
<FILENAME>ebs-201906030xex102.htm
<DESCRIPTION>EXHIBIT 10..2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9024FE9167E17E8AA17725696D3238A6"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 10.2</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment</font><font style="font-family:inherit;font-size:11pt;">&#8221;), dated as of June 27, 2019, among EMERGENT BIOSOLUTIONS INC., a Delaware corporation (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Borrower</font><font style="font-family:inherit;font-size:11pt;">&#8221;), the Guarantors (as defined in the Credit Agreement referred to below) party hereto, the Lenders party hereto (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Consenting Lenders</font><font style="font-family:inherit;font-size:11pt;">&#8221;), and WELLS FARGO BANK, NATIONAL ASSOCIATION, as administrative agent (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Administrative Agent</font><font style="font-family:inherit;font-size:11pt;">&#8221;). Unless otherwise indicated, all capitalized terms used herein and not otherwise defined herein shall have the respective meanings provided such terms in the Credit Agreement referred to below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">W I T N E S S E T H:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, the Borrower, the lenders party thereto from time to time (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Lenders</font><font style="font-family:inherit;font-size:11pt;">&#8221;) and the Administrative Agent have entered into that certain Amended and Restated Credit Agreement, dated as of October 15, 2018 (as amended, supplemented or otherwise modified prior to the date hereof, the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Existing Credit Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;; the Existing Credit Agreement, as amended by this Amendment, the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Credit Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, the Borrower has requested, and subject to the terms and conditions set forth herein, the Administrative Agent and the Consenting Lenders have agreed, to certain amendments to the Existing Credit Agreement as more specifically set forth herein;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is agreed as follows: </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">SECTION 1.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendments to Existing Credit Agreement</font><font style="font-family:inherit;font-size:11pt;">.  Effective as of the Amendment Effective Date (as defined in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 2</font><font style="font-family:inherit;font-size:11pt;">&#32;below) and subject to the terms and conditions set forth herein and in reliance upon the representations and warranties set forth herein, the Existing Credit Agreement is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Article I</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Existing Credit Agreement is hereby amended by adding the following defined terms in appropriate alphabetical order:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Covenant Relief Period</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the period commencing with the First Amendment Effective Date and ending on the date that the Borrower provides the financial statements referred to in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 8.1(a)</font><font style="font-family:inherit;font-size:11pt;">&#32;for the fiscal year ended December 31, 2019, together with a duly completed Compliance Certificate for such period pursuant to </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section&#160;8.2(a)</font><font style="font-family:inherit;font-size:11pt;">&#32;demonstrating compliance with the financial covenants set forth in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.11</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">First Amendment Effective Date</font><font style="font-family:inherit;font-size:11pt;">&#8221; means June 27, 2019.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">PTE</font><font style="font-family:inherit;font-size:11pt;">&#8221; means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Article I</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Existing Credit Agreement is hereby amended by adding the following new </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 1.16</font><font style="font-family:inherit;font-size:11pt;">&#32;thereto and in connection therewith the table of contents shall be amended to include a reference to &#8220;SECTION 1.16 Divisions&#8221;:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;SECTION 1.16   </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Divisions</font><font style="font-family:inherit;font-size:11pt;">.  For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#8217;s laws): (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Equity Interests at such time.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 5.13(a)</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Existing Credit Agreement is hereby amended by adding the parenthetical &#8220;(without giving effect to the increased maximum Consolidated Net Leverage Ratio levels permitted during the Covenant Relief Period set forth in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.11(b)</font><font style="font-family:inherit;font-size:11pt;">)&#8221; immediately following the reference to &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.11</font><font style="font-family:inherit;font-size:11pt;">&#8221; in proviso (B) of such Section.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.2</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Existing Credit Agreement is hereby amended by adding the parenthetical &#8220;(without giving effect to the increased maximum Consolidated Net Leverage Ratio levels permitted during the Covenant Relief Period set forth in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.11(b)</font><font style="font-family:inherit;font-size:11pt;">)&#8221; immediately following the reference to &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.11</font><font style="font-family:inherit;font-size:11pt;">&#8221; in clause (g)(iv)(A) of such Section.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.3</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Existing Credit Agreement is hereby amended by adding the parenthetical &#8220;(without giving effect to the increased maximum Consolidated Net Leverage Ratio levels permitted during the Covenant Relief Period set forth in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.11(b)</font><font style="font-family:inherit;font-size:11pt;">)&#8221; immediately following the reference to &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.11(b)</font><font style="font-family:inherit;font-size:11pt;">&#8221; in clause (h)(ii)(A) of such Section.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.6</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Existing Credit Agreement is hereby amended by replacing the proviso at the end of clause (d) of such Section with &#8220;; </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:11pt;">&#32;that the aggregate amount of Restricted Payments made pursuant to this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.6(d)</font><font style="font-family:inherit;font-size:11pt;">&#32;shall not exceed (x) $100,000,000 per calendar year and (y) $25,000,000 during the Covenant Relief Period;&#8221;.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.11</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Existing Credit Agreement is hereby amended by (i) replacing the word &#8220;Permit&#8221; in the first sentence of such Section with &#8220;Subject to the sentence below during the Covenant Relief Period, permit&#8221; and (ii) adding the following paragraph to the end of clause (b) of such Section as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Notwithstanding any of the foregoing, the maximum Consolidated Net Leverage Ratio permitted pursuant to </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.11(b)</font><font style="font-family:inherit;font-size:11pt;">&#32;during the Covenant Relief Period as of the last day of the applicable Measurement Period of the Borrower shall be (x) 4.95 to 1.00 for the fiscal quarter ended June 30, 2019 and (y) 4.75 to 1.00 for the fiscal quarter ended September 30, 2019, after which the maximum Consolidated Net Leverage Ratio permitted pursuant to this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 9.11(b)</font><font style="font-family:inherit;font-size:11pt;">&#32;shall be subject to the levels set forth in the table above.&#8221; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Article XII</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Existing Credit Agreement is hereby amended by adding the following new </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 12.26</font><font style="font-family:inherit;font-size:11pt;">&#32;thereto and in connection therewith the table of contents shall be amended to include a reference to &#8220;SECTION 12.26 Acknowledgement Regarding Any Supported QFCs&#8221;:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;SECTION 12.26   </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Acknowledgement Regarding Any Supported QFCs</font><font style="font-family:inherit;font-size:11pt;">.  To the extent that the Loan Documents provide support, through a guarantee or otherwise, for Hedge Agreements or any other agreement or instrument that is a QFC (such support, &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">QFC Credit Support</font><font style="font-family:inherit;font-size:11pt;">&#8221; and, each such QFC, a &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Supported QFC</font><font style="font-family:inherit;font-size:11pt;">&#8221;), the parties acknowledge and agree as follows with respect to the resolution power of the FDIC under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">U.S. Special Resolution Regimes</font><font style="font-family:inherit;font-size:11pt;">&#8221;) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and/or of the United States or any other state of the United States):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">In the event a Covered Entity that is party to a Supported QFC (each, a &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Covered Party</font><font style="font-family:inherit;font-size:11pt;">&#8221;) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">As used in this </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 12.26</font><font style="font-family:inherit;font-size:11pt;">, the following terms have the following meanings:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">BHC Act Affiliate</font><font style="font-family:inherit;font-size:11pt;">&#8221; of a party means an &#8220;affiliate&#8221; (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Covered Entity</font><font style="font-family:inherit;font-size:11pt;">&#8221; means any of the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Default Right</font><font style="font-family:inherit;font-size:11pt;">&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">QFC</font><font style="font-family:inherit;font-size:11pt;">&#8221; has the meaning assigned to the term &#8220;qualified financial contract&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. 5390(c)(8)(D).&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SECTION 2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Conditions of Effectiveness of Amendment</font><font style="font-family:inherit;font-size:11pt;">.  This Amendment, and the amendments set forth in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 1</font><font style="font-family:inherit;font-size:11pt;">&#32;above, shall become effective on the date (such date, the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment Effective Date</font><font style="font-family:inherit;font-size:11pt;">&#8221;) when the Administrative Agent shall have received this Amendment, duly executed by a Responsible Officer of the Borrower, the Guarantors existing as of the Amendment Effective Date, the Administrative Agent and the Required Lenders.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SECTION 3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:11pt;">. To induce the Administrative Agent and the Lenders to enter into this Amendment, each Credit Party represents and warrants to the Administrative Agent and the Lenders on and as of the Amendment Effective Date that, in each case:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)&#160;&#160;&#160;&#160;the representations and warranties of each Credit Party set forth in the Credit Agreement and in each other Loan Document to which it is a party are true and correct in all material respects on and as of the Amendment Effective Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, in which case they shall be true and correct in all material respects as of such earlier date; </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:11pt;">&#32;that any representation and warranty that is qualified as to &#8220;materiality,&#8221; &#8220;Material Adverse Effect&#8221; or similar language shall be true and correct (after giving effect to any qualification therein) in all respects on such respective dates;  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)&#160;&#160;&#160;&#160;no Default or Event of Default has occurred and is continuing;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)&#160;&#160;&#160;&#160;it </font><font style="font-family:inherit;font-size:11pt;">has all requisite power and authority and has taken all necessary corporate and other action to authorize the execution, delivery and performance of this Amendment and each other document executed in connection herewith to which it is a party in accordance with their respective terms and the transactions contemplated hereby</font><font style="font-family:inherit;font-size:11pt;">; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)&#160;&#160;&#160;&#160;this Amendment and each other document executed in connection herewith has been duly executed and delivered by the duly authorized officers of each Credit Party, and each such document constitutes the legal, valid and binding obligation of each such Credit Party, enforceable in accordance with its terms, </font><font style="font-family:inherit;font-size:11pt;">subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors&#8217; rights generally and subject to general principals of equity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SECTION 4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Reference to and Effect on the Credit Agreement and the Loan Documents</font><font style="font-family:inherit;font-size:11pt;">.   Except as expressly provided herein, the Existing Credit Agreement and the other Loan Documents shall remain unmodified and in full force and effect.  This Amendment shall not be deemed (a) to be a waiver of, or consent to, or a modification or amendment of, any other term or condition of the Existing Credit Agreement or any other Loan Document other than as expressly set forth herein, (b) to prejudice any right or rights which the Administrative Agent or the Lenders may now have or may have in the future under or in connection with the Existing Credit Agreement or the other Loan Documents or any of the instruments or agreements referred to therein, as the same may be amended, restated, supplemented or modified from time to time, or (c) to be a commitment or any other undertaking or expression of any willingness to engage in any further discussion with the Borrower, any of its Subsidiaries or any other Person with respect to any other waiver, amendment, modification or any other change to the Existing Credit Agreement or the Loan Documents or any rights or remedies arising in favor of the Lenders or the Administrative Agent, or any of them, under or with respect to any such documents.  References in the Credit Agreement to &#8220;this Agreement&#8221; (and indirect references such as &#8220;hereunder&#8221;, &#8220;hereby&#8221;, &#8220;herein&#8221;, &#8220;hereof&#8221; or other words of like import) and in any Loan Document to the &#8220;Credit Agreement&#8221; shall be deemed to be references to the Existing Credit Agreement as modified hereby.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SECTION 5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Further Assurances</font><font style="font-family:inherit;font-size:11pt;">.  Each Credit Party agrees to, to the extent required by the Loan Documents, make, execute and deliver all such additional and further acts, things, deeds, instruments and documents as the Administrative Agent may reasonably require for the purposes of implementing or effectuating the provisions of this Amendment and the other Loan Documents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SECTION 6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Acknowledgement and Reaffirmation</font><font style="font-family:inherit;font-size:11pt;">. Each Credit Party (a) consents to this Amendment and agrees that the transactions contemplated by this Amendment shall not limit or diminish the obligations of such Person under, or release such Person from any obligations under, any of the Loan Documents to which it is a party (as amended pursuant to this Amendment), (b) confirms and reaffirms its obligations under each of the Loan Documents to which it is a party (as amended pursuant to this Amendment) and (c) agrees that each of the Loan Documents to which it is a party (as amended pursuant to this Amendment) remains in full force and effect and is hereby ratified and confirmed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SECTION 7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Costs and Expenses</font><font style="font-family:inherit;font-size:11pt;">. The Borrower hereby reconfirms its obligations pursuant to </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 12.3(a)</font><font style="font-family:inherit;font-size:11pt;">&#32;of the Credit Agreement to pay and reimburse the Administrative Agent in accordance with the terms thereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SECTION 8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:11pt;">. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SECTION 9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:11pt;">. This Amendment may be executed in any number of counterparts and by the different parties hereto on separate counterparts, each of which counterparts when executed and delivered shall be an original, but all of which shall together constitute one and the same instrument. Delivery by facsimile or electronic transmission of an executed counterpart of a signature page to this Amendment shall be effective as delivery of an original executed counterpart of this Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SECTION 10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:11pt;">.  This Amendment is the entire agreement, and supersedes any prior agreements and contemporaneous oral agreements, of the parties concerning its subject matter.  This Amendment is a Loan Document and is subject to the terms and conditions of the Credit Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SECTION 11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:11pt;">.  This Amendment shall be binding on and inure to the benefit of the parties hereto and their successors and permitted assigns.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[The remainder of this page is intentionally left blank.]</font></div><div><a name="sF8DCDE5BC81BE16367C825696D63371F"></a></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the parties hereto have caused their duly authorized officers to execute and deliver this Amendment as of the date first above written.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">EMERGENT BIOSOLUTIONS INC., as Borrower</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Richard S. Lindahl&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Richard S. Lindahl</font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   EVP, Chief Financial Officer and Treasurer</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">CANGENE BIOPHARMA LLC, as Guarantor</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Richard S. Lindahl&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Richard S. Lindahl</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Treasurer&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">EMERGENT BIODEFENSE OPERATIONS LANSING LLC, as Guarantor</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Richard S. Lindahl&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Richard S. Lindahl</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Treasurer &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC, as Guarantor</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Richard S. Lindahl&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Richard S. Lindahl</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Executive Manager </font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC., as Guarantor</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Richard S. Lindahl&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Richard S. Lindahl </font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Treasurer &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">EMERGENT INTERNATIONAL INC., as Guarantor</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Richard S. Lindahl&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Richard S. Lindahl</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Treasurer &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">EMERGENT TRAVEL HEALTH INC. (FORMERLY</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">KNOWN AS PAXVAX, INC.), as Guarantor</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Richard S. Lindahl&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Richard S. Lindahl</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   CFO and Treasurer &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ADAPT PHARMA INC., as Guarantor</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Richard S. Lindahl&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Richard S. Lindahl</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Treasurer &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent, Swingline Lender, Issuing Lender and Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Kent S. Davis</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;Name: Kent S. Davis</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;Title:   Managing Director </font></div><div style="line-height:120%;text-align:left;padding-left:384px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">JPMORGAN CHASE BANK, N.A., as Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Anthony Galea&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Anthony Galea</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Executive Director </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">PNC BANK, NATIONAL ASSOCIATION, as Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Eric H. Williams&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Eric H. Williams </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Senior Vice President </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ROYAL BANK OF CANADA, as Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Steven T. Bachman&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Steven T. Bachman</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Authorized Signatory </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">BMO HARRIS BANK, N.A., as Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Eric Oppenheimer</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:11pt;">&#32;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Eric Oppenheimer </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Managing Director </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">CAPITAL ONE, N.A., as Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Jeffrey Schaal</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;Name: Jeffrey Schaal </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Duly Authorized Signatory </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">CITIZENS BANK, N.A., as Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Jack J. Euston</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:  Jack J. Euston</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:    Vice President </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">MUFG UNION BANK, N.A., as Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Teuta Ghilaga</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:  Teuta Ghilaga</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:    Director </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">REGIONS BANK, as Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Ned Spitzer</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Ned Spitzer</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Managing Director </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SUNTRUST BANK, as Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Katherine Bass</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:  Katherine Bass </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:    Director </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">THE HUNTINGTON NATIONAL BANK, as Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Joseph A. Miller</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Joseph A. Miller </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Managing Director </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">BANK OF AMERICA, N.A., as Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ H. Hope Walker</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: H. Hope Walker </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Senior Vice President </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">BANK OF THE WEST, as a Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Harry Yergey</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Harry Yergey</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Managing Director </font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Michael Weinert</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Michael Weinert </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Director </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">DNB CAPITAL LLC, as a Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Kristi Birkeland Sorensen</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Kristi Birkeland Sorensen </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Senior Vice President</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;Head of Corporate Banking</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Devan Patel</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Devan Patel </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Vice President </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">FIRST NATIONAL BANK, as a Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Douglas T. Brown</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Douglas T. Brown </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Senior Vice President </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">FIFTH THIRD BANK, as a Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Vera B. McEvoy</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Vera B. McEvoy</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:    Director II</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">HSBC BANK USA, N.A., as a Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Reed R. Menefee</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Reed R. Menefee</font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Managing Director </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">MORGAN STANLEY BANK, as a Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Jackson Eng</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Jackson Eng </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Authorized Signatory </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">TD BANK, N.A., as a Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Shivani Agarwal</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Shivani Agarwal </font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Senior Vice President </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">U.S. BANK NATIONAL ASSOCIATION, as a Lender</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:240px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Tom Priedeman</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Tom Priedeman </font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Vice President </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">117427862_4</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ebs-20190630xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s746E86B828A25083829538226F798992"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CERTIFICATION</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Robert G. Kramer, Sr., certify that:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this Quarterly Report on Form </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">10-Q</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of Emergent BioSolutions Inc.;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date:&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">August&#160;1, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/ROBERT G. KRAMER, SR.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robert G. Kramer, Sr.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ebs-20190630xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0855AEEEAF5154E6A839A048C6497FF2"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CERTIFICATION</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Richard S. Lindahl, certify that:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this Quarterly Report on Form </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">10-Q</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of Emergent BioSolutions Inc.;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date:&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">August&#160;1, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/RICHARD S. LINDAHL</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Richard S. Lindahl</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ebs-20190630xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF6966E83AA5054EE895F4144640A0E18"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the Quarterly Report on Form </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10-Q</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of Emergent BioSolutions Inc. (the "Company") for the period ended&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Robert G. Kramer, Sr., Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><div style="line-height:120%;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date:&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">August&#160;1, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/ROBERT G. KRAMER, SR.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robert G. Kramer, Sr.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ebs-20190630xex322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9F518C43BAD461E2BB9D255EE083FB54"></a></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT 32.2</font></div><div style="line-height:144%;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:144%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the Quarterly Report on Form </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10-Q</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of Emergent BioSolutions Inc. (the "Company") for the period ended&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Richard S. Lindahl, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:1px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:10pt;padding-left:1px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:144%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date:&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">August&#160;1, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:144%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">/s/RICHARD S. LINDAHL</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Richard S. Lindahl</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ebs-20190630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://emergentbiosolutions.com/20190630" xmlns:ebs="http://emergentbiosolutions.com/20190630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20190630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20190630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20190630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20190630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="Acquisitions" roleURI="http://emergentbiosolutions.com/role/Acquisitions">
        <link:definition>2103100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAdaptNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails">
        <link:definition>2403402 - Disclosure - Acquisitions - Adapt Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails" roleURI="http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails">
        <link:definition>2403404 - Disclosure - Acquisitions - Adapt Preliminary Allocation of Purchase Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAdaptTotalPurchasePriceDetails" roleURI="http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails">
        <link:definition>2403403 - Disclosure - Acquisitions - Adapt Total Purchase Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsImpactOfBusinessAcquisitionsDetails" roleURI="http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails">
        <link:definition>2403407 - Disclosure - Acquisitions - Impact of Business Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsPaxvaxNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails">
        <link:definition>2403405 - Disclosure - Acquisitions - PaxVax Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails" roleURI="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails">
        <link:definition>2403406 - Disclosure - Acquisitions - PaxVax Preliminary Allocation of Purchase Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://emergentbiosolutions.com/role/AcquisitionsTables">
        <link:definition>2303301 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndPrinciplesOfConsolidation" roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation">
        <link:definition>2102100 - Disclosure - Basis of Presentation and Principles of Consolidation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndPrinciplesOfConsolidationDetails" roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails">
        <link:definition>2402402 - Disclosure - Basis of Presentation and Principles of Consolidation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndPrinciplesOfConsolidationPolicies" roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Principles of Consolidation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Business" roleURI="http://emergentbiosolutions.com/role/Business">
        <link:definition>2101100 - Disclosure - Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessDetails" roleURI="http://emergentbiosolutions.com/role/BusinessDetails">
        <link:definition>2401401 - Disclosure - Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://emergentbiosolutions.com/role/CommitmentsAndContingencies">
        <link:definition>2116100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2416401 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>1005000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>1005501 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveLossIncome" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingentConsideration" roleURI="http://emergentbiosolutions.com/role/ContingentConsideration">
        <link:definition>2108100 - Disclosure - Contingent Consideration</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingentConsiderationDetails" roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationDetails">
        <link:definition>2408402 - Disclosure - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingentConsiderationTables" roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationTables">
        <link:definition>2308301 - Disclosure - Contingent Consideration (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://emergentbiosolutions.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://emergentbiosolutions.com/role/Debt">
        <link:definition>2110100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDebtNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails">
        <link:definition>2410403 - Disclosure - Debt Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleDetails" roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails">
        <link:definition>2410402 - Disclosure - Debt - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://emergentbiosolutions.com/role/DebtTables">
        <link:definition>2310301 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedBenefitPlan" roleURI="http://emergentbiosolutions.com/role/DefinedBenefitPlan">
        <link:definition>2115100 - Disclosure - Defined benefit plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedBenefitPlanDetails" roleURI="http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails">
        <link:definition>2415402 - Disclosure - Defined benefit plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedBenefitPlanTables" roleURI="http://emergentbiosolutions.com/role/DefinedBenefitPlanTables">
        <link:definition>2315301 - Disclosure - Defined benefit plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsAndHedgingActivities" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities">
        <link:definition>2109100 - Disclosure - Derivative Instruments and Hedging Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails">
        <link:definition>2409405 - Disclosure - Derivative Instruments and Hedging Activities - Cash Flow Hedging on AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails">
        <link:definition>2409403 - Disclosure - Derivative Instruments and Hedging Activities - Derivative Designated as Cash Flow Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails">
        <link:definition>2409404 - Disclosure - Derivative Instruments and Hedging Activities - Fair Value by Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails">
        <link:definition>2409402 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsAndHedgingActivitiesTables" roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables">
        <link:definition>2309301 - Disclosure - Derivative Instruments and Hedging Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://emergentbiosolutions.com/role/IncomeTaxes">
        <link:definition>2112100 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://emergentbiosolutions.com/role/IncomeTaxesDetails">
        <link:definition>2412401 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://emergentbiosolutions.com/role/IntangibleAssets">
        <link:definition>2107100 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails">
        <link:definition>2407403 - Disclosure - Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails">
        <link:definition>2407402 - Disclosure - Intangible Assets - Schedule of Finite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsTables">
        <link:definition>2307301 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://emergentbiosolutions.com/role/Inventories">
        <link:definition>2104100 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://emergentbiosolutions.com/role/InventoriesDetails">
        <link:definition>2404402 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://emergentbiosolutions.com/role/InventoriesTables">
        <link:definition>2304301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://emergentbiosolutions.com/role/Leases">
        <link:definition>2106100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsOfLeaseExpenseDetails" roleURI="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails">
        <link:definition>2406403 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>2406404 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://emergentbiosolutions.com/role/LeasesTables">
        <link:definition>2306301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossEarningsPerShare" roleURI="http://emergentbiosolutions.com/role/LossEarningsPerShare">
        <link:definition>2113100 - Disclosure - (Loss) earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossEarningsPerShareDetails" roleURI="http://emergentbiosolutions.com/role/LossEarningsPerShareDetails">
        <link:definition>2413402 - Disclosure - (Loss) earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossEarningsPerShareTables" roleURI="http://emergentbiosolutions.com/role/LossEarningsPerShareTables">
        <link:definition>2313301 - Disclosure - (Loss) earnings per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipment" roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment">
        <link:definition>2105100 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2405402 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentTables" roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables">
        <link:definition>2305301 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://emergentbiosolutions.com/role/RevenueRecognition">
        <link:definition>2111100 - Disclosure - Revenue recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionAccountsReceivableDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails">
        <link:definition>2411405 - Disclosure - Revenue recognition - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractLiabilitiesDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails">
        <link:definition>2411404 - Disclosure - Revenue recognition - Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationOfRevenueDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails">
        <link:definition>2411403 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>2411402 - Disclosure - Revenue recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionTables">
        <link:definition>2311301 - Disclosure - Revenue recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensation">
        <link:definition>2114100 - Disclosure - Share-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationDetails" roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails">
        <link:definition>2414401 - Disclosure - Share-based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalInformation" roleURI="http://emergentbiosolutions.com/role/SupplementalInformation">
        <link:definition>2117100 - Disclosure - Supplemental Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalInformationDetails" roleURI="http://emergentbiosolutions.com/role/SupplementalInformationDetails">
        <link:definition>2417402 - Disclosure - Supplemental Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalInformationTables" roleURI="http://emergentbiosolutions.com/role/SupplementalInformationTables">
        <link:definition>2317301 - Disclosure - Supplemental Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="ebs_AdaptAndPaxVaxMember" name="AdaptAndPaxVaxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_AdaptPharmaMember" name="AdaptPharmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_AmendedCreditAgreementMember" name="AmendedCreditAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" name="CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ebs_ChangeInFairValueOfContingentConsideration" name="ChangeInFairValueOfContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_ChangeinContractWithCustomerLiabilityRollForward" name="ChangeinContractWithCustomerLiabilityRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_ContractManufacturingMember" name="ContractManufacturingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_ContractWithCustomerLiabilityAdditions" name="ContractWithCustomerLiabilityAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_ContractsAndGrantsMember" name="ContractsAndGrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_ConvertibleSeniorNotesDue2021Member" name="ConvertibleSeniorNotesDue2021Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_CreditAgreementMember" name="CreditAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" name="DebtInstrumentCovenantDebtServiceCoverageRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted" name="DebtInstrumentCovenantNetLeverageRatioAdjusted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" name="DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantNetLeverageRatioFour" name="DebtInstrumentCovenantNetLeverageRatioFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantNetLeverageRatioOne" name="DebtInstrumentCovenantNetLeverageRatioOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" name="DebtInstrumentCovenantNetLeverageRatioRollingPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantNetLeverageRatioThree" name="DebtInstrumentCovenantNetLeverageRatioThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentCovenantNetLeverageRatioTwo" name="DebtInstrumentCovenantNetLeverageRatioTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_DebtInstrumentRestrictedPaymentsLimitAmount" name="DebtInstrumentRestrictedPaymentsLimitAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_ImpactOfBusinessAcquisitionsAbstract" name="ImpactOfBusinessAcquisitionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_ImpactOfBusinessAcquisitionsTableTextBlock" name="ImpactOfBusinessAcquisitionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_InProcessResearchAndDevelopment" name="InProcessResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ebs_LesseeOperatingLeaseTerminationPeriod" name="LesseeOperatingLeaseTerminationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_LockUpPeriodForAdjustmentOfFairValue" name="LockUpPeriodForAdjustmentOfFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_NumberOfBusinessAcquisitions" name="NumberOfBusinessAcquisitions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="ebs_NumberOfEmployees" name="NumberOfEmployees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_NumberOfLendingInstitutions" name="NumberOfLendingInstitutions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_OperatingLeaseOtherLiabilityCurrent" name="OperatingLeaseOtherLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ebs_OtherLongTermDebtFacilityMember" name="OtherLongTermDebtFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_PaxVaxMember" name="PaxVaxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" name="PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" name="PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" name="PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_PresentValueDiscountRate" name="PresentValueDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_RaxibacumabMember" name="RaxibacumabMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock" name="ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="ebs_ScheduleofAccountsReceivableNetTableTextBlock" name="ScheduleofAccountsReceivableNetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_ShareholderClassActionLawsuitMember" name="ShareholderClassActionLawsuitMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_TermLoanFacilityMember" name="TermLoanFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_VaxchoraMember" name="VaxchoraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ebs_VivotifMember" name="VivotifMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ebs-20190630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Acquisitions" xlink:href="ebs-20190630.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails" xlink:href="ebs-20190630.xsd#AcquisitionsAdaptNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails" xlink:href="ebs-20190630.xsd#AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails" xlink:href="ebs-20190630.xsd#AcquisitionsAdaptTotalPurchasePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails" xlink:href="ebs-20190630.xsd#AcquisitionsImpactOfBusinessAcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails" xlink:href="ebs-20190630.xsd#AcquisitionsPaxvaxNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails" xlink:href="ebs-20190630.xsd#AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsTables" xlink:href="ebs-20190630.xsd#AcquisitionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" xlink:href="ebs-20190630.xsd#BasisOfPresentationAndPrinciplesOfConsolidation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:href="ebs-20190630.xsd#BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:href="ebs-20190630.xsd#BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Business" xlink:href="ebs-20190630.xsd#Business" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BusinessDetails" xlink:href="ebs-20190630.xsd#BusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CommitmentsAndContingencies" xlink:href="ebs-20190630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="ebs-20190630.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ebs-20190630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="ebs-20190630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfComprehensiveLossIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsideration" xlink:href="ebs-20190630.xsd#ContingentConsideration" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationDetails" xlink:href="ebs-20190630.xsd#ContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationTables" xlink:href="ebs-20190630.xsd#ContingentConsiderationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CoverPage" xlink:href="ebs-20190630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Debt" xlink:href="ebs-20190630.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails" xlink:href="ebs-20190630.xsd#DebtDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:href="ebs-20190630.xsd#DebtScheduleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTables" xlink:href="ebs-20190630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DefinedBenefitPlan" xlink:href="ebs-20190630.xsd#DefinedBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails" xlink:href="ebs-20190630.xsd#DefinedBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DefinedBenefitPlanTables" xlink:href="ebs-20190630.xsd#DefinedBenefitPlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivities" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncomeTaxes" xlink:href="ebs-20190630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncomeTaxesDetails" xlink:href="ebs-20190630.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssets" xlink:href="ebs-20190630.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails" xlink:href="ebs-20190630.xsd#IntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="ebs-20190630.xsd#IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsTables" xlink:href="ebs-20190630.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Inventories" xlink:href="ebs-20190630.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesDetails" xlink:href="ebs-20190630.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesTables" xlink:href="ebs-20190630.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Leases" xlink:href="ebs-20190630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:href="ebs-20190630.xsd#LeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:href="ebs-20190630.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:href="ebs-20190630.xsd#LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesTables" xlink:href="ebs-20190630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LossEarningsPerShare" xlink:href="ebs-20190630.xsd#LossEarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LossEarningsPerShareDetails" xlink:href="ebs-20190630.xsd#LossEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LossEarningsPerShareTables" xlink:href="ebs-20190630.xsd#LossEarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment" xlink:href="ebs-20190630.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails" xlink:href="ebs-20190630.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables" xlink:href="ebs-20190630.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:href="ebs-20190630.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:href="ebs-20190630.xsd#RevenueRecognitionAccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:href="ebs-20190630.xsd#RevenueRecognitionContractLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" xlink:href="ebs-20190630.xsd#RevenueRecognitionDisaggregationOfRevenueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ebs-20190630.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:href="ebs-20190630.xsd#RevenueRecognitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensation" xlink:href="ebs-20190630.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails" xlink:href="ebs-20190630.xsd#ShareBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SupplementalInformation" xlink:href="ebs-20190630.xsd#SupplementalInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SupplementalInformationDetails" xlink:href="ebs-20190630.xsd#SupplementalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SupplementalInformationTables" xlink:href="ebs-20190630.xsd#SupplementalInformationTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9ad6eb0b-0be8-3959-8888-f510808da951" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9ad6eb0b-0be8-3959-8888-f510808da951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_395f9bb0-2492-f247-ce6b-39e67453292c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_395f9bb0-2492-f247-ce6b-39e67453292c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8ce68675-8129-3ab4-cbd9-33127f150e28" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8ce68675-8129-3ab4-cbd9-33127f150e28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_4969e367-c531-0df1-f44b-bfbc106efa7e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_4969e367-c531-0df1-f44b-bfbc106efa7e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_fbe331bf-e36a-7435-2eec-e3249b6c0997" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_fbe331bf-e36a-7435-2eec-e3249b6c0997" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" xlink:label="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_808c8606-0f95-b16b-a9dd-d849aca21643" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_808c8606-0f95-b16b-a9dd-d849aca21643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_49b08da0-3c0d-5e6e-be00-f4ff19b686d5" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_49b08da0-3c0d-5e6e-be00-f4ff19b686d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_9fd4e909-6e77-b96d-24a2-93ffef186798" xlink:type="locator" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_5840b857-19b3-74ef-161f-d849ac88ad7a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_9fd4e909-6e77-b96d-24a2-93ffef186798" xlink:to="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_5840b857-19b3-74ef-161f-d849ac88ad7a" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_45cad26a-d637-63b9-c84c-d849acab0678" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_9fd4e909-6e77-b96d-24a2-93ffef186798" xlink:to="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_45cad26a-d637-63b9-c84c-d849acab0678" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_395f9bb0-2492-f247-ce6b-39e67453292c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_395f9bb0-2492-f247-ce6b-39e67453292c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8ce68675-8129-3ab4-cbd9-33127f150e28" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8ce68675-8129-3ab4-cbd9-33127f150e28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9ad6eb0b-0be8-3959-8888-f510808da951" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9ad6eb0b-0be8-3959-8888-f510808da951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_03034168-0c29-957e-9b7e-01ea7f13c7d8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_03034168-0c29-957e-9b7e-01ea7f13c7d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_4969e367-c531-0df1-f44b-bfbc106efa7e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_4969e367-c531-0df1-f44b-bfbc106efa7e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_090d08a1-b8fd-3634-47b8-7dcb68699de1" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_090d08a1-b8fd-3634-47b8-7dcb68699de1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_fbe331bf-e36a-7435-2eec-e3249b6c0997" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_fbe331bf-e36a-7435-2eec-e3249b6c0997" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" xlink:label="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_808c8606-0f95-b16b-a9dd-d849aca21643" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1184f71b-eb96-34a8-7c86-c43ab50947af" xlink:to="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_808c8606-0f95-b16b-a9dd-d849aca21643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_9fd4e909-6e77-b96d-24a2-93ffef186798" xlink:type="locator" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_3D993A064359BEB40A2F206FE70A3C79" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_9fd4e909-6e77-b96d-24a2-93ffef186798" xlink:to="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_3D993A064359BEB40A2F206FE70A3C79" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/Business" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e2b0aef-f283-e3cd-a77b-e835b6efc171" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e2b0aef-f283-e3cd-a77b-e835b6efc171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_InProcessResearchAndDevelopment" xlink:label="loc_ebs_InProcessResearchAndDevelopment_a4801d57-38f8-116d-9e2d-d849ac7c6e2d" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_ebs_InProcessResearchAndDevelopment_a4801d57-38f8-116d-9e2d-d849ac7c6e2d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_70b30340-b55c-aed7-73f5-36d397294f84" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_TreasuryStockValue_70b30340-b55c-aed7-73f5-36d397294f84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1c24f6a3-e8ba-9221-ee1e-4678b4a6cab8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1c24f6a3-e8ba-9221-ee1e-4678b4a6cab8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c575cd94-2e5c-db53-1e93-d54553800310" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c575cd94-2e5c-db53-1e93-d54553800310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4d10fc1d-2b1e-a08d-3574-d1bbfff59d2f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4d10fc1d-2b1e-a08d-3574-d1bbfff59d2f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0d8925ae-714a-26e4-aa69-2d9eac65a5c6" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_LongTermDebtCurrent_0d8925ae-714a-26e4-aa69-2d9eac65a5c6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_bd5d5ca5-7d41-2f41-654a-b2433f675680" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_bd5d5ca5-7d41-2f41-654a-b2433f675680" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8ca40fc7-564f-832a-56a7-2cfd188fe573" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8ca40fc7-564f-832a-56a7-2cfd188fe573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d4a92697-d008-996b-823a-bd9a56a04b3a" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d4a92697-d008-996b-823a-bd9a56a04b3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_35daa78b-69b1-a085-04d1-e403e60f5923" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_35daa78b-69b1-a085-04d1-e403e60f5923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_365325f2-cb4b-9d57-d769-4a5672f16cd9" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_365325f2-cb4b-9d57-d769-4a5672f16cd9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_22d4264a-c9a9-de0b-92b4-2261a21c1a6a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_22d4264a-c9a9-de0b-92b4-2261a21c1a6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForPreviousAcquisition" xlink:label="loc_us-gaap_PaymentsForPreviousAcquisition_15e0d59c-694f-a85a-bf05-43f9a919374e" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsForPreviousAcquisition_15e0d59c-694f-a85a-bf05-43f9a919374e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b412c390-dfec-d4c8-f13e-036e3b49278c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b412c390-dfec-d4c8-f13e-036e3b49278c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ChangeInFairValueOfContingentConsideration" xlink:label="loc_ebs_ChangeInFairValueOfContingentConsideration_99273215-35dd-5190-d206-d849ac823586" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_ebs_ChangeInFairValueOfContingentConsideration_99273215-35dd-5190-d206-d849ac823586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_bb8c0c41-60b6-6ad9-c835-6a671aae07c5" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_bb8c0c41-60b6-6ad9-c835-6a671aae07c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d3f88de-7d0f-fe63-f176-2a8af9ecbcbd" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d3f88de-7d0f-fe63-f176-2a8af9ecbcbd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_714a30d1-878f-1497-8ad1-4b1e113da228" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_714a30d1-878f-1497-8ad1-4b1e113da228" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_42b0774e-f480-247a-c948-c32e3f0232eb" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e68ce304-18e4-96c0-3260-363a872863db" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_42b0774e-f480-247a-c948-c32e3f0232eb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsideration" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DefinedBenefitPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f8c4af80-3396-31ad-927b-214035fcad4c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_50c65441-5a4a-7b70-8a6f-4bdf84901dd7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f8c4af80-3396-31ad-927b-214035fcad4c" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_50c65441-5a4a-7b70-8a6f-4bdf84901dd7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9eb8402e-17f1-615b-f0e0-f772c38d36ef" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f8c4af80-3396-31ad-927b-214035fcad4c" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9eb8402e-17f1-615b-f0e0-f772c38d36ef" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DefinedBenefitPlanTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaap_GoodwillGross_ffb428e6-c1e5-8a3b-839c-4bf16d5f7341" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:to="loc_us-gaap_GoodwillGross_ffb428e6-c1e5-8a3b-839c-4bf16d5f7341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a49df76-38f6-6baa-87dd-2e9a7efd8303" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a49df76-38f6-6baa-87dd-2e9a7efd8303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/Inventories" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_b1399fc2-f1bd-2a05-e4cb-8c363da2af9e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_b1399fc2-f1bd-2a05-e4cb-8c363da2af9e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_02cb866c-0b1c-51f5-8ed3-3272dfc8c769" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_02cb866c-0b1c-51f5-8ed3-3272dfc8c769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c2dd0840-de07-383b-bde9-fb229532490d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c2dd0840-de07-383b-bde9-fb229532490d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_d5a06061-b83d-0d55-b7d3-e1229681b86d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_0c835b1b-073b-1726-45ed-7f72b8f658d6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d5a06061-b83d-0d55-b7d3-e1229681b86d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_0c835b1b-073b-1726-45ed-7f72b8f658d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_ebcb44d8-f146-8715-996b-062bb9d8d43e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d5a06061-b83d-0d55-b7d3-e1229681b86d" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_ebcb44d8-f146-8715-996b-062bb9d8d43e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="locator" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_OperatingLeaseOtherLiabilityCurrent" xlink:label="loc_ebs_OperatingLeaseOtherLiabilityCurrent_c852416c-cb3a-2033-50a0-d849acba1a53" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:to="loc_ebs_OperatingLeaseOtherLiabilityCurrent_c852416c-cb3a-2033-50a0-d849acba1a53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LossEarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LossEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dd9a981-e559-d141-f1c2-4db79f71a7ef" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dd9a981-e559-d141-f1c2-4db79f71a7ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e52bef3f-d63a-d129-8b6a-48192f5d97b3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e52bef3f-d63a-d129-8b6a-48192f5d97b3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LossEarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BilledContractReceivables" xlink:label="loc_us-gaap_BilledContractReceivables_17edd2f4-dc10-b559-a189-a4160ac43b09" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:to="loc_us-gaap_BilledContractReceivables_17edd2f4-dc10-b559-a189-a4160ac43b09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="loc_us-gaap_UnbilledContractsReceivable_23384b56-6cf2-724a-29ad-e9ae99b07b45" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:to="loc_us-gaap_UnbilledContractsReceivable_23384b56-6cf2-724a-29ad-e9ae99b07b45" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ShareBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/SupplementalInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/SupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_61d6663d-71dc-4159-c90b-9591805979c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ce4b89e-fa52-7101-5bea-622168a4559a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_61d6663d-71dc-4159-c90b-9591805979c3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/SupplementalInformationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ebs-20190630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Acquisitions" xlink:href="ebs-20190630.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails" xlink:href="ebs-20190630.xsd#AcquisitionsAdaptNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails" xlink:href="ebs-20190630.xsd#AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails" xlink:href="ebs-20190630.xsd#AcquisitionsAdaptTotalPurchasePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails" xlink:href="ebs-20190630.xsd#AcquisitionsImpactOfBusinessAcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails" xlink:href="ebs-20190630.xsd#AcquisitionsPaxvaxNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails" xlink:href="ebs-20190630.xsd#AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsTables" xlink:href="ebs-20190630.xsd#AcquisitionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" xlink:href="ebs-20190630.xsd#BasisOfPresentationAndPrinciplesOfConsolidation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:href="ebs-20190630.xsd#BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:href="ebs-20190630.xsd#BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Business" xlink:href="ebs-20190630.xsd#Business" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BusinessDetails" xlink:href="ebs-20190630.xsd#BusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CommitmentsAndContingencies" xlink:href="ebs-20190630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="ebs-20190630.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ebs-20190630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="ebs-20190630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfComprehensiveLossIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsideration" xlink:href="ebs-20190630.xsd#ContingentConsideration" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationDetails" xlink:href="ebs-20190630.xsd#ContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationTables" xlink:href="ebs-20190630.xsd#ContingentConsiderationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CoverPage" xlink:href="ebs-20190630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Debt" xlink:href="ebs-20190630.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails" xlink:href="ebs-20190630.xsd#DebtDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:href="ebs-20190630.xsd#DebtScheduleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTables" xlink:href="ebs-20190630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DefinedBenefitPlan" xlink:href="ebs-20190630.xsd#DefinedBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails" xlink:href="ebs-20190630.xsd#DefinedBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DefinedBenefitPlanTables" xlink:href="ebs-20190630.xsd#DefinedBenefitPlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivities" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncomeTaxes" xlink:href="ebs-20190630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncomeTaxesDetails" xlink:href="ebs-20190630.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssets" xlink:href="ebs-20190630.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails" xlink:href="ebs-20190630.xsd#IntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="ebs-20190630.xsd#IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsTables" xlink:href="ebs-20190630.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Inventories" xlink:href="ebs-20190630.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesDetails" xlink:href="ebs-20190630.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesTables" xlink:href="ebs-20190630.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Leases" xlink:href="ebs-20190630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:href="ebs-20190630.xsd#LeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:href="ebs-20190630.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:href="ebs-20190630.xsd#LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesTables" xlink:href="ebs-20190630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LossEarningsPerShare" xlink:href="ebs-20190630.xsd#LossEarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LossEarningsPerShareDetails" xlink:href="ebs-20190630.xsd#LossEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LossEarningsPerShareTables" xlink:href="ebs-20190630.xsd#LossEarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment" xlink:href="ebs-20190630.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails" xlink:href="ebs-20190630.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables" xlink:href="ebs-20190630.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:href="ebs-20190630.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:href="ebs-20190630.xsd#RevenueRecognitionAccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:href="ebs-20190630.xsd#RevenueRecognitionContractLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" xlink:href="ebs-20190630.xsd#RevenueRecognitionDisaggregationOfRevenueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ebs-20190630.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:href="ebs-20190630.xsd#RevenueRecognitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensation" xlink:href="ebs-20190630.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails" xlink:href="ebs-20190630.xsd#ShareBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SupplementalInformation" xlink:href="ebs-20190630.xsd#SupplementalInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SupplementalInformationDetails" xlink:href="ebs-20190630.xsd#SupplementalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SupplementalInformationTables" xlink:href="ebs-20190630.xsd#SupplementalInformationTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_96EB7281007F32A5A81149ADB44D2449" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:to="loc_srt_RestatementAxis_96EB7281007F32A5A81149ADB44D2449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_190A7C586FE00A29BA7E49ADB44D0172_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_96EB7281007F32A5A81149ADB44D2449" xlink:to="loc_srt_RestatementDomain_190A7C586FE00A29BA7E49ADB44D0172_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_190A7C586FE00A29BA7E49ADB44D0172" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_96EB7281007F32A5A81149ADB44D2449" xlink:to="loc_srt_RestatementDomain_190A7C586FE00A29BA7E49ADB44D0172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_FF9DA3F32F9C7486266A49ADB44D93BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_190A7C586FE00A29BA7E49ADB44D0172" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_FF9DA3F32F9C7486266A49ADB44D93BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5CFA91D1E2044D0FE88249ADB44DC33F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5CFA91D1E2044D0FE88249ADB44DC33F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A777488AD2BAB612CCBD49ADB44EBB8A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5CFA91D1E2044D0FE88249ADB44DC33F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A777488AD2BAB612CCBD49ADB44EBB8A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A777488AD2BAB612CCBD49ADB44EBB8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5CFA91D1E2044D0FE88249ADB44DC33F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A777488AD2BAB612CCBD49ADB44EBB8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9711F94ACCF299F348C549ADB44E8B06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A777488AD2BAB612CCBD49ADB44EBB8A" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9711F94ACCF299F348C549ADB44E8B06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_82EF094D398FCDA2B62449ADB44E738B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:to="loc_srt_RangeAxis_82EF094D398FCDA2B62449ADB44E738B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D47A2179F6F77503B27A49ADB44E71E1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_82EF094D398FCDA2B62449ADB44E738B" xlink:to="loc_srt_RangeMember_D47A2179F6F77503B27A49ADB44E71E1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D47A2179F6F77503B27A49ADB44E71E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_82EF094D398FCDA2B62449ADB44E738B" xlink:to="loc_srt_RangeMember_D47A2179F6F77503B27A49ADB44E71E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D4426059F6229585828949ADB44F88CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D47A2179F6F77503B27A49ADB44E71E1" xlink:to="loc_srt_MaximumMember_D4426059F6229585828949ADB44F88CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B2E42849D39F67D06A0C49ADB44FB02E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B2E42849D39F67D06A0C49ADB44FB02E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB4CAFF4A951807A3B1649ADB44F5157_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B2E42849D39F67D06A0C49ADB44FB02E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB4CAFF4A951807A3B1649ADB44F5157_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB4CAFF4A951807A3B1649ADB44F5157" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B2E42849D39F67D06A0C49ADB44FB02E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB4CAFF4A951807A3B1649ADB44F5157" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AdaptPharmaMember" xlink:label="loc_ebs_AdaptPharmaMember_91FE3FEB5229677D22B649ADB44F2189" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB4CAFF4A951807A3B1649ADB44F5157" xlink:to="loc_ebs_AdaptPharmaMember_91FE3FEB5229677D22B649ADB44F2189" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_NumberOfEmployees" xlink:label="loc_ebs_NumberOfEmployees_615C1608393956ADE87949ADB4503506" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_ebs_NumberOfEmployees_615C1608393956ADE87949ADB4503506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B65AC27A1BA2697C7C0449ADB45073DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B65AC27A1BA2697C7C0449ADB45073DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_3A9788EE68B416C166FA49ADB45011FC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_3A9788EE68B416C166FA49ADB45011FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D1D0273CB7FEF5F1838F49ADB45009A3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D1D0273CB7FEF5F1838F49ADB45009A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A7AFD0A6A713EB2A09B349ADB451AD18" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A7AFD0A6A713EB2A09B349ADB451AD18" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_LockUpPeriodForAdjustmentOfFairValue" xlink:label="loc_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_FA7CDC1299EFA7BF245849ADB451DBE9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_FA7CDC1299EFA7BF245849ADB451DBE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_B7D6D6D9EC902822296749ADB4512947" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_B7D6D6D9EC902822296749ADB4512947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E9A9A0A666C67D836FBF49ADB4519AD0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E9A9A0A666C67D836FBF49ADB4519AD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_28FA85139870F6578D0949ADB4519320" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_28FA85139870F6578D0949ADB4519320" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PresentValueDiscountRate" xlink:label="loc_ebs_PresentValueDiscountRate_33B8ABF1F6E4673B283749ADB4526E64" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_ebs_PresentValueDiscountRate_33B8ABF1F6E4673B283749ADB4526E64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_03B42FD20E7C6DD3ED5849ADB452C0D5" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_03B42FD20E7C6DD3ED5849ADB452C0D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_6AE6AFFB3A2EB107880549ADB452D48E" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_Goodwill_6AE6AFFB3A2EB107880549ADB452D48E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_778CE49F9A48286C687D493CBD220C70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2FD53AF24947C417819C493CBD21E42F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_778CE49F9A48286C687D493CBD220C70" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2FD53AF24947C417819C493CBD21E42F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A50792DA873573B29800493CBD21B785" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2FD53AF24947C417819C493CBD21E42F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A50792DA873573B29800493CBD21B785" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D387C811B4FB3C0EA7A0493CBD210CFC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A50792DA873573B29800493CBD21B785" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D387C811B4FB3C0EA7A0493CBD210CFC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D387C811B4FB3C0EA7A0493CBD210CFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A50792DA873573B29800493CBD21B785" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D387C811B4FB3C0EA7A0493CBD210CFC" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AdaptPharmaMember" xlink:label="loc_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D387C811B4FB3C0EA7A0493CBD210CFC" xlink:to="loc_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_97EF82C64873128B3D26493CBD22507B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2FD53AF24947C417819C493CBD21E42F" xlink:to="loc_srt_RestatementAxis_97EF82C64873128B3D26493CBD22507B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_59053682F1057F0616A9493CBD228273_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_97EF82C64873128B3D26493CBD22507B" xlink:to="loc_srt_RestatementDomain_59053682F1057F0616A9493CBD228273_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_59053682F1057F0616A9493CBD228273" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_97EF82C64873128B3D26493CBD22507B" xlink:to="loc_srt_RestatementDomain_59053682F1057F0616A9493CBD228273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_881D0B701A86DDEB861C493CBD226776" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_59053682F1057F0616A9493CBD228273" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_881D0B701A86DDEB861C493CBD226776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_778CE49F9A48286C687D493CBD220C70" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_84604ABF98FBA41543E5493CBD230A54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_84604ABF98FBA41543E5493CBD230A54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9A8FDC7C69E97F6E65B6493CBD2319EF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9A8FDC7C69E97F6E65B6493CBD2319EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_B530DE03BC5CEADAD35D493CBD23215B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_B530DE03BC5CEADAD35D493CBD23215B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_D4FCCBF7A1E4BC218C13493CBD249AE1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_D4FCCBF7A1E4BC218C13493CBD249AE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_E84055513B5F8E98FC96493CBD2417CD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_E84055513B5F8E98FC96493CBD2417CD" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" xlink:label="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_B40CF74457EEE846E69C493CBD2429BF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_B40CF74457EEE846E69C493CBD2429BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_1CE49621DA7208B0799F493CBD24FEF1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_1CE49621DA7208B0799F493CBD24FEF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_BE9B303FF722592D3BAC493CBD25B21A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_BE9B303FF722592D3BAC493CBD25B21A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1509A1A4AED4C6764333493CBD253DBA" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1509A1A4AED4C6764333493CBD253DBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_91E2E16CACBA790D94F2493CBD250DE0" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_91E2E16CACBA790D94F2493CBD250DE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3E1B21928FD8E20E164D493CBD25794E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_Goodwill_3E1B21928FD8E20E164D493CBD25794E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7145C6735FD5EF0BACA9493CBD25AD9F" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7145C6735FD5EF0BACA9493CBD25AD9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:to="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:to="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_B98CEC0B00FF2AA417C6495AC18A8ABC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_B98CEC0B00FF2AA417C6495AC18A8ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_B76ABB8FB04AACA25DAC495DD17D26DD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_B76ABB8FB04AACA25DAC495DD17D26DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7D5CEFE9F324F29C9AC1493CBD2696C8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7D5CEFE9F324F29C9AC1493CBD2696C8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_90C910FAC29B39DA6B8F493CBD2C3234" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE3A80555B935C0AB1C1493CBD2BD532" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90C910FAC29B39DA6B8F493CBD2C3234" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE3A80555B935C0AB1C1493CBD2BD532" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2E4D30CAA15DB30B6571493CBD2B04D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE3A80555B935C0AB1C1493CBD2BD532" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2E4D30CAA15DB30B6571493CBD2B04D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E9865182283B5588EAC8493CBD2B8935_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2E4D30CAA15DB30B6571493CBD2B04D4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E9865182283B5588EAC8493CBD2B8935_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E9865182283B5588EAC8493CBD2B8935" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2E4D30CAA15DB30B6571493CBD2B04D4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E9865182283B5588EAC8493CBD2B8935" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AdaptPharmaMember" xlink:label="loc_ebs_AdaptPharmaMember_628FC6B523A127ED296C493CBD2B0D88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E9865182283B5588EAC8493CBD2B8935" xlink:to="loc_ebs_AdaptPharmaMember_628FC6B523A127ED296C493CBD2B0D88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_37BCB6003E103E32F408493CBD2C1B64" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE3A80555B935C0AB1C1493CBD2BD532" xlink:to="loc_srt_RestatementAxis_37BCB6003E103E32F408493CBD2C1B64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_6DC736B92B9B9B5E467D493CBD2CDF79_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_37BCB6003E103E32F408493CBD2C1B64" xlink:to="loc_srt_RestatementDomain_6DC736B92B9B9B5E467D493CBD2CDF79_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_6DC736B92B9B9B5E467D493CBD2CDF79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_37BCB6003E103E32F408493CBD2C1B64" xlink:to="loc_srt_RestatementDomain_6DC736B92B9B9B5E467D493CBD2CDF79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3BE609142CCB21BEBEF0493CBD2CA03C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_6DC736B92B9B9B5E467D493CBD2CDF79" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3BE609142CCB21BEBEF0493CBD2CA03C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A4645AF3D3F3CFD1E754493CBD2D0FB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90C910FAC29B39DA6B8F493CBD2C3234" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_A4645AF3D3F3CFD1E754493CBD2D0FB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2481038A9F271975DEEC493CBD2D94AA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90C910FAC29B39DA6B8F493CBD2C3234" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2481038A9F271975DEEC493CBD2D94AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_54B31425AE51B24341DF493CBD2D3914" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90C910FAC29B39DA6B8F493CBD2C3234" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_54B31425AE51B24341DF493CBD2D3914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_68C81610150D2FFE37B8493CBD2D3534" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90C910FAC29B39DA6B8F493CBD2C3234" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_68C81610150D2FFE37B8493CBD2D3534" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_51D216E6F109471A4376205677DB6BEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A6BB2E05EE945846F3C205677DAC9F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_51D216E6F109471A4376205677DB6BEC" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A6BB2E05EE945846F3C205677DAC9F5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_39A3DFD7384A6B613ACA205677DA08A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A6BB2E05EE945846F3C205677DAC9F5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_39A3DFD7384A6B613ACA205677DA08A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33AE0CFA2562FDFF4FC5205677DBA744_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_39A3DFD7384A6B613ACA205677DA08A6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33AE0CFA2562FDFF4FC5205677DBA744_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33AE0CFA2562FDFF4FC5205677DBA744" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_39A3DFD7384A6B613ACA205677DA08A6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33AE0CFA2562FDFF4FC5205677DBA744" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AdaptAndPaxVaxMember" xlink:label="loc_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33AE0CFA2562FDFF4FC5205677DBA744" xlink:to="loc_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_NumberOfBusinessAcquisitions" xlink:label="loc_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_51D216E6F109471A4376205677DB6BEC" xlink:to="loc_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ImpactOfBusinessAcquisitionsAbstract" xlink:label="loc_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_51D216E6F109471A4376205677DB6BEC" xlink:to="loc_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8D89EDD31C13B9DEB09F205677DC0E1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8D89EDD31C13B9DEB09F205677DC0E1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_4AE35CA614946F231B1E205677DCDABF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:to="loc_us-gaap_OperatingIncomeLoss_4AE35CA614946F231B1E205677DCDABF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E95F32B56ACC18CA8918D849D612584A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E95F32B56ACC18CA8918D849D612584A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E95F32B56ACC18CA8918D849D612584A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6F93CECCA10D30D57E45D849D614A582" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_6F93CECCA10D30D57E45D849D614A582" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_VivotifMember" xlink:label="loc_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:to="loc_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_VaxchoraMember" xlink:label="loc_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:to="loc_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0D2E15560694BDBDD524D849D6140E04" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E95F32B56ACC18CA8918D849D612584A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0D2E15560694BDBDD524D849D6140E04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0654AA7A99F194F8B5D7D849D615D1BA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0D2E15560694BDBDD524D849D6140E04" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0654AA7A99F194F8B5D7D849D615D1BA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0654AA7A99F194F8B5D7D849D615D1BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0D2E15560694BDBDD524D849D6140E04" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0654AA7A99F194F8B5D7D849D615D1BA" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PaxVaxMember" xlink:label="loc_ebs_PaxVaxMember_B66AC5DCDB5BEF0C2B69D849D6152D45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0654AA7A99F194F8B5D7D849D615D1BA" xlink:to="loc_ebs_PaxVaxMember_B66AC5DCDB5BEF0C2B69D849D6152D45" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_NumberOfEmployees" xlink:label="loc_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B3057A07E9F3D537F4AED849D616954A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B3057A07E9F3D537F4AED849D616954A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_24C27871FCBBF30867DED849D616DFCD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_24C27871FCBBF30867DED849D616DFCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_75390C3C0551FAFF0D11D849D61667BD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_75390C3C0551FAFF0D11D849D61667BD" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PresentValueDiscountRate" xlink:label="loc_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_A98EBF9EBD9AFF151359D849D616D0AC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_us-gaap_Goodwill_A98EBF9EBD9AFF151359D849D616D0AC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_A30FE185C635C579E194493CBD0D0B42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE8E3C339305B9EEC826493CBD0B0B6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A30FE185C635C579E194493CBD0D0B42" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE8E3C339305B9EEC826493CBD0B0B6E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_EF82BCD1C2D25B76B9B7493CBD0B483C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE8E3C339305B9EEC826493CBD0B0B6E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_EF82BCD1C2D25B76B9B7493CBD0B483C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E468CF582F04C67FA62C493CBD0CEEC8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_EF82BCD1C2D25B76B9B7493CBD0B483C" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E468CF582F04C67FA62C493CBD0CEEC8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E468CF582F04C67FA62C493CBD0CEEC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_EF82BCD1C2D25B76B9B7493CBD0B483C" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E468CF582F04C67FA62C493CBD0CEEC8" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PaxVaxMember" xlink:label="loc_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E468CF582F04C67FA62C493CBD0CEEC8" xlink:to="loc_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE8E3C339305B9EEC826493CBD0B0B6E" xlink:to="loc_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6" xlink:to="loc_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6" xlink:to="loc_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_B80235663B0D5CDCA203493CBD0D3E25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_B80235663B0D5CDCA203493CBD0D3E25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A30FE185C635C579E194493CBD0D0B42" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C5FE8142A70AB354650E493CBD0DBC17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C5FE8142A70AB354650E493CBD0DBC17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_284E689CF5F83D17E8ED493CBD0E8E8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_284E689CF5F83D17E8ED493CBD0E8E8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6EBE1955007E2B674E40493CBD0E02C2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6EBE1955007E2B674E40493CBD0E02C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1438892828F9D2390D5B493CBD0ED79F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1438892828F9D2390D5B493CBD0ED79F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_A611E3758EE0DCE7D0B4493CBD0E4D08" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_A611E3758EE0DCE7D0B4493CBD0E4D08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_59616110BFF9734CCB0C493CBD0E75BA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_59616110BFF9734CCB0C493CBD0E75BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_95213AD4903B0BB3E5ED493CBD0EC663" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_95213AD4903B0BB3E5ED493CBD0EC663" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" xlink:label="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92835BFC2C859A8BB4C493CBD0F385C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92835BFC2C859A8BB4C493CBD0F385C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823EF9FAE8C7267C7156493CBD0F4893" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823EF9FAE8C7267C7156493CBD0F4893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A7C9A22C38080FF3B6EE493CBD0F05B0" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A7C9A22C38080FF3B6EE493CBD0F05B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4886872206C70BE213A7493CBD101695" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_Goodwill_4886872206C70BE213A7493CBD101695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B2EC7757ADC88305215F493CBD10ADEE" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B2EC7757ADC88305215F493CBD10ADEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:to="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_D0436772963D7FF737A149540EFE7120" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_D0436772963D7FF737A149540EFE7120" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:to="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_9BB2080D607CB401E10849547B341491" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_9BB2080D607CB401E10849547B341491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7B8F342BA8651501B8424958D3284217" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7B8F342BA8651501B8424958D3284217" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_710BB0C30C1D77AA0DB1D849D4359CE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_710BB0C30C1D77AA0DB1D849D4359CE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_EAFAC73C1E95447BFEEDD849D4350714" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_EAFAC73C1E95447BFEEDD849D4350714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_15401EA82B2E68B540F2D849D435E448" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:to="loc_us-gaap_OperatingLeaseLiability_15401EA82B2E68B540F2D849D435E448" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/Business" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566" xlink:to="loc_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D" xlink:to="loc_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0" xlink:to="loc_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0" xlink:to="loc_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ShareholderClassActionLawsuitMember" xlink:label="loc_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70" xlink:to="loc_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_A50E9B37733E5BB40CB6D849D43F19AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_A50E9B37733E5BB40CB6D849D43F19AA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208" xlink:to="loc_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106" xlink:to="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106" xlink:to="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6D6E0EB3E0BA11ACEF8820C8555269DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:to="loc_us-gaap_CommonStockMember_6D6E0EB3E0BA11ACEF8820C8555269DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4EAAC9BB35131878319820C85552B631" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4EAAC9BB35131878319820C85552B631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_1A80A41CD00897DB525920C855528BA2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:to="loc_us-gaap_TreasuryStockMember_1A80A41CD00897DB525920C855528BA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F71673ACF88509FF885220C85552F53C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F71673ACF88509FF885220C85552F53C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_C0D3998F77BD1B3D515020C855529747" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:to="loc_us-gaap_RetainedEarningsMember_C0D3998F77BD1B3D515020C855529747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B264010A44F7FEA7033620C85553036B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_CommonStockSharesIssued_B264010A44F7FEA7033620C85553036B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E94FFAC0F4DA62D00FC920C8555337D4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_StockholdersEquity_E94FFAC0F4DA62D00FC920C8555337D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE48144E672319E4EC8B20C8555475C0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE48144E672319E4EC8B20C8555475C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_F67C7519D562D237F13B20C85554AAFB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_F67C7519D562D237F13B20C85554AAFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21EB85CBB02D937AF77320C855545792" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21EB85CBB02D937AF77320C855545792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_B6A76952761BA107AC2F20C85554A078" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_B6A76952761BA107AC2F20C85554A078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E8E1BBB2E61F517D2AC820C85554DF9A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_NetIncomeLoss_E8E1BBB2E61F517D2AC820C85554DF9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_399C116C3E04922C118B20C855557136" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_399C116C3E04922C118B20C855557136" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_539BB2C8D01FD291C0C32A8A1C594898" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_StatementTable_539BB2C8D01FD291C0C32A8A1C594898" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_539BB2C8D01FD291C0C32A8A1C594898" xlink:to="loc_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED" xlink:to="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED" xlink:to="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_6DAABF2038F9AFBD59A72A8A1C5A820C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:to="loc_us-gaap_ProductMember_6DAABF2038F9AFBD59A72A8A1C5A820C" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:to="loc_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractsAndGrantsMember" xlink:label="loc_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:to="loc_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E03C0C2575E201E50E592A8A1C61BCF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E03C0C2575E201E50E592A8A1C61BCF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5C2F6A77A2DE6791A7642A8A1C61FAF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5C2F6A77A2DE6791A7642A8A1C61FAF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EA2DCA0250263241A4D72A8A1C62BA32" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_EA2DCA0250263241A4D72A8A1C62BA32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_06E0E2133759621C01C32A8A1C628EBB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_06E0E2133759621C01C32A8A1C628EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D61A838C43340154DA4A2A8A1C622D1D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_D61A838C43340154DA4A2A8A1C622D1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_76BDCF334BE6F98C52872A8A1C62FB3B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:to="loc_us-gaap_OperatingExpenses_76BDCF334BE6F98C52872A8A1C62FB3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8C9F5F6C31D156DEC7A52A8A1C637A30" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_OperatingIncomeLoss_8C9F5F6C31D156DEC7A52A8A1C637A30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_798497C8C5ED5B4F14EC2A8A1C6399F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:to="loc_us-gaap_InterestExpense_798497C8C5ED5B4F14EC2A8A1C6399F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_FF2AEA776074ECD7FA462A8A1C63801B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_FF2AEA776074ECD7FA462A8A1C63801B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4A107193415103C675A92A8A1C6323F9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4A107193415103C675A92A8A1C6323F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_347D619286BD0ABD41032A8A1C633F5F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_347D619286BD0ABD41032A8A1C633F5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5D0CC6AEBBE5DA9AA5542A8A1C64C79B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5D0CC6AEBBE5DA9AA5542A8A1C64C79B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_27EA59D52C643BE47B9B2A8A1C64FE99" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_NetIncomeLoss_27EA59D52C643BE47B9B2A8A1C64FE99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_82971E18464E84A744C02A8A1C6451D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E" xlink:to="loc_us-gaap_EarningsPerShareBasic_82971E18464E84A744C02A8A1C6451D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_FAE454C5583115005AF92A8A1C64E015" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E" xlink:to="loc_us-gaap_EarningsPerShareDiluted_FAE454C5583115005AF92A8A1C64E015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D1D012B0C4F0B7DD27D82A8A1C65C9E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D1D012B0C4F0B7DD27D82A8A1C65C9E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_FF9F0D66C6BE45F8E7DE2A8A1C6592A1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_FF9F0D66C6BE45F8E7DE2A8A1C6592A1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsideration" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_RaxibacumabMember" xlink:label="loc_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F" xlink:to="loc_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_C8C41F1E85419C783ED72073BB55AED3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_C8C41F1E85419C783ED72073BB55AED3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:to="loc_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6" xlink:to="loc_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6" xlink:to="loc_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_0CEF79926B528CD2B1C4493CBC4DF392" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_0CEF79926B528CD2B1C4493CBC4DF392" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_TermLoanFacilityMember" xlink:label="loc_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:to="loc_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:to="loc_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_CreditAgreementMember" xlink:label="loc_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:to="loc_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AmendedCreditAgreementMember" xlink:label="loc_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:to="loc_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ConvertibleSeniorNotesDue2021Member" xlink:label="loc_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:to="loc_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:to="loc_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E" xlink:to="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E" xlink:to="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_237E8601900F543B781F493CBC4F510E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:to="loc_us-gaap_EurodollarMember_237E8601900F543B781F493CBC4F510E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_AFF6E0E56A1967BC4BC3493CBC4FC3C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_AFF6E0E56A1967BC4BC3493CBC4FC3C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_3B1B55543EEC4BBB7589493CBC507BD6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:to="loc_us-gaap_BaseRateMember_3B1B55543EEC4BBB7589493CBC507BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_16F63BD165442C439150493CBC501B9C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:to="loc_srt_RangeAxis_16F63BD165442C439150493CBC501B9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A23300F623EEC2E58C06493CBC50BC50_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_16F63BD165442C439150493CBC501B9C" xlink:to="loc_srt_RangeMember_A23300F623EEC2E58C06493CBC50BC50_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A23300F623EEC2E58C06493CBC50BC50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_16F63BD165442C439150493CBC501B9C" xlink:to="loc_srt_RangeMember_A23300F623EEC2E58C06493CBC50BC50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_BBE837576BA60CA8F2F5493CBC5023FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A23300F623EEC2E58C06493CBC50BC50" xlink:to="loc_srt_MinimumMember_BBE837576BA60CA8F2F5493CBC5023FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_0349CAC4E878B0913E1A493CBC50E0C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A23300F623EEC2E58C06493CBC50BC50" xlink:to="loc_srt_MaximumMember_0349CAC4E878B0913E1A493CBC50E0C5" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_NumberOfLendingInstitutions" xlink:label="loc_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_FCD0DE37262E0611FCC0493CBC519991" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_FCD0DE37262E0611FCC0493CBC519991" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_BD5E669A5D8502DE7DB4493CBC51C8CE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_BD5E669A5D8502DE7DB4493CBC51C8CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_951E255E840E0521F0B7493CBC5167C2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_951E255E840E0521F0B7493CBC5167C2" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioThree" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioFour" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentRestrictedPaymentsLimitAmount" xlink:label="loc_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4D5BC057F3454FC0149A493CBC54F5F3" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4D5BC057F3454FC0149A493CBC54F5F3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F556FBC17ACE177A20C54DCE2894178C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_64D313E7E6A3E83007864DCE2892D005" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F556FBC17ACE177A20C54DCE2894178C" xlink:to="loc_us-gaap_DebtInstrumentTable_64D313E7E6A3E83007864DCE2892D005" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_DD0EF677EF6B7C5818FF4DCE289229A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_64D313E7E6A3E83007864DCE2892D005" xlink:to="loc_us-gaap_CreditFacilityAxis_DD0EF677EF6B7C5818FF4DCE289229A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_5BF76BC327380D953C2F4DCE28928C6B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_DD0EF677EF6B7C5818FF4DCE289229A6" xlink:to="loc_us-gaap_CreditFacilityDomain_5BF76BC327380D953C2F4DCE28928C6B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_5BF76BC327380D953C2F4DCE28928C6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_DD0EF677EF6B7C5818FF4DCE289229A6" xlink:to="loc_us-gaap_CreditFacilityDomain_5BF76BC327380D953C2F4DCE28928C6B" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_TermLoanFacilityMember" xlink:label="loc_ebs_TermLoanFacilityMember_82FE57DA662CBF73FFCF4DCE28926E77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5BF76BC327380D953C2F4DCE28928C6B" xlink:to="loc_ebs_TermLoanFacilityMember_82FE57DA662CBF73FFCF4DCE28926E77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_F3706060B8D018119AAD4DCE28937894" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5BF76BC327380D953C2F4DCE28928C6B" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_F3706060B8D018119AAD4DCE28937894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_029E03D092F8415D40664DCE28935A57" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_64D313E7E6A3E83007864DCE2892D005" xlink:to="loc_us-gaap_DebtInstrumentAxis_029E03D092F8415D40664DCE28935A57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7144AFF279F6C187DE094DCE2893A319_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_029E03D092F8415D40664DCE28935A57" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7144AFF279F6C187DE094DCE2893A319_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7144AFF279F6C187DE094DCE2893A319" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_029E03D092F8415D40664DCE28935A57" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7144AFF279F6C187DE094DCE2893A319" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ConvertibleSeniorNotesDue2021Member" xlink:label="loc_ebs_ConvertibleSeniorNotesDue2021Member_628C3A5667207C2B05B94DCE289393AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7144AFF279F6C187DE094DCE2893A319" xlink:to="loc_ebs_ConvertibleSeniorNotesDue2021Member_628C3A5667207C2B05B94DCE289393AF" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_OtherLongTermDebtFacilityMember" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7144AFF279F6C187DE094DCE2893A319" xlink:to="loc_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_267B55325F6285A988934DCE28949E31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F556FBC17ACE177A20C54DCE2894178C" xlink:to="loc_us-gaap_LongTermDebt_267B55325F6285A988934DCE28949E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_CF7F79918C0F1725AAA04DCE2894F886" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F556FBC17ACE177A20C54DCE2894178C" xlink:to="loc_us-gaap_LongTermDebtCurrent_CF7F79918C0F1725AAA04DCE2894F886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_585D22DC2E8731131A224DCE28949885" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F556FBC17ACE177A20C54DCE2894178C" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_585D22DC2E8731131A224DCE28949885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_325E2D7C257C4ADCFCCF4DCE28943786" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F556FBC17ACE177A20C54DCE2894178C" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_325E2D7C257C4ADCFCCF4DCE28943786" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DefinedBenefitPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DefinedBenefitPlanTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_65DEB15D913A01F60EE32F38D6985166" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_6EA96ACDEFF63FD091D92F38D6966D3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_65DEB15D913A01F60EE32F38D6985166" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_6EA96ACDEFF63FD091D92F38D6966D3B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_6EA96ACDEFF63FD091D92F38D6966D3B" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886" xlink:to="loc_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886" xlink:to="loc_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_CF751B8252880F4CD7592F38D696BB55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A" xlink:to="loc_us-gaap_CashFlowHedgingMember_CF751B8252880F4CD7592F38D696BB55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_6EA96ACDEFF63FD091D92F38D6966D3B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaap_InterestExpenseMember_F453CD76102ECBA3020F2F38D697D72C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B" xlink:to="loc_us-gaap_InterestExpenseMember_F453CD76102ECBA3020F2F38D697D72C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7A6E6E36264AA18C96442F38D697CA9E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_6EA96ACDEFF63FD091D92F38D6966D3B" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7A6E6E36264AA18C96442F38D697CA9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_A7F348BC4D4B5577AAEB2F38D697C8A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7A6E6E36264AA18C96442F38D697CA9E" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_A7F348BC4D4B5577AAEB2F38D697C8A3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_A7F348BC4D4B5577AAEB2F38D697C8A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7A6E6E36264AA18C96442F38D697CA9E" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_A7F348BC4D4B5577AAEB2F38D697C8A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_A5A73CA6C58F7FAD7D862F38D6988D50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_A7F348BC4D4B5577AAEB2F38D697C8A3" xlink:to="loc_us-gaap_InterestRateSwapMember_A5A73CA6C58F7FAD7D862F38D6988D50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_5C19E5799221CDFD03E62F38D698D2F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_65DEB15D913A01F60EE32F38D6985166" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_5C19E5799221CDFD03E62F38D698D2F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B926E7A619CBAB5D87222F38D69860A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_65DEB15D913A01F60EE32F38D6985166" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B926E7A619CBAB5D87222F38D69860A6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_00852E82789B2FD58CD12F38D6A383E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:to="loc_us-gaap_HedgingDesignationAxis_00852E82789B2FD58CD12F38D6A383E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_BA837989C497D02092812F38D6A3AB64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_00852E82789B2FD58CD12F38D6A383E0" xlink:to="loc_us-gaap_HedgingDesignationDomain_BA837989C497D02092812F38D6A3AB64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_BA837989C497D02092812F38D6A3AB64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_00852E82789B2FD58CD12F38D6A383E0" xlink:to="loc_us-gaap_HedgingDesignationDomain_BA837989C497D02092812F38D6A3AB64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_F262C52522DC53FCB98C2F38D6A495FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_BA837989C497D02092812F38D6A3AB64" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_F262C52522DC53FCB98C2F38D6A495FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_C192CDE0D25E37ED1ECD2F38D6A461D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_C192CDE0D25E37ED1ECD2F38D6A461D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6D861BABBD6A825668802F38D6A43509_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_C192CDE0D25E37ED1ECD2F38D6A461D1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6D861BABBD6A825668802F38D6A43509_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6D861BABBD6A825668802F38D6A43509" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_C192CDE0D25E37ED1ECD2F38D6A461D1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6D861BABBD6A825668802F38D6A43509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_7FF1A3A1DACAEF03373F2F38D6A4C78F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6D861BABBD6A825668802F38D6A43509" xlink:to="loc_us-gaap_InterestRateSwapMember_7FF1A3A1DACAEF03373F2F38D6A4C78F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_5B00F642E42C645033D42F38D6A5EBED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_5B00F642E42C645033D42F38D6A5EBED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_AC669F8D55E973CD12862F38D6A565D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:to="loc_invest_DerivativeNotionalAmount_AC669F8D55E973CD12862F38D6A565D2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ACF4AB501F3AA608093120CA657F180B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8E3A997A120870C802F720CA657D8E74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ACF4AB501F3AA608093120CA657F180B" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8E3A997A120870C802F720CA657D8E74" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2804497F05504EB4573C20D6BEB811F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8E3A997A120870C802F720CA657D8E74" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2804497F05504EB4573C20D6BEB811F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1BFE3C7CACA88739E3E020D6BEBA1612_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2804497F05504EB4573C20D6BEB811F2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1BFE3C7CACA88739E3E020D6BEBA1612_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1BFE3C7CACA88739E3E020D6BEBA1612" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2804497F05504EB4573C20D6BEB811F2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1BFE3C7CACA88739E3E020D6BEBA1612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_4AAE24DF930AC06C5D2620D6E8D969F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1BFE3C7CACA88739E3E020D6BEBA1612" xlink:to="loc_us-gaap_InterestRateSwapMember_4AAE24DF930AC06C5D2620D6E8D969F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_5C1C38A92AC252B90AD720CA657D9A10" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8E3A997A120870C802F720CA657D8E74" xlink:to="loc_us-gaap_HedgingDesignationAxis_5C1C38A92AC252B90AD720CA657D9A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_15CB0AED88B100DB062720CA657D6536_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_5C1C38A92AC252B90AD720CA657D9A10" xlink:to="loc_us-gaap_HedgingDesignationDomain_15CB0AED88B100DB062720CA657D6536_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_15CB0AED88B100DB062720CA657D6536" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_5C1C38A92AC252B90AD720CA657D9A10" xlink:to="loc_us-gaap_HedgingDesignationDomain_15CB0AED88B100DB062720CA657D6536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_FEA8DD1CAD94057A8C8020CA657EAC2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_15CB0AED88B100DB062720CA657D6536" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_FEA8DD1CAD94057A8C8020CA657EAC2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_B80C6CD40792532DB0C720CA657E239F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8E3A997A120870C802F720CA657D8E74" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_B80C6CD40792532DB0C720CA657E239F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B80C6CD40792532DB0C720CA657E239F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B80C6CD40792532DB0C720CA657E239F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_16C31A8606B7F16FB68C20CA657EC65D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA" xlink:to="loc_us-gaap_OtherAssetsMember_16C31A8606B7F16FB68C20CA657EC65D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesMember" xlink:label="loc_us-gaap_OtherLiabilitiesMember_710EF45ACEA9EDC936BC20CA657EB4AA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA" xlink:to="loc_us-gaap_OtherLiabilitiesMember_710EF45ACEA9EDC936BC20CA657EB4AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2B7442801E6890EFB9BF20CA657F2ACE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ACF4AB501F3AA608093120CA657F180B" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2B7442801E6890EFB9BF20CA657F2ACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3B49ACA19B8658F1F65520CA657FAF26" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ACF4AB501F3AA608093120CA657F180B" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3B49ACA19B8658F1F65520CA657FAF26" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_6686C923BC59F583B4802F38D6A8DFD7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_833498BBCBCAAD23BCA32F38D6A733CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_6686C923BC59F583B4802F38D6A8DFD7" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_833498BBCBCAAD23BCA32F38D6A733CB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3F92A93829C2A1FA51A22F38D6A76891" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_833498BBCBCAAD23BCA32F38D6A733CB" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3F92A93829C2A1FA51A22F38D6A76891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6FF5CDB79C23B27A260D2F38D6A7C728_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3F92A93829C2A1FA51A22F38D6A76891" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6FF5CDB79C23B27A260D2F38D6A7C728_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6FF5CDB79C23B27A260D2F38D6A7C728" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3F92A93829C2A1FA51A22F38D6A76891" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6FF5CDB79C23B27A260D2F38D6A7C728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_DE6EA5EB2634B79CDFDA2F38D6A70CE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6FF5CDB79C23B27A260D2F38D6A7C728" xlink:to="loc_us-gaap_InterestRateSwapMember_DE6EA5EB2634B79CDFDA2F38D6A70CE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_AE8907DA146CBBC768722F38D6A858CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_6686C923BC59F583B4802F38D6A8DFD7" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_AE8907DA146CBBC768722F38D6A858CA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_055E30809844174EC19D499D6D6A813E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_055E30809844174EC19D499D6D6A813E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07644AA8BB5AA8848A30499D6D6C5280" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07644AA8BB5AA8848A30499D6D6C5280" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments_EF82DAEF47BB58D566B1499D6D6D3CB5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments_EF82DAEF47BB58D566B1499D6D6D3CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D" xlink:to="loc_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C" xlink:to="loc_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C" xlink:to="loc_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_FCBE04044132AAA99ADD499D6D6E4BD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:to="loc_srt_MinimumMember_FCBE04044132AAA99ADD499D6D6E4BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_FA31D112DDBAE1546FAE499D6D6ED29F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:to="loc_srt_MaximumMember_FA31D112DDBAE1546FAE499D6D6ED29F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1EE12843DD06393AB284499D6D6EFB56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1EE12843DD06393AB284499D6D6EFB56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5549CBA2D1856F4F13F1499D6D6FA30E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5549CBA2D1856F4F13F1499D6D6FA30E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_EED16116EF1CD41C16D1499D6D6F8205" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_EED16116EF1CD41C16D1499D6D6F8205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D5EDAC8C7691E523284B499D6D6F20A7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D5EDAC8C7691E523284B499D6D6F20A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_EDFC1BF4C5A790046332499D6D6F9834" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_EDFC1BF4C5A790046332499D6D6F9834" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/Inventories" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/InventoriesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/InventoriesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D13613A72B42A0EB41CCD849D539CFF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442" xlink:to="loc_srt_RangeAxis_D13613A72B42A0EB41CCD849D539CFF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6B1B70F8AF4C55F2E536D849D5390CD2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_D13613A72B42A0EB41CCD849D539CFF9" xlink:to="loc_srt_RangeMember_6B1B70F8AF4C55F2E536D849D5390CD2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6B1B70F8AF4C55F2E536D849D5390CD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_D13613A72B42A0EB41CCD849D539CFF9" xlink:to="loc_srt_RangeMember_6B1B70F8AF4C55F2E536D849D5390CD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_12555973B4B48F2DC9F8D849D53ADC7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6B1B70F8AF4C55F2E536D849D5390CD2" xlink:to="loc_srt_MinimumMember_12555973B4B48F2DC9F8D849D53ADC7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_F898484A96149DBD8AF2D849D53A9E58" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6B1B70F8AF4C55F2E536D849D5390CD2" xlink:to="loc_srt_MaximumMember_F898484A96149DBD8AF2D849D53A9E58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_37F17FD1D06D0D8DD53BD849D53A9695" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_37F17FD1D06D0D8DD53BD849D53A9695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8EEFE3B14793AB01746AD849D53B083B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8EEFE3B14793AB01746AD849D53B083B" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_LesseeOperatingLeaseTerminationPeriod" xlink:label="loc_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:to="loc_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LossEarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LossEarningsPerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LossEarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LandAndLandImprovementsMember" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_2AD7334D8CD22358C896205677C174DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_2AD7334D8CD22358C896205677C174DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_FFC8747ACA7CD203B572205677C19F15" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_FFC8747ACA7CD203B572205677C19F15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_C1C818480E65B825F64D205677C139ED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_C1C818480E65B825F64D205677C139ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_87D07A1EE3D52BCCB949205677C2597B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_87D07A1EE3D52BCCB949205677C2597B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_AAEF3DAA79A23C0874A3205677C2E723" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:to="loc_us-gaap_ConstructionInProgressMember_AAEF3DAA79A23C0874A3205677C2E723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_BD68B8EA336AA67455A5205677C27D82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_BD68B8EA336AA67455A5205677C27D82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3D8ADD5CAAA59EE9A9E5205677C350FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3D8ADD5CAAA59EE9A9E5205677C350FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3DC5DF4A9C572CD6AE26205677C3E8EE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3DC5DF4A9C572CD6AE26205677C3E8EE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_3411F454F38AA9D50E1B3EEE3193EA2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:to="loc_srt_ProductOrServiceAxis_3411F454F38AA9D50E1B3EEE3193EA2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_232DDB37D1C4BB6614283EEE31949ED5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3411F454F38AA9D50E1B3EEE3193EA2F" xlink:to="loc_srt_ProductsAndServicesDomain_232DDB37D1C4BB6614283EEE31949ED5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_232DDB37D1C4BB6614283EEE31949ED5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3411F454F38AA9D50E1B3EEE3193EA2F" xlink:to="loc_srt_ProductsAndServicesDomain_232DDB37D1C4BB6614283EEE31949ED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_46C6EC4740CFCFF915FA3EEE31949938" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_232DDB37D1C4BB6614283EEE31949ED5" xlink:to="loc_us-gaap_ProductMember_46C6EC4740CFCFF915FA3EEE31949938" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_537661271A587D03F3BF3EEE319448C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_232DDB37D1C4BB6614283EEE31949ED5" xlink:to="loc_ebs_ContractManufacturingMember_537661271A587D03F3BF3EEE319448C8" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractsAndGrantsMember" xlink:label="loc_ebs_ContractsAndGrantsMember_C7BBBF44D9AD5DDF02B43EEE3195B33F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_232DDB37D1C4BB6614283EEE31949ED5" xlink:to="loc_ebs_ContractsAndGrantsMember_C7BBBF44D9AD5DDF02B43EEE3195B33F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:to="loc_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E" xlink:to="loc_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E" xlink:to="loc_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_E4ABEDFE2D629882264A3EEE319A5DBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:to="loc_country_US_E4ABEDFE2D629882264A3EEE319A5DBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_DA8F0273A4169A70D61E3EEE319BE401" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:to="loc_us-gaap_NonUsMember_DA8F0273A4169A70D61E3EEE319BE401" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_390FF8F3FE97177DC1033EEE319B73AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_390FF8F3FE97177DC1033EEE319B73AB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ShareBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:to="loc_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0" xlink:to="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0" xlink:to="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_A971A5FF244CE28285E12F38D6481F11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_A971A5FF244CE28285E12F38D6481F11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5D4FF62F6F1AC96481162F38D648E1C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5D4FF62F6F1AC96481162F38D648E1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3E8AD76BE38FB2A234632F38D648F72A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3E8AD76BE38FB2A234632F38D648F72A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:to="loc_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8898D45131822641B82F2F38D6483CA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8898D45131822641B82F2F38D6483CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0465741328C89918370A2F38D648C7AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0465741328C89918370A2F38D648C7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_877984351CC0CBC266062F38D648B022" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_877984351CC0CBC266062F38D648B022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8B1E8BEE3322120D62482F38D648F6AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8B1E8BEE3322120D62482F38D648F6AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1619BD869C58D29B01242F38D648C17C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1619BD869C58D29B01242F38D648C17C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_AFAC7FEC13D28E501EA72F38D648AEA5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_AFAC7FEC13D28E501EA72F38D648AEA5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SupplementalInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SupplementalInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SupplementalInformationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ebs-20190630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_B008804A6C3BEF5D8B76210F9A8F7CB4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_B008804A6C3BEF5D8B76210F9A8F7CB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B008804A6C3BEF5D8B76210F9A8F7CB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B008804A6C3BEF5D8B76210F9A8F7CB4" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_B008804A6C3BEF5D8B76210F9A8F7CB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_73CA4C5FCACAF461410A210F9A8FA5EE_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_73CA4C5FCACAF461410A210F9A8FA5EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective annual tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_73CA4C5FCACAF461410A210F9A8FA5EE_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_73CA4C5FCACAF461410A210F9A8FA5EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_73CA4C5FCACAF461410A210F9A8FA5EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_73CA4C5FCACAF461410A210F9A8FA5EE" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_73CA4C5FCACAF461410A210F9A8FA5EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_154F202481E51171E87B210F9A8FC6D3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_154F202481E51171E87B210F9A8FC6D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discrete tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_154F202481E51171E87B210F9A8FC6D3_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_154F202481E51171E87B210F9A8FC6D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_154F202481E51171E87B210F9A8FC6D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_154F202481E51171E87B210F9A8FC6D3" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_154F202481E51171E87B210F9A8FC6D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_DEF7DE5B35599A34319E2073BB5319D6_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_DEF7DE5B35599A34319E2073BB5319D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DEF7DE5B35599A34319E2073BB5319D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DEF7DE5B35599A34319E2073BB5319D6" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_DEF7DE5B35599A34319E2073BB5319D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE63C7D9A09BC56A43AE2073BB53DE80_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE63C7D9A09BC56A43AE2073BB53DE80" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE63C7D9A09BC56A43AE2073BB53DE80_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE63C7D9A09BC56A43AE2073BB53DE80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE63C7D9A09BC56A43AE2073BB53DE80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE63C7D9A09BC56A43AE2073BB53DE80" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE63C7D9A09BC56A43AE2073BB53DE80" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FF62B86E2D7AC7AE33AB2073BB54835A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FF62B86E2D7AC7AE33AB2073BB54835A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone achievement - asset acquisition</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FF62B86E2D7AC7AE33AB2073BB54835A_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FF62B86E2D7AC7AE33AB2073BB54835A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FF62B86E2D7AC7AE33AB2073BB54835A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FF62B86E2D7AC7AE33AB2073BB54835A" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FF62B86E2D7AC7AE33AB2073BB54835A" xlink:type="arc" />
    <link:label id="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment_9645D332DF1BD6E31A132073BB5400B9_terseLabel_en-US" xlink:label="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment_9645D332DF1BD6E31A132073BB5400B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement period adjustment</link:label>
    <link:label id="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment_9645D332DF1BD6E31A132073BB5400B9_label_en-US" xlink:label="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment_9645D332DF1BD6E31A132073BB5400B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Measurement Period Adjustment</link:label>
    <link:label id="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment_9645D332DF1BD6E31A132073BB5400B9_documentation_en-US" xlink:label="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment_9645D332DF1BD6E31A132073BB5400B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Measurement Period Adjustment</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment" xlink:label="loc_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment_9645D332DF1BD6E31A132073BB5400B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment_9645D332DF1BD6E31A132073BB5400B9" xlink:to="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment_9645D332DF1BD6E31A132073BB5400B9" xlink:type="arc" />
    <link:label id="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_9973E404F99E1C3DFD3D2073BB542987_terseLabel_en-US" xlink:label="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_9973E404F99E1C3DFD3D2073BB542987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_9973E404F99E1C3DFD3D2073BB542987_label_en-US" xlink:label="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_9973E404F99E1C3DFD3D2073BB542987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Fair Value</link:label>
    <link:label id="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_9973E404F99E1C3DFD3D2073BB542987_documentation_en-US" xlink:label="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_9973E404F99E1C3DFD3D2073BB542987" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Fair Value</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" xlink:label="loc_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_9973E404F99E1C3DFD3D2073BB542987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_9973E404F99E1C3DFD3D2073BB542987" xlink:to="lab_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_9973E404F99E1C3DFD3D2073BB542987" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8CFBDCFDF821F2205EBD2073BB545430_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8CFBDCFDF821F2205EBD2073BB545430" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8CFBDCFDF821F2205EBD2073BB545430_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8CFBDCFDF821F2205EBD2073BB545430" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8CFBDCFDF821F2205EBD2073BB545430" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8CFBDCFDF821F2205EBD2073BB545430" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8CFBDCFDF821F2205EBD2073BB545430" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6AB7015F60F09EE749CE2073BB54D3BC_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6AB7015F60F09EE749CE2073BB54D3BC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6AB7015F60F09EE749CE2073BB54D3BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6AB7015F60F09EE749CE2073BB54D3BC" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6AB7015F60F09EE749CE2073BB54D3BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F" xlink:type="arc" />
    <link:label id="lab_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A_terseLabel_en-US" xlink:label="lab_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raxibacumab</link:label>
    <link:label id="lab_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A_label_en-US" xlink:label="lab_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raxibacumab [Member]</link:label>
    <link:label id="lab_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A_documentation_en-US" xlink:label="lab_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Raxibacumab [Member]</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_RaxibacumabMember" xlink:label="loc_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A" xlink:to="lab_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_C8C41F1E85419C783ED72073BB55AED3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_C8C41F1E85419C783ED72073BB55AED3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability increase</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_C8C41F1E85419C783ED72073BB55AED3_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_C8C41F1E85419C783ED72073BB55AED3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_C8C41F1E85419C783ED72073BB55AED3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_C8C41F1E85419C783ED72073BB55AED3" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_C8C41F1E85419C783ED72073BB55AED3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B7533BEBAAF0CB5E572CD849D4A4979E_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B7533BEBAAF0CB5E572CD849D4A4979E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B7533BEBAAF0CB5E572CD849D4A4979E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B7533BEBAAF0CB5E572CD849D4A4979E" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B7533BEBAAF0CB5E572CD849D4A4979E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8BDDB64360359E1303B7D849D4A45BF7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_8BDDB64360359E1303B7D849D4A45BF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8BDDB64360359E1303B7D849D4A45BF7_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_8BDDB64360359E1303B7D849D4A45BF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8BDDB64360359E1303B7D849D4A45BF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_8BDDB64360359E1303B7D849D4A45BF7" xlink:to="lab_us-gaap_NumberOfOperatingSegments_8BDDB64360359E1303B7D849D4A45BF7" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077_label_en-US" xlink:label="lab_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="lab_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_0D2FC7C30A23BFDA3AF92F38D85DAF81_terseLabel_en-US" xlink:label="lab_dei_DocumentType_0D2FC7C30A23BFDA3AF92F38D85DAF81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_0D2FC7C30A23BFDA3AF92F38D85DAF81_label_en-US" xlink:label="lab_dei_DocumentType_0D2FC7C30A23BFDA3AF92F38D85DAF81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_0D2FC7C30A23BFDA3AF92F38D85DAF81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_0D2FC7C30A23BFDA3AF92F38D85DAF81" xlink:to="lab_dei_DocumentType_0D2FC7C30A23BFDA3AF92F38D85DAF81" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_14E9858DA9FF2F980B9C2F38D85DECF0_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_14E9858DA9FF2F980B9C2F38D85DECF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_14E9858DA9FF2F980B9C2F38D85DECF0_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_14E9858DA9FF2F980B9C2F38D85DECF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_14E9858DA9FF2F980B9C2F38D85DECF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_14E9858DA9FF2F980B9C2F38D85DECF0" xlink:to="lab_dei_DocumentQuarterlyReport_14E9858DA9FF2F980B9C2F38D85DECF0" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_D98BBD38BE7A244C12842F38D85DBA47_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_D98BBD38BE7A244C12842F38D85DBA47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_D98BBD38BE7A244C12842F38D85DBA47_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_D98BBD38BE7A244C12842F38D85DBA47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D98BBD38BE7A244C12842F38D85DBA47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_D98BBD38BE7A244C12842F38D85DBA47" xlink:to="lab_dei_DocumentPeriodEndDate_D98BBD38BE7A244C12842F38D85DBA47" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_4E435893B40C71E282112F38D85D25BB_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_4E435893B40C71E282112F38D85D25BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_4E435893B40C71E282112F38D85D25BB_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_4E435893B40C71E282112F38D85D25BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_4E435893B40C71E282112F38D85D25BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_4E435893B40C71E282112F38D85D25BB" xlink:to="lab_dei_DocumentTransitionReport_4E435893B40C71E282112F38D85D25BB" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_2DE4DB57B8FFE23F828D2F38D85D7846_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_2DE4DB57B8FFE23F828D2F38D85D7846" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_2DE4DB57B8FFE23F828D2F38D85D7846_label_en-US" xlink:label="lab_dei_EntityFileNumber_2DE4DB57B8FFE23F828D2F38D85D7846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_2DE4DB57B8FFE23F828D2F38D85D7846" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_2DE4DB57B8FFE23F828D2F38D85D7846" xlink:to="lab_dei_EntityFileNumber_2DE4DB57B8FFE23F828D2F38D85D7846" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_975ECDB5D056B72A543C2F38D85D3B19_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_975ECDB5D056B72A543C2F38D85D3B19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_975ECDB5D056B72A543C2F38D85D3B19_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_975ECDB5D056B72A543C2F38D85D3B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_975ECDB5D056B72A543C2F38D85D3B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_975ECDB5D056B72A543C2F38D85D3B19" xlink:to="lab_dei_EntityIncorporationStateCountryCode_975ECDB5D056B72A543C2F38D85D3B19" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3C3A779E7932AA1CE7492F38D85DE5CF_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_3C3A779E7932AA1CE7492F38D85DE5CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3C3A779E7932AA1CE7492F38D85DE5CF_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_3C3A779E7932AA1CE7492F38D85DE5CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_3C3A779E7932AA1CE7492F38D85DE5CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_3C3A779E7932AA1CE7492F38D85DE5CF" xlink:to="lab_dei_EntityTaxIdentificationNumber_3C3A779E7932AA1CE7492F38D85DE5CF" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_9A9D5467BEC65F99542A2F38D85D6099_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_9A9D5467BEC65F99542A2F38D85D6099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_9A9D5467BEC65F99542A2F38D85D6099_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_9A9D5467BEC65F99542A2F38D85D6099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_9A9D5467BEC65F99542A2F38D85D6099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_9A9D5467BEC65F99542A2F38D85D6099" xlink:to="lab_dei_EntityAddressAddressLine1_9A9D5467BEC65F99542A2F38D85D6099" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine2_CFFA437C44AE437A267E2F38D85DEC59_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2_CFFA437C44AE437A267E2F38D85DEC59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_CFFA437C44AE437A267E2F38D85DEC59_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2_CFFA437C44AE437A267E2F38D85DEC59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_CFFA437C44AE437A267E2F38D85DEC59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_CFFA437C44AE437A267E2F38D85DEC59" xlink:to="lab_dei_EntityAddressAddressLine2_CFFA437C44AE437A267E2F38D85DEC59" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_A18E5D8F48E8D235154E2F38D85DCA6C_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_A18E5D8F48E8D235154E2F38D85DCA6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_A18E5D8F48E8D235154E2F38D85DCA6C_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_A18E5D8F48E8D235154E2F38D85DCA6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_A18E5D8F48E8D235154E2F38D85DCA6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_A18E5D8F48E8D235154E2F38D85DCA6C" xlink:to="lab_dei_EntityAddressCityOrTown_A18E5D8F48E8D235154E2F38D85DCA6C" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_1AF31FCC746F5BB4BF8B2F38D85DCA0E_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_1AF31FCC746F5BB4BF8B2F38D85DCA0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1AF31FCC746F5BB4BF8B2F38D85DCA0E_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_1AF31FCC746F5BB4BF8B2F38D85DCA0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_1AF31FCC746F5BB4BF8B2F38D85DCA0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_1AF31FCC746F5BB4BF8B2F38D85DCA0E" xlink:to="lab_dei_EntityAddressStateOrProvince_1AF31FCC746F5BB4BF8B2F38D85DCA0E" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_4C5966976AC3976E95592F38D85D9A21_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_4C5966976AC3976E95592F38D85D9A21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4C5966976AC3976E95592F38D85D9A21_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_4C5966976AC3976E95592F38D85D9A21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_4C5966976AC3976E95592F38D85D9A21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_4C5966976AC3976E95592F38D85D9A21" xlink:to="lab_dei_EntityAddressPostalZipCode_4C5966976AC3976E95592F38D85D9A21" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_D84006D0AF0DE39659512F38D85DB2D5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_D84006D0AF0DE39659512F38D85DB2D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_D84006D0AF0DE39659512F38D85DB2D5_label_en-US" xlink:label="lab_dei_CityAreaCode_D84006D0AF0DE39659512F38D85DB2D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_D84006D0AF0DE39659512F38D85DB2D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_D84006D0AF0DE39659512F38D85DB2D5" xlink:to="lab_dei_CityAreaCode_D84006D0AF0DE39659512F38D85DB2D5" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_B44083F90E356B71DAC22F38D85D47B4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_B44083F90E356B71DAC22F38D85D47B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_B44083F90E356B71DAC22F38D85D47B4_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_B44083F90E356B71DAC22F38D85D47B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_B44083F90E356B71DAC22F38D85D47B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_B44083F90E356B71DAC22F38D85D47B4" xlink:to="lab_dei_LocalPhoneNumber_B44083F90E356B71DAC22F38D85D47B4" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_B929196EDC33B03B7C872F38D85D6C16_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_B929196EDC33B03B7C872F38D85D6C16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_B929196EDC33B03B7C872F38D85D6C16_label_en-US" xlink:label="lab_dei_Security12bTitle_B929196EDC33B03B7C872F38D85D6C16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_B929196EDC33B03B7C872F38D85D6C16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_B929196EDC33B03B7C872F38D85D6C16" xlink:to="lab_dei_Security12bTitle_B929196EDC33B03B7C872F38D85D6C16" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_83C62B76B04DA6CAA25D2F38D85D9A08_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_83C62B76B04DA6CAA25D2F38D85D9A08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_83C62B76B04DA6CAA25D2F38D85D9A08_label_en-US" xlink:label="lab_dei_TradingSymbol_83C62B76B04DA6CAA25D2F38D85D9A08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_83C62B76B04DA6CAA25D2F38D85D9A08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_83C62B76B04DA6CAA25D2F38D85D9A08" xlink:to="lab_dei_TradingSymbol_83C62B76B04DA6CAA25D2F38D85D9A08" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_1032C78E1971241164F32F38D85DAD9C_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_1032C78E1971241164F32F38D85DAD9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_1032C78E1971241164F32F38D85DAD9C_label_en-US" xlink:label="lab_dei_SecurityExchangeName_1032C78E1971241164F32F38D85DAD9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_1032C78E1971241164F32F38D85DAD9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_1032C78E1971241164F32F38D85DAD9C" xlink:to="lab_dei_SecurityExchangeName_1032C78E1971241164F32F38D85DAD9C" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_D378BBCA2E199F33BDC52F38D85D20C4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_D378BBCA2E199F33BDC52F38D85D20C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_D378BBCA2E199F33BDC52F38D85D20C4_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_D378BBCA2E199F33BDC52F38D85D20C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_D378BBCA2E199F33BDC52F38D85D20C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_D378BBCA2E199F33BDC52F38D85D20C4" xlink:to="lab_dei_EntityCurrentReportingStatus_D378BBCA2E199F33BDC52F38D85D20C4" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_C938546D109108044ED12F38D85D7052_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_C938546D109108044ED12F38D85D7052" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_C938546D109108044ED12F38D85D7052_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_C938546D109108044ED12F38D85D7052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_C938546D109108044ED12F38D85D7052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_C938546D109108044ED12F38D85D7052" xlink:to="lab_dei_EntityInteractiveDataCurrent_C938546D109108044ED12F38D85D7052" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_AF389B88ECFEB3A2981F2F38D85D3DF2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_AF389B88ECFEB3A2981F2F38D85D3DF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_AF389B88ECFEB3A2981F2F38D85D3DF2_label_en-US" xlink:label="lab_dei_EntityFilerCategory_AF389B88ECFEB3A2981F2F38D85D3DF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_AF389B88ECFEB3A2981F2F38D85D3DF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_AF389B88ECFEB3A2981F2F38D85D3DF2" xlink:to="lab_dei_EntityFilerCategory_AF389B88ECFEB3A2981F2F38D85D3DF2" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_585E5F79CAF89DC3F2532F38D85D3F99_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_585E5F79CAF89DC3F2532F38D85D3F99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_585E5F79CAF89DC3F2532F38D85D3F99_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_585E5F79CAF89DC3F2532F38D85D3F99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_585E5F79CAF89DC3F2532F38D85D3F99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_585E5F79CAF89DC3F2532F38D85D3F99" xlink:to="lab_dei_EntitySmallBusiness_585E5F79CAF89DC3F2532F38D85D3F99" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_660C2B64139C83EFABB22F38D85D3361_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_660C2B64139C83EFABB22F38D85D3361" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_660C2B64139C83EFABB22F38D85D3361_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_660C2B64139C83EFABB22F38D85D3361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_660C2B64139C83EFABB22F38D85D3361" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_660C2B64139C83EFABB22F38D85D3361" xlink:to="lab_dei_EntityEmergingGrowthCompany_660C2B64139C83EFABB22F38D85D3361" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_401DCD758ED33D329F4C2F38D85DA76A_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_401DCD758ED33D329F4C2F38D85DA76A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_401DCD758ED33D329F4C2F38D85DA76A_label_en-US" xlink:label="lab_dei_EntityShellCompany_401DCD758ED33D329F4C2F38D85DA76A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_401DCD758ED33D329F4C2F38D85DA76A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_401DCD758ED33D329F4C2F38D85DA76A" xlink:to="lab_dei_EntityShellCompany_401DCD758ED33D329F4C2F38D85DA76A" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_C3837A9DE61ECC64ACF52F38D85D5B09_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_C3837A9DE61ECC64ACF52F38D85D5B09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_C3837A9DE61ECC64ACF52F38D85D5B09_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_C3837A9DE61ECC64ACF52F38D85D5B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_C3837A9DE61ECC64ACF52F38D85D5B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_C3837A9DE61ECC64ACF52F38D85D5B09" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_C3837A9DE61ECC64ACF52F38D85D5B09" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_D8652EA74694F00579372F38D85D7F34_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_D8652EA74694F00579372F38D85D7F34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_D8652EA74694F00579372F38D85D7F34_label_en-US" xlink:label="lab_dei_EntityRegistrantName_D8652EA74694F00579372F38D85D7F34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_D8652EA74694F00579372F38D85D7F34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_D8652EA74694F00579372F38D85D7F34" xlink:to="lab_dei_EntityRegistrantName_D8652EA74694F00579372F38D85D7F34" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_D02F1EE1E6498CB574742F38D85DAABD_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_D02F1EE1E6498CB574742F38D85DAABD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_D02F1EE1E6498CB574742F38D85DAABD_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_D02F1EE1E6498CB574742F38D85DAABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_D02F1EE1E6498CB574742F38D85DAABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_D02F1EE1E6498CB574742F38D85DAABD" xlink:to="lab_dei_EntityCentralIndexKey_D02F1EE1E6498CB574742F38D85DAABD" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1506AA874485EA61D3AD2F38D85DC090_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_1506AA874485EA61D3AD2F38D85DC090" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1506AA874485EA61D3AD2F38D85DC090_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_1506AA874485EA61D3AD2F38D85DC090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_1506AA874485EA61D3AD2F38D85DC090" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_1506AA874485EA61D3AD2F38D85DC090" xlink:to="lab_dei_CurrentFiscalYearEndDate_1506AA874485EA61D3AD2F38D85DC090" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_90BE5B58B69ED4A72AFB2F38D85D1C39_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_90BE5B58B69ED4A72AFB2F38D85D1C39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_90BE5B58B69ED4A72AFB2F38D85D1C39_label_en-US" xlink:label="lab_dei_AmendmentFlag_90BE5B58B69ED4A72AFB2F38D85D1C39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_90BE5B58B69ED4A72AFB2F38D85D1C39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_90BE5B58B69ED4A72AFB2F38D85D1C39" xlink:to="lab_dei_AmendmentFlag_90BE5B58B69ED4A72AFB2F38D85D1C39" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_5750341152C71AD3010F2F38D85D5911_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_5750341152C71AD3010F2F38D85D5911" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5750341152C71AD3010F2F38D85D5911_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_5750341152C71AD3010F2F38D85D5911" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_5750341152C71AD3010F2F38D85D5911" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_5750341152C71AD3010F2F38D85D5911" xlink:to="lab_dei_DocumentFiscalYearFocus_5750341152C71AD3010F2F38D85D5911" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_40B06F423C0DE60E16AA2F38D85DAD0B_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_40B06F423C0DE60E16AA2F38D85DAD0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_40B06F423C0DE60E16AA2F38D85DAD0B_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_40B06F423C0DE60E16AA2F38D85DAD0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_40B06F423C0DE60E16AA2F38D85DAD0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_40B06F423C0DE60E16AA2F38D85DAD0B" xlink:to="lab_dei_DocumentFiscalPeriodFocus_40B06F423C0DE60E16AA2F38D85DAD0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_205DBDFD3057DB51C645493CBD0BF193_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_205DBDFD3057DB51C645493CBD0BF193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_205DBDFD3057DB51C645493CBD0BF193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_205DBDFD3057DB51C645493CBD0BF193" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_205DBDFD3057DB51C645493CBD0BF193" xlink:type="arc" />
    <link:label id="lab_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31_terseLabel_en-US" xlink:label="lab_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PaxVax</link:label>
    <link:label id="lab_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31_label_en-US" xlink:label="lab_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PaxVax [Member]</link:label>
    <link:label id="lab_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31_documentation_en-US" xlink:label="lab_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition on October 4, 2018.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PaxVaxMember" xlink:label="loc_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31" xlink:to="lab_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31" xlink:type="arc" />
    <link:label id="lab_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6_label_en-US" xlink:label="lab_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6" xlink:to="lab_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6" xlink:type="arc" />
    <link:label id="lab_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C_label_en-US" xlink:label="lab_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C" xlink:to="lab_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C" xlink:type="arc" />
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_B80235663B0D5CDCA203493CBD0D3E25_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember_B80235663B0D5CDCA203493CBD0D3E25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_B80235663B0D5CDCA203493CBD0D3E25_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember_B80235663B0D5CDCA203493CBD0D3E25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_B80235663B0D5CDCA203493CBD0D3E25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember_B80235663B0D5CDCA203493CBD0D3E25" xlink:to="lab_srt_ScenarioPreviouslyReportedMember_B80235663B0D5CDCA203493CBD0D3E25" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of tangible assets acquired and liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C5FE8142A70AB354650E493CBD0DBC17_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C5FE8142A70AB354650E493CBD0DBC17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C5FE8142A70AB354650E493CBD0DBC17_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C5FE8142A70AB354650E493CBD0DBC17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C5FE8142A70AB354650E493CBD0DBC17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C5FE8142A70AB354650E493CBD0DBC17" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C5FE8142A70AB354650E493CBD0DBC17" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_284E689CF5F83D17E8ED493CBD0E8E8C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_284E689CF5F83D17E8ED493CBD0E8E8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_284E689CF5F83D17E8ED493CBD0E8E8C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_284E689CF5F83D17E8ED493CBD0E8E8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_284E689CF5F83D17E8ED493CBD0E8E8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_284E689CF5F83D17E8ED493CBD0E8E8C" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_284E689CF5F83D17E8ED493CBD0E8E8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6EBE1955007E2B674E40493CBD0E02C2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6EBE1955007E2B674E40493CBD0E02C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6EBE1955007E2B674E40493CBD0E02C2_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6EBE1955007E2B674E40493CBD0E02C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6EBE1955007E2B674E40493CBD0E02C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6EBE1955007E2B674E40493CBD0E02C2" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6EBE1955007E2B674E40493CBD0E02C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1438892828F9D2390D5B493CBD0ED79F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1438892828F9D2390D5B493CBD0ED79F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1438892828F9D2390D5B493CBD0ED79F_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1438892828F9D2390D5B493CBD0ED79F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1438892828F9D2390D5B493CBD0ED79F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1438892828F9D2390D5B493CBD0ED79F" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1438892828F9D2390D5B493CBD0ED79F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_A611E3758EE0DCE7D0B4493CBD0E4D08_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_A611E3758EE0DCE7D0B4493CBD0E4D08" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_A611E3758EE0DCE7D0B4493CBD0E4D08_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_A611E3758EE0DCE7D0B4493CBD0E4D08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_A611E3758EE0DCE7D0B4493CBD0E4D08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_A611E3758EE0DCE7D0B4493CBD0E4D08" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_A611E3758EE0DCE7D0B4493CBD0E4D08" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_59616110BFF9734CCB0C493CBD0E75BA_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_59616110BFF9734CCB0C493CBD0E75BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_59616110BFF9734CCB0C493CBD0E75BA_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_59616110BFF9734CCB0C493CBD0E75BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_59616110BFF9734CCB0C493CBD0E75BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_59616110BFF9734CCB0C493CBD0E75BA" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_59616110BFF9734CCB0C493CBD0E75BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_95213AD4903B0BB3E5ED493CBD0EC663_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_95213AD4903B0BB3E5ED493CBD0EC663" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_95213AD4903B0BB3E5ED493CBD0EC663_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_95213AD4903B0BB3E5ED493CBD0EC663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_95213AD4903B0BB3E5ED493CBD0EC663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_95213AD4903B0BB3E5ED493CBD0EC663" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_95213AD4903B0BB3E5ED493CBD0EC663" xlink:type="arc" />
    <link:label id="lab_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F_negatedLabel_en-US" xlink:label="lab_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F_label_en-US" xlink:label="lab_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses and Other Liabilities</link:label>
    <link:label id="lab_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F_documentation_en-US" xlink:label="lab_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accrued expenses and other liabilities, assumed at the acquisition date.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" xlink:label="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F" xlink:to="lab_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92835BFC2C859A8BB4C493CBD0F385C_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92835BFC2C859A8BB4C493CBD0F385C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total fair value of tangible assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92835BFC2C859A8BB4C493CBD0F385C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92835BFC2C859A8BB4C493CBD0F385C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92835BFC2C859A8BB4C493CBD0F385C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92835BFC2C859A8BB4C493CBD0F385C" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92835BFC2C859A8BB4C493CBD0F385C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823EF9FAE8C7267C7156493CBD0F4893_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823EF9FAE8C7267C7156493CBD0F4893" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823EF9FAE8C7267C7156493CBD0F4893_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823EF9FAE8C7267C7156493CBD0F4893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823EF9FAE8C7267C7156493CBD0F4893" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823EF9FAE8C7267C7156493CBD0F4893" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823EF9FAE8C7267C7156493CBD0F4893" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A7C9A22C38080FF3B6EE493CBD0F05B0_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A7C9A22C38080FF3B6EE493CBD0F05B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A7C9A22C38080FF3B6EE493CBD0F05B0_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A7C9A22C38080FF3B6EE493CBD0F05B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A7C9A22C38080FF3B6EE493CBD0F05B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A7C9A22C38080FF3B6EE493CBD0F05B0" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A7C9A22C38080FF3B6EE493CBD0F05B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_4886872206C70BE213A7493CBD101695_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_4886872206C70BE213A7493CBD101695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4886872206C70BE213A7493CBD101695_label_en-US" xlink:label="lab_us-gaap_Goodwill_4886872206C70BE213A7493CBD101695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4886872206C70BE213A7493CBD101695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_4886872206C70BE213A7493CBD101695" xlink:to="lab_us-gaap_Goodwill_4886872206C70BE213A7493CBD101695" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B2EC7757ADC88305215F493CBD10ADEE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B2EC7757ADC88305215F493CBD10ADEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B2EC7757ADC88305215F493CBD10ADEE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B2EC7757ADC88305215F493CBD10ADEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B2EC7757ADC88305215F493CBD10ADEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B2EC7757ADC88305215F493CBD10ADEE" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_B2EC7757ADC88305215F493CBD10ADEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Period Adjustments</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:type="arc" />
    <link:label id="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7_negatedTerseLabel_en-US" xlink:label="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities, measurement period adjustment</link:label>
    <link:label id="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7_label_en-US" xlink:label="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expenses And Other Liabilities</link:label>
    <link:label id="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7_documentation_en-US" xlink:label="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expenses And Other Liabilities</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7" xlink:to="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_D0436772963D7FF737A149540EFE7120_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_D0436772963D7FF737A149540EFE7120" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total fair value of tangible assets acquired and liabilities assumed, measurement period adjustments</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_D0436772963D7FF737A149540EFE7120_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_D0436772963D7FF737A149540EFE7120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_D0436772963D7FF737A149540EFE7120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_D0436772963D7FF737A149540EFE7120" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_D0436772963D7FF737A149540EFE7120" xlink:type="arc" />
    <link:label id="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7_terseLabel_en-US" xlink:label="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development, measurement period adjustment</link:label>
    <link:label id="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7_label_en-US" xlink:label="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Finite-lived Intangible Assets</link:label>
    <link:label id="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7_documentation_en-US" xlink:label="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Finite-lived Intangible Assets</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7" xlink:to="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_9BB2080D607CB401E10849547B341491_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_9BB2080D607CB401E10849547B341491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, measurement period adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_9BB2080D607CB401E10849547B341491_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_9BB2080D607CB401E10849547B341491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_9BB2080D607CB401E10849547B341491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_9BB2080D607CB401E10849547B341491" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_9BB2080D607CB401E10849547B341491" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7B8F342BA8651501B8424958D3284217_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7B8F342BA8651501B8424958D3284217" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7B8F342BA8651501B8424958D3284217_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7B8F342BA8651501B8424958D3284217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7B8F342BA8651501B8424958D3284217" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7B8F342BA8651501B8424958D3284217" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7B8F342BA8651501B8424958D3284217" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0AC5A0FA47143F018EE4D849D4B4F5D6_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0AC5A0FA47143F018EE4D849D4B4F5D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0AC5A0FA47143F018EE4D849D4B4F5D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0AC5A0FA47143F018EE4D849D4B4F5D6" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0AC5A0FA47143F018EE4D849D4B4F5D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_54EC51DA33B71166565CD849D4B497C2_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_54EC51DA33B71166565CD849D4B497C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation and consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_54EC51DA33B71166565CD849D4B497C2_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_54EC51DA33B71166565CD849D4B497C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_54EC51DA33B71166565CD849D4B497C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_54EC51DA33B71166565CD849D4B497C2" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_54EC51DA33B71166565CD849D4B497C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BA73BBB82A54F98DEB2D849D4B5CF1C_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BA73BBB82A54F98DEB2D849D4B5CF1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted and New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BA73BBB82A54F98DEB2D849D4B5CF1C_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BA73BBB82A54F98DEB2D849D4B5CF1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BA73BBB82A54F98DEB2D849D4B5CF1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BA73BBB82A54F98DEB2D849D4B5CF1C" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BA73BBB82A54F98DEB2D849D4B5CF1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_6F93CECCA10D30D57E45D849D614A582_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_6F93CECCA10D30D57E45D849D614A582" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_6F93CECCA10D30D57E45D849D614A582_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_6F93CECCA10D30D57E45D849D614A582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6F93CECCA10D30D57E45D849D614A582" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_6F93CECCA10D30D57E45D849D614A582" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_6F93CECCA10D30D57E45D849D614A582" xlink:type="arc" />
    <link:label id="lab_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E_terseLabel_en-US" xlink:label="lab_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vivotif</link:label>
    <link:label id="lab_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E_label_en-US" xlink:label="lab_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vivotif [Member]</link:label>
    <link:label id="lab_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E_documentation_en-US" xlink:label="lab_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This is a live attenuated vaccine for oral administration to prevent typhoid fever.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_VivotifMember" xlink:label="loc_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E" xlink:to="lab_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E" xlink:type="arc" />
    <link:label id="lab_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA_terseLabel_en-US" xlink:label="lab_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaxchora</link:label>
    <link:label id="lab_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA_label_en-US" xlink:label="lab_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaxchora [Member]</link:label>
    <link:label id="lab_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA_documentation_en-US" xlink:label="lab_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This is a live attenuated cholera vaccine and the first vaccine approved by the FDA for the prevention of cholera infection</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_VaxchoraMember" xlink:label="loc_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA" xlink:to="lab_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA" xlink:type="arc" />
    <link:label id="lab_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36_terseLabel_en-US" xlink:label="lab_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36_label_en-US" xlink:label="lab_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Employees</link:label>
    <link:label id="lab_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36_documentation_en-US" xlink:label="lab_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of persons employed by the entity</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_NumberOfEmployees" xlink:label="loc_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36" xlink:to="lab_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_24C27871FCBBF30867DED849D616DFCD_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_24C27871FCBBF30867DED849D616DFCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired intangible asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_24C27871FCBBF30867DED849D616DFCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_24C27871FCBBF30867DED849D616DFCD" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_24C27871FCBBF30867DED849D616DFCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_75390C3C0551FAFF0D11D849D61667BD_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_75390C3C0551FAFF0D11D849D61667BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_75390C3C0551FAFF0D11D849D61667BD_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_75390C3C0551FAFF0D11D849D61667BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_75390C3C0551FAFF0D11D849D61667BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_75390C3C0551FAFF0D11D849D61667BD" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_75390C3C0551FAFF0D11D849D61667BD" xlink:type="arc" />
    <link:label id="lab_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261_terseLabel_en-US" xlink:label="lab_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value, discount rate</link:label>
    <link:label id="lab_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261_label_en-US" xlink:label="lab_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Present Value, Discount Rate</link:label>
    <link:label id="lab_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261_documentation_en-US" xlink:label="lab_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure present value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PresentValueDiscountRate" xlink:label="loc_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261" xlink:to="lab_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_F0A5B0C759EDA407B05C2073BB60F5C5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_F0A5B0C759EDA407B05C2073BB60F5C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_F0A5B0C759EDA407B05C2073BB60F5C5_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_F0A5B0C759EDA407B05C2073BB60F5C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_F0A5B0C759EDA407B05C2073BB60F5C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_F0A5B0C759EDA407B05C2073BB60F5C5" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_F0A5B0C759EDA407B05C2073BB60F5C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_0618F38323519089006CD849D469F017_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_0618F38323519089006CD849D469F017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0618F38323519089006CD849D469F017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0618F38323519089006CD849D469F017" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_0618F38323519089006CD849D469F017" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1479817990AC6D9E41E4D849D4691141_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_1479817990AC6D9E41E4D849D4691141" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1479817990AC6D9E41E4D849D4691141_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_1479817990AC6D9E41E4D849D4691141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1479817990AC6D9E41E4D849D4691141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_1479817990AC6D9E41E4D849D4691141" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_1479817990AC6D9E41E4D849D4691141" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_A6A88A69374845D134FAD849D53E6120_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_A6A88A69374845D134FAD849D53E6120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_A6A88A69374845D134FAD849D53E6120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A6A88A69374845D134FAD849D53E6120" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_A6A88A69374845D134FAD849D53E6120" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AE52ACA92AEF8851EB8FD849D53E5135_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AE52ACA92AEF8851EB8FD849D53E5135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AE52ACA92AEF8851EB8FD849D53E5135_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AE52ACA92AEF8851EB8FD849D53E5135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AE52ACA92AEF8851EB8FD849D53E5135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AE52ACA92AEF8851EB8FD849D53E5135" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AE52ACA92AEF8851EB8FD849D53E5135" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_CD6B49DEA54E3AA021ACD849D53F9348_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_CD6B49DEA54E3AA021ACD849D53F9348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_CD6B49DEA54E3AA021ACD849D53F9348_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_CD6B49DEA54E3AA021ACD849D53F9348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_CD6B49DEA54E3AA021ACD849D53F9348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_CD6B49DEA54E3AA021ACD849D53F9348" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_CD6B49DEA54E3AA021ACD849D53F9348" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_8DCF60E06CE036EAF419D849D53F26BF_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_8DCF60E06CE036EAF419D849D53F26BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_8DCF60E06CE036EAF419D849D53F26BF_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_8DCF60E06CE036EAF419D849D53F26BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8DCF60E06CE036EAF419D849D53F26BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_8DCF60E06CE036EAF419D849D53F26BF" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_8DCF60E06CE036EAF419D849D53F26BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5D21C751F8257E1B31F2D849D53F29B9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_5D21C751F8257E1B31F2D849D53F29B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5D21C751F8257E1B31F2D849D53F29B9_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_5D21C751F8257E1B31F2D849D53F29B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5D21C751F8257E1B31F2D849D53F29B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_5D21C751F8257E1B31F2D849D53F29B9" xlink:to="lab_us-gaap_PreferredStockSharesIssued_5D21C751F8257E1B31F2D849D53F29B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_C86E0B839177B0C28E4AD849D53FB06B_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_C86E0B839177B0C28E4AD849D53FB06B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_C86E0B839177B0C28E4AD849D53FB06B_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_C86E0B839177B0C28E4AD849D53FB06B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_C86E0B839177B0C28E4AD849D53FB06B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_C86E0B839177B0C28E4AD849D53FB06B" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_C86E0B839177B0C28E4AD849D53FB06B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_B11DBB15B8AF1E7BE969D849D540AF47_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_B11DBB15B8AF1E7BE969D849D540AF47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_B11DBB15B8AF1E7BE969D849D540AF47_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_B11DBB15B8AF1E7BE969D849D540AF47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_B11DBB15B8AF1E7BE969D849D540AF47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_B11DBB15B8AF1E7BE969D849D540AF47" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_B11DBB15B8AF1E7BE969D849D540AF47" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_D569D6EF4CB50019F2E0D849D5409221_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_D569D6EF4CB50019F2E0D849D5409221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_D569D6EF4CB50019F2E0D849D5409221_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_D569D6EF4CB50019F2E0D849D5409221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_D569D6EF4CB50019F2E0D849D5409221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_D569D6EF4CB50019F2E0D849D5409221" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_D569D6EF4CB50019F2E0D849D5409221" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_36E09CC885BB570B76D3D849D5406B9A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_36E09CC885BB570B76D3D849D5406B9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_36E09CC885BB570B76D3D849D5406B9A_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_36E09CC885BB570B76D3D849D5406B9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_36E09CC885BB570B76D3D849D5406B9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_36E09CC885BB570B76D3D849D5406B9A" xlink:to="lab_us-gaap_CommonStockSharesIssued_36E09CC885BB570B76D3D849D5406B9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_B90964ABB5D7633F191AD849D5400A3F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_B90964ABB5D7633F191AD849D5400A3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_B90964ABB5D7633F191AD849D5400A3F_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_B90964ABB5D7633F191AD849D5400A3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B90964ABB5D7633F191AD849D5400A3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_B90964ABB5D7633F191AD849D5400A3F" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_B90964ABB5D7633F191AD849D5400A3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_9F87BB02AC52F01581A8D849D5408AA2_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_9F87BB02AC52F01581A8D849D5408AA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_9F87BB02AC52F01581A8D849D5408AA2_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_9F87BB02AC52F01581A8D849D5408AA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_9F87BB02AC52F01581A8D849D5408AA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_9F87BB02AC52F01581A8D849D5408AA2" xlink:to="lab_us-gaap_TreasuryStockShares_9F87BB02AC52F01581A8D849D5408AA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_17E4E52CEC1682971BFBD849D60E0538_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_17E4E52CEC1682971BFBD849D60E0538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_17E4E52CEC1682971BFBD849D60E0538_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_17E4E52CEC1682971BFBD849D60E0538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_17E4E52CEC1682971BFBD849D60E0538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_17E4E52CEC1682971BFBD849D60E0538" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_17E4E52CEC1682971BFBD849D60E0538" xlink:type="arc" />
    <link:label id="lab_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153_terseLabel_en-US" xlink:label="lab_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adapt And PaxVax</link:label>
    <link:label id="lab_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153_label_en-US" xlink:label="lab_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adapt And PaxVax [Member]</link:label>
    <link:label id="lab_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153_documentation_en-US" xlink:label="lab_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adapt And PaxVax [Member]</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AdaptAndPaxVaxMember" xlink:label="loc_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153" xlink:to="lab_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153" xlink:type="arc" />
    <link:label id="lab_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D_terseLabel_en-US" xlink:label="lab_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of business acquisitions</link:label>
    <link:label id="lab_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D_label_en-US" xlink:label="lab_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Business Acquisitions</link:label>
    <link:label id="lab_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D_documentation_en-US" xlink:label="lab_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Business Acquisitions</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_NumberOfBusinessAcquisitions" xlink:label="loc_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D" xlink:to="lab_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D" xlink:type="arc" />
    <link:label id="lab_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623_terseLabel_en-US" xlink:label="lab_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of Business Acquisitions [Abstract]</link:label>
    <link:label id="lab_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623_label_en-US" xlink:label="lab_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of Business Acquisitions [Abstract]</link:label>
    <link:label id="lab_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623_documentation_en-US" xlink:label="lab_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3e9a79ca-9c5f-2a65-3fac-a5d12d315cc7</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ImpactOfBusinessAcquisitionsAbstract" xlink:label="loc_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:to="lab_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8D89EDD31C13B9DEB09F205677DC0E1C_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8D89EDD31C13B9DEB09F205677DC0E1C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8D89EDD31C13B9DEB09F205677DC0E1C_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8D89EDD31C13B9DEB09F205677DC0E1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8D89EDD31C13B9DEB09F205677DC0E1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8D89EDD31C13B9DEB09F205677DC0E1C" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8D89EDD31C13B9DEB09F205677DC0E1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4AE35CA614946F231B1E205677DCDABF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_4AE35CA614946F231B1E205677DCDABF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4AE35CA614946F231B1E205677DCDABF_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_4AE35CA614946F231B1E205677DCDABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_4AE35CA614946F231B1E205677DCDABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_4AE35CA614946F231B1E205677DCDABF" xlink:to="lab_us-gaap_OperatingIncomeLoss_4AE35CA614946F231B1E205677DCDABF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:to="lab_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:to="lab_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A1C20824B31138F6F8494DCE29EF312C_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A1C20824B31138F6F8494DCE29EF312C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A1C20824B31138F6F8494DCE29EF312C_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A1C20824B31138F6F8494DCE29EF312C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A1C20824B31138F6F8494DCE29EF312C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A1C20824B31138F6F8494DCE29EF312C" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A1C20824B31138F6F8494DCE29EF312C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_09BFD731A5FB9032F38B4DCE29F02F8C_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_09BFD731A5FB9032F38B4DCE29F02F8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_09BFD731A5FB9032F38B4DCE29F02F8C_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_09BFD731A5FB9032F38B4DCE29F02F8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_09BFD731A5FB9032F38B4DCE29F02F8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_09BFD731A5FB9032F38B4DCE29F02F8C" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_09BFD731A5FB9032F38B4DCE29F02F8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_D87110AD8329D20F1CEB4DCE29F0D195_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_D87110AD8329D20F1CEB4DCE29F0D195" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_D87110AD8329D20F1CEB4DCE29F0D195_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_D87110AD8329D20F1CEB4DCE29F0D195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_D87110AD8329D20F1CEB4DCE29F0D195" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_D87110AD8329D20F1CEB4DCE29F0D195" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_D87110AD8329D20F1CEB4DCE29F0D195" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_AE41BA2D8EAA7F788D574DCE29F06313_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_AE41BA2D8EAA7F788D574DCE29F06313" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_AE41BA2D8EAA7F788D574DCE29F06313_label_en-US" xlink:label="lab_us-gaap_InventoryNet_AE41BA2D8EAA7F788D574DCE29F06313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_AE41BA2D8EAA7F788D574DCE29F06313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_AE41BA2D8EAA7F788D574DCE29F06313" xlink:to="lab_us-gaap_InventoryNet_AE41BA2D8EAA7F788D574DCE29F06313" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B631D6227087DE4164764DCE29F04A7D_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B631D6227087DE4164764DCE29F04A7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B631D6227087DE4164764DCE29F04A7D_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B631D6227087DE4164764DCE29F04A7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B631D6227087DE4164764DCE29F04A7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B631D6227087DE4164764DCE29F04A7D" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B631D6227087DE4164764DCE29F04A7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_8087114B9FDD2659E2C94DCE29F0FDBE_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8087114B9FDD2659E2C94DCE29F0FDBE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_8087114B9FDD2659E2C94DCE29F0FDBE_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8087114B9FDD2659E2C94DCE29F0FDBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8087114B9FDD2659E2C94DCE29F0FDBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_8087114B9FDD2659E2C94DCE29F0FDBE" xlink:to="lab_us-gaap_AssetsCurrent_8087114B9FDD2659E2C94DCE29F0FDBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_DE3AFCD485435F72F2024DCE29F0B2E4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_DE3AFCD485435F72F2024DCE29F0B2E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_DE3AFCD485435F72F2024DCE29F0B2E4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_DE3AFCD485435F72F2024DCE29F0B2E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_DE3AFCD485435F72F2024DCE29F0B2E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_DE3AFCD485435F72F2024DCE29F0B2E4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_DE3AFCD485435F72F2024DCE29F0B2E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_505F6E9921880C443AE04DCE29F171AA_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_505F6E9921880C443AE04DCE29F171AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_505F6E9921880C443AE04DCE29F171AA_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_505F6E9921880C443AE04DCE29F171AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_505F6E9921880C443AE04DCE29F171AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_505F6E9921880C443AE04DCE29F171AA" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_505F6E9921880C443AE04DCE29F171AA" xlink:type="arc" />
    <link:label id="lab_ebs_InProcessResearchAndDevelopment_E4DCBAB09DDE6F03D0824DCE29F15A52_terseLabel_en-US" xlink:label="lab_ebs_InProcessResearchAndDevelopment_E4DCBAB09DDE6F03D0824DCE29F15A52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_ebs_InProcessResearchAndDevelopment_E4DCBAB09DDE6F03D0824DCE29F15A52_label_en-US" xlink:label="lab_ebs_InProcessResearchAndDevelopment_E4DCBAB09DDE6F03D0824DCE29F15A52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research And Development</link:label>
    <link:label id="lab_ebs_InProcessResearchAndDevelopment_E4DCBAB09DDE6F03D0824DCE29F15A52_documentation_en-US" xlink:label="lab_ebs_InProcessResearchAndDevelopment_E4DCBAB09DDE6F03D0824DCE29F15A52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount of purchased research and development assets acquired in a business combination that have an indefinite life until completion or abandonment of the associated research and development efforts.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_InProcessResearchAndDevelopment" xlink:label="loc_ebs_InProcessResearchAndDevelopment_E4DCBAB09DDE6F03D0824DCE29F15A52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_InProcessResearchAndDevelopment_E4DCBAB09DDE6F03D0824DCE29F15A52" xlink:to="lab_ebs_InProcessResearchAndDevelopment_E4DCBAB09DDE6F03D0824DCE29F15A52" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_452EE9F2499FEA02BA414DCE29F17455_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_452EE9F2499FEA02BA414DCE29F17455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_452EE9F2499FEA02BA414DCE29F17455_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_452EE9F2499FEA02BA414DCE29F17455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_452EE9F2499FEA02BA414DCE29F17455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_452EE9F2499FEA02BA414DCE29F17455" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_452EE9F2499FEA02BA414DCE29F17455" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_5B4F71C07BF40138FB5C4DCE29F1E3EE_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_5B4F71C07BF40138FB5C4DCE29F1E3EE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_5B4F71C07BF40138FB5C4DCE29F1E3EE_label_en-US" xlink:label="lab_us-gaap_Assets_5B4F71C07BF40138FB5C4DCE29F1E3EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_5B4F71C07BF40138FB5C4DCE29F1E3EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_5B4F71C07BF40138FB5C4DCE29F1E3EE" xlink:to="lab_us-gaap_Assets_5B4F71C07BF40138FB5C4DCE29F1E3EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_9FCA9C4CF92F030344614DCE29F2BBAC_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_9FCA9C4CF92F030344614DCE29F2BBAC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_9FCA9C4CF92F030344614DCE29F2BBAC_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_9FCA9C4CF92F030344614DCE29F2BBAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9FCA9C4CF92F030344614DCE29F2BBAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_9FCA9C4CF92F030344614DCE29F2BBAC" xlink:to="lab_us-gaap_AccountsPayableCurrent_9FCA9C4CF92F030344614DCE29F2BBAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_FBEAEEE4C25B1B4843844DCE29F2610C_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_FBEAEEE4C25B1B4843844DCE29F2610C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_FBEAEEE4C25B1B4843844DCE29F2610C_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_FBEAEEE4C25B1B4843844DCE29F2610C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_FBEAEEE4C25B1B4843844DCE29F2610C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_FBEAEEE4C25B1B4843844DCE29F2610C" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_FBEAEEE4C25B1B4843844DCE29F2610C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_943CC3198F7970E643814DCE29F2C9CF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_943CC3198F7970E643814DCE29F2C9CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration, current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_943CC3198F7970E643814DCE29F2C9CF_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_943CC3198F7970E643814DCE29F2C9CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_943CC3198F7970E643814DCE29F2C9CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_943CC3198F7970E643814DCE29F2C9CF" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_943CC3198F7970E643814DCE29F2C9CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_469D5E2A416146B85A7F4DCE29F22291_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_469D5E2A416146B85A7F4DCE29F22291" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_469D5E2A416146B85A7F4DCE29F22291_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_469D5E2A416146B85A7F4DCE29F22291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_469D5E2A416146B85A7F4DCE29F22291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_469D5E2A416146B85A7F4DCE29F22291" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_469D5E2A416146B85A7F4DCE29F22291" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_ABAD764CB3062650345A4DCE29F3352C_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_ABAD764CB3062650345A4DCE29F3352C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_ABAD764CB3062650345A4DCE29F3352C_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_ABAD764CB3062650345A4DCE29F3352C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_ABAD764CB3062650345A4DCE29F3352C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_ABAD764CB3062650345A4DCE29F3352C" xlink:to="lab_us-gaap_LongTermDebtCurrent_ABAD764CB3062650345A4DCE29F3352C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_18E6D492E0DA91D3C63A4DCE29F3D96F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_18E6D492E0DA91D3C63A4DCE29F3D96F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_18E6D492E0DA91D3C63A4DCE29F3D96F_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_18E6D492E0DA91D3C63A4DCE29F3D96F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_18E6D492E0DA91D3C63A4DCE29F3D96F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_18E6D492E0DA91D3C63A4DCE29F3D96F" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_18E6D492E0DA91D3C63A4DCE29F3D96F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_C359C4EEC9E8456F03C14DCE29F314E2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_C359C4EEC9E8456F03C14DCE29F314E2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_C359C4EEC9E8456F03C14DCE29F314E2_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_C359C4EEC9E8456F03C14DCE29F314E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_C359C4EEC9E8456F03C14DCE29F314E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_C359C4EEC9E8456F03C14DCE29F314E2" xlink:to="lab_us-gaap_LiabilitiesCurrent_C359C4EEC9E8456F03C14DCE29F314E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7819925543AB434208B44DCE29F381AA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7819925543AB434208B44DCE29F381AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7819925543AB434208B44DCE29F381AA_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7819925543AB434208B44DCE29F381AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7819925543AB434208B44DCE29F381AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7819925543AB434208B44DCE29F381AA" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7819925543AB434208B44DCE29F381AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_43F3EE791979D043745F4DCE29F3CA38_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_43F3EE791979D043745F4DCE29F3CA38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_43F3EE791979D043745F4DCE29F3CA38_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_43F3EE791979D043745F4DCE29F3CA38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_43F3EE791979D043745F4DCE29F3CA38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_43F3EE791979D043745F4DCE29F3CA38" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_43F3EE791979D043745F4DCE29F3CA38" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_75274260D07B782353D94DCE29F3BA1B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_75274260D07B782353D94DCE29F3BA1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_75274260D07B782353D94DCE29F3BA1B_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_75274260D07B782353D94DCE29F3BA1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_75274260D07B782353D94DCE29F3BA1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_75274260D07B782353D94DCE29F3BA1B" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_75274260D07B782353D94DCE29F3BA1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_365EF916D8B8B0DB27654DCE29F427A8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_365EF916D8B8B0DB27654DCE29F427A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_365EF916D8B8B0DB27654DCE29F427A8_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_365EF916D8B8B0DB27654DCE29F427A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_365EF916D8B8B0DB27654DCE29F427A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_365EF916D8B8B0DB27654DCE29F427A8" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_365EF916D8B8B0DB27654DCE29F427A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6CD672BC2EA2CBD042EF4DCE29F4A632_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_6CD672BC2EA2CBD042EF4DCE29F4A632" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6CD672BC2EA2CBD042EF4DCE29F4A632_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_6CD672BC2EA2CBD042EF4DCE29F4A632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6CD672BC2EA2CBD042EF4DCE29F4A632" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_6CD672BC2EA2CBD042EF4DCE29F4A632" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_6CD672BC2EA2CBD042EF4DCE29F4A632" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_66D3ACE401C50B4CF70A4DCE29F44DB0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_66D3ACE401C50B4CF70A4DCE29F44DB0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_66D3ACE401C50B4CF70A4DCE29F44DB0_label_en-US" xlink:label="lab_us-gaap_Liabilities_66D3ACE401C50B4CF70A4DCE29F44DB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_66D3ACE401C50B4CF70A4DCE29F44DB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_66D3ACE401C50B4CF70A4DCE29F44DB0" xlink:to="lab_us-gaap_Liabilities_66D3ACE401C50B4CF70A4DCE29F44DB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_BD5CA3ED45C6A904DFE04DCE29F4615F_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_BD5CA3ED45C6A904DFE04DCE29F4615F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Notes 8 &amp; 16)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_BD5CA3ED45C6A904DFE04DCE29F4615F_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_BD5CA3ED45C6A904DFE04DCE29F4615F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_BD5CA3ED45C6A904DFE04DCE29F4615F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_BD5CA3ED45C6A904DFE04DCE29F4615F" xlink:to="lab_us-gaap_CommitmentsAndContingencies_BD5CA3ED45C6A904DFE04DCE29F4615F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_EA51510F3964AF1BE0114DCE29F4B3B0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_EA51510F3964AF1BE0114DCE29F4B3B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding at both 2019 and 2018</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_EA51510F3964AF1BE0114DCE29F4B3B0_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_EA51510F3964AF1BE0114DCE29F4B3B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_EA51510F3964AF1BE0114DCE29F4B3B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_EA51510F3964AF1BE0114DCE29F4B3B0" xlink:to="lab_us-gaap_PreferredStockValue_EA51510F3964AF1BE0114DCE29F4B3B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_DCDF1A650828B7597B224DCE29F56C75_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_DCDF1A650828B7597B224DCE29F56C75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 200.0 shares authorized, 52.7 shares issued and 51.6 shares outstanding at 2019; 52.4 shares issued and 51.2 shares outstanding at 2018</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_DCDF1A650828B7597B224DCE29F56C75_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_DCDF1A650828B7597B224DCE29F56C75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_DCDF1A650828B7597B224DCE29F56C75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_DCDF1A650828B7597B224DCE29F56C75" xlink:to="lab_us-gaap_CommonStockValue_DCDF1A650828B7597B224DCE29F56C75" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_CB9C3D6E34A5EA1CFE5D4DCE29F5EBDC_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_CB9C3D6E34A5EA1CFE5D4DCE29F5EBDC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, 1.2 common shares at both 2019 and 2018</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_CB9C3D6E34A5EA1CFE5D4DCE29F5EBDC_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_CB9C3D6E34A5EA1CFE5D4DCE29F5EBDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_CB9C3D6E34A5EA1CFE5D4DCE29F5EBDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_CB9C3D6E34A5EA1CFE5D4DCE29F5EBDC" xlink:to="lab_us-gaap_TreasuryStockValue_CB9C3D6E34A5EA1CFE5D4DCE29F5EBDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_599169E2FB6C219EC85C4DCE29F5A87F_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_599169E2FB6C219EC85C4DCE29F5A87F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_599169E2FB6C219EC85C4DCE29F5A87F_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_599169E2FB6C219EC85C4DCE29F5A87F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_599169E2FB6C219EC85C4DCE29F5A87F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_599169E2FB6C219EC85C4DCE29F5A87F" xlink:to="lab_us-gaap_AdditionalPaidInCapital_599169E2FB6C219EC85C4DCE29F5A87F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE09FEBBCCD18E8CEE64DCE29F5D67D_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE09FEBBCCD18E8CEE64DCE29F5D67D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE09FEBBCCD18E8CEE64DCE29F5D67D_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE09FEBBCCD18E8CEE64DCE29F5D67D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE09FEBBCCD18E8CEE64DCE29F5D67D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE09FEBBCCD18E8CEE64DCE29F5D67D" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE09FEBBCCD18E8CEE64DCE29F5D67D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C8CC09E936E3E4A72EC54DCE29F5F209_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C8CC09E936E3E4A72EC54DCE29F5F209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C8CC09E936E3E4A72EC54DCE29F5F209_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C8CC09E936E3E4A72EC54DCE29F5F209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C8CC09E936E3E4A72EC54DCE29F5F209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C8CC09E936E3E4A72EC54DCE29F5F209" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C8CC09E936E3E4A72EC54DCE29F5F209" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_8D4B129F43F4B92522694DCE29F6A6C0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_8D4B129F43F4B92522694DCE29F6A6C0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8D4B129F43F4B92522694DCE29F6A6C0_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_8D4B129F43F4B92522694DCE29F6A6C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8D4B129F43F4B92522694DCE29F6A6C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_8D4B129F43F4B92522694DCE29F6A6C0" xlink:to="lab_us-gaap_StockholdersEquity_8D4B129F43F4B92522694DCE29F6A6C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_B1D5AAF387186B1FAFF34DCE29F63C1D_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_B1D5AAF387186B1FAFF34DCE29F63C1D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_B1D5AAF387186B1FAFF34DCE29F63C1D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_B1D5AAF387186B1FAFF34DCE29F63C1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_B1D5AAF387186B1FAFF34DCE29F63C1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_B1D5AAF387186B1FAFF34DCE29F63C1D" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_B1D5AAF387186B1FAFF34DCE29F63C1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_8C0BC96F35B76849F9FC2F38D6482F2E_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_8C0BC96F35B76849F9FC2F38D6482F2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8C0BC96F35B76849F9FC2F38D6482F2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8C0BC96F35B76849F9FC2F38D6482F2E" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_8C0BC96F35B76849F9FC2F38D6482F2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0_label_en-US" xlink:label="lab_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0" xlink:to="lab_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B_label_en-US" xlink:label="lab_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:to="lab_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_A971A5FF244CE28285E12F38D6481F11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_A971A5FF244CE28285E12F38D6481F11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_A971A5FF244CE28285E12F38D6481F11_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_A971A5FF244CE28285E12F38D6481F11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_A971A5FF244CE28285E12F38D6481F11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_A971A5FF244CE28285E12F38D6481F11" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_A971A5FF244CE28285E12F38D6481F11" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5D4FF62F6F1AC96481162F38D648E1C3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5D4FF62F6F1AC96481162F38D648E1C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5D4FF62F6F1AC96481162F38D648E1C3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5D4FF62F6F1AC96481162F38D648E1C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5D4FF62F6F1AC96481162F38D648E1C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5D4FF62F6F1AC96481162F38D648E1C3" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5D4FF62F6F1AC96481162F38D648E1C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3E8AD76BE38FB2A234632F38D648F72A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3E8AD76BE38FB2A234632F38D648F72A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3E8AD76BE38FB2A234632F38D648F72A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3E8AD76BE38FB2A234632F38D648F72A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3E8AD76BE38FB2A234632F38D648F72A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3E8AD76BE38FB2A234632F38D648F72A" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3E8AD76BE38FB2A234632F38D648F72A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346" xlink:to="lab_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8898D45131822641B82F2F38D6483CA6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_8898D45131822641B82F2F38D6483CA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8898D45131822641B82F2F38D6483CA6_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_8898D45131822641B82F2F38D6483CA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8898D45131822641B82F2F38D6483CA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_8898D45131822641B82F2F38D6483CA6" xlink:to="lab_us-gaap_EmployeeStockOptionMember_8898D45131822641B82F2F38D6483CA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0465741328C89918370A2F38D648C7AE_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_0465741328C89918370A2F38D648C7AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0465741328C89918370A2F38D648C7AE_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_0465741328C89918370A2F38D648C7AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0465741328C89918370A2F38D648C7AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_0465741328C89918370A2F38D648C7AE" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_0465741328C89918370A2F38D648C7AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued or granted during period [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued or Granted During Period, Share-based Compensation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_877984351CC0CBC266062F38D648B022_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_877984351CC0CBC266062F38D648B022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_877984351CC0CBC266062F38D648B022_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_877984351CC0CBC266062F38D648B022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_877984351CC0CBC266062F38D648B022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_877984351CC0CBC266062F38D648B022" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_877984351CC0CBC266062F38D648B022" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8B1E8BEE3322120D62482F38D648F6AE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8B1E8BEE3322120D62482F38D648F6AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8B1E8BEE3322120D62482F38D648F6AE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8B1E8BEE3322120D62482F38D648F6AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8B1E8BEE3322120D62482F38D648F6AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8B1E8BEE3322120D62482F38D648F6AE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8B1E8BEE3322120D62482F38D648F6AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1619BD869C58D29B01242F38D648C17C_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1619BD869C58D29B01242F38D648C17C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1619BD869C58D29B01242F38D648C17C_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1619BD869C58D29B01242F38D648C17C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1619BD869C58D29B01242F38D648C17C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1619BD869C58D29B01242F38D648C17C" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1619BD869C58D29B01242F38D648C17C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_AFAC7FEC13D28E501EA72F38D648AEA5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_AFAC7FEC13D28E501EA72F38D648AEA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_AFAC7FEC13D28E501EA72F38D648AEA5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_AFAC7FEC13D28E501EA72F38D648AEA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_AFAC7FEC13D28E501EA72F38D648AEA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_AFAC7FEC13D28E501EA72F38D648AEA5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_AFAC7FEC13D28E501EA72F38D648AEA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F7DCACBFB935145F564FD849D5291C98_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F7DCACBFB935145F564FD849D5291C98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F7DCACBFB935145F564FD849D5291C98_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F7DCACBFB935145F564FD849D5291C98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_F7DCACBFB935145F564FD849D5291C98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_F7DCACBFB935145F564FD849D5291C98" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F7DCACBFB935145F564FD849D5291C98" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_25996E40FE337D498084D849D337DE35_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_25996E40FE337D498084D849D337DE35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_25996E40FE337D498084D849D337DE35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_25996E40FE337D498084D849D337DE35" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_25996E40FE337D498084D849D337DE35" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_A8CF40B682E5ED86E3F0D849D3378C67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_A8CF40B682E5ED86E3F0D849D3378C67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_A8CF40B682E5ED86E3F0D849D3378C67_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_A8CF40B682E5ED86E3F0D849D3378C67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_A8CF40B682E5ED86E3F0D849D3378C67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_A8CF40B682E5ED86E3F0D849D3378C67" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_A8CF40B682E5ED86E3F0D849D3378C67" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10AE1ECCE85406C14D69499D6CF207A4_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10AE1ECCE85406C14D69499D6CF207A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10AE1ECCE85406C14D69499D6CF207A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10AE1ECCE85406C14D69499D6CF207A4" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10AE1ECCE85406C14D69499D6CF207A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_CE779E6103690345C100499D6CF38E82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_CE779E6103690345C100499D6CF38E82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_CE779E6103690345C100499D6CF38E82_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_CE779E6103690345C100499D6CF38E82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_CE779E6103690345C100499D6CF38E82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_CE779E6103690345C100499D6CF38E82" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_CE779E6103690345C100499D6CF38E82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8E93701C8B2DAE38FD4F499D6CF42557_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8E93701C8B2DAE38FD4F499D6CF42557" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8E93701C8B2DAE38FD4F499D6CF42557_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8E93701C8B2DAE38FD4F499D6CF42557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8E93701C8B2DAE38FD4F499D6CF42557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8E93701C8B2DAE38FD4F499D6CF42557" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8E93701C8B2DAE38FD4F499D6CF42557" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1" xlink:to="lab_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_710BB0C30C1D77AA0DB1D849D4359CE0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_710BB0C30C1D77AA0DB1D849D4359CE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_710BB0C30C1D77AA0DB1D849D4359CE0_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_710BB0C30C1D77AA0DB1D849D4359CE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_710BB0C30C1D77AA0DB1D849D4359CE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_710BB0C30C1D77AA0DB1D849D4359CE0" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_710BB0C30C1D77AA0DB1D849D4359CE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_EAFAC73C1E95447BFEEDD849D4350714_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_EAFAC73C1E95447BFEEDD849D4350714" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_EAFAC73C1E95447BFEEDD849D4350714_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_EAFAC73C1E95447BFEEDD849D4350714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_EAFAC73C1E95447BFEEDD849D4350714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_EAFAC73C1E95447BFEEDD849D4350714" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_EAFAC73C1E95447BFEEDD849D4350714" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_15401EA82B2E68B540F2D849D435E448_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_15401EA82B2E68B540F2D849D435E448" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_15401EA82B2E68B540F2D849D435E448_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_15401EA82B2E68B540F2D849D435E448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_15401EA82B2E68B540F2D849D435E448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_15401EA82B2E68B540F2D849D435E448" xlink:to="lab_us-gaap_OperatingLeaseLiability_15401EA82B2E68B540F2D849D435E448" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_2DE39F95209C3FCCFF7C2085BA7151A2_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_2DE39F95209C3FCCFF7C2085BA7151A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_2DE39F95209C3FCCFF7C2085BA7151A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_2DE39F95209C3FCCFF7C2085BA7151A2" xlink:to="lab_us-gaap_LeasesAbstract_2DE39F95209C3FCCFF7C2085BA7151A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_F31AEE91EFC02F364EE6209118438ECC_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_F31AEE91EFC02F364EE6209118438ECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_F31AEE91EFC02F364EE6209118438ECC_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_F31AEE91EFC02F364EE6209118438ECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_F31AEE91EFC02F364EE6209118438ECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_F31AEE91EFC02F364EE6209118438ECC" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_F31AEE91EFC02F364EE6209118438ECC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_421E7DA2457ED92265AA2091A0A13B7E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock_421E7DA2457ED92265AA2091A0A13B7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_421E7DA2457ED92265AA2091A0A13B7E_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock_421E7DA2457ED92265AA2091A0A13B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_421E7DA2457ED92265AA2091A0A13B7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock_421E7DA2457ED92265AA2091A0A13B7E" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock_421E7DA2457ED92265AA2091A0A13B7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07644AA8BB5AA8848A30499D6D6C5280_periodStartLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07644AA8BB5AA8848A30499D6D6C5280" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets (excluding goodwill)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07644AA8BB5AA8848A30499D6D6C5280_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07644AA8BB5AA8848A30499D6D6C5280" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07644AA8BB5AA8848A30499D6D6C5280" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07644AA8BB5AA8848A30499D6D6C5280" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07644AA8BB5AA8848A30499D6D6C5280" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments_EF82DAEF47BB58D566B1499D6D6D3CB5_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments_EF82DAEF47BB58D566B1499D6D6D3CB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets, purchase accounting adjustments</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments_EF82DAEF47BB58D566B1499D6D6D3CB5_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments_EF82DAEF47BB58D566B1499D6D6D3CB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments_EF82DAEF47BB58D566B1499D6D6D3CB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments_EF82DAEF47BB58D566B1499D6D6D3CB5" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments_EF82DAEF47BB58D566B1499D6D6D3CB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2DAEEF323C1716FEAEDF499D6D6DE8B3_periodEndLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2DAEEF323C1716FEAEDF499D6D6DE8B3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets (excluding goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2DAEEF323C1716FEAEDF499D6D6DE8B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2DAEEF323C1716FEAEDF499D6D6DE8B3" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2DAEEF323C1716FEAEDF499D6D6DE8B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C_label_en-US" xlink:label="lab_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C" xlink:to="lab_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224_terseLabel_en-US" xlink:label="lab_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224_label_en-US" xlink:label="lab_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:to="lab_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_FCBE04044132AAA99ADD499D6D6E4BD6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_FCBE04044132AAA99ADD499D6D6E4BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_FCBE04044132AAA99ADD499D6D6E4BD6_label_en-US" xlink:label="lab_srt_MinimumMember_FCBE04044132AAA99ADD499D6D6E4BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_FCBE04044132AAA99ADD499D6D6E4BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_FCBE04044132AAA99ADD499D6D6E4BD6" xlink:to="lab_srt_MinimumMember_FCBE04044132AAA99ADD499D6D6E4BD6" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_FA31D112DDBAE1546FAE499D6D6ED29F_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_FA31D112DDBAE1546FAE499D6D6ED29F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_FA31D112DDBAE1546FAE499D6D6ED29F_label_en-US" xlink:label="lab_srt_MaximumMember_FA31D112DDBAE1546FAE499D6D6ED29F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_FA31D112DDBAE1546FAE499D6D6ED29F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_FA31D112DDBAE1546FAE499D6D6ED29F" xlink:to="lab_srt_MaximumMember_FA31D112DDBAE1546FAE499D6D6ED29F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1EE12843DD06393AB284499D6D6EFB56_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1EE12843DD06393AB284499D6D6EFB56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization period of intangible asset</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1EE12843DD06393AB284499D6D6EFB56_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1EE12843DD06393AB284499D6D6EFB56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1EE12843DD06393AB284499D6D6EFB56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1EE12843DD06393AB284499D6D6EFB56" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1EE12843DD06393AB284499D6D6EFB56" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5549CBA2D1856F4F13F1499D6D6FA30E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5549CBA2D1856F4F13F1499D6D6FA30E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5549CBA2D1856F4F13F1499D6D6FA30E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5549CBA2D1856F4F13F1499D6D6FA30E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5549CBA2D1856F4F13F1499D6D6FA30E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5549CBA2D1856F4F13F1499D6D6FA30E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5549CBA2D1856F4F13F1499D6D6FA30E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_EED16116EF1CD41C16D1499D6D6F8205_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_EED16116EF1CD41C16D1499D6D6F8205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_EED16116EF1CD41C16D1499D6D6F8205_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_EED16116EF1CD41C16D1499D6D6F8205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_EED16116EF1CD41C16D1499D6D6F8205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_EED16116EF1CD41C16D1499D6D6F8205" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_EED16116EF1CD41C16D1499D6D6F8205" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D5EDAC8C7691E523284B499D6D6F20A7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D5EDAC8C7691E523284B499D6D6F20A7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D5EDAC8C7691E523284B499D6D6F20A7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D5EDAC8C7691E523284B499D6D6F20A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D5EDAC8C7691E523284B499D6D6F20A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D5EDAC8C7691E523284B499D6D6F20A7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D5EDAC8C7691E523284B499D6D6F20A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_EDFC1BF4C5A790046332499D6D6F9834_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_EDFC1BF4C5A790046332499D6D6F9834" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_EDFC1BF4C5A790046332499D6D6F9834_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_EDFC1BF4C5A790046332499D6D6F9834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_EDFC1BF4C5A790046332499D6D6F9834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_EDFC1BF4C5A790046332499D6D6F9834" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_EDFC1BF4C5A790046332499D6D6F9834" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF" xlink:to="lab_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillGross_A1C8DC6CA1BD1EF6186E499D6D705335_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross_A1C8DC6CA1BD1EF6186E499D6D705335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, cost</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_A1C8DC6CA1BD1EF6186E499D6D705335_label_en-US" xlink:label="lab_us-gaap_GoodwillGross_A1C8DC6CA1BD1EF6186E499D6D705335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaap_GoodwillGross_A1C8DC6CA1BD1EF6186E499D6D705335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross_A1C8DC6CA1BD1EF6186E499D6D705335" xlink:to="lab_us-gaap_GoodwillGross_A1C8DC6CA1BD1EF6186E499D6D705335" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_39DF55CEBBE079FCBF94499D6D70C5E3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_39DF55CEBBE079FCBF94499D6D70C5E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, acquired during period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_39DF55CEBBE079FCBF94499D6D70C5E3_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_39DF55CEBBE079FCBF94499D6D70C5E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_39DF55CEBBE079FCBF94499D6D70C5E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_39DF55CEBBE079FCBF94499D6D70C5E3" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_39DF55CEBBE079FCBF94499D6D70C5E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_0AF22965EC1D5764656B499D6D70C4E2_totalLabel_en-US" xlink:label="lab_us-gaap_Goodwill_0AF22965EC1D5764656B499D6D70C4E2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0AF22965EC1D5764656B499D6D70C4E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_0AF22965EC1D5764656B499D6D70C4E2" xlink:to="lab_us-gaap_Goodwill_0AF22965EC1D5764656B499D6D70C4E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_4B68C3B680DEE02D85E5D849D3BCC18E_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_4B68C3B680DEE02D85E5D849D3BCC18E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4B68C3B680DEE02D85E5D849D3BCC18E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4B68C3B680DEE02D85E5D849D3BCC18E" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_4B68C3B680DEE02D85E5D849D3BCC18E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BilledContractReceivables_004EB539A86571F829B3D849D3BC39E0_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables_004EB539A86571F829B3D849D3BC39E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Billed, net</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_004EB539A86571F829B3D849D3BC39E0_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables_004EB539A86571F829B3D849D3BC39E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BilledContractReceivables" xlink:label="loc_us-gaap_BilledContractReceivables_004EB539A86571F829B3D849D3BC39E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables_004EB539A86571F829B3D849D3BC39E0" xlink:to="lab_us-gaap_BilledContractReceivables_004EB539A86571F829B3D849D3BC39E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_B05BD53022724FA3AF33D849D3BD0797_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable_B05BD53022724FA3AF33D849D3BD0797" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_B05BD53022724FA3AF33D849D3BD0797_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable_B05BD53022724FA3AF33D849D3BD0797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="loc_us-gaap_UnbilledContractsReceivable_B05BD53022724FA3AF33D849D3BD0797" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable_B05BD53022724FA3AF33D849D3BD0797" xlink:to="lab_us-gaap_UnbilledContractsReceivable_B05BD53022724FA3AF33D849D3BD0797" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_EE4999D417407D8AFDD0D849D3BD10CD_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_EE4999D417407D8AFDD0D849D3BD10CD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_EE4999D417407D8AFDD0D849D3BD10CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_EE4999D417407D8AFDD0D849D3BD10CD" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_EE4999D417407D8AFDD0D849D3BD10CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_253EA23C6B21FC13A181D849D503905E_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_253EA23C6B21FC13A181D849D503905E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_253EA23C6B21FC13A181D849D503905E_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_253EA23C6B21FC13A181D849D503905E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_253EA23C6B21FC13A181D849D503905E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_253EA23C6B21FC13A181D849D503905E" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_253EA23C6B21FC13A181D849D503905E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_02DC7487D444FF4E0270D849D5034DD1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_02DC7487D444FF4E0270D849D5034DD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rollforward of Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_02DC7487D444FF4E0270D849D5034DD1_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_02DC7487D444FF4E0270D849D5034DD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_02DC7487D444FF4E0270D849D5034DD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_02DC7487D444FF4E0270D849D5034DD1" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_02DC7487D444FF4E0270D849D5034DD1" xlink:type="arc" />
    <link:label id="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_DE56EA153F9B900B5E92D849D503CEEC_terseLabel_en-US" xlink:label="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_DE56EA153F9B900B5E92D849D503CEEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Receivable, Net</link:label>
    <link:label id="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_DE56EA153F9B900B5E92D849D503CEEC_label_en-US" xlink:label="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_DE56EA153F9B900B5E92D849D503CEEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:label id="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_DE56EA153F9B900B5E92D849D503CEEC_documentation_en-US" xlink:label="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_DE56EA153F9B900B5E92D849D503CEEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ScheduleofAccountsReceivableNetTableTextBlock" xlink:label="loc_ebs_ScheduleofAccountsReceivableNetTableTextBlock_DE56EA153F9B900B5E92D849D503CEEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ScheduleofAccountsReceivableNetTableTextBlock_DE56EA153F9B900B5E92D849D503CEEC" xlink:to="lab_ebs_ScheduleofAccountsReceivableNetTableTextBlock_DE56EA153F9B900B5E92D849D503CEEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2AC86940C25B4101919DD849D4BDD9D2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2AC86940C25B4101919DD849D4BDD9D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2AC86940C25B4101919DD849D4BDD9D2_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2AC86940C25B4101919DD849D4BDD9D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2AC86940C25B4101919DD849D4BDD9D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2AC86940C25B4101919DD849D4BDD9D2" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2AC86940C25B4101919DD849D4BDD9D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_A787CEFCE1AB059E48EED849D4BD75C8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_A787CEFCE1AB059E48EED849D4BD75C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_A787CEFCE1AB059E48EED849D4BD75C8_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_A787CEFCE1AB059E48EED849D4BD75C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_A787CEFCE1AB059E48EED849D4BD75C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_A787CEFCE1AB059E48EED849D4BD75C8" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_A787CEFCE1AB059E48EED849D4BD75C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_FE9C761E81044D5AA11DD849D4BD3390_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_FE9C761E81044D5AA11DD849D4BD3390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_FE9C761E81044D5AA11DD849D4BD3390_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_FE9C761E81044D5AA11DD849D4BD3390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_FE9C761E81044D5AA11DD849D4BD3390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_FE9C761E81044D5AA11DD849D4BD3390" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_FE9C761E81044D5AA11DD849D4BD3390" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_A3EA70FE09E34A943AA2D849D4BDE0F6_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_A3EA70FE09E34A943AA2D849D4BDE0F6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_A3EA70FE09E34A943AA2D849D4BDE0F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_A3EA70FE09E34A943AA2D849D4BDE0F6" xlink:to="lab_us-gaap_InventoryNet_A3EA70FE09E34A943AA2D849D4BDE0F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_E23C4D1F6CE00EB92499499D6C3509E1_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_E23C4D1F6CE00EB92499499D6C3509E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_E23C4D1F6CE00EB92499499D6C3509E1_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_E23C4D1F6CE00EB92499499D6C3509E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_E23C4D1F6CE00EB92499499D6C3509E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_E23C4D1F6CE00EB92499499D6C3509E1" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_E23C4D1F6CE00EB92499499D6C3509E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_E8FC56F5DA2057DD4022D849D381BF01_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_E8FC56F5DA2057DD4022D849D381BF01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_E8FC56F5DA2057DD4022D849D381BF01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_E8FC56F5DA2057DD4022D849D381BF01" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_E8FC56F5DA2057DD4022D849D381BF01" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_8E14F15131BCBBB5D567D849D382E733_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_8E14F15131BCBBB5D567D849D382E733" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_8E14F15131BCBBB5D567D849D382E733_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_8E14F15131BCBBB5D567D849D382E733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_8E14F15131BCBBB5D567D849D382E733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_8E14F15131BCBBB5D567D849D382E733" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_8E14F15131BCBBB5D567D849D382E733" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0DE5F0B930B83F05125E493CBCD6F32E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0DE5F0B930B83F05125E493CBCD6F32E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0DE5F0B930B83F05125E493CBCD6F32E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_0DE5F0B930B83F05125E493CBCD6F32E" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0DE5F0B930B83F05125E493CBCD6F32E" xlink:type="arc" />
    <link:label id="lab_ebs_OperatingLeaseOtherLiabilityCurrent_B9401503922F3557B554493CBCD6336D_terseLabel_en-US" xlink:label="lab_ebs_OperatingLeaseOtherLiabilityCurrent_B9401503922F3557B554493CBCD6336D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_ebs_OperatingLeaseOtherLiabilityCurrent_B9401503922F3557B554493CBCD6336D_label_en-US" xlink:label="lab_ebs_OperatingLeaseOtherLiabilityCurrent_B9401503922F3557B554493CBCD6336D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Other Liability, Current</link:label>
    <link:label id="lab_ebs_OperatingLeaseOtherLiabilityCurrent_B9401503922F3557B554493CBCD6336D_documentation_en-US" xlink:label="lab_ebs_OperatingLeaseOtherLiabilityCurrent_B9401503922F3557B554493CBCD6336D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Other Liability, Current</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_OperatingLeaseOtherLiabilityCurrent" xlink:label="loc_ebs_OperatingLeaseOtherLiabilityCurrent_B9401503922F3557B554493CBCD6336D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OperatingLeaseOtherLiabilityCurrent_B9401503922F3557B554493CBCD6336D" xlink:to="lab_ebs_OperatingLeaseOtherLiabilityCurrent_B9401503922F3557B554493CBCD6336D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_D07B130EE23FD274459D493CBCD71DE7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_D07B130EE23FD274459D493CBCD71DE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_D07B130EE23FD274459D493CBCD71DE7_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_D07B130EE23FD274459D493CBCD71DE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_D07B130EE23FD274459D493CBCD71DE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_D07B130EE23FD274459D493CBCD71DE7" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_D07B130EE23FD274459D493CBCD71DE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_B8946A352983B9A6A268493CBCD71906_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_B8946A352983B9A6A268493CBCD71906" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_B8946A352983B9A6A268493CBCD71906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_B8946A352983B9A6A268493CBCD71906" xlink:to="lab_us-gaap_OperatingLeaseLiability_B8946A352983B9A6A268493CBCD71906" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostAbstract_4B517772BEB87476FDBA493CBCD797C2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract_4B517772BEB87476FDBA493CBCD797C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_4B517772BEB87476FDBA493CBCD797C2_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract_4B517772BEB87476FDBA493CBCD797C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_4B517772BEB87476FDBA493CBCD797C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract_4B517772BEB87476FDBA493CBCD797C2" xlink:to="lab_us-gaap_LeaseCostAbstract_4B517772BEB87476FDBA493CBCD797C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_52E6764F108A067F983E493CBCD72355_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_52E6764F108A067F983E493CBCD72355" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Lease Term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_52E6764F108A067F983E493CBCD72355_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_52E6764F108A067F983E493CBCD72355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_52E6764F108A067F983E493CBCD72355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_52E6764F108A067F983E493CBCD72355" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_52E6764F108A067F983E493CBCD72355" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_74044925BD2752792916493CBCD8140B_terseLabel_en-US" xlink:label="lab_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_74044925BD2752792916493CBCD8140B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_74044925BD2752792916493CBCD8140B_label_en-US" xlink:label="lab_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_74044925BD2752792916493CBCD8140B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Financing Lease, Lease Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectFinancingLeaseLeaseIncomeAbstract" xlink:label="loc_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_74044925BD2752792916493CBCD8140B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_74044925BD2752792916493CBCD8140B" xlink:to="lab_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_74044925BD2752792916493CBCD8140B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9551845A471A9C12F112493CBCD8C2F2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9551845A471A9C12F112493CBCD8C2F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9551845A471A9C12F112493CBCD8C2F2_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9551845A471A9C12F112493CBCD8C2F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9551845A471A9C12F112493CBCD8C2F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9551845A471A9C12F112493CBCD8C2F2" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9551845A471A9C12F112493CBCD8C2F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_0802CC3281EB7DA0114E2F38D6909F2E_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_0802CC3281EB7DA0114E2F38D6909F2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0802CC3281EB7DA0114E2F38D6909F2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0802CC3281EB7DA0114E2F38D6909F2E" xlink:to="lab_us-gaap_DebtDisclosureAbstract_0802CC3281EB7DA0114E2F38D6909F2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_3F8CB0A127DFBC6D9CFD2F38D6903D9A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_3F8CB0A127DFBC6D9CFD2F38D6903D9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_3F8CB0A127DFBC6D9CFD2F38D6903D9A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_3F8CB0A127DFBC6D9CFD2F38D6903D9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_3F8CB0A127DFBC6D9CFD2F38D6903D9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_3F8CB0A127DFBC6D9CFD2F38D6903D9A" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_3F8CB0A127DFBC6D9CFD2F38D6903D9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_D767217F471923F4478ED849D472FA65_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_D767217F471923F4478ED849D472FA65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_D767217F471923F4478ED849D472FA65_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_D767217F471923F4478ED849D472FA65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_D767217F471923F4478ED849D472FA65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_D767217F471923F4478ED849D472FA65" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_D767217F471923F4478ED849D472FA65" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_E7B7DCB4B6BD875870A7D849D4727CD3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_E7B7DCB4B6BD875870A7D849D4727CD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_E7B7DCB4B6BD875870A7D849D4727CD3_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_E7B7DCB4B6BD875870A7D849D4727CD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_E7B7DCB4B6BD875870A7D849D4727CD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_E7B7DCB4B6BD875870A7D849D4727CD3" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_E7B7DCB4B6BD875870A7D849D4727CD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCostsCurrent_AC41A6B9733E55DD4ED4D849D4721772_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrent_AC41A6B9733E55DD4ED4D849D4721772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred costs, current</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCurrent_AC41A6B9733E55DD4ED4D849D4721772_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrent_AC41A6B9733E55DD4ED4D849D4721772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent_AC41A6B9733E55DD4ED4D849D4721772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCurrent_AC41A6B9733E55DD4ED4D849D4721772" xlink:to="lab_us-gaap_DeferredCostsCurrent_AC41A6B9733E55DD4ED4D849D4721772" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_FE667CC937CD2AD95480205677C0A10F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_FE667CC937CD2AD95480205677C0A10F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_FE667CC937CD2AD95480205677C0A10F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_FE667CC937CD2AD95480205677C0A10F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_FE667CC937CD2AD95480205677C0A10F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_2AD7334D8CD22358C896205677C174DE_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember_2AD7334D8CD22358C896205677C174DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land and improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_2AD7334D8CD22358C896205677C174DE_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember_2AD7334D8CD22358C896205677C174DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LandAndLandImprovementsMember" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_2AD7334D8CD22358C896205677C174DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember_2AD7334D8CD22358C896205677C174DE" xlink:to="lab_us-gaap_LandAndLandImprovementsMember_2AD7334D8CD22358C896205677C174DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_FFC8747ACA7CD203B572205677C19F15_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember_FFC8747ACA7CD203B572205677C19F15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings, building improvements and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_FFC8747ACA7CD203B572205677C19F15_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember_FFC8747ACA7CD203B572205677C19F15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_FFC8747ACA7CD203B572205677C19F15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember_FFC8747ACA7CD203B572205677C19F15" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember_FFC8747ACA7CD203B572205677C19F15" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_C1C818480E65B825F64D205677C139ED_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_C1C818480E65B825F64D205677C139ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_C1C818480E65B825F64D205677C139ED_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_C1C818480E65B825F64D205677C139ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_C1C818480E65B825F64D205677C139ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_C1C818480E65B825F64D205677C139ED" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_C1C818480E65B825F64D205677C139ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_87D07A1EE3D52BCCB949205677C2597B_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_87D07A1EE3D52BCCB949205677C2597B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_87D07A1EE3D52BCCB949205677C2597B_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_87D07A1EE3D52BCCB949205677C2597B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_87D07A1EE3D52BCCB949205677C2597B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_87D07A1EE3D52BCCB949205677C2597B" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_87D07A1EE3D52BCCB949205677C2597B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_AAEF3DAA79A23C0874A3205677C2E723_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_AAEF3DAA79A23C0874A3205677C2E723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_AAEF3DAA79A23C0874A3205677C2E723_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_AAEF3DAA79A23C0874A3205677C2E723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_AAEF3DAA79A23C0874A3205677C2E723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_AAEF3DAA79A23C0874A3205677C2E723" xlink:to="lab_us-gaap_ConstructionInProgressMember_AAEF3DAA79A23C0874A3205677C2E723" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_BD68B8EA336AA67455A5205677C27D82_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_BD68B8EA336AA67455A5205677C27D82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_BD68B8EA336AA67455A5205677C27D82_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_BD68B8EA336AA67455A5205677C27D82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_BD68B8EA336AA67455A5205677C27D82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_BD68B8EA336AA67455A5205677C27D82" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_BD68B8EA336AA67455A5205677C27D82" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3D8ADD5CAAA59EE9A9E5205677C350FC_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3D8ADD5CAAA59EE9A9E5205677C350FC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3D8ADD5CAAA59EE9A9E5205677C350FC_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3D8ADD5CAAA59EE9A9E5205677C350FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3D8ADD5CAAA59EE9A9E5205677C350FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3D8ADD5CAAA59EE9A9E5205677C350FC" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3D8ADD5CAAA59EE9A9E5205677C350FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3DC5DF4A9C572CD6AE26205677C3E8EE_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3DC5DF4A9C572CD6AE26205677C3E8EE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3DC5DF4A9C572CD6AE26205677C3E8EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3DC5DF4A9C572CD6AE26205677C3E8EE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3DC5DF4A9C572CD6AE26205677C3E8EE" xlink:type="arc" />
    <link:label id="lab_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2_terseLabel_en-US" xlink:label="lab_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adapt Pharma</link:label>
    <link:label id="lab_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2_label_en-US" xlink:label="lab_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adapt Pharma [Member]</link:label>
    <link:label id="lab_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2_documentation_en-US" xlink:label="lab_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business acquisition on October 15, 2018.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AdaptPharmaMember" xlink:label="loc_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2" xlink:to="lab_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_1CE49621DA7208B0799F493CBD24FEF1_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_1CE49621DA7208B0799F493CBD24FEF1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability, net of current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_1CE49621DA7208B0799F493CBD24FEF1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_1CE49621DA7208B0799F493CBD24FEF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_1CE49621DA7208B0799F493CBD24FEF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_1CE49621DA7208B0799F493CBD24FEF1" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_1CE49621DA7208B0799F493CBD24FEF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_3E1B21928FD8E20E164D493CBD25794E_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_3E1B21928FD8E20E164D493CBD25794E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3E1B21928FD8E20E164D493CBD25794E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_3E1B21928FD8E20E164D493CBD25794E" xlink:to="lab_us-gaap_Goodwill_3E1B21928FD8E20E164D493CBD25794E" xlink:type="arc" />
    <link:label id="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69_terseLabel_en-US" xlink:label="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets, measurements period adjustments</link:label>
    <link:label id="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69_label_en-US" xlink:label="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses and Other Assets</link:label>
    <link:label id="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69_documentation_en-US" xlink:label="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses and Other Assets</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69" xlink:to="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69" xlink:type="arc" />
    <link:label id="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6_negatedTerseLabel_en-US" xlink:label="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability, net, measurement period adjustments</link:label>
    <link:label id="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6_label_en-US" xlink:label="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities Noncurrent</link:label>
    <link:label id="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6_documentation_en-US" xlink:label="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities Noncurrent</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6" xlink:to="lab_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2BCF25CDF0B933A02248D849D3E69F80_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2BCF25CDF0B933A02248D849D3E69F80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2BCF25CDF0B933A02248D849D3E69F80_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2BCF25CDF0B933A02248D849D3E69F80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2BCF25CDF0B933A02248D849D3E69F80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2BCF25CDF0B933A02248D849D3E69F80" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2BCF25CDF0B933A02248D849D3E69F80" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_CB04CB4E13F7C28AF8802F38D648CD3D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_CB04CB4E13F7C28AF8802F38D648CD3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_CB04CB4E13F7C28AF8802F38D648CD3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CB04CB4E13F7C28AF8802F38D648CD3D" xlink:to="lab_us-gaap_EarningsPerShareAbstract_CB04CB4E13F7C28AF8802F38D648CD3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_AAC7D867A5412671A5F22F38D6480444_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_AAC7D867A5412671A5F22F38D6480444" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_AAC7D867A5412671A5F22F38D6480444_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_AAC7D867A5412671A5F22F38D6480444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_AAC7D867A5412671A5F22F38D6480444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_AAC7D867A5412671A5F22F38D6480444" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_AAC7D867A5412671A5F22F38D6480444" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5EC73D17C492893510132F38D648FDE3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5EC73D17C492893510132F38D648FDE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) earnings</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5EC73D17C492893510132F38D648FDE3_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5EC73D17C492893510132F38D648FDE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5EC73D17C492893510132F38D648FDE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5EC73D17C492893510132F38D648FDE3" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5EC73D17C492893510132F38D648FDE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7127EA8054B9FBFF51D52F38D648876E_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7127EA8054B9FBFF51D52F38D648876E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7127EA8054B9FBFF51D52F38D648876E_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7127EA8054B9FBFF51D52F38D648876E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7127EA8054B9FBFF51D52F38D648876E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7127EA8054B9FBFF51D52F38D648876E" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7127EA8054B9FBFF51D52F38D648876E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C334E5434D539FC979862F38D6484016_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C334E5434D539FC979862F38D6484016" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares-basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C334E5434D539FC979862F38D6484016_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C334E5434D539FC979862F38D6484016" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C334E5434D539FC979862F38D6484016" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C334E5434D539FC979862F38D6484016" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C334E5434D539FC979862F38D6484016" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A91FB40B097C003D612D2F38D6487D6A_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A91FB40B097C003D612D2F38D6487D6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities-equity awards (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A91FB40B097C003D612D2F38D6487D6A_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A91FB40B097C003D612D2F38D6487D6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A91FB40B097C003D612D2F38D6487D6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A91FB40B097C003D612D2F38D6487D6A" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A91FB40B097C003D612D2F38D6487D6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_150413DDCECDC5AEF3762F38D648BA4F_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_150413DDCECDC5AEF3762F38D648BA4F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares-diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_150413DDCECDC5AEF3762F38D648BA4F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_150413DDCECDC5AEF3762F38D648BA4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_150413DDCECDC5AEF3762F38D648BA4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_150413DDCECDC5AEF3762F38D648BA4F" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_150413DDCECDC5AEF3762F38D648BA4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_DCA28BBC1AE8B471CAA22F38D648ED4C_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_DCA28BBC1AE8B471CAA22F38D648ED4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_DCA28BBC1AE8B471CAA22F38D648ED4C_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_DCA28BBC1AE8B471CAA22F38D648ED4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_DCA28BBC1AE8B471CAA22F38D648ED4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_DCA28BBC1AE8B471CAA22F38D648ED4C" xlink:to="lab_us-gaap_EarningsPerShareBasic_DCA28BBC1AE8B471CAA22F38D648ED4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_699B1932E37156AF61E12F38D648A5B1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_699B1932E37156AF61E12F38D648A5B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_699B1932E37156AF61E12F38D648A5B1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_699B1932E37156AF61E12F38D648A5B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_699B1932E37156AF61E12F38D648A5B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_699B1932E37156AF61E12F38D648A5B1" xlink:to="lab_us-gaap_EarningsPerShareDiluted_699B1932E37156AF61E12F38D648A5B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8F2887E737F160AEB4552F38D648852A_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8F2887E737F160AEB4552F38D648852A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8F2887E737F160AEB4552F38D648852A_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8F2887E737F160AEB4552F38D648852A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8F2887E737F160AEB4552F38D648852A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8F2887E737F160AEB4552F38D648852A" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8F2887E737F160AEB4552F38D648852A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_C9C2C2C725CEBA9AF34A499DF9CE7215_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_C9C2C2C725CEBA9AF34A499DF9CE7215" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_C9C2C2C725CEBA9AF34A499DF9CE7215_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_C9C2C2C725CEBA9AF34A499DF9CE7215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_C9C2C2C725CEBA9AF34A499DF9CE7215" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_C9C2C2C725CEBA9AF34A499DF9CE7215" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_C9C2C2C725CEBA9AF34A499DF9CE7215" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_BE44815EDB7A83C6F641205677C860C0_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_BE44815EDB7A83C6F641205677C860C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_BE44815EDB7A83C6F641205677C860C0_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_BE44815EDB7A83C6F641205677C860C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_BE44815EDB7A83C6F641205677C860C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_BE44815EDB7A83C6F641205677C860C0" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_BE44815EDB7A83C6F641205677C860C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_CC91D3F5E8AA955C8C0320C855515A2F_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_CC91D3F5E8AA955C8C0320C855515A2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_CC91D3F5E8AA955C8C0320C855515A2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_CC91D3F5E8AA955C8C0320C855515A2F" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_CC91D3F5E8AA955C8C0320C855515A2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9_label_en-US" xlink:label="lab_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9" xlink:to="lab_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:to="lab_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_6D6E0EB3E0BA11ACEF8820C8555269DB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_6D6E0EB3E0BA11ACEF8820C8555269DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$0.001 Par Value Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_6D6E0EB3E0BA11ACEF8820C8555269DB_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_6D6E0EB3E0BA11ACEF8820C8555269DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6D6E0EB3E0BA11ACEF8820C8555269DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_6D6E0EB3E0BA11ACEF8820C8555269DB" xlink:to="lab_us-gaap_CommonStockMember_6D6E0EB3E0BA11ACEF8820C8555269DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4EAAC9BB35131878319820C85552B631_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_4EAAC9BB35131878319820C85552B631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4EAAC9BB35131878319820C85552B631_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_4EAAC9BB35131878319820C85552B631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4EAAC9BB35131878319820C85552B631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_4EAAC9BB35131878319820C85552B631" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_4EAAC9BB35131878319820C85552B631" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_1A80A41CD00897DB525920C855528BA2_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_1A80A41CD00897DB525920C855528BA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_1A80A41CD00897DB525920C855528BA2_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_1A80A41CD00897DB525920C855528BA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_1A80A41CD00897DB525920C855528BA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_1A80A41CD00897DB525920C855528BA2" xlink:to="lab_us-gaap_TreasuryStockMember_1A80A41CD00897DB525920C855528BA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F71673ACF88509FF885220C85552F53C_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F71673ACF88509FF885220C85552F53C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F71673ACF88509FF885220C85552F53C_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F71673ACF88509FF885220C85552F53C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F71673ACF88509FF885220C85552F53C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F71673ACF88509FF885220C85552F53C" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F71673ACF88509FF885220C85552F53C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_C0D3998F77BD1B3D515020C855529747_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_C0D3998F77BD1B3D515020C855529747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_C0D3998F77BD1B3D515020C855529747_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_C0D3998F77BD1B3D515020C855529747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_C0D3998F77BD1B3D515020C855529747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_C0D3998F77BD1B3D515020C855529747" xlink:to="lab_us-gaap_RetainedEarningsMember_C0D3998F77BD1B3D515020C855529747" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208" xlink:to="lab_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_B264010A44F7FEA7033620C85553036B_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_B264010A44F7FEA7033620C85553036B" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B264010A44F7FEA7033620C85553036B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_B264010A44F7FEA7033620C85553036B" xlink:to="lab_us-gaap_CommonStockSharesIssued_B264010A44F7FEA7033620C85553036B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_E94FFAC0F4DA62D00FC920C8555337D4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_E94FFAC0F4DA62D00FC920C8555337D4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E94FFAC0F4DA62D00FC920C8555337D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_E94FFAC0F4DA62D00FC920C8555337D4" xlink:to="lab_us-gaap_StockholdersEquity_E94FFAC0F4DA62D00FC920C8555337D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE48144E672319E4EC8B20C8555475C0_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE48144E672319E4EC8B20C8555475C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of new revenue accounting standard (ASC 606), net of tax</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE48144E672319E4EC8B20C8555475C0_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE48144E672319E4EC8B20C8555475C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE48144E672319E4EC8B20C8555475C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE48144E672319E4EC8B20C8555475C0" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE48144E672319E4EC8B20C8555475C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_F67C7519D562D237F13B20C85554AAFB_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_F67C7519D562D237F13B20C85554AAFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, as adjusted</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_F67C7519D562D237F13B20C85554AAFB_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_F67C7519D562D237F13B20C85554AAFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_F67C7519D562D237F13B20C85554AAFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_F67C7519D562D237F13B20C85554AAFB" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_F67C7519D562D237F13B20C85554AAFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21EB85CBB02D937AF77320C855545792_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21EB85CBB02D937AF77320C855545792" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee equity plans activity (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21EB85CBB02D937AF77320C855545792_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21EB85CBB02D937AF77320C855545792" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21EB85CBB02D937AF77320C855545792" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21EB85CBB02D937AF77320C855545792" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21EB85CBB02D937AF77320C855545792" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_B6A76952761BA107AC2F20C85554A078_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_B6A76952761BA107AC2F20C85554A078" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee equity plans activity</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_B6A76952761BA107AC2F20C85554A078_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_B6A76952761BA107AC2F20C85554A078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_B6A76952761BA107AC2F20C85554A078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_B6A76952761BA107AC2F20C85554A078" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_B6A76952761BA107AC2F20C85554A078" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_E8E1BBB2E61F517D2AC820C85554DF9A_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_E8E1BBB2E61F517D2AC820C85554DF9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_E8E1BBB2E61F517D2AC820C85554DF9A_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_E8E1BBB2E61F517D2AC820C85554DF9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E8E1BBB2E61F517D2AC820C85554DF9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_E8E1BBB2E61F517D2AC820C85554DF9A" xlink:to="lab_us-gaap_NetIncomeLoss_E8E1BBB2E61F517D2AC820C85554DF9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_399C116C3E04922C118B20C855557136_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_399C116C3E04922C118B20C855557136" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_399C116C3E04922C118B20C855557136_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_399C116C3E04922C118B20C855557136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_399C116C3E04922C118B20C855557136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_399C116C3E04922C118B20C855557136" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_399C116C3E04922C118B20C855557136" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_325DAAB8A69FFCDABC7D20C8555576B7_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_325DAAB8A69FFCDABC7D20C8555576B7" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_325DAAB8A69FFCDABC7D20C8555576B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_325DAAB8A69FFCDABC7D20C8555576B7" xlink:to="lab_us-gaap_CommonStockSharesIssued_325DAAB8A69FFCDABC7D20C8555576B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_46E0A9D9AF6A8BA47EF120C85555EF37_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_46E0A9D9AF6A8BA47EF120C85555EF37" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_46E0A9D9AF6A8BA47EF120C85555EF37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_46E0A9D9AF6A8BA47EF120C85555EF37" xlink:to="lab_us-gaap_StockholdersEquity_46E0A9D9AF6A8BA47EF120C85555EF37" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8CD9682698F38D384A01D849D3DF5CDC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_8CD9682698F38D384A01D849D3DF5CDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8CD9682698F38D384A01D849D3DF5CDC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_8CD9682698F38D384A01D849D3DF5CDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_8CD9682698F38D384A01D849D3DF5CDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_8CD9682698F38D384A01D849D3DF5CDC" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_8CD9682698F38D384A01D849D3DF5CDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C87EFDF30C0B4C0DC8DC4996D114B084_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C87EFDF30C0B4C0DC8DC4996D114B084" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C87EFDF30C0B4C0DC8DC4996D114B084" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C87EFDF30C0B4C0DC8DC4996D114B084" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C87EFDF30C0B4C0DC8DC4996D114B084" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_ED9AF9C94A129CCE0D1C4996D11516B7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_ED9AF9C94A129CCE0D1C4996D11516B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_ED9AF9C94A129CCE0D1C4996D11516B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_ED9AF9C94A129CCE0D1C4996D11516B7" xlink:to="lab_us-gaap_NetIncomeLoss_ED9AF9C94A129CCE0D1C4996D11516B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_F7E4D592DC40C91757154996D1157A11_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_F7E4D592DC40C91757154996D1157A11" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translations, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_F7E4D592DC40C91757154996D1157A11_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_F7E4D592DC40C91757154996D1157A11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_F7E4D592DC40C91757154996D1157A11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_F7E4D592DC40C91757154996D1157A11" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_F7E4D592DC40C91757154996D1157A11" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_D2D8A0E8CF05A16CB4B44996D1150F61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_D2D8A0E8CF05A16CB4B44996D1150F61" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_D2D8A0E8CF05A16CB4B44996D1150F61_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_D2D8A0E8CF05A16CB4B44996D1150F61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_D2D8A0E8CF05A16CB4B44996D1150F61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_D2D8A0E8CF05A16CB4B44996D1150F61" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_D2D8A0E8CF05A16CB4B44996D1150F61" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_BE00A4E7DAC2CA0D7BF64996D115109C_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_BE00A4E7DAC2CA0D7BF64996D115109C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_BE00A4E7DAC2CA0D7BF64996D115109C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_BE00A4E7DAC2CA0D7BF64996D115109C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_BE00A4E7DAC2CA0D7BF64996D115109C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_BE00A4E7DAC2CA0D7BF64996D115109C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_BE00A4E7DAC2CA0D7BF64996D115109C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9A9DD2BB2AE03516B5584996D1165095_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9A9DD2BB2AE03516B5584996D1165095" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive (loss) income, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9A9DD2BB2AE03516B5584996D1165095" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9A9DD2BB2AE03516B5584996D1165095" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9A9DD2BB2AE03516B5584996D1165095" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_EE077370C86E6A170E154996D116194D_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_EE077370C86E6A170E154996D116194D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_EE077370C86E6A170E154996D116194D_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_EE077370C86E6A170E154996D116194D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_EE077370C86E6A170E154996D116194D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_EE077370C86E6A170E154996D116194D" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_EE077370C86E6A170E154996D116194D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2FB493E91E7A7A2253200AC34D33A031_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2FB493E91E7A7A2253200AC34D33A031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2FB493E91E7A7A2253200AC34D33A031_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2FB493E91E7A7A2253200AC34D33A031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2FB493E91E7A7A2253200AC34D33A031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2FB493E91E7A7A2253200AC34D33A031" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2FB493E91E7A7A2253200AC34D33A031" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A45C19BB35B8B217C416D849D4F3CA5E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A45C19BB35B8B217C416D849D4F3CA5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A45C19BB35B8B217C416D849D4F3CA5E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A45C19BB35B8B217C416D849D4F3CA5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A45C19BB35B8B217C416D849D4F3CA5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A45C19BB35B8B217C416D849D4F3CA5E" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A45C19BB35B8B217C416D849D4F3CA5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9D7ECF76D53569BE3250210F9A8D5DE5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_9D7ECF76D53569BE3250210F9A8D5DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Loss) earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9D7ECF76D53569BE3250210F9A8D5DE5_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_9D7ECF76D53569BE3250210F9A8D5DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9D7ECF76D53569BE3250210F9A8D5DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_9D7ECF76D53569BE3250210F9A8D5DE5" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_9D7ECF76D53569BE3250210F9A8D5DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66ECEC38B57AF024F4EE499DFAE4C204_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66ECEC38B57AF024F4EE499DFAE4C204" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66ECEC38B57AF024F4EE499DFAE4C204_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66ECEC38B57AF024F4EE499DFAE4C204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66ECEC38B57AF024F4EE499DFAE4C204" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66ECEC38B57AF024F4EE499DFAE4C204" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66ECEC38B57AF024F4EE499DFAE4C204" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_6A585B75BBE9091B6855499DFAE59778_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_6A585B75BBE9091B6855499DFAE59778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6A585B75BBE9091B6855499DFAE59778_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_6A585B75BBE9091B6855499DFAE59778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6A585B75BBE9091B6855499DFAE59778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_6A585B75BBE9091B6855499DFAE59778" xlink:to="lab_us-gaap_ShareBasedCompensation_6A585B75BBE9091B6855499DFAE59778" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_D37F7A3DAC0C311EADB0499DFAE51D9B_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_D37F7A3DAC0C311EADB0499DFAE51D9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_D37F7A3DAC0C311EADB0499DFAE51D9B_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_D37F7A3DAC0C311EADB0499DFAE51D9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_D37F7A3DAC0C311EADB0499DFAE51D9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_D37F7A3DAC0C311EADB0499DFAE51D9B" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_D37F7A3DAC0C311EADB0499DFAE51D9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_AA2685E7C75416DF3F7D499DFAE69C0E_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_AA2685E7C75416DF3F7D499DFAE69C0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_AA2685E7C75416DF3F7D499DFAE69C0E_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_AA2685E7C75416DF3F7D499DFAE69C0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_AA2685E7C75416DF3F7D499DFAE69C0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_AA2685E7C75416DF3F7D499DFAE69C0E" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_AA2685E7C75416DF3F7D499DFAE69C0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_91708EEE1C0486B04278499DFAE62804_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_91708EEE1C0486B04278499DFAE62804" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_91708EEE1C0486B04278499DFAE62804_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_91708EEE1C0486B04278499DFAE62804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91708EEE1C0486B04278499DFAE62804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91708EEE1C0486B04278499DFAE62804" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_91708EEE1C0486B04278499DFAE62804" xlink:type="arc" />
    <link:label id="lab_ebs_ChangeInFairValueOfContingentConsideration_63CE88F09CE8D1B05155499DFAE618C1_terseLabel_en-US" xlink:label="lab_ebs_ChangeInFairValueOfContingentConsideration_63CE88F09CE8D1B05155499DFAE618C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration, net</link:label>
    <link:label id="lab_ebs_ChangeInFairValueOfContingentConsideration_63CE88F09CE8D1B05155499DFAE618C1_label_en-US" xlink:label="lab_ebs_ChangeInFairValueOfContingentConsideration_63CE88F09CE8D1B05155499DFAE618C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Consideration</link:label>
    <link:label id="lab_ebs_ChangeInFairValueOfContingentConsideration_63CE88F09CE8D1B05155499DFAE618C1_documentation_en-US" xlink:label="lab_ebs_ChangeInFairValueOfContingentConsideration_63CE88F09CE8D1B05155499DFAE618C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value measurement of contingent value rights and contingent purchase considerations granted under purchase agreements.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ChangeInFairValueOfContingentConsideration" xlink:label="loc_ebs_ChangeInFairValueOfContingentConsideration_63CE88F09CE8D1B05155499DFAE618C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ChangeInFairValueOfContingentConsideration_63CE88F09CE8D1B05155499DFAE618C1" xlink:to="lab_ebs_ChangeInFairValueOfContingentConsideration_63CE88F09CE8D1B05155499DFAE618C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_07BEEE7A5C7405D1F496499DFAE64337_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_07BEEE7A5C7405D1F496499DFAE64337" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_07BEEE7A5C7405D1F496499DFAE64337_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_07BEEE7A5C7405D1F496499DFAE64337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_07BEEE7A5C7405D1F496499DFAE64337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_07BEEE7A5C7405D1F496499DFAE64337" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_07BEEE7A5C7405D1F496499DFAE64337" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0ECC35FC26D5E01A799E499DFAE662A4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0ECC35FC26D5E01A799E499DFAE662A4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0ECC35FC26D5E01A799E499DFAE662A4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0ECC35FC26D5E01A799E499DFAE662A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0ECC35FC26D5E01A799E499DFAE662A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0ECC35FC26D5E01A799E499DFAE662A4" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0ECC35FC26D5E01A799E499DFAE662A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_169A2DDCABE7157156DE499DFAE73D48_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_169A2DDCABE7157156DE499DFAE73D48" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_169A2DDCABE7157156DE499DFAE73D48_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_169A2DDCABE7157156DE499DFAE73D48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_169A2DDCABE7157156DE499DFAE73D48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_169A2DDCABE7157156DE499DFAE73D48" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_169A2DDCABE7157156DE499DFAE73D48" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E5C4C29E15BFB75D200A499DFAE7E5ED_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E5C4C29E15BFB75D200A499DFAE7E5ED" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E5C4C29E15BFB75D200A499DFAE7E5ED_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E5C4C29E15BFB75D200A499DFAE7E5ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E5C4C29E15BFB75D200A499DFAE7E5ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E5C4C29E15BFB75D200A499DFAE7E5ED" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E5C4C29E15BFB75D200A499DFAE7E5ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_63D3EACBD63E7F6D4F9A499DFAE79AE5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_63D3EACBD63E7F6D4F9A499DFAE79AE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_63D3EACBD63E7F6D4F9A499DFAE79AE5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_63D3EACBD63E7F6D4F9A499DFAE79AE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_63D3EACBD63E7F6D4F9A499DFAE79AE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_63D3EACBD63E7F6D4F9A499DFAE79AE5" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_63D3EACBD63E7F6D4F9A499DFAE79AE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_D27BC4E486A2EDCD9CC2499DFAE7E446_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_D27BC4E486A2EDCD9CC2499DFAE7E446" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_D27BC4E486A2EDCD9CC2499DFAE7E446_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_D27BC4E486A2EDCD9CC2499DFAE7E446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_D27BC4E486A2EDCD9CC2499DFAE7E446" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_D27BC4E486A2EDCD9CC2499DFAE7E446" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_D27BC4E486A2EDCD9CC2499DFAE7E446" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B1D69A4B75433F6E1326499DFAE7DC9C_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B1D69A4B75433F6E1326499DFAE7DC9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B1D69A4B75433F6E1326499DFAE7DC9C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B1D69A4B75433F6E1326499DFAE7DC9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B1D69A4B75433F6E1326499DFAE7DC9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B1D69A4B75433F6E1326499DFAE7DC9C" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B1D69A4B75433F6E1326499DFAE7DC9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_E4C9C16851B5B9A9968F499DFAE87F0F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_E4C9C16851B5B9A9968F499DFAE87F0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_E4C9C16851B5B9A9968F499DFAE87F0F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_E4C9C16851B5B9A9968F499DFAE87F0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_E4C9C16851B5B9A9968F499DFAE87F0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_E4C9C16851B5B9A9968F499DFAE87F0F" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_E4C9C16851B5B9A9968F499DFAE87F0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_65177F18D4EB1902EA06499DFAE80448_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_65177F18D4EB1902EA06499DFAE80448" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_65177F18D4EB1902EA06499DFAE80448_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_65177F18D4EB1902EA06499DFAE80448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65177F18D4EB1902EA06499DFAE80448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65177F18D4EB1902EA06499DFAE80448" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_65177F18D4EB1902EA06499DFAE80448" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7A93B250CD550B66DD66499DFAE8C324_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7A93B250CD550B66DD66499DFAE8C324" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7A93B250CD550B66DD66499DFAE8C324_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7A93B250CD550B66DD66499DFAE8C324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7A93B250CD550B66DD66499DFAE8C324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7A93B250CD550B66DD66499DFAE8C324" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7A93B250CD550B66DD66499DFAE8C324" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForPreviousAcquisition_5F4E337960806D91DCFB49A467EBC73C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForPreviousAcquisition_5F4E337960806D91DCFB49A467EBC73C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment from prior asset acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsForPreviousAcquisition_5F4E337960806D91DCFB49A467EBC73C_label_en-US" xlink:label="lab_us-gaap_PaymentsForPreviousAcquisition_5F4E337960806D91DCFB49A467EBC73C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Previous Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForPreviousAcquisition" xlink:label="loc_us-gaap_PaymentsForPreviousAcquisition_5F4E337960806D91DCFB49A467EBC73C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForPreviousAcquisition_5F4E337960806D91DCFB49A467EBC73C" xlink:to="lab_us-gaap_PaymentsForPreviousAcquisition_5F4E337960806D91DCFB49A467EBC73C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_B176A22AD75493E1023C499DFAE8C950_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_B176A22AD75493E1023C499DFAE8C950" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_B176A22AD75493E1023C499DFAE8C950_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_B176A22AD75493E1023C499DFAE8C950" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_B176A22AD75493E1023C499DFAE8C950" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_B176A22AD75493E1023C499DFAE8C950" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_B176A22AD75493E1023C499DFAE8C950" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_FA67405568F2D82EE445499DFAE917FE_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_FA67405568F2D82EE445499DFAE917FE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_FA67405568F2D82EE445499DFAE917FE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_FA67405568F2D82EE445499DFAE917FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_FA67405568F2D82EE445499DFAE917FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_FA67405568F2D82EE445499DFAE917FE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_FA67405568F2D82EE445499DFAE917FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by (used in) financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_EBD3F53C5E66FABF3397499DFAEB10B5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit_EBD3F53C5E66FABF3397499DFAEB10B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_EBD3F53C5E66FABF3397499DFAEB10B5_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit_EBD3F53C5E66FABF3397499DFAEB10B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_EBD3F53C5E66FABF3397499DFAEB10B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit_EBD3F53C5E66FABF3397499DFAEB10B5" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit_EBD3F53C5E66FABF3397499DFAEB10B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_9432EF02C0DBA9643CB6499DFAEB754E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit_9432EF02C0DBA9643CB6499DFAEB754E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_9432EF02C0DBA9643CB6499DFAEB754E_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit_9432EF02C0DBA9643CB6499DFAEB754E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_9432EF02C0DBA9643CB6499DFAEB754E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit_9432EF02C0DBA9643CB6499DFAEB754E" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit_9432EF02C0DBA9643CB6499DFAEB754E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_5B5AF8D215ABD9C536B7499DFAEB651B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes_5B5AF8D215ABD9C536B7499DFAEB651B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on term loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_5B5AF8D215ABD9C536B7499DFAEB651B_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes_5B5AF8D215ABD9C536B7499DFAEB651B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Medium-term Notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_5B5AF8D215ABD9C536B7499DFAEB651B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfMediumTermNotes_5B5AF8D215ABD9C536B7499DFAEB651B" xlink:to="lab_us-gaap_RepaymentsOfMediumTermNotes_5B5AF8D215ABD9C536B7499DFAEB651B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_EDEDCD835885FE9647C1499DFAEBC230_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_EDEDCD835885FE9647C1499DFAEBC230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuances of stock under share-based benefit plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_EDEDCD835885FE9647C1499DFAEBC230_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_EDEDCD835885FE9647C1499DFAEBC230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_EDEDCD835885FE9647C1499DFAEBC230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_EDEDCD835885FE9647C1499DFAEBC230" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_EDEDCD835885FE9647C1499DFAEBC230" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2C69A216BA6A451628CC499DFAEB831C_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2C69A216BA6A451628CC499DFAEB831C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Taxes paid on behalf of employees for equity activity</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2C69A216BA6A451628CC499DFAEB831C_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2C69A216BA6A451628CC499DFAEB831C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2C69A216BA6A451628CC499DFAEB831C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2C69A216BA6A451628CC499DFAEB831C" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2C69A216BA6A451628CC499DFAEB831C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_195B309C9A0D6130A25F499DFAEBF9E1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_195B309C9A0D6130A25F499DFAEBF9E1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payments</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_195B309C9A0D6130A25F499DFAEBF9E1_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_195B309C9A0D6130A25F499DFAEBF9E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_195B309C9A0D6130A25F499DFAEBF9E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_195B309C9A0D6130A25F499DFAEBF9E1" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_195B309C9A0D6130A25F499DFAEBF9E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A5A724523D610A780008499DFAEBD38B_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A5A724523D610A780008499DFAEBD38B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A5A724523D610A780008499DFAEBD38B_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A5A724523D610A780008499DFAEBD38B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A5A724523D610A780008499DFAEBD38B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A5A724523D610A780008499DFAEBD38B" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A5A724523D610A780008499DFAEBD38B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_457FC1B56F8FA68E276B499DFAEBC505_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_457FC1B56F8FA68E276B499DFAEBC505" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_457FC1B56F8FA68E276B499DFAEBC505_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_457FC1B56F8FA68E276B499DFAEBC505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_457FC1B56F8FA68E276B499DFAEBC505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_457FC1B56F8FA68E276B499DFAEBC505" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_457FC1B56F8FA68E276B499DFAEBC505" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C5F89BF03F1178E6E8D499DFAEBE107_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C5F89BF03F1178E6E8D499DFAEBE107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C5F89BF03F1178E6E8D499DFAEBE107_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C5F89BF03F1178E6E8D499DFAEBE107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C5F89BF03F1178E6E8D499DFAEBE107" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C5F89BF03F1178E6E8D499DFAEBE107" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C5F89BF03F1178E6E8D499DFAEBE107" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D6139CD2F55588FBB947499DFAEB02B3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D6139CD2F55588FBB947499DFAEB02B3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D6139CD2F55588FBB947499DFAEB02B3_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D6139CD2F55588FBB947499DFAEB02B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D6139CD2F55588FBB947499DFAEB02B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D6139CD2F55588FBB947499DFAEB02B3" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D6139CD2F55588FBB947499DFAEB02B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73C5BFA0379063C7F7CC499DFAEC6F64_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73C5BFA0379063C7F7CC499DFAEC6F64" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73C5BFA0379063C7F7CC499DFAEC6F64_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73C5BFA0379063C7F7CC499DFAEC6F64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73C5BFA0379063C7F7CC499DFAEC6F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73C5BFA0379063C7F7CC499DFAEC6F64" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73C5BFA0379063C7F7CC499DFAEC6F64" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FBDD66AE402C913C6163499DFAEC6F72_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FBDD66AE402C913C6163499DFAEC6F72" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FBDD66AE402C913C6163499DFAEC6F72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FBDD66AE402C913C6163499DFAEC6F72" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FBDD66AE402C913C6163499DFAEC6F72" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F40159969015F67F68C5210F9A8691B6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F40159969015F67F68C5210F9A8691B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Net Income per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F40159969015F67F68C5210F9A8691B6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F40159969015F67F68C5210F9A8691B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F40159969015F67F68C5210F9A8691B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F40159969015F67F68C5210F9A8691B6" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F40159969015F67F68C5210F9A8691B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_7491E29C7387DB894CD92A8A1C59D2F0_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_7491E29C7387DB894CD92A8A1C59D2F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_7491E29C7387DB894CD92A8A1C59D2F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_7491E29C7387DB894CD92A8A1C59D2F0" xlink:to="lab_us-gaap_IncomeStatementAbstract_7491E29C7387DB894CD92A8A1C59D2F0" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED" xlink:to="lab_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:to="lab_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_6DAABF2038F9AFBD59A72A8A1C5A820C_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_6DAABF2038F9AFBD59A72A8A1C5A820C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_6DAABF2038F9AFBD59A72A8A1C5A820C_label_en-US" xlink:label="lab_us-gaap_ProductMember_6DAABF2038F9AFBD59A72A8A1C5A820C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_6DAABF2038F9AFBD59A72A8A1C5A820C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_6DAABF2038F9AFBD59A72A8A1C5A820C" xlink:to="lab_us-gaap_ProductMember_6DAABF2038F9AFBD59A72A8A1C5A820C" xlink:type="arc" />
    <link:label id="lab_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F_terseLabel_en-US" xlink:label="lab_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract manufacturing</link:label>
    <link:label id="lab_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F_label_en-US" xlink:label="lab_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Manufacturing [Member]</link:label>
    <link:label id="lab_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F_documentation_en-US" xlink:label="lab_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue earned during the period arising from manufacturing sale under the terms of a contract.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F" xlink:to="lab_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F" xlink:type="arc" />
    <link:label id="lab_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641_terseLabel_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contracts and grants</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641_label_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contracts and Grants [Member]</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641_documentation_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractsAndGrantsMember" xlink:label="loc_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641" xlink:to="lab_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160" xlink:to="lab_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E03C0C2575E201E50E592A8A1C61BCF8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E03C0C2575E201E50E592A8A1C61BCF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E03C0C2575E201E50E592A8A1C61BCF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E03C0C2575E201E50E592A8A1C61BCF8" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E03C0C2575E201E50E592A8A1C61BCF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:to="lab_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5C2F6A77A2DE6791A7642A8A1C61FAF5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_5C2F6A77A2DE6791A7642A8A1C61FAF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product sales and contract manufacturing</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5C2F6A77A2DE6791A7642A8A1C61FAF5_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_5C2F6A77A2DE6791A7642A8A1C61FAF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5C2F6A77A2DE6791A7642A8A1C61FAF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_5C2F6A77A2DE6791A7642A8A1C61FAF5" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_5C2F6A77A2DE6791A7642A8A1C61FAF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_EA2DCA0250263241A4D72A8A1C62BA32_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_EA2DCA0250263241A4D72A8A1C62BA32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_EA2DCA0250263241A4D72A8A1C62BA32_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_EA2DCA0250263241A4D72A8A1C62BA32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EA2DCA0250263241A4D72A8A1C62BA32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_EA2DCA0250263241A4D72A8A1C62BA32" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_EA2DCA0250263241A4D72A8A1C62BA32" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_06E0E2133759621C01C32A8A1C628EBB_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_06E0E2133759621C01C32A8A1C628EBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_06E0E2133759621C01C32A8A1C628EBB_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_06E0E2133759621C01C32A8A1C628EBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_06E0E2133759621C01C32A8A1C628EBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_06E0E2133759621C01C32A8A1C628EBB" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_06E0E2133759621C01C32A8A1C628EBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_D61A838C43340154DA4A2A8A1C622D1D_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_D61A838C43340154DA4A2A8A1C622D1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquisition-related intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_D61A838C43340154DA4A2A8A1C622D1D_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_D61A838C43340154DA4A2A8A1C622D1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D61A838C43340154DA4A2A8A1C622D1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_D61A838C43340154DA4A2A8A1C622D1D" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_D61A838C43340154DA4A2A8A1C622D1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_76BDCF334BE6F98C52872A8A1C62FB3B_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_76BDCF334BE6F98C52872A8A1C62FB3B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_76BDCF334BE6F98C52872A8A1C62FB3B_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_76BDCF334BE6F98C52872A8A1C62FB3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_76BDCF334BE6F98C52872A8A1C62FB3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_76BDCF334BE6F98C52872A8A1C62FB3B" xlink:to="lab_us-gaap_OperatingExpenses_76BDCF334BE6F98C52872A8A1C62FB3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8C9F5F6C31D156DEC7A52A8A1C637A30_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_8C9F5F6C31D156DEC7A52A8A1C637A30" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income from operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8C9F5F6C31D156DEC7A52A8A1C637A30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_8C9F5F6C31D156DEC7A52A8A1C637A30" xlink:to="lab_us-gaap_OperatingIncomeLoss_8C9F5F6C31D156DEC7A52A8A1C637A30" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_798497C8C5ED5B4F14EC2A8A1C6399F0_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_798497C8C5ED5B4F14EC2A8A1C6399F0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_798497C8C5ED5B4F14EC2A8A1C6399F0_label_en-US" xlink:label="lab_us-gaap_InterestExpense_798497C8C5ED5B4F14EC2A8A1C6399F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_798497C8C5ED5B4F14EC2A8A1C6399F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_798497C8C5ED5B4F14EC2A8A1C6399F0" xlink:to="lab_us-gaap_InterestExpense_798497C8C5ED5B4F14EC2A8A1C6399F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_FF2AEA776074ECD7FA462A8A1C63801B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_FF2AEA776074ECD7FA462A8A1C63801B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_FF2AEA776074ECD7FA462A8A1C63801B_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_FF2AEA776074ECD7FA462A8A1C63801B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_FF2AEA776074ECD7FA462A8A1C63801B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_FF2AEA776074ECD7FA462A8A1C63801B" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_FF2AEA776074ECD7FA462A8A1C63801B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_4A107193415103C675A92A8A1C6323F9_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_4A107193415103C675A92A8A1C6323F9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_4A107193415103C675A92A8A1C6323F9_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_4A107193415103C675A92A8A1C6323F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4A107193415103C675A92A8A1C6323F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4A107193415103C675A92A8A1C6323F9" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_4A107193415103C675A92A8A1C6323F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_347D619286BD0ABD41032A8A1C633F5F_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_347D619286BD0ABD41032A8A1C633F5F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_347D619286BD0ABD41032A8A1C633F5F_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_347D619286BD0ABD41032A8A1C633F5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_347D619286BD0ABD41032A8A1C633F5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_347D619286BD0ABD41032A8A1C633F5F" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_347D619286BD0ABD41032A8A1C633F5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5D0CC6AEBBE5DA9AA5542A8A1C64C79B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_5D0CC6AEBBE5DA9AA5542A8A1C64C79B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5D0CC6AEBBE5DA9AA5542A8A1C64C79B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_5D0CC6AEBBE5DA9AA5542A8A1C64C79B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5D0CC6AEBBE5DA9AA5542A8A1C64C79B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5D0CC6AEBBE5DA9AA5542A8A1C64C79B" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_5D0CC6AEBBE5DA9AA5542A8A1C64C79B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_27EA59D52C643BE47B9B2A8A1C64FE99_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_27EA59D52C643BE47B9B2A8A1C64FE99" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_27EA59D52C643BE47B9B2A8A1C64FE99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_27EA59D52C643BE47B9B2A8A1C64FE99" xlink:to="lab_us-gaap_NetIncomeLoss_27EA59D52C643BE47B9B2A8A1C64FE99" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per common share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E" xlink:to="lab_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_82971E18464E84A744C02A8A1C6451D6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_82971E18464E84A744C02A8A1C6451D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_82971E18464E84A744C02A8A1C6451D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_82971E18464E84A744C02A8A1C6451D6" xlink:to="lab_us-gaap_EarningsPerShareBasic_82971E18464E84A744C02A8A1C6451D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_FAE454C5583115005AF92A8A1C64E015_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_FAE454C5583115005AF92A8A1C64E015" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_FAE454C5583115005AF92A8A1C64E015" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_FAE454C5583115005AF92A8A1C64E015" xlink:to="lab_us-gaap_EarningsPerShareDiluted_FAE454C5583115005AF92A8A1C64E015" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing (loss) income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D1D012B0C4F0B7DD27D82A8A1C65C9E8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D1D012B0C4F0B7DD27D82A8A1C65C9E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D1D012B0C4F0B7DD27D82A8A1C65C9E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D1D012B0C4F0B7DD27D82A8A1C65C9E8" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D1D012B0C4F0B7DD27D82A8A1C65C9E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_FF9F0D66C6BE45F8E7DE2A8A1C6592A1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_FF9F0D66C6BE45F8E7DE2A8A1C6592A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_FF9F0D66C6BE45F8E7DE2A8A1C6592A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_FF9F0D66C6BE45F8E7DE2A8A1C6592A1" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_FF9F0D66C6BE45F8E7DE2A8A1C6592A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_569B9295EFC759084EBBD849D43DF247_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_569B9295EFC759084EBBD849D43DF247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_569B9295EFC759084EBBD849D43DF247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_569B9295EFC759084EBBD849D43DF247" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_569B9295EFC759084EBBD849D43DF247" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D" xlink:to="lab_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0_label_en-US" xlink:label="lab_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0" xlink:to="lab_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70" xlink:to="lab_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70" xlink:type="arc" />
    <link:label id="lab_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5_terseLabel_en-US" xlink:label="lab_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholder Class Action Lawsuit</link:label>
    <link:label id="lab_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5_label_en-US" xlink:label="lab_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5_documentation_en-US" xlink:label="lab_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shareholder Class Action Lawsuit [Member]</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ShareholderClassActionLawsuitMember" xlink:label="loc_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5" xlink:to="lab_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566" xlink:to="lab_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_A50E9B37733E5BB40CB6D849D43F19AA_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_A50E9B37733E5BB40CB6D849D43F19AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_A50E9B37733E5BB40CB6D849D43F19AA_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_A50E9B37733E5BB40CB6D849D43F19AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_A50E9B37733E5BB40CB6D849D43F19AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_A50E9B37733E5BB40CB6D849D43F19AA" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_A50E9B37733E5BB40CB6D849D43F19AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_F5D727551368E8623A822073BB5EAC60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_F5D727551368E8623A822073BB5EAC60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_F5D727551368E8623A822073BB5EAC60_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_F5D727551368E8623A822073BB5EAC60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_F5D727551368E8623A822073BB5EAC60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_F5D727551368E8623A822073BB5EAC60" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_F5D727551368E8623A822073BB5EAC60" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:to="lab_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6" xlink:to="lab_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:to="lab_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_0CEF79926B528CD2B1C4493CBC4DF392_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_0CEF79926B528CD2B1C4493CBC4DF392" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior secured credit agreement - Revolver loan due 2023</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_0CEF79926B528CD2B1C4493CBC4DF392_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_0CEF79926B528CD2B1C4493CBC4DF392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_0CEF79926B528CD2B1C4493CBC4DF392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_0CEF79926B528CD2B1C4493CBC4DF392" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember_0CEF79926B528CD2B1C4493CBC4DF392" xlink:type="arc" />
    <link:label id="lab_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A_terseLabel_en-US" xlink:label="lab_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior secured credit agreement - Term loan due 2023</link:label>
    <link:label id="lab_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A_label_en-US" xlink:label="lab_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A_documentation_en-US" xlink:label="lab_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term loan dated December 2013.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_TermLoanFacilityMember" xlink:label="loc_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A" xlink:to="lab_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266" xlink:to="lab_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:type="arc" />
    <link:label id="lab_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1_terseLabel_en-US" xlink:label="lab_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Credit Agreement</link:label>
    <link:label id="lab_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1_label_en-US" xlink:label="lab_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1_documentation_en-US" xlink:label="lab_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit agreement dated September 2017.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_CreditAgreementMember" xlink:label="loc_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1" xlink:to="lab_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1" xlink:type="arc" />
    <link:label id="lab_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D_terseLabel_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D_label_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D_documentation_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended credit agreement dated October 15, 2018.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AmendedCreditAgreementMember" xlink:label="loc_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D" xlink:to="lab_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D" xlink:type="arc" />
    <link:label id="lab_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415_terseLabel_en-US" xlink:label="lab_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.875% Convertible Senior Notes due 2021</link:label>
    <link:label id="lab_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415_label_en-US" xlink:label="lab_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes Due 2021 [Member]</link:label>
    <link:label id="lab_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415_documentation_en-US" xlink:label="lab_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes Due 2021 [Member]</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ConvertibleSeniorNotesDue2021Member" xlink:label="loc_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415" xlink:to="lab_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E" xlink:to="lab_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:to="lab_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:type="arc" />
    <link:label id="lab_us-gaap_EurodollarMember_237E8601900F543B781F493CBC4F510E_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember_237E8601900F543B781F493CBC4F510E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eurocurrency</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_237E8601900F543B781F493CBC4F510E_label_en-US" xlink:label="lab_us-gaap_EurodollarMember_237E8601900F543B781F493CBC4F510E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_237E8601900F543B781F493CBC4F510E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember_237E8601900F543B781F493CBC4F510E" xlink:to="lab_us-gaap_EurodollarMember_237E8601900F543B781F493CBC4F510E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_AFF6E0E56A1967BC4BC3493CBC4FC3C2_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember_AFF6E0E56A1967BC4BC3493CBC4FC3C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_AFF6E0E56A1967BC4BC3493CBC4FC3C2_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember_AFF6E0E56A1967BC4BC3493CBC4FC3C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Funds Effective Swap Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_AFF6E0E56A1967BC4BC3493CBC4FC3C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember_AFF6E0E56A1967BC4BC3493CBC4FC3C2" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember_AFF6E0E56A1967BC4BC3493CBC4FC3C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BaseRateMember_3B1B55543EEC4BBB7589493CBC507BD6_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember_3B1B55543EEC4BBB7589493CBC507BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_3B1B55543EEC4BBB7589493CBC507BD6_label_en-US" xlink:label="lab_us-gaap_BaseRateMember_3B1B55543EEC4BBB7589493CBC507BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_3B1B55543EEC4BBB7589493CBC507BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember_3B1B55543EEC4BBB7589493CBC507BD6" xlink:to="lab_us-gaap_BaseRateMember_3B1B55543EEC4BBB7589493CBC507BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="lab_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:type="arc" />
    <link:label id="lab_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299_terseLabel_en-US" xlink:label="lab_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of lending institutions</link:label>
    <link:label id="lab_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299_label_en-US" xlink:label="lab_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Lending Institutions</link:label>
    <link:label id="lab_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299_documentation_en-US" xlink:label="lab_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of lending institutions in which the entity has a credit facility.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_NumberOfLendingInstitutions" xlink:label="loc_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299" xlink:to="lab_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_FCD0DE37262E0611FCC0493CBC519991_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_FCD0DE37262E0611FCC0493CBC519991" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_FCD0DE37262E0611FCC0493CBC519991_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_FCD0DE37262E0611FCC0493CBC519991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_FCD0DE37262E0611FCC0493CBC519991" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_FCD0DE37262E0611FCC0493CBC519991" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_FCD0DE37262E0611FCC0493CBC519991" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_BD5E669A5D8502DE7DB4493CBC51C8CE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_BD5E669A5D8502DE7DB4493CBC51C8CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_BD5E669A5D8502DE7DB4493CBC51C8CE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_BD5E669A5D8502DE7DB4493CBC51C8CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_BD5E669A5D8502DE7DB4493CBC51C8CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_BD5E669A5D8502DE7DB4493CBC51C8CE" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_BD5E669A5D8502DE7DB4493CBC51C8CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_951E255E840E0521F0B7493CBC5167C2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_951E255E840E0521F0B7493CBC5167C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_951E255E840E0521F0B7493CBC5167C2_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_951E255E840E0521F0B7493CBC5167C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_951E255E840E0521F0B7493CBC5167C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_951E255E840E0521F0B7493CBC5167C2" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_951E255E840E0521F0B7493CBC5167C2" xlink:type="arc" />
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of original principal amount required to repay in the first two years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay in First Two Years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in the first two years.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA" xlink:type="arc" />
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of original principal amount required to repay during the third year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay During the Third Year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in the third year.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA" xlink:type="arc" />
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of original principal amount required to repay remaining year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay Remaining Years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in remaining years.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB" xlink:type="arc" />
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF_terseLabel_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right</link:label>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF_label_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Proceeds Excess Amount from Dispositions of Property or Casualty Events Subject to Certain Reinvestment Right</link:label>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF_documentation_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF" xlink:to="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, net leverage ratio rolling period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, debt service coverage ratio</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Debt Service Coverage Ratio</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Debt Service Coverage Ratio</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340" xlink:to="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, net leverage ratio through June 30, 2019</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, One</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, One</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, net leverage ratio to September 30, 2019</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Two</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Two</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, net leverage ratio from October 1, 2019 to September 29, 2020</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Three</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Three</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioThree" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, net leverage ratio thereafter</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Four</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Four</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioFour" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, net leverage ratio, adjusted</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Adjusted</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Adjusted</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, net leverage ratio adjustment period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB" xlink:type="arc" />
    <link:label id="lab_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, restricted payments limit, amount</link:label>
    <link:label id="lab_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF_label_en-US" xlink:label="lab_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Restricted Payments Limit, Amount</link:label>
    <link:label id="lab_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Restricted Payments Limit, Amount</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentRestrictedPaymentsLimitAmount" xlink:label="loc_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF" xlink:to="lab_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4D5BC057F3454FC0149A493CBC54F5F3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4D5BC057F3454FC0149A493CBC54F5F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4D5BC057F3454FC0149A493CBC54F5F3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4D5BC057F3454FC0149A493CBC54F5F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4D5BC057F3454FC0149A493CBC54F5F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4D5BC057F3454FC0149A493CBC54F5F3" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4D5BC057F3454FC0149A493CBC54F5F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseCostAbstract_7AFD04D0E82CD3C9D0D10AC34DBE185A_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseCostAbstract_7AFD04D0E82CD3C9D0D10AC34DBE185A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost:</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseCostAbstract_7AFD04D0E82CD3C9D0D10AC34DBE185A_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseCostAbstract_7AFD04D0E82CD3C9D0D10AC34DBE185A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Cost [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseCostAbstract" xlink:label="loc_us-gaap_FinanceLeaseCostAbstract_7AFD04D0E82CD3C9D0D10AC34DBE185A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseCostAbstract_7AFD04D0E82CD3C9D0D10AC34DBE185A" xlink:to="lab_us-gaap_FinanceLeaseCostAbstract_7AFD04D0E82CD3C9D0D10AC34DBE185A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A611B36EEF48BD07340D0AC34DBE0482_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A611B36EEF48BD07340D0AC34DBE0482" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A611B36EEF48BD07340D0AC34DBE0482_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A611B36EEF48BD07340D0AC34DBE0482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A611B36EEF48BD07340D0AC34DBE0482" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A611B36EEF48BD07340D0AC34DBE0482" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A611B36EEF48BD07340D0AC34DBE0482" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_337064DF10FBD319708A0AC34DBE2787_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense_337064DF10FBD319708A0AC34DBE2787" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_337064DF10FBD319708A0AC34DBE2787_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense_337064DF10FBD319708A0AC34DBE2787" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_337064DF10FBD319708A0AC34DBE2787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense_337064DF10FBD319708A0AC34DBE2787" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense_337064DF10FBD319708A0AC34DBE2787" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_8FE4877C1A3F33F08C4A0AC34DBEDEFF_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_8FE4877C1A3F33F08C4A0AC34DBEDEFF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_8FE4877C1A3F33F08C4A0AC34DBEDEFF_label_en-US" xlink:label="lab_us-gaap_LeaseCost_8FE4877C1A3F33F08C4A0AC34DBEDEFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_8FE4877C1A3F33F08C4A0AC34DBEDEFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_8FE4877C1A3F33F08C4A0AC34DBEDEFF" xlink:to="lab_us-gaap_LeaseCost_8FE4877C1A3F33F08C4A0AC34DBEDEFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_F12142E7FBDBB9C3B16DD849D3614906_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_F12142E7FBDBB9C3B16DD849D3614906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_F12142E7FBDBB9C3B16DD849D3614906_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_F12142E7FBDBB9C3B16DD849D3614906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_F12142E7FBDBB9C3B16DD849D3614906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_F12142E7FBDBB9C3B16DD849D3614906" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_F12142E7FBDBB9C3B16DD849D3614906" xlink:type="arc" />
    <link:label id="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_CD14CF85BE2440DE6C17D849D361B63F_terseLabel_en-US" xlink:label="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_CD14CF85BE2440DE6C17D849D361B63F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Leases Supplemental Balance Sheets</link:label>
    <link:label id="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_CD14CF85BE2440DE6C17D849D361B63F_label_en-US" xlink:label="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_CD14CF85BE2440DE6C17D849D361B63F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Leases Supplemental Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_CD14CF85BE2440DE6C17D849D361B63F_documentation_en-US" xlink:label="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_CD14CF85BE2440DE6C17D849D361B63F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Leases Supplemental Balance Sheets [Table Text Block]</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock" xlink:label="loc_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_CD14CF85BE2440DE6C17D849D361B63F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_CD14CF85BE2440DE6C17D849D361B63F" xlink:to="lab_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_CD14CF85BE2440DE6C17D849D361B63F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_37F17FD1D06D0D8DD53BD849D53A9695_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_37F17FD1D06D0D8DD53BD849D53A9695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_37F17FD1D06D0D8DD53BD849D53A9695_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_37F17FD1D06D0D8DD53BD849D53A9695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_37F17FD1D06D0D8DD53BD849D53A9695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_37F17FD1D06D0D8DD53BD849D53A9695" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_37F17FD1D06D0D8DD53BD849D53A9695" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8EEFE3B14793AB01746AD849D53B083B_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8EEFE3B14793AB01746AD849D53B083B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8EEFE3B14793AB01746AD849D53B083B_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8EEFE3B14793AB01746AD849D53B083B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8EEFE3B14793AB01746AD849D53B083B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8EEFE3B14793AB01746AD849D53B083B" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_8EEFE3B14793AB01746AD849D53B083B" xlink:type="arc" />
    <link:label id="lab_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6_terseLabel_en-US" xlink:label="lab_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, termination period</link:label>
    <link:label id="lab_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6_label_en-US" xlink:label="lab_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:label id="lab_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6_documentation_en-US" xlink:label="lab_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_LesseeOperatingLeaseTerminationPeriod" xlink:label="loc_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6" xlink:to="lab_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_A4645AF3D3F3CFD1E754493CBD2D0FB3_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_A4645AF3D3F3CFD1E754493CBD2D0FB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_A4645AF3D3F3CFD1E754493CBD2D0FB3_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_A4645AF3D3F3CFD1E754493CBD2D0FB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A4645AF3D3F3CFD1E754493CBD2D0FB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_A4645AF3D3F3CFD1E754493CBD2D0FB3" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_A4645AF3D3F3CFD1E754493CBD2D0FB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2481038A9F271975DEEC493CBD2D94AA_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2481038A9F271975DEEC493CBD2D94AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2481038A9F271975DEEC493CBD2D94AA_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2481038A9F271975DEEC493CBD2D94AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2481038A9F271975DEEC493CBD2D94AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2481038A9F271975DEEC493CBD2D94AA" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2481038A9F271975DEEC493CBD2D94AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_3411F454F38AA9D50E1B3EEE3193EA2F_verboseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_3411F454F38AA9D50E1B3EEE3193EA2F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_3411F454F38AA9D50E1B3EEE3193EA2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_3411F454F38AA9D50E1B3EEE3193EA2F" xlink:to="lab_srt_ProductOrServiceAxis_3411F454F38AA9D50E1B3EEE3193EA2F" xlink:type="arc" />
    <link:label id="lab_ebs_ContractManufacturingMember_537661271A587D03F3BF3EEE319448C8_verboseLabel_en-US" xlink:label="lab_ebs_ContractManufacturingMember_537661271A587D03F3BF3EEE319448C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract manufacturing</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_537661271A587D03F3BF3EEE319448C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractManufacturingMember_537661271A587D03F3BF3EEE319448C8" xlink:to="lab_ebs_ContractManufacturingMember_537661271A587D03F3BF3EEE319448C8" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E" xlink:to="lab_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:to="lab_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:type="arc" />
    <link:label id="lab_country_US_E4ABEDFE2D629882264A3EEE319A5DBB_terseLabel_en-US" xlink:label="lab_country_US_E4ABEDFE2D629882264A3EEE319A5DBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Government</link:label>
    <link:label id="lab_country_US_E4ABEDFE2D629882264A3EEE319A5DBB_label_en-US" xlink:label="lab_country_US_E4ABEDFE2D629882264A3EEE319A5DBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_E4ABEDFE2D629882264A3EEE319A5DBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_E4ABEDFE2D629882264A3EEE319A5DBB" xlink:to="lab_country_US_E4ABEDFE2D629882264A3EEE319A5DBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_DA8F0273A4169A70D61E3EEE319BE401_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_DA8F0273A4169A70D61E3EEE319BE401" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S. Government</link:label>
    <link:label id="lab_us-gaap_NonUsMember_DA8F0273A4169A70D61E3EEE319BE401_label_en-US" xlink:label="lab_us-gaap_NonUsMember_DA8F0273A4169A70D61E3EEE319BE401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_DA8F0273A4169A70D61E3EEE319BE401" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_DA8F0273A4169A70D61E3EEE319BE401" xlink:to="lab_us-gaap_NonUsMember_DA8F0273A4169A70D61E3EEE319BE401" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B65AC27A1BA2697C7C0449ADB45073DB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B65AC27A1BA2697C7C0449ADB45073DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B65AC27A1BA2697C7C0449ADB45073DB_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B65AC27A1BA2697C7C0449ADB45073DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B65AC27A1BA2697C7C0449ADB45073DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B65AC27A1BA2697C7C0449ADB45073DB" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B65AC27A1BA2697C7C0449ADB45073DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_3A9788EE68B416C166FA49ADB45011FC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_3A9788EE68B416C166FA49ADB45011FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_3A9788EE68B416C166FA49ADB45011FC_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_3A9788EE68B416C166FA49ADB45011FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_3A9788EE68B416C166FA49ADB45011FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_3A9788EE68B416C166FA49ADB45011FC" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_3A9788EE68B416C166FA49ADB45011FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D1D0273CB7FEF5F1838F49ADB45009A3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D1D0273CB7FEF5F1838F49ADB45009A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred, equity interests issued and issuable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D1D0273CB7FEF5F1838F49ADB45009A3_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D1D0273CB7FEF5F1838F49ADB45009A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D1D0273CB7FEF5F1838F49ADB45009A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D1D0273CB7FEF5F1838F49ADB45009A3" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D1D0273CB7FEF5F1838F49ADB45009A3" xlink:type="arc" />
    <link:label id="lab_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624_terseLabel_en-US" xlink:label="lab_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lock-up period for adjustment of fair value</link:label>
    <link:label id="lab_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624_label_en-US" xlink:label="lab_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lock-up Period for Adjustment of Fair Value</link:label>
    <link:label id="lab_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624_documentation_en-US" xlink:label="lab_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The lock-up period considered for adjustment of fair value, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_LockUpPeriodForAdjustmentOfFairValue" xlink:label="loc_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624" xlink:to="lab_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_B7D6D6D9EC902822296749ADB4512947_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_B7D6D6D9EC902822296749ADB4512947" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_B7D6D6D9EC902822296749ADB4512947_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_B7D6D6D9EC902822296749ADB4512947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_B7D6D6D9EC902822296749ADB4512947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_B7D6D6D9EC902822296749ADB4512947" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_B7D6D6D9EC902822296749ADB4512947" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_437B8930D644B20551D7D849D37AA4A6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_437B8930D644B20551D7D849D37AA4A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_437B8930D644B20551D7D849D37AA4A6_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_437B8930D644B20551D7D849D37AA4A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_437B8930D644B20551D7D849D37AA4A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_437B8930D644B20551D7D849D37AA4A6" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_437B8930D644B20551D7D849D37AA4A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B00C654627F4FAD2715CD849D37A98AC_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B00C654627F4FAD2715CD849D37A98AC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B00C654627F4FAD2715CD849D37A98AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B00C654627F4FAD2715CD849D37A98AC" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B00C654627F4FAD2715CD849D37A98AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8D2A8E9CDA5C1BA7BE4BD849D558A84C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8D2A8E9CDA5C1BA7BE4BD849D558A84C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8D2A8E9CDA5C1BA7BE4BD849D558A84C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8D2A8E9CDA5C1BA7BE4BD849D558A84C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8D2A8E9CDA5C1BA7BE4BD849D558A84C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8D2A8E9CDA5C1BA7BE4BD849D558A84C" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8D2A8E9CDA5C1BA7BE4BD849D558A84C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_29125D7B9FB1AB9F1C2FD849D558B6DC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_29125D7B9FB1AB9F1C2FD849D558B6DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_29125D7B9FB1AB9F1C2FD849D558B6DC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_29125D7B9FB1AB9F1C2FD849D558B6DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_29125D7B9FB1AB9F1C2FD849D558B6DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_29125D7B9FB1AB9F1C2FD849D558B6DC" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_29125D7B9FB1AB9F1C2FD849D558B6DC" xlink:type="arc" />
    <link:label id="lab_ebs_ImpactOfBusinessAcquisitionsTableTextBlock_28A6330D86F92115CF65D849D5582FAD_terseLabel_en-US" xlink:label="lab_ebs_ImpactOfBusinessAcquisitionsTableTextBlock_28A6330D86F92115CF65D849D5582FAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of Business Acquisitions</link:label>
    <link:label id="lab_ebs_ImpactOfBusinessAcquisitionsTableTextBlock_28A6330D86F92115CF65D849D5582FAD_label_en-US" xlink:label="lab_ebs_ImpactOfBusinessAcquisitionsTableTextBlock_28A6330D86F92115CF65D849D5582FAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of Business Acquisitions [Table Text Block]</link:label>
    <link:label id="lab_ebs_ImpactOfBusinessAcquisitionsTableTextBlock_28A6330D86F92115CF65D849D5582FAD_documentation_en-US" xlink:label="lab_ebs_ImpactOfBusinessAcquisitionsTableTextBlock_28A6330D86F92115CF65D849D5582FAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of revenue and earnings of business acquisitions included in consolidated financial statements.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ImpactOfBusinessAcquisitionsTableTextBlock" xlink:label="loc_ebs_ImpactOfBusinessAcquisitionsTableTextBlock_28A6330D86F92115CF65D849D5582FAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ImpactOfBusinessAcquisitionsTableTextBlock_28A6330D86F92115CF65D849D5582FAD" xlink:to="lab_ebs_ImpactOfBusinessAcquisitionsTableTextBlock_28A6330D86F92115CF65D849D5582FAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_94056978FE7CA192A8E4D849D5179122_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_94056978FE7CA192A8E4D849D5179122" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_94056978FE7CA192A8E4D849D5179122_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_94056978FE7CA192A8E4D849D5179122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_94056978FE7CA192A8E4D849D5179122" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_94056978FE7CA192A8E4D849D5179122" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_94056978FE7CA192A8E4D849D5179122" xlink:type="arc" />
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E_terseLabel_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E_label_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long Term Debt Facility [Member]</link:label>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E_documentation_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Long Term Debt Facility [Member]</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_OtherLongTermDebtFacilityMember" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E" xlink:to="lab_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_267B55325F6285A988934DCE28949E31_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_267B55325F6285A988934DCE28949E31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_267B55325F6285A988934DCE28949E31_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_267B55325F6285A988934DCE28949E31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_267B55325F6285A988934DCE28949E31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_267B55325F6285A988934DCE28949E31" xlink:to="lab_us-gaap_LongTermDebt_267B55325F6285A988934DCE28949E31" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_CF7F79918C0F1725AAA04DCE2894F886_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_CF7F79918C0F1725AAA04DCE2894F886" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt, net of debt issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_CF7F79918C0F1725AAA04DCE2894F886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_CF7F79918C0F1725AAA04DCE2894F886" xlink:to="lab_us-gaap_LongTermDebtCurrent_CF7F79918C0F1725AAA04DCE2894F886" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_585D22DC2E8731131A224DCE28949885_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_585D22DC2E8731131A224DCE28949885" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_585D22DC2E8731131A224DCE28949885_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_585D22DC2E8731131A224DCE28949885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_585D22DC2E8731131A224DCE28949885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_585D22DC2E8731131A224DCE28949885" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_585D22DC2E8731131A224DCE28949885" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1C272F2A5DE9B9757DC9D849D3D7206F_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1C272F2A5DE9B9757DC9D849D3D7206F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1C272F2A5DE9B9757DC9D849D3D7206F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1C272F2A5DE9B9757DC9D849D3D7206F" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1C272F2A5DE9B9757DC9D849D3D7206F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_87F938EEB186F5634E26D849D3D71B03_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_87F938EEB186F5634E26D849D3D71B03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_87F938EEB186F5634E26D849D3D71B03_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_87F938EEB186F5634E26D849D3D71B03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_87F938EEB186F5634E26D849D3D71B03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_87F938EEB186F5634E26D849D3D71B03" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_87F938EEB186F5634E26D849D3D71B03" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8E3A997A120870C802F720CA657D8E74_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8E3A997A120870C802F720CA657D8E74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8E3A997A120870C802F720CA657D8E74_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8E3A997A120870C802F720CA657D8E74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8E3A997A120870C802F720CA657D8E74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8E3A997A120870C802F720CA657D8E74" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8E3A997A120870C802F720CA657D8E74" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_2804497F05504EB4573C20D6BEB811F2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_2804497F05504EB4573C20D6BEB811F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_2804497F05504EB4573C20D6BEB811F2_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_2804497F05504EB4573C20D6BEB811F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2804497F05504EB4573C20D6BEB811F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2804497F05504EB4573C20D6BEB811F2" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_2804497F05504EB4573C20D6BEB811F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_1BFE3C7CACA88739E3E020D6BEBA1612_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_1BFE3C7CACA88739E3E020D6BEBA1612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_1BFE3C7CACA88739E3E020D6BEBA1612_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_1BFE3C7CACA88739E3E020D6BEBA1612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1BFE3C7CACA88739E3E020D6BEBA1612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1BFE3C7CACA88739E3E020D6BEBA1612" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_1BFE3C7CACA88739E3E020D6BEBA1612" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_4AAE24DF930AC06C5D2620D6E8D969F8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_4AAE24DF930AC06C5D2620D6E8D969F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_4AAE24DF930AC06C5D2620D6E8D969F8_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_4AAE24DF930AC06C5D2620D6E8D969F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_4AAE24DF930AC06C5D2620D6E8D969F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_4AAE24DF930AC06C5D2620D6E8D969F8" xlink:to="lab_us-gaap_InterestRateSwapMember_4AAE24DF930AC06C5D2620D6E8D969F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_5C1C38A92AC252B90AD720CA657D9A10_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_5C1C38A92AC252B90AD720CA657D9A10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_5C1C38A92AC252B90AD720CA657D9A10_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_5C1C38A92AC252B90AD720CA657D9A10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_5C1C38A92AC252B90AD720CA657D9A10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_5C1C38A92AC252B90AD720CA657D9A10" xlink:to="lab_us-gaap_HedgingDesignationAxis_5C1C38A92AC252B90AD720CA657D9A10" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_15CB0AED88B100DB062720CA657D6536_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_15CB0AED88B100DB062720CA657D6536" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_15CB0AED88B100DB062720CA657D6536_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_15CB0AED88B100DB062720CA657D6536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_15CB0AED88B100DB062720CA657D6536" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_15CB0AED88B100DB062720CA657D6536" xlink:to="lab_us-gaap_HedgingDesignationDomain_15CB0AED88B100DB062720CA657D6536" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_FEA8DD1CAD94057A8C8020CA657EAC2F_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_FEA8DD1CAD94057A8C8020CA657EAC2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_FEA8DD1CAD94057A8C8020CA657EAC2F_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_FEA8DD1CAD94057A8C8020CA657EAC2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_FEA8DD1CAD94057A8C8020CA657EAC2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_FEA8DD1CAD94057A8C8020CA657EAC2F" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_FEA8DD1CAD94057A8C8020CA657EAC2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_B80C6CD40792532DB0C720CA657E239F_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_B80C6CD40792532DB0C720CA657E239F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_B80C6CD40792532DB0C720CA657E239F_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_B80C6CD40792532DB0C720CA657E239F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_B80C6CD40792532DB0C720CA657E239F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B80C6CD40792532DB0C720CA657E239F" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_B80C6CD40792532DB0C720CA657E239F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_7907F257E6296CCFA99F20CA657ED4CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsMember_16C31A8606B7F16FB68C20CA657EC65D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember_16C31A8606B7F16FB68C20CA657EC65D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_16C31A8606B7F16FB68C20CA657EC65D_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember_16C31A8606B7F16FB68C20CA657EC65D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_16C31A8606B7F16FB68C20CA657EC65D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember_16C31A8606B7F16FB68C20CA657EC65D" xlink:to="lab_us-gaap_OtherAssetsMember_16C31A8606B7F16FB68C20CA657EC65D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_710EF45ACEA9EDC936BC20CA657EB4AA_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember_710EF45ACEA9EDC936BC20CA657EB4AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_710EF45ACEA9EDC936BC20CA657EB4AA_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember_710EF45ACEA9EDC936BC20CA657EB4AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesMember" xlink:label="loc_us-gaap_OtherLiabilitiesMember_710EF45ACEA9EDC936BC20CA657EB4AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember_710EF45ACEA9EDC936BC20CA657EB4AA" xlink:to="lab_us-gaap_OtherLiabilitiesMember_710EF45ACEA9EDC936BC20CA657EB4AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_ACF4AB501F3AA608093120CA657F180B_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_ACF4AB501F3AA608093120CA657F180B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_ACF4AB501F3AA608093120CA657F180B_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_ACF4AB501F3AA608093120CA657F180B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ACF4AB501F3AA608093120CA657F180B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ACF4AB501F3AA608093120CA657F180B" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_ACF4AB501F3AA608093120CA657F180B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_2B7442801E6890EFB9BF20CA657F2ACE_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_2B7442801E6890EFB9BF20CA657F2ACE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_2B7442801E6890EFB9BF20CA657F2ACE_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_2B7442801E6890EFB9BF20CA657F2ACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2B7442801E6890EFB9BF20CA657F2ACE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_2B7442801E6890EFB9BF20CA657F2ACE" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_2B7442801E6890EFB9BF20CA657F2ACE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3B49ACA19B8658F1F65520CA657FAF26_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3B49ACA19B8658F1F65520CA657FAF26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3B49ACA19B8658F1F65520CA657FAF26_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3B49ACA19B8658F1F65520CA657FAF26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3B49ACA19B8658F1F65520CA657FAF26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3B49ACA19B8658F1F65520CA657FAF26" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3B49ACA19B8658F1F65520CA657FAF26" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_E94AB37129AF5AE7EB72D849D4ABB8AB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_E94AB37129AF5AE7EB72D849D4ABB8AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_E94AB37129AF5AE7EB72D849D4ABB8AB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_E94AB37129AF5AE7EB72D849D4ABB8AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_E94AB37129AF5AE7EB72D849D4ABB8AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_E94AB37129AF5AE7EB72D849D4ABB8AB" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_E94AB37129AF5AE7EB72D849D4ABB8AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_5B00F642E42C645033D42F38D6A5EBED_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld_5B00F642E42C645033D42F38D6A5EBED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Instruments</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_5B00F642E42C645033D42F38D6A5EBED_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld_5B00F642E42C645033D42F38D6A5EBED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_5B00F642E42C645033D42F38D6A5EBED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld_5B00F642E42C645033D42F38D6A5EBED" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld_5B00F642E42C645033D42F38D6A5EBED" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_AC669F8D55E973CD12862F38D6A565D2_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_AC669F8D55E973CD12862F38D6A565D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_AC669F8D55E973CD12862F38D6A565D2_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_AC669F8D55E973CD12862F38D6A565D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_AC669F8D55E973CD12862F38D6A565D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_AC669F8D55E973CD12862F38D6A565D2" xlink:to="lab_invest_DerivativeNotionalAmount_AC669F8D55E973CD12862F38D6A565D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A" xlink:to="lab_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowHedgingMember_CF751B8252880F4CD7592F38D696BB55_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_CF751B8252880F4CD7592F38D696BB55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_CF751B8252880F4CD7592F38D696BB55_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_CF751B8252880F4CD7592F38D696BB55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_CF751B8252880F4CD7592F38D696BB55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember_CF751B8252880F4CD7592F38D696BB55" xlink:to="lab_us-gaap_CashFlowHedgingMember_CF751B8252880F4CD7592F38D696BB55" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseMember_F453CD76102ECBA3020F2F38D697D72C_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember_F453CD76102ECBA3020F2F38D697D72C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_F453CD76102ECBA3020F2F38D697D72C_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember_F453CD76102ECBA3020F2F38D697D72C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaap_InterestExpenseMember_F453CD76102ECBA3020F2F38D697D72C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember_F453CD76102ECBA3020F2F38D697D72C" xlink:to="lab_us-gaap_InterestExpenseMember_F453CD76102ECBA3020F2F38D697D72C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_5C19E5799221CDFD03E62F38D698D2F1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_5C19E5799221CDFD03E62F38D698D2F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gain/(Loss) Recognized in OCI on Derivative</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_5C19E5799221CDFD03E62F38D698D2F1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_5C19E5799221CDFD03E62F38D698D2F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_5C19E5799221CDFD03E62F38D698D2F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_5C19E5799221CDFD03E62F38D698D2F1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_5C19E5799221CDFD03E62F38D698D2F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B926E7A619CBAB5D87222F38D69860A6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B926E7A619CBAB5D87222F38D69860A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B926E7A619CBAB5D87222F38D69860A6_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B926E7A619CBAB5D87222F38D69860A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B926E7A619CBAB5D87222F38D69860A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B926E7A619CBAB5D87222F38D69860A6" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B926E7A619CBAB5D87222F38D69860A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_AE8907DA146CBBC768722F38D6A858CA_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_AE8907DA146CBBC768722F38D6A858CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_AE8907DA146CBBC768722F38D6A858CA_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_AE8907DA146CBBC768722F38D6A858CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_AE8907DA146CBBC768722F38D6A858CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_AE8907DA146CBBC768722F38D6A858CA" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_AE8907DA146CBBC768722F38D6A858CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_3729CD7CF2D17CE5E178D849D50FE04A_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_3729CD7CF2D17CE5E178D849D50FE04A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_3729CD7CF2D17CE5E178D849D50FE04A_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_3729CD7CF2D17CE5E178D849D50FE04A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_3729CD7CF2D17CE5E178D849D50FE04A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_3729CD7CF2D17CE5E178D849D50FE04A" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_3729CD7CF2D17CE5E178D849D50FE04A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C60D23EDD38AD8F76863205677C61BBB_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C60D23EDD38AD8F76863205677C61BBB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C60D23EDD38AD8F76863205677C61BBB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C60D23EDD38AD8F76863205677C61BBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C60D23EDD38AD8F76863205677C61BBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C60D23EDD38AD8F76863205677C61BBB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_C60D23EDD38AD8F76863205677C61BBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2B23AF730C46C4C32E88499D6D25E8BB_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_2B23AF730C46C4C32E88499D6D25E8BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2B23AF730C46C4C32E88499D6D25E8BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_2B23AF730C46C4C32E88499D6D25E8BB" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_2B23AF730C46C4C32E88499D6D25E8BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_001539F5F2DD283C9C58D849D32F29B2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_001539F5F2DD283C9C58D849D32F29B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_001539F5F2DD283C9C58D849D32F29B2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_001539F5F2DD283C9C58D849D32F29B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_001539F5F2DD283C9C58D849D32F29B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_001539F5F2DD283C9C58D849D32F29B2" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_001539F5F2DD283C9C58D849D32F29B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_172943AD8EED24AA4017205676E19435_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost_172943AD8EED24AA4017205676E19435" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_172943AD8EED24AA4017205676E19435_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost_172943AD8EED24AA4017205676E19435" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_172943AD8EED24AA4017205676E19435" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost_172943AD8EED24AA4017205676E19435" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost_172943AD8EED24AA4017205676E19435" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_C45C294705969D1D542D205676E2E270_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_C45C294705969D1D542D205676E2E270" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expected return on plan assets, net of expenses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_C45C294705969D1D542D205676E2E270_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_C45C294705969D1D542D205676E2E270" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_C45C294705969D1D542D205676E2E270" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_C45C294705969D1D542D205676E2E270" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_C45C294705969D1D542D205676E2E270" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8E80EAE8BBDE74812FD6205676E2DE5C_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8E80EAE8BBDE74812FD6205676E2DE5C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total pension expense</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8E80EAE8BBDE74812FD6205676E2DE5C_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8E80EAE8BBDE74812FD6205676E2DE5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8E80EAE8BBDE74812FD6205676E2DE5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8E80EAE8BBDE74812FD6205676E2DE5C" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8E80EAE8BBDE74812FD6205676E2DE5C" xlink:type="arc" />
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD_terseLabel_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD_label_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD_documentation_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD" xlink:to="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_9BA42E17FE7B4BFEDC59E6BB02917D09_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_9BA42E17FE7B4BFEDC59E6BB02917D09" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_9BA42E17FE7B4BFEDC59E6BB02917D09_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_9BA42E17FE7B4BFEDC59E6BB02917D09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9BA42E17FE7B4BFEDC59E6BB02917D09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_9BA42E17FE7B4BFEDC59E6BB02917D09" xlink:to="lab_us-gaap_ContractWithCustomerLiability_9BA42E17FE7B4BFEDC59E6BB02917D09" xlink:type="arc" />
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_4E4CB9035F681132DDDAE6BB02918FC0_terseLabel_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions_4E4CB9035F681132DDDAE6BB02918FC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferral of revenue</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_4E4CB9035F681132DDDAE6BB02918FC0_label_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions_4E4CB9035F681132DDDAE6BB02918FC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Additions</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_4E4CB9035F681132DDDAE6BB02918FC0_documentation_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions_4E4CB9035F681132DDDAE6BB02918FC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.</link:label>
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractWithCustomerLiabilityAdditions" xlink:label="loc_ebs_ContractWithCustomerLiabilityAdditions_4E4CB9035F681132DDDAE6BB02918FC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractWithCustomerLiabilityAdditions_4E4CB9035F681132DDDAE6BB02918FC0" xlink:to="lab_ebs_ContractWithCustomerLiabilityAdditions_4E4CB9035F681132DDDAE6BB02918FC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_184B5BF4547B7CFE5ABFE6BB0291E983_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_184B5BF4547B7CFE5ABFE6BB0291E983" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_184B5BF4547B7CFE5ABFE6BB0291E983_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_184B5BF4547B7CFE5ABFE6BB0291E983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_184B5BF4547B7CFE5ABFE6BB0291E983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_184B5BF4547B7CFE5ABFE6BB0291E983" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_184B5BF4547B7CFE5ABFE6BB0291E983" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_458BA953277EC0F9D70EE6BB0291A788_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_458BA953277EC0F9D70EE6BB0291A788" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_458BA953277EC0F9D70EE6BB0291A788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_458BA953277EC0F9D70EE6BB0291A788" xlink:to="lab_us-gaap_ContractWithCustomerLiability_458BA953277EC0F9D70EE6BB0291A788" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_3E3350699FFBC31C75BF20CA8F414826_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_3E3350699FFBC31C75BF20CA8F414826" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_3E3350699FFBC31C75BF20CA8F414826_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_3E3350699FFBC31C75BF20CA8F414826" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_3E3350699FFBC31C75BF20CA8F414826" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_3E3350699FFBC31C75BF20CA8F414826" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_3E3350699FFBC31C75BF20CA8F414826" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0AB82CCA58ACE4AB6BDC20D21824F807_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0AB82CCA58ACE4AB6BDC20D21824F807" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0AB82CCA58ACE4AB6BDC20D21824F807_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0AB82CCA58ACE4AB6BDC20D21824F807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0AB82CCA58ACE4AB6BDC20D21824F807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0AB82CCA58ACE4AB6BDC20D21824F807" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0AB82CCA58ACE4AB6BDC20D21824F807" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_058CA819160920CA779C20D32CEE76D7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_058CA819160920CA779C20D32CEE76D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_058CA819160920CA779C20D32CEE76D7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_058CA819160920CA779C20D32CEE76D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_058CA819160920CA779C20D32CEE76D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_058CA819160920CA779C20D32CEE76D7" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_058CA819160920CA779C20D32CEE76D7" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ebs-20190630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Acquisitions" xlink:href="ebs-20190630.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails" xlink:href="ebs-20190630.xsd#AcquisitionsAdaptNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails" xlink:href="ebs-20190630.xsd#AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails" xlink:href="ebs-20190630.xsd#AcquisitionsAdaptTotalPurchasePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails" xlink:href="ebs-20190630.xsd#AcquisitionsImpactOfBusinessAcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails" xlink:href="ebs-20190630.xsd#AcquisitionsPaxvaxNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails" xlink:href="ebs-20190630.xsd#AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AcquisitionsTables" xlink:href="ebs-20190630.xsd#AcquisitionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" xlink:href="ebs-20190630.xsd#BasisOfPresentationAndPrinciplesOfConsolidation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:href="ebs-20190630.xsd#BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:href="ebs-20190630.xsd#BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Business" xlink:href="ebs-20190630.xsd#Business" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BusinessDetails" xlink:href="ebs-20190630.xsd#BusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CommitmentsAndContingencies" xlink:href="ebs-20190630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="ebs-20190630.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ebs-20190630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="ebs-20190630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfComprehensiveLossIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ebs-20190630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsideration" xlink:href="ebs-20190630.xsd#ContingentConsideration" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationDetails" xlink:href="ebs-20190630.xsd#ContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ContingentConsiderationTables" xlink:href="ebs-20190630.xsd#ContingentConsiderationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CoverPage" xlink:href="ebs-20190630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Debt" xlink:href="ebs-20190630.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails" xlink:href="ebs-20190630.xsd#DebtDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:href="ebs-20190630.xsd#DebtScheduleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTables" xlink:href="ebs-20190630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DefinedBenefitPlan" xlink:href="ebs-20190630.xsd#DefinedBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails" xlink:href="ebs-20190630.xsd#DefinedBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DefinedBenefitPlanTables" xlink:href="ebs-20190630.xsd#DefinedBenefitPlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivities" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" xlink:href="ebs-20190630.xsd#DerivativeInstrumentsAndHedgingActivitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncomeTaxes" xlink:href="ebs-20190630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncomeTaxesDetails" xlink:href="ebs-20190630.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssets" xlink:href="ebs-20190630.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails" xlink:href="ebs-20190630.xsd#IntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="ebs-20190630.xsd#IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleAssetsTables" xlink:href="ebs-20190630.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Inventories" xlink:href="ebs-20190630.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesDetails" xlink:href="ebs-20190630.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesTables" xlink:href="ebs-20190630.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Leases" xlink:href="ebs-20190630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:href="ebs-20190630.xsd#LeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:href="ebs-20190630.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:href="ebs-20190630.xsd#LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesTables" xlink:href="ebs-20190630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LossEarningsPerShare" xlink:href="ebs-20190630.xsd#LossEarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LossEarningsPerShareDetails" xlink:href="ebs-20190630.xsd#LossEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LossEarningsPerShareTables" xlink:href="ebs-20190630.xsd#LossEarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment" xlink:href="ebs-20190630.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails" xlink:href="ebs-20190630.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables" xlink:href="ebs-20190630.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:href="ebs-20190630.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:href="ebs-20190630.xsd#RevenueRecognitionAccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:href="ebs-20190630.xsd#RevenueRecognitionContractLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" xlink:href="ebs-20190630.xsd#RevenueRecognitionDisaggregationOfRevenueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ebs-20190630.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:href="ebs-20190630.xsd#RevenueRecognitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensation" xlink:href="ebs-20190630.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails" xlink:href="ebs-20190630.xsd#ShareBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SupplementalInformation" xlink:href="ebs-20190630.xsd#SupplementalInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SupplementalInformationDetails" xlink:href="ebs-20190630.xsd#SupplementalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SupplementalInformationTables" xlink:href="ebs-20190630.xsd#SupplementalInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_0AFA413A91CFA71F4AA2D849D4ABC9B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_E94AB37129AF5AE7EB72D849D4ABB8AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0AFA413A91CFA71F4AA2D849D4ABC9B4" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_E94AB37129AF5AE7EB72D849D4ABB8AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5A5F2E17A7FE123911C849ADB44C6084" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5A5F2E17A7FE123911C849ADB44C6084" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_96EB7281007F32A5A81149ADB44D2449" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:to="loc_srt_RestatementAxis_96EB7281007F32A5A81149ADB44D2449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_190A7C586FE00A29BA7E49ADB44D0172" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_96EB7281007F32A5A81149ADB44D2449" xlink:to="loc_srt_RestatementDomain_190A7C586FE00A29BA7E49ADB44D0172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_FF9DA3F32F9C7486266A49ADB44D93BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_190A7C586FE00A29BA7E49ADB44D0172" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_FF9DA3F32F9C7486266A49ADB44D93BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5CFA91D1E2044D0FE88249ADB44DC33F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5CFA91D1E2044D0FE88249ADB44DC33F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A777488AD2BAB612CCBD49ADB44EBB8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5CFA91D1E2044D0FE88249ADB44DC33F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A777488AD2BAB612CCBD49ADB44EBB8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9711F94ACCF299F348C549ADB44E8B06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A777488AD2BAB612CCBD49ADB44EBB8A" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9711F94ACCF299F348C549ADB44E8B06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_82EF094D398FCDA2B62449ADB44E738B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:to="loc_srt_RangeAxis_82EF094D398FCDA2B62449ADB44E738B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D47A2179F6F77503B27A49ADB44E71E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_82EF094D398FCDA2B62449ADB44E738B" xlink:to="loc_srt_RangeMember_D47A2179F6F77503B27A49ADB44E71E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D4426059F6229585828949ADB44F88CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D47A2179F6F77503B27A49ADB44E71E1" xlink:to="loc_srt_MaximumMember_D4426059F6229585828949ADB44F88CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B2E42849D39F67D06A0C49ADB44FB02E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B2E42849D39F67D06A0C49ADB44FB02E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB4CAFF4A951807A3B1649ADB44F5157" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B2E42849D39F67D06A0C49ADB44FB02E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB4CAFF4A951807A3B1649ADB44F5157" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AdaptPharmaMember" xlink:label="loc_ebs_AdaptPharmaMember_91FE3FEB5229677D22B649ADB44F2189" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB4CAFF4A951807A3B1649ADB44F5157" xlink:to="loc_ebs_AdaptPharmaMember_91FE3FEB5229677D22B649ADB44F2189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B6492F3D4816C1CBB07149ADB44C620A" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_NumberOfEmployees" xlink:label="loc_ebs_NumberOfEmployees_615C1608393956ADE87949ADB4503506" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_ebs_NumberOfEmployees_615C1608393956ADE87949ADB4503506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B65AC27A1BA2697C7C0449ADB45073DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B65AC27A1BA2697C7C0449ADB45073DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_3A9788EE68B416C166FA49ADB45011FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_3A9788EE68B416C166FA49ADB45011FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D1D0273CB7FEF5F1838F49ADB45009A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_D1D0273CB7FEF5F1838F49ADB45009A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A7AFD0A6A713EB2A09B349ADB451AD18" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_A7AFD0A6A713EB2A09B349ADB451AD18" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_LockUpPeriodForAdjustmentOfFairValue" xlink:label="loc_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_ebs_LockUpPeriodForAdjustmentOfFairValue_9F3BD22C0BD70D6287E749ADB4516624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_FA7CDC1299EFA7BF245849ADB451DBE9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_FA7CDC1299EFA7BF245849ADB451DBE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_B7D6D6D9EC902822296749ADB4512947" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_B7D6D6D9EC902822296749ADB4512947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E9A9A0A666C67D836FBF49ADB4519AD0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_E9A9A0A666C67D836FBF49ADB4519AD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_28FA85139870F6578D0949ADB4519320" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_28FA85139870F6578D0949ADB4519320" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PresentValueDiscountRate" xlink:label="loc_ebs_PresentValueDiscountRate_33B8ABF1F6E4673B283749ADB4526E64" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_ebs_PresentValueDiscountRate_33B8ABF1F6E4673B283749ADB4526E64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_03B42FD20E7C6DD3ED5849ADB452C0D5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_03B42FD20E7C6DD3ED5849ADB452C0D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_6AE6AFFB3A2EB107880549ADB452D48E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ED55B0F910108E3000749ADB450C99C" xlink:to="loc_us-gaap_Goodwill_6AE6AFFB3A2EB107880549ADB452D48E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_71CE87F2667FFFB803FB493CBD20D3D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2FD53AF24947C417819C493CBD21E42F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_71CE87F2667FFFB803FB493CBD20D3D3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2FD53AF24947C417819C493CBD21E42F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A50792DA873573B29800493CBD21B785" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2FD53AF24947C417819C493CBD21E42F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A50792DA873573B29800493CBD21B785" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D387C811B4FB3C0EA7A0493CBD210CFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A50792DA873573B29800493CBD21B785" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D387C811B4FB3C0EA7A0493CBD210CFC" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AdaptPharmaMember" xlink:label="loc_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D387C811B4FB3C0EA7A0493CBD210CFC" xlink:to="loc_ebs_AdaptPharmaMember_3CFDECD42DF2ED59FE22493CBD210FC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_97EF82C64873128B3D26493CBD22507B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2FD53AF24947C417819C493CBD21E42F" xlink:to="loc_srt_RestatementAxis_97EF82C64873128B3D26493CBD22507B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_59053682F1057F0616A9493CBD228273" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_97EF82C64873128B3D26493CBD22507B" xlink:to="loc_srt_RestatementDomain_59053682F1057F0616A9493CBD228273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_881D0B701A86DDEB861C493CBD226776" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_59053682F1057F0616A9493CBD228273" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_881D0B701A86DDEB861C493CBD226776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_778CE49F9A48286C687D493CBD220C70" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2FD53AF24947C417819C493CBD21E42F" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_778CE49F9A48286C687D493CBD220C70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_778CE49F9A48286C687D493CBD220C70" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_84604ABF98FBA41543E5493CBD230A54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_84604ABF98FBA41543E5493CBD230A54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9A8FDC7C69E97F6E65B6493CBD2319EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9A8FDC7C69E97F6E65B6493CBD2319EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_B530DE03BC5CEADAD35D493CBD23215B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_B530DE03BC5CEADAD35D493CBD23215B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_D4FCCBF7A1E4BC218C13493CBD249AE1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_D4FCCBF7A1E4BC218C13493CBD249AE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_E84055513B5F8E98FC96493CBD2417CD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_E84055513B5F8E98FC96493CBD2417CD" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" xlink:label="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_B40CF74457EEE846E69C493CBD2429BF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_B40CF74457EEE846E69C493CBD2429BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_1CE49621DA7208B0799F493CBD24FEF1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_1CE49621DA7208B0799F493CBD24FEF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_BE9B303FF722592D3BAC493CBD25B21A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_BE9B303FF722592D3BAC493CBD25B21A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1509A1A4AED4C6764333493CBD253DBA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1509A1A4AED4C6764333493CBD253DBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_91E2E16CACBA790D94F2493CBD250DE0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_91E2E16CACBA790D94F2493CBD250DE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3E1B21928FD8E20E164D493CBD25794E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_Goodwill_3E1B21928FD8E20E164D493CBD25794E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7145C6735FD5EF0BACA9493CBD25AD9F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7145C6735FD5EF0BACA9493CBD25AD9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_711387D11E0EF796CA82493CBD237DA8" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:to="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_54E11EF9251DB8BC8F2C493CBD246C69" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:to="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent_ECEEB04FF9245C83D9FD493CBD2408B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_B98CEC0B00FF2AA417C6495AC18A8ABC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_B98CEC0B00FF2AA417C6495AC18A8ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_B76ABB8FB04AACA25DAC495DD17D26DD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_B76ABB8FB04AACA25DAC495DD17D26DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7D5CEFE9F324F29C9AC1493CBD2696C8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_879BED364D6B079647E24962D369D05B" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7D5CEFE9F324F29C9AC1493CBD2696C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C59501FF5F558BAA1394493CBD2A2F8D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE3A80555B935C0AB1C1493CBD2BD532" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C59501FF5F558BAA1394493CBD2A2F8D" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE3A80555B935C0AB1C1493CBD2BD532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2E4D30CAA15DB30B6571493CBD2B04D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE3A80555B935C0AB1C1493CBD2BD532" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2E4D30CAA15DB30B6571493CBD2B04D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E9865182283B5588EAC8493CBD2B8935" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2E4D30CAA15DB30B6571493CBD2B04D4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E9865182283B5588EAC8493CBD2B8935" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AdaptPharmaMember" xlink:label="loc_ebs_AdaptPharmaMember_628FC6B523A127ED296C493CBD2B0D88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E9865182283B5588EAC8493CBD2B8935" xlink:to="loc_ebs_AdaptPharmaMember_628FC6B523A127ED296C493CBD2B0D88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_37BCB6003E103E32F408493CBD2C1B64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE3A80555B935C0AB1C1493CBD2BD532" xlink:to="loc_srt_RestatementAxis_37BCB6003E103E32F408493CBD2C1B64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_6DC736B92B9B9B5E467D493CBD2CDF79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_37BCB6003E103E32F408493CBD2C1B64" xlink:to="loc_srt_RestatementDomain_6DC736B92B9B9B5E467D493CBD2CDF79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_3BE609142CCB21BEBEF0493CBD2CA03C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_6DC736B92B9B9B5E467D493CBD2CDF79" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_3BE609142CCB21BEBEF0493CBD2CA03C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_90C910FAC29B39DA6B8F493CBD2C3234" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE3A80555B935C0AB1C1493CBD2BD532" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_90C910FAC29B39DA6B8F493CBD2C3234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_A4645AF3D3F3CFD1E754493CBD2D0FB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90C910FAC29B39DA6B8F493CBD2C3234" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_A4645AF3D3F3CFD1E754493CBD2D0FB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2481038A9F271975DEEC493CBD2D94AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90C910FAC29B39DA6B8F493CBD2C3234" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2481038A9F271975DEEC493CBD2D94AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_54B31425AE51B24341DF493CBD2D3914" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90C910FAC29B39DA6B8F493CBD2C3234" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_54B31425AE51B24341DF493CBD2D3914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_68C81610150D2FFE37B8493CBD2D3534" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_90C910FAC29B39DA6B8F493CBD2C3234" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_68C81610150D2FFE37B8493CBD2D3534" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2FFE07984D34A0FBFDA3205677DA3A2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A6BB2E05EE945846F3C205677DAC9F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2FFE07984D34A0FBFDA3205677DA3A2F" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A6BB2E05EE945846F3C205677DAC9F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_39A3DFD7384A6B613ACA205677DA08A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A6BB2E05EE945846F3C205677DAC9F5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_39A3DFD7384A6B613ACA205677DA08A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33AE0CFA2562FDFF4FC5205677DBA744" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_39A3DFD7384A6B613ACA205677DA08A6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33AE0CFA2562FDFF4FC5205677DBA744" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AdaptAndPaxVaxMember" xlink:label="loc_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_33AE0CFA2562FDFF4FC5205677DBA744" xlink:to="loc_ebs_AdaptAndPaxVaxMember_23A1A51B5B5F1225ACDA205677DBD153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_51D216E6F109471A4376205677DB6BEC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A6BB2E05EE945846F3C205677DAC9F5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_51D216E6F109471A4376205677DB6BEC" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_NumberOfBusinessAcquisitions" xlink:label="loc_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_51D216E6F109471A4376205677DB6BEC" xlink:to="loc_ebs_NumberOfBusinessAcquisitions_154529C4DD105F8924EC205677DB465D" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ImpactOfBusinessAcquisitionsAbstract" xlink:label="loc_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_51D216E6F109471A4376205677DB6BEC" xlink:to="loc_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8D89EDD31C13B9DEB09F205677DC0E1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8D89EDD31C13B9DEB09F205677DC0E1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_4AE35CA614946F231B1E205677DCDABF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ImpactOfBusinessAcquisitionsAbstract_1C6E4044C44A8E9923B8205677DC4623" xlink:to="loc_us-gaap_OperatingIncomeLoss_4AE35CA614946F231B1E205677DCDABF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_CA49DCB7817526B31D02D849D612BB19" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E95F32B56ACC18CA8918D849D612584A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_CA49DCB7817526B31D02D849D612BB19" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E95F32B56ACC18CA8918D849D612584A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E95F32B56ACC18CA8918D849D612584A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F8175889E0E77A7E7605D849D613C273" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6F93CECCA10D30D57E45D849D614A582" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_6F93CECCA10D30D57E45D849D614A582" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_VivotifMember" xlink:label="loc_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:to="loc_ebs_VivotifMember_635E45B606CA5F89F453D849D614A62E" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_VaxchoraMember" xlink:label="loc_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_EA47E2E5837DF3F516ECD849D613D4A4" xlink:to="loc_ebs_VaxchoraMember_79FD42E963E1F183B7C7D849D61400DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0D2E15560694BDBDD524D849D6140E04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E95F32B56ACC18CA8918D849D612584A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0D2E15560694BDBDD524D849D6140E04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0654AA7A99F194F8B5D7D849D615D1BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0D2E15560694BDBDD524D849D6140E04" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0654AA7A99F194F8B5D7D849D615D1BA" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PaxVaxMember" xlink:label="loc_ebs_PaxVaxMember_B66AC5DCDB5BEF0C2B69D849D6152D45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0654AA7A99F194F8B5D7D849D615D1BA" xlink:to="loc_ebs_PaxVaxMember_B66AC5DCDB5BEF0C2B69D849D6152D45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E95F32B56ACC18CA8918D849D612584A" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_NumberOfEmployees" xlink:label="loc_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_ebs_NumberOfEmployees_7C342BBE1ABBC5343303D849D615EC36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B3057A07E9F3D537F4AED849D616954A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B3057A07E9F3D537F4AED849D616954A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_24C27871FCBBF30867DED849D616DFCD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_24C27871FCBBF30867DED849D616DFCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_75390C3C0551FAFF0D11D849D61667BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_75390C3C0551FAFF0D11D849D61667BD" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PresentValueDiscountRate" xlink:label="loc_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_ebs_PresentValueDiscountRate_B1D6744EC7606A46BBD8D849D6163261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_A98EBF9EBD9AFF151359D849D616D0AC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B4FF575F1005D5A3413D849D615AC21" xlink:to="loc_us-gaap_Goodwill_A98EBF9EBD9AFF151359D849D616D0AC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_205DBDFD3057DB51C645493CBD0BF193" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE8E3C339305B9EEC826493CBD0B0B6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_205DBDFD3057DB51C645493CBD0BF193" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE8E3C339305B9EEC826493CBD0B0B6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_EF82BCD1C2D25B76B9B7493CBD0B483C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE8E3C339305B9EEC826493CBD0B0B6E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_EF82BCD1C2D25B76B9B7493CBD0B483C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E468CF582F04C67FA62C493CBD0CEEC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_EF82BCD1C2D25B76B9B7493CBD0B483C" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E468CF582F04C67FA62C493CBD0CEEC8" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PaxVaxMember" xlink:label="loc_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E468CF582F04C67FA62C493CBD0CEEC8" xlink:to="loc_ebs_PaxVaxMember_886250FE07EEFA2579D4493CBD0CBE31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE8E3C339305B9EEC826493CBD0B0B6E" xlink:to="loc_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_8D91900240C1F09A63BA493CBD0C30B6" xlink:to="loc_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_B80235663B0D5CDCA203493CBD0D3E25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_82C5AA4593D074B5DBAF493CBD0C619C" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_B80235663B0D5CDCA203493CBD0D3E25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_A30FE185C635C579E194493CBD0D0B42" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FE8E3C339305B9EEC826493CBD0B0B6E" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_A30FE185C635C579E194493CBD0D0B42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_A30FE185C635C579E194493CBD0D0B42" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C5FE8142A70AB354650E493CBD0DBC17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_C5FE8142A70AB354650E493CBD0DBC17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_284E689CF5F83D17E8ED493CBD0E8E8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_284E689CF5F83D17E8ED493CBD0E8E8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6EBE1955007E2B674E40493CBD0E02C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6EBE1955007E2B674E40493CBD0E02C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1438892828F9D2390D5B493CBD0ED79F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_1438892828F9D2390D5B493CBD0ED79F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_A611E3758EE0DCE7D0B4493CBD0E4D08" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_A611E3758EE0DCE7D0B4493CBD0E4D08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_59616110BFF9734CCB0C493CBD0E75BA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_59616110BFF9734CCB0C493CBD0E75BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_95213AD4903B0BB3E5ED493CBD0EC663" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_95213AD4903B0BB3E5ED493CBD0EC663" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities" xlink:label="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities_6D95B60032C6E13C7A92493CBD0FF11F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92835BFC2C859A8BB4C493CBD0F385C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A92835BFC2C859A8BB4C493CBD0F385C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823EF9FAE8C7267C7156493CBD0F4893" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823EF9FAE8C7267C7156493CBD0F4893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A7C9A22C38080FF3B6EE493CBD0F05B0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A7C9A22C38080FF3B6EE493CBD0F05B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4886872206C70BE213A7493CBD101695" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_Goodwill_4886872206C70BE213A7493CBD101695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B2EC7757ADC88305215F493CBD10ADEE" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_B2EC7757ADC88305215F493CBD10ADEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract_FAF34DB7A9389AD8B226493CBD0D5C85" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:to="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities_AE7DCCA1F064130673D3493CBD0F44A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_D0436772963D7FF737A149540EFE7120" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod_D0436772963D7FF737A149540EFE7120" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets" xlink:label="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:to="loc_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets_C39BE5ADA5D0B9F3575B493CBD0FC1A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_9BB2080D607CB401E10849547B341491" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_9BB2080D607CB401E10849547B341491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7B8F342BA8651501B8424958D3284217" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract_D81CD7D2B279D5C6B5004955F065F311" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_7B8F342BA8651501B8424958D3284217" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_E0BFBDB776AB2082293FD849D557D278" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8D2A8E9CDA5C1BA7BE4BD849D558A84C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_E0BFBDB776AB2082293FD849D557D278" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8D2A8E9CDA5C1BA7BE4BD849D558A84C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_29125D7B9FB1AB9F1C2FD849D558B6DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_E0BFBDB776AB2082293FD849D557D278" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_29125D7B9FB1AB9F1C2FD849D558B6DC" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ImpactOfBusinessAcquisitionsTableTextBlock" xlink:label="loc_ebs_ImpactOfBusinessAcquisitionsTableTextBlock_28A6330D86F92115CF65D849D5582FAD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_E0BFBDB776AB2082293FD849D557D278" xlink:to="loc_ebs_ImpactOfBusinessAcquisitionsTableTextBlock_28A6330D86F92115CF65D849D5582FAD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0DA786C292A015C265ECD849D5297891" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_F7DCACBFB935145F564FD849D5291C98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0DA786C292A015C265ECD849D5297891" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_F7DCACBFB935145F564FD849D5291C98" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_23A4D991A6EA68ACCB14D849D433E20E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23A4D991A6EA68ACCB14D849D433E20E" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5C7176DF979BE7467573D849D4340D17" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_710BB0C30C1D77AA0DB1D849D4359CE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8E1177E88FA7102C8C8AD849D43484F1" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_710BB0C30C1D77AA0DB1D849D4359CE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_FDFBF8F5DC04DC635CD7D849D434EC16" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_EAFAC73C1E95447BFEEDD849D4350714" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_EAFAC73C1E95447BFEEDD849D4350714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_15401EA82B2E68B540F2D849D435E448" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_BF116FEB6EBB7DCFEC41D849D4350800" xlink:to="loc_us-gaap_OperatingLeaseLiability_15401EA82B2E68B540F2D849D435E448" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0AC5A0FA47143F018EE4D849D4B4F5D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_54EC51DA33B71166565CD849D4B497C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0AC5A0FA47143F018EE4D849D4B4F5D6" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_54EC51DA33B71166565CD849D4B497C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BA73BBB82A54F98DEB2D849D4B5CF1C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0AC5A0FA47143F018EE4D849D4B4F5D6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BA73BBB82A54F98DEB2D849D4B5CF1C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Business" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_969BB341FE4EBB0F68CFD849D60E9779" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_17E4E52CEC1682971BFBD849D60E0538" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_969BB341FE4EBB0F68CFD849D60E9779" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_17E4E52CEC1682971BFBD849D60E0538" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B7533BEBAAF0CB5E572CD849D4A4979E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8BDDB64360359E1303B7D849D4A45BF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B7533BEBAAF0CB5E572CD849D4A4979E" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8BDDB64360359E1303B7D849D4A45BF7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_81F7BDA72DC6B69D2C28D849D50F4703" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_3729CD7CF2D17CE5E178D849D50FE04A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_81F7BDA72DC6B69D2C28D849D50F4703" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_3729CD7CF2D17CE5E178D849D50FE04A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_569B9295EFC759084EBBD849D43DF247" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_569B9295EFC759084EBBD849D43DF247" xlink:to="loc_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D" xlink:to="loc_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_3EDFF28973CD9CD07327D849D43EF3C0" xlink:to="loc_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ShareholderClassActionLawsuitMember" xlink:label="loc_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_E8D482669259004B6B44D849D43E1C70" xlink:to="loc_ebs_ShareholderClassActionLawsuitMember_6CB5EF53D1789A2BA7C7D849D43E3CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_95C6878B244DD7689E46D849D43D275D" xlink:to="loc_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_A50E9B37733E5BB40CB6D849D43F19AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_425F630E15BB552A54F3D849D43F0566" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_A50E9B37733E5BB40CB6D849D43F19AA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_A171737A991FEE2208D44DCE29EE7BEA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A171737A991FEE2208D44DCE29EE7BEA" xlink:to="loc_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:to="loc_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A1C20824B31138F6F8494DCE29EF312C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A1C20824B31138F6F8494DCE29EF312C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_09BFD731A5FB9032F38B4DCE29F02F8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_09BFD731A5FB9032F38B4DCE29F02F8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_D87110AD8329D20F1CEB4DCE29F0D195" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_D87110AD8329D20F1CEB4DCE29F0D195" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_AE41BA2D8EAA7F788D574DCE29F06313" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:to="loc_us-gaap_InventoryNet_AE41BA2D8EAA7F788D574DCE29F06313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B631D6227087DE4164764DCE29F04A7D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B631D6227087DE4164764DCE29F04A7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8087114B9FDD2659E2C94DCE29F0FDBE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_540FD740C7AACE50BAA64DCE29EFB4B5" xlink:to="loc_us-gaap_AssetsCurrent_8087114B9FDD2659E2C94DCE29F0FDBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_DE3AFCD485435F72F2024DCE29F0B2E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_DE3AFCD485435F72F2024DCE29F0B2E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_505F6E9921880C443AE04DCE29F171AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_505F6E9921880C443AE04DCE29F171AA" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_InProcessResearchAndDevelopment" xlink:label="loc_ebs_InProcessResearchAndDevelopment_E4DCBAB09DDE6F03D0824DCE29F15A52" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:to="loc_ebs_InProcessResearchAndDevelopment_E4DCBAB09DDE6F03D0824DCE29F15A52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_708E70A89D0807C7A07A4DCE29F16AF4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:to="loc_us-gaap_Goodwill_708E70A89D0807C7A07A4DCE29F16AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_452EE9F2499FEA02BA414DCE29F17455" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_452EE9F2499FEA02BA414DCE29F17455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_5B4F71C07BF40138FB5C4DCE29F1E3EE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FB1DC34ECDD8BA79F03E4DCE29EF4AEB" xlink:to="loc_us-gaap_Assets_5B4F71C07BF40138FB5C4DCE29F1E3EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_004BFB4F81E68541FBE04DCE29F12B0F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A171737A991FEE2208D44DCE29EE7BEA" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_004BFB4F81E68541FBE04DCE29F12B0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_004BFB4F81E68541FBE04DCE29F12B0F" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9FCA9C4CF92F030344614DCE29F2BBAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:to="loc_us-gaap_AccountsPayableCurrent_9FCA9C4CF92F030344614DCE29F2BBAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_FBEAEEE4C25B1B4843844DCE29F2610C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_FBEAEEE4C25B1B4843844DCE29F2610C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_943CC3198F7970E643814DCE29F2C9CF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_943CC3198F7970E643814DCE29F2C9CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_469D5E2A416146B85A7F4DCE29F22291" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_469D5E2A416146B85A7F4DCE29F22291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_ABAD764CB3062650345A4DCE29F3352C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:to="loc_us-gaap_LongTermDebtCurrent_ABAD764CB3062650345A4DCE29F3352C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_18E6D492E0DA91D3C63A4DCE29F3D96F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_18E6D492E0DA91D3C63A4DCE29F3D96F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_C359C4EEC9E8456F03C14DCE29F314E2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8FB9A7BAC9C9BFDF6C064DCE29F1E2F8" xlink:to="loc_us-gaap_LiabilitiesCurrent_C359C4EEC9E8456F03C14DCE29F314E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7819925543AB434208B44DCE29F381AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_004BFB4F81E68541FBE04DCE29F12B0F" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7819925543AB434208B44DCE29F381AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_43F3EE791979D043745F4DCE29F3CA38" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_004BFB4F81E68541FBE04DCE29F12B0F" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_43F3EE791979D043745F4DCE29F3CA38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_75274260D07B782353D94DCE29F3BA1B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_004BFB4F81E68541FBE04DCE29F12B0F" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_75274260D07B782353D94DCE29F3BA1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_365EF916D8B8B0DB27654DCE29F427A8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_004BFB4F81E68541FBE04DCE29F12B0F" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_365EF916D8B8B0DB27654DCE29F427A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6CD672BC2EA2CBD042EF4DCE29F4A632" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_004BFB4F81E68541FBE04DCE29F12B0F" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6CD672BC2EA2CBD042EF4DCE29F4A632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_66D3ACE401C50B4CF70A4DCE29F44DB0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_004BFB4F81E68541FBE04DCE29F12B0F" xlink:to="loc_us-gaap_Liabilities_66D3ACE401C50B4CF70A4DCE29F44DB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_BD5CA3ED45C6A904DFE04DCE29F4615F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_004BFB4F81E68541FBE04DCE29F12B0F" xlink:to="loc_us-gaap_CommitmentsAndContingencies_BD5CA3ED45C6A904DFE04DCE29F4615F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_F26A76175CE2CA2BB4204DCE29F46474" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_004BFB4F81E68541FBE04DCE29F12B0F" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_F26A76175CE2CA2BB4204DCE29F46474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_EA51510F3964AF1BE0114DCE29F4B3B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_F26A76175CE2CA2BB4204DCE29F46474" xlink:to="loc_us-gaap_PreferredStockValue_EA51510F3964AF1BE0114DCE29F4B3B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_DCDF1A650828B7597B224DCE29F56C75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_F26A76175CE2CA2BB4204DCE29F46474" xlink:to="loc_us-gaap_CommonStockValue_DCDF1A650828B7597B224DCE29F56C75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_CB9C3D6E34A5EA1CFE5D4DCE29F5EBDC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_F26A76175CE2CA2BB4204DCE29F46474" xlink:to="loc_us-gaap_TreasuryStockValue_CB9C3D6E34A5EA1CFE5D4DCE29F5EBDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_599169E2FB6C219EC85C4DCE29F5A87F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_F26A76175CE2CA2BB4204DCE29F46474" xlink:to="loc_us-gaap_AdditionalPaidInCapital_599169E2FB6C219EC85C4DCE29F5A87F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE09FEBBCCD18E8CEE64DCE29F5D67D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_F26A76175CE2CA2BB4204DCE29F46474" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8EE09FEBBCCD18E8CEE64DCE29F5D67D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C8CC09E936E3E4A72EC54DCE29F5F209" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_F26A76175CE2CA2BB4204DCE29F46474" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C8CC09E936E3E4A72EC54DCE29F5F209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8D4B129F43F4B92522694DCE29F6A6C0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_F26A76175CE2CA2BB4204DCE29F46474" xlink:to="loc_us-gaap_StockholdersEquity_8D4B129F43F4B92522694DCE29F6A6C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_B1D5AAF387186B1FAFF34DCE29F63C1D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_004BFB4F81E68541FBE04DCE29F12B0F" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_B1D5AAF387186B1FAFF34DCE29F63C1D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_A6A88A69374845D134FAD849D53E6120" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AE52ACA92AEF8851EB8FD849D53E5135" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A6A88A69374845D134FAD849D53E6120" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AE52ACA92AEF8851EB8FD849D53E5135" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AE52ACA92AEF8851EB8FD849D53E5135" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_CD6B49DEA54E3AA021ACD849D53F9348" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_CD6B49DEA54E3AA021ACD849D53F9348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8DCF60E06CE036EAF419D849D53F26BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8DCF60E06CE036EAF419D849D53F26BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5D21C751F8257E1B31F2D849D53F29B9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5D21C751F8257E1B31F2D849D53F29B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_C86E0B839177B0C28E4AD849D53FB06B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_C86E0B839177B0C28E4AD849D53FB06B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_B11DBB15B8AF1E7BE969D849D540AF47" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_B11DBB15B8AF1E7BE969D849D540AF47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_D569D6EF4CB50019F2E0D849D5409221" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_D569D6EF4CB50019F2E0D849D5409221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_36E09CC885BB570B76D3D849D5406B9A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:to="loc_us-gaap_CommonStockSharesIssued_36E09CC885BB570B76D3D849D5406B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B90964ABB5D7633F191AD849D5400A3F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_B90964ABB5D7633F191AD849D5400A3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_9F87BB02AC52F01581A8D849D5408AA2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_53D27C1D361E963D0075D849D53F5D92" xlink:to="loc_us-gaap_TreasuryStockShares_9F87BB02AC52F01581A8D849D5408AA2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66ECEC38B57AF024F4EE499DFAE4C204" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66ECEC38B57AF024F4EE499DFAE4C204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CBBBAA8CBD4EAF6C42B2499DFAE513AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66ECEC38B57AF024F4EE499DFAE4C204" xlink:to="loc_us-gaap_NetIncomeLoss_CBBBAA8CBD4EAF6C42B2499DFAE513AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66ECEC38B57AF024F4EE499DFAE4C204" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6A585B75BBE9091B6855499DFAE59778" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:to="loc_us-gaap_ShareBasedCompensation_6A585B75BBE9091B6855499DFAE59778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_D37F7A3DAC0C311EADB0499DFAE51D9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_D37F7A3DAC0C311EADB0499DFAE51D9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_AA2685E7C75416DF3F7D499DFAE69C0E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_AA2685E7C75416DF3F7D499DFAE69C0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91708EEE1C0486B04278499DFAE62804" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91708EEE1C0486B04278499DFAE62804" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ChangeInFairValueOfContingentConsideration" xlink:label="loc_ebs_ChangeInFairValueOfContingentConsideration_63CE88F09CE8D1B05155499DFAE618C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:to="loc_ebs_ChangeInFairValueOfContingentConsideration_63CE88F09CE8D1B05155499DFAE618C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_07BEEE7A5C7405D1F496499DFAE64337" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_07BEEE7A5C7405D1F496499DFAE64337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23EF016B159F6652FD5E499DFAE5428B" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0ECC35FC26D5E01A799E499DFAE662A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0ECC35FC26D5E01A799E499DFAE662A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_169A2DDCABE7157156DE499DFAE73D48" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_169A2DDCABE7157156DE499DFAE73D48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E5C4C29E15BFB75D200A499DFAE7E5ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E5C4C29E15BFB75D200A499DFAE7E5ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_63D3EACBD63E7F6D4F9A499DFAE79AE5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_63D3EACBD63E7F6D4F9A499DFAE79AE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_D27BC4E486A2EDCD9CC2499DFAE7E446" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_D27BC4E486A2EDCD9CC2499DFAE7E446" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B1D69A4B75433F6E1326499DFAE7DC9C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B1D69A4B75433F6E1326499DFAE7DC9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_E4C9C16851B5B9A9968F499DFAE87F0F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A96A1F6448EA83D6472D499DFAE613AA" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_E4C9C16851B5B9A9968F499DFAE87F0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65177F18D4EB1902EA06499DFAE80448" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_66ECEC38B57AF024F4EE499DFAE4C204" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65177F18D4EB1902EA06499DFAE80448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7A93B250CD550B66DD66499DFAE8C324" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7A93B250CD550B66DD66499DFAE8C324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForPreviousAcquisition" xlink:label="loc_us-gaap_PaymentsForPreviousAcquisition_5F4E337960806D91DCFB49A467EBC73C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7" xlink:to="loc_us-gaap_PaymentsForPreviousAcquisition_5F4E337960806D91DCFB49A467EBC73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_B176A22AD75493E1023C499DFAE8C950" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_B176A22AD75493E1023C499DFAE8C950" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_FA67405568F2D82EE445499DFAE917FE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_889945E90CDC0BBBEB35499DFAE877B7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_FA67405568F2D82EE445499DFAE917FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_EBD3F53C5E66FABF3397499DFAEB10B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_EBD3F53C5E66FABF3397499DFAEB10B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_9432EF02C0DBA9643CB6499DFAEB754E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_9432EF02C0DBA9643CB6499DFAEB754E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_5B5AF8D215ABD9C536B7499DFAEB651B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_5B5AF8D215ABD9C536B7499DFAEB651B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_EDEDCD835885FE9647C1499DFAEBC230" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_EDEDCD835885FE9647C1499DFAEBC230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2C69A216BA6A451628CC499DFAEB831C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2C69A216BA6A451628CC499DFAEB831C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_195B309C9A0D6130A25F499DFAEBF9E1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_195B309C9A0D6130A25F499DFAEBF9E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A5A724523D610A780008499DFAEBD38B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A5A724523D610A780008499DFAEBD38B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_457FC1B56F8FA68E276B499DFAEBC505" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_02B3E636398C75ACEC7B499DFAE996AD" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_457FC1B56F8FA68E276B499DFAEBC505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C5F89BF03F1178E6E8D499DFAEBE107" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C5F89BF03F1178E6E8D499DFAEBE107" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D6139CD2F55588FBB947499DFAEB02B3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_D6139CD2F55588FBB947499DFAEB02B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73C5BFA0379063C7F7CC499DFAEC6F64" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73C5BFA0379063C7F7CC499DFAEC6F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FBDD66AE402C913C6163499DFAEC6F72" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8C230D807B5166C79ECC499DFAE44DDC" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_FBDD66AE402C913C6163499DFAEC6F72" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_CC91D3F5E8AA955C8C0320C855515A2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_CC91D3F5E8AA955C8C0320C855515A2F" xlink:to="loc_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_240BB3660DBCF36D9D0B20C855510106" xlink:to="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6D6E0EB3E0BA11ACEF8820C8555269DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:to="loc_us-gaap_CommonStockMember_6D6E0EB3E0BA11ACEF8820C8555269DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4EAAC9BB35131878319820C85552B631" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4EAAC9BB35131878319820C85552B631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_1A80A41CD00897DB525920C855528BA2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:to="loc_us-gaap_TreasuryStockMember_1A80A41CD00897DB525920C855528BA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F71673ACF88509FF885220C85552F53C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F71673ACF88509FF885220C85552F53C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_C0D3998F77BD1B3D515020C855529747" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2CED24D27BA75A649AFA20C855517C2E" xlink:to="loc_us-gaap_RetainedEarningsMember_C0D3998F77BD1B3D515020C855529747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4AE83EFE1FA3A5B2968D20C85551E6C9" xlink:to="loc_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AEC67B1EDDC3856AA34F20C855531208" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B264010A44F7FEA7033620C85553036B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_CommonStockSharesIssued_B264010A44F7FEA7033620C85553036B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E94FFAC0F4DA62D00FC920C8555337D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_StockholdersEquity_E94FFAC0F4DA62D00FC920C8555337D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE48144E672319E4EC8B20C8555475C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE48144E672319E4EC8B20C8555475C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_F67C7519D562D237F13B20C85554AAFB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_F67C7519D562D237F13B20C85554AAFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21EB85CBB02D937AF77320C855545792" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21EB85CBB02D937AF77320C855545792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_B6A76952761BA107AC2F20C85554A078" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_B6A76952761BA107AC2F20C85554A078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E8E1BBB2E61F517D2AC820C85554DF9A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_NetIncomeLoss_E8E1BBB2E61F517D2AC820C85554DF9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_399C116C3E04922C118B20C855557136" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_399C116C3E04922C118B20C855557136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_325DAAB8A69FFCDABC7D20C8555576B7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_CommonStockSharesIssued_325DAAB8A69FFCDABC7D20C8555576B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_46E0A9D9AF6A8BA47EF120C85555EF37" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9A745D4EAB573F0709E120C855535253" xlink:to="loc_us-gaap_StockholdersEquity_46E0A9D9AF6A8BA47EF120C85555EF37" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_865427DA76A6D525F7C7D849D3B4F76B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_A7AA206B3D04D7505D41D849D3B43123" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_865427DA76A6D525F7C7D849D3B4F76B" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_A7AA206B3D04D7505D41D849D3B43123" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C87EFDF30C0B4C0DC8DC4996D114B084" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_ED9AF9C94A129CCE0D1C4996D11516B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C87EFDF30C0B4C0DC8DC4996D114B084" xlink:to="loc_us-gaap_NetIncomeLoss_ED9AF9C94A129CCE0D1C4996D11516B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C87EFDF30C0B4C0DC8DC4996D114B084" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_F7E4D592DC40C91757154996D1157A11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_F7E4D592DC40C91757154996D1157A11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_D2D8A0E8CF05A16CB4B44996D1150F61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_D2D8A0E8CF05A16CB4B44996D1150F61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_BE00A4E7DAC2CA0D7BF64996D115109C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_BE00A4E7DAC2CA0D7BF64996D115109C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9A9DD2BB2AE03516B5584996D1165095" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6A7015C01D21A28CA9C24996D1150315" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9A9DD2BB2AE03516B5584996D1165095" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_EE077370C86E6A170E154996D116194D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C87EFDF30C0B4C0DC8DC4996D114B084" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_EE077370C86E6A170E154996D116194D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_7491E29C7387DB894CD92A8A1C59D2F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_539BB2C8D01FD291C0C32A8A1C594898" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7491E29C7387DB894CD92A8A1C59D2F0" xlink:to="loc_us-gaap_StatementTable_539BB2C8D01FD291C0C32A8A1C594898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_539BB2C8D01FD291C0C32A8A1C594898" xlink:to="loc_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_30B0FBCEE227E00988622A8A1C5A47ED" xlink:to="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_6DAABF2038F9AFBD59A72A8A1C5A820C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:to="loc_us-gaap_ProductMember_6DAABF2038F9AFBD59A72A8A1C5A820C" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:to="loc_ebs_ContractManufacturingMember_5E1F67354B6B695C86C92A8A1C5B0F3F" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractsAndGrantsMember" xlink:label="loc_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49B205A3324AC771F80B2A8A1C5A4E29" xlink:to="loc_ebs_ContractsAndGrantsMember_E357C2E35D6C9C5342DD2A8A1C5B9641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_539BB2C8D01FD291C0C32A8A1C594898" xlink:to="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E03C0C2575E201E50E592A8A1C61BCF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_D559355CBBC0292BB6DC2A8A1C605160" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_E03C0C2575E201E50E592A8A1C61BCF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5C2F6A77A2DE6791A7642A8A1C61FAF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5C2F6A77A2DE6791A7642A8A1C61FAF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EA2DCA0250263241A4D72A8A1C62BA32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_EA2DCA0250263241A4D72A8A1C62BA32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_06E0E2133759621C01C32A8A1C628EBB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_06E0E2133759621C01C32A8A1C628EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D61A838C43340154DA4A2A8A1C622D1D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_D61A838C43340154DA4A2A8A1C622D1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_76BDCF334BE6F98C52872A8A1C62FB3B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709D7AE5D51C7ECFC4D02A8A1C61DA9B" xlink:to="loc_us-gaap_OperatingExpenses_76BDCF334BE6F98C52872A8A1C62FB3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8C9F5F6C31D156DEC7A52A8A1C637A30" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_OperatingIncomeLoss_8C9F5F6C31D156DEC7A52A8A1C637A30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_798497C8C5ED5B4F14EC2A8A1C6399F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:to="loc_us-gaap_InterestExpense_798497C8C5ED5B4F14EC2A8A1C6399F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_FF2AEA776074ECD7FA462A8A1C63801B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_FF2AEA776074ECD7FA462A8A1C63801B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4A107193415103C675A92A8A1C6323F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_42F3BB244AADFDDDB8022A8A1C637DC4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4A107193415103C675A92A8A1C6323F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_347D619286BD0ABD41032A8A1C633F5F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_347D619286BD0ABD41032A8A1C633F5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5D0CC6AEBBE5DA9AA5542A8A1C64C79B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5D0CC6AEBBE5DA9AA5542A8A1C64C79B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_27EA59D52C643BE47B9B2A8A1C64FE99" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_NetIncomeLoss_27EA59D52C643BE47B9B2A8A1C64FE99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_82971E18464E84A744C02A8A1C6451D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E" xlink:to="loc_us-gaap_EarningsPerShareBasic_82971E18464E84A744C02A8A1C6451D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_FAE454C5583115005AF92A8A1C64E015" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08AB327B0DB5C9FAAABC2A8A1C64AC8E" xlink:to="loc_us-gaap_EarningsPerShareDiluted_FAE454C5583115005AF92A8A1C64E015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CE404E840120FE687ECD2A8A1C5BA69F" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D1D012B0C4F0B7DD27D82A8A1C65C9E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D1D012B0C4F0B7DD27D82A8A1C65C9E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_FF9F0D66C6BE45F8E7DE2A8A1C6592A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_68DDAF7C98E3C9E985712A8A1C65A9C0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_FF9F0D66C6BE45F8E7DE2A8A1C6592A1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsideration" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_B3609003C5AFF5782CBD2073BB60FCE7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_F0A5B0C759EDA407B05C2073BB60F5C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_B3609003C5AFF5782CBD2073BB60FCE7" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_F0A5B0C759EDA407B05C2073BB60F5C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DEF7DE5B35599A34319E2073BB5319D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DEF7DE5B35599A34319E2073BB5319D6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE63C7D9A09BC56A43AE2073BB53DE80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE63C7D9A09BC56A43AE2073BB53DE80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FF62B86E2D7AC7AE33AB2073BB54835A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FF62B86E2D7AC7AE33AB2073BB54835A" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment" xlink:label="loc_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment_9645D332DF1BD6E31A132073BB5400B9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:to="loc_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment_9645D332DF1BD6E31A132073BB5400B9" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue" xlink:label="loc_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_9973E404F99E1C3DFD3D2073BB542987" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:to="loc_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue_9973E404F99E1C3DFD3D2073BB542987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8CFBDCFDF821F2205EBD2073BB545430" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8CFBDCFDF821F2205EBD2073BB545430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6AB7015F60F09EE749CE2073BB54D3BC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6DEB3D216B64B27747572073BB53C410" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6AB7015F60F09EE749CE2073BB54D3BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DEF7DE5B35599A34319E2073BB5319D6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B7C8D5AB5885F78030F92073BB54BD9B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_RaxibacumabMember" xlink:label="loc_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C1BA880F128FCFCD3EC42073BB55C78F" xlink:to="loc_ebs_RaxibacumabMember_DBDC9A31B763B9F7A4EA2073BB550A7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B8B4F5F4F50098D2FAAA2073BB545C9A" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_C8C41F1E85419C783ED72073BB55AED3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_649D3A6916E90D960B292073BB559A76" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_C8C41F1E85419C783ED72073BB55AED3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ContingentConsiderationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_35BEC977577EE08D68C82073BB5D9DC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_F5D727551368E8623A822073BB5EAC60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_35BEC977577EE08D68C82073BB5D9DC4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_F5D727551368E8623A822073BB5EAC60" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_0D2FC7C30A23BFDA3AF92F38D85DAF81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_DocumentType_0D2FC7C30A23BFDA3AF92F38D85DAF81" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_14E9858DA9FF2F980B9C2F38D85DECF0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_DocumentQuarterlyReport_14E9858DA9FF2F980B9C2F38D85DECF0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D98BBD38BE7A244C12842F38D85DBA47" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_DocumentPeriodEndDate_D98BBD38BE7A244C12842F38D85DBA47" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_4E435893B40C71E282112F38D85D25BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_DocumentTransitionReport_4E435893B40C71E282112F38D85D25BB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_2DE4DB57B8FFE23F828D2F38D85D7846" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityFileNumber_2DE4DB57B8FFE23F828D2F38D85D7846" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_975ECDB5D056B72A543C2F38D85D3B19" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityIncorporationStateCountryCode_975ECDB5D056B72A543C2F38D85D3B19" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_3C3A779E7932AA1CE7492F38D85DE5CF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityTaxIdentificationNumber_3C3A779E7932AA1CE7492F38D85DE5CF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_9A9D5467BEC65F99542A2F38D85D6099" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityAddressAddressLine1_9A9D5467BEC65F99542A2F38D85D6099" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_CFFA437C44AE437A267E2F38D85DEC59" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityAddressAddressLine2_CFFA437C44AE437A267E2F38D85DEC59" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_A18E5D8F48E8D235154E2F38D85DCA6C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityAddressCityOrTown_A18E5D8F48E8D235154E2F38D85DCA6C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_1AF31FCC746F5BB4BF8B2F38D85DCA0E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityAddressStateOrProvince_1AF31FCC746F5BB4BF8B2F38D85DCA0E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_4C5966976AC3976E95592F38D85D9A21" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityAddressPostalZipCode_4C5966976AC3976E95592F38D85D9A21" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_D84006D0AF0DE39659512F38D85DB2D5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_CityAreaCode_D84006D0AF0DE39659512F38D85DB2D5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_B44083F90E356B71DAC22F38D85D47B4" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_LocalPhoneNumber_B44083F90E356B71DAC22F38D85D47B4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_B929196EDC33B03B7C872F38D85D6C16" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_Security12bTitle_B929196EDC33B03B7C872F38D85D6C16" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_83C62B76B04DA6CAA25D2F38D85D9A08" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_TradingSymbol_83C62B76B04DA6CAA25D2F38D85D9A08" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_1032C78E1971241164F32F38D85DAD9C" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_SecurityExchangeName_1032C78E1971241164F32F38D85DAD9C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_D378BBCA2E199F33BDC52F38D85D20C4" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityCurrentReportingStatus_D378BBCA2E199F33BDC52F38D85D20C4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_C938546D109108044ED12F38D85D7052" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityInteractiveDataCurrent_C938546D109108044ED12F38D85D7052" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_AF389B88ECFEB3A2981F2F38D85D3DF2" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityFilerCategory_AF389B88ECFEB3A2981F2F38D85D3DF2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_585E5F79CAF89DC3F2532F38D85D3F99" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntitySmallBusiness_585E5F79CAF89DC3F2532F38D85D3F99" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_660C2B64139C83EFABB22F38D85D3361" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityEmergingGrowthCompany_660C2B64139C83EFABB22F38D85D3361" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_401DCD758ED33D329F4C2F38D85DA76A" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityShellCompany_401DCD758ED33D329F4C2F38D85DA76A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_C3837A9DE61ECC64ACF52F38D85D5B09" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_C3837A9DE61ECC64ACF52F38D85D5B09" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_D8652EA74694F00579372F38D85D7F34" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityRegistrantName_D8652EA74694F00579372F38D85D7F34" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_D02F1EE1E6498CB574742F38D85DAABD" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_EntityCentralIndexKey_D02F1EE1E6498CB574742F38D85DAABD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_1506AA874485EA61D3AD2F38D85DC090" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_CurrentFiscalYearEndDate_1506AA874485EA61D3AD2F38D85DC090" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_90BE5B58B69ED4A72AFB2F38D85D1C39" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_AmendmentFlag_90BE5B58B69ED4A72AFB2F38D85D1C39" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_5750341152C71AD3010F2F38D85D5911" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_DocumentFiscalYearFocus_5750341152C71AD3010F2F38D85D5911" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_40B06F423C0DE60E16AA2F38D85DAD0B" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_C479DFD7E6BAFE2A4D222F38D85DC077" xlink:to="loc_dei_DocumentFiscalPeriodFocus_40B06F423C0DE60E16AA2F38D85DAD0B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_A6C3E93B1EDD06942E36499DF9CD12B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_C9C2C2C725CEBA9AF34A499DF9CE7215" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A6C3E93B1EDD06942E36499DF9CD12B7" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_C9C2C2C725CEBA9AF34A499DF9CE7215" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_22A3108B1A89877CADE1493CBC4CD581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_22A3108B1A89877CADE1493CBC4CD581" xlink:to="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:to="loc_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_141C0D81C7D574DA24B7493CBC4D56A6" xlink:to="loc_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_0CEF79926B528CD2B1C4493CBC4DF392" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_0CEF79926B528CD2B1C4493CBC4DF392" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_TermLoanFacilityMember" xlink:label="loc_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_615A01BBDCBF902EA954493CBC4D20DC" xlink:to="loc_ebs_TermLoanFacilityMember_B69DC66E256F1D8FDC89493CBC4E252A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:to="loc_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2499F30CFE71D409D46F493CBC4E4266" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_CreditAgreementMember" xlink:label="loc_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:to="loc_ebs_CreditAgreementMember_35C22E6CDE33282218FE493CBC4E45D1" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_AmendedCreditAgreementMember" xlink:label="loc_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:to="loc_ebs_AmendedCreditAgreementMember_3EB3E2D069EE1D08A17C493CBC4F317D" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ConvertibleSeniorNotesDue2021Member" xlink:label="loc_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B49B626396655B381A55493CBC4E5580" xlink:to="loc_ebs_ConvertibleSeniorNotesDue2021Member_92666EA851D24F60E496493CBC4FF415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:to="loc_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_844CF15B80382833941E493CBC4FB39E" xlink:to="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_237E8601900F543B781F493CBC4F510E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:to="loc_us-gaap_EurodollarMember_237E8601900F543B781F493CBC4F510E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_AFF6E0E56A1967BC4BC3493CBC4FC3C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_AFF6E0E56A1967BC4BC3493CBC4FC3C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_3B1B55543EEC4BBB7589493CBC507BD6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0EE84AAEFE31DE01FF93493CBC4F5266" xlink:to="loc_us-gaap_BaseRateMember_3B1B55543EEC4BBB7589493CBC507BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_16F63BD165442C439150493CBC501B9C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:to="loc_srt_RangeAxis_16F63BD165442C439150493CBC501B9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A23300F623EEC2E58C06493CBC50BC50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_16F63BD165442C439150493CBC501B9C" xlink:to="loc_srt_RangeMember_A23300F623EEC2E58C06493CBC50BC50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_BBE837576BA60CA8F2F5493CBC5023FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A23300F623EEC2E58C06493CBC50BC50" xlink:to="loc_srt_MinimumMember_BBE837576BA60CA8F2F5493CBC5023FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_0349CAC4E878B0913E1A493CBC50E0C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A23300F623EEC2E58C06493CBC50BC50" xlink:to="loc_srt_MaximumMember_0349CAC4E878B0913E1A493CBC50E0C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_AEDE5AC412AF317C5D78493CBC4D1390" xlink:to="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_NumberOfLendingInstitutions" xlink:label="loc_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_NumberOfLendingInstitutions_95C25B058BBF4598ADC2493CBC51F299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_FCD0DE37262E0611FCC0493CBC519991" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_FCD0DE37262E0611FCC0493CBC519991" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_BD5E669A5D8502DE7DB4493CBC51C8CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_BD5E669A5D8502DE7DB4493CBC51C8CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_951E255E840E0521F0B7493CBC5167C2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_951E255E840E0521F0B7493CBC5167C2" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_767BC46E9EC41CD30B5B493CBC5278CA" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_7A44D9F9EAD6B4BA4BE4493CBC52ACDA" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_1519DFCB2CED2AD106A7493CBC5267DB" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_A5A847BDE663072240E9493CBC52BFAF" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_4478C9433C97B3F4598C493CBC529876" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_6C757EBC2BA38259428C493CBC52A340" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_B5E313E809DEFD8376C7493CBC53A0CC" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_41E7C8ECA9EB33E712A2493CBC5330AB" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioThree" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioThree_0108967962F44E5D44C3493CBC536ABB" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioFour" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioFour_9B360500FC2F950825A6493CBC53C8F2" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted_6B450486EEE165C4B6B0493CBC53E0B1" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9B841A1D0EB66937A02D493CBC5355DB" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_DebtInstrumentRestrictedPaymentsLimitAmount" xlink:label="loc_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_ebs_DebtInstrumentRestrictedPaymentsLimitAmount_EF7CE5818FDB79BB3DDB493CBC53A2FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4D5BC057F3454FC0149A493CBC54F5F3" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97CE8D7B5879E5010835493CBC51E915" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4D5BC057F3454FC0149A493CBC54F5F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_423EB18F36AB1F1AA0704DCE28919F2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_64D313E7E6A3E83007864DCE2892D005" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_423EB18F36AB1F1AA0704DCE28919F2D" xlink:to="loc_us-gaap_DebtInstrumentTable_64D313E7E6A3E83007864DCE2892D005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_DD0EF677EF6B7C5818FF4DCE289229A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64D313E7E6A3E83007864DCE2892D005" xlink:to="loc_us-gaap_CreditFacilityAxis_DD0EF677EF6B7C5818FF4DCE289229A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_5BF76BC327380D953C2F4DCE28928C6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_DD0EF677EF6B7C5818FF4DCE289229A6" xlink:to="loc_us-gaap_CreditFacilityDomain_5BF76BC327380D953C2F4DCE28928C6B" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_TermLoanFacilityMember" xlink:label="loc_ebs_TermLoanFacilityMember_82FE57DA662CBF73FFCF4DCE28926E77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5BF76BC327380D953C2F4DCE28928C6B" xlink:to="loc_ebs_TermLoanFacilityMember_82FE57DA662CBF73FFCF4DCE28926E77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_F3706060B8D018119AAD4DCE28937894" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5BF76BC327380D953C2F4DCE28928C6B" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_F3706060B8D018119AAD4DCE28937894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_029E03D092F8415D40664DCE28935A57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64D313E7E6A3E83007864DCE2892D005" xlink:to="loc_us-gaap_DebtInstrumentAxis_029E03D092F8415D40664DCE28935A57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7144AFF279F6C187DE094DCE2893A319" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_029E03D092F8415D40664DCE28935A57" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7144AFF279F6C187DE094DCE2893A319" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ConvertibleSeniorNotesDue2021Member" xlink:label="loc_ebs_ConvertibleSeniorNotesDue2021Member_628C3A5667207C2B05B94DCE289393AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7144AFF279F6C187DE094DCE2893A319" xlink:to="loc_ebs_ConvertibleSeniorNotesDue2021Member_628C3A5667207C2B05B94DCE289393AF" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_OtherLongTermDebtFacilityMember" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7144AFF279F6C187DE094DCE2893A319" xlink:to="loc_ebs_OtherLongTermDebtFacilityMember_1C79EEC00C7877E6D46E4DCE2893375E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F556FBC17ACE177A20C54DCE2894178C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64D313E7E6A3E83007864DCE2892D005" xlink:to="loc_us-gaap_DebtInstrumentLineItems_F556FBC17ACE177A20C54DCE2894178C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_267B55325F6285A988934DCE28949E31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F556FBC17ACE177A20C54DCE2894178C" xlink:to="loc_us-gaap_LongTermDebt_267B55325F6285A988934DCE28949E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_CF7F79918C0F1725AAA04DCE2894F886" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F556FBC17ACE177A20C54DCE2894178C" xlink:to="loc_us-gaap_LongTermDebtCurrent_CF7F79918C0F1725AAA04DCE2894F886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_585D22DC2E8731131A224DCE28949885" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F556FBC17ACE177A20C54DCE2894178C" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_585D22DC2E8731131A224DCE28949885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_325E2D7C257C4ADCFCCF4DCE28943786" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F556FBC17ACE177A20C54DCE2894178C" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_325E2D7C257C4ADCFCCF4DCE28943786" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0802CC3281EB7DA0114E2F38D6909F2E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_3F8CB0A127DFBC6D9CFD2F38D6903D9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0802CC3281EB7DA0114E2F38D6909F2E" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_3F8CB0A127DFBC6D9CFD2F38D6903D9A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DefinedBenefitPlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_48604C5147BB1BD410E6D849D3E6FCFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2BCF25CDF0B933A02248D849D3E69F80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_48604C5147BB1BD410E6D849D3E6FCFA" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2BCF25CDF0B933A02248D849D3E69F80" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1D7DA25947CE41F7578A205676E15962" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_172943AD8EED24AA4017205676E19435" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1D7DA25947CE41F7578A205676E15962" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_172943AD8EED24AA4017205676E19435" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_C45C294705969D1D542D205676E2E270" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1D7DA25947CE41F7578A205676E15962" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_C45C294705969D1D542D205676E2E270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8E80EAE8BBDE74812FD6205676E2DE5C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1D7DA25947CE41F7578A205676E15962" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8E80EAE8BBDE74812FD6205676E2DE5C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DefinedBenefitPlanTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_25996E40FE337D498084D849D337DE35" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_A8CF40B682E5ED86E3F0D849D3378C67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_25996E40FE337D498084D849D337DE35" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_A8CF40B682E5ED86E3F0D849D3378C67" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1C272F2A5DE9B9757DC9D849D3D7206F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_87F938EEB186F5634E26D849D3D71B03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1C272F2A5DE9B9757DC9D849D3D7206F" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_87F938EEB186F5634E26D849D3D71B03" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C00C8EB1D551F35810582F38D695B51F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_6EA96ACDEFF63FD091D92F38D6966D3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C00C8EB1D551F35810582F38D695B51F" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_6EA96ACDEFF63FD091D92F38D6966D3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_6EA96ACDEFF63FD091D92F38D6966D3B" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A176A92ACABE1BB57FFD2F38D6964886" xlink:to="loc_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_CF751B8252880F4CD7592F38D696BB55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_DD5B93863865AA7C038E2F38D696046A" xlink:to="loc_us-gaap_CashFlowHedgingMember_CF751B8252880F4CD7592F38D696BB55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_6EA96ACDEFF63FD091D92F38D6966D3B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_168368C08C832BC7D4162F38D697F3F7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaap_InterestExpenseMember_F453CD76102ECBA3020F2F38D697D72C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B96EE2218C539A2801E12F38D697AA5B" xlink:to="loc_us-gaap_InterestExpenseMember_F453CD76102ECBA3020F2F38D697D72C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7A6E6E36264AA18C96442F38D697CA9E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_6EA96ACDEFF63FD091D92F38D6966D3B" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7A6E6E36264AA18C96442F38D697CA9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_A7F348BC4D4B5577AAEB2F38D697C8A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7A6E6E36264AA18C96442F38D697CA9E" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_A7F348BC4D4B5577AAEB2F38D697C8A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_A5A73CA6C58F7FAD7D862F38D6988D50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_A7F348BC4D4B5577AAEB2F38D697C8A3" xlink:to="loc_us-gaap_InterestRateSwapMember_A5A73CA6C58F7FAD7D862F38D6988D50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_65DEB15D913A01F60EE32F38D6985166" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_6EA96ACDEFF63FD091D92F38D6966D3B" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_65DEB15D913A01F60EE32F38D6985166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_5C19E5799221CDFD03E62F38D698D2F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_65DEB15D913A01F60EE32F38D6985166" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_5C19E5799221CDFD03E62F38D698D2F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B926E7A619CBAB5D87222F38D69860A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_65DEB15D913A01F60EE32F38D6985166" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B926E7A619CBAB5D87222F38D69860A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_E184E8C48062703EE93C2F38D6A237DC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_E184E8C48062703EE93C2F38D6A237DC" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_00852E82789B2FD58CD12F38D6A383E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:to="loc_us-gaap_HedgingDesignationAxis_00852E82789B2FD58CD12F38D6A383E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_BA837989C497D02092812F38D6A3AB64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_00852E82789B2FD58CD12F38D6A383E0" xlink:to="loc_us-gaap_HedgingDesignationDomain_BA837989C497D02092812F38D6A3AB64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_F262C52522DC53FCB98C2F38D6A495FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_BA837989C497D02092812F38D6A3AB64" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_F262C52522DC53FCB98C2F38D6A495FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_C192CDE0D25E37ED1ECD2F38D6A461D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_C192CDE0D25E37ED1ECD2F38D6A461D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6D861BABBD6A825668802F38D6A43509" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_C192CDE0D25E37ED1ECD2F38D6A461D1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6D861BABBD6A825668802F38D6A43509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_7FF1A3A1DACAEF03373F2F38D6A4C78F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6D861BABBD6A825668802F38D6A43509" xlink:to="loc_us-gaap_InterestRateSwapMember_7FF1A3A1DACAEF03373F2F38D6A4C78F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_A5241F1393926E38CEEE2F38D6A3C6C7" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_5B00F642E42C645033D42F38D6A5EBED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_5B00F642E42C645033D42F38D6A5EBED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_AC669F8D55E973CD12862F38D6A565D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3CD24F90B1EEBB0020E92F38D6A4DA76" xlink:to="loc_invest_DerivativeNotionalAmount_AC669F8D55E973CD12862F38D6A565D2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5AA8E4B0816D067FF43F20CA657322A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15AE8DE7CE4EB6186AF720C854856D7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5AA8E4B0816D067FF43F20CA657322A1" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15AE8DE7CE4EB6186AF720C854856D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_09E2EFD06FF651841BE220D6BEB83EF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15AE8DE7CE4EB6186AF720C854856D7A" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_09E2EFD06FF651841BE220D6BEB83EF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_A14866CCDA4A10CF3B2820D6BEB93E5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_09E2EFD06FF651841BE220D6BEB83EF6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_A14866CCDA4A10CF3B2820D6BEB93E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_6F4DB545C97AF6D3BB9620D6E8D97453" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_A14866CCDA4A10CF3B2820D6BEB93E5B" xlink:to="loc_us-gaap_InterestRateSwapMember_6F4DB545C97AF6D3BB9620D6E8D97453" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_5AB3792CD653E45F4EC320C8548588AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15AE8DE7CE4EB6186AF720C854856D7A" xlink:to="loc_us-gaap_HedgingDesignationAxis_5AB3792CD653E45F4EC320C8548588AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_03C215FB6DA1A3CC552720C854856F32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_5AB3792CD653E45F4EC320C8548588AD" xlink:to="loc_us-gaap_HedgingDesignationDomain_03C215FB6DA1A3CC552720C854856F32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8F1E7D06D0FEBFA0FDA920C85486862D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_03C215FB6DA1A3CC552720C854856F32" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8F1E7D06D0FEBFA0FDA920C85486862D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7103A8C33AB54B76485F20C854863871" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15AE8DE7CE4EB6186AF720C854856D7A" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7103A8C33AB54B76485F20C854863871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_FF6C52ABE247F4AB257520C854863EE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7103A8C33AB54B76485F20C854863871" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_FF6C52ABE247F4AB257520C854863EE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_28DC9AC4180D4F1BE1CE20C85487F2F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FF6C52ABE247F4AB257520C854863EE9" xlink:to="loc_us-gaap_OtherAssetsMember_28DC9AC4180D4F1BE1CE20C85487F2F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesMember" xlink:label="loc_us-gaap_OtherLiabilitiesMember_31399158AFF8E915910F20C85487BA93" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FF6C52ABE247F4AB257520C854863EE9" xlink:to="loc_us-gaap_OtherLiabilitiesMember_31399158AFF8E915910F20C85487BA93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_F3AC4C320CA027D45F3B20C8548780B5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15AE8DE7CE4EB6186AF720C854856D7A" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_F3AC4C320CA027D45F3B20C8548780B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_B6A7252351E8951D96C820C85487F2AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F3AC4C320CA027D45F3B20C8548780B5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_B6A7252351E8951D96C820C85487F2AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_B2561D910F01A85E32EC20C854884FCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F3AC4C320CA027D45F3B20C8548780B5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_B2561D910F01A85E32EC20C854884FCF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_96F0D6B1E36B45A353A32F38D6A610B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_833498BBCBCAAD23BCA32F38D6A733CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_96F0D6B1E36B45A353A32F38D6A610B9" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_833498BBCBCAAD23BCA32F38D6A733CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3F92A93829C2A1FA51A22F38D6A76891" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_833498BBCBCAAD23BCA32F38D6A733CB" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3F92A93829C2A1FA51A22F38D6A76891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6FF5CDB79C23B27A260D2F38D6A7C728" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3F92A93829C2A1FA51A22F38D6A76891" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6FF5CDB79C23B27A260D2F38D6A7C728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_DE6EA5EB2634B79CDFDA2F38D6A70CE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6FF5CDB79C23B27A260D2F38D6A7C728" xlink:to="loc_us-gaap_InterestRateSwapMember_DE6EA5EB2634B79CDFDA2F38D6A70CE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_6686C923BC59F583B4802F38D6A8DFD7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_833498BBCBCAAD23BCA32F38D6A733CB" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_6686C923BC59F583B4802F38D6A8DFD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_AE8907DA146CBBC768722F38D6A858CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_6686C923BC59F583B4802F38D6A8DFD7" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_AE8907DA146CBBC768722F38D6A858CA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_36EE2B0224CE8460519120CA8F3D9F8A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_D4D01A9EE62AFD247CAA20C854967C84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_36EE2B0224CE8460519120CA8F3D9F8A" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_D4D01A9EE62AFD247CAA20C854967C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0AB82CCA58ACE4AB6BDC20D21824F807" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_36EE2B0224CE8460519120CA8F3D9F8A" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_0AB82CCA58ACE4AB6BDC20D21824F807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_058CA819160920CA779C20D32CEE76D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_36EE2B0224CE8460519120CA8F3D9F8A" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_058CA819160920CA779C20D32CEE76D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3E961EB9A3C89F266EC9D849D3DFD968" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_8CD9682698F38D384A01D849D3DF5CDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3E961EB9A3C89F266EC9D849D3DFD968" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_8CD9682698F38D384A01D849D3DF5CDC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B008804A6C3BEF5D8B76210F9A8F7CB4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_73CA4C5FCACAF461410A210F9A8FA5EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B008804A6C3BEF5D8B76210F9A8F7CB4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_73CA4C5FCACAF461410A210F9A8FA5EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_154F202481E51171E87B210F9A8FC6D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B008804A6C3BEF5D8B76210F9A8F7CB4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_154F202481E51171E87B210F9A8FC6D3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D02347BADDB521ED318E499D6C344FA8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_E23C4D1F6CE00EB92499499D6C3509E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D02347BADDB521ED318E499D6C344FA8" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_E23C4D1F6CE00EB92499499D6C3509E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00F984F50CFACE048264499D6D24131D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2B23AF730C46C4C32E88499D6D25E8BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00F984F50CFACE048264499D6D24131D" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2B23AF730C46C4C32E88499D6D25E8BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_34633010222443F99746499D6D263B44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00F984F50CFACE048264499D6D24131D" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_34633010222443F99746499D6D263B44" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C3C9854D412EC64FDF77499D6D684177" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C3C9854D412EC64FDF77499D6D684177" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9C370296C39F1213E25C499D6D69DD3F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_055E30809844174EC19D499D6D6A813E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EF93E6BC489F2D0F12F5499D6D6A9476" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_055E30809844174EC19D499D6D6A813E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_0B33689916CA846FB0DE499D6D6975CC" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6D72EECFDA8328ACCE34499D6D6C5F71" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07644AA8BB5AA8848A30499D6D6C5280" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_07644AA8BB5AA8848A30499D6D6C5280" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments_EF82DAEF47BB58D566B1499D6D6D3CB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments_EF82DAEF47BB58D566B1499D6D6D3CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2DAEEF323C1716FEAEDF499D6D6DE8B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_8A7943519CFAD2D90078499D6D6C3AED" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2DAEEF323C1716FEAEDF499D6D6DE8B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C3C9854D412EC64FDF77499D6D684177" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D" xlink:to="loc_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_95CAD968B9D648061AE2499D6D6D069C" xlink:to="loc_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_FCBE04044132AAA99ADD499D6D6E4BD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:to="loc_srt_MinimumMember_FCBE04044132AAA99ADD499D6D6E4BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_FA31D112DDBAE1546FAE499D6D6ED29F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3FD01A0E3A87746D8D24499D6D6DB224" xlink:to="loc_srt_MaximumMember_FA31D112DDBAE1546FAE499D6D6ED29F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_EF3D5067C8E6A56D5CF1499D6D6DC20D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1EE12843DD06393AB284499D6D6EFB56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1EE12843DD06393AB284499D6D6EFB56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_B9EF865A30C12B9637BB499D6D6ECAD3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5549CBA2D1856F4F13F1499D6D6FA30E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5549CBA2D1856F4F13F1499D6D6FA30E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_EED16116EF1CD41C16D1499D6D6F8205" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_EED16116EF1CD41C16D1499D6D6F8205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D5EDAC8C7691E523284B499D6D6F20A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_D5EDAC8C7691E523284B499D6D6F20A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_EDFC1BF4C5A790046332499D6D6F9834" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2A8A858E64B176751F5C499D6D6FD8E0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_EDFC1BF4C5A790046332499D6D6F9834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C3C9854D412EC64FDF77499D6D684177" xlink:to="loc_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaap_GoodwillGross_A1C8DC6CA1BD1EF6186E499D6D705335" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF" xlink:to="loc_us-gaap_GoodwillGross_A1C8DC6CA1BD1EF6186E499D6D705335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_9854EAD31B7E24AF7B1D499D6D70AFF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_9854EAD31B7E24AF7B1D499D6D70AFF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_39DF55CEBBE079FCBF94499D6D70C5E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_39DF55CEBBE079FCBF94499D6D70C5E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0AF22965EC1D5764656B499D6D70C4E2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_D7C15D87DEC30D9F2CDF499D6D6F25BF" xlink:to="loc_us-gaap_Goodwill_0AF22965EC1D5764656B499D6D70C4E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10AE1ECCE85406C14D69499D6CF207A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_CE779E6103690345C100499D6CF38E82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10AE1ECCE85406C14D69499D6CF207A4" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_CE779E6103690345C100499D6CF38E82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8E93701C8B2DAE38FD4F499D6CF42557" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10AE1ECCE85406C14D69499D6CF207A4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8E93701C8B2DAE38FD4F499D6CF42557" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0618F38323519089006CD849D469F017" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1479817990AC6D9E41E4D849D4691141" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0618F38323519089006CD849D469F017" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1479817990AC6D9E41E4D849D4691141" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1CE7AA61C1D76096B0DBD849D4BC7D53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2AC86940C25B4101919DD849D4BDD9D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1CE7AA61C1D76096B0DBD849D4BC7D53" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2AC86940C25B4101919DD849D4BDD9D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_A787CEFCE1AB059E48EED849D4BD75C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1CE7AA61C1D76096B0DBD849D4BC7D53" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_A787CEFCE1AB059E48EED849D4BD75C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_FE9C761E81044D5AA11DD849D4BD3390" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1CE7AA61C1D76096B0DBD849D4BC7D53" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_FE9C761E81044D5AA11DD849D4BD3390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_A3EA70FE09E34A943AA2D849D4BDE0F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1CE7AA61C1D76096B0DBD849D4BC7D53" xlink:to="loc_us-gaap_InventoryNet_A3EA70FE09E34A943AA2D849D4BDE0F6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_C374889BCCC76975FEDCD849D4EE8DDB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A45C19BB35B8B217C416D849D4F3CA5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_C374889BCCC76975FEDCD849D4EE8DDB" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_A45C19BB35B8B217C416D849D4F3CA5E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_2DE39F95209C3FCCFF7C2085BA7151A2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_F31AEE91EFC02F364EE6209118438ECC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2DE39F95209C3FCCFF7C2085BA7151A2" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_F31AEE91EFC02F364EE6209118438ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_421E7DA2457ED92265AA2091A0A13B7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2DE39F95209C3FCCFF7C2085BA7151A2" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_421E7DA2457ED92265AA2091A0A13B7E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_13DF51EC0682C0F7645D0AC34DBD043D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseCostAbstract" xlink:label="loc_us-gaap_FinanceLeaseCostAbstract_7AFD04D0E82CD3C9D0D10AC34DBE185A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_13DF51EC0682C0F7645D0AC34DBD043D" xlink:to="loc_us-gaap_FinanceLeaseCostAbstract_7AFD04D0E82CD3C9D0D10AC34DBE185A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A611B36EEF48BD07340D0AC34DBE0482" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseCostAbstract_7AFD04D0E82CD3C9D0D10AC34DBE185A" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_A611B36EEF48BD07340D0AC34DBE0482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_337064DF10FBD319708A0AC34DBE2787" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseCostAbstract_7AFD04D0E82CD3C9D0D10AC34DBE185A" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_337064DF10FBD319708A0AC34DBE2787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_8FE4877C1A3F33F08C4A0AC34DBEDEFF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseCostAbstract_7AFD04D0E82CD3C9D0D10AC34DBE185A" xlink:to="loc_us-gaap_LeaseCost_8FE4877C1A3F33F08C4A0AC34DBEDEFF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_4F6502E75B2D57154C12D849D539D4B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4F6502E75B2D57154C12D849D539D4B3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D13613A72B42A0EB41CCD849D539CFF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442" xlink:to="loc_srt_RangeAxis_D13613A72B42A0EB41CCD849D539CFF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6B1B70F8AF4C55F2E536D849D5390CD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_D13613A72B42A0EB41CCD849D539CFF9" xlink:to="loc_srt_RangeMember_6B1B70F8AF4C55F2E536D849D5390CD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_12555973B4B48F2DC9F8D849D53ADC7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6B1B70F8AF4C55F2E536D849D5390CD2" xlink:to="loc_srt_MinimumMember_12555973B4B48F2DC9F8D849D53ADC7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_F898484A96149DBD8AF2D849D53A9E58" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6B1B70F8AF4C55F2E536D849D5390CD2" xlink:to="loc_srt_MaximumMember_F898484A96149DBD8AF2D849D53A9E58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_422E16FDFB2D9216542BD849D539A442" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_37F17FD1D06D0D8DD53BD849D53A9695" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_37F17FD1D06D0D8DD53BD849D53A9695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8EEFE3B14793AB01746AD849D53B083B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8EEFE3B14793AB01746AD849D53B083B" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_LesseeOperatingLeaseTerminationPeriod" xlink:label="loc_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_74087543DC42148951DED849D53AD588" xlink:to="loc_ebs_LesseeOperatingLeaseTerminationPeriod_570A585FEEAAAE96FAEFD849D53B33E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_645CD5E90AC4707BADC7493CBCD64A58" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_645CD5E90AC4707BADC7493CBCD64A58" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0DE5F0B930B83F05125E493CBCD6F32E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0DE5F0B930B83F05125E493CBCD6F32E" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_OperatingLeaseOtherLiabilityCurrent" xlink:label="loc_ebs_OperatingLeaseOtherLiabilityCurrent_B9401503922F3557B554493CBCD6336D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C" xlink:to="loc_ebs_OperatingLeaseOtherLiabilityCurrent_B9401503922F3557B554493CBCD6336D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_D07B130EE23FD274459D493CBCD71DE7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_D07B130EE23FD274459D493CBCD71DE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_B8946A352983B9A6A268493CBCD71906" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ECA8A409962ABD23C814493CBCD6050C" xlink:to="loc_us-gaap_OperatingLeaseLiability_B8946A352983B9A6A268493CBCD71906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_4B517772BEB87476FDBA493CBCD797C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_645CD5E90AC4707BADC7493CBCD64A58" xlink:to="loc_us-gaap_LeaseCostAbstract_4B517772BEB87476FDBA493CBCD797C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_52E6764F108A067F983E493CBCD72355" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4B517772BEB87476FDBA493CBCD797C2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_52E6764F108A067F983E493CBCD72355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectFinancingLeaseLeaseIncomeAbstract" xlink:label="loc_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_74044925BD2752792916493CBCD8140B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_645CD5E90AC4707BADC7493CBCD64A58" xlink:to="loc_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_74044925BD2752792916493CBCD8140B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9551845A471A9C12F112493CBCD8C2F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract_74044925BD2752792916493CBCD8140B" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9551845A471A9C12F112493CBCD8C2F2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_E5A63E432FBB48C0CBBED849D3601A93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_F12142E7FBDBB9C3B16DD849D3614906" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_E5A63E432FBB48C0CBBED849D3601A93" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_F12142E7FBDBB9C3B16DD849D3614906" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock" xlink:label="loc_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_CD14CF85BE2440DE6C17D849D361B63F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_E5A63E432FBB48C0CBBED849D3601A93" xlink:to="loc_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock_CD14CF85BE2440DE6C17D849D361B63F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LossEarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_DA4364E20922C8C9D24A210F9A8D27AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9D7ECF76D53569BE3250210F9A8D5DE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DA4364E20922C8C9D24A210F9A8D27AF" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9D7ECF76D53569BE3250210F9A8D5DE5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LossEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_CB04CB4E13F7C28AF8802F38D648CD3D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_AAC7D867A5412671A5F22F38D6480444" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CB04CB4E13F7C28AF8802F38D648CD3D" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_AAC7D867A5412671A5F22F38D6480444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5EC73D17C492893510132F38D648FDE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_AAC7D867A5412671A5F22F38D6480444" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_5EC73D17C492893510132F38D648FDE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7127EA8054B9FBFF51D52F38D648876E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CB04CB4E13F7C28AF8802F38D648CD3D" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7127EA8054B9FBFF51D52F38D648876E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C334E5434D539FC979862F38D6484016" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7127EA8054B9FBFF51D52F38D648876E" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C334E5434D539FC979862F38D6484016" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A91FB40B097C003D612D2F38D6487D6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7127EA8054B9FBFF51D52F38D648876E" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_A91FB40B097C003D612D2F38D6487D6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_150413DDCECDC5AEF3762F38D648BA4F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7127EA8054B9FBFF51D52F38D648876E" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_150413DDCECDC5AEF3762F38D648BA4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_DCA28BBC1AE8B471CAA22F38D648ED4C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CB04CB4E13F7C28AF8802F38D648CD3D" xlink:to="loc_us-gaap_EarningsPerShareBasic_DCA28BBC1AE8B471CAA22F38D648ED4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_699B1932E37156AF61E12F38D648A5B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CB04CB4E13F7C28AF8802F38D648CD3D" xlink:to="loc_us-gaap_EarningsPerShareDiluted_699B1932E37156AF61E12F38D648A5B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8F2887E737F160AEB4552F38D648852A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CB04CB4E13F7C28AF8802F38D648CD3D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8F2887E737F160AEB4552F38D648852A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LossEarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_47ABAED1247CB6770BDC210F9A85B28E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F40159969015F67F68C5210F9A8691B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_47ABAED1247CB6770BDC210F9A85B28E" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_F40159969015F67F68C5210F9A8691B6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_1DA6DD23F18ED972A979205677C871F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_BE44815EDB7A83C6F641205677C860C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_1DA6DD23F18ED972A979205677C871F4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_BE44815EDB7A83C6F641205677C860C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_FE667CC937CD2AD95480205677C0A10F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_FE667CC937CD2AD95480205677C0A10F" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AEE764D45C79DDB7D7F205677C1617F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LandAndLandImprovementsMember" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_2AD7334D8CD22358C896205677C174DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_2AD7334D8CD22358C896205677C174DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_FFC8747ACA7CD203B572205677C19F15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_FFC8747ACA7CD203B572205677C19F15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_C1C818480E65B825F64D205677C139ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_C1C818480E65B825F64D205677C139ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_87D07A1EE3D52BCCB949205677C2597B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_87D07A1EE3D52BCCB949205677C2597B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_AAEF3DAA79A23C0874A3205677C2E723" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3CC2EFA5EE32F1986237205677C10688" xlink:to="loc_us-gaap_ConstructionInProgressMember_AAEF3DAA79A23C0874A3205677C2E723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E574D58ACC5DE799B672205677C0795D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_77A5074188BEE2DA2BEE205677C2FC4F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_BD68B8EA336AA67455A5205677C27D82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_BD68B8EA336AA67455A5205677C27D82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3D8ADD5CAAA59EE9A9E5205677C350FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3D8ADD5CAAA59EE9A9E5205677C350FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3DC5DF4A9C572CD6AE26205677C3E8EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_C6FC164060684ECE1F5B205677C274EF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3DC5DF4A9C572CD6AE26205677C3E8EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_0F1ECD2D740A3DC8E3C2205677C6DCA9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C60D23EDD38AD8F76863205677C61BBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_0F1ECD2D740A3DC8E3C2205677C6DCA9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_C60D23EDD38AD8F76863205677C61BBB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_167A2FF983034395ECA6D849D5178407" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_94056978FE7CA192A8E4D849D5179122" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_167A2FF983034395ECA6D849D5178407" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_94056978FE7CA192A8E4D849D5179122" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4B68C3B680DEE02D85E5D849D3BCC18E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BilledContractReceivables" xlink:label="loc_us-gaap_BilledContractReceivables_004EB539A86571F829B3D849D3BC39E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4B68C3B680DEE02D85E5D849D3BCC18E" xlink:to="loc_us-gaap_BilledContractReceivables_004EB539A86571F829B3D849D3BC39E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="loc_us-gaap_UnbilledContractsReceivable_B05BD53022724FA3AF33D849D3BD0797" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4B68C3B680DEE02D85E5D849D3BCC18E" xlink:to="loc_us-gaap_UnbilledContractsReceivable_B05BD53022724FA3AF33D849D3BD0797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_EE4999D417407D8AFDD0D849D3BD10CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4B68C3B680DEE02D85E5D849D3BCC18E" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_EE4999D417407D8AFDD0D849D3BD10CD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9F7961411AF7282B633EE6BB0290E1CF" xlink:type="locator" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9F7961411AF7282B633EE6BB0290E1CF" xlink:to="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9BA42E17FE7B4BFEDC59E6BB02917D09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9BA42E17FE7B4BFEDC59E6BB02917D09" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractWithCustomerLiabilityAdditions" xlink:label="loc_ebs_ContractWithCustomerLiabilityAdditions_4E4CB9035F681132DDDAE6BB02918FC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD" xlink:to="loc_ebs_ContractWithCustomerLiabilityAdditions_4E4CB9035F681132DDDAE6BB02918FC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_184B5BF4547B7CFE5ABFE6BB0291E983" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_184B5BF4547B7CFE5ABFE6BB0291E983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_458BA953277EC0F9D70EE6BB0291A788" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_168380908048EA6D1A03E6BB0290C4FD" xlink:to="loc_us-gaap_ContractWithCustomerLiability_458BA953277EC0F9D70EE6BB0291A788" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7FB6C79B08666FF2099D3EEE3193DBFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7FB6C79B08666FF2099D3EEE3193DBFF" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_3411F454F38AA9D50E1B3EEE3193EA2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:to="loc_srt_ProductOrServiceAxis_3411F454F38AA9D50E1B3EEE3193EA2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_232DDB37D1C4BB6614283EEE31949ED5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3411F454F38AA9D50E1B3EEE3193EA2F" xlink:to="loc_srt_ProductsAndServicesDomain_232DDB37D1C4BB6614283EEE31949ED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_46C6EC4740CFCFF915FA3EEE31949938" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_232DDB37D1C4BB6614283EEE31949ED5" xlink:to="loc_us-gaap_ProductMember_46C6EC4740CFCFF915FA3EEE31949938" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractManufacturingMember" xlink:label="loc_ebs_ContractManufacturingMember_537661271A587D03F3BF3EEE319448C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_232DDB37D1C4BB6614283EEE31949ED5" xlink:to="loc_ebs_ContractManufacturingMember_537661271A587D03F3BF3EEE319448C8" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ContractsAndGrantsMember" xlink:label="loc_ebs_ContractsAndGrantsMember_C7BBBF44D9AD5DDF02B43EEE3195B33F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_232DDB37D1C4BB6614283EEE31949ED5" xlink:to="loc_ebs_ContractsAndGrantsMember_C7BBBF44D9AD5DDF02B43EEE3195B33F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:to="loc_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_24EAC963599C64EEA49C3EEE319AB17E" xlink:to="loc_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_E4ABEDFE2D629882264A3EEE319A5DBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:to="loc_country_US_E4ABEDFE2D629882264A3EEE319A5DBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_DA8F0273A4169A70D61E3EEE319BE401" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6201E9D1EF2E61C61CC63EEE319A5F7F" xlink:to="loc_us-gaap_NonUsMember_DA8F0273A4169A70D61E3EEE319BE401" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_86633882161D25B0EF893EEE31938013" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_390FF8F3FE97177DC1033EEE319B73AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6AC9BA293BD1FFFAAFD53EEE319B9211" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_390FF8F3FE97177DC1033EEE319B73AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3547776FBB58514FAB5CD849D4716339" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_09DCAABB0CA84BE59C9FD849D471756D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3547776FBB58514FAB5CD849D4716339" xlink:to="loc_us-gaap_NumberOfOperatingSegments_09DCAABB0CA84BE59C9FD849D471756D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_D767217F471923F4478ED849D472FA65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3547776FBB58514FAB5CD849D4716339" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_D767217F471923F4478ED849D472FA65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_E7B7DCB4B6BD875870A7D849D4727CD3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3547776FBB58514FAB5CD849D4716339" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_E7B7DCB4B6BD875870A7D849D4727CD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent_AC41A6B9733E55DD4ED4D849D4721772" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3547776FBB58514FAB5CD849D4716339" xlink:to="loc_us-gaap_DeferredCostsCurrent_AC41A6B9733E55DD4ED4D849D4721772" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_94A4771890BCB015CE00D849D502F478" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_253EA23C6B21FC13A181D849D503905E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_94A4771890BCB015CE00D849D502F478" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_253EA23C6B21FC13A181D849D503905E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_02DC7487D444FF4E0270D849D5034DD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_94A4771890BCB015CE00D849D502F478" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_02DC7487D444FF4E0270D849D5034DD1" xlink:type="arc" />
    <link:loc xlink:href="ebs-20190630.xsd#ebs_ScheduleofAccountsReceivableNetTableTextBlock" xlink:label="loc_ebs_ScheduleofAccountsReceivableNetTableTextBlock_DE56EA153F9B900B5E92D849D503CEEC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_94A4771890BCB015CE00D849D502F478" xlink:to="loc_ebs_ScheduleofAccountsReceivableNetTableTextBlock_DE56EA153F9B900B5E92D849D503CEEC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_BD96F35C6D03B47B81FA0AC34D33F9A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2FB493E91E7A7A2253200AC34D33A031" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_BD96F35C6D03B47B81FA0AC34D33F9A6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2FB493E91E7A7A2253200AC34D33A031" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8C0BC96F35B76849F9FC2F38D6482F2E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8C0BC96F35B76849F9FC2F38D6482F2E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:to="loc_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_631C4B5772F40D1273F12F38D6484BE0" xlink:to="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_A971A5FF244CE28285E12F38D6481F11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_A971A5FF244CE28285E12F38D6481F11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5D4FF62F6F1AC96481162F38D648E1C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5D4FF62F6F1AC96481162F38D648E1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3E8AD76BE38FB2A234632F38D648F72A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_11EC414A5BF9F7A1C10C2F38D648774B" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3E8AD76BE38FB2A234632F38D648F72A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:to="loc_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_746FA2A8422440B6FF1D2F38D6487346" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8898D45131822641B82F2F38D6483CA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8898D45131822641B82F2F38D6483CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0465741328C89918370A2F38D648C7AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EE6E54D03F72A8F513AD2F38D6487D84" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0465741328C89918370A2F38D648C7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7AE08CBA254ED5C9E3082F38D6486633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEAD9172C7AB420B80DA2F38D64873BC" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_877984351CC0CBC266062F38D648B022" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_877984351CC0CBC266062F38D648B022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8B1E8BEE3322120D62482F38D648F6AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8B1E8BEE3322120D62482F38D648F6AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1619BD869C58D29B01242F38D648C17C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1619BD869C58D29B01242F38D648C17C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_AFAC7FEC13D28E501EA72F38D648AEA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_FB97A500ABFE3A8D46D72F38D648AFDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_AFAC7FEC13D28E501EA72F38D648AEA5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SupplementalInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_E8FC56F5DA2057DD4022D849D381BF01" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_8E14F15131BCBBB5D567D849D382E733" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_E8FC56F5DA2057DD4022D849D381BF01" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_8E14F15131BCBBB5D567D849D382E733" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_6E2EEE7C220E4B1FAB9BD849D379C5EF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4F5F5CBC07D1098A2301D849D379158B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_6E2EEE7C220E4B1FAB9BD849D379C5EF" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4F5F5CBC07D1098A2301D849D379158B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_437B8930D644B20551D7D849D37AA4A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_6E2EEE7C220E4B1FAB9BD849D379C5EF" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_437B8930D644B20551D7D849D37AA4A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B00C654627F4FAD2715CD849D37A98AC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_6E2EEE7C220E4B1FAB9BD849D379C5EF" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B00C654627F4FAD2715CD849D37A98AC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SupplementalInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_A5A7EEBAF0694C7D6AE9D849D32FDD2E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_001539F5F2DD283C9C58D849D32F29B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_A5A7EEBAF0694C7D6AE9D849D32FDD2E" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_001539F5F2DD283C9C58D849D32F29B2" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>chart-03d50f56d7cd54f29ca.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chart-03d50f56d7cd54f29ca.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $L 2H# 2(  A$! Q$!_\0
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MH_9"_P##)^$?_D.OU'HH _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\
MX)(?](Z/V0O_  R?A'_Y#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\
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M],FN]%U_Q))X+DT'PU9Z5::YJ.GS:EI[Z%I,/A>_LKB&^\,SWFBSV=W+]X4
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M)]T?[\?_ *,6O\,7_@H)_P GZ?MN?]G=_M)_^KE\:4 ?Z^__  1,_P"42/\
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MEUOPQ"]H/@9\&?!'B;QKX/TGX;^$?'>H>'?B+/XN^%'B'0]1\/6]MX6T+3O
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M%%% %/4/^/&\_P"O6Y_]$25_EG7_ /Q^WG_7W=?^E,M?ZF.H?\>-Y_UZW/\
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MN_VD_P#U<OC2O]SJ3[H_WX__ $8M?X8O_!03_D_3]MS_ +.[_:3_ /5R^-*
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M *4RU_=GT*O^;D?]VC_[\I_ _P!.#_FV?_=X?^^P5*<GWU_WE_F*;3D^^O\
MO+_,5_=A_!$=UZK\S_1U_P""<_\ R8?^R#_V;M\*/_42T^OM&OB[_@G/_P F
M'_L@_P#9NWPH_P#42T^OM&O\3.,_^2PXJ_[*/.__ %98D_W*X,_Y(_A/_LFL
MB_\ 57A0HHHKYH^E C/6FE$;&Y%; (&Y0< D$@9' )521W*KGH,.HH 9Y<>,
M>6F/3:N.YZ8QU)/XGUI51$SL15S@G:H7)  !. ,X  'L .@IU% !1110 444
M4 %%%% #)/NC_?C_ /1BU_AB_P#!03_D_3]MS_L[O]I/_P!7+XTK_<ZD^Z/]
M^/\ ]&+7^&+_ ,%!/^3]/VW/^SN_VD__ %<OC2@#_7W_ .")G_*)'_@G1_V:
M#\$?_4/LJ_4:ORY_X(F?\HD?^"='_9H/P1_]0^RK]1J "ODO]O7_ ),C_:[_
M .S:_C7_ .J\U^OK2ODO]O7_ ),C_:[_ .S:_C7_ .J\U^OH.$O^2JX9_P"R
M@R;_ -6.&/G^+?\ DE>)O^R?SG_U78D_S;#U_!?Y"DI3U_!?Y"DK_;@_PPEN
M_5_F:V@_\AO1_P#L+:5_Z<;6O]3!/N+_ +J_R%?Y9^@_\AO1_P#L+:5_Z<;6
MO]3!/N+_ +J_R%?P=]-3^-X<?X.+?SX9/[[^A!_"\2O^OG"/_I/$HZBBBOX8
M/[T"BBB@ HHHH **** "BBB@"GJ'_'C>?]>MS_Z(DK_+.O\ _C]O/^ONZ_\
M2F6O]3'4/^/&\_Z];G_T1)7^6=?_ /'[>?\ 7W=?^E,M?W9]"K_FY'_=H_\
MORG\#_3@_P";9_\ =X?^^P5*<GWU_P!Y?YBFTY/OK_O+_,5_=A_!$=UZK\S_
M $=?^"<__)A_[(/_ &;M\*/_ %$M/K[1KXN_X)S_ /)A_P"R#_V;M\*/_42T
M^OM&O\3.,_\ DL.*O^RCSO\ ]66)/]RN#/\ DC^$_P#LFLB_]5>%"BBBOFCZ
M4**** "BBB@ HHHH **** "BBB@!DGW1_OQ_^C%K_#%_X*"?\GZ?MN?]G=_M
M)_\ JY?&E?[G4GW1_OQ_^C%K_#%_X*"?\GZ?MN?]G=_M)_\ JY?&E '^OO\
M\$3/^42/_!.C_LT'X(_^H?95^HU?ES_P1,_Y1(_\$Z/^S0?@C_ZA]E7ZC4 %
M?)?[>O\ R9'^UW_V;7\:_P#U7FOU]:5\E_MZ_P#)D?[7?_9M?QK_ /5>:_7T
M'"7_ "57#/\ V4&3?^K'#'S_ !;_ ,DKQ-_V3^<_^J[$G^;8>OX+_(4E*>OX
M+_(4E?[<'^&$MWZO\S6T'_D-Z/\ ]A;2O_3C:U_J8)]Q?]U?Y"O\L_0?^0WH
M_P#V%M*_].-K7^I@GW%_W5_D*_@[Z:G\;PX_P<6_GPR?WW]"#^%XE?\ 7SA'
M_P!)XE'4445_#!_>@4444 %%%% !1110 4444 4]0_X\;S_KUN?_ $1)7^6=
M?_\ '[>?]?=U_P"E,M?ZF.H?\>-Y_P!>MS_Z(DK_ "SK_P#X_;S_ *^[K_TI
MEK^[/H5?\W(_[M'_ -^4_@?Z<'_-L_\ N\/_ 'V"I3D^^O\ O+_,4VG)]]?]
MY?YBO[L/X(CNO5?F?Z.O_!.?_DP_]D'_ +-V^%'_ *B6GU]HU\7?\$Y_^3#_
M -D'_LW;X4?^HEI]?:-?XF<9_P#)8<5?]E'G?_JRQ)_N5P9_R1_"?_9-9%_Z
MJ\*%%%%?-'TH4444 %%%% !1110 4444 %%%% #)/NC_ 'X__1BU_AB_\%!/
M^3]/VW/^SN_VD_\ U<OC2O\ <ZD^Z/\ ?C_]&+7^&+_P4$_Y/T_;<_[.[_:3
M_P#5R^-* /\ 7W_X(F?\HD?^"='_ &:#\$?_ %#[*OU&K\N?^")G_*)'_@G1
M_P!F@_!'_P!0^RK]1J "ODO]O7_DR/\ :[_[-K^-?_JO-?KZTKR_XV_#"Q^-
MGP=^*?P>U/5;W0M.^*7P]\7_  ^OM:TZ"VN=0TFT\7Z%?:%<:C96]X&M)[JS
MBOGN((;E3!)+&JRC86KU^'\70P&?9)CL3)PPV"S?+<7B)J,IN%##8RC6JR4(
M*4Y.-.$FHQBY2M:*;:1Y'$&$KX_(<[P.%BIXG&Y1F6$P\'*,%.OB<%6HT8N<
MVH04JDXIRDU&*=Y-)-G^80>OX+_(4E?UY?\ $-C\&/\ HYOXM=NO@WP$?_9*
M/^(;'X,?]'-_%K_PC/ 7_P 17^GO_$T7@U_T4.-_\,.=^7_4#Y_AZV_RU?T4
M_&AMO^P,NU?_ $/\GZV_ZB_/\/6W\D>@_P#(;T?_ +"VE?\ IQM:_P!3!/N+
M_NK_ "%?S:6?_!MU\&K.[M;M/VF?BT[6MU;7*J?!O@(!FMIXYU4GRS@,8P"<
M' .<'&*_I, P /0 ?E7\I?29\3^#?$FIP9+A+,:V/63QXA6/]M@,;@?8O,/[
M#>%Y?KE"C[7G^I8B_L^;DY%S\O-&_P#6?T8/"KC/PQI\:QXOP&'P+SJ?#TL!
M]7Q^#QRJK+XYTL5S?5*U7V7)]=P]O:*//S/EOR2LM%%%?RP?U<%%%% !1110
M 4444 %%%% %/4/^/&\_Z];G_P!$25_EG7__ !^WG_7W=?\ I3+7^ICJ'_'C
M>?\ 7K<_^B)*_P LZ_\ ^/V\_P"ONZ_]*9:_NSZ%7_-R/^[1_P#?E/X'^G!_
MS;/_ +O#_P!]@J4Y/OK_ +R_S%-IR??7_>7^8K^[#^"([KU7YG^CK_P3G_Y,
M/_9!_P"S=OA1_P"HEI]?:-?%W_!.?_DP_P#9!_[-V^%'_J):?7VC7^)G&?\
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M6=?_ /'[>?\ 7W=?^E,M?ZF.H?\ 'C>?]>MS_P"B)*_RSK__ (_;S_K[NO\
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M %%%% !1110 4444 %%%% !1110 4444 4]0_P"/&\_Z];G_ -$25_EG7_\
MQ^WG_7W=?^E,M?ZF.H?\>-Y_UZW/_HB2O\LZ_P#^/V\_Z^[K_P!*9:_NSZ%7
M_-R/^[1_]^4_@?Z<'_-L_P#N\/\ WV"I3D^^O^\O\Q3:<GWU_P!Y?YBO[L/X
M(CNO5?F?Z.O_  3G_P"3#_V0?^S=OA1_ZB6GU]HU\7?\$Y_^3#_V0?\ LW;X
M4?\ J):?7VC7^)G&?_)8<5?]E'G?_JRQ)_N5P9_R1_"?_9-9%_ZJ\*%%%%?-
M'TH4444 %%%% !1110 4444 %%%% #)/NC_?C_\ 1BU_AB_\%!/^3]/VW/\
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M4 %%%% !1110 4444 %%%% %/4/^/&\_Z];G_P!$25_EG7__ !^WG_7W=?\
MI3+7^ICJ'_'C>?\ 7K<_^B)*_P M&^C<WMYA'/\ I=U_"?\ GYE]J_NSZ%7_
M #<C_NT?_?E/X'^F^G_QK/3_ *+#_P!]@HTY/OK_ +R_S%+Y<G_/-_\ OEO\
M*<D<FY?D?[P_A;U'M7]UW7=??_7=?>?P0D[K3JOS7^:^\_T<O^"<_P#R8?\
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MDZQ'JEYH^O21^)?"^J:!XAL[#4[7[T^&_P .O!'PA^'_ (*^%GPU\-Z;X/\
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M_$NN"L'-<!'_ ,$P?V;)?C9XP^,^LZC\9/$D'C;]H#1?VJ-:^#>N?%[Q3/\
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MVJZI?W5Q-<7^IZMJM[>:GJNI75WJ.H7=Q>7,TS^IT44 %%%% #)/NC_?C_\
M1BU_AB_\%!/^3]/VW/\ L[O]I/\ ]7+XTK_<ZD^Z/]^/_P!&+7^&+_P4$_Y/
MT_;<_P"SN_VD_P#U<OC2@#_7W_X(F?\ *)'_ ()T?]F@_!'_ -0^RK]1J_R3
M_P!FW_@Z?_X*:_LL? /X0?LX_#+0_P!EZ;X>_!'X>^&/AIX,F\3_  E\2ZIX
MBE\.>$M-ATK2GUO4K/XDZ7;7^IM:P(;R[AT^S2XG+RBWC+L#[;_Q&.?\%;_^
MA?\ V0O_  R_B[_Y[% '^J'17^5Y_P 1CG_!6_\ Z%_]D+_PR_B[_P">Q1_Q
M&.?\%;_^A?\ V0O_  R_B[_Y[% '^J'17^5Y_P 1CG_!6_\ Z%_]D+_PR_B[
M_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[% '^J'17^5Y_P 1CG_!6_\ Z%_]
MD+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[% '^J'17^5Y_P 1CG_!
M6_\ Z%_]D+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[% '^J'17^5Y
M_P 1CG_!6_\ Z%_]D+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[% '
M^J'17^5Y_P 1CG_!6_\ Z%_]D+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_
MB[_Y[% '^J'17^5Y_P 1CG_!6_\ Z%_]D+_PR_B[_P">Q1_Q&.?\%;_^A?\
MV0O_  R_B[_Y[% '^J'17^5Y_P 1CG_!6_\ Z%_]D+_PR_B[_P">Q1_Q&.?\
M%;_^A?\ V0O_  R_B[_Y[% '^J'17^5Y_P 1CG_!6_\ Z%_]D+_PR_B[_P">
MQ1_Q&.?\%;_^A?\ V0O_  R_B[_Y[% '^J'17^5Y_P 1CG_!6_\ Z%_]D+_P
MR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[% '^J'17^5Y_P 1CG_!6_\
MZ%_]D+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[% '^J'17^5Y_P 1
MCG_!6_\ Z%_]D+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[% '^J'1
M7^5Y_P 1CG_!6_\ Z%_]D+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y
M[% '^J'17^5Y_P 1CG_!6_\ Z%_]D+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_
M  R_B[_Y[% '^J'17^5Y_P 1CG_!6_\ Z%_]D+_PR_B[_P">Q1_Q&.?\%;_^
MA?\ V0O_  R_B[_Y[% '^J'17^5Y_P 1CG_!6_\ Z%_]D+_PR_B[_P">Q1_Q
M&.?\%;_^A?\ V0O_  R_B[_Y[% '^J'17^5Y_P 1CG_!6_\ Z%_]D+_PR_B[
M_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[% '^J!)]T?[\?\ Z,6O\,7_ (*"
M?\GZ?MN?]G=_M)_^KE\:5^_)_P"#QO\ X*W'_F7_ -D+J#_R1;Q=V((Z_%@]
MQ]1U&#S7\QGQ:^)?B+XT?%7XF?&+Q@FF1>+?BQ\0?&?Q+\41Z+:/I^C1^(O'
C?B/4O%&MII-A)/=/9:8FIZK=+86CW-P]M:B*%IYBAD8 _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>chart-8b90b56754be58a0a19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chart-8b90b56754be58a0a19.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &$ 2T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]H?\ @DI_
MP22_X)E?%[_@F9^PI\3OB;^PE^R]XY^(7CO]E[X0^*/&?C+Q/\)/#6K^(O$_
MB/5O"MG<:KK>MZI>6\MS?ZGJ-T7N;RZF8O-/([' VJOZ(?\ #DO_ ()(?](Z
M/V0O_#)^$?\ Y#I?^")G_*)'_@G1_P!F@_!'_P!0^RK]1J /RX_X<E_\$D/^
MD='[(7_AD_"/_P AT?\ #DO_ ()(?](Z/V0O_#)^$?\ Y#K]1Z* /RX_X<E_
M\$D/^D='[(7_ (9/PC_\AT?\.2_^"2'_ $CH_9"_\,GX1_\ D.OU'HH _+C_
M (<E_P#!)#_I'1^R%_X9/PC_ /(='_#DO_@DA_TCH_9"_P##)^$?_D.OU'HH
M _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\ X)(?](Z/V0O_  R?A'_Y
M#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\ #DO_ ()(?](Z/V0O_#)^
M$?\ Y#K]1Z* /RX_X<E_\$D/^D='[(7_ (9/PC_\AT?\.2_^"2'_ $CH_9"_
M\,GX1_\ D.OU'HH _+C_ (<E_P#!)#_I'1^R%_X9/PC_ /(='_#DO_@DA_TC
MH_9"_P##)^$?_D.OU'HH _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\
MX)(?](Z/V0O_  R?A'_Y#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\
M#DO_ ()(?](Z/V0O_#)^$?\ Y#K]1Z* /RX_X<E_\$D/^D='[(7_ (9/PC_\
MAT?\.2_^"2'_ $CH_9"_\,GX1_\ D.OU'HH _+C_ (<E_P#!)#_I'1^R%_X9
M/PC_ /(='_#DO_@DA_TCH_9"_P##)^$?_D.OU'HH _+C_AR7_P $D/\ I'1^
MR%_X9/PC_P#(='_#DO\ X)(?](Z/V0O_  R?A'_Y#K]1Z* /RX_X<E_\$D/^
MD='[(7_AD_"/_P AT?\ #DO_ ()(?](Z/V0O_#)^$?\ Y#K]1Z* /RX_X<E_
M\$D/^D='[(7_ (9/PC_\AT?\.2_^"2'_ $CH_9"_\,GX1_\ D.OU'HH _+C_
M (<E_P#!)#_I'1^R%_X9/PC_ /(='_#DO_@DA_TCH_9"_P##)^$?_D.OU'HH
M _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\ X)(?](Z/V0O_  R?A'_Y
M#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\ #DO_ ()(?](Z/V0O_#)^
M$?\ Y#K]1Z* /RX_X<E_\$D/^D='[(7_ (9/PC_\AU_#;_P=[?L;?LI_L?\
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M?@[^P!\)_P!E37?@K^RS^UE\,)];^,=M\9?V2?%'QG^)7@*T\%_"+Q+\1O\
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M3_LY_"[PAX&GT'X)_!;3+6;5EU#QWXHU[Q;)8W6FZ;%??T'4 %%%% !1110
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M /)]7[87_9RGQB_]375*_LOZ&7_)6<9?]DYA/_5I1/XL^FM_R2'!W_90XO\
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M^R>P?_JRIGUU1117^>1_HR%%%% !1110 4444 %%%% !7^=Y_P 'PW_)5_\
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MB$R:/J/QXU34S\"I(;[X8&7XMR>&1\-)-!Q;3608 _J8!SS_ )_S[45\2?\
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M;N^LM%NO$NM2V4<TC%?MQ21I8[>S2V^7?^"[!(_9N^$Q!(/_  O*R&02./\
MA /&_'%?RS;W_O-_WT?\:Y?H]_1$X+\7_#3+N-L[XFXGRS'XS,LVP53"96\J
M6#C3R_%O#TIP^MY?B*W/."O4O5:YK\JBFDNGZ1GTQN-/!CQ/S#@;).%N%\VR
M_!Y9E&.AC,TEFJQDZF8X2&)JPDL)CJ%'DIR;C3M34K?$V]3^TS3/VZ_^"<^B
M^(];\7Z/\9_@GI7BOQ+'!%XB\3:=I/V'Q!KT5J +6/6M;M/#<.J:LEL% @34
M+NY6' \L*0,&D?MU?\$YO#^NZ_XHT+XS_!/1O$GBJ2*;Q-X@TG2?[-UOQ%+
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M*OU&H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_-Y_X*#_\
M)]7[87_9RGQB_P#4UU2O](:O\WG_ (*#_P#)]7[87_9RGQB_]375*_LOZ&7_
M "5G&7_9.83_ -6E$_BSZ:W_ "2'!W_90XO_ -5\CX]HHHK_ $-/\X@HHHH
M4=?P;^1K_2-_8"_Y,>_9#_[-M^#'_J :%7^;D.OX-_(U_I&_L!?\F/?LA_\
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MF_Y.0^+O_9$)/_4_\)5_4W7^+?TX?^3_ .>?]B'AC_U4T#_<7Z"?_*/&0?\
M8^XF_P#5G,****_D,_L0*_SO/^#X;_DJ_P#P3Q_[)]^T;_ZE/PHK_1#K_.\_
MX/AO^2K_ /!/'_LGW[1O_J4_"B@#^OW_ ((F?\HD?^"='_9H/P1_]0^RK]1J
M_+G_ ((F?\HD?^"='_9H/P1_]0^RK]1J "BBB@ HHHH **** "BBB@ HHHH
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M6K/]"OV>G$.:YUQOX@4LPKPJTZ/"N J4XQH4:5IO-Z46VZ4(-W3M9W1^;?\
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M=6T;XKVOB"]36];MM#MUTZ/P=XKTUFBN;F.1)9OM5_;@0* QC+R9PAS^ ?\
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MV3IT.EU_$O\ \-6?M0_]')_M ?\ AZ?B9_\ -12K^U7^U"64']I+]H#E@/\
MDM/Q,[G_ +&BC_B2_//^BZRK_P ,^+\O^HSU_#S!?39X?=O^,%SC6W_,WP7E
M_P!0OK_6_P#IE#H.OX@@\>H('\J6OS6_X)!^*?$_C3_@G9^SIXF\9>)/$'B[
MQ)J=C\0FU+Q#XIUK4_$.NZBUM\6?'=G;-?ZQK%U>ZC>&WM+>WM+<W%S)Y-K!
M!;Q;(88T7]*&S@XZ_P"<D>I Y [FOY"XDR:?#G$6?</5:\,54R+.<SR>IB:<
M'3AB)Y9C:^"G7A3E*4J<*LJ#J1A*4G%247)M7/[$X:SJGQ)P[D/$-*A/"TL]
MR;*\YIX:I-5)X>&:8&ACH4)U(J,9RI1KJG*:C%2E%M))V%I,C.,C.,XSSCUQ
MUQ7\MVG_ +9O[6OPW_X*PP> OVM_C#^T3^SGX4UCXA^)/ G@3P=KG[.OA7Q[
M^P+\3?A%XR_:/;P-^SK:>&/BG\.I[[QAX$^*/Q,\$ZMX-LI/C!\7_%7ANZT/
M]H'4;OX;W?A*Z\"7NF>%Y_H#XH?%K]N+X$_MK?LD>!9/VP[+X\_'']I+]JS7
M;;XD_L&> _AQ\./^%,?!W_@G<EYXU6\^.3:ZG@.Q^//@GQ/\*]"M?!-]>_$[
MXC?$=_#?Q4^*NKZK\-?"?A74M)CLGT_Q3VS^A'(SC(R.2,\@'H<49&<9&1R1
MGD ]#BOY[M0^+G[<7P6_;K_9"^$NN?M@6/[2GQT_:$^-'Q$U3]I7]BSP#\.O
MAW:? 7]G+]B*+2?B!?>&/C;H7B:U\ :?\<OAKJW@._A^&WAC3-<^,GQ UBV^
M/WC?7?$_A_P[I+PZ3:G3O'/@U^W+^UWK?@#]@W_@H=X@^.NNZ]\-/VZ/V_+#
M]EO7OV,+GP%\,K+X9?"GX+?%?XM?&+X+_"'5/!?BS3_!5M\9V^,_PZU+P3X4
M\8_%'6_%?CW5_#GB9K_QWH2^$_#]AI7AX:: ?TZ$@=2!SCDXY/0<]Z6ORM_X
M*/:M\7_ ND3_ !BUW]O:T_8)_9&^%/PJ\5Z_XT\9^ O!?PX\5?&SQI\=;C5]
M/C^'/AV.+XS> ?B)X1UGP"FGVMU:Z?\ #+P+HMO\5?BOXZUK3O"VFZA'8/#!
M-](?\$__ (C?M"_%S]BS]F7XE_M6^"8_AW^T1XV^#O@WQ%\6/"":;)H<FE^*
MM0T\232WOAV8";PKJFK6(L=<U?PC.!-X2U74[SPW*%?2RJ@'V%7\(O[;#(?V
MP?VH/G3CX]?%$$;UR"/%NI @C/!!!!!Y!!%?W=5^9_Q$^%'PKU/Q]XTU+4_A
MC\.=2U&_\3ZU>7VH:AX%\*7M]>W=Q?323W5Y>76D2W-U<SR,9)KB>62:5R7D
M=F)-?UC]$SQ8P?A-Q/Q7F>,R;$YU'-LAPV A1PV+I8.5&5+,:6(=24ZM&NII
MJ/*HJ*:>MS^1?I>>$6,\7N%N%,JP>=8;)993GV)Q\ZV)PE7%QK1JX">'5.,:
M5:BX23ES<S<DUI9'\:VY?[Z?]]K_ (T;E_OI_P!]K_C7]?'_  IGX/?]$D^%
MW_AN_!O_ ,I:3_A3?P<QG_A4WPMQZ_\ "O/!N/3K_8N.O%?W9_Q.;DG_ $0F
M:_\ A[PG_P [S^!?^))<Z_Z+W*__  RXOR_ZC?7\/,_D(W+_ 'T_[[7_ !HW
M+_?3_OM?\:_KX_X4S\'?^B2_"[_PW?@W_P"4M ^#7P=/3X2_"T_3X>>#3_[A
M:/\ B<W(_P#HA,U_\/>$_P#F /\ B27.O^B]RO\ \,N+\O\ J-]?P\S^08LN
M#\Z=#_&G^-?W@?L6D']D7]F0@@@_ ?X58(((/_%&:1R"."/<5\<?\*9^#O\
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M!_\ D9=8_P"P&?\ TOM*^J*_#^.O^2BQ'_8/@_\ U'@?NW ?_).8?_L(Q?\
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M-/XZ\5>"XM/#>&[+PS/XV@MM%\-23:7X?ETD3S3/_+I_PT'\?/\ HN7QF_\
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M5S^XO_@B[_RC1_9F_P"P?\2/_5P_$&F?\%B_^3&?'O\ V./PO_\ 4UTVM_\
MX) Z,/#_ /P3K_9STA;M;T6=C\0U^U+&(A*9?BSX\G.$624+L,IC(\QN5)."
M2!S_ /P6,('[#'CTLRJ/^$Q^%_+,%'_(ZZ;W8@?K7^4_"M&IA_I?Y;AZT>2M
M0\?G1JP;3<*E+CN<*D6XMQ?+*+5XMIVNFUJ?ZV\3UJ>)^AYF>(H2]I1Q'T?Z
M=:C-1E'GIU> Z,Z<N62C-<T9)\LHJ2O9I.Z/X\:4,R@A690PPP5F4,.>& (#
M#D\-D<GCFH_,B_YZQ?\ ?V/_ .*H\R+_ )ZQ?]_8_P#XJO\ =5Q;WBWZH_P)
MY)_R2_\  7_D2;FV[-S;,YV;FV9]=F=N[WQGWI=[C=B23Y^'.]\N,$8<[OG&
M"1ALU%YD7_/6+_O['_\ %4>9%_SUB_[^Q_\ Q5+E?\N^^F^J?;ND_5(.27\D
MO_ 7Y>7DON78?7ZT?\$6_P#D]*W_ .R2_$7_ -'>&:_)3S(O^>L7_?V/_P"*
MK]:?^"+3HW[:=L%DC8_\*E^(O"R(Q_UWAGL&)_2OQSZ0R?\ Q [Q4T?_ "1.
M>]'_ - <S]N^C9&2\>O":\9+_C-\CW37_,7 _KRK\=?BM_R5'XB_]CIXA_\
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M_3T3]6\0O]QR_P#["Y_^F9'R_P#$CXU>'OAIXJ^%G@_4M#\8:UJOQ6\=^'?
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MO_J4_"BO]$.O\[S_ (/AO^2K_P#!/'_LGW[1O_J4_"B@#^OW_@B9_P HD?\
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MA_\ <5'_  L__J"_^5#_ .XJ\GHH]K/^9_<O\O+\^[&J--M+EW:ZR_S/UO\
M@9J?]L_"OPIJ?D?9_M4.IGR?,\W9Y>MZE#CS-D>[/E[ON+C..<9,OQF_Y$2^
M_P"O[2O_ $NBK$_9P_Y(OX)_ZX:Q_P"I%J];?QF_Y$2^_P"O[2O_ $NBK\5P
M[;XT@WN^(W?_ ,.+/V_$)+@F26RX;II>BR^)\=UX=\5_VF/@!\"KVVT_XQ_%
MOP?\-[N\TA]?MX_%,VJVT;:)'<W%E+JTMW9Z5?6-I8175I<PR3WMS;"-H)&<
M"("0^XUX%\:?#OC3QOXH^ ?@S3K#4+KX6R_%.]\=?&J:WOHX--DT3X8^#-9\
M4_#?POK=BUU#+J6D^+OC(/ MSJ%G#:WEO>6O@]].U=4TN^F2;]JQU2O2P[EA
MTG6<Z<(IPE47OS46Y*&JBD^:3Z13ZV/PO"PHSK*-=M4E&I.;C4C3E:G"51J,
MI0G%S:BU"#2YYN,%)-EO_AICX ?\+/M?@L?BUX03XKWVN3>&;+P#-)J]OK][
MXBMM*O-<N-$LUN-)BTZZU.'1M.U#5)+2WU"21;"POK@_)9W!BZ3XA_&OX/\
MPDGT&V^*7Q0\"?#RX\423Q^'H?&/B73=!DU9;2:SMKVZMQ?31^5I=A<ZCIUK
MJ.MWAM=#TZZU'3[6_P!2MKB_M(IN3A\.^-O$G[3VH^*O$]MJ<?PW^&_P=\,Z
M!\*;J\U%9]'U#XB_%#Q/XON?C-XDAT]+J::'5_#G@SPE\-?!L%_=V4,EOI7B
MOQ7;:3)-#K^L@_%/QE\#?'GQMXS\9_&/PKX$_:-\.7_Q@_9?\(?#KP#X$\+W
MWP,T[6/AK\5_!7BOXRWB^&_VE+?Q3X@\0^&=5^"WC#_A//#7B37]%T^[\:^
M=6L['Q)8^--%U+6CX+LX?-KX_'4,/5J*C[6H\34A1C&C4=J%)\KG*$7>7/.T
M*;<H74XS=HZONH83"5JU.$JWLH?5Z4ZKEB*.M>K9QA";II1C&G)5*EZ<W!PJ
M4F^;E9^J'_ZORKUKX*?\CPG_ &!]1_\ 0[2O%M*CU"+2M+BU8Z<VK1:7IL6K
M'2(IK?2#JL=A;QZF=(@N/](@T@WZW)TJ"X_?P:?]FBG_ 'J/7M/P4_Y'A/\
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M# ZXY/4^N.E)@<<#CIP./IZ4M% !7K7P4_Y'A/\ L#ZC_P"AVE>2UZU\%/\
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M;$_Y$3PQ_P!CA%_Z8]9K\[Z]K@O_ )$-#_K_ (G_ -.L\3C?_D?UO^P?#?\
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M[\.TU]^ @CY5_P"$F\._]!O3?_ I/\:/^$F\._\ 0;TW_P "D_QKYKHK]O\
M;R[+^K?Y/[_(_"O81[R_#_+U_I:_2G_"3>'?^@WIO_@4G^-'_"3>'?\ H-Z;
M_P"!2?XU\UT4>WEV7]6_R?W^0>PCWE^'^7K_ $M?I3_A)O#O_0;TW_P*3_&O
M8_@5K6D7WCU(++4K*ZG_ +$U-_*@G1Y-B/9[GV@YVKN&3VR,U\$5](?LJ?\
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MNGS12?O*[:G"<9VCS6@TE*7+S2Y4T_ACPK\</B+XF^+$OB^^U/XB:+\&KO\
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M_G>?\'PW_)5_^">/_9/OVC?_ %*?A17^B'7^=Y_P?#?\E7_X)X_]D^_:-_\
M4I^%% ']?O\ P1,_Y1(_\$Z/^S0?@C_ZA]E7ZC5^7/\ P1,_Y1(_\$Z/^S0?
M@C_ZA]E7ZC4 %'2BD;H?H?Y4 ?RY_P#!0[XS_"_PK^V#\7=!\0^,=.TO5[!_
M!0O+&>VU626 W/@#PQ=0;WMM.GA/F6\T4J[)7PK@-M;*CXGG_:#^"T\,T'_"
MQ=/@\Z&:'S[:VUN.Y@,L;QB:WD;1I%CN(2WFP2-'(L<R([1R!2C<%_P6 )_X
M>)_M#\G_ %OPS[_]4D\#U^:63ZG\S0!]UZ);_LW:.-;-Q^T%\5_$<^L^,XOB
M3%?>)/&^IW.I>'OB5#';6T?Q \*W^C^ ="GT7Q0=/M1H\TK&]T6ZT6ZU'2[O
M1)[;4;M9>[\-^-OV>O"U_9ZKI_Q>\2W.J#Q'JWBSQ'J6K^)/%6I7?Q"U[5O"
M>G^"EO/B)OT*&V\30:)H&D:/;>%=+CMM+TCPQ+H^ESZ380&U"/\ FNL@=WC2
M0/(AC#QHX:1#*N^(/&I+H94^>(.JF5/GC#+S2A]P#*VY6 965@RLK#(964E6
M4@@A@2""""0: /U+\)_%O]GWP5H[Z'H/CVS2QEUOQ5XBE-ZOB"^NIM6\9^*=
M9\8Z]<S74ND"27[1K>O:A) K _9[0V]FK-';(QZ9?VB/@MD?\7 TGJ/^7/7/
M7_L$U^1B2K(',<J2".62"0QRI((YX2!-!(8V;RYX2RB:!]LL18"1%)&9%)R.
M3U'<^M ']_G_  3Q\0Z+XJ_8[^#6O^'M0BU31]0L_%S6=] D\<4X@\?^*K68
MHES%!,NRX@EB.^)"2A(!4@GO?VLK^QTWX+ZW=ZC>6MA:IK'AA'N;R>.V@5I-
M;M4C5I961 SN0J@G+,0!S7S3_P $@.?^"=/[..?^@=\0?_5L>.Z](_X*)?\
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M\<7"VO@R;XE^)M-TB_\ "7PKB\62R1?\(U)\2=>\*IKL<]O/IK7$%Q#+)]O
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M8>(M'75=(G^S:QHMY/92O)INN:/<_P"C:OHFIQ6>K:7<$0W]E;R,JD ^)O\
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M 5_G>?\ !\-_R5?_ ()X_P#9/OVC?_4I^%%?Z(=?YWG_  ?#?\E7_P"">/\
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M_'/PX\?^-OACJ/@>?P/K@\;>&?$NE>"O''@K6_$^E76J-J6D2Z-X7U#0&O\
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M_P"2K_\ !/'_ +)]^T;_ .I3\**_T0Z_SO/^#X;_ )*O_P $\?\ LGW[1O\
MZE/PHH _)+]FW_@Z?_X*:_LL? /X0?LX_#+0_P!EZ;X>_!'X>^&/AIX,F\3_
M  E\2ZIXBE\.>$M-ATK2GUO4K/XDZ7;7^IM:P(;R[AT^S2XG+RBWC+L#[;_Q
M&.?\%;_^A?\ V0O_  R_B[_Y[%%% !_Q&.?\%;_^A?\ V0O_  R_B[_Y[%'_
M !&.?\%;_P#H7_V0O_#+^+O_ )[%%% !_P 1CG_!6_\ Z%_]D+_PR_B[_P">
MQ1_Q&.?\%;_^A?\ V0O_  R_B[_Y[%%% !_Q&.?\%;_^A?\ V0O_  R_B[_Y
M[%'_ !&.?\%;_P#H7_V0O_#+^+O_ )[%%% !_P 1CG_!6_\ Z%_]D+_PR_B[
M_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[%%% !_Q&.?\%;_^A?\ V0O_  R_
MB[_Y[%'_ !&.?\%;_P#H7_V0O_#+^+O_ )[%%% !_P 1CG_!6_\ Z%_]D+_P
MR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[%%% !_Q&.?\%;_^A?\ V0O_
M  R_B[_Y[%'_ !&.?\%;_P#H7_V0O_#+^+O_ )[%%% !_P 1CG_!6_\ Z%_]
MD+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[%%% !_Q&.?\%;_^A?\
MV0O_  R_B[_Y[%'_ !&.?\%;_P#H7_V0O_#+^+O_ )[%%% !_P 1CG_!6_\
MZ%_]D+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[%%% !_Q&.?\%;_^
MA?\ V0O_  R_B[_Y[%'_ !&.?\%;_P#H7_V0O_#+^+O_ )[%%% !_P 1CG_!
M6_\ Z%_]D+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[%%% !_Q&.?\
M%;_^A?\ V0O_  R_B[_Y[%'_ !&.?\%;_P#H7_V0O_#+^+O_ )[%%% !_P 1
MCG_!6_\ Z%_]D+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[%%% !_Q
M&.?\%;_^A?\ V0O_  R_B[_Y[%'_ !&.?\%;_P#H7_V0O_#+^+O_ )[%%% !
M_P 1CG_!6_\ Z%_]D+_PR_B[_P">Q1_Q&.?\%;_^A?\ V0O_  R_B[_Y[%%%
M !_Q&.?\%;_^A?\ V0O_  R_B[_Y[%'_ !&.?\%;_P#H7_V0O_#+^+O_ )[%
M%% !_P 1CG_!6_\ Z%_]D+_PR_B[_P">Q7Y'?\%,_P#@KI^U9_P5AUSX1>(/
MVH]/^$MC?_!32O&.C^#A\*_!FI^$(9;3QS>^'[[6CK2ZGXH\327\J3^&M.^P
1M%+:);(UUNCE>X+J44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>chart-1352e58451d95236ac3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chart-1352e58451d95236ac3.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $L 2H# 2(  A$! Q$!_\0
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MH_9"_P##)^$?_D.OU'HH _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\
MX)(?](Z/V0O_  R?A'_Y#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\
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M+'K6L02Z5I3WFH1M;@ ^C:* <]/\_P">]% !1110 R3[H_WX_P#T8M?X8O\
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M /QRO\L[[?>_\_EW_P"!5S_\=H^WWO\ S^7?_@5<_P#QVC_B2K_JY'_FH_\
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MG[4WQ<_:8^%_A3PEX&^*%Y+JG[,WPL_9$^ ,OC+XE>&=)A\%W6N>+8;>_P#
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M@KM<UK/_ #0I/]9)_OM_Z$:97]L1_P"#=S]APDG_ (3?]I'DD_\ (^^">_\
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M#1M6T+4?B-XB-AK6F7^DWP@T7P9%,;/4K2:RN1#*?#C^5*8)Y/+DV-L?#%6
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MBBBOG#Z0**** "BBB@ K^-G_ (./_P#DZKX&?]F\G_U9OBVO[)J_C9_X./\
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MZ=.?L6L75C)=-<Z=-ID$N@7MP\U[X9>?4CX=N-,.L:K]L /P,_:ALKC]IO\
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M7VK;?A[]EO\ 9H\(^ _#/PM\*?L]?!#PQ\,_!?C;0/B5X/\ AWX=^%7@70_
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M /!$S_E$C_P3H_[-!^"/_J'V5?J-7Y<_\$3/^42/_!.C_LT'X(_^H?95^HU
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M(I_^$JTOP_X.TN!]&UGQ3/\ 0?Z_\=_]%KQ;_P")'G'_ ,V>7Y]V?/\ ^H/
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MH?$'2A;Z[/;?"30]#NM6FT;3GTA?V(\<>'?V</V=/V:_C&OC'2?#7P\_9O\
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MQ_X+N?$X72=6\12_$*VU;2M,MP#]?H_^"7_[->FQW$/@?QS^V5\.)A<)/O\
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MMJVCZ5XVL_#VHZY?ZII]A/?3W>D30WL5C9V5S!+86L%K']>>$_AMX%\"ZO\
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M^/\ ]&+7^&+_ ,%!/^3]/VW/^SN_VD__ %<OC2O]SJ3[H_WX_P#T8M?X8O\
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M+L_!7]E#X7?L'ZI\"/AM^SO\1O%?Q_C\&ZO;?LLZ=\//V?\ ]HCX^R>"]/\
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ML/$GCKQ$EHGB#QGKUEX:T_3+;5_%>NK86(UGQ#?Q3ZKJAM+8WMU,88ROH=%
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ME_%W_P ]B@#_ %0Z*_RO/^(QS_@K?_T+_P"R%_X9?Q=_\]BC_B,<_P""M_\
MT+_[(7_AE_%W_P ]B@#_ %0Z*_RO/^(QS_@K?_T+_P"R%_X9?Q=_\]BC_B,<
M_P""M_\ T+_[(7_AE_%W_P ]B@#_ %0Z*_RO/^(QS_@K?_T+_P"R%_X9?Q=_
M\]BC_B,<_P""M_\ T+_[(7_AE_%W_P ]B@#_ %0Z*_RO/^(QS_@K?_T+_P"R
M%_X9?Q=_\]BC_B,<_P""M_\ T+_[(7_AE_%W_P ]B@#_ %0Z*_RO/^(QS_@K
M?_T+_P"R%_X9?Q=_\]BC_B,<_P""M_\ T+_[(7_AE_%W_P ]B@#_ %0Z*_RO
M/^(QS_@K?_T+_P"R%_X9?Q=_\]BC_B,<_P""M_\ T+_[(7_AE_%W_P ]B@#_
M %0Z*_RO/^(QS_@K?_T+_P"R%_X9?Q=_\]BC_B,<_P""M_\ T+_[(7_AE_%W
M_P ]B@#_ %0Z*_RO/^(QS_@K?_T+_P"R%_X9?Q=_\]BC_B,<_P""M_\ T+_[
M(7_AE_%W_P ]B@#_ %0Z*_RO/^(QS_@K?_T+_P"R%_X9?Q=_\]BC_B,<_P""
MM_\ T+_[(7_AE_%W_P ]B@#_ %0Z*_RO/^(QS_@K?_T+_P"R%_X9?Q=_\]BC
M_B,<_P""M_\ T+_[(7_AE_%W_P ]B@#_ %0Z*_RO/^(QS_@K?_T+_P"R%_X9
M?Q=_\]BC_B,<_P""M_\ T+_[(7_AE_%W_P ]B@#_ %0)/NC_ 'X__1BU_AB_
M\%!/^3]/VW/^SN_VD_\ U<OC2OWY/_!XW_P5N/\ S+_[(74'_DBWB[L01U^+
M![CZCJ,'FOYC/BU\2_$7QH^*OQ,^,7C!-,B\6_%CX@^,_B7XHCT6T?3]&C\1
E>._$>I>*-;32;"2>Z>RTQ-3U6Z6PM'N;A[:U$4+3S%#(P!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>chart-c40b459aee255b80b3c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chart-c40b459aee255b80b3c.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $L 2H# 2(  A$! Q$!_\0
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MH_9"_P##)^$?_D.OU'HH _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\
MX)(?](Z/V0O_  R?A'_Y#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\
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MZ* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\ #DO_ ()(?](Z/V0O_#)^$?\
MY#K]1Z* /RX_X<E_\$D/^D='[(7_ (9/PC_\AT?\.2_^"2'_ $CH_9"_\,GX
M1_\ D.OU'HH _+9_^")G_!)$ '_AW1^R%]Y!_P D3\(]W4'I9CL?IZ@CBO\
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M $_6_@Y:0I::YIW@6:"U\8->:Z&F7]F:0 #. !DDG QDGJ3[GN>]+0 4444
M%%%% !1110 4444 %%%% #)/NC_?C_\ 1BU_AB_\%!/^3]/VW/\ L[O]I/\
M]7+XTK_<ZD^Z/]^/_P!&+7^&+_P4$_Y/T_;<_P"SN_VD_P#U<OC2@#_7W_X(
MF?\ *)'_ ()T?]F@_!'_ -0^RK]1J_+G_@B9_P HD?\ @G1_V:#\$?\ U#[*
MOU&H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#!\5:E<Z-X:\0
M:M9B(W>F:'J^HVPF0R0FXL=-NKJ 2HK(SQ^;"GF*KH63*AE)R/XGT_X.$?V]
M2D;-I?[/F6CC8X^&?B3&716./^+C=,GBO[4/'_\ R(WC'_L5?$?_ *9+^O\
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M],S_ )*K@[_L08S_ -6#/]&_H4_\DEQC_P!E#A?_ %74PHHHK^-#^U0HHHH
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M"BBB@#Z[_8!_Y/C_ &0/^SE?@Q_ZG>CU_I&U_FY?L _\GQ_L@?\ 9ROP8_\
M4[T>O](VO\\OIF?\E5P=_P!B#&?^K!G^C?T*?^22XQ_[*'"_^JZF%%%%?QH?
MVJ%%%% !1110 4444 %%%% #)/NC_?C_ /1BU_AB_P#!03_D_3]MS_L[O]I/
M_P!7+XTK_<ZD^Z/]^/\ ]&+7^&+_ ,%!/^3]/VW/^SN_VD__ %<OC2@#_7W_
M .")G_*)'_@G1_V:#\$?_4/LJ_4:ORY_X(F?\HD?^"='_9H/P1_]0^RK]1J
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M_I7#XZBBBO[D/X."BBB@#Z[_ & ?^3X_V0/^SE?@Q_ZG>CU_I&U_FY?L _\
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M$-[K.JWX!]UT444 %%%% #)/NC_?C_\ 1BU_AB_\%!/^3]/VW/\ L[O]I/\
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MPR\/?&O]I'X@?%;]H27X]ZKX6L_ACXI\.?M-_#KQ[9>%_"B^'O'&NZWXNO\
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MGX<6EW:^$_B9K?@;PWJ'B>R>5]"?3=0N]0NM,EFU;6/"K>'K(^!]8U1[O4O
MYN-4/A:YTHZM?^=^1/\ P4R_X+"?'+]B3]IA_@E\/_AA\)O%GA]?AWX-\8C5
M_&;>,QK)OO$ESX@AN[4C0M=TZQ^R0#2(3;_Z/YV9)?-D<% GY\?\1('[5/\
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M\LQE7!5JM%SQ\)NE4G1G.GSPC/D<>:,7=+_1+W)DG>,G ^_QQZ#.![D $]Z
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M%%%% !1110!R/C__ )$;QC_V*OB/_P!,E_7^7&G^KB_ZXP_^BDK_ %'/'_\
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M'?\ )(\+?]DYD?\ ZK,*%%%%?.'T84444 %%%% '(^/_ /D1O&/_ &*OB/\
M],E_7^7&G^KB_P"N,/\ Z*2O]1SQ_P#\B-XQ_P"Q5\1_^F2_K_+C3_5Q?]<8
M?_125_>GT*_]T\1?^PCA;_TWQ ?P!]-W_>?#G_KUQ3_Z5P^.HHHK^Y#^#@HH
MHH ^N_V ?^3X_P!D#_LY7X,?^IWH]?Z1M?YN7[ /_)\?[('_ &<K\&/_ %.]
M'K_2-K_/+Z9G_)5<'?\ 8@QG_JP9_HW]"G_DDN,?^RAPO_JNIG\.7_!P%_R?
M])_V0SX5_P#I?XWK\1*_;O\ X. O^3_I/^R&?"O_ -+_ !O7XB5_7_@O_P F
MIX _[)?*?_46!_''CA_R=SQ"_P"RFS#_ -+04445^G'Y6%.3[Z_[R_S%-IR?
M?7_>7^8H''=>J_,_T$?^".'_ "C5_99_[%CQE_ZM/QY7Z:U^97_!'#_E&K^R
MS_V+'C+_ -6GX\K]-:_Q=\2_^3C^('_9;<5_^KW'G^W'AG_R;?P^_P"R(X4_
M]4. "BBBOB3[<9)]T?[\?_HQ:_PQ?^"@G_)^G[;G_9W?[2?_ *N7QI7^YU)]
MT?[\?_HQ:_PQ?^"@G_)^G[;G_9W?[2?_ *N7QI0!_K[_ /!$S_E$C_P3H_[-
M!^"/_J'V5?J-7Y<_\$3/^42/_!.C_LT'X(_^H?95^HU !2-T/T/\J6D;H?H?
MY4X[KU7Y@?P ?\%HO^4E?[2O_7Y\,?\ U3?P_K\MZ_4C_@M%_P I*_VE?^OS
MX8_^J;^']?EO7^SWAA_R;7P]_P"R(X4_]46 /\3/%3_DYWB+_P!ESQ9_ZO<>
M%%%%?<GP04HZ_@W\C24HZ_@W\C0..Z]5^9_I#?\ !/G_ ),8_9!_[-N^#?\
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M?^#/BIXW_94T7]J#P?XS\._M]?M=?MK>$KCX2:3\54^&EYX1\>Z5^U'J[?\
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M/_2A_P""?/\ R8Q^R#_V;=\&_P#U!-%K[!KX^_X)\_\ )C'[(/\ V;=\&_\
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MK&C7PM+?R_3]=_9<_9U\4>*/^$Q\2?!7X;>(-=;X'ZW^S5)+K7A/2M3TZ?X
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M.,R^L_5,/4RK,L-"?U3!U\=7YJ]?#4Z,.3#8:M-<\US."A&\I13_ %4\?_\
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M?@M_V<=I7_JL?B17^9OAK_RD;E?_ &76=?\ IW,S_4#Q0_Y1MS;_ +(+(O\
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M0]JI?5Z^:?V9B'0C1EBJ<:RG)_HW^P"<_MQ_L@>W[2GP7 ] !XZT8  =
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MA2>_NO"_A'PQX;NM4.[4KG0- TK1[B_._P W%W-I]I;RSH),2"-V,0D <)O
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MB\;3R_"145'"X*&)JU8X3#Q4()4:"ITTH12C:,;%?U0?\&T7^M_;&_W?@/\
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MZA_7[OO_ &7_ ."?3I_PPQ^R#\R_\FW?!O\ B'_0B:+[U^4__!QZRG]DKX+
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M37]C?\3F\'_]$AQ/T_Y?93Y7_P"8SU^[[_XP_P"))^+O^BTX9Z?\PN;>5_\
MF']?N^_^1&BOZ[O^(6C]A3_HY'_@HE_XD]H__P ZFC_B%H_84_Z.1_X*)?\
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M0O\ PR_B[_Y[% '^J'17^5Y_Q&.?\%;_ /H7_P!D+_PR_B[_ .>Q1_Q&.?\
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M ?ZH=%?Y7G_$8Y_P5O\ ^A?_ &0O_#+^+O\ Y[%'_$8Y_P %;_\ H7_V0O\
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M  5O_P"A?_9"_P##+^+O_GL4 ?ZH=%?Y7G_$8Y_P5O\ ^A?_ &0O_#+^+O\
MY[%'_$8Y_P %;_\ H7_V0O\ PR_B[_Y[% '^J!)]T?[\?_HQ:_PQ?^"@G_)^
MG[;G_9W?[2?_ *N7QI7[\G_@\;_X*W'_ )E_]D+J#_R1;Q=V((Z_%@]Q]1U&
M#S7\QGQ:^)?B+XT?%7XF?&+Q@FF1>+?BQ\0?&?Q+\41Z+:/I^C1^(O'?B/4O
@%&MII-A)/=/9:8FIZK=+86CW-P]M:B*%IYBAD8 __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>chart-fc671f5e2a225299909.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chart-fc671f5e2a225299909.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $L 2H# 2(  A$! Q$!_\0
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MH_9"_P##)^$?_D.OU'HH _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\
MX)(?](Z/V0O_  R?A'_Y#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\
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M<E_\$D/^D='[(7_AD_"/_P AT?\ #DO_ ()(?](Z/V0O_#)^$?\ Y#K]1Z*
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M^!7QM.O:)H?BW2]3^*FB^-?@]\9OB5=>-H_B'-K?Q+\"^(=3UC2-!DBO.G^
M/@S6]?\ V%O^"^?P&^$7[7EEX*^(,/[>_P"T!%X=_: ^.GQ]CM]7N?!_AOX
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M% !7]6__  ;0_P#((_;'_P"PG\!__3?\5J_E(K^K?_@VA_Y!'[8__83^ _\
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M 4444 %%%% !1110 5_&S_P<?_\ )U7P,_[-Y/\ ZLWQ;7]DU?QL_P#!Q_\
M\G5? S_LWD_^K-\6U_1OT5O^3PY5_P!BC/?_ % F?S;]*_\ Y,WG'_8TR3_U
M/I'\[M%%%?ZEG^4(4444 %?U;_\ !M#_ ,@C]L?_ +"?P'_]-_Q6K^4BOZM_
M^#:'_D$?MC_]A/X#_P#IO^*U?@OTFO\ DRO&'^+AW_UJLC/Z ^B[_P GOX._
MZ]\1_P#K+YR?U(U^27_!5+]CO]HG]K/P9X3T/X30_LR?%CP19ZUX#7QC^SA^
MU;\*-.\4>!-;O=)^,WPZ\8O\2O#_ ,1--\OQ?X8U'2O!_A_Q1X+\:^#6CU31
M/B!\/?$VLZ9I:Z)XKBL+G4_UCOKZSTRRN]1U"YAL[&PM;B]O;NYD6*WM;2TA
M>XN;B>5B%CA@@CDEED8A4C1F)P#7Q</^"DG[ [ ,/VO_ -GLA@&!_P"%G^&\
M%6 ((_TOH000>X-?Y:Y=D>=9PJLLIRC-,TC0<%7EEV Q6-5%U>;V:JO#4JBI
MNIR3Y%/E<E"3C=1=O]7,QSO)LH=*.;9OEF6.NIN@LPQ^%P3K*FXJHZ2Q-6G[
M10<X<[A?EYH\UKH_*OX__P#!+G]N";_@F]\,?^":G[.?CS]E'5OASIMGX9UW
MQ[\1/C+<?&_PEJ^@^*O"G[4FF_M,Z'X(^#_@?P=IOQ#L=*^#/AQM)T[X7>"=
M%\3^+KSQ%X4^'NFZ/IJWVHW.F)<R_2?[0?[,G_!1S]HSX=^&=&^)EI_P3-^(
M]KXB\':[X>^*'[.WQI^$?Q-^+GP)\%_$"#Q3XN7P9\>_@_XZO]*T/XFZMXJB
M^'GB2WT'Q+X"\7:+HFGIJMDUWX(\=>$A>:I<ZI]A?\/(_P!@C_H[[]GO_P .
M?X;_ /DNC_AY'^P1_P!'??L]_P#AS_#?_P EUZ7^I7&/_1)\2_\ ABS3R_ZA
M?-'F_P"NG!W_ $5?#7_A\RS_ .:O/\^S/SJ^-'_!*3XS:S\&_P!C+X8^%[_]
MBW]I3Q?^S-\"M,^#=W\=/VY_@5XZ\?\ Q;TSQ1I-II<%E\7/"&O>%O&MRGBK
M08KBU>_O_P!GCXEQ7_A'Q'J&F>&M1U;Q_P#:],NGOO>E_P""8]WJ'[)^@?\
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M/_J'V5?J-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\;/\
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M2TUS1KIK74=(U.WC87VD:E 1%=+9ZI:V=Q<:9=V&KVT<NEZC8WEQ\X_\%0/
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MG_!1_P (?M&?MK_ GPA\.?'.KZSX>_8YMO\ @H'\=O'&A:]??#*Q\(+=^)_
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MP@G\;>*_B1K]AX^73/"'Q#_X2>R\)>%_&WQ#TS2O"5O? ']T%%-0810!@!0
M.>@&!UY_/GUYIU !1110 4444 %%%% !7\;/_!Q__P G5? S_LWD_P#JS?%M
M?V35_&S_ ,''_P#R=5\#/^S>3_ZLWQ;7]&_16_Y/#E7_ &*,]_\ 4"9_-OTK
M_P#DS><?]C3)/_4^D?SNT445_J6?Y0A1110 5_5O_P &T/\ R"/VQ_\ L)_
M?_TW_%:OY2*_JW_X-H?^01^V/_V$_@/_ .F_XK5^"_2:_P"3*\8?XN'?_6JR
M,_H#Z+O_ ">_@[_KWQ'_ .LOG)_2E\5O^28?$7_L1/&/_J-ZG7^7G%_J;?\
MZ]K;_P!$1U_J&?%;_DF'Q%_[$3QC_P"HWJ=?Y><7^IM_^O:V_P#1$=?C'T+/
M]Q\0_P#L+X:_],YV?M_TW/\ >_#S_KQQ)_Z7D@^BBBO[A/X0"BBB@!LG^JG_
M .O>X_\ 1$E?ZBGPU_Y)YX%_[$WPK_Z8-.K_ "ZY/]5/_P!>]Q_Z(DK_ %%/
MAK_R3SP+_P!B;X5_],&G5_#OTT_]S\//^PCB?_TWD!_>/T(O]Y\1?^O'#/\
MZ<SL[:BBBOX)/[_&2?='^_'_ .C%K_#%_P""@G_)^G[;G_9W?[2?_JY?&E?[
MG4GW1_OQ_P#HQ:_PQ?\ @H)_R?I^VY_V=W^TG_ZN7QI0!_K[_P#!$S_E$C_P
M3H_[-!^"/_J'V5?J-7Y<_P#!$S_E$C_P3H_[-!^"/_J'V5?J-0 444AX!^AH
M6K2[@(Q3E6*_0D CN#U!!'!!'(."*S-(T?1- T^'2M"TS3-$TNW>=[?3M(L[
M73+"![JYFO+IH+.RC@MX6N;RXN+NX,<:^==7$]Q)NFFD=OX\?^"H_P#P4?\
MVV_@3^W7\=OA9\)OV@/$W@SX?^%;KP$GA_PS8:!X"O;33%U;X8^#-<U%8;K6
M/"6I:E*+K5=2OKU_M-[.4DN72(QPK'$GY_\ _#WS_@I#_P!'4>,?_"6^%_\
M\P=?U'D'T3^.N(<BR7/\)G_"5'"9YE.79OAJ6)Q6<QQ%+#YEA*&,HTZ\:625
M::K0IUU&JJ=6I!3BU"<XVD_Y6X@^EOP#PYGV=\/8W(N+:N+R+-\QR?%5</A<
MHEAZN(RS&5<%6J4)5,YIU)4:E2C.=)U*5.HZ;BYTX2O$_P!!_,>"-_7_ *:'
M/X'=D'W!!HS'C&\8YY,A+<YZ,6W#J<8/';%?Y\'_  ]\_P""D/\ T=1XQ_\
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M?KWH =7\;/\ P<?_ /)U7P,_[-Y/_JS?%M?V35_&S_P<?_\ )U7P,_[-Y/\
MZLWQ;7]&_16_Y/#E7_8HSW_U F?S;]*__DS><?\ 8TR3_P!3Z1_.[1117^I9
M_E"%%%% !7]6_P#P;0_\@C]L?_L)_ ?_ --_Q6K^4BOZM_\ @VA_Y!'[8_\
MV$_@/_Z;_BM7X+])K_DRO&'^+AW_ -:K(S^@/HN_\GOX._Z]\1_^LOG)_2E\
M5O\ DF'Q%_[$3QC_ .HWJ=?Y><7^IM_^O:V_]$1U_J&?%;_DF'Q%_P"Q$\8_
M^HWJ=?Y><7^IM_\ KVMO_1$=?C'T+/\ <?$/_L+X:_\ 3.=G[?\ 3<_WOP\_
MZ\<2?^EY(/HHHK^X3^$ HHHH ;)_JI_^O>X_]$25_J*?#7_DGG@7_L3?"O\
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M3'>7]SS_  ];?T]_#W]AC]C'X4?#;QU\'/AO^RE^SOX+^%7Q054^)GP[\/\
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MZM_^#:'_ )!'[8__ &$_@/\ ^F_XK5^"_2:_Y,KQA_BX=_\ 6JR,_H#Z+O\
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MR% 'OO[*Y)_:@_9O)))/Q_\ @P22<DG_ (67X7Y)/)-<\>%WD&"XGKX?&\V
MQF3YC"&7>QE)894J==X"G2Q=>OB,2L/@L(YTH8?G5">)Q6,Q-.GAX3I8:EUK
MBN/$.8\)X?$8#EQ^#SS*ISS+V\$\3*K6PT<?5JX3#X?#89XC'8N-.K/$.#KP
MPV$P>&G4KSA5Q%;_ $RUZ'_>?_T-J_C;_P"#C_\ Y.J^!G_9O)_]6;XMK^R1
M>A_WG_\ 0VK^-O\ X./_ /DZKX&?]F\G_P!6;XMK_/;Z*W_)X<J_[%&>_P#J
M!,_T3^E=_P F:S?_ +&>1_\ J?2/YW:***_U+/\ *(**7:P4,5;:3@-@[2?0
M'H3[9I* "OZM_P#@VA_Y!'[8_P#V$_@/_P"F_P"*U?RD5_5M_P &T3+_ &3^
MV.,C/]I_ ?C.3QI_Q6SP.>._I7X+])K_ ),KQA_BX=_]:K(S^@/HN_\ )[^#
MO^O?$7_K,9R?TI_%;_DF'Q%_[$3QC_ZC>IU_EYQ?ZFW_ .O:V_\ 1$=?ZA/Q
M7D4?##XC$[E"^ _&)9F5D10/#FIY+.P"*H[LS  <D@<U_EH:AXU\%Z%!"=;\
M9>$-&V6UOO&J^*=!TYUVPJK QWFH0R AE92-N0P*D!@0/Q'Z&>)PV%RWQ$JX
MG$4</26+X:;J5ZL*,$O8YWJYU)1BDNK;TZG[M]-3"XG%X_P\I87#U\35=#B2
MU/#TJE:H[U,E6D*<92>O9'4T5Y._QU^#XD\JU\?Z/K$P(!A\-6NM^+),DJ %
M'A?2M85C\Q. Q("2G_EC-L^0OVN?VJO%G@GP]X6L_A/;>)_#TWB2[U0WWC'Q
M%X$UO03';Z9#ITD>G^&X_&&D6L5U<7/]H&?4+U+"62RMXK:.!HVNI)%_JGBK
MQ-X-X2R#,^(<9G&#S'#Y72ISJX+),9@<RS*M.OB*6%HTJ.&I8J*4IUZ].,IU
MZE&C2BY5*M2$8MG\F<)^%O&O%_$.5\.X/)L9EN(S6K4A2QN=X/'Y;EE&%'#U
M<56JUL54PDVX0H4*DE"A3KUJDDH4J4YR2?Z*T5\,_L/_ !W\?_&;PYXTL/B#
M+_:^H>#KS1/L?B@65M92ZC;:Y'JA;3M02RAM[.:]L'TP317,4$4TUK=%;H2-
M%%*_W-7K\&<6Y7QUPSE7%>2PQ=/+<WI5JE"GCJ,</BZ4L-BJ^"Q%&O3A4K4U
M.EBL-6I\U*M5I5%%5*52<)1D_&XVX/S7@+BC-N$L[EA*F99/5H4\14P%:6(P
ME6.)PE#'8>M0JSIT:CA5PN)HU.6K1I5:;DZ=6G"<9139/]5/_P!>]Q_Z(DK_
M %%/AK_R3SP+_P!B;X5_],&G5_EUR?ZJ?_KWN/\ T1)7^HI\-?\ DGG@7_L3
M?"O_ *8-.K^1?II_[GX>?]A'$_\ Z;R _L?Z$7^\^(O_ %XX9_\ 3F=G;444
M5_!)_?XR3[H_WX__ $8M?X8O_!03_D_3]MS_ +.[_:3_ /5R^-*_W.I/NC_?
MC_\ 1BU_AB_\%!/^3]/VW/\ L[O]I/\ ]7+XTH _U]_^")G_ "B1_P""='_9
MH/P1_P#4/LJ_4:ORY_X(F?\ *)'_ ()T?]F@_!'_ -0^RK]1J "D;H?H?Y4M
M(W0_0_RIQW7JOS _@!_X+0';_P %+/VE#@'%[\,3AAE3CX.?#XX(XR#T(STK
M\B[CPY>ZA-91ZMXCO-4TK3=>TSQ)9V<^G6,.I2W^B:N=<T.UU/6X'47NEZ-J
M<6FW-E!;Z7I][<#2;"WU/4;Z$7(N_P!<_P#@M%_RDK_:5_Z_/AC_ .J;^']?
MEO7^Q_A]EF#S+PT\.8XR%:I"GP1PNO90Q>,P]&K&>1Y9*=+%4<-7HTL90FZ4
M%/#XN%>A.*E"=.4)SC+_ !<\1<TQN6>*'B3+!3HTJE3CGBE^UG@\'B:]&<,\
MS.,*N$KXK#UJV"KP56;AB,'.A7A/EG"HITZ<H\3:>"K>TCTW3%U&1_"VBZXG
MB/2/#QL8%>VU&#4[O6M/M)]7$S2W>A:/K%U_:>DZ<;*&ZAGM=/@O-2OK*PBM
MY(]?\-^*M8\.:YH$/C"Q@EUV;Q3:3:C?>$8KYK3PSXAM[RRLM#M+2SUW1XS>
M:%97?D1:[=37,VHM$L][9"1VKNJ*^JI<,Y-0P];"4</B*6'KX=X2I2I9GFM.
M/U3V=.C3PE-PQL94<+AJ5-4L%A:,J>'P%.I7C@J=!8G$*K\E4XISNMB:.+K8
MC#5L1A\0L73JULKRFJ_KGM9UJF,J*>!E&MB\36J.KC<5653$8^I3H3QM3$2P
MV&=+D+/P]JS^&K7P[X@URTU5(VTZSOY],T-]#BU3P[IUO:P_V#<6DNM:PT:Z
ME]D2'5[V.[/VS3IKNPCM+87#3K>T?P^FD7EY<K>M<PRK?PV-N]K##)96^J^(
M-0\4:A'<7:N\NHR/K&I7'V60K:0V=BD=LMM).]S>3]#16D.'<GIXG!XQ86<L
M5@*%/#86O5QF.KU88>C=TJ$YU\34EB*-.HW6A3Q#JPCB%'$J*Q$(5(Q4XESJ
MKAL;@Y8NG'"YA7J8G%8>C@L!0I3Q-;E56O3C0PU-8>M4A!49U</[*<L/S89R
M="<Z<O[BO^#?K_DP*'_LMWQ6_P#1OA^OLC_@J+_RCX_:Y_[(GXL_]%VU?&__
M  ;]?\F!0_\ 9;OBM_Z-\/U]D?\ !47_ )1\?M<_]D3\6?\ HNVK_+CBW_E(
M['_]G3P?_J_PI_JUPA_RCE@/^S88O_U18@_SL)/]9)_OM_Z$:93Y/]9)_OM_
MZ$:97^L$=EZ+\C_(@****8!7O7[*W_)S_P"S?_V7[X+_ /JR_"]>"U[U^RM_
MR<_^S?\ ]E^^"_\ ZLOPO7E9[_R(\Y_[%68_^HE8]GAS_DH<A_['.5_^IU _
MTS%Z'_>?_P!#:OXV_P#@X_\ ^3JO@9_V;R?_ %9OBVO[)%Z'_>?_ -#:OXV_
M^#C_ /Y.J^!G_9O)_P#5F^+:_P R?HK?\GARK_L49[_Z@3/]1/I7?\F:S?\
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MZC>Z99WVLZ<-/M](NWFTZZM]8U""YG>!I[,WENZ._F?@;3M6/PLT_P ,^(?
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M7D@\DGJ<_6C)XY/'3V^GI117]PG\(!1110 V3F*<GK]GN/\ T1)7^HI\-?\
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M!_\ TW_%:OY2*_JW_P"#:'_D$?MC_P#83^ __IO^*U?@OTFO^3*\8?XN'?\
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M['_\.<7_ .DJ'_!93_Q.0_\ SK:\,^*?_!NG^SI\<=8T[Q#\9OVW_P#@J/\
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MGW1_OQ_^C%K_  Q?^"@G_)^G[;G_ &=W^TG_ .KE\:5_N=2?='^_'_Z,6O\
M#%_X*"?\GZ?MN?\ 9W?[2?\ ZN7QI0!_K[_\$3/^42/_  3H_P"S0?@C_P"H
M?95^HU?ES_P1,_Y1(_\ !.C_ +-!^"/_ *A]E7ZC4 %%%%  2!U_SG@?K7Q9
M\&O^"BG[$W[0?Q;U3X&?!K]H_P"''Q!^)^FIXHEMO#NA7^HM;^*H?!&H+I?C
M6?X=>([W3+/PI\48/!NH,+3Q;/\ #?7/%<7AJ?*:T]D%9E]P_:(\$>+/B7\
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MA\4_B9=:S=>"KCQCX_TGPQ\-K;2].TOQ#9R ']&M%%% '@G[1'[4'P$_9/\
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M[1R1LKHS*P)_EN_;GOY/$_CGXX_'G]E;6/VW+"V_X*-?L9^'_AAXX^&^A_\
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M0O\ PR_B[_Y[%'_$8Y_P5O\ ^A?_ &0O_#+^+O\ Y[% '^J'17^5Y_Q&.?\
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M?\1CG_!6_P#Z%_\ 9"_\,OXN_P#GL4 ?ZH=%?Y7G_$8Y_P %;_\ H7_V0O\
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MW1_OQ_\ HQ:_PQ?^"@G_ "?I^VY_V=W^TG_ZN7QI7[\G_@\;_P""MQ_YE_\
M9"Z@_P#)%O%W8@CK\6#W'U'48/-?S&?%KXE^(OC1\5?B9\8O&":9%XM^+'Q!
M\9_$OQ1'HMH^GZ-'XB\=^(]2\4:VFDV$D]T]EIB:GJMTMA:/<W#VUJ(H6GF*
%&1@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>chart-fc88426c8115514eb1d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chart-fc88426c8115514eb1d.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $L 2H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]H?\ @DI_
MP22_X)E?%[_@F9^PI\3OB;^PE^R]XY^(7CO]E[X0^*/&?C+Q/\)/#6K^(O$_
MB/5O"MG<:KK>MZI>6\MS?ZGJ-T7N;RZF8O-/([' VJOZ(?\ #DO_ ()(?](Z
M/V0O_#)^$?\ Y#I?^")G_*)'_@G1_P!F@_!'_P!0^RK]1J /RX_X<E_\$D/^
MD='[(7_AD_"/_P AT?\ #DO_ ()(?](Z/V0O_#)^$?\ Y#K]1Z* /RX_X<E_
M\$D/^D='[(7_ (9/PC_\AT?\.2_^"2'_ $CH_9"_\,GX1_\ D.OU'HH _+C_
M (<E_P#!)#_I'1^R%_X9/PC_ /(='_#DO_@DA_TCH_9"_P##)^$?_D.OU'HH
M _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\ X)(?](Z/V0O_  R?A'_Y
M#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\ #DO_ ()(?](Z/V0O_#)^
M$?\ Y#K]1Z* /RX_X<E_\$D/^D='[(7_ (9/PC_\AT?\.2_^"2'_ $CH_9"_
M\,GX1_\ D.OU'HH _+C_ (<E_P#!)#_I'1^R%_X9/PC_ /(='_#DO_@DA_TC
MH_9"_P##)^$?_D.OU'HH _+C_AR7_P $D/\ I'1^R%_X9/PC_P#(='_#DO\
MX)(?](Z/V0O_  R?A'_Y#K]1Z* /RX_X<E_\$D/^D='[(7_AD_"/_P AT?\
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MJEOINDP0ZOJ:7?XP?\1+I_Z,X/\ X?D?_.FH_P"(ET_]&<'_ ,/R/_G34?\
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MQ_V-,D_]3Z1_.[1117^I9_E"%%%% !7]6_\ P;0_\@C]L?\ ["?P'_\ 3?\
M%:OY2*_JW_X-H?\ D$?MC_\ 83^ _P#Z;_BM7X+])K_DRO&'^+AW_P!:K(S^
M@/HN_P#)[^#O^O?$?_K+YR?U(T445_E"?ZX!1110 4444 %%%% !1110 R3[
MH_WX_P#T8M?X8O\ P4$_Y/T_;<_[.[_:3_\ 5R^-*_W.I/NC_?C_ /1BU_AB
M_P#!03_D_3]MS_L[O]I/_P!7+XTH _U]_P#@B9_RB1_X)T?]F@_!'_U#[*OU
M&K\N?^")G_*)'_@G1_V:#\$?_4/LJ_4:@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OXV?^#C_P#Y.J^!G_9O)_\ 5F^+:_LFK^-G_@X__P"3
MJO@9_P!F\G_U9OBVOZ-^BM_R>'*O^Q1GO_J!,_FWZ5__ "9O./\ L:9)_P"I
M](_G=HHHK_4L_P H0HHHH *_JW_X-H?^01^V/_V$_@/_ .F_XK5_*17]6_\
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M 4444 %%%% !1110 5_&S_P<?_\ )U7P,_[-Y/\ ZLWQ;7]DU?QL_P#!Q_\
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M* "BBB@ HHHH **** "OXV?^#C__ ).J^!G_ &;R?_5F^+:_LFK^-G_@X_\
M^3JO@9_V;R?_ %9OBVOZ-^BM_P GARK_ +%&>_\ J!,_FWZ5_P#R9O./^QID
MG_J?2/YW:***_P!2S_*$**** "OZM_\ @VA_Y!'[8_\ V$_@/_Z;_BM7\I%?
MU;_\&T/_ ""/VQ_^PG\!_P#TW_%:OP7Z37_)E>,/\7#O_K59&?T!]%W_ )/?
MP=_U[XC_ /67SD_J1HHHK_*$_P!< HHHH **** "BBB@ HHHH 9)]T?[\?\
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MU/0_$<\VI_#:PU/6]!\006T4FB6TNG007YU&ZU:]TW2=4T:6:[T6Q+SV\O\
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MPRN-R12.O3*HS#(ZC(!%1X(."#G.,=\^F/6BS[!==PK^K?\ X-H?^01^V/\
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M6?!GP[^)/PHTGXO?LX?!7]G/QQ\1M4^)WPL\$>"_&/BK]H+_ (0KX.:)X?\
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MY?&E '^OO_P1,_Y1(_\ !.C_ +-!^"/_ *A]E7ZC5^7/_!$S_E$C_P $Z/\
MLT'X(_\ J'V5?J-0 4C=#]#_ "I:1NA^A_E3CNO5?F!_ !_P6B_Y25_M*_\
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M'.J6;SQ?]IX2OB6G@9Y:J/L71Q6&Y$UBJG/S*=[1M:SO_<__ ,/]_P#@GO\
M]#!\7/\ PT7B#_Y)H_X?[_\ !/?_ *&#XN?^&B\0?_)-?PQT5_2G_$HOA5_T
M$\6?^'? ^7_4H\OQ?<_F/_B<3Q5_Z!.%/_#7C/+_ *F?E^+[G]SG_#_?_@GO
M_P!#!\7/_#1>(/\ Y)H_X?[_ /!/?_H8/BY_X:+Q!_\ )-?PQT4?\2B^%7_0
M3Q9_X=\#Y?\ 4H\OQ?</^)Q/%7_H$X4_\->,\O\ J9^7XON?W-M_P7X_X)[*
MK,?$'Q<PJLY_XM%X@/"J6/'VGG@'CO7[.:/JEIKFDZ9K-B9&LM6T^RU.T:6-
MH93:ZA:Q7EN9(F^:*0PS(7C;YD;*GD&O\L:3_53_ /7O<?\ HB2O]13X:_\
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M_C9_X./_ /DZKX&?]F\G_P!6;XMK^C?HK?\ )X<J_P"Q1GO_ *@3/YM^E?\
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M;E'BCX?:PY">)/#MQL:22)"VJZ.<V^I0DQ/<5_8Y_P &T/\ R"/VQ_\ L)_
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M(O\ >?$7_KQPS_Z<SL[:BBBOX)/[_&2?='^_'_Z,6O\ #%_X*"?\GZ?MN?\
M9W?[2?\ ZN7QI7^YU)]T?[\?_HQ:_P ,7_@H)_R?I^VY_P!G=_M)_P#JY?&E
M '^OO_P1,_Y1(_\ !.C_ +-!^"/_ *A]E7ZC5^7/_!$S_E$C_P $Z/\ LT'X
M(_\ J'V5?J-0 4C=#]#_ "I:1NA^A_E3CNO5?F!_ !_P6B_Y25_M*_\ 7Y\,
M?_5-_#^ORWK]2/\ @M%_RDK_ &E?^OSX8_\ JF_A_7Y;U_L]X8?\FU\/?^R(
MX4_]46 /\3/%3_DYWB+_ -ESQ9_ZO<>%%%%?<GP04444 ?W%?\&_7_)@4/\
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M2@Y_,C\B1_2OXVO^#C__ ).J^!G_ &;R?_5F^+:^C^BM_P GARK_ +%&>_\
MJ!,^9^E?KX-YQ_V-,D_]3Z1_.[1117^I9_E"%%%% !7]6_\ P;0_\@C]L?\
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MN+MJKJKG:=GV.VHHHK^"C^_ADGW1_OQ_^C%K_#%_X*"?\GZ?MN?]G=_M)_\
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MH>(VTFYNK&'Q9X@6Z>;5+6&:X_L_3=.T+2)[Z^O=,NY$^N/V5O\ DY_]F_\
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MK^N\_P#!K1^PH22?VDO^"B1).2?^&GM'Y)_[I32?\0M'["G_ $<C_P %$O\
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MM*?6]2L_B3I=M?ZFUK AO+N'3[-+B<O*+>,NP/MO_$8Y_P %;_\ H7_V0O\
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M  5O_P"A?_9"_P##+^+O_GL4 ?ZH=%?Y7G_$8Y_P5O\ ^A?_ &0O_#+^+O\
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KH^GZ-'XB\=^(]2\4:VFDV$D]T]EIB:GJMTMA:/<W#VUJ(H6GF*&1@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>emergentlogocmykregistered.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 emergentlogocmykregistered.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %- P\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WZBBBD,**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DICR
M)$A:1U50,DL>*Y^_\;Z!8$AKY9G'\, +Y_$<?K1>V[-*=&I5=H1;.D[4E><7
MOQ5096QTYF]&F<+^@S_.N?NOB+X@N,^7-#;#_IE%D@?\"S4.I%'HTLEQ=3=6
M]3V?(]13'FCC7=)(BCU9@!7@-QXBUFZ)\[4[I@>JB4@'\ 0*SW=Y&+.S,QZE
MB2?UJ75\CNAP[/[<TCZ DU[2(>)=3M$/^U,H_K59O%N@("3JUKQZ2 UX-12]
MJ^QT1X>I]9O[CW;_ (3+P]_T%(/S-*OC#P^QP-5M_P 6Q7A%%'M)%?ZO4?YF
M>_1^)M#E(":M9DGH/.4$_K5V*^M+C_47,,G^XX-?.E%'M?(S?#L>D_P/I/(]
M12U\[0:GJ%L<V]]<Q?[DK+_6M>U\<^(K7 &HM(OI*BMG\<9_6J]JNIRSX>K+
MX))GN/6C%>56?Q3OH\"\L()AW,;%#^N?Z5TEA\2=$NL+<&:T;UD3*_FN?UQ5
M*<7U."KE6+IZN#^1V-+5*RU2QU!=]I=PS+_TS<''UJY5:' XN+LU86BBB@04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 444UG5%+,P  Y).* %H. .37&:W\1-,TXM%9_Z=../W9P@/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML7LS0HHHJCSPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS5V"&*WA6*&-8XT "JHP !Z5)WHC!1#'9C5Q<M=(]$+1115'GA1110 4444
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MZCBO<+&\AO[*&[@;,4J!U/L1FM(S4CQ,PRZ>#DKZI[,LC/>EI*Q->\36'AZ
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MIJ,5JD95LPQ-:')4G= W2OGG5_\ D-7_ /U\2?\ H1KZ&/3\*^>=7_Y#5_\
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M_P#017M=>*?$+_D<KO\ W8__ $$5%78]/(/]Z?H_T.7KK/AQ_P C=%_UR?\
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M?Z0_^SU%/XD>OG/^Y3^7YGI=%%%=!\,%%%% "'I^%?/.K_\ (:O_ /KXD_\
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M4_\ KW?^5:/8\+#_ ,:/JCP2BBBN8_2%L>W?#_\ Y$K3_K)_Z,:NFKF?A_\
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M1MU5U!%6NM% )M.Z9PM]\,-+G8M:7,]MG^'[ZC\^?UK+;X43@_+JR%?> _\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@".21(8R\CJB#JS' HCD2:,/&ZNAZ,IR*P?'/\
MR)NH_P"ZO_H0H\#?\B=IW^ZW_H1I7]ZQO[#_ &?VU^MOPN=%1113, HHHH 0
MC-'>BLS7-631-'GU%XVD6+;E5(R<D#^M'0<8N<E&.[-/O1CFJ.D:BNK:7!?(
MA19EW!2>15[K1TT"47&3B]T0&[M_M'D&XB$W3RRPW?E4X/%<M-X-6;Q>->-X
MP8.K^3L]%"XSGVS754DWU+JQII+D=]-?4****9F%%%% !1110 4444 %%%%
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M?B>*Y3X7V;0Z)<73# GFPONJ\?SR/PH?Q(*'NX.JWU:2-KQS_P B;J/^ZO\
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M'L""3].,?C6OX4LFT_PSI]LZ[76+<PQT+?,?U-/[?R'+3 )/K*Z^XYSXJ?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>ebs-20190630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:ebs="http://emergentbiosolutions.com/20190630"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ebs-20190630.xsd" xlink:type="simple"/>
    <context id="FD2019Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2019-07-26</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1Jan01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="D2019Q2Oct16-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-16</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_VaxchoraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:VaxchoraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-04</startDate>
            <endDate>2018-10-04</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-04</startDate>
            <endDate>2018-10-04</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-04</instant>
        </period>
    </context>
    <context id="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_VivotifMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:VivotifMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-04</startDate>
            <endDate>2018-10-04</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptAndPaxVaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:AdaptAndPaxVaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-04</instant>
        </period>
    </context>
    <context id="D2018Q4Oct04-Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-04</startDate>
            <endDate>2018-10-04</endDate>
        </period>
    </context>
    <context id="D2019Q2Oct05-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:PaxVaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-05</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_RaxibacumabMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:RaxibacumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-29</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2019Q2Jun01-Jun30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct15_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_FederalFundsEffectiveSwapRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="D2019Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:ConvertibleSeniorNotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_LitigationCaseAxis_ebs_ShareholderClassActionLawsuitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:ShareholderClassActionLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <unit id="instrument">
        <measure>ebs:instrument</measure>
    </unit>
    <unit id="segment">
        <measure>ebs:segment</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="employee">
        <measure>ebs:employee</measure>
    </unit>
    <unit id="acquisition">
        <measure>ebs:acquisition</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2019Q2YTD"
      id="Fact-633500DED1F4BF58F196D849934C811B-wk-Fact-633500DED1F4BF58F196D849934C811B">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q2YTD"
      id="Fact-2FA0529C4504CEE71F4ED84993464F39-wk-Fact-2FA0529C4504CEE71F4ED84993464F39">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q2YTD"
      id="Fact-8E766C8D6844019AFF6BD849934B8A9B-wk-Fact-8E766C8D6844019AFF6BD849934B8A9B">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q2YTD"
      id="Fact-39072BBAD513B04F4BD6D849934431B1-wk-Fact-39072BBAD513B04F4BD6D849934431B1">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q2YTD"
      id="Fact-1A34215A6114696E8063D8499340B004-wk-Fact-1A34215A6114696E8063D8499340B004">0001367644</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="FD2019Q2YTD"
      id="Fact-B3F6E151CFE2EED78B58D84993011B2F-wk-Fact-B3F6E151CFE2EED78B58D84993011B2F">Emergent BioSolutions Inc.</dei:EntityRegistrantName>
    <ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod
      contextRef="D2019Q2Jun01-Jun30"
      id="Fact-2A03403A030216A3E3E321093923D758-wk-Fact-2A03403A030216A3E3E321093923D758">P12M</ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod>
    <ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod
      contextRef="D2019Q2Jun01-Jun30"
      id="Fact-8B1EFCC5E5368BAAE96C2108FAB890A7-wk-Fact-8B1EFCC5E5368BAAE96C2108FAB890A7">P12M</ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod>
    <ebs:LockUpPeriodForAdjustmentOfFairValue
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      id="Fact-F260B6C6DD3982B1D7D3D84993208256-wk-Fact-F260B6C6DD3982B1D7D3D84993208256">P2Y</ebs:LockUpPeriodForAdjustmentOfFairValue>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="Fact-1A7A89DDE6C999F9E6DF2086FA579DF9-wk-Fact-1A7A89DDE6C999F9E6DF2086FA579DF9"
      unitRef="shares">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-A342D42E47C998CA0659D849934F5CA4-wk-Fact-A342D42E47C998CA0659D849934F5CA4"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-28AD6FF06800448FCC97D84992F7AC01-wk-Fact-28AD6FF06800448FCC97D84992F7AC01"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-4ABB77FA5885B84DDEA8D84993465755-wk-Fact-4ABB77FA5885B84DDEA8D84993465755"
      unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-81771B26A04EC162D8EED849934B3D7A-wk-Fact-81771B26A04EC162D8EED849934B3D7A"
      unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-E1E4968E58EEDCAF4EB2D84992FF0291-wk-Fact-E1E4968E58EEDCAF4EB2D84992FF0291"
      unitRef="shares">52400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q2"
      decimals="-5"
      id="Fact-C7DB2D25D2DCB25909BED84992FEBBC4-wk-Fact-C7DB2D25D2DCB25909BED84992FEBBC4"
      unitRef="shares">52700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-5072EC13163953EE3D92D84992F784B7-wk-Fact-5072EC13163953EE3D92D84992F784B7"
      unitRef="shares">51200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2"
      decimals="-5"
      id="Fact-F0673B56D186B1F9DD00D8499345C94D-wk-Fact-F0673B56D186B1F9DD00D8499345C94D"
      unitRef="shares">51600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="Fact-032708EBC94F8F4DA859211DB81400F6-wk-Fact-032708EBC94F8F4DA859211DB81400F6"
      unitRef="usd">3200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="Fact-4F1A902A54F8D066E7D7D849932EB424-wk-Fact-4F1A902A54F8D066E7D7D849932EB424">P22Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-10FA5BCA54E05A324A68D849932F3022-wk-Fact-10FA5BCA54E05A324A68D849932F3022">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember"
      id="Fact-B1D092BCDB05B3A1547DD849932DFD1D-wk-Fact-B1D092BCDB05B3A1547DD849932DFD1D">P22Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-B9628CE24AEF5E79D891D849932CD1A1-wk-Fact-B9628CE24AEF5E79D891D849932CD1A1">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-166D97F36502E68698B0D849934DFCDD-wk-Fact-166D97F36502E68698B0D849934DFCDD"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-2A25587A2EA4A9E87B6AD8499300796E-wk-Fact-2A25587A2EA4A9E87B6AD8499300796E"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-23659D7E85AD01EEF88DD84992FA5AB5-wk-Fact-23659D7E85AD01EEF88DD84992FA5AB5"
      unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-559FD8D702A8CEEBDFEAD849934EB344-wk-Fact-559FD8D702A8CEEBDFEAD849934EB344"
      unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-D470E5B8CC0A026089D0D84992F64C99-wk-Fact-D470E5B8CC0A026089D0D84992F64C99"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q2"
      decimals="-5"
      id="Fact-91427E27D78562DF4FEFD8499345CDDE-wk-Fact-91427E27D78562DF4FEFD8499345CDDE"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-926A78DDB7E4A03F4ABAD849934E47B8-wk-Fact-926A78DDB7E4A03F4ABAD849934E47B8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2019Q2"
      decimals="-5"
      id="Fact-124E9F4D9A287416384CD8499345B615-wk-Fact-124E9F4D9A287416384CD8499345B615"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="Fact-790EF2D77CD7456B190BD849933598B6-wk-Fact-790EF2D77CD7456B190BD849933598B6">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact-2521576F449A80F27EDFD84993328F41-wk-Fact-2521576F449A80F27EDFD84993328F41">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="4"
      id="Fact-330109A5D113009A5AF3D8499337534C-wk-Fact-330109A5D113009A5AF3D8499337534C"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"
      decimals="4"
      id="Fact-57D6C9692EF29E6F36CDD8499336DC5B-wk-Fact-57D6C9692EF29E6F36CDD8499336DC5B"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="4"
      id="Fact-E6F88B549C357D672F49D84993329813-wk-Fact-E6F88B549C357D672F49D84993329813"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="4"
      id="Fact-3E7AF7A4FE361AD854CBD84993325550-wk-Fact-3E7AF7A4FE361AD854CBD84993325550"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"
      decimals="4"
      id="Fact-12C699CA865D16C280D6D8499335F48E-wk-Fact-12C699CA865D16C280D6D8499335F48E"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="4"
      id="Fact-1A38FD7962734E4396A7D8499335893A-wk-Fact-1A38FD7962734E4396A7D8499335893A"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:TreasuryStockShares
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-9C2072E5F4FF04FEC05AD8499343C1FC-wk-Fact-9C2072E5F4FF04FEC05AD8499343C1FC"
      unitRef="shares">1200000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="FI2019Q2"
      decimals="-5"
      id="Fact-B5EBFBD936C1A40FA8CDD84992F69164-wk-Fact-B5EBFBD936C1A40FA8CDD84992F69164"
      unitRef="shares">1200000</us-gaap:TreasuryStockShares>
    <dei:DocumentType
      contextRef="FD2019Q2YTD"
      id="d374411422e600-wk-Fact-CE516FC5B4A898DC9F7BD870EC3DC66A">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2019Q2YTD"
      id="d374411422e635-wk-Fact-D5DD5966B88107330E6BD84E72ABC1D1">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q2YTD"
      id="d374411422e677-wk-Fact-EEDCD96BAB9CA2D7CD222F4D228C6B8C">2019-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q2YTD"
      id="d374411422e715-wk-Fact-2E251E1B50C915444822D84EBB192205">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q2YTD"
      id="d374411422e762-wk-Fact-BA772165577EB323AF1ED8709A151A9C">001-33137</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q2YTD"
      id="d374411422e793-wk-Fact-9A4BEA10BC73BDA8F014D84F78FC527E">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q2YTD"
      id="d374411422e803-wk-Fact-8E9FB54E32010778E776D84FC2CDF3CE">14-1902018</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q2YTD"
      id="d374411422e831-wk-Fact-DBDE0DCD8850005C550D2A8E053DB513">400 Professional Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="FD2019Q2YTD"
      id="d374411422e847-wk-Fact-C2A7FF656B3500EFB4A12A8E4A3061DB">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q2YTD"
      id="d374411422e863-wk-Fact-E34F8434D72E43580BBB2A8E8AD8E6D4">Gaithersburg</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q2YTD"
      id="d374411422e868-wk-Fact-7FB1C4C0A795610424FB2A8EC5CB2937">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q2YTD"
      id="d374411422e873-wk-Fact-F03A85D27971330A8EFAD85038DD7B4B">20879</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q2YTD"
      id="d374411422e895-wk-Fact-D909599260976C428C18D850CAC1A09C">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q2YTD"
      id="d374411422e900-wk-Fact-FF0A615E0F3A41DE53BBD85112C6ECBA">631-3200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q2YTD"
      id="d374411422e953-wk-Fact-2D7F08B785BA5BB823D4D851C9D12584">Common Stock, Par Value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q2YTD"
      id="d374411422e958-wk-Fact-86341F3959A8D859B58FD852049AE728">EBS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q2YTD"
      id="d374411422e963-wk-Fact-33B9BBCC4094C42031D1D8524CF36606">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q2YTD"
      id="d374411422e972-wk-Fact-895C663B0772AA5AB940D85309A5AA92">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q2YTD"
      id="d374411422e990-wk-Fact-796FF079E75B04ED201ED85372F0C9A6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q2YTD"
      id="d374411422e1020-wk-Fact-4DB970E6D5E5C014E9A82A8FB9697528">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q2YTD"
      id="d374411422e1056-wk-Fact-14B4AC70BEC8BC2A0AEA2A9014E74F4E">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q2YTD"
      id="d374411422e1078-wk-Fact-DF1C4F1A77B9921FC2772A905E01ABF2">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q2YTD"
      id="d374411422e1090-wk-Fact-B9C50C21B049F75672FFF6E10694C705">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2019Q3Jul26"
      decimals="-5"
      id="d374411422e1106-wk-Fact-FED1A04800107DB1A114D849934675DA"
      unitRef="shares">51600000</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e752-wk-Fact-6CA7FDAA9259FA7C68D2D8499320BDDE"
      unitRef="usd">177400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e771-wk-Fact-5D4E7B3352A75B0F2A05D84992FD64FA"
      unitRef="usd">112200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e786-wk-Fact-B9C41DB0950C2A663727D84993021485"
      unitRef="usd">200000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e805-wk-Fact-44A59C06CCAA8245F02CD849932174C5"
      unitRef="usd">200000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e825-wk-Fact-A88953A1A1C03C0062A4D84992F80FB1"
      unitRef="usd">218100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e844-wk-Fact-5624509D06373D0CA867D84992FD89D0"
      unitRef="usd">262500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e864-wk-Fact-10DA71DCD649ED36B6D3D84992F794DC"
      unitRef="usd">232000000.0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e883-wk-Fact-C6A98BDF9041D79AA0CBD84993196BE5"
      unitRef="usd">205800000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e903-wk-Fact-4634D0A8146EC3C727D20ACE35633E63"
      unitRef="usd">65000000.0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e922-wk-Fact-B4560EB1444301088AC6D849930742AC"
      unitRef="usd">40100000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e942-wk-Fact-750C9B5A6BEF421975DD0ACE35435A5F"
      unitRef="usd">692700000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e961-wk-Fact-3599C1364ED3CCD717550ACE35248F32"
      unitRef="usd">620800000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1022-wk-Fact-1CEE78D1635C9E8C9F7DD8499312146B"
      unitRef="usd">520500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1041-wk-Fact-A2A3491175BAC7A69E11D84992FE01C5"
      unitRef="usd">510200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1062-wk-Fact-FE4ECDD57018F5D60735D8499306CC08"
      unitRef="usd">742400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1081-wk-Fact-69E40D411BA61D68402FD84993190E23"
      unitRef="usd">761600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <ebs:InProcessResearchAndDevelopment
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1101-wk-Fact-6F81C8C3571BE73E120CD84993082DA3"
      unitRef="usd">41000000.0</ebs:InProcessResearchAndDevelopment>
    <ebs:InProcessResearchAndDevelopment
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1120-wk-Fact-8B732AAB5AD51B438FD4D84992FC06B9"
      unitRef="usd">50000000.0</ebs:InProcessResearchAndDevelopment>
    <us-gaap:Goodwill
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1140-wk-Fact-DB909FD2CAB8A2E53C25D84992FF1DFA"
      unitRef="usd">268300000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1159-wk-Fact-8DEC0005C0EAFE923857D84993239E34"
      unitRef="usd">259700000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1179-wk-Fact-997D38E6FE71AC07FF840ACE35349412"
      unitRef="usd">56400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1198-wk-Fact-0050FDE657BC3A35F7DDD84993244253"
      unitRef="usd">27100000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1223-wk-Fact-BFCA1AE5B25C1940FAE40ACE34F56EC2"
      unitRef="usd">2321300000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1242-wk-Fact-4B8732A2A9AE7ABD66990ACE35051DA5"
      unitRef="usd">2229400000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1385-wk-Fact-A35825C452EB9BE7AA79D84993238F37"
      unitRef="usd">124500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1404-wk-Fact-3A5BC904134AE3B47C9BD849930FBF60"
      unitRef="usd">80700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1419-wk-Fact-71002ADA47EFC5B61667D8499323B0B3"
      unitRef="usd">54800000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1438-wk-Fact-EFC9101D85A80C19D87BD8499321E583"
      unitRef="usd">30700000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1458-wk-Fact-F33F9D2812CBF5E99CCAD849930735B7"
      unitRef="usd">54600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1477-wk-Fact-A8CABA014494591D9ACBD84992F87ED2"
      unitRef="usd">5600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1498-wk-Fact-9D7FA89106A10ACF5D96D84992F8F1F0"
      unitRef="usd">44700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1517-wk-Fact-5F71788CEFFD4A7A0BF4D849932146FF"
      unitRef="usd">58200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1537-wk-Fact-C06927FD4A5E3D153EA6D84992FA7654"
      unitRef="usd">10100000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1556-wk-Fact-720282BBC8CDC2055C5DD8499301C100"
      unitRef="usd">10100000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1576-wk-Fact-5A16393C4F46E08E9DDD0ACE34E6B7FB"
      unitRef="usd">12500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1595-wk-Fact-5BEC15CD0EECECAC2F61D84993033514"
      unitRef="usd">15100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1615-wk-Fact-1FFE2263889E8673C6E40ACE3553A6E7"
      unitRef="usd">301200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1634-wk-Fact-533E39F880035C0B5BC70ACE3515323A"
      unitRef="usd">200400000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1654-wk-Fact-2D50EEF0D8061536707FD84992F959B3"
      unitRef="usd">10400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1673-wk-Fact-143AF016C4D0C236184BD8499310C013"
      unitRef="usd">54400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1693-wk-Fact-5684FE71939B0564A1CAD8499314675E"
      unitRef="usd">830400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1712-wk-Fact-75E6B826C88E6B401542D849930F45CA"
      unitRef="usd">784500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1732-wk-Fact-F8587F470D18A089A210D849931A07D3"
      unitRef="usd">65600000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1751-wk-Fact-3DA7ACFDDB3F4939749AD84993130455"
      unitRef="usd">67500000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1771-wk-Fact-588FF4786B98BDA87338D849931A45FB"
      unitRef="usd">77000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1790-wk-Fact-08ADFF214BCA83FB6FB2D849931F0A04"
      unitRef="usd">62500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1810-wk-Fact-BB34F4626CF61D44F3370ACE356330F3"
      unitRef="usd">47800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1829-wk-Fact-C1C75462575F42DA1303D8499322B6D4"
      unitRef="usd">49200000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1854-wk-Fact-730B53D4A98A987E8EEA0ACE35535AAC"
      unitRef="usd">1332400000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1873-wk-Fact-9A94E1215FD08984AD620ACE356350A9"
      unitRef="usd">1218500000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q2"
      id="d374409672e1888-wk-Fact-D0917CB3AC1DD27240AFD84993201A8C"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d374409672e1906-wk-Fact-6E54F817BA4218234B62D84993161809"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e1967-wk-Fact-77E0C134362802B1A217D84993003A3A"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e1986-wk-Fact-4EE6146A40839CAA1FE6D8499312E409"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e2006-wk-Fact-0208442C2B6D55F7B4E5D84993130D82"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e2025-wk-Fact-727F49DBDACE775F3610D84993237E2F"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e2045-wk-Fact-26396D2B911CD1EC1BACD84993109107"
      unitRef="usd">39700000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e2065-wk-Fact-E7B4820E4E6D7EB9ADACD849931145D4"
      unitRef="usd">39600000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e2086-wk-Fact-59DA6ED0660CBAA670DCD849931FBE7B"
      unitRef="usd">701800000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e2105-wk-Fact-C56FA79E07A6F6AFB04BD8499317C6B9"
      unitRef="usd">688600000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e2125-wk-Fact-905111246D4FA94C4E21D84992FFB13E"
      unitRef="usd">-5000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e2145-wk-Fact-AAD4EABBCD043CCAC462D84993105BC2"
      unitRef="usd">-5500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e2166-wk-Fact-7BD4E44266377A71871FD84993221A15"
      unitRef="usd">331700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e2185-wk-Fact-3F36C1EFE3099B33F76CD84992FEE651"
      unitRef="usd">367300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e2205-wk-Fact-3426FA62817349CDE2680ACE3553FBC6"
      unitRef="usd">988900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e2224-wk-Fact-B4353C2A4F51AFB1781E0ACE3534119C"
      unitRef="usd">1010900000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374409672e2249-wk-Fact-18D607088DEDCAA5943C0ACE3563DDBF"
      unitRef="usd">2321300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374409672e2268-wk-Fact-BCE723F7CC0C73C8BDBF0ACE35A8F222"
      unitRef="usd">2229400000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d374415026e882-wk-Fact-88076C57679DEBBE211ED8499305E222"
      unitRef="usd">183500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d374415026e901-wk-Fact-03C6DD3FE93475379D53D84992F6A572"
      unitRef="usd">180100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d374415026e920-wk-Fact-D3E43AE69523DCD4EE9BD849933CA0FF"
      unitRef="usd">336500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d374415026e940-wk-Fact-C239168A4E13BC91AFC1D84993402A50"
      unitRef="usd">255800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d374415026e955-wk-Fact-6CD0E930F110BBC79097D8499344AE28"
      unitRef="usd">18700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d374415026e974-wk-Fact-5F10A1FE3C8C63F7E0FAD849933D6AEA"
      unitRef="usd">23600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d374415026e993-wk-Fact-25CD4F38EEECA1E915A0D8499300583A"
      unitRef="usd">34600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d374415026e1013-wk-Fact-F4AEB1569AD0C8F57AC8D84993046424"
      unitRef="usd">49800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember"
      decimals="-5"
      id="d374415026e1033-wk-Fact-6CAE36F4026D53DEBBECD8499307243D"
      unitRef="usd">41000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember"
      decimals="-5"
      id="d374415026e1052-wk-Fact-D368A395B32B7D3E19B2D8499342140F"
      unitRef="usd">16500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember"
      decimals="-5"
      id="d374415026e1071-wk-Fact-8323D54F6C251661152ED849933B4536"
      unitRef="usd">62800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember"
      decimals="-5"
      id="d374415026e1091-wk-Fact-159F13845B496BD4A6AAD849934CA9C8"
      unitRef="usd">32400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e1111-wk-Fact-7AE92434260DD4FB2CF8D849934D3C6E"
      unitRef="usd">243200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e1130-wk-Fact-EA0211D77CFC99544611D8499308E5C8"
      unitRef="usd">220200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e1149-wk-Fact-8AF29B1E3DD6C78B7907D849934FCD81"
      unitRef="usd">433900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e1169-wk-Fact-75FE50318A68C4409098D849934304DC"
      unitRef="usd">338000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e1353-wk-Fact-BC9413A8EE13E48DB795D84992FB2BB9"
      unitRef="usd">100800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e1372-wk-Fact-CD7467FE4985ABB39350D84992FC83FA"
      unitRef="usd">85300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e1391-wk-Fact-836C345479CB7FB8BD11D84993433694"
      unitRef="usd">192700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e1411-wk-Fact-82D63DA99E1978686086D849933B35E5"
      unitRef="usd">139400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e1431-wk-Fact-F91644A6679F4021812AD849934CA920"
      unitRef="usd">63900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e1450-wk-Fact-DA635381279112F8A7D4D8499304E143"
      unitRef="usd">24700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e1469-wk-Fact-4D3B3459E1B8FF2126E5D84992F802F9"
      unitRef="usd">110000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e1489-wk-Fact-7817EAF32F82F2A1600CD849933E3F48"
      unitRef="usd">53800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e1510-wk-Fact-28FFDE0BF31DADA8B19FD8499301CAFB"
      unitRef="usd">70800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e1529-wk-Fact-68B5192079967326094FD849934DA25A"
      unitRef="usd">39500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e1548-wk-Fact-8207B37E2BD12B59D6E5D84992FED7C4"
      unitRef="usd">136400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e1568-wk-Fact-CAAF25D22A31CAE05C66D84992F9306D"
      unitRef="usd">79700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e1588-wk-Fact-38FAEE743CD4490EC338D849930066FB"
      unitRef="usd">14700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e1607-wk-Fact-91C07E9A1D86B917DC36D84993429398"
      unitRef="usd">3900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e1626-wk-Fact-F2D6BB1B4B9EB2F408EFD84992FE3070"
      unitRef="usd">29200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e1646-wk-Fact-D5704BA4F2023D767670D84992F932EB"
      unitRef="usd">7800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e1666-wk-Fact-4C627DB7235FEA6A1B5FD84993438ED2"
      unitRef="usd">250200000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e1685-wk-Fact-E299E0095131A754D6E2D84993025885"
      unitRef="usd">153400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e1704-wk-Fact-41289C5F0EDC59E69031D84992FB62CE"
      unitRef="usd">468300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e1724-wk-Fact-AEB42FF49DA433FA6C14D84992FA7D02"
      unitRef="usd">280700000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e1826-wk-Fact-E1FA88E10CACDEECF57AD84992FF59FB"
      unitRef="usd">-7000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e1846-wk-Fact-B023BA349C18D956057DD849933DD842"
      unitRef="usd">66800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e1865-wk-Fact-6DC9C2468432039C61EBD8499341D785"
      unitRef="usd">-34400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e1886-wk-Fact-F228648F5E239B2BE170D8499308D1D6"
      unitRef="usd">57300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e2070-wk-Fact-C087CCE9758F68C53B9AD84992FCC638"
      unitRef="usd">9500000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e2090-wk-Fact-D60803BEA92C84D7E828D84993078F69"
      unitRef="usd">1000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e2110-wk-Fact-37BC4CB7E332A044112BD84993460A22"
      unitRef="usd">19000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e2131-wk-Fact-3202B85C26E0464C0F48D849934159A9"
      unitRef="usd">1200000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e2152-wk-Fact-6DCDBD4DE0D1D3C27F7CD849933DA0F2"
      unitRef="usd">1400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e2171-wk-Fact-EDF9EB933542A19CC891D84993417ED4"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e2190-wk-Fact-371C4DD2F986DD21488ED84992F6F294"
      unitRef="usd">400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e2210-wk-Fact-6F7BA23D1D790B6E8F87D849934D7480"
      unitRef="usd">300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e2230-wk-Fact-C350B661BFEAA69EBB3ED849933F71E1"
      unitRef="usd">-8100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e2250-wk-Fact-C4AE18B0B41827559EAED84993091084"
      unitRef="usd">-1000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e2270-wk-Fact-D0296EF7F1B7F7412777D84993068AAA"
      unitRef="usd">-18600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e2291-wk-Fact-D872ACFD2B20499F3358D8499308AD17"
      unitRef="usd">-900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e2395-wk-Fact-5EE662F0B8EF11EBEFBFD849933D8864"
      unitRef="usd">-15100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e2415-wk-Fact-298034CC7080FB1000ABD8499300ADB5"
      unitRef="usd">65800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e2434-wk-Fact-C993B2D0EAA2F737C3FDD849933ED6B3"
      unitRef="usd">-53000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e2455-wk-Fact-8B6C249A640EE6B23D0AD84992F698AA"
      unitRef="usd">56400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e2475-wk-Fact-1C0B214C1AC186F572ACD84992FE8A34"
      unitRef="usd">-5600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e2495-wk-Fact-D07E37ACA7D991D30539D84992FA4AB9"
      unitRef="usd">15700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e2514-wk-Fact-3C8C05A9BD9F0006EED6D84992FEDC0F"
      unitRef="usd">-17400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e2535-wk-Fact-C864500EC8153E8B1CA4D84993419963"
      unitRef="usd">11200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e2560-wk-Fact-D743C8D6F80F558CBC290AC7114D7930"
      unitRef="usd">-9500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e2580-wk-Fact-6A5AA47224555576B480D849933E5596"
      unitRef="usd">50100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e2599-wk-Fact-F8F669F62D331789D59FD84992F9F119"
      unitRef="usd">-35600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e2620-wk-Fact-2EED907790460F1DF430D849934BDBA8"
      unitRef="usd">45200000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d374415026e2804-wk-Fact-7090664CCD3C5A1ED984D8499303C361"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d374415026e2824-wk-Fact-D0A64B8EAE0004E47B12D8499303D192"
      unitRef="usdPerShare">1.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d374415026e2843-wk-Fact-942BAE68901FFA254237D84993449FB1"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q2YTD"
      decimals="2"
      id="d374415026e2864-wk-Fact-4C84A2D71E9B4E703742D849933F78FA"
      unitRef="usdPerShare">0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d374415026e2884-wk-Fact-35C4160347E4E5189413D84992FC2D0C"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d374415026e2904-wk-Fact-9C4E901483C9A5C87F06D84993017C7A"
      unitRef="usdPerShare">0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d374415026e2923-wk-Fact-5FE71E088EBD1B785B06D849933F0F9D"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q2YTD"
      decimals="2"
      id="d374415026e2944-wk-Fact-EE1327C309A8868B9739D849930225C0"
      unitRef="usdPerShare">0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e3041-wk-Fact-604D294840B21CF66CB1D84992F67E5B"
      unitRef="shares">51500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e3060-wk-Fact-6F53F55F8F03B9782E00D849934F1265"
      unitRef="shares">49900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e3079-wk-Fact-D473C427EEC3F9B8B9B8D84992FBCF74"
      unitRef="shares">51300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e3099-wk-Fact-2B2B237C358CCD4D03BAD84993464804"
      unitRef="shares">49700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374415026e3119-wk-Fact-BEBD441B08D611CB9B81D84992FD4F85"
      unitRef="shares">51500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374415026e3138-wk-Fact-428DB6DF8872466C8F67D84993452A7C"
      unitRef="shares">51200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374415026e3157-wk-Fact-82D7F8E323F4CB1ACD59D84992FF590D"
      unitRef="shares">51300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374415026e3177-wk-Fact-6361343FA5C0CEA88D03D849934F771E"
      unitRef="shares">51000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374409671e800-wk-Fact-D743C8D6F80F558CBC290AC7114D7930"
      unitRef="usd">-9500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374409671e820-wk-Fact-6A5AA47224555576B480D849933E5596"
      unitRef="usd">50100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374409671e839-wk-Fact-F8F669F62D331789D59FD84992F9F119"
      unitRef="usd">-35600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374409671e860-wk-Fact-2EED907790460F1DF430D849934BDBA8"
      unitRef="usd">45200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374409671e953-wk-Fact-DD739EED5B5361CD056FD84993237E35"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374409671e972-wk-Fact-5BFB46AE7E1F05344EDDD849931DE1A1"
      unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374409671e992-wk-Fact-DEDC5DF683A2507A69F5D84993211D89"
      unitRef="usd">1700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374409671e1012-wk-Fact-211BEAA3753DF66F74CED849931B7893"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374409671e1033-wk-Fact-EB0834D2D34C0526CD750ACA6E3173B0"
      unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374409671e1053-wk-Fact-18078FDCC3D74201AAF40ACA6E2B3145"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374409671e1072-wk-Fact-FE18D26C8ADB4A769B820ACA6E440C26"
      unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374409671e1093-wk-Fact-16AB9DF66313E2E3FD110ACA6E3AEFC9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374409671e1113-wk-Fact-0071F5022E8AF89320F2D849931D9ABD"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374409671e1133-wk-Fact-2DF3FE6CDC2119F2F7BAD849931E839D"
      unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374409671e1153-wk-Fact-1F771DD02ADFBCFFDCE40AC789070A05"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374409671e1173-wk-Fact-3C68A22FA66FBCD106BCD849931E2D0D"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374409671e1199-wk-Fact-95AC380DA86514E6D33ED849931D7121"
      unitRef="usd">-10000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374409671e1219-wk-Fact-8B23FC4598C1FB5B2EA4D849932105CF"
      unitRef="usd">48900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374409671e1238-wk-Fact-48348395C316A53C3A3ED84993229EE0"
      unitRef="usd">-35100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374409671e1259-wk-Fact-5771ECB6DAD5D327A19DD849931F7ADA"
      unitRef="usd">44500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e750-wk-Fact-F8F669F62D331789D59FD84992F9F119"
      unitRef="usd">-35600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e770-wk-Fact-2EED907790460F1DF430D849934BDBA8"
      unitRef="usd">45200000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e826-wk-Fact-6C68AB26B84C2F387FD4D849931EB87A"
      unitRef="usd">14900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e845-wk-Fact-4729652EBCBBBCF1ED1FD849931B5C98"
      unitRef="usd">11700000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e865-wk-Fact-9B247D9DA9E6DE290D51205CC1A8C2A0"
      unitRef="usd">55100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e884-wk-Fact-146549FB6BC6D3488654D849931C18B9"
      unitRef="usd">24700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e904-wk-Fact-33FEE785CA428397506FD84993146283"
      unitRef="usd">1500000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e923-wk-Fact-6F670712B3DE770BEEDCD8499311F56C"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e943-wk-Fact-798BB97F971A27773696D849931777EA"
      unitRef="usd">-1300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e963-wk-Fact-5B0942CF3423DE657BFDD849931BE8B9"
      unitRef="usd">8500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <ebs:ChangeInFairValueOfContingentConsideration
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e983-wk-Fact-EE481DD852320D2A886CD849931E6965"
      unitRef="usd">5500000</ebs:ChangeInFairValueOfContingentConsideration>
    <ebs:ChangeInFairValueOfContingentConsideration
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1002-wk-Fact-A0E154D44CA3AF539C95D849930F0C4C"
      unitRef="usd">1700000</ebs:ChangeInFairValueOfContingentConsideration>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1022-wk-Fact-7E1DC485ADE32B53F7D7D84993181055"
      unitRef="usd">-2900000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1041-wk-Fact-A6871E5C36C55151C07CD849930740A6"
      unitRef="usd">-1200000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1103-wk-Fact-F84583569E41C92103CDD84993185CDF"
      unitRef="usd">-44600000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1122-wk-Fact-EF3DB5B1EE8FAE2FAC92D849931664CE"
      unitRef="usd">46200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1143-wk-Fact-A5D1F4B248D651A2BF38D8499309C6FE"
      unitRef="usd">26100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1163-wk-Fact-0A91AB4EEB98E4473FD7D849931C1A93"
      unitRef="usd">-3400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1183-wk-Fact-2622BA7D4B9DBBA8E2F1205CC1E10238"
      unitRef="usd">44900000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1203-wk-Fact-4C64ACD2FEC767FE68D3205CC18C2248"
      unitRef="usd">9300000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1224-wk-Fact-65DEC97C5335ED0E1780D8499309EFFE"
      unitRef="usd">42600000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1243-wk-Fact-65F6420BA5A3A12EA466D8499310E12A"
      unitRef="usd">-4400000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1264-wk-Fact-0BD3AF04A99F2BA5366CD849931ECE55"
      unitRef="usd">6900000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1283-wk-Fact-884951A9D6E6FDC0FC4FD8499316645D"
      unitRef="usd">5600000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1303-wk-Fact-A13D8C7726425BD83F2BD849930E2CDF"
      unitRef="usd">-13500000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1323-wk-Fact-EEA1CF7E3D4540870F57D84993112BB5"
      unitRef="usd">-8600000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1344-wk-Fact-971FD998A98B9DFD9541D849931A227F"
      unitRef="usd">16400000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1363-wk-Fact-711B7BDFEB08F0B89AC0D849931E1B7B"
      unitRef="usd">100000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1383-wk-Fact-69C5AF9771FD2CE579BA205CC1D38BB6"
      unitRef="usd">69000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1402-wk-Fact-899E9E15C02ACDB8D931205CC1C4ECA2"
      unitRef="usd">33600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1463-wk-Fact-7A1F45131DBD50F50C32D84993159E46"
      unitRef="usd">35500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1483-wk-Fact-B9C62CDCBFEAFB9552FAD849930802E4"
      unitRef="usd">25200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForPreviousAcquisition
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1505-wk-Fact-60EBCBD7116C086793D445FF545396DD"
      unitRef="usd">10000000.0</us-gaap:PaymentsForPreviousAcquisition>
    <us-gaap:PaymentsForPreviousAcquisition
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1525-wk-Fact-9D941AB1105F8880CAC245FF5472E356"
      unitRef="usd">0</us-gaap:PaymentsForPreviousAcquisition>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1545-wk-Fact-B5B5335AD4A88472A03F205EC8CD57F1"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1564-wk-Fact-676CB6C79BC78C4526AE205EC8C62569"
      unitRef="usd">2600000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1584-wk-Fact-F74DE832DD9C0266699B205CC19AFFB2"
      unitRef="usd">-45500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1604-wk-Fact-CAB605F5179A6A462C9B205CC17D67D2"
      unitRef="usd">-22600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1666-wk-Fact-F396DF4928EE381FAE72D849931B326F"
      unitRef="usd">130000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1685-wk-Fact-69B04E6110F50ED96015D84993201D4D"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1705-wk-Fact-9C27A50EEE09A8CBB84AD849931FF9F9"
      unitRef="usd">80000000.0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1725-wk-Fact-F367C67F5C32B344E0F2D84993117442"
      unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1745-wk-Fact-9BD45498A2B067672263D849931E4079"
      unitRef="usd">5600000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1765-wk-Fact-4A5D6E79036E8F546D6AD849931E7A89"
      unitRef="usd">0</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1785-wk-Fact-2C16A89326A71BDA5C29D849931388CF"
      unitRef="usd">4600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1804-wk-Fact-33ABDE25371D50B8A8D7D8499318DED8"
      unitRef="usd">8500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1824-wk-Fact-D5458B1D209CEBE42438D8499308BD3F"
      unitRef="usd">6300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1844-wk-Fact-62A237065735961D385DD8499308973D"
      unitRef="usd">6000000.0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1865-wk-Fact-4D2877C06F40C4EF7A05D8499309668D"
      unitRef="usd">1000000.0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1885-wk-Fact-31263A08A121CBE6B6EDD84993205330"
      unitRef="usd">1300000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1906-wk-Fact-55BC8876E28F54A3C344D849931B9E94"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1925-wk-Fact-CC0227CB4E083E47711BD849931DFB65"
      unitRef="usd">100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1947-wk-Fact-BED71B2F9CA4EF83C30A205CC1B6D3E1"
      unitRef="usd">41700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e1966-wk-Fact-81169E2E625AF8EF6075205CC163F2A2"
      unitRef="usd">1100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e1986-wk-Fact-1015F5340F25015F4D3AD8499335C5D7"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e2005-wk-Fact-1B090A66FA10202078B3D8499332692C"
      unitRef="usd">-100000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374413382e2026-wk-Fact-ED4C81D13835AA9741A2D8499318C9A3"
      unitRef="usd">65200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374413382e2045-wk-Fact-976C2F59E46E5468E9CBD8499313E18B"
      unitRef="usd">12000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374413382e2065-wk-Fact-8DD36C3DCC90E3398706D84993149DCA"
      unitRef="usd">112400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-5"
      id="d374413382e2084-wk-Fact-E03DD34EEE4AE6C73690D849931B708A"
      unitRef="usd">179300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374413382e2109-wk-Fact-9A111BE18CEE889F3286D84993178D44"
      unitRef="usd">177600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q2"
      decimals="-5"
      id="d374413382e2128-wk-Fact-0D132E5959EB1358DF80D84993094107"
      unitRef="usd">191300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e1127-wk-Fact-DF3F9BFC46AA162061832060B1A929CB"
      unitRef="shares">52400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d374420172e1146-wk-Fact-0AA68506EA84EF382B3B2060AD25C79F"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e1165-wk-Fact-F480243440E5E6780D002060ADB34E8A"
      unitRef="usd">688600000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d374420172e1180-wk-Fact-25DAAA90CB7BDAB93FFE2060AFB5FE5D"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d374420172e1200-wk-Fact-8384AAFA8E2BA738DAFE2060B1FE57DE"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e1220-wk-Fact-BF912D07EFCD8B1B05482060B2E3A470"
      unitRef="usd">-5500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e1241-wk-Fact-258F4C55E4A5D30995DC2060AB720E4B"
      unitRef="usd">367300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374420172e1260-wk-Fact-B4353C2A4F51AFB1781E0ACE3534119C"
      unitRef="usd">1010900000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e1280-wk-Fact-DE81B2827C2C5B21915C2060AEAFD6A4"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e1313-wk-Fact-2EF44F64E68958AF30172060AD29C2F5"
      unitRef="usd">13200000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d374420172e1347-wk-Fact-DE41F93B77DA26F465562060ABB35B7F"
      unitRef="usd">-100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374420172e1406-wk-Fact-9D6E34F8DBA94EFFC8152060B3553BCA"
      unitRef="usd">13100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e1537-wk-Fact-2CA3415AB5BFC93512DF2060AB810F9A"
      unitRef="usd">-35600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374420172e1557-wk-Fact-F8F669F62D331789D59FD84992F9F119"
      unitRef="usd">-35600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e1669-wk-Fact-1DB6EE77B0D01CA3E7F62060AD309E17"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374420172e1708-wk-Fact-1F771DD02ADFBCFFDCE40AC789070A05"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e1733-wk-Fact-2717E9F07256943640B92060B00DA6F7"
      unitRef="shares">52700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d374420172e1752-wk-Fact-62221AE53C842ABA34252060AFD476AC"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e1771-wk-Fact-DB2714766F53017108B72060B34B477C"
      unitRef="usd">701800000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d374420172e1786-wk-Fact-9054E5B6AC8EA99821112060B016217B"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d374420172e1806-wk-Fact-DA7EA47F43F64B3A97492060B0E38114"
      unitRef="usd">-39700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e1826-wk-Fact-7BED963FB6A25CC3D88F2060AFFBA392"
      unitRef="usd">-5000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e1847-wk-Fact-1A8EACCBD733363A52AA2060AFDD99A7"
      unitRef="usd">331700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374420172e1866-wk-Fact-3426FA62817349CDE2680ACE3553FBC6"
      unitRef="usd">988900000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e2044-wk-Fact-D3520E0A2616979AB1002060ABDF230F"
      unitRef="shares">52600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d374420172e2062-wk-Fact-38E350398C9D9198897C2060B0C874C0"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e2080-wk-Fact-8CB43AC6F73E193ABC982060AD834B8F"
      unitRef="usd">690100000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d374420172e2094-wk-Fact-CCF2405617361AF64D262060B1762C90"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d374420172e2113-wk-Fact-72358FAD7469C8BE5E062060ABD02E2C"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e2132-wk-Fact-0EFAF3127A5D8449D04A2060B2F75936"
      unitRef="usd">-4500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e2152-wk-Fact-3D98EE478D0B34FC531F2060B1491520"
      unitRef="usd">341200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1"
      decimals="-5"
      id="d374420172e2170-wk-Fact-C2B1B61974154C70E7472060AFE8B936"
      unitRef="usd">987300000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e2190-wk-Fact-9292219CB4E96C4746D12060B2D77368"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e2221-wk-Fact-DF57480934ECF5574CFA2060AC6CE6EA"
      unitRef="usd">11700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d374420172e2253-wk-Fact-FB5FC15B876915FDF86C2060AD43A556"
      unitRef="usd">-100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374420172e2308-wk-Fact-5710C04D96CF96C656FC2060AB4ACBD2"
      unitRef="usd">11600000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e2440-wk-Fact-129FC81C13FF44BA87B02060B3356D2B"
      unitRef="usd">-9500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374420172e2460-wk-Fact-D743C8D6F80F558CBC290AC7114D7930"
      unitRef="usd">-9500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e2572-wk-Fact-D38DB35BBE491844CECB2060AE5EFCC3"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374420172e2612-wk-Fact-0071F5022E8AF89320F2D849931D9ABD"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e2638-wk-Fact-2717E9F07256943640B92060B00DA6F7"
      unitRef="shares">52700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d374420172e2656-wk-Fact-62221AE53C842ABA34252060AFD476AC"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e2674-wk-Fact-DB2714766F53017108B72060B34B477C"
      unitRef="usd">701800000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d374420172e2688-wk-Fact-9054E5B6AC8EA99821112060B016217B"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d374420172e2707-wk-Fact-DA7EA47F43F64B3A97492060B0E38114"
      unitRef="usd">-39700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e2726-wk-Fact-7BED963FB6A25CC3D88F2060AFFBA392"
      unitRef="usd">-5000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e2746-wk-Fact-1A8EACCBD733363A52AA2060AFDD99A7"
      unitRef="usd">331700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374420172e2764-wk-Fact-3426FA62817349CDE2680ACE3553FBC6"
      unitRef="usd">988900000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e2942-wk-Fact-6FA33A0D6C651869BB052060AF1F46F6"
      unitRef="shares">50600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d374420172e2960-wk-Fact-BFFD019483468B140A6E2060B260136B"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e2978-wk-Fact-16EA6A006758778BED612060AF4F7877"
      unitRef="usd">618400000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d374420172e2992-wk-Fact-FF6F6756D27CD055A45C2060B272295E"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d374420172e3011-wk-Fact-8215D14708821E3C8BD52060B33F429E"
      unitRef="usd">-39500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e3030-wk-Fact-A427031C5C45768444FC2060AC103DE9"
      unitRef="usd">-3800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e3050-wk-Fact-E1E1171FBFEF8A9D8E782060B35F01AC"
      unitRef="usd">337100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-5"
      id="d374420172e3068-wk-Fact-7775F946258B8FAC0C612060AC2FC7B2"
      unitRef="usd">912300000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e3194-wk-Fact-828CF22DFE1AA732826D206322A45BAC"
      unitRef="usd">-32500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1Jan01"
      decimals="-5"
      id="d374420172e3214-wk-Fact-CAB2F585A76BD88A3263206322A03858"
      unitRef="usd">-32500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CommonStockSharesIssued
      contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e3240-wk-Fact-080A5FB9DF42A20935F32063EE9D4061"
      unitRef="shares">50600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
      contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d374420172e3254-wk-Fact-6129255B08195147EFE62063F09531AD"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
      contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e3273-wk-Fact-1CFD769DCEEAD3F967D02063F2A006DE"
      unitRef="usd">618400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
    <us-gaap:CommonStockSharesIssued
      contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d374420172e3293-wk-Fact-46C23BBF213429E675172063F49863A6"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
      contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d374420172e3308-wk-Fact-0EF30E910D8DAF3F6CD22063F6A0529B"
      unitRef="usd">-39500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
      contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e3328-wk-Fact-60CE32D50E1A74C660102063F87F7756"
      unitRef="usd">-3800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
      contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e3349-wk-Fact-EC504C56162E1A616EBA2063FBBC618D"
      unitRef="usd">304600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
      contextRef="I2018Q1Jan01"
      decimals="-5"
      id="d374420172e3368-wk-Fact-01798B7F5AE2A741A5452063FDB3EE4A"
      unitRef="usd">879800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e3393-wk-Fact-BC18BE16A690E8D81EF62060AFAE2998"
      unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e3424-wk-Fact-06AB402B0E9D6C3405352060B0014B08"
      unitRef="usd">14100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d374420172e3456-wk-Fact-03587C926CB40EE9FC832060AD4A0A73"
      unitRef="usd">-100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374420172e3512-wk-Fact-5F8D943B5DDB2255FF872060B3221136"
      unitRef="usd">14000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e3637-wk-Fact-C133E6B004E3700514E02060AD0AAB79"
      unitRef="usd">45200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374420172e3655-wk-Fact-2EED907790460F1DF430D849934BDBA8"
      unitRef="usd">45200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e3761-wk-Fact-DED9A027A706948A40992060AFF1287D"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374420172e3799-wk-Fact-3C68A22FA66FBCD106BCD849931E2D0D"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e3825-wk-Fact-420D8E6BFD2786ADE71B2060AC018809"
      unitRef="shares">51200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d374420172e3843-wk-Fact-533B2BF3661F3955825E2060B2EB4C59"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e3861-wk-Fact-FE5E1895F04576FE53002060ACB5EDC0"
      unitRef="usd">632500000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d374420172e3875-wk-Fact-273211CECF0B715BA4E62060AD026FAA"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d374420172e3894-wk-Fact-39560FDA5BCA8E635D3B2060B32A5287"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e3913-wk-Fact-8CDF1D7CBBA4FA5CA0AB2060B301AAC1"
      unitRef="usd">-4500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e3933-wk-Fact-FA3417207E002D6DE6942060AF4831D6"
      unitRef="usd">349800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2"
      decimals="-5"
      id="d374420172e3951-wk-Fact-F4A7C7D211ED420BB1572060AD19696A"
      unitRef="usd">938300000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e4130-wk-Fact-B39E8F4C42340FD87E9A2060AEBFB905"
      unitRef="shares">51000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d374420172e4148-wk-Fact-16C46071F09456CB30E92060B30CD771"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e4166-wk-Fact-EF370D03939352A234AD2060AD15EF7B"
      unitRef="usd">624400000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d374420172e4180-wk-Fact-3A0435D3CA52C790BBDB2060AFC7A7FF"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d374420172e4199-wk-Fact-E4F4DFE5A956E360CD5C2060B0395F6B"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e4218-wk-Fact-D6133E85406578D8DB7D2060B0335C3C"
      unitRef="usd">-3300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e4238-wk-Fact-AEAE688FE3F05DC0FF372060AC3C97FB"
      unitRef="usd">299700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1"
      decimals="-5"
      id="d374420172e4256-wk-Fact-6B8722E80A13159476532060AD56CA24"
      unitRef="usd">881300000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e4276-wk-Fact-121F2293210B63E896032060B1168E8B"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e4307-wk-Fact-13B6F0994DF48D6357BD2060AC1FBCD4"
      unitRef="usd">8100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374420172e4394-wk-Fact-9D45128FA0C7E5AA2D572060AFC12F94"
      unitRef="usd">8100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e4519-wk-Fact-F4D1C73D4A7C44BD61852060B2CE00C4"
      unitRef="usd">50100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374420172e4537-wk-Fact-6A5AA47224555576B480D849933E5596"
      unitRef="usd">50100000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e4643-wk-Fact-6DD198419A3D026907272060AD34ABD5"
      unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374420172e4681-wk-Fact-2DF3FE6CDC2119F2F7BAD849931E839D"
      unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d374420172e4707-wk-Fact-420D8E6BFD2786ADE71B2060AC018809"
      unitRef="shares">51200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d374420172e4725-wk-Fact-533B2BF3661F3955825E2060B2EB4C59"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d374420172e4743-wk-Fact-FE5E1895F04576FE53002060ACB5EDC0"
      unitRef="usd">632500000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="INF"
      id="d374420172e4757-wk-Fact-273211CECF0B715BA4E62060AD026FAA"
      unitRef="shares">1200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d374420172e4776-wk-Fact-39560FDA5BCA8E635D3B2060B32A5287"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d374420172e4795-wk-Fact-8CDF1D7CBBA4FA5CA0AB2060B301AAC1"
      unitRef="usd">-4500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d374420172e4815-wk-Fact-FA3417207E002D6DE6942060AF4831D6"
      unitRef="usd">349800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2"
      decimals="-5"
      id="d374420172e4833-wk-Fact-F4A7C7D211ED420BB1572060AD19696A"
      unitRef="usd">938300000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-FB7E68EF5FA261F05D63D849935F4815-0-wk-Fact-197B28CE62C5160D2083D849931227D2">Business&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Emergent is a global life sciences company focused on providing specialty products for civilian and military populations that address accidental, deliberate and naturally occurring PHTs. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The Company is focused on innovative preparedness and response products and solutions addressing the following four distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives (CBRNE); emerging infectious diseases (EID); travelers&#x2019; diseases; and opioids. The USG is the Company's largest customer and provides the Company with substantial funding for the development of a number of the Company's product candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The majority of the Company's revenue comes from a product portfolio that includes: &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Vaccines and Anti-Infectives&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; - &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;BioThrax&#xae; (Anthrax Vaccine Adsorbed), ACAM2000&#xae; (Smallpox (Vaccinia) Vaccine, Live), Vaxchora&#xae; (Cholera Vaccine, Live, Oral), and Vivotif&#xae; (Typhoid Vaccine, Live, Oral Ty21a).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Devices&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; - &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;NARCAN&#xae; (naloxone HCl) Nasal Spray for opioid overdose, RSDL&#xae; (Reactive Skin Decontamination Lotion Kit), and the Trobigard&#xae; (atropine sulfate, obidoxime chloride a nerve agent countermeasure) auto-injector.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;"&gt;Antibody Therapeutics - &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;raxibacumab (Anthrax Monoclonal antibody therapeutic for anthrax),&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;Anthrasil&#xae;( Anthrax Immune Globulin Intravenous (Human)), BAT&#xae;(Botulism Antitoxin Heptavalent), and VIGIV (Vaccinia Immune Globulin Intravenous (Human) therapeutic) for complications from smallpox vaccinations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The Company also generates revenue from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;contract development and manufacturing services&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; including &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;pharmaceutical product process development, manufacturing and filling services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, laboratory analytical development support, aseptic filling, lyophilization, final packaging and accelerated and ongoing stability studies, as well as manufacturing of vial and pre-filled syringe formats, bulk drug products and finished units of clinical and commercial drugs. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;We operate as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d374415124e656-wk-Fact-5A9CEE1F5ED7B6AAB186D8499312BF92"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-B5AA59006CB87DA0CA1CD8499360B3BE-0-wk-Fact-010D4421E7C1B3714FB1D849932EE30A">Basis of Presentation and Principles of Consolidation&lt;div style="line-height:120%;padding-bottom:8px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, as filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, as filed with the SEC, except for recently adopted accounting standards.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has interest rate swaps and contingent consideration liabilities that are measured at fair value on a recurring basis (Note 8 and Note 9). The Company also records the assets and liabilities of acquisitions at fair value (Note 3). As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;no&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; other significant assets or liabilities that were measured at fair value on a non-recurring basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-02, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, which increases transparency and comparability among organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The Company adopted the new standard effective January 1, 2019 using the modified retrospective approach. As of January 1, 2019 total right of use assets increased &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;text-align:right;"&gt;&lt;span&gt;$13.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, while total operating lease liabilities increased &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;font-weight:bold;text-align:right;"&gt;&lt;span&gt;$14.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;. There was no adjustment to the opening balance of retained earnings as of January 1, 2019. The standard will not materially affect the Company's consolidated net earnings. The Company continues to apply the legacy guidance from the old lease accounting standard, including its disclosure requirements, in the comparative periods presented. The Company did not reassess existing contracts for lease classification or the classification of existing leases or associated costs. The Company will not reflect leases with an initial term of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;12&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; months or less as a right of use asset or liability, but will recognize those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. In addition, the Company will account for non-lease components of the arrangement separate from lease components (see Note 6).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;SEC Simplification&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;In August 2018, the SEC issued Final Rule Release No. 33-10532, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Disclosure Update and Simplification&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, which makes a number of changes meant to simplify interim disclosures. The new rule requires a presentation of changes in stockholders&#x2019; equity and noncontrolling interest in the form of a reconciliation, for the current and comparative year-to-date interim periods. The Company adopted the new disclosure requirements beginning in its March 31, 2019 Form 10-Q and included these disclosures in the condensed consolidated statements of changes in stockholders' equity. The additional elements of this release did not have a material impact on the Company's overall condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;Tax Effects from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;In February 2018, the FASB issued ASU 2018-02,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;"&gt;&#160;Income Statement&#x2014;Reporting Comprehensive Income (Topic 220):&#160;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;. ASU 2018-02 provides the option to reclassify certain income tax effects related to the Tax Cuts and Jobs Act passed in December of 2017 between accumulated other comprehensive income and retained earnings and also requires additional disclosures.&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The Company adopted the new standard effective January 1, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;.&#160;There was no impact for the adoption of ASU 2018-02 on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;In June 2016, the FASB issued&#160;ASU 2016-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;. ASU 2016-13 provides&#160;guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking &#x201c;expected loss&#x201d; model that is likely to result in the earlier recognition of allowances for losses. The guidance was further amended in January 2019 to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;clarify or address stakeholders&#x2019; specific issues about certain aspects of the amendments in the update and in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;May 2019 to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;provide an option to irrevocably elect the fair value option for certain financial assets previously measured on an amortized cost basis. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The guidance&#160;is effective for annual periods beginning after December 15, 2019, including interim periods within those years, but early adoption is permitted. The Company is currently evaluating the effect that the pronouncement will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;In January 2017, the FASB issued ASU 2017-04,&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;. ASU 2017-04 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-04 is effective for annual and interim goodwill tests beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates on or after January 1, 2017. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;In August 2018 the FASB issued ASU No. 2018-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;. This new standard modifies certain disclosure requirements on fair value measurements. This new standard will be effective for the Company on January 1, 2020. The Company does not expect that the adoption of this new standard will have a material impact on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;Compensation -&#160;Retirement Benefits - Defined Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;In August 2018, the FASB issued ASU 2018-14, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Compensation - Retirement Benefits - Defined Benefit Plans - General&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;. ASU 2018-14 modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. ASU 2018-14 is effective for&#160;all entities for fiscal years ending after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-14 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;There are no other recently issued accounting pronouncements that are expected to have a material impact on the Company's financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-63407DE5606D5987F408D849935FF0F5-0-wk-Fact-66F9FAFE8AC731D81186D849932E15DC">&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, as filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-7832D170B1393697772DD84993604ED0-0-wk-Fact-9BCB39685F4E5105A75ED849932FE289">&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-02, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, which increases transparency and comparability among organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The Company adopted the new standard effective January 1, 2019 using the modified retrospective approach. As of January 1, 2019 total right of use assets increased &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;text-align:right;"&gt;&lt;span&gt;$13.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, while total operating lease liabilities increased &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;font-weight:bold;text-align:right;"&gt;&lt;span&gt;$14.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;. There was no adjustment to the opening balance of retained earnings as of January 1, 2019. The standard will not materially affect the Company's consolidated net earnings. The Company continues to apply the legacy guidance from the old lease accounting standard, including its disclosure requirements, in the comparative periods presented. The Company did not reassess existing contracts for lease classification or the classification of existing leases or associated costs. The Company will not reflect leases with an initial term of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;12&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; months or less as a right of use asset or liability, but will recognize those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. In addition, the Company will account for non-lease components of the arrangement separate from lease components (see Note 6).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;SEC Simplification&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;In August 2018, the SEC issued Final Rule Release No. 33-10532, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Disclosure Update and Simplification&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, which makes a number of changes meant to simplify interim disclosures. The new rule requires a presentation of changes in stockholders&#x2019; equity and noncontrolling interest in the form of a reconciliation, for the current and comparative year-to-date interim periods. The Company adopted the new disclosure requirements beginning in its March 31, 2019 Form 10-Q and included these disclosures in the condensed consolidated statements of changes in stockholders' equity. The additional elements of this release did not have a material impact on the Company's overall condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;Tax Effects from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;In February 2018, the FASB issued ASU 2018-02,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;"&gt;&#160;Income Statement&#x2014;Reporting Comprehensive Income (Topic 220):&#160;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;. ASU 2018-02 provides the option to reclassify certain income tax effects related to the Tax Cuts and Jobs Act passed in December of 2017 between accumulated other comprehensive income and retained earnings and also requires additional disclosures.&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The Company adopted the new standard effective January 1, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;.&#160;There was no impact for the adoption of ASU 2018-02 on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;In June 2016, the FASB issued&#160;ASU 2016-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;. ASU 2016-13 provides&#160;guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking &#x201c;expected loss&#x201d; model that is likely to result in the earlier recognition of allowances for losses. The guidance was further amended in January 2019 to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;clarify or address stakeholders&#x2019; specific issues about certain aspects of the amendments in the update and in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;May 2019 to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;provide an option to irrevocably elect the fair value option for certain financial assets previously measured on an amortized cost basis. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The guidance&#160;is effective for annual periods beginning after December 15, 2019, including interim periods within those years, but early adoption is permitted. The Company is currently evaluating the effect that the pronouncement will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;In January 2017, the FASB issued ASU 2017-04,&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;. ASU 2017-04 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-04 is effective for annual and interim goodwill tests beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates on or after January 1, 2017. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;In August 2018 the FASB issued ASU No. 2018-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;. This new standard modifies certain disclosure requirements on fair value measurements. This new standard will be effective for the Company on January 1, 2020. The Company does not expect that the adoption of this new standard will have a material impact on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;"&gt;Compensation -&#160;Retirement Benefits - Defined Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;In August 2018, the FASB issued ASU 2018-14, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Compensation - Retirement Benefits - Defined Benefit Plans - General&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;. ASU 2018-14 modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. ASU 2018-14 is effective for&#160;all entities for fiscal years ending after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-14 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d374406785e668-wk-Fact-64383CE1B1FAE9A38798D849932F8745"
      unitRef="usd">13400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d374406785e672-wk-Fact-EF9DB71FBFF838338CDFD8499331F0A0"
      unitRef="usd">14000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-A664ABEE18BF87DD2269D849935F550F-0-wk-Fact-0810F3940BB3C36DEDCED849931D9177">Acquisitions&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;"&gt;Adapt&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;On October 15, 2018, the Company acquired Adapt, a company focused on developing new treatment options and commercializing products addressing opioid overdose and addiction. Adapt's NARCAN&#xae; (naloxone HCl) Nasal Spray marketed product is the first needle-free formulation of naloxone approved by the FDA and Health Canada for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. This acquisition includes approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; employees, located in the U.S., Canada, and Ireland, including those responsible for supply chain management, research and development, government affairs, and commercial operations. The products and product candidates within Adapt's portfolio are consistent with the Company's mission and expands the Company's core business of addressing &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;public health threats&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;Under the acquisition method of accounting, the assets and liabilities of Adapt have been recorded as of October 15, 2018, the acquisition date, at their respective fair values, and combined with those of the Company. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;As the Company continues to finalize the fair value of assets acquired and liabilities assumed, purchase price adjustments have been recorded and additional purchase price adjustments may be recorded during the measurement period. The Company reflects measurement period adjustments in the period in which the adjustments occur. The adjustments for the&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; resulted from the receipt of additional financial information &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;associated with certain acquired contract assets and the value of associated contingent purchase consideration&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;. These adjustments did not impact the Company's statements of operations. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, certain fair value estimates relating to&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; intangible assets acquired and income taxes could be&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; subject to further adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The total purchase price, revised for current period adjustments is summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;October 15, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;581.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value of contingent purchase consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Preliminary purchase consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;667.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Updated purchase consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;668.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The Company issued &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;733,309&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; shares of common stock at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$60.44&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; per share, the closing price of Emergent's common stock on October 15, 2018, with a total value of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$44.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;. The &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$44.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; value of the common shares issued has been adjusted to a fair value of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$37.7&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; million considering a discount for lack of marketability due&#160;to a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;two&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;-year lock-up period beginning on October 15, 2018. The remaining contingent consideration payable for the acquisition consists of up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$100 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; in cash based on the achievement of certain sales milestones through 2022, which the Company has determined had a fair value of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;48.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; million as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; and for the payment of additional consideration based on the collectability of identified acquired contract assets.&#160;The fair value of the contingent purchase consideration is based on management&#x2019;s assessment of the potential future realization of the contingent purchase consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;payments. This assessment is based on inputs that have no observable market inputs (Level 3). The obligation is measured using a discounted cash flow model.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at October 15, 2018 updated for measurement period adjustments recorded through &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;October 15, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Measurement Period Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Updated  October 15, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Estimated fair value of tangible assets acquired and liabilities assumed:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(32.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(32.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(50.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(50.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(62.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(62.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total estimated fair value of tangible assets acquired and liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(56.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(54.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;534.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;534.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;149.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;148.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;667.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;668.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The Company determined the estimated fair value of the intangible asset using the income approach. The preliminary estimated fair value of the intangible asset acquired for Adapt's marketed product NARCAN&#xae; Nasal Spray is valued at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$534.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; million. The Company has determined the useful life of the NARCAN&#xae; Nasal Spray intangible asset to be &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; years. The Company estimated the fair value of the NARCAN&#xae; Nasal Spray intangible asset using the income approach which is based on the present value of future cash flows with a discount rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;10.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Adapt. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value these intangible assets. The projected cash flows from the NARCAN&#xae; Nasal Spray intangible asset were based on key assumptions including: estimates of revenues and operating profits, and risks related to the viability of and potential alternative treatments in any future target markets. The fair value measurements are based on significant unobservable inputs that are developed by the Company using estimates and assumptions of the respective market and market penetration of the acquired company's products.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The intangible asset associated with the IPR&amp;amp;D acquired from Adapt is related to a product candidate. Management determined that the estimated acquisition-date fair value of intangible assets related to IPR&amp;amp;D was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$41.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; million. The estimated fair value was determined using the income approach, which discounts expected future cash flows to present value. The Company estimated the fair value using a discount rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;11.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Adapt and IPR&amp;amp;D assets at a similar stage of development as the product candidate. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value the IPR&amp;amp;D. The projected cash flows for the product candidate were based on key assumptions including: estimates of revenues and operating profits, the stage of development of pipeline programs on the acquisition date; the time and resources needed to complete the development and approval of the product candidate; the life of the potential commercialized product and associated risks, including the inherent difficulties and uncertainties in developing a product candidate, such as obtaining marketing approval from the FDA and other regulatory agencies; and risks related to the viability of and potential for alternative treatments in any future target markets. IPR&amp;amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts (see Note 7).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The Company determined the fair value of inventory using the comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete/dispose of the inventory with a profit on those costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The Company has recorded &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$148.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; million in goodwill related to the Adapt acquisition, which is calculated as the purchase price paid in excess of the fair value of the tangible and intangible assets acquired representing the future economic benefits the Company expects to receive as a result of the acquisition. The goodwill created from the Adapt acquisition is associated with early stage pipeline products. Substantially all of the goodwill generated from the Adapt acquisition is not expected to be deductible for tax purposes due to the legal structure of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;PaxVax&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;On October 4, 2018, the Company completed the acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases. This acquisition includes Vivotif&#xae; (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever, Vaxchora&#xae; (Cholera Vaccine, Live, Oral), the only FDA-licensed vaccine for the prevention of cholera, and clinical-stage vaccine candidates targeting chikungunya and other emerging infectious diseases, European-based current good manufacturing practices (cGMP) biologics manufacturing facilities, and approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;250&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; employees including those in research and development, manufacturing, and commercial operations with a specialty vaccines salesforce in the U.S. and in select European countries. The products and product candidates within PaxVax's portfolio are consistent with the Company&#x2019;s mission and will expand the Company&#x2019;s core business of addressing PHTs. In addition, the acquisition expands the Company's manufacturing infrastructure and related capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The Company paid cash consideration of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$273.1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; million for PaxVax. As of the date of this filing, the accounting for the PaxVax acquisition is preliminary due to the Company's need to gather data to assess the fair value of property, plant and equipment, intangible assets and accounting for taxes. The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at October 4, 2018 updated for measurement period adjustments recorded through &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;October 4, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Measurement Period Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Updated October 4, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Estimated fair value of tangible assets acquired and liabilities assumed:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(33.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(34.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total estimated fair value of tangible assets acquired and liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;61.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;273.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;273.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The preliminary estimated fair value of the intangible assets acquired for PaxVax's marketed products is a total of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$133.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; million. The Company determined the estimated fair value of the intangible assets using the income approach, which is based on the present value of future cash flows. The fair value measurements are based on significant unobservable inputs that are developed by the Company using estimates and assumptions of the respective market and market penetration of the acquired products. The Company has determined that the weighted average useful lives of the intangible assets to be &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; years. The Company estimated the fair value of the Vivotif and Vaxchora intangible assets &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;using a present value discount rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;14.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;15.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, respectively, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of PaxVax. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value these intangible assets. The projected cash flows from these intangible assets were based on key assumptions, including: estimates of revenues and operating profits, and risks related to the viability of and potential alternative treatments in any future target markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The intangible asset associated with the IPR&amp;amp;D &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;the measurement of the amounts recognized as of that date. The Company estimates the fair value based on the income approach. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The Company determined the fair value of the inventory using the comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete/dispose of the inventory with a profit on those costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The Company determined the fair value of the property, plant and equipment utilizing both the cost approach and the sales comparison approach. The cost approach is determined by establishing replacement cost of the asset and then subtracting any value that has been lost due to economic obsolescence, functional obsolescence, or physical deterioration. The sales comparison approach values an asset based on the market price of assets with comparable features such as design, location, size, construction, materials, use, capacity, specification, operational characteristics and other features or descriptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The Company recorded approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$71.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; million in goodwill related to the PaxVax acquisition, calculated as the purchase price paid in the acquisition that was in excess of the fair value of the tangible and intangible assets acquired representing the future economic benefits the Company expects to receive as a result of the acquisition. The goodwill created from the PaxVax acquisition is associated with early stage pipeline products along with potential contract manufacturing services. The majority of the goodwill generated from the PaxVax acquisition is expected to be deductible for tax purposes based upon the structure used in the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Impact of Business Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The operations of each of the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; business acquisitions discussed above were included in the consolidated financial statements as of each of their respective acquisition dates. The following table presents their revenue and earnings as reported within the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:694px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:429px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:117px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:117px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three months ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six months ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;88.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;163.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <ebs:NumberOfEmployees
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-1"
      id="d374424724e604-wk-Fact-B3711FC027FFD765F4D7D84993153F85"
      unitRef="employee">50</ebs:NumberOfEmployees>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-73412ED114C778BC5A01D849935F5FFA-0-wk-Fact-9F408F5F572315CA550CD849931C64CD">&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The total purchase price, revised for current period adjustments is summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;October 15, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;581.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value of contingent purchase consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Preliminary purchase consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;667.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Updated purchase consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;668.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e695-wk-Fact-85270F5C1743B3009B04D84993051A62"
      unitRef="usd">581500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e715-wk-Fact-97F16201FD7414080B8DD8499306A5A5"
      unitRef="usd">37700000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e740-wk-Fact-89C7C8797948AFB144A6D8499306A10A"
      unitRef="usd">48000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2018Q4Oct15-Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e765-wk-Fact-CA5E9AA2287FAECDF92FD8499305807F"
      unitRef="usd">667200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e790-wk-Fact-575B971A7D76E7D28386D84993060CA1"
      unitRef="usd">1500000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e820-wk-Fact-9B615F6B1FBC23C58772D849930739E3"
      unitRef="usd">668700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="INF"
      id="d374424724e832-wk-Fact-F7FF2B633F4C28ABFBC2D849931AA232"
      unitRef="shares">733309</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="INF"
      id="d374424724e836-wk-Fact-343C160120E8C8DBF87DD8499315ED71"
      unitRef="usdPerShare">60.44</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e840-wk-Fact-EE45079896DC2642C2DBD849931EF0B0"
      unitRef="usd">44300000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e844-wk-Fact-EE45079896DC2642C2DBD849931EF0B0"
      unitRef="usd">44300000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e848-wk-Fact-97F16201FD7414080B8DD8499306A5A5"
      unitRef="usd">37700000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="I2018Q4Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-6"
      id="d374424724e857-wk-Fact-B8D6B9134B8B18E9D939D849931E61FB"
      unitRef="usd">100000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e861-wk-Fact-89C7C8797948AFB144A6D8499306A10A"
      unitRef="usd">48000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-1E523F6934243B8ED1F8D849935F8F3F-0-wk-Fact-2D8EFA6ABE2504DA9D32D8499319C5D3">&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at October 15, 2018 updated for measurement period adjustments recorded through &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;October 15, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Measurement Period Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Updated  October 15, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Estimated fair value of tangible assets acquired and liabilities assumed:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(32.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(32.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(50.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(50.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(62.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(62.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total estimated fair value of tangible assets acquired and liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(56.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(54.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;534.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;534.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;149.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;148.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;667.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;668.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at October 4, 2018 updated for measurement period adjustments recorded through &lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;.&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;October 4, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Measurement Period Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Updated October 4, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Estimated fair value of tangible assets acquired and liabilities assumed:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(33.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(34.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total estimated fair value of tangible assets acquired and liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;133.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;61.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;273.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;273.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1039-wk-Fact-B19474CD4680718E2D8FD849934EC32A"
      unitRef="usd">17700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1077-wk-Fact-748233C9E14062C75C0FD849934CC506"
      unitRef="usd">17700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1093-wk-Fact-EB3EE9DDD9002025F669D849934CA257"
      unitRef="usd">21300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1131-wk-Fact-422CEAC8A5EA1AF3AD0FD84992F9235C"
      unitRef="usd">21300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1152-wk-Fact-BD7D6050F6A7AB293FFDD84992FA810B"
      unitRef="usd">41400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1190-wk-Fact-A35549106229FD6322D2D849934EEC67"
      unitRef="usd">41400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1211-wk-Fact-50CE81BECDBC5CFF6CC0D84992F85209"
      unitRef="usd">7800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <ebs:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets
      contextRef="D2019Q2Oct16-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1230-wk-Fact-16C6934A9EFCCE91C6BFD849934C27A2"
      unitRef="usd">3000000.0</ebs:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1249-wk-Fact-62886B00918F2C6467F7D849934FFC54"
      unitRef="usd">10800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1270-wk-Fact-83BFD960099859CB3A07D84992FB4567"
      unitRef="usd">32200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1309-wk-Fact-FA800A70B4B89D2527F1D84992F8DD34"
      unitRef="usd">32200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1331-wk-Fact-8A89EBC96E6589A8C25CD84992F794DB"
      unitRef="usd">50400000</ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities>
    <ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1370-wk-Fact-A45B0DC6760D9716E64ED84992F6D6DB"
      unitRef="usd">50400000</ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1392-wk-Fact-14E70D146E4A317AA5C8D8499304DE2F"
      unitRef="usd">62400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
    <ebs:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent
      contextRef="D2019Q2Oct16-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1412-wk-Fact-69D81EFFAF9EF66900EDD84992F9A2B1"
      unitRef="usd">500000</ebs:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1432-wk-Fact-00434CF33E1D1B60C343D84993021E1D"
      unitRef="usd">62900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1454-wk-Fact-BC72454FFA222A041ABDD84992FB9E07"
      unitRef="usd">-56800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod
      contextRef="D2019Q2Oct16-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1474-wk-Fact-C6A0413D2B1BC7660D1AD84992FB66D8"
      unitRef="usd">-2500000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1493-wk-Fact-61BA540152F4340CD8CCD849934C83CA"
      unitRef="usd">-54300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d374424724e1578-wk-Fact-ADA71E23AF5C425A7590D84992F95D30"
      unitRef="usd">41000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1616-wk-Fact-504CB8DF796A0AF67A27D849934DFEDA"
      unitRef="usd">41000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1637-wk-Fact-CFBDE830FCA0D30C5C3DD84992FB60D6"
      unitRef="usd">534000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1675-wk-Fact-5A528E8C18A23F1C35C2D84992F777DE"
      unitRef="usd">534000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1696-wk-Fact-CDA2C1C60532BF1BF876D849934EA25D"
      unitRef="usd">149000000.0</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="D2019Q2Oct16-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1715-wk-Fact-DB552347A11C833C2ED6D849934ECC55"
      unitRef="usd">-1000000.0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1735-wk-Fact-E88DEF3F287FC34BCC5CD84993025599"
      unitRef="usd">148000000.0</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2018Q4Oct15-Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1761-wk-Fact-CA5E9AA2287FAECDF92FD8499305807F"
      unitRef="usd">667200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
      contextRef="D2019Q2Oct16-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1780-wk-Fact-3AA15105B068070FEDB5D84993016DC4"
      unitRef="usd">1500000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1799-wk-Fact-9B615F6B1FBC23C58772D849930739E3"
      unitRef="usd">668700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1812-wk-Fact-CFBDE830FCA0D30C5C3DD84992FB60D6"
      unitRef="usd">534000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      id="d374424724e1816-wk-Fact-A53BC27E2DBE692BF405D8499318BAAD">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <ebs:PresentValueDiscountRate
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="INF"
      id="d374424724e1820-wk-Fact-A58B1FF87BB549646368D8499316847B"
      unitRef="number">0.105</ebs:PresentValueDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2018Q4Oct15_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d374424724e1828-wk-Fact-ADA71E23AF5C425A7590D84992F95D30"
      unitRef="usd">41000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <ebs:PresentValueDiscountRate
      contextRef="D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="INF"
      id="d374424724e1832-wk-Fact-A14A528B22870598DE01D849931608D9"
      unitRef="number">0.110</ebs:PresentValueDiscountRate>
    <us-gaap:Goodwill
      contextRef="I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember"
      decimals="-5"
      id="d374424724e1842-wk-Fact-E88DEF3F287FC34BCC5CD84993025599"
      unitRef="usd">148000000.0</us-gaap:Goodwill>
    <ebs:NumberOfEmployees
      contextRef="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-1"
      id="d374424724e1852-wk-Fact-A9241F5B60395BA6CBDAD8499316C537"
      unitRef="employee">250</ebs:NumberOfEmployees>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e1859-wk-Fact-1519335EB80108461268D8499319DD64"
      unitRef="usd">273100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2028-wk-Fact-122C41F2DC3FCB378A36D84992F8B339"
      unitRef="usd">9000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2066-wk-Fact-D76856C69AFB84A34536D849934141E1"
      unitRef="usd">9000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2082-wk-Fact-083E57354FBF8249AAFED84993445455"
      unitRef="usd">4100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2120-wk-Fact-5D1A8C326AAE571683D1D84992FC026B"
      unitRef="usd">4100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2141-wk-Fact-4D42B6F0B1DB695D1973D84993429314"
      unitRef="usd">19700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2179-wk-Fact-2362F8C3D5CCBC448E13D84993457878"
      unitRef="usd">19700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2200-wk-Fact-2E9F1A0905404347ED0AD84992FA46BB"
      unitRef="usd">12200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2238-wk-Fact-434C9092BC1A2045E7E1D849934EDA1C"
      unitRef="usd">12200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2259-wk-Fact-26F7B95B5638A7872F1AD84993425293"
      unitRef="usd">57800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2297-wk-Fact-6ED1C0802D66D2523CF4D84992F74337"
      unitRef="usd">57800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2318-wk-Fact-736BE453D97C8B00C7DFD84992FD5266"
      unitRef="usd">3800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2356-wk-Fact-C10AD37A918472F768DDD849934FD53C"
      unitRef="usd">3800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2377-wk-Fact-5C28F1B4B4FD22C0A212D84993441189"
      unitRef="usd">3500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2416-wk-Fact-2356F2333A662EE078E3D849934D7778"
      unitRef="usd">3500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities
      contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2438-wk-Fact-EC3D95B7A1D508A36980D849934164AF"
      unitRef="usd">33600000</ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities>
    <ebs:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities
      contextRef="D2019Q2Oct05-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2458-wk-Fact-7E6A40B0F2CBA2D81D22206FEE9A8A46"
      unitRef="usd">400000</ebs:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities>
    <ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2478-wk-Fact-FBC3A0CD94643FCF0098D84993433A87"
      unitRef="usd">34000000.0</ebs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2500-wk-Fact-7E1A8BC7C8C9337DFFFFD8499343E092"
      unitRef="usd">69500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod
      contextRef="D2019Q2Oct05-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2519-wk-Fact-783EF8D3D513777D6EB2206D0B58A63A"
      unitRef="usd">400000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2539-wk-Fact-A2F45F017F8344AE273B206DDAE0C3AD"
      unitRef="usd">69100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2623-wk-Fact-35349A14065AB090293DD84992FFDA26"
      unitRef="usd">9000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <ebs:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets
      contextRef="D2019Q2Oct05-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2642-wk-Fact-3B473A645FEF2C6FFD38D84992FCA5C6"
      unitRef="usd">-9000000.0</ebs:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2662-wk-Fact-D1A027F240154F2ADB24D84993442F59"
      unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2683-wk-Fact-410C4FD19C02A09C3952D849934E30B8"
      unitRef="usd">133000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2721-wk-Fact-AE189DD5599DDAE8C2F2D8499316BA55"
      unitRef="usd">133000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="I2018Q4Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2742-wk-Fact-5CC3C3BFC3BF8F54F5CAD84992F93A52"
      unitRef="usd">61600000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="D2019Q2Oct05-Jun30_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2761-wk-Fact-36D757AA2BD3951F8663D84992F67D0A"
      unitRef="usd">9400000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2780-wk-Fact-FCD51E7F089449CE1E52D849931B521E"
      unitRef="usd">71000000.0</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2018Q4Oct04-Oct04_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2806-wk-Fact-9DADD6EE6E7FB1870007D849934E1034"
      unitRef="usd">273100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374424724e2825-wk-Fact-DFB43E02AF53FCF8CB7C4958D376A52A"
      unitRef="usd">0</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2844-wk-Fact-1519335EB80108461268D8499319DD64"
      unitRef="usd">273100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2857-wk-Fact-AE189DD5599DDAE8C2F2D8499316BA55"
      unitRef="usd">133000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      id="d374424724e2861-wk-Fact-682CF320E3933FDC7F6CD8499317DCEC">P19Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <ebs:PresentValueDiscountRate
      contextRef="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_VivotifMember"
      decimals="INF"
      id="d374424724e2868-wk-Fact-E5A2EB7440877457209FD849931ADCC4"
      unitRef="number">0.145</ebs:PresentValueDiscountRate>
    <ebs:PresentValueDiscountRate
      contextRef="D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ebs_VaxchoraMember"
      decimals="INF"
      id="d374424724e2872-wk-Fact-6294EA594EC4DFF846E2D8499319F991"
      unitRef="number">0.150</ebs:PresentValueDiscountRate>
    <us-gaap:Goodwill
      contextRef="I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember"
      decimals="-5"
      id="d374424724e2891-wk-Fact-FCD51E7F089449CE1E52D849931B521E"
      unitRef="usd">71000000.0</us-gaap:Goodwill>
    <ebs:NumberOfBusinessAcquisitions
      contextRef="FI2019Q2"
      decimals="INF"
      id="d374424724e2905-wk-Fact-499845D59A16EE98F041D849931DD995"
      unitRef="acquisition">2</ebs:NumberOfBusinessAcquisitions>
    <ebs:ImpactOfBusinessAcquisitionsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-631FF31A2D52FC9147F1D849935FB776-0-wk-Fact-D261551E39F54995C03ED849931E3807">The following table presents their revenue and earnings as reported within the consolidated financial statements.&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:694px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:429px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:117px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:117px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three months ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six months ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;88.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;163.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</ebs:ImpactOfBusinessAcquisitionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember"
      decimals="-5"
      id="d374424724e3025-wk-Fact-5734024D724714B52A2C206C3A967AC5"
      unitRef="usd">88200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember"
      decimals="-5"
      id="d374424724e3044-wk-Fact-457746BA4B9820BE2E7AD8499303B809"
      unitRef="usd">163100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember"
      decimals="-5"
      id="d374424724e3059-wk-Fact-85679CF5CF31CC53B83A206C3BF9FE72"
      unitRef="usd">8200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember"
      decimals="-5"
      id="d374424724e3078-wk-Fact-5E940714B5074EF05F70D8499304E401"
      unitRef="usd">4400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-4A22B99FE5E90103669FD84993609DD9-0-wk-Fact-0830CFAE9D0A5ED19944D8499333A3BC">Inventories&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The components of inventory are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;66.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;119.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;103.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;46.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;232.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;205.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-874F84A90EFB118DE0B3D84993605080-0-wk-Fact-EB0A289AD53A4EC94837D84993345D95">&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The components of inventory are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;66.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;119.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;103.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;46.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;232.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;205.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374420633e684-wk-Fact-E406C21AD50EECE8CAB1D8499323383B"
      unitRef="usd">66300000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374420633e703-wk-Fact-6180BD0A7996ECF8EF1FD8499310DFCC"
      unitRef="usd">51800000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374420633e723-wk-Fact-F6EE305F6E87216A5A51D8499317AC35"
      unitRef="usd">119100000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374420633e742-wk-Fact-2407BD2436DC1883FDC7D8499323C0F6"
      unitRef="usd">103200000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374420633e767-wk-Fact-0CF5E4F8FEC2E25B0535D84993032C9A"
      unitRef="usd">46600000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374420633e786-wk-Fact-606FF4C6B79B1374B4B2D8499311126F"
      unitRef="usd">50800000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374420633e816-wk-Fact-10DA71DCD649ED36B6D3D84992F794DC"
      unitRef="usd">232000000.0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374420633e835-wk-Fact-C6A98BDF9041D79AA0CBD84993196BE5"
      unitRef="usd">205800000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-893A98B84763B6FD3419D84993605EB2-0-wk-Fact-11A6AC23A50732D43EAAD849932D5EBB">Property, Plant and Equipment&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;Property, plant and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land and improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;46.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;228.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;216.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;318.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;293.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;56.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction-in-progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;59.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;709.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;681.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(189.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(171.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;520.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;510.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-4F081C3E57117742A4BAD8499360867B-0-wk-Fact-F20DA7B3BE258FDC9EEAD849932F17E3">&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;Property, plant and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land and improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;46.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;228.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;216.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;318.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;293.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;56.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction-in-progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;59.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;709.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;681.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(189.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(171.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;520.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;510.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember"
      decimals="-5"
      id="d374423088e684-wk-Fact-907684047EB19971B1C6D84993244135"
      unitRef="usd">46700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndLandImprovementsMember"
      decimals="-5"
      id="d374423088e703-wk-Fact-6750B927B2997FEF0691D8499324D5F8"
      unitRef="usd">44600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"
      decimals="-5"
      id="d374423088e723-wk-Fact-1BA43575A2E8D7F12F04D849931C8944"
      unitRef="usd">228000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"
      decimals="-5"
      id="d374423088e742-wk-Fact-A39AAEA313BFEB28B682D849930F3195"
      unitRef="usd">216200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-5"
      id="d374423088e767-wk-Fact-7A53A1F8751AD833FF5AD8499314EF1C"
      unitRef="usd">318800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-5"
      id="d374423088e786-wk-Fact-4688B8115E95E6DC5771D84993136017"
      unitRef="usd">293900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="-5"
      id="d374423088e811-wk-Fact-C30F358BD068249A02EAD8499320BE4F"
      unitRef="usd">56300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="-5"
      id="d374423088e830-wk-Fact-BC5367AFDB1622C506DED84993115C84"
      unitRef="usd">55200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-5"
      id="d374423088e855-wk-Fact-5243E5BDEB23C9BECA6BD849932265E2"
      unitRef="usd">59900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-5"
      id="d374423088e874-wk-Fact-F07D757BD617FA53497BD8499313D736"
      unitRef="usd">71800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374423088e899-wk-Fact-3AAEF2BCCB28FFA4081FD8499312CE46"
      unitRef="usd">709700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374423088e918-wk-Fact-E9C460827CCF0EE8CB5AD8499326B371"
      unitRef="usd">681700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374423088e943-wk-Fact-22FD2875F947A67725D9D8499315D9BC"
      unitRef="usd">189200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374423088e963-wk-Fact-A0A7D8EEBE0BA48461F4D849932C2CB3"
      unitRef="usd">171500000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374423088e994-wk-Fact-1CEE78D1635C9E8C9F7DD8499312146B"
      unitRef="usd">520500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374423088e1013-wk-Fact-A2A3491175BAC7A69E11D84992FE01C5"
      unitRef="usd">510200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-12A83200390F22E2354ED84993609EC0-0-wk-Fact-48FA24CBE4C5E9AEB936D8499322C060">Leases&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The Company has operating leases for corporate offices, research and development facilities and manufacturing facilities. We determine if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately. The Company's leases have remaining lease terms of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; year to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; years, some of which include options to extend the leases for up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; years, and some of which include options to terminate the leases within &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three months ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six months ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;"&gt;(In millions, except lease term and discount rate)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;15.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;14.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;16.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating leases:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted Average Remaining Lease Term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;10.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-3C2C0F01091C718713BD20915C12C5EF-0-wk-Fact-12E1F1468B55CCB54CBC2091A0AB0BCE">Leases&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The Company has operating leases for corporate offices, research and development facilities and manufacturing facilities. We determine if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately. The Company's leases have remaining lease terms of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; year to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; years, some of which include options to extend the leases for up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; years, and some of which include options to terminate the leases within &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three months ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six months ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;"&gt;(In millions, except lease term and discount rate)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;15.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;14.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;16.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating leases:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted Average Remaining Lease Term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;10.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember"
      id="d374421974e608-wk-Fact-15824D6408ACF5B1A765D849931C1770">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember"
      id="d374421974e612-wk-Fact-9898F224E8A0F01F6FF8D8499321B1FD">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q2"
      id="d374421974e616-wk-Fact-F78F2679AFF909EC6B00D84993255038">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ebs:LesseeOperatingLeaseTerminationPeriod
      contextRef="FD2019Q2YTD"
      id="d374421974e620-wk-Fact-92BD8E70875102D1988DD8499325A1AA">P1Y</ebs:LesseeOperatingLeaseTerminationPeriod>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-1F3C2C4610D8FBD14CA1D8499360BE48-0-wk-Fact-7005115D2DE4841AF71FD84993252C47">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three months ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six months ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease cost:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374421974e803-wk-Fact-725D552158279F5467C12F4405946F6F"
      unitRef="usd">700000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374421974e822-wk-Fact-9D6328E6012241854316D84993350133"
      unitRef="usd">1300000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374421974e842-wk-Fact-5767B626DD84076326EC2F44057574F8"
      unitRef="usd">200000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374421974e861-wk-Fact-21ACE9167960BF8B39BED84993365237"
      unitRef="usd">300000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374421974e891-wk-Fact-9F678F81613521BE2AA32075E9D9C70B"
      unitRef="usd">900000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374421974e910-wk-Fact-BA60E27E713FA54C25242075E9C0412E"
      unitRef="usd">1600000</us-gaap:LeaseCost>
    <ebs:ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-2196423E918770EAB0DBD8499360D4AE-0-wk-Fact-8EB49FB3A8CF0DCFFF54D84993228010">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;"&gt;(In millions, except lease term and discount rate)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;15.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;14.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;16.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating leases:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted Average Remaining Lease Term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;10.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</ebs:ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374421974e994-wk-Fact-93FF9A4DE8197388A9EDD84993013EAC"
      unitRef="usd">15700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <ebs:OperatingLeaseOtherLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374421974e1050-wk-Fact-062FB893FD2CD5E1F57ED84993051A6C"
      unitRef="usd">1900000</ebs:OperatingLeaseOtherLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374421974e1080-wk-Fact-5907FA891CD30FF38B46D84993034707"
      unitRef="usd">14600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374421974e1115-wk-Fact-F1BED82045F3E41AC9CCD84993106DB0"
      unitRef="usd">16500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q2"
      id="d374421974e1200-wk-Fact-6B890051845B6A73677CD849930496B4">P10Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q2"
      decimals="4"
      id="d374421974e1230-wk-Fact-26AB18B31392659E6B51D8499305017B"
      unitRef="number">0.0462</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-A0F8A54C8AF5430EB91FD84993616E86-0-wk-Fact-47678418347EEEBE9EEDD849932E78D4">Intangible Assets&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The Company's intangible as&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;sets consist of products acquired via business combinations or asset acquisitions. The following table summarizes the carrying amount of the Company's intangible assets and goodwill, net of accumulated amortization:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="24" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Estimated Life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Measurement Period Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Gross Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;5-22&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;818.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;828.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(86.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;742.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;50.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;41.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;41.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;259.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;8.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;268.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;268.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="24" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Estimated Life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Measurement Period Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Gross Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5-22&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;151.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;667.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;818.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(56.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;761.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;210.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;259.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;259.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, the Company recorded amortization expense for intangible assets of $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; million and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$7.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, respectively. During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;three months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, the Company recorded amortization expense for intangible assets of $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;14.7&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; million and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; million, respectively. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, the weighted average amortization period remaining for intangible assets was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"&gt;&lt;span&gt;14.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; years. IPR&amp;amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-E6BDE15025C3F286212ED849936127D0-0-wk-Fact-C82EA5434454CA196B13D849932397CF">The following table summarizes the carrying amount of the Company's intangible assets and goodwill, net of accumulated amortization:&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="24" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Estimated Life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Measurement Period Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Gross Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;5-22&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;818.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;828.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(86.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;742.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;50.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;41.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;41.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;259.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;8.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;268.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;268.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-5BB02749AABD58FD378AD84993611798-0-wk-Fact-6BFFE4810FD968A76701D8499323D0C1">The following table summarizes the carrying amount of the Company's intangible assets and goodwill, net of accumulated amortization:&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="24" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Estimated Life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Measurement Period Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Gross Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;5-22&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;818.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;828.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(86.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;742.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;50.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;41.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;41.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;259.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;8.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;268.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;268.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374426739e921-wk-Fact-21F1656CB2F2F565B17AD849933C0EAA"
      unitRef="usd">818400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374426739e960-wk-Fact-37398DD2C1B87FCB227DD849933D11D3"
      unitRef="usd">10000000.0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374426739e979-wk-Fact-594F1671C30A84700399D849933E0BB9"
      unitRef="usd">828400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374426739e998-wk-Fact-96B044CD3BEA5CD564D9D849933E76F3"
      unitRef="usd">86000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374426739e1019-wk-Fact-0C7C73A51E98CE241DE3D849933F6B5F"
      unitRef="usd">742400000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d374426739e1039-wk-Fact-775AB680CDD8596A5FDED849933DF070"
      unitRef="usd">50000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments
      contextRef="FD2019Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d374426739e1058-wk-Fact-FE92E4E2815B27C43FF0D849933EDD71"
      unitRef="usd">-9000000.0</us-gaap:IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d374426739e1098-wk-Fact-D562AB7E7152D961D21CD849933FC030"
      unitRef="usd">41000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d374426739e1137-wk-Fact-D562AB7E7152D961D21CD849933FC030"
      unitRef="usd">41000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillGross
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374426739e1162-wk-Fact-532AAB61E2D687450027D849933CFCFC"
      unitRef="usd">259700000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374426739e1181-wk-Fact-7C04505F32C2E5F28A97D84993409574"
      unitRef="usd">8600000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillGross
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374426739e1220-wk-Fact-AF9555A03A8E631ED89FD849933DD1D5"
      unitRef="usd">268300000</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374426739e1259-wk-Fact-DB909FD2CAB8A2E53C25D84992FF1DFA"
      unitRef="usd">268300000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2017Q4"
      decimals="-5"
      id="d374426739e1582-wk-Fact-EF2E5562D3626927B520207B09419698"
      unitRef="usd">151400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d374426739e1621-wk-Fact-80C3B8CE2FC3A1E07DB9207B0C2F890B"
      unitRef="usd">667000000.0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374426739e1640-wk-Fact-21F1656CB2F2F565B17AD849933C0EAA"
      unitRef="usd">818400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374426739e1659-wk-Fact-441BEC23B26CD009426B207B0F7080B6"
      unitRef="usd">56800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374426739e1680-wk-Fact-6453C4600CA3ACC30F48207B110BD163"
      unitRef="usd">761600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d374426739e1700-wk-Fact-B00FCC92115D95D80E78207BE6CA3CAF"
      unitRef="usd">50000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d374426739e1758-wk-Fact-775AB680CDD8596A5FDED849933DF070"
      unitRef="usd">50000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d374426739e1797-wk-Fact-775AB680CDD8596A5FDED849933DF070"
      unitRef="usd">50000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillGross
      contextRef="FI2017Q4"
      decimals="-5"
      id="d374426739e1822-wk-Fact-012C4B681D6DF7836508207B730DEE1C"
      unitRef="usd">49100000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d374426739e1860-wk-Fact-B50149B40558D008B7B0207D8C8AA6F7"
      unitRef="usd">210600000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillGross
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374426739e1880-wk-Fact-532AAB61E2D687450027D849933CFCFC"
      unitRef="usd">259700000</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374426739e1919-wk-Fact-8DEC0005C0EAFE923857D84993239E34"
      unitRef="usd">259700000</us-gaap:Goodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374426739e1947-wk-Fact-F2D6BB1B4B9EB2F408EFD84992FE3070"
      unitRef="usd">29200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374426739e1951-wk-Fact-D5704BA4F2023D767670D84992F932EB"
      unitRef="usd">7800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374426739e1964-wk-Fact-38FAEE743CD4490EC338D849930066FB"
      unitRef="usd">14700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374426739e1968-wk-Fact-91C07E9A1D86B917DC36D84993429398"
      unitRef="usd">3900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="FD2019Q2YTD"
      id="d374426739e1976-wk-Fact-F04F3CFEF96CF746E40ED8499326499F">P14Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-54F35EFC16A8F19EECB4D84993614552-0-wk-Fact-9C3E53E7311D5E71E9D3D849932C5B36">Contingent Consideration&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;Contingent consideration liabilities associated with business combinations are fair value measurement items. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date with the exception of the milestone achievement. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market (Level 3). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The Company also has contingent consideration associated with its asset acquisitions. These liabilities are not recorded as level 3 fair value measurements, but rather are accrued when the milestone has been achieved and is payable.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The following table is a reconciliation of the beginning and ending balance of contingent considerations and is based on level 3 significant unobservable inputs, other than the raxibacumb milestone accrual, which is based on achievement of contractual milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"&gt;Balance at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;60.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Milestone achievement - asset acquisition&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Measurement period adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(12.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"&gt;Balance at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;65.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, a contingent milestone was achieved related to the Company's acquisition of raxibacumab in October 2017. The acquisition of raxibacumab was accounted for as an asset acquisition and therefore the achievement of the $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; million milestone resulted in an increase to the contingent consideration liability with a corresponding increase in intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-9280D05FE31334007B2BD8499361EFA2-0-wk-Fact-5A938659885F6F696CC0D849932C9977">&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The following table is a reconciliation of the beginning and ending balance of contingent considerations and is based on level 3 significant unobservable inputs, other than the raxibacumb milestone accrual, which is based on achievement of contractual milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"&gt;Balance at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;60.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Milestone achievement - asset acquisition&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Measurement period adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(12.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"&gt;Balance at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;65.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374427024e659-wk-Fact-6A4BA0304E5F8679C1E6D849933F32B4"
      unitRef="usd">60000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374427024e674-wk-Fact-053597C207D81F51A2F5D849933EE98B"
      unitRef="usd">10000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <ebs:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374427024e694-wk-Fact-41D029A1FF713769F640D849933EDD6F"
      unitRef="usd">1500000</ebs:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment>
    <ebs:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374427024e714-wk-Fact-FD457FE3CF200D06D71BD84993071BB7"
      unitRef="usd">5500000</ebs:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374427024e734-wk-Fact-E036C77736D926D5B46DD8499341C0B6"
      unitRef="usd">12000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374427024e760-wk-Fact-1AB45EED046D40E7F418D849933E712A"
      unitRef="usd">65000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ebs_RaxibacumabMember"
      decimals="-5"
      id="d374427024e776-wk-Fact-C7CBC04D8363447FCC8BD849932C0F4F"
      unitRef="usd">10000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-6E567451DE879754B60BD84993618334-0-wk-Fact-696256DA45386C5A51FCD849932F658D">Derivative Instruments and Hedging Activities&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Risk Management Objective of Using Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The Company is exposed to certain risk arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from the Company's senior secured credit agreement's payments of variable interest rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Accounting Policy for Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The Company's interest rate swaps qualify for hedge accounting as cash flow hedges. All derivatives are recorded on the balance sheet at fair value.&#160;Hedge accounting provides for the matching of the timing of gain or loss recognition on these interest rate swaps with the recognition of the changes in interest expense on the Company's variable rate debt. For derivatives designated as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#x2019;s variable-rate debt. The cash flows from the designated interest rate swaps are classified as a component of operating cash flows, similar to interest expense.&#160;If current fair values of designated interest rate swaps&#160;re&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;mained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&#160;of net deferred gains from&#160;accumulated other comprehensive loss&#160;into income over the next&#160;twelve&#160;months. All outstanding cash flow hedges mature in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Number of Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;350.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The table below presents the fair value of the Company&#x2019;s derivative financial instruments designated as hedges as well as their classification on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Asset Derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Liability Derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. To comply with the provisions of ASC 820, Fair Value Measurement, we incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#x2019;s nonperformance risk. These credit valuation adjustments were concluded to not be significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Hedging derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Amount of Gain/(Loss) Recognized in OCI on Derivative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Location of Gain or (Loss) Reclassified from Accumulated OCI into Income &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-5"
      id="d374430797e612-wk-Fact-6A6E9AE458921D6C2B7A0B6FCE5AB7AD"
      unitRef="usd">400000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-D1610045F8B4FD9441370AF5245E9B7C-0-wk-Fact-2EADCC84E01854D48F580AF57CED39C8">&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Number of Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;350.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="INF"
      id="d374430797e677-wk-Fact-56E619A1DED7054EA1520AFC3661C0AA"
      unitRef="instrument">7</us-gaap:NumberOfInterestRateDerivativesHeld>
    <invest:DerivativeNotionalAmount
      contextRef="FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="INF"
      id="d374430797e692-wk-Fact-C12CE4B6D12D8F2C4C350AFAF39A1A11"
      unitRef="usd">350000000.0</invest:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-C1A954C929BC9C3D065E20D13DF8D374-0-wk-Fact-2B3525B4FFAF8F4DFCAD20D218386F79">&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The table below presents the fair value of the Company&#x2019;s derivative financial instruments designated as hedges as well as their classification on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Asset Derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Liability Derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d374430797e993-wk-Fact-15C0E1D89399E6C59C070AF03634D335"
      unitRef="usd">400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d374430797e1007-wk-Fact-8F1214052823F2E541730AF036248A7C"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d374430797e1026-wk-Fact-84EFD3E7AD4D663B5BE70AF0C88FAE20"
      unitRef="usd">1600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d374430797e1046-wk-Fact-D559576FB509C3BA5EBC0AF0C88AA38F"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-60D92F6E9D265FD9FF1C20D2DDF5B748-0-wk-Fact-8E22D78D491100E6C5C620D32D0720F6">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income.&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Hedging derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Amount of Gain/(Loss) Recognized in OCI on Derivative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Location of Gain or (Loss) Reclassified from Accumulated OCI into Income &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-5"
      id="d374430797e1241-wk-Fact-246F25FD60CF9902633B0B03DFE71274"
      unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember"
      decimals="-5"
      id="d374430797e1250-wk-Fact-79BFA566CD15EF8B64E60B03E275EAA3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember"
      decimals="-5"
      id="d374430797e1274-wk-Fact-7A9D13DCD4551F6751000B02FBFB6536"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2018Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember"
      decimals="0"
      id="d374430797e1289-wk-Fact-25E5CC51B6D9716CC4510B02FBFF97BE"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-03E02AEE51C3E416F4CAF6E8EE8E3B64-0-wk-Fact-27A17E9D41333ED2F011F6E9661B51D0">Debt&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The components of debt are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Senior secured credit agreement - Term loan due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;441.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;447.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Senior secured credit agreement - Revolver loan due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;398.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;348.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.875% Convertible Senior Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;853.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;808.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of long-term debt, net of debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(10.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(12.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;830.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;784.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:11pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Senior Secured Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;On September 29, 2017, the Company entered into a senior secured credit agreement (the &#x201c;2017 Credit Agreement&#x201d;) with &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; lending financial institutions. On October 15, 2018, the Company entered into an Amended and Restated Credit Agreement (the "Amended Credit Agreement") with multiple lending institutions, which modified the 2017 Credit Agreement. The Amended Credit Agreement (i) increased the revolving credit facility (the "Revolving Credit Facility") from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;$600 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, (ii) extended the maturity of the Revolving Credit Facility from September 29, 2022 to October 13, 2023, (iii) provided for a term loan in the original principal amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;$450 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; (the "Term Loan Facility," and together with the Revolving Credit Facility, the "Senior Secured Credit Facilities"). The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") if requirements relating to net leverage ratio will be maintained on a pro forma basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Borrowings under the Revolving Credit Facility and the Term Loan Facility will bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;1.25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;2.00%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;0.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, and a eurocurrency rate for an interest period of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;one month&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; plus &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;) plus a margin ranging from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;0.25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;1.00%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, depending on the Company's consolidated net leverage ratio. The Company is required to make quarterly payments under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;0.15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;0.30%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; per annum, depending on the Company's consolidated net leverage ratio, in respect of the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments based on an annual percentage equal to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;2.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;7.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature (unless earlier terminated) on October 13, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The Amended Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;$100 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; during the term of the Amended Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The Amended Credit Agreement contains financial covenants, which were amended in June 2019. The financial covenants require the quarterly presentation of a minimum consolidated 12 month rolling debt service coverage ratio of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;2.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; to 1.00, and an amended maximum consolidated net leverage ratio of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;4.95&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; to 1.00 for the quarter ended June 30, 2019, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;4.75&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; to 1.00 for the quarter ending September 30, 2019, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;3.75&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; to 1.00 for the quarterly filing periods from October 1, 2019 through September 29, 2020 and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; to 1.0 thereafter, which may be adjusted to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;4.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; to 1.00 for a four quarter period in connection with a material permitted acquisition. The Amended Credit Agreement also contains affirmative and negative covenants, which were also amended in June 2019 to limit the amount of restricted payments as defined in the Amended Credit Agreement to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;$25 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; until the filing of the Company's December 31, 2019 Form 10-K. Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments and enter into certain merger or consolidation transactions. As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;2.875% Convertible Senior Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;On January 29, 2014, the Company issued &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;2.875%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; convertible senior notes due 2021 (the "Notes"). The Notes bear interest at a rate of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;2.875%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; per year, payable semi-annually in arrears on January 15 and July 15 of each year. The Notes mature on January 15, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-925FA57456F4B000E2AEF6EB4EA34672-0-wk-Fact-155A22E4A0BE8A0B6FA4F6EB959AB55B">&lt;div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The components of debt are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Senior secured credit agreement - Term loan due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;441.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;447.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Senior secured credit agreement - Revolver loan due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;398.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;348.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.875% Convertible Senior Notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;853.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;808.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of long-term debt, net of debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(10.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(10.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(12.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;830.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;784.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:11pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q2_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember"
      decimals="-5"
      id="d374429617e682-wk-Fact-4C9707CB10EBF01153E8F6ECD889B673"
      unitRef="usd">441600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember"
      decimals="-5"
      id="d374429617e701-wk-Fact-95B2EF867CD25D8E60D7F6ECDA3625CB"
      unitRef="usd">447200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q2_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="-5"
      id="d374429617e721-wk-Fact-C7C71CE8BAF2CA3C52F6F6ECD833C3D1"
      unitRef="usd">398000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember"
      decimals="-5"
      id="d374429617e740-wk-Fact-83ADF04A0B2BAC43D849F6ECD9381C9A"
      unitRef="usd">348000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member"
      decimals="-5"
      id="d374429617e765-wk-Fact-DE0DC91F1975582ACC62F6ECD8413600"
      unitRef="usd">10600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member"
      decimals="-5"
      id="d374429617e784-wk-Fact-DF4B006BF973FACF5B92F6ECD986C876"
      unitRef="usd">10600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember"
      decimals="-5"
      id="d374429617e809-wk-Fact-F03401CE498B2C499FFFF6ECD85CEE77"
      unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ebs_OtherLongTermDebtFacilityMember"
      decimals="-5"
      id="d374429617e828-wk-Fact-9D7BF4241D092693944CF6ECD9FDB49E"
      unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374429617e853-wk-Fact-3B06B24D8397685F5C08F6ECDA17F2D7"
      unitRef="usd">853200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374429617e872-wk-Fact-791222ED800E8945B47DF6ECD8D69BED"
      unitRef="usd">808800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374429617e897-wk-Fact-C06927FD4A5E3D153EA6D84992FA7654"
      unitRef="usd">10100000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374429617e917-wk-Fact-720282BBC8CDC2055C5DD8499301C100"
      unitRef="usd">10100000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374429617e943-wk-Fact-A67148F72E2BC9C306E6F6ED9E39BEBF"
      unitRef="usd">12700000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374429617e963-wk-Fact-8C3EDE4853D78780C615F6ED9E2F9B0B"
      unitRef="usd">14200000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374429617e994-wk-Fact-5684FE71939B0564A1CAD8499314675E"
      unitRef="usd">830400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374429617e1013-wk-Fact-75E6B826C88E6B401542D849930F45CA"
      unitRef="usd">784500000</us-gaap:LongTermDebtNoncurrent>
    <ebs:NumberOfLendingInstitutions
      contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember"
      decimals="INF"
      id="d374429617e1031-wk-Fact-850CD9B28465B4E8004BF6FF15C1314F"
      unitRef="number">4</ebs:NumberOfLendingInstitutions>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="I2018Q4Oct15_us-gaap_DebtInstrumentAxis_ebs_CreditAgreementMember"
      decimals="INF"
      id="d374429617e1035-wk-Fact-4588DA14684479652BA0F7029A54D38B"
      unitRef="usd">200000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="FI2019Q2_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d374429617e1039-wk-Fact-307D7F235FFA16893593F7031BE1B27D"
      unitRef="usd">600000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="I2018Q4Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d374429617e1043-wk-Fact-A399127CB531A8CA0419F7051F84FB89"
      unitRef="usd">450000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="INF"
      id="d374429617e1052-wk-Fact-6186A58A4120DEBD92FAF70AE5AA8578"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="INF"
      id="d374429617e1056-wk-Fact-E0CD5CF0F05A3AD627E8F70AE5DEE0E1"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_FederalFundsEffectiveSwapRateMember"
      decimals="INF"
      id="d374429617e1060-wk-Fact-61770D59E1AAC5580F5BF70D5BCFB1EF"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q4Oct15-Oct15_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_EurodollarMember"
      decimals="INF"
      id="d374429617e1068-wk-Fact-F5B741B6D2844B51AACDF7103150074A"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember"
      decimals="INF"
      id="d374429617e1073-wk-Fact-377699A9BCC560CCABB2F710B9543E42"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember"
      decimals="INF"
      id="d374429617e1077-wk-Fact-1B1B0B517F042D4483FBF710B6F12A2C"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d374429617e1081-wk-Fact-F6A16487A1A8AB2C0AE8F711ED8C20A0"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="D2018Q4Oct15-Oct15_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d374429617e1085-wk-Fact-A944EFE0B0F761DF2066F711ED28B5B5"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears
      contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d374429617e1089-wk-Fact-EAF605F3D011F0F00CD7F7159844002C"
      unitRef="number">0.025</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear
      contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d374429617e1093-wk-Fact-7B6C18E87F2DAF3D48C2F716B266E549"
      unitRef="number">0.05</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears
      contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d374429617e1098-wk-Fact-B2E323244EF0A7CAD227F717E1429265"
      unitRef="number">0.075</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears>
    <ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight
      contextRef="D2018Q4Oct15-Oct15_us-gaap_CreditFacilityAxis_ebs_TermLoanFacilityMember_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d374429617e1107-wk-Fact-87814807083CF30C0D49F71DC05EB669"
      unitRef="usd">100000000</ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight>
    <ebs:DebtInstrumentCovenantDebtServiceCoverageRatio
      contextRef="D2019Q2Jun01-Jun30"
      decimals="INF"
      id="d374429617e1117-wk-Fact-AB1E939355DB85A67C1320EEA097E80C"
      unitRef="number">2.50</ebs:DebtInstrumentCovenantDebtServiceCoverageRatio>
    <ebs:DebtInstrumentCovenantNetLeverageRatioOne
      contextRef="D2019Q2Jun01-Jun30"
      decimals="INF"
      id="d374429617e1121-wk-Fact-AA9A929BCC56550E187F20F086CF9AEA"
      unitRef="number">4.95</ebs:DebtInstrumentCovenantNetLeverageRatioOne>
    <ebs:DebtInstrumentCovenantNetLeverageRatioTwo
      contextRef="D2019Q2Jun01-Jun30"
      decimals="INF"
      id="d374429617e1125-wk-Fact-819E252A46F6D32380EB20F0DF8E435F"
      unitRef="number">4.75</ebs:DebtInstrumentCovenantNetLeverageRatioTwo>
    <ebs:DebtInstrumentCovenantNetLeverageRatioThree
      contextRef="D2019Q2Jun01-Jun30"
      decimals="INF"
      id="d374429617e1129-wk-Fact-FB70CC9B4246DA84FE9B20F12F4B9014"
      unitRef="number">3.75</ebs:DebtInstrumentCovenantNetLeverageRatioThree>
    <ebs:DebtInstrumentCovenantNetLeverageRatioFour
      contextRef="D2019Q2Jun01-Jun30"
      decimals="INF"
      id="d374429617e1133-wk-Fact-E7A5B600BDE207B4787D20F1ACC5272C"
      unitRef="number">3.50</ebs:DebtInstrumentCovenantNetLeverageRatioFour>
    <ebs:DebtInstrumentCovenantNetLeverageRatioAdjusted
      contextRef="D2019Q2Jun01-Jun30"
      decimals="INF"
      id="d374429617e1138-wk-Fact-DB63FBCA19C68AA85EB620F4B795FD44"
      unitRef="number">4.00</ebs:DebtInstrumentCovenantNetLeverageRatioAdjusted>
    <ebs:DebtInstrumentRestrictedPaymentsLimitAmount
      contextRef="D2019Q2Jun01-Jun30_us-gaap_DebtInstrumentAxis_ebs_AmendedCreditAgreementMember"
      decimals="INF"
      id="d374429617e1142-wk-Fact-B4C1AE05A471ACA5E18A21053C2E963E"
      unitRef="usd">25000000</ebs:DebtInstrumentRestrictedPaymentsLimitAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member"
      decimals="INF"
      id="d374429617e1156-wk-Fact-22849E165EB0E18EC19CF71F65C5F910"
      unitRef="number">0.02875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2014Q1Jan29_us-gaap_DebtInstrumentAxis_ebs_ConvertibleSeniorNotesDue2021Member"
      decimals="INF"
      id="d374429617e1160-wk-Fact-22849E165EB0E18EC19CF71F65C5F910"
      unitRef="number">0.02875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-6CF040923B626EE508A5D84993622CB9-0-wk-Fact-565B3F8BF768B6EC8468D849932E390C">Revenue recognition&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The Company operates as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; operating segment. Therefore, results of its operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. The Company's revenues disaggregated by the major sources were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended June 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;94.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;88.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;183.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;169.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;180.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contract manufacturing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;18.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;18.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contracts and grants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;38.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;41.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;132.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;110.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;243.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;185.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;220.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six months ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six Months Ended June 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;167.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;168.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;336.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;235.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;255.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contract manufacturing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;34.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;34.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contracts and grants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;58.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;62.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;226.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;207.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;433.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;266.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;72.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;338.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Contract liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;When performance obligations are not transferred to a customer at the end of a reporting period, the amount allocated to those performance obligations is reflected as deferred revenue on the consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the rollforward of deferred revenue contract liability balances: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"&gt;&lt;span&gt;73.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferral of revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;23.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue recognized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"&gt;&lt;span&gt;89.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Transaction price allocated to remaining performance obligations&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, the Company had expected future revenues associated with performance obligations that have not been satisfied of approximately $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;533.2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; million. The Company expects to recognize a majority of these revenues within the next &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; months, with the remainder recognized thereafter. However, the amount and timing of revenue recognition for unsatisfied performance obligations can materially change due to timing of funding appropriations from the USG and the overall success of the Company's development activities associated with its PHT product candidates that are then receiving development funding support from the USG under development contracts. In addition, the amount of future revenues associated with unsatisfied performance obligations excludes the value associated with unexercised option periods in the Company's contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Contract assets&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The Company considers unbilled accounts receivables and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment, as contract assets. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, the Company had contract assets associated with deferred costs of $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;26.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; million and $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; million, respectively, which is reflected as a component of prepaid expenses and other current assets on the Company's consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Accounts receivable&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Accounts receivable including unbilled accounts receivable contract assets consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Billed, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;179.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;234.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unbilled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;38.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;218.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;262.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, allowances for doubtful accounts were de minimis.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d374430789e601-wk-Fact-5A9CEE1F5ED7B6AAB186D8499312BF92"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-FDA72BCD65523C0AE303D84993616615-0-wk-Fact-115081BD78ED76A476E0D8499308A4DE">The Company's revenues disaggregated by the major sources were as follows:&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended June 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;94.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;88.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;183.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;169.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;180.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contract manufacturing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;18.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;18.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contracts and grants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;38.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;41.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;132.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;110.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;243.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;185.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;220.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six months ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six Months Ended June 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;167.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;168.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;336.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;235.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;255.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contract manufacturing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;34.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;34.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contracts and grants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;58.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;4.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;62.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;226.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;207.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;433.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;266.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;72.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;338.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e915-wk-Fact-2C1B64A05A1B1495D4CAD8499342F2FE"
      unitRef="usd">94600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e934-wk-Fact-16DFAD2B67B7BE3D352FD84993074C17"
      unitRef="usd">88900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d374430789e954-wk-Fact-88076C57679DEBBE211ED8499305E222"
      unitRef="usd">183500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e973-wk-Fact-BA723188CEA5132C171FD8499313B83D"
      unitRef="usd">169900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e992-wk-Fact-1DEBA0CA65229BDCF11ED849933DDFFD"
      unitRef="usd">10200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d374430789e1012-wk-Fact-03C6DD3FE93475379D53D84992F6A572"
      unitRef="usd">180100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e1032-wk-Fact-7215B9863C7B83BC7119D8499318242A"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e1051-wk-Fact-C730182948DA9595F9DCD84992FE730A"
      unitRef="usd">18700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d374430789e1070-wk-Fact-6CD0E930F110BBC79097D8499344AE28"
      unitRef="usd">18700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e1090-wk-Fact-8C2110899BA54F513BA9D8499340C1CE"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e1109-wk-Fact-7AA32AB27DB747611A88D8499309A6FD"
      unitRef="usd">23600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d374430789e1129-wk-Fact-5F10A1FE3C8C63F7E0FAD849933D6AEA"
      unitRef="usd">23600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e1154-wk-Fact-41524DBEDCBC420FBD96D84993422E9A"
      unitRef="usd">38300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e1173-wk-Fact-69A2753E0905296BACF9D8499312C53D"
      unitRef="usd">2700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember"
      decimals="-5"
      id="d374430789e1192-wk-Fact-6CAE36F4026D53DEBBECD8499307243D"
      unitRef="usd">41000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e1212-wk-Fact-D9E237DD4240C40D66FFD849931134CC"
      unitRef="usd">15300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e1231-wk-Fact-6321B5B006F414E6C4EFD8499340E28C"
      unitRef="usd">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember"
      decimals="-5"
      id="d374430789e1251-wk-Fact-D368A395B32B7D3E19B2D8499342140F"
      unitRef="usd">16500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e1281-wk-Fact-7E596EE54239BF64C71DD849931455DB"
      unitRef="usd">132900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e1300-wk-Fact-9E1E272C8731FB73DAF9D849930F6685"
      unitRef="usd">110300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374430789e1320-wk-Fact-7AE92434260DD4FB2CF8D849934D3C6E"
      unitRef="usd">243200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e1339-wk-Fact-7E0B17BFA057007FFD02D84993431FF9"
      unitRef="usd">185200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e1358-wk-Fact-F081B65075B50FE98893D84993414816"
      unitRef="usd">35000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374430789e1378-wk-Fact-EA0211D77CFC99544611D8499308E5C8"
      unitRef="usd">220200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e1691-wk-Fact-66074840E0A5CAAA19EAD8499306E523"
      unitRef="usd">167900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e1710-wk-Fact-7051ECE89437C0705258D8499330AF4F"
      unitRef="usd">168600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d374430789e1730-wk-Fact-D3E43AE69523DCD4EE9BD849933CA0FF"
      unitRef="usd">336500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e1749-wk-Fact-91D6A5A24AB782C05AB2D8499331DC0B"
      unitRef="usd">235900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e1768-wk-Fact-9107ACC563DEA513F8F4D84993059224"
      unitRef="usd">19900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d374430789e1788-wk-Fact-C239168A4E13BC91AFC1D84993402A50"
      unitRef="usd">255800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e1808-wk-Fact-2C218482470FDB2CEF93D84993332EA3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e1827-wk-Fact-E797128F678D70B2632CD849933197AC"
      unitRef="usd">34600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d374430789e1846-wk-Fact-25CD4F38EEECA1E915A0D8499300583A"
      unitRef="usd">34600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e1866-wk-Fact-DF6DFD06A4FBA9C2C4C7D849932EEA9C"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e1885-wk-Fact-80BA061FE0B93FEBB555D84993268C29"
      unitRef="usd">49800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractManufacturingMember"
      decimals="-5"
      id="d374430789e1905-wk-Fact-F4AEB1569AD0C8F57AC8D84993046424"
      unitRef="usd">49800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e1930-wk-Fact-6BDF87279E2D9F64969CD849932EC8EF"
      unitRef="usd">58700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e1949-wk-Fact-63F4319ACA5896D3FEC2D8499330AF35"
      unitRef="usd">4100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember"
      decimals="-5"
      id="d374430789e1968-wk-Fact-8323D54F6C251661152ED849933B4536"
      unitRef="usd">62800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e1988-wk-Fact-9314FCCE18C5F07B5840D8499305AA15"
      unitRef="usd">30100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e2007-wk-Fact-AE52F28085DFEBABB29DD8499331AD04"
      unitRef="usd">2300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ebs_ContractsAndGrantsMember"
      decimals="-5"
      id="d374430789e2027-wk-Fact-159F13845B496BD4A6AAD849934CA9C8"
      unitRef="usd">32400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e2057-wk-Fact-AB0B9EB138AC191583C9D849932BF5A1"
      unitRef="usd">226600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e2076-wk-Fact-CD82C827E6E01552AAFFD849933099DF"
      unitRef="usd">207300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374430789e2096-wk-Fact-8AF29B1E3DD6C78B7907D849934FCD81"
      unitRef="usd">433900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d374430789e2115-wk-Fact-4168A530F427F8CD8543D8499330602C"
      unitRef="usd">266000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d374430789e2134-wk-Fact-AF339F8CCD6820A3A553D849932D352F"
      unitRef="usd">72000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374430789e2154-wk-Fact-75FE50318A68C4409098D849934304DC"
      unitRef="usd">338000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-8DD02916948ACF01FF2DD8499361CFCD-0-wk-Fact-611C491FEDDCF9D9B80ED849933C076D">The following table presents the rollforward of deferred revenue contract liability balances: &lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"&gt;&lt;span&gt;73.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferral of revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;23.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue recognized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"&gt;&lt;span&gt;89.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374430789e2229-wk-Fact-2B1F26CC045FE0825735D8499331A261"
      unitRef="usd">73100000</us-gaap:ContractWithCustomerLiability>
    <ebs:ContractWithCustomerLiabilityAdditions
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374430789e2249-wk-Fact-A7C611749CAC4C976C50D84993314FF5"
      unitRef="usd">23800000</ebs:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374430789e2274-wk-Fact-16DE932FF380E82AE1EFD8499332D24A"
      unitRef="usd">7400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374430789e2305-wk-Fact-B7D7022A4D3BFD478C07D84993324384"
      unitRef="usd">89500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374430789e2326-wk-Fact-3C062667E1FD9918BA95D8499319D933"
      unitRef="usd">533200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="FI2019Q2"
      id="d374430789e2330-wk-Fact-6B5A843D983E1E609F7BD849931211B1">P24M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:DeferredCostsCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374430789e2350-wk-Fact-F47F15BF81F89467CFF7D849932D3680"
      unitRef="usd">26500000</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374430789e2354-wk-Fact-4B9A37AA1E032D97B611D849932FD486"
      unitRef="usd">1200000</us-gaap:DeferredCostsCurrent>
    <ebs:ScheduleofAccountsReceivableNetTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-26636B8665F7A186EE72D84993621F07-0-wk-Fact-BF05E96D1327B00AE79AD8499317C93D">&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Accounts receivable including unbilled accounts receivable contract assets consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Billed, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;179.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;234.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unbilled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;38.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;218.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;262.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</ebs:ScheduleofAccountsReceivableNetTableTextBlock>
    <us-gaap:BilledContractReceivables
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374430789e2450-wk-Fact-C3063E7AA45E0C8C8133D84993388312"
      unitRef="usd">179500000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374430789e2468-wk-Fact-0ADF81F1BD7895703EB2D8499339BD23"
      unitRef="usd">234000000.0</us-gaap:BilledContractReceivables>
    <us-gaap:UnbilledContractsReceivable
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374430789e2488-wk-Fact-281DBDD5CB140063D293D8499338359E"
      unitRef="usd">38600000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374430789e2506-wk-Fact-51C9FBFC507A82E56057D849933876EB"
      unitRef="usd">28500000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374430789e2536-wk-Fact-A88953A1A1C03C0062A4D84992F80FB1"
      unitRef="usd">218100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374430789e2554-wk-Fact-5624509D06373D0CA867D84992FD89D0"
      unitRef="usd">262500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-C1196BB4C415AEC55591D8499362C352-0-wk-Fact-8D909E68E43CFAB9A737D84993389CA4">Income taxes &lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The estimated effective annual tax rate for the Company, which excludes discrete adjustments, was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;27%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, respectively. The increase in the estimated effective annual tax rate is primarily due to the impact of foreign and state taxes. For each of the six month periods ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, the Company recorded a discrete tax benefit of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$3.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, primarily due to activity associated with equity awards. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;three months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, the Company recorded a discrete tax benefit of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;$0.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, respectively, also primarily due to activity associated with equity awards&lt;/span&gt;&lt;span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;. &lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d374430949e601-wk-Fact-9C9164CB9FFAF7237EBAD8499339C9B1"
      unitRef="number">0.27</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2018Q2YTD"
      decimals="2"
      id="d374430949e605-wk-Fact-8494FDDFA30C646A1A58D849933812AF"
      unitRef="number">0.25</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374430949e630-wk-Fact-C350A08FE7588070EED7D8499339EB08"
      unitRef="usd">3200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374430949e645-wk-Fact-52900CEA8135C329A029211C88B12EBD"
      unitRef="usd">1400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374430949e649-wk-Fact-C4E07D4E53F69EE2297E211CBF86DEA3"
      unitRef="usd">900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-41D9866491C4D8905542D849936289F4-0-wk-Fact-7E56E3EA6364400FE179D849932F8901">arnings per share&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The following table presents the calculation of basic and diluted net (loss) income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net (loss) earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(9.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(35.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of shares&#x2014;basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;51.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;51.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive securities&#x2014;equity awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of shares&#x2014;diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;51.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;51.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net (loss) earnings per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net (loss) earnings per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;For the three and six months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, basic earnings per share is computed by dividing net gain/(loss) by the weighted average number of shares of common stock outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;For the three and six months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, diluted earnings per share is computed using the treasury method by dividing net loss by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. No adjustment for the potential dilutive effect of dilutive securities is reported as the effect would have been anti-dilutive for the three and six months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; due to the Company's net loss. The s&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;hare-based awards that were excluded from the calculation of diluted loss per share, because they were anti-dilutive, were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;&lt;span&gt;3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt; for the three and six months ended June 30, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-246A0B0492C997A6F682D849936294A3-0-wk-Fact-5030E8CE606F4406F752D84993309151">&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;The following table presents the calculation of basic and diluted net (loss) income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net (loss) earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(9.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(35.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of shares&#x2014;basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;51.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;51.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive securities&#x2014;equity awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of shares&#x2014;diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;51.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;51.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net (loss) earnings per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net (loss) earnings per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374432199e906-wk-Fact-3DEE1DB2F7CE5FC56F910AD63787861D"
      unitRef="usd">-9500000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d374432199e926-wk-Fact-BD6EEF1FC891BC717D7BF73A591B134F"
      unitRef="usd">50100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374432199e946-wk-Fact-D502B06148AFF8C3996BF73A6CD06CA0"
      unitRef="usd">-35600000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d374432199e966-wk-Fact-41759653833EDF33A8DAF6DE20D25EEB"
      unitRef="usd">45200000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d374432199e1160-wk-Fact-249E34FBEEA91948C2A2D8499337C607"
      unitRef="shares">51500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q2QTD"
      decimals="0"
      id="d374432199e1179-wk-Fact-ED841A50DECF9836B4ABD84993316548"
      unitRef="shares">49900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d374432199e1198-wk-Fact-856CB77C93E0A1473181F73A6E773568"
      unitRef="shares">51300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q2YTD"
      decimals="0"
      id="d374432199e1218-wk-Fact-CD8CBCC1EE178E6E3AA3F6DE20FF501F"
      unitRef="shares">49700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d374432199e1243-wk-Fact-7F5E27597B72E3BC1B4CD8499336E640"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q2QTD"
      decimals="0"
      id="d374432199e1262-wk-Fact-036C603FAE0BC4B44F7AD8499334EE18"
      unitRef="shares">1300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d374432199e1281-wk-Fact-AE843246D23137C0A257F73A6F560BFF"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q2YTD"
      decimals="0"
      id="d374432199e1301-wk-Fact-648B67B027B0AF90AD41F6DE20C61945"
      unitRef="shares">1300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d374432199e1326-wk-Fact-DD6492E03A56A2656BB7D84993341077"
      unitRef="shares">51500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q2QTD"
      decimals="0"
      id="d374432199e1345-wk-Fact-6D20B9CA5221D3C5A871D8499334AC41"
      unitRef="shares">51200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d374432199e1364-wk-Fact-04A5DC09FE931F6D409AF73A703168FA"
      unitRef="shares">51300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q2YTD"
      decimals="0"
      id="d374432199e1384-wk-Fact-9A3CC8B61E79A1F29CB3F6DE20FCD225"
      unitRef="shares">51000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d374432199e1501-wk-Fact-7090664CCD3C5A1ED984D8499303C361"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d374432199e1521-wk-Fact-D0A64B8EAE0004E47B12D8499303D192"
      unitRef="usdPerShare">1.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d374432199e1541-wk-Fact-942BAE68901FFA254237D84993449FB1"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q2YTD"
      decimals="2"
      id="d374432199e1561-wk-Fact-4C84A2D71E9B4E703742D849933F78FA"
      unitRef="usdPerShare">0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d374432199e1587-wk-Fact-35C4160347E4E5189413D84992FC2D0C"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d374432199e1607-wk-Fact-9C4E901483C9A5C87F06D84993017C7A"
      unitRef="usdPerShare">0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d374432199e1627-wk-Fact-5FE71E088EBD1B785B06D849933F0F9D"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q2YTD"
      decimals="2"
      id="d374432199e1647-wk-Fact-EE1327C309A8868B9739D849930225C0"
      unitRef="usdPerShare">0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374432199e1684-wk-Fact-D107D657392AAB4531C52086143635B6"
      unitRef="shares">3000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-056B27D598271EE74B94D8499362DF67-0-wk-Fact-63DB5029280DFFD6A4F6D849933AA46C">Share-based compensation&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;, the Company granted stock options to purchase &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; restricted stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. The grants vest over &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; equal annual installments beginning on the day prior to the anniversary of the grant date.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d374432743e605-wk-Fact-C1066C0406258632725BD849933AE0B2"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d374432743e609-wk-Fact-E5979AD010C93E778B42D84993391A81"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-58F5A70BB7DF519062B9D84993624CD9-0-wk-Fact-32D14169EAC6A6995C6AD8499334E6A6">Defined benefit plan&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The Company sponsors a defined benefit pension plan covering eligible employees in Switzerland (the Swiss Plan). Under the Swiss Plan, the Company and certain of its employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#x2019;s contribution. The Swiss Plan assets are comprised of an insurance contract that has a fair value consistent with its contract value based on the practicability exception using level 3 inputs. The entire liability is listed as non-current, because plan assets are greater than the expected benefit payments over the next year. The Company recognizes pension expense as a component of selling, general and administrative expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The measurement date used for the Swiss Plan is December 31, annually. The expense components of the Swiss Plan consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six months ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expected return on plan assets, net of expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&#160;&#160;Total pension expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-C7256C9979733087C0ACD8499362BD63-0-wk-Fact-365B776B1D64BB8201FCD84993357958">The expense components of the Swiss Plan consisted of the following:&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Three Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;Six months ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expected return on plan assets, net of expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;&#160;&#160;Total pension expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374432503e688-wk-Fact-5C13FB1D0B218C088DE0D8499332179F"
      unitRef="usd">300000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374432503e707-wk-Fact-7841B8C095DF40C72D1DD84993345F20"
      unitRef="usd">600000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374432503e727-wk-Fact-D8EC74E71B6160D1A02AD84993379982"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374432503e747-wk-Fact-697F26574246A0760695D8499337AB9C"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d374432503e778-wk-Fact-D26D1A0F3FEEC0E8AAB0D8499339222B"
      unitRef="usd">200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d374432503e797-wk-Fact-48B9097A72DF98D10251D8499333CB0A"
      unitRef="usd">500000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-654716BE39FEC6FE3191D8499362B50D-0-wk-Fact-3EA8DFC573AB6E16E208D8499336F7DE">Commitments and Contingencies &lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;ANDA Litigation - Perrigo 4mg&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;On September 14, 2018, Adapt Pharma Inc., Adapt Pharma Operations Limited and Adapt Pharma Ltd. (collectively, Adapt Pharma), and Opiant Pharmaceuticals, Inc. (Opiant), received notice from Perrigo UK FINCO Limited Partnership (Perrigo) that Perrigo had filed an Abbreviated New Drug Application (ANDA) with the FDA, seeking regulatory approval to market a generic version of NARCAN&#xae; (naloxone hydrochloride) Nasal Spray 4mg/spray before the expiration of U.S. Patent Nos. 9,211,253 (the &#x2018;253 Patent), 9,468,747 (the &#x2018;747 Patent), 9,561,177 (the &#x2018;177 Patent), 9,629,965 (the &#x2018;965 Patent), and 9,775,838 (the &#x2018;838 Patent). On or about October 25, 2018, Perrigo sent a subsequent notice letter relating to U.S. Patent No. 10,085,937 (the &#x2018;937 Patent). Perrigo&#x2019;s notice letters assert that its generic product will not infringe any valid and enforceable claim of these patents. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;On October 25, 2018, Emergent BioSolutions&#x2019; Adapt Pharma subsidiaries and Opiant (collectively, Plaintiffs), filed a complaint for patent infringement of the &#x2018;253, &#x2018;747, &#x2018;177, &#x2018;965, and the &#x2018;838 Patents against Perrigo in the United States District Court for the District of New Jersey arising from Perrigo&#x2019;s ANDA filing with the FDA. Plaintiffs filed a second complaint against Perrigo on December 7, 2018, for the infringement of the &#x2018;937 Patent. As a result of timely filing the first lawsuit in accordance with the Hatch-Waxman Act, a 30-month stay of approval will be imposed by the FDA on Perrigo&#x2019;s ANDA, which is expected to remain in effect until March 2021 absent an earlier judgment, unfavorable to the Plaintiffs, by the Court. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;ANDA Litigation - Teva 2mg&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;On or about February 27, 2018, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva Pharmaceuticals Industries Ltd. and Teva Pharmaceuticals USA, Inc. (collectively Teva), that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#xae; (naloxone hydrochloride) Nasal Spray 2 mg/spray before the expiration of U.S. Patent No. 9,480,644 (the &#x2018;644 Patent), and U.S. Patent No. 9,707,226 (the '226 Patent). Teva's notice letter asserts that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '644 Patent or the '226 Patent, or that the '644 Patent and '226 Patent are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;ANDA Litigation - Teva 4mg&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;On or about September 13, 2016, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#xae; (naloxone hydrochloride) Nasal Spray 4 mg/spray before the expiration of the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received additional notices from Teva relating to the '747, the '177, the '965, the '838, and the &#x2018;937 Patents. Teva's notice letters assert that the commercial manufacture, use or sale of &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;its generic drug product described in its ANDA will not infringe the '253, the '747, the '177, the '965, the '838, or the &#x2018;937 Patent, or that the '253, the '747, the '177, the '965, the '838, and the &#x2018;937 Patents are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant also filed complaints for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '747, the '177, the '965, and the '838 Patents. All five proceedings have been consolidated. As of the date of this filing, Adapt Pharma Inc., Adapt Pharma Operations Limited, and Opiant, have not filed a complaint related to the &#x2018;937 Patent. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;In the complaints described in the paragraphs above, the Plaintiffs seek, among other relief, orders that the effective date of FDA approvals of the Teva ANDA products and the Perrigo ANDA product be a date not earlier than the expiration of the patents listed for each product, equitable relief enjoining Teva and Perrigo from making, using, offering to sell, selling, or importing the products that are the subject of Teva and Perrigo&#x2019;s respective ANDAs, until after the expiration of the patents listed for each product, and monetary relief or other relief as deemed just and proper by the court.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;"&gt;Shareholder Class Action Lawsuit filed July 19, 2016&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;On July 19, 2016, Plaintiff William Sponn (Sponn), filed a putative class action complaint in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#x2019;s common stock between January 11, 2016 and June 21, 2016, inclusive (the Class Period), seeking to pursue remedies under the Exchange Act against the Company and certain of its senior officers and directors (collectively, the Defendants). The complaint alleged, among other things, that the Defendants made materially false and misleading statements about the government&#x2019;s demand for BioThrax and expectations that the Company&#x2019;s five-year exclusive procurement contract with &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;the U.S. Department of Health and Human Services (HHS)&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt; would be renewed, and omitted certain material facts. Sponn sought unspecified damages, including legal costs. On October 25, 2016, the court added City of Cape Coral Municipal Firefighters&#x2019; Retirement Plan and City of Sunrise Police Officers&#x2019; Retirement Plan as plaintiffs and appointed them Lead Plaintiffs and Robbins Geller Rudman&#160;&amp;amp; Dowd LLP as Lead Counsel. On December 27, 2016, the plaintiffs filed an amended complaint that cited the same class period, named the same defendants and made similar allegations to the original complaint. The Defendants filed a Motion to Dismiss on February 27, 2017. The plaintiffs filed an opposition brief on April 28, 2017. The Defendants&#x2019; Motion to Dismiss was heard and denied on July 6, 2017. The Defendants filed an answer on July 28, 2017. The parties then engaged in the discovery process. The plaintiffs filed an amended motion for class certification and appointment of Lead Plaintiffs, Sponn, and Geoffrey L. Flagstad (Flagstad) as Class Representatives on December 20, 2017. A hearing on that motion was heard on May 2, 2018. On June 8, 2018 the Court granted class certification with a shortened class period, from May 5, 2016 to June 21, 2016. In that same order, the court appointed Flagstad as Class Representative and Robbins Geller Rudman&#160;&amp;amp; Dowd LLP as Class Counsel. The Defendants have denied, and continue to deny, any and all allegations of fault, liability, wrongdoing, or damages. However, recognizing the risk, time, and expense of litigating any case to trial, on August 27, 2018, the Defendants reached an agreement in principle with plaintiffs to settle all of the related claims of any individual plaintiff that purchased or acquired Company stock from January 11, 2016 to June 21, 2016, for $&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&lt;span&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"&gt;&#160;million, an amount that was paid by the Company&#x2019;s insurance carrier. The settlement required no payment by any of the Defendants. The Defendants continue to deny any and all liability. The parties executed the settlement agreement on October 16, 2018 and filed the agreement with the court on October 17, 2018. The court granted preliminary approval of the settlement on October 18, 2018. At the time of the approval of the settlement on January 22, 2019, there were no objections to the settlement, but there were two shareholders who had submitted opt-outs so that they could be excluded from the settlement. On January 25, 2019, the court issued an order and final judgment approving the settlement. The time to file a notice of appeal has passed.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;"&gt; &lt;/span&gt;Defendants continue to believe that the allegations in the complaint are without merit.</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="FD2019Q2YTD_srt_LitigationCaseAxis_ebs_ShareholderClassActionLawsuitMember"
      decimals="-5"
      id="d374432674e635-wk-Fact-D7D5C808851FF3E9970FD84993366B6F"
      unitRef="usd">6500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-CCCA959578AFA7A326F3D84993633F05-0-wk-Fact-EAF1C81DEBA93FD99A56D84993114E6D">Supplemental Information&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;177.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;177.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-4DED785670F00BF1BD45D8499363B19A-0-wk-Fact-AD059E90F85E0C58ED28D8499315F27B">&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;177.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"&gt;&lt;span&gt;177.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374433036e684-wk-Fact-6CA7FDAA9259FA7C68D2D8499320BDDE"
      unitRef="usd">177400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374433036e703-wk-Fact-5D4E7B3352A75B0F2A05D84992FD64FA"
      unitRef="usd">112200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374433036e723-wk-Fact-D13020F931652E7731E5D849933A39E2"
      unitRef="usd">200000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374433036e742-wk-Fact-DAC97C22E0D2D2261AB8D849933A390F"
      unitRef="usd">200000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2"
      decimals="-5"
      id="d374433036e772-wk-Fact-9A111BE18CEE889F3286D84993178D44"
      unitRef="usd">177600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-5"
      id="d374433036e791-wk-Fact-8DD36C3DCC90E3398706D84993149DCA"
      unitRef="usd">112400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6849705232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jul. 26, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">14-1902018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Professional Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">631-3200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EBS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Emergent BioSolutions Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001367644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843045232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 177.4<span></span>
</td>
<td class="nump">$ 112.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">218.1<span></span>
</td>
<td class="nump">262.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">232.0<span></span>
</td>
<td class="nump">205.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">65.0<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">692.7<span></span>
</td>
<td class="nump">620.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">520.5<span></span>
</td>
<td class="nump">510.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">742.4<span></span>
</td>
<td class="nump">761.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_InProcessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">41.0<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">268.3<span></span>
</td>
<td class="nump">259.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,321.3<span></span>
</td>
<td class="nump">2,229.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">124.5<span></span>
</td>
<td class="nump">80.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">54.8<span></span>
</td>
<td class="nump">30.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration, current portion</a></td>
<td class="nump">54.6<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">44.7<span></span>
</td>
<td class="nump">58.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Debt, current portion</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">301.2<span></span>
</td>
<td class="nump">200.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">54.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of debt</a></td>
<td class="nump">830.4<span></span>
</td>
<td class="nump">784.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">65.6<span></span>
</td>
<td class="nump">67.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">77.0<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">47.8<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,332.4<span></span>
</td>
<td class="nump">1,218.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 8 &amp; 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding at both 2019 and 2018</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200.0 shares authorized, 52.7 shares issued and 51.6 shares outstanding at 2019; 52.4 shares issued and 51.2 shares outstanding at 2018</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 1.2 common shares at both 2019 and 2018</a></td>
<td class="num">(39.7)<span></span>
</td>
<td class="num">(39.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">701.8<span></span>
</td>
<td class="nump">688.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5.0)<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">331.7<span></span>
</td>
<td class="nump">367.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">988.9<span></span>
</td>
<td class="nump">1,010.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 2,321.3<span></span>
</td>
<td class="nump">$ 2,229.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_InProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of purchased research and development assets acquired in a business combination that have an indefinite life until completion or abandonment of the associated research and development efforts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_InProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6841802848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">52,700,000<span></span>
</td>
<td class="nump">52,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">51,600,000<span></span>
</td>
<td class="nump">51,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6830981920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 243.2<span></span>
</td>
<td class="nump">$ 220.2<span></span>
</td>
<td class="nump">$ 433.9<span></span>
</td>
<td class="nump">$ 338.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales and contract manufacturing</a></td>
<td class="nump">100.8<span></span>
</td>
<td class="nump">85.3<span></span>
</td>
<td class="nump">192.7<span></span>
</td>
<td class="nump">139.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">63.9<span></span>
</td>
<td class="nump">24.7<span></span>
</td>
<td class="nump">110.0<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">70.8<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
<td class="nump">136.4<span></span>
</td>
<td class="nump">79.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquisition-related intangible assets</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">250.2<span></span>
</td>
<td class="nump">153.4<span></span>
</td>
<td class="nump">468.3<span></span>
</td>
<td class="nump">280.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="nump">66.8<span></span>
</td>
<td class="num">(34.4)<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(9.5)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(19.0)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(8.1)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(18.6)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">(Loss) income before income taxes</a></td>
<td class="num">(15.1)<span></span>
</td>
<td class="nump">65.8<span></span>
</td>
<td class="num">(53.0)<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
<td class="num">(17.4)<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (9.5)<span></span>
</td>
<td class="nump">$ 50.1<span></span>
</td>
<td class="num">$ (35.6)<span></span>
</td>
<td class="nump">$ 45.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (loss) income per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="nump">$ 0.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Shares used in computing (loss) income per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">51,500,000<span></span>
</td>
<td class="nump">49,900,000<span></span>
</td>
<td class="nump">51,300,000<span></span>
</td>
<td class="nump">49,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">51,500,000<span></span>
</td>
<td class="nump">51,200,000<span></span>
</td>
<td class="nump">51,300,000<span></span>
</td>
<td class="nump">51,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 183.5<span></span>
</td>
<td class="nump">$ 180.1<span></span>
</td>
<td class="nump">$ 336.5<span></span>
</td>
<td class="nump">$ 255.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractManufacturingMember', window );">Contract manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">34.6<span></span>
</td>
<td class="nump">49.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 41.0<span></span>
</td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="nump">$ 62.8<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6841803424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive (Loss) Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (9.5)<span></span>
</td>
<td class="nump">$ 50.1<span></span>
</td>
<td class="num">$ (35.6)<span></span>
</td>
<td class="nump">$ 45.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translations, net of tax</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive (loss) income, net of tax</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (10.0)<span></span>
</td>
<td class="nump">$ 48.9<span></span>
</td>
<td class="num">$ (35.1)<span></span>
</td>
<td class="nump">$ 44.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6849597824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (35.6)<span></span>
</td>
<td class="nump">$ 45.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">55.1<span></span>
</td>
<td class="nump">24.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ChangeInFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration, net</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">44.6<span></span>
</td>
<td class="num">(46.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(26.1)<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(44.9)<span></span>
</td>
<td class="num">(9.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">42.6<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(13.5)<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">16.4<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities:</a></td>
<td class="nump">69.0<span></span>
</td>
<td class="nump">33.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment and other</a></td>
<td class="num">(35.5)<span></span>
</td>
<td class="num">(25.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForPreviousAcquisition', window );">Milestone payment from prior asset acquisition</a></td>
<td class="num">(10.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities:</a></td>
<td class="num">(45.5)<span></span>
</td>
<td class="num">(22.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from revolving credit facility</a></td>
<td class="nump">130.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal payments on revolving credit facility</a></td>
<td class="num">(80.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfMediumTermNotes', window );">Principal payments on term loan facility</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuances of stock under share-based benefit plans</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid on behalf of employees for equity activity</a></td>
<td class="num">(6.3)<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration payments</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities:</a></td>
<td class="nump">41.7<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">65.2<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">112.4<span></span>
</td>
<td class="nump">179.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 177.6<span></span>
</td>
<td class="nump">$ 191.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement of contingent value rights and contingent purchase considerations granted under purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPreviousAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow representing an adjustment to the purchase price of a previous acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPreviousAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=107668666&amp;loc=SL79513924-113897<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6842993040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>$0.001 Par Value Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 912.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 618.4<span></span>
</td>
<td class="num">$ (39.5)<span></span>
</td>
<td class="num">$ (3.8)<span></span>
</td>
<td class="nump">$ 337.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Employee equity plans activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee equity plans activity</a></td>
<td class="nump">14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">45.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2018</a></td>
<td class="nump">938.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">632.5<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="nump">349.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2018</a></td>
<td class="nump">881.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">624.4<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="nump">299.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Employee equity plans activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee equity plans activity</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">50.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2018</a></td>
<td class="nump">$ 938.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">632.5<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="nump">349.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="num">(52,400,000)<span></span>
</td>
<td class="num">(52,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,010.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">688.6<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
<td class="nump">367.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Employee equity plans activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee equity plans activity</a></td>
<td class="nump">13.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(35.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="num">(52,700,000)<span></span>
</td>
<td class="num">(52,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">$ 988.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">701.8<span></span>
</td>
<td class="num">$ (39.7)<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="nump">331.7<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">987.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">690.1<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="nump">341.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Employee equity plans activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee equity plans activity</a></td>
<td class="nump">11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="num">(52,700,000)<span></span>
</td>
<td class="num">(52,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">$ 988.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 701.8<span></span>
</td>
<td class="num">$ (39.7)<span></span>
</td>
<td class="num">$ (5.0)<span></span>
</td>
<td class="nump">$ 331.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838476304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6839148128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business</a></td>
<td class="text">Business<div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Emergent is a global life sciences company focused on providing specialty products for civilian and military populations that address accidental, deliberate and naturally occurring PHTs. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company is focused on innovative preparedness and response products and solutions addressing the following four distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives (CBRNE); emerging infectious diseases (EID); travelers&#8217; diseases; and opioids. The USG is the Company's largest customer and provides the Company with substantial funding for the development of a number of the Company's product candidates. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The majority of the Company's revenue comes from a product portfolio that includes: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Vaccines and Anti-Infectives</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> - </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">BioThrax&#174; (Anthrax Vaccine Adsorbed), ACAM2000&#174; (Smallpox (Vaccinia) Vaccine, Live), Vaxchora&#174; (Cholera Vaccine, Live, Oral), and Vivotif&#174; (Typhoid Vaccine, Live, Oral Ty21a).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Devices</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> - </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">NARCAN&#174; (naloxone HCl) Nasal Spray for opioid overdose, RSDL&#174; (Reactive Skin Decontamination Lotion Kit), and the Trobigard&#174; (atropine sulfate, obidoxime chloride a nerve agent countermeasure) auto-injector.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#00497f;font-weight:bold;">Antibody Therapeutics - </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">raxibacumab (Anthrax Monoclonal antibody therapeutic for anthrax),</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Anthrasil&#174;( Anthrax Immune Globulin Intravenous (Human)), BAT&#174;(Botulism Antitoxin Heptavalent), and VIGIV (Vaccinia Immune Globulin Intravenous (Human) therapeutic) for complications from smallpox vaccinations.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company also generates revenue from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">contract development and manufacturing services</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> including </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">pharmaceutical product process development, manufacturing and filling services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, laboratory analytical development support, aseptic filling, lyophilization, final packaging and accelerated and ongoing stability studies, as well as manufacturing of vial and pre-filled syringe formats, bulk drug products and finished units of clinical and commercial drugs. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> operating segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6839086720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Principles of Consolidation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text">Basis of Presentation and Principles of Consolidation<div style="line-height:120%;padding-bottom:8px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Basis of Presentation </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, as filed with the SEC.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Significant Accounting Policies</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, as filed with the SEC, except for recently adopted accounting standards.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Fair Value Measurements</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has interest rate swaps and contingent consideration liabilities that are measured at fair value on a recurring basis (Note 8 and Note 9). The Company also records the assets and liabilities of acquisitions at fair value (Note 3). As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">no</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> other significant assets or liabilities that were measured at fair value on a non-recurring basis. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-02, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, which increases transparency and comparability among organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The Company adopted the new standard effective January 1, 2019 using the modified retrospective approach. As of January 1, 2019 total right of use assets increased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;text-align:right;"><span>$13.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, while total operating lease liabilities increased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;font-weight:bold;text-align:right;"><span>$14.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">. There was no adjustment to the opening balance of retained earnings as of January 1, 2019. The standard will not materially affect the Company's consolidated net earnings. The Company continues to apply the legacy guidance from the old lease accounting standard, including its disclosure requirements, in the comparative periods presented. The Company did not reassess existing contracts for lease classification or the classification of existing leases or associated costs. The Company will not reflect leases with an initial term of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> months or less as a right of use asset or liability, but will recognize those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. In addition, the Company will account for non-lease components of the arrangement separate from lease components (see Note 6).</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">SEC Simplification</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In August 2018, the SEC issued Final Rule Release No. 33-10532, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Disclosure Update and Simplification</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, which makes a number of changes meant to simplify interim disclosures. The new rule requires a presentation of changes in stockholders&#8217; equity and noncontrolling interest in the form of a reconciliation, for the current and comparative year-to-date interim periods. The Company adopted the new disclosure requirements beginning in its March 31, 2019 Form 10-Q and included these disclosures in the condensed consolidated statements of changes in stockholders' equity. The additional elements of this release did not have a material impact on the Company's overall condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Tax Effects from Accumulated Other Comprehensive Income</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">In February 2018, the FASB issued ASU 2018-02,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;">&#160;Income Statement&#8212;Reporting Comprehensive Income (Topic 220):&#160;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. ASU 2018-02 provides the option to reclassify certain income tax effects related to the Tax Cuts and Jobs Act passed in December of 2017 between accumulated other comprehensive income and retained earnings and also requires additional disclosures.&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company adopted the new standard effective January 1, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">.&#160;There was no impact for the adoption of ASU 2018-02 on the Company's condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Financial Instruments - Credit Losses</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">In June 2016, the FASB issued&#160;ASU 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;">Financial Instruments - Credit Losses</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. ASU 2016-13 provides&#160;guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking &#8220;expected loss&#8221; model that is likely to result in the earlier recognition of allowances for losses. The guidance was further amended in January 2019 to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">clarify or address stakeholders&#8217; specific issues about certain aspects of the amendments in the update and in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">May 2019 to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">provide an option to irrevocably elect the fair value option for certain financial assets previously measured on an amortized cost basis. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The guidance&#160;is effective for annual periods beginning after December 15, 2019, including interim periods within those years, but early adoption is permitted. The Company is currently evaluating the effect that the pronouncement will have on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">In January 2017, the FASB issued ASU 2017-04,&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. ASU 2017-04 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-04 is effective for annual and interim goodwill tests beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates on or after January 1, 2017. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In August 2018 the FASB issued ASU No. 2018-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">. This new standard modifies certain disclosure requirements on fair value measurements. This new standard will be effective for the Company on January 1, 2020. The Company does not expect that the adoption of this new standard will have a material impact on the Company's disclosures.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Compensation -&#160;Retirement Benefits - Defined Benefit Plans</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In August 2018, the FASB issued ASU 2018-14, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Compensation - Retirement Benefits - Defined Benefit Plans - General</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">. ASU 2018-14 modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. ASU 2018-14 is effective for&#160;all entities for fiscal years ending after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-14 on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">There are no other recently issued accounting pronouncements that are expected to have a material impact on the Company's financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846473648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Adapt</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">On October 15, 2018, the Company acquired Adapt, a company focused on developing new treatment options and commercializing products addressing opioid overdose and addiction. Adapt's NARCAN&#174; (naloxone HCl) Nasal Spray marketed product is the first needle-free formulation of naloxone approved by the FDA and Health Canada for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. This acquisition includes approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>50</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> employees, located in the U.S., Canada, and Ireland, including those responsible for supply chain management, research and development, government affairs, and commercial operations. The products and product candidates within Adapt's portfolio are consistent with the Company's mission and expands the Company's core business of addressing </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">public health threats</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Under the acquisition method of accounting, the assets and liabilities of Adapt have been recorded as of October 15, 2018, the acquisition date, at their respective fair values, and combined with those of the Company. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">As the Company continues to finalize the fair value of assets acquired and liabilities assumed, purchase price adjustments have been recorded and additional purchase price adjustments may be recorded during the measurement period. The Company reflects measurement period adjustments in the period in which the adjustments occur. The adjustments for the&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> resulted from the receipt of additional financial information </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">associated with certain acquired contract assets and the value of associated contingent purchase consideration</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">. These adjustments did not impact the Company's statements of operations. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, certain fair value estimates relating to</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> intangible assets acquired and income taxes could be</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> subject to further adjustment.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The total purchase price, revised for current period adjustments is summarized below:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">October 15, 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>581.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>37.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of contingent purchase consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>48.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preliminary purchase consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>667.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Updated purchase consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>668.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company issued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>733,309</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> shares of common stock at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$60.44</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> per share, the closing price of Emergent's common stock on October 15, 2018, with a total value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$44.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. The </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$44.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> value of the common shares issued has been adjusted to a fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$37.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million considering a discount for lack of marketability due&#160;to a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">two</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">-year lock-up period beginning on October 15, 2018. The remaining contingent consideration payable for the acquisition consists of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$100 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> in cash based on the achievement of certain sales milestones through 2022, which the Company has determined had a fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>48.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and for the payment of additional consideration based on the collectability of identified acquired contract assets.&#160;The fair value of the contingent purchase consideration is based on management&#8217;s assessment of the potential future realization of the contingent purchase consideration </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">payments. This assessment is based on inputs that have no observable market inputs (Level 3). The obligation is measured using a discounted cash flow model.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at October 15, 2018 updated for measurement period adjustments recorded through </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">October 15, 2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Measurement Period Adjustments</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Updated  October 15, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Estimated fair value of tangible assets acquired and liabilities assumed:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>41.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>41.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(32.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(32.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(50.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(50.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(62.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(62.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total estimated fair value of tangible assets acquired and liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(56.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(54.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>534.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>534.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>149.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>148.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>667.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>668.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company determined the estimated fair value of the intangible asset using the income approach. The preliminary estimated fair value of the intangible asset acquired for Adapt's marketed product NARCAN&#174; Nasal Spray is valued at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$534.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million. The Company has determined the useful life of the NARCAN&#174; Nasal Spray intangible asset to be </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>15</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> years. The Company estimated the fair value of the NARCAN&#174; Nasal Spray intangible asset using the income approach which is based on the present value of future cash flows with a discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>10.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Adapt. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value these intangible assets. The projected cash flows from the NARCAN&#174; Nasal Spray intangible asset were based on key assumptions including: estimates of revenues and operating profits, and risks related to the viability of and potential alternative treatments in any future target markets. The fair value measurements are based on significant unobservable inputs that are developed by the Company using estimates and assumptions of the respective market and market penetration of the acquired company's products.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The intangible asset associated with the IPR&amp;D acquired from Adapt is related to a product candidate. Management determined that the estimated acquisition-date fair value of intangible assets related to IPR&amp;D was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$41.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million. The estimated fair value was determined using the income approach, which discounts expected future cash flows to present value. The Company estimated the fair value using a discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>11.0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Adapt and IPR&amp;D assets at a similar stage of development as the product candidate. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value the IPR&amp;D. The projected cash flows for the product candidate were based on key assumptions including: estimates of revenues and operating profits, the stage of development of pipeline programs on the acquisition date; the time and resources needed to complete the development and approval of the product candidate; the life of the potential commercialized product and associated risks, including the inherent difficulties and uncertainties in developing a product candidate, such as obtaining marketing approval from the FDA and other regulatory agencies; and risks related to the viability of and potential for alternative treatments in any future target markets. IPR&amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts (see Note 7).</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company determined the fair value of inventory using the comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete/dispose of the inventory with a profit on those costs. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company has recorded </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$148.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million in goodwill related to the Adapt acquisition, which is calculated as the purchase price paid in excess of the fair value of the tangible and intangible assets acquired representing the future economic benefits the Company expects to receive as a result of the acquisition. The goodwill created from the Adapt acquisition is associated with early stage pipeline products. Substantially all of the goodwill generated from the Adapt acquisition is not expected to be deductible for tax purposes due to the legal structure of the transaction.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">PaxVax</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">On October 4, 2018, the Company completed the acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases. This acquisition includes Vivotif&#174; (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever, Vaxchora&#174; (Cholera Vaccine, Live, Oral), the only FDA-licensed vaccine for the prevention of cholera, and clinical-stage vaccine candidates targeting chikungunya and other emerging infectious diseases, European-based current good manufacturing practices (cGMP) biologics manufacturing facilities, and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>250</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> employees including those in research and development, manufacturing, and commercial operations with a specialty vaccines salesforce in the U.S. and in select European countries. The products and product candidates within PaxVax's portfolio are consistent with the Company&#8217;s mission and will expand the Company&#8217;s core business of addressing PHTs. In addition, the acquisition expands the Company's manufacturing infrastructure and related capabilities.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company paid cash consideration of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$273.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million for PaxVax. As of the date of this filing, the accounting for the PaxVax acquisition is preliminary due to the Company's need to gather data to assess the fair value of property, plant and equipment, intangible assets and accounting for taxes. The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at October 4, 2018 updated for measurement period adjustments recorded through </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">October 4, 2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Measurement Period Adjustments</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Updated October 4, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Estimated fair value of tangible assets acquired and liabilities assumed:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>57.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>57.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(33.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(34.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total estimated fair value of tangible assets acquired and liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>69.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>69.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>61.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>273.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>273.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The preliminary estimated fair value of the intangible assets acquired for PaxVax's marketed products is a total of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$133.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million. The Company determined the estimated fair value of the intangible assets using the income approach, which is based on the present value of future cash flows. The fair value measurements are based on significant unobservable inputs that are developed by the Company using estimates and assumptions of the respective market and market penetration of the acquired products. The Company has determined that the weighted average useful lives of the intangible assets to be </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>19</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> years. The Company estimated the fair value of the Vivotif and Vaxchora intangible assets </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">using a present value discount rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>14.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>15.0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, respectively, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of PaxVax. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value these intangible assets. The projected cash flows from these intangible assets were based on key assumptions, including: estimates of revenues and operating profits, and risks related to the viability of and potential alternative treatments in any future target markets.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The intangible asset associated with the IPR&amp;D </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the measurement of the amounts recognized as of that date. The Company estimates the fair value based on the income approach. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company determined the fair value of the inventory using the comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete/dispose of the inventory with a profit on those costs.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company determined the fair value of the property, plant and equipment utilizing both the cost approach and the sales comparison approach. The cost approach is determined by establishing replacement cost of the asset and then subtracting any value that has been lost due to economic obsolescence, functional obsolescence, or physical deterioration. The sales comparison approach values an asset based on the market price of assets with comparable features such as design, location, size, construction, materials, use, capacity, specification, operational characteristics and other features or descriptions.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company recorded approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$71.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million in goodwill related to the PaxVax acquisition, calculated as the purchase price paid in the acquisition that was in excess of the fair value of the tangible and intangible assets acquired representing the future economic benefits the Company expects to receive as a result of the acquisition. The goodwill created from the PaxVax acquisition is associated with early stage pipeline products along with potential contract manufacturing services. The majority of the goodwill generated from the PaxVax acquisition is expected to be deductible for tax purposes based upon the structure used in the acquisition.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#160;</span><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Impact of Business Acquisitions</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The operations of each of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>two</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> business acquisitions discussed above were included in the consolidated financial statements as of each of their respective acquisition dates. The following table presents their revenue and earnings as reported within the consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:694px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:429px;"/><td style="width:9px;"/><td style="width:117px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:117px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>88.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>163.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6839095360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The components of inventory are as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>66.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>119.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>103.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>46.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>232.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>205.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846499792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Property, plant and equipment consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land and improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>44.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings, building improvements and leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>228.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>216.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>318.8</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>293.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>56.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction-in-progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>59.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>709.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>681.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(189.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(171.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>520.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>510.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846484784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company has operating leases for corporate offices, research and development facilities and manufacturing facilities. We determine if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately. The Company's leases have remaining lease terms of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> year to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>15</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> years, some of which include options to extend the leases for up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> years, and some of which include options to terminate the leases within </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> year.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The components of lease expense were as follows:&#160;</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest on lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:48%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;">(In millions, except lease term and discount rate)</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>14.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating leases:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted Average Remaining Lease Term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted Average Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.62</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">%</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company has operating leases for corporate offices, research and development facilities and manufacturing facilities. We determine if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses an implicit rate when readily determinable. At the beginning of a lease, the operating lease ROU asset also includes any concentrated lease payments expected to be paid and excludes lease incentives. The Company's lease ROU asset may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise those options. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are accounted for separately. The Company's leases have remaining lease terms of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> year to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>15</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> years, some of which include options to extend the leases for up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> years, and some of which include options to terminate the leases within </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> year.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The components of lease expense were as follows:&#160;</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest on lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:48%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;">(In millions, except lease term and discount rate)</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>14.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating leases:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted Average Remaining Lease Term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted Average Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.62</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">%</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846542080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">Intangible Assets<div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company's intangible as</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">sets consist of products acquired via business combinations or asset acquisitions. The following table summarizes the carrying amount of the Company's intangible assets and goodwill, net of accumulated amortization:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:18%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="24" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Estimated Life (years)</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cost</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Measurement Period Adjustment</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Additions</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Gross Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amortization</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">5-22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>818.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>828.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(86.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>742.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">indefinite</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">indefinite</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>259.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>8.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>268.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>268.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:18%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="24" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Estimated Life (years)</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cost</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Measurement Period Adjustment</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Additions</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Gross Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5-22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>151.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>667.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>818.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(56.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>761.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">indefinite</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">indefinite</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>210.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>259.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>259.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company recorded amortization expense for intangible assets of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>29.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$7.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, respectively. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company recorded amortization expense for intangible assets of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>14.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>3.9</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million, respectively. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the weighted average amortization period remaining for intangible assets was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:normal;"><span>14.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> years. IPR&amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846517120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Consideration<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Contingent Consideration</a></td>
<td class="text">Contingent Consideration<div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Contingent consideration liabilities associated with business combinations are fair value measurement items. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date with the exception of the milestone achievement. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market (Level 3). </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company also has contingent consideration associated with its asset acquisitions. These liabilities are not recorded as level 3 fair value measurements, but rather are accrued when the milestone has been achieved and is payable.  </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The following table is a reconciliation of the beginning and ending balance of contingent considerations and is based on level 3 significant unobservable inputs, other than the raxibacumb milestone accrual, which is based on achievement of contractual milestones. </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>60.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Milestone achievement - asset acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Measurement period adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(12.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;">Balance at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>65.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, a contingent milestone was achieved related to the Company's acquisition of raxibacumab in October 2017. The acquisition of raxibacumab was accounted for as an asset acquisition and therefore the achievement of the $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>10.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> million milestone resulted in an increase to the contingent consideration liability with a corresponding increase in intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846503600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments and Hedging Activities Disclosure</a></td>
<td class="text">Derivative Instruments and Hedging Activities<div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Risk Management Objective of Using Derivatives</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company is exposed to certain risk arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from the Company's senior secured credit agreement's payments of variable interest rate debt.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Accounting Policy for Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company's interest rate swaps qualify for hedge accounting as cash flow hedges. All derivatives are recorded on the balance sheet at fair value.&#160;Hedge accounting provides for the matching of the timing of gain or loss recognition on these interest rate swaps with the recognition of the changes in interest expense on the Company's variable rate debt. For derivatives designated as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#8217;s variable-rate debt. The cash flows from the designated interest rate swaps are classified as a component of operating cash flows, similar to interest expense.&#160;If current fair values of designated interest rate swaps&#160;re</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">mained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$0.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#160;of net deferred gains from&#160;accumulated other comprehensive loss&#160;into income over the next&#160;twelve&#160;months. All outstanding cash flow hedges mature in October 2023.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk: </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:61%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Number of Instruments</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Notional</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>350.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:11%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Asset Derivatives</span></div></td><td colspan="8" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Liability Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="2" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. To comply with the provisions of ASC 820, Fair Value Measurement, we incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were concluded to not be significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Hedging derivatives</span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount of Gain/(Loss) Recognized in OCI on Derivative</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Location of Gain or (Loss) Reclassified from Accumulated OCI into Income </span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:middle;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:middle;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846604288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The components of debt are as follows:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior secured credit agreement - Term loan due 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>441.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>447.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior secured credit agreement - Revolver loan due 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>398.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>348.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.875% Convertible Senior Notes due 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>853.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>808.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of long-term debt, net of debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unamortized debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(12.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>830.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>784.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Senior Secured Credit Agreement</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On September 29, 2017, the Company entered into a senior secured credit agreement (the &#8220;2017 Credit Agreement&#8221;) with </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>four</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> lending financial institutions. On October 15, 2018, the Company entered into an Amended and Restated Credit Agreement (the "Amended Credit Agreement") with multiple lending institutions, which modified the 2017 Credit Agreement. The Amended Credit Agreement (i) increased the revolving credit facility (the "Revolving Credit Facility") from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>$200 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>$600 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, (ii) extended the maturity of the Revolving Credit Facility from September 29, 2022 to October 13, 2023, (iii) provided for a term loan in the original principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>$450 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> (the "Term Loan Facility," and together with the Revolving Credit Facility, the "Senior Secured Credit Facilities"). The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") if requirements relating to net leverage ratio will be maintained on a pro forma basis.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Borrowings under the Revolving Credit Facility and the Term Loan Facility will bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>1.25%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>2.00%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>0.50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, and a eurocurrency rate for an interest period of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">one month</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> plus </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>1%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">) plus a margin ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>0.25%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>1.00%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, depending on the Company's consolidated net leverage ratio. The Company is required to make quarterly payments under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>0.15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>0.30%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> per annum, depending on the Company's consolidated net leverage ratio, in respect of the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments based on an annual percentage equal to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>2.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>7.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature (unless earlier terminated) on October 13, 2023.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Amended Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>$100 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> during the term of the Amended Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Amended Credit Agreement contains financial covenants, which were amended in June 2019. The financial covenants require the quarterly presentation of a minimum consolidated 12 month rolling debt service coverage ratio of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>2.50</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to 1.00, and an amended maximum consolidated net leverage ratio of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>4.95</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to 1.00 for the quarter ended June 30, 2019, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>4.75</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to 1.00 for the quarter ending September 30, 2019, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>3.75</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to 1.00 for the quarterly filing periods from October 1, 2019 through September 29, 2020 and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>3.50</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to 1.0 thereafter, which may be adjusted to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>4.00</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> to 1.00 for a four quarter period in connection with a material permitted acquisition. The Amended Credit Agreement also contains affirmative and negative covenants, which were also amended in June 2019 to limit the amount of restricted payments as defined in the Amended Credit Agreement to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>$25 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> until the filing of the Company's December 31, 2019 Form 10-K. Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments and enter into certain merger or consolidation transactions. As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">2.875% Convertible Senior Notes due 2021</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On January 29, 2014, the Company issued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>2.875%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> convertible senior notes due 2021 (the "Notes"). The Notes bear interest at a rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>2.875%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> per year, payable semi-annually in arrears on January 15 and July 15 of each year. The Notes mature on January 15, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846560608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue recognition</a></td>
<td class="text">Revenue recognition<div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The Company operates as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> operating segment. Therefore, results of its operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. The Company's revenues disaggregated by the major sources were as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>94.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>88.9</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>183.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>169.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>180.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>38.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>132.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>110.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>243.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>185.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>220.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>167.9</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>168.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>336.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>235.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>19.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>255.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>34.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>34.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>58.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>62.8</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>226.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>207.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>433.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>266.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>72.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>338.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Contract liabilities </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">When performance obligations are not transferred to a customer at the end of a reporting period, the amount allocated to those performance obligations is reflected as deferred revenue on the consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the rollforward of deferred revenue contract liability balances: </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"><span>73.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferral of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>23.8</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(7.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"><span>89.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Transaction price allocated to remaining performance obligations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, the Company had expected future revenues associated with performance obligations that have not been satisfied of approximately $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>533.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> million. The Company expects to recognize a majority of these revenues within the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>24</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> months, with the remainder recognized thereafter. However, the amount and timing of revenue recognition for unsatisfied performance obligations can materially change due to timing of funding appropriations from the USG and the overall success of the Company's development activities associated with its PHT product candidates that are then receiving development funding support from the USG under development contracts. In addition, the amount of future revenues associated with unsatisfied performance obligations excludes the value associated with unexercised option periods in the Company's contracts. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Contract assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company considers unbilled accounts receivables and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment, as contract assets. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, the Company had contract assets associated with deferred costs of $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>26.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> million and $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>1.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> million, respectively, which is reflected as a component of prepaid expenses and other current assets on the Company's consolidated balance sheets. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Accounts receivable</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Accounts receivable including unbilled accounts receivable contract assets consist of the following: </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Billed, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>179.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>234.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unbilled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>38.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>218.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>262.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, allowances for doubtful accounts were de minimis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6831964480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes <div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The estimated effective annual tax rate for the Company, which excludes discrete adjustments, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>27%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>25%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, respectively. The increase in the estimated effective annual tax rate is primarily due to the impact of foreign and state taxes. For each of the six month periods ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company recorded a discrete tax benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$3.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, primarily due to activity associated with equity awards. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three months ended June 30, 2019</span><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company recorded a discrete tax benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$1.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>$0.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, respectively, also primarily due to activity associated with equity awards</span><span style="font-family:;font-size:10pt;color:#2c2c2c;font-weight:bold;">. </span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846536896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) earnings per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">(Loss) earnings per share</a></td>
<td class="text">arnings per share<div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The following table presents the calculation of basic and diluted net (loss) income per share:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Numerator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(9.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(35.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of shares&#8212;basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>51.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive securities&#8212;equity awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of shares&#8212;diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>51.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) earnings per share - basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.18</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) earnings per share - diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.18</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">For the three and six months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, basic earnings per share is computed by dividing net gain/(loss) by the weighted average number of shares of common stock outstanding during the period.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">For the three and six months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, diluted earnings per share is computed using the treasury method by dividing net loss by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. No adjustment for the potential dilutive effect of dilutive securities is reported as the effect would have been anti-dilutive for the three and six months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> due to the Company's net loss. The s</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">hare-based awards that were excluded from the calculation of diluted loss per share, because they were anti-dilutive, were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"><span>3.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> for the three and six months ended June 30, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6839112720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Share-based compensation</a></td>
<td class="text">Share-based compensation<div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company granted stock options to purchase </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>0.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> shares of common stock and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>0.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> restricted stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. The grants vest over </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> equal annual installments beginning on the day prior to the anniversary of the grant date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6839048560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined benefit plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined benefit plan</a></td>
<td class="text">Defined benefit plan<div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company sponsors a defined benefit pension plan covering eligible employees in Switzerland (the Swiss Plan). Under the Swiss Plan, the Company and certain of its employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. The Swiss Plan assets are comprised of an insurance contract that has a fair value consistent with its contract value based on the practicability exception using level 3 inputs. The entire liability is listed as non-current, because plan assets are greater than the expected benefit payments over the next year. The Company recognizes pension expense as a component of selling, general and administrative expense.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The measurement date used for the Swiss Plan is December 31, annually. The expense components of the Swiss Plan consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected return on plan assets, net of expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;Total pension expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846503600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Perrigo 4mg</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On September 14, 2018, Adapt Pharma Inc., Adapt Pharma Operations Limited and Adapt Pharma Ltd. (collectively, Adapt Pharma), and Opiant Pharmaceuticals, Inc. (Opiant), received notice from Perrigo UK FINCO Limited Partnership (Perrigo) that Perrigo had filed an Abbreviated New Drug Application (ANDA) with the FDA, seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 4mg/spray before the expiration of U.S. Patent Nos. 9,211,253 (the &#8216;253 Patent), 9,468,747 (the &#8216;747 Patent), 9,561,177 (the &#8216;177 Patent), 9,629,965 (the &#8216;965 Patent), and 9,775,838 (the &#8216;838 Patent). On or about October 25, 2018, Perrigo sent a subsequent notice letter relating to U.S. Patent No. 10,085,937 (the &#8216;937 Patent). Perrigo&#8217;s notice letters assert that its generic product will not infringe any valid and enforceable claim of these patents. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On October 25, 2018, Emergent BioSolutions&#8217; Adapt Pharma subsidiaries and Opiant (collectively, Plaintiffs), filed a complaint for patent infringement of the &#8216;253, &#8216;747, &#8216;177, &#8216;965, and the &#8216;838 Patents against Perrigo in the United States District Court for the District of New Jersey arising from Perrigo&#8217;s ANDA filing with the FDA. Plaintiffs filed a second complaint against Perrigo on December 7, 2018, for the infringement of the &#8216;937 Patent. As a result of timely filing the first lawsuit in accordance with the Hatch-Waxman Act, a 30-month stay of approval will be imposed by the FDA on Perrigo&#8217;s ANDA, which is expected to remain in effect until March 2021 absent an earlier judgment, unfavorable to the Plaintiffs, by the Court. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Teva 2mg</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On or about February 27, 2018, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva Pharmaceuticals Industries Ltd. and Teva Pharmaceuticals USA, Inc. (collectively Teva), that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 2 mg/spray before the expiration of U.S. Patent No. 9,480,644 (the &#8216;644 Patent), and U.S. Patent No. 9,707,226 (the '226 Patent). Teva's notice letter asserts that the commercial manufacture, use or sale of its generic drug product described in its ANDA will not infringe the '644 Patent or the '226 Patent, or that the '644 Patent and '226 Patent are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">ANDA Litigation - Teva 4mg</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">On or about September 13, 2016, Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received notice from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone hydrochloride) Nasal Spray 4 mg/spray before the expiration of the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant received additional notices from Teva relating to the '747, the '177, the '965, the '838, and the &#8216;937 Patents. Teva's notice letters assert that the commercial manufacture, use or sale of </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">its generic drug product described in its ANDA will not infringe the '253, the '747, the '177, the '965, the '838, or the &#8216;937 Patent, or that the '253, the '747, the '177, the '965, the '838, and the &#8216;937 Patents are invalid or unenforceable. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '253 Patent. Adapt Pharma Inc. and Adapt Pharma Operations Limited and Opiant also filed complaints for patent infringement against Teva in the United States District Court for the District of New Jersey with respect to the '747, the '177, the '965, and the '838 Patents. All five proceedings have been consolidated. As of the date of this filing, Adapt Pharma Inc., Adapt Pharma Operations Limited, and Opiant, have not filed a complaint related to the &#8216;937 Patent. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In the complaints described in the paragraphs above, the Plaintiffs seek, among other relief, orders that the effective date of FDA approvals of the Teva ANDA products and the Perrigo ANDA product be a date not earlier than the expiration of the patents listed for each product, equitable relief enjoining Teva and Perrigo from making, using, offering to sell, selling, or importing the products that are the subject of Teva and Perrigo&#8217;s respective ANDAs, until after the expiration of the patents listed for each product, and monetary relief or other relief as deemed just and proper by the court.</span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">Shareholder Class Action Lawsuit filed July 19, 2016</span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">On July 19, 2016, Plaintiff William Sponn (Sponn), filed a putative class action complaint in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#8217;s common stock between January 11, 2016 and June 21, 2016, inclusive (the Class Period), seeking to pursue remedies under the Exchange Act against the Company and certain of its senior officers and directors (collectively, the Defendants). The complaint alleged, among other things, that the Defendants made materially false and misleading statements about the government&#8217;s demand for BioThrax and expectations that the Company&#8217;s five-year exclusive procurement contract with </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">the U.S. Department of Health and Human Services (HHS)</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"> would be renewed, and omitted certain material facts. Sponn sought unspecified damages, including legal costs. On October 25, 2016, the court added City of Cape Coral Municipal Firefighters&#8217; Retirement Plan and City of Sunrise Police Officers&#8217; Retirement Plan as plaintiffs and appointed them Lead Plaintiffs and Robbins Geller Rudman&#160;&amp; Dowd LLP as Lead Counsel. On December 27, 2016, the plaintiffs filed an amended complaint that cited the same class period, named the same defendants and made similar allegations to the original complaint. The Defendants filed a Motion to Dismiss on February 27, 2017. The plaintiffs filed an opposition brief on April 28, 2017. The Defendants&#8217; Motion to Dismiss was heard and denied on July 6, 2017. The Defendants filed an answer on July 28, 2017. The parties then engaged in the discovery process. The plaintiffs filed an amended motion for class certification and appointment of Lead Plaintiffs, Sponn, and Geoffrey L. Flagstad (Flagstad) as Class Representatives on December 20, 2017. A hearing on that motion was heard on May 2, 2018. On June 8, 2018 the Court granted class certification with a shortened class period, from May 5, 2016 to June 21, 2016. In that same order, the court appointed Flagstad as Class Representative and Robbins Geller Rudman&#160;&amp; Dowd LLP as Class Counsel. The Defendants have denied, and continue to deny, any and all allegations of fault, liability, wrongdoing, or damages. However, recognizing the risk, time, and expense of litigating any case to trial, on August 27, 2018, the Defendants reached an agreement in principle with plaintiffs to settle all of the related claims of any individual plaintiff that purchased or acquired Company stock from January 11, 2016 to June 21, 2016, for $</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;"><span>6.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">&#160;million, an amount that was paid by the Company&#8217;s insurance carrier. The settlement required no payment by any of the Defendants. The Defendants continue to deny any and all liability. The parties executed the settlement agreement on October 16, 2018 and filed the agreement with the court on October 17, 2018. The court granted preliminary approval of the settlement on October 18, 2018. At the time of the approval of the settlement on January 22, 2019, there were no objections to the settlement, but there were two shareholders who had submitted opt-outs so that they could be excluded from the settlement. On January 25, 2019, the court issued an order and final judgment approving the settlement. The time to file a notice of appeal has passed.</span><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;"> </span>Defendants continue to believe that the allegations in the complaint are without merit.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6838808608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Information</a></td>
<td class="text">Supplemental Information<div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The following table provides a reconciliation of cash, cash equivalents and restricted cash:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>177.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>112.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>177.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>112.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6839205792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Principles of Consolidation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation and consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, as filed with the SEC.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and New Accounting Pronouncements</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-style:normal;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-02, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Leases</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, which increases transparency and comparability among organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The Company adopted the new standard effective January 1, 2019 using the modified retrospective approach. As of January 1, 2019 total right of use assets increased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;text-align:right;"><span>$13.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, while total operating lease liabilities increased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;font-weight:bold;text-align:right;"><span>$14.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">. There was no adjustment to the opening balance of retained earnings as of January 1, 2019. The standard will not materially affect the Company's consolidated net earnings. The Company continues to apply the legacy guidance from the old lease accounting standard, including its disclosure requirements, in the comparative periods presented. The Company did not reassess existing contracts for lease classification or the classification of existing leases or associated costs. The Company will not reflect leases with an initial term of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> months or less as a right of use asset or liability, but will recognize those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. In addition, the Company will account for non-lease components of the arrangement separate from lease components (see Note 6).</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">SEC Simplification</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In August 2018, the SEC issued Final Rule Release No. 33-10532, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Disclosure Update and Simplification</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, which makes a number of changes meant to simplify interim disclosures. The new rule requires a presentation of changes in stockholders&#8217; equity and noncontrolling interest in the form of a reconciliation, for the current and comparative year-to-date interim periods. The Company adopted the new disclosure requirements beginning in its March 31, 2019 Form 10-Q and included these disclosures in the condensed consolidated statements of changes in stockholders' equity. The additional elements of this release did not have a material impact on the Company's overall condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Tax Effects from Accumulated Other Comprehensive Income</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">In February 2018, the FASB issued ASU 2018-02,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;">&#160;Income Statement&#8212;Reporting Comprehensive Income (Topic 220):&#160;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. ASU 2018-02 provides the option to reclassify certain income tax effects related to the Tax Cuts and Jobs Act passed in December of 2017 between accumulated other comprehensive income and retained earnings and also requires additional disclosures.&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The Company adopted the new standard effective January 1, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">.&#160;There was no impact for the adoption of ASU 2018-02 on the Company's condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-left:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0094ff;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Financial Instruments - Credit Losses</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">In June 2016, the FASB issued&#160;ASU 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;">Financial Instruments - Credit Losses</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. ASU 2016-13 provides&#160;guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking &#8220;expected loss&#8221; model that is likely to result in the earlier recognition of allowances for losses. The guidance was further amended in January 2019 to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">clarify or address stakeholders&#8217; specific issues about certain aspects of the amendments in the update and in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">May 2019 to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">provide an option to irrevocably elect the fair value option for certain financial assets previously measured on an amortized cost basis. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The guidance&#160;is effective for annual periods beginning after December 15, 2019, including interim periods within those years, but early adoption is permitted. The Company is currently evaluating the effect that the pronouncement will have on its consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">In January 2017, the FASB issued ASU 2017-04,&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-style:italic;font-weight:bold;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">. ASU 2017-04 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-04 is effective for annual and interim goodwill tests beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates on or after January 1, 2017. The Company is currently evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In August 2018 the FASB issued ASU No. 2018-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">. This new standard modifies certain disclosure requirements on fair value measurements. This new standard will be effective for the Company on January 1, 2020. The Company does not expect that the adoption of this new standard will have a material impact on the Company's disclosures.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00497f;font-style:italic;font-weight:bold;">Compensation -&#160;Retirement Benefits - Defined Benefit Plans</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">In August 2018, the FASB issued ASU 2018-14, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Compensation - Retirement Benefits - Defined Benefit Plans - General</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">. ASU 2018-14 modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. ASU 2018-14 is effective for&#160;all entities for fiscal years ending after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-14 on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6703657008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Total purchase price</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The total purchase price, revised for current period adjustments is summarized below:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">October 15, 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>581.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>37.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of contingent purchase consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>48.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preliminary purchase consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>667.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Updated purchase consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>668.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at October 15, 2018 updated for measurement period adjustments recorded through </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">October 15, 2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Measurement Period Adjustments</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Updated  October 15, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Estimated fair value of tangible assets acquired and liabilities assumed:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>41.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>41.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(32.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(32.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(50.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(50.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(62.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(62.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total estimated fair value of tangible assets acquired and liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(56.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(54.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>534.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>534.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>149.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>148.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>667.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>668.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div>The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at October 4, 2018 updated for measurement period adjustments recorded through <span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">.</span><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">October 4, 2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Measurement Period Adjustments</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Updated October 4, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Estimated fair value of tangible assets acquired and liabilities assumed:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>57.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>57.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(3.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(33.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(34.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total estimated fair value of tangible assets acquired and liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>69.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>69.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>133.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>61.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>273.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>273.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ImpactOfBusinessAcquisitionsTableTextBlock', window );">Impact of Business Acquisitions</a></td>
<td class="text">The following table presents their revenue and earnings as reported within the consolidated financial statements.<div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:694px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:429px;"/><td style="width:9px;"/><td style="width:117px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:117px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>88.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>163.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ImpactOfBusinessAcquisitionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue and earnings of business acquisitions included in consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ImpactOfBusinessAcquisitionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6844499024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The components of inventory are as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>66.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work-in-process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>119.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>103.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>46.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>232.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>205.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846590528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">Property, plant and equipment consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land and improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>44.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings, building improvements and leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>228.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>216.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>318.8</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>293.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Software</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>56.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>55.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction-in-progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>59.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>71.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>709.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>681.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(189.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(171.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>520.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>510.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846480896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The components of lease expense were as follows:&#160;</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease cost:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest on lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock', window );">Schedule of Leases Supplemental Balance Sheets</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:48%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;font-style:italic;">(In millions, except lease term and discount rate)</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>14.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating leases:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted Average Remaining Lease Term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted Average Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.62</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">%</span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Leases Supplemental Balance Sheets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6834912320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets</a></td>
<td class="text">The following table summarizes the carrying amount of the Company's intangible assets and goodwill, net of accumulated amortization:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:18%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="24" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Estimated Life (years)</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cost</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Measurement Period Adjustment</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Additions</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Gross Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amortization</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">5-22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>818.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>828.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(86.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>742.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">indefinite</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">indefinite</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>259.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>8.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>268.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>268.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table summarizes the carrying amount of the Company's intangible assets and goodwill, net of accumulated amortization:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:18%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="24" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Estimated Life (years)</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Cost</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Measurement Period Adjustment</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Additions</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Gross Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amortization</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">5-22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>818.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>828.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(86.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>742.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">indefinite</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>50.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">indefinite</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>259.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>8.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>268.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>268.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6839035792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Consideration (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The following table is a reconciliation of the beginning and ending balance of contingent considerations and is based on level 3 significant unobservable inputs, other than the raxibacumb milestone accrual, which is based on achievement of contractual milestones. </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>60.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Milestone achievement - asset acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Measurement period adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(12.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;">Balance at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>65.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6836344672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Derivative Instruments</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk: </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:61%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Number of Instruments</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Notional</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>350.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:11%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Asset Derivatives</span></div></td><td colspan="8" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Liability Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="2" style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Balance Sheet Location</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Derivative Instruments, Gain (Loss)</a></td>
<td class="text">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income.<div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Hedging derivatives</span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount of Gain/(Loss) Recognized in OCI on Derivative</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Location of Gain or (Loss) Reclassified from Accumulated OCI into Income </span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest Rate Swaps</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:middle;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:middle;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846524288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The components of debt are as follows:</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior secured credit agreement - Term loan due 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>441.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>447.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior secured credit agreement - Revolver loan due 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>398.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>348.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.875% Convertible Senior Notes due 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>853.2</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>808.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of long-term debt, net of debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unamortized debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(12.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>830.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>784.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:11pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:11pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6831708688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The Company's revenues disaggregated by the major sources were as follows:<div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>94.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>88.9</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>183.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>169.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>180.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>38.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>132.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>110.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>243.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>185.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>220.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Non-U.S.<br/>Government</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>167.9</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>168.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>336.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>235.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>19.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>255.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>34.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>34.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contracts and grants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>58.7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>62.8</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>226.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>207.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>433.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>266.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>72.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>338.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Rollforward of Contract Liabilities</a></td>
<td class="text">The following table presents the rollforward of deferred revenue contract liability balances: <div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"><span>73.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferral of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>23.8</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(7.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;font-weight:bold;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;font-weight:bold;"><span>89.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ScheduleofAccountsReceivableNetTableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Accounts receivable including unbilled accounts receivable contract assets consist of the following: </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Billed, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>179.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>234.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unbilled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>38.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>218.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>262.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ScheduleofAccountsReceivableNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Accounts Receivable, Net [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ScheduleofAccountsReceivableNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6839111280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Income per Share</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c2c2c;font-weight:bold;">The following table presents the calculation of basic and diluted net (loss) income per share:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Numerator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(9.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(35.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of shares&#8212;basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>51.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive securities&#8212;equity awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of shares&#8212;diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>51.5</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>51.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) earnings per share - basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.18</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) earnings per share - diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.18</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846483984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined benefit plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Net Benefit Costs</a></td>
<td class="text">The expense components of the Swiss Plan consisted of the following:<div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Three Months Ended June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">Six months ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected return on plan assets, net of expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;Total pension expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6846517120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Cash Flow, Supplemental Disclosures</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">The following table provides a reconciliation of cash, cash equivalents and restricted cash:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Demi,sans-serif;font-size:10pt;color:#ffffff;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>177.4</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>112.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1b51bf;"><span>177.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>112.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6834220176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6842279536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Principles of Consolidation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6831053632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Adapt Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 15, 2018 </div>
<div>USD ($) </div>
<div>employee </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="nump">$ 54.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268.3<span></span>
</td>
<td class="nump">$ 259.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ebs_AdaptPharmaMember', window );">Adapt Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock issued for acquisition (in shares) | shares</a></td>
<td class="nump">733,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 60.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Consideration transferred, equity interests issued and issuable</a></td>
<td class="nump">$ 44.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Equity</a></td>
<td class="nump">$ 37.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_LockUpPeriodForAdjustmentOfFairValue', window );">Lock-up period for adjustment of fair value</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired intangible asset</a></td>
<td class="nump">$ 534.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible asset</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PresentValueDiscountRate', window );">Present value, discount rate</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 41.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">148.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">22 years<span></span>
</td>
<td class="text">22 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Adapt Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D | Adapt Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PresentValueDiscountRate', window );">Present value, discount rate</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported | Adapt Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired intangible asset</a></td>
<td class="nump">$ 534.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">149.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported | IPR&amp;D | Adapt Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 41.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_LockUpPeriodForAdjustmentOfFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The lock-up period considered for adjustment of fair value, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_LockUpPeriodForAdjustmentOfFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PresentValueDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure present value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PresentValueDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ebs_AdaptPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ebs_AdaptPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6831114064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Adapt Total Purchase Price (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 15, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ebs_AdaptPharmaMember', window );">Adapt Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition</a></td>
<td class="nump">$ 581.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Equity</a></td>
<td class="nump">37.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">668.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ebs_AdaptPharmaMember', window );">Adapt Pharma | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">$ 667.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ebs_AdaptPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ebs_AdaptPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6830981008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Adapt Preliminary Allocation of Purchase Price (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 15, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract', window );"><strong>Estimated fair value of tangible assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268.3<span></span>
</td>
<td class="nump">$ 268.3<span></span>
</td>
<td class="nump">$ 259.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract', window );"><strong>Measurement Period Adjustments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, measurement period adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ebs_AdaptPharmaMember', window );">Adapt Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract', window );"><strong>Estimated fair value of tangible assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 17.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">21.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">41.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(32.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(50.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability, net of current</a></td>
<td class="num">(62.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total fair value of tangible assets acquired and liabilities assumed</a></td>
<td class="num">(54.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired in-process research and development</a></td>
<td class="nump">41.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired intangible asset</a></td>
<td class="nump">534.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">148.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">668.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract', window );"><strong>Measurement Period Adjustments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets', window );">Prepaid expenses and other assets, measurements period adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability, net, measurement period adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod', window );">Total fair value of tangible assets acquired and liabilities assumed, measurement period adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, measurement period adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ebs_AdaptPharmaMember', window );">Adapt Pharma | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract', window );"><strong>Estimated fair value of tangible assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">17.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">21.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">41.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(32.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(50.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability, net of current</a></td>
<td class="num">(62.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total fair value of tangible assets acquired and liabilities assumed</a></td>
<td class="num">(56.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired intangible asset</a></td>
<td class="nump">534.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">149.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">$ 667.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses and Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses and other liabilities, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in income that would have been recognized in previous periods if the adjustments to provisional amounts were recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ebs_AdaptPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ebs_AdaptPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6849554640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - PaxVax Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 04, 2018 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268.3<span></span>
</td>
<td class="nump">$ 259.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ebs_PaxVaxMember', window );">PaxVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">$ 273.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired intangible asset</a></td>
<td class="nump">$ 133.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average amortization period</a></td>
<td class="text">19 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 71.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_VivotifMember', window );">Vivotif | PaxVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PresentValueDiscountRate', window );">Present value, discount rate</a></td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_VaxchoraMember', window );">Vaxchora | PaxVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PresentValueDiscountRate', window );">Present value, discount rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PresentValueDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure present value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PresentValueDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ebs_PaxVaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ebs_PaxVaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_VivotifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_VivotifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_VaxchoraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_VaxchoraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843110240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - PaxVax Preliminary Allocation of Purchase Price (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract', window );"><strong>Estimated fair value of tangible assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268.3<span></span>
</td>
<td class="nump">$ 268.3<span></span>
</td>
<td class="nump">$ 259.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract', window );"><strong>Measurement Period Adjustments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, measurement period adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ebs_PaxVaxMember', window );">PaxVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract', window );"><strong>Estimated fair value of tangible assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">57.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(34.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total fair value of tangible assets acquired and liabilities assumed</a></td>
<td class="nump">69.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired intangible assets</a></td>
<td class="nump">133.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">71.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">273.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract', window );"><strong>Measurement Period Adjustments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities', window );">Accrued expenses and other liabilities, measurement period adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod', window );">Total fair value of tangible assets acquired and liabilities assumed, measurement period adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets', window );">Acquired in-process research and development, measurement period adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, measurement period adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ebs_PaxVaxMember', window );">PaxVax | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract', window );"><strong>Estimated fair value of tangible assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">57.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(33.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total fair value of tangible assets acquired and liabilities assumed</a></td>
<td class="nump">69.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired in-process research and development</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired intangible assets</a></td>
<td class="nump">133.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">61.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">$ 273.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expenses And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Finite-lived Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses and other liabilities, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in income that would have been recognized in previous periods if the adjustments to provisional amounts were recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ebs_PaxVaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ebs_PaxVaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6853515920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Impact of Business Acquisitions (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>acquisition</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>acquisition</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_NumberOfBusinessAcquisitions', window );">Number of business acquisitions | acquisition</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ImpactOfBusinessAcquisitionsAbstract', window );"><strong>Impact of Business Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 243.2<span></span>
</td>
<td class="nump">$ 220.2<span></span>
</td>
<td class="nump">$ 433.9<span></span>
</td>
<td class="nump">$ 338.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="nump">$ 66.8<span></span>
</td>
<td class="num">(34.4)<span></span>
</td>
<td class="nump">$ 57.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ebs_AdaptAndPaxVaxMember', window );">Adapt And PaxVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ImpactOfBusinessAcquisitionsAbstract', window );"><strong>Impact of Business Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">88.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">$ 8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ImpactOfBusinessAcquisitionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>3e9a79ca-9c5f-2a65-3fac-a5d12d315cc7</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ImpactOfBusinessAcquisitionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfBusinessAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Business Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfBusinessAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ebs_AdaptAndPaxVaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ebs_AdaptAndPaxVaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6664755120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 66.3<span></span>
</td>
<td class="nump">$ 51.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">119.1<span></span>
</td>
<td class="nump">103.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">46.6<span></span>
</td>
<td class="nump">50.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 232.0<span></span>
</td>
<td class="nump">$ 205.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6842447200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 709.7<span></span>
</td>
<td class="nump">$ 681.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(189.2)<span></span>
</td>
<td class="num">(171.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">520.5<span></span>
</td>
<td class="nump">510.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">46.7<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings, building improvements and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">228.0<span></span>
</td>
<td class="nump">216.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">318.8<span></span>
</td>
<td class="nump">293.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">56.3<span></span>
</td>
<td class="nump">55.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 59.9<span></span>
</td>
<td class="nump">$ 71.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843451888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_LesseeOperatingLeaseTerminationPeriod', window );">Operating lease, termination period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6842804736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6834893216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 15.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_OperatingLeaseOtherLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">14.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 16.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted Average Remaining Lease Term (years)</a></td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average Discount Rate</a></td>
<td class="nump">4.62%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseOtherLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Other Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseOtherLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectFinancingLeaseLeaseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectFinancingLeaseLeaseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6844946784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Finite-lived Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 828.4<span></span>
</td>
<td class="nump">$ 818.4<span></span>
</td>
<td class="nump">$ 151.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">667.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(86.0)<span></span>
</td>
<td class="num">(56.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">742.4<span></span>
</td>
<td class="nump">761.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, cost</a></td>
<td class="nump">268.3<span></span>
</td>
<td class="nump">259.7<span></span>
</td>
<td class="nump">$ 49.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, measurement period adjustments</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, acquired during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 268.3<span></span>
</td>
<td class="nump">$ 259.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible asset</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible asset</a></td>
<td class="text">22 years<span></span>
</td>
<td class="text">22 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Indefinite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets (excluding goodwill)</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments', window );">Indefinite-lived intangible assets, purchase accounting adjustments</a></td>
<td class="num">(9.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets (excluding goodwill)</a></td>
<td class="nump">$ 41.0<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit, from purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6844579936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">$ 14.7<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 29.2<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843506640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Consideration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">$ 60.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Milestone achievement - asset acquisition</a></td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment', window );">Measurement period adjustment</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue', window );">Change in fair value</a></td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">(12.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">65.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ebs_RaxibacumabMember', window );">Raxibacumab</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration liability increase</a></td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Measurement Period Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ebs_RaxibacumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ebs_RaxibacumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6831742432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swaps</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6844729472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Derivative Designated as Cash Flow Hedges (Details) - Designated as Hedging Instrument - Interest Rate Swaps<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>instrument</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Instruments | instrument</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Notional | $</a></td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6844623280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Fair Value by Balance Sheet Location (Details) - Interest Rate Swaps - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset Derivatives</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability Derivatives</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109247956&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109247956&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6844686608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Cash Flow Hedging on AOCI (Details) - Interest Rate Swaps - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Amount of Gain/(Loss) Recognized in OCI on Derivative</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6843925008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 853.2<span></span>
</td>
<td class="nump">$ 808.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of debt issuance costs</a></td>
<td class="num">(10.1)<span></span>
</td>
<td class="num">(10.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(12.7)<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of debt</a></td>
<td class="nump">830.4<span></span>
</td>
<td class="nump">784.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_ConvertibleSeniorNotesDue2021Member', window );">2.875% Convertible Senior Notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember', window );">Senior secured credit agreement - Term loan due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">441.6<span></span>
</td>
<td class="nump">447.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Senior secured credit agreement - Revolver loan due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 398.0<span></span>
</td>
<td class="nump">$ 348.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_ConvertibleSeniorNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_ConvertibleSeniorNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6853897184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 15, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 29, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod', window );">Debt instrument, covenant, net leverage ratio rolling period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio', window );">Debt instrument, covenant, debt service coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioOne', window );">Debt instrument, covenant, net leverage ratio through June 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioTwo', window );">Debt instrument, covenant, net leverage ratio to September 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioThree', window );">Debt instrument, covenant, net leverage ratio from October 1, 2019 to September 29, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioFour', window );">Debt instrument, covenant, net leverage ratio thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted', window );">Debt instrument, covenant, net leverage ratio, adjusted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod', window );">Debt instrument, covenant, net leverage ratio adjustment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_CreditAgreementMember', window );">2017 Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_NumberOfLendingInstitutions', window );">Number of lending institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentRestrictedPaymentsLimitAmount', window );">Debt instrument, restricted payments limit, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Federal Funds Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Base Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_ConvertibleSeniorNotesDue2021Member', window );">2.875% Convertible Senior Notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.875%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Senior secured credit agreement - Revolver loan due 2023 | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember', window );">Senior secured credit agreement - Term loan due 2023 | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears', window );">Percentage of original principal amount required to repay in the first two years</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear', window );">Percentage of original principal amount required to repay during the third year</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears', window );">Percentage of original principal amount required to repay remaining year</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight', window );">Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt Service Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantDebtServiceCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, Adjusted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentRestrictedPaymentsLimitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Restricted Payments Limit, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentRestrictedPaymentsLimitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfLendingInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of lending institutions in which the entity has a credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfLendingInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in the third year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in the first two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in remaining years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_ConvertibleSeniorNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_ConvertibleSeniorNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6844589936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 533.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred costs, current</a></td>
<td class="nump">$ 26.5<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6842989504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 243.2<span></span>
</td>
<td class="nump">$ 220.2<span></span>
</td>
<td class="nump">$ 433.9<span></span>
</td>
<td class="nump">$ 338.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">132.9<span></span>
</td>
<td class="nump">185.2<span></span>
</td>
<td class="nump">226.6<span></span>
</td>
<td class="nump">266.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">110.3<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="nump">207.3<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">183.5<span></span>
</td>
<td class="nump">180.1<span></span>
</td>
<td class="nump">336.5<span></span>
</td>
<td class="nump">255.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">94.6<span></span>
</td>
<td class="nump">169.9<span></span>
</td>
<td class="nump">167.9<span></span>
</td>
<td class="nump">235.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">88.9<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">168.6<span></span>
</td>
<td class="nump">19.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractManufacturingMember', window );">Contract manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">34.6<span></span>
</td>
<td class="nump">49.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractManufacturingMember', window );">Contract manufacturing | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractManufacturingMember', window );">Contract manufacturing | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">34.6<span></span>
</td>
<td class="nump">49.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">41.0<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="nump">62.8<span></span>
</td>
<td class="nump">32.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">38.3<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">58.7<span></span>
</td>
<td class="nump">30.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6844357520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Contract Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ChangeinContractWithCustomerLiabilityRollForward', window );"><strong>Change in Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability, beginning balance</a></td>
<td class="nump">$ 73.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ContractWithCustomerLiabilityAdditions', window );">Deferral of revenue</a></td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="num">(7.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability, ending balance</a></td>
<td class="nump">$ 89.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ChangeinContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ChangeinContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6844116160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue recognition - Accounts Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed, net</a></td>
<td class="nump">$ 179.5<span></span>
</td>
<td class="nump">$ 234.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled</a></td>
<td class="nump">38.6<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total, net</a></td>
<td class="nump">$ 218.1<span></span>
</td>
<td class="nump">$ 262.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68054760&amp;loc=d3e55302-109406<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6844049040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective annual tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Discrete tax benefit</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6845774592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) earnings per share (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net (loss) earnings</a></td>
<td class="num">$ (9.5)<span></span>
</td>
<td class="nump">$ 50.1<span></span>
</td>
<td class="num">$ (35.6)<span></span>
</td>
<td class="nump">$ 45.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares-basic (in shares)</a></td>
<td class="nump">51,500,000<span></span>
</td>
<td class="nump">49,900,000<span></span>
</td>
<td class="nump">51,300,000<span></span>
</td>
<td class="nump">49,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities-equity awards (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares-diluted (in shares)</a></td>
<td class="nump">51,500,000<span></span>
</td>
<td class="nump">51,200,000<span></span>
</td>
<td class="nump">51,300,000<span></span>
</td>
<td class="nump">51,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="nump">$ 0.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6845568704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted (in shares)</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock issued or granted during period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6845761552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined benefit plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Net service cost</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets, net of expenses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Total pension expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=112275985&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=112275985&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=112275985&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6836406800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=ebs_ShareholderClassActionLawsuitMember', window );">Shareholder Class Action Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="nump">$ 6.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ebs_ShareholderClassActionLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ebs_ShareholderClassActionLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6831091840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 177.4<span></span>
</td>
<td class="nump">$ 112.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 177.6<span></span>
</td>
<td class="nump">$ 112.4<span></span>
</td>
<td class="nump">$ 191.3<span></span>
</td>
<td class="nump">$ 179.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6837691488">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">$ (32,500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1', window );">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1</td>
<td class="nump">879,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1', window );">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CommonStockSharesIssued</td>
<td class="nump">50,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1', window );">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1</td>
<td class="num">$ (39,500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CommonStockSharesIssued</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1', window );">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1</td>
<td class="num">$ (3,800,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1', window );">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1</td>
<td class="nump">618,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">(32,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1', window );">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1</td>
<td class="nump">$ 304,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity including the portion attributable to noncontrolling interests, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_RNPFXP=F__L?%%4';PZR[D%U!+ P04    "  2DP%/F5R<(Q &  "<)P
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MR[GIY6%H3_.9<'(]F-[\#U!+ P04    "  2DP%/;D+XE$\"  !1"   &
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M/E=5:VSP@6=GQ='DA]M-89[;[C*VU_5P8#[<M-5E_#' O_TBL?X?4$L#!!0
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M[EA5K>Y<1D$W8&>='QX7A3ZV_=>T^UZ/1Y/C15O=S+%K^#C[W?P/4$L#!!0
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M83A F@!Y"1!B,$"9 '4)4,,C^"; OP3(:# @, '!5TG!8$!H L*ODH9'B$Q
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MK4$NY!8@&W@V "CE7WVZ4]A8E1CO%@H;CD+'@]0M%#_U$T.\7CGT0\9$W<*
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MT+DP_>CG9KIH4^'TD-X0F1]R_1M02P,$%     @ $I,!3Z>0=(ZP 0  T@,
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ML?\UH@,O97?E1ZCU'VPQ%-0N'&_\V4QC-AD.^_D'L>4;%Z]02P,$%     @
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M=MIH95O*)JI:J956J=H^L_;XH@#C EZG?U_ CNNV5EZ &>:<.3,,^83FV78
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M9SN.V6AXTTT_B,W?./\ 4$L#!!0    ( !*3 4]O2C*7M0$  -(#   9
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M>%D(J*V??G-S/;WE:6%5/[<I6?X5Q3]02P,$%     @ $I,!3Y(,WQ/4 0
MG 0  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL=53K;ML@%'X5Q ,4
MAR1.%MF6FE;5)JU2U&GM;V(?7U0P'N"X??L!=ETO97\,Y_!=SL% ,DCUJFL
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M?"57I5Z]\:7*<>(3 @&E]0K,+3=X B&\D$OCUZR)EY">N-Z_JW\*M;M:KLS
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MX/9Z>LN3854_CRE9_A7%'U!+ P04    "  2DP%/%; 9@,,!   W!   &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6QM5/]OG" 4_U<(?T Y\6R[BYKT
MVC1;LB67+NM^YO2II" .\.S^^P%:YV[\(O#X?'D/>.:3TF^F [#H78K>%+BS
M=C@08JH.)#,W:H#>[31*2V;=4K?$#!I8'4A2$+K;W1+)>(_+/,1.NLS5: 7O
MX:21&:5D^O<1A)H*G."/P MO.^L#I,P'UL)WL#^&DW8KLJK47$)ON.J1AJ;
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MK0O'K_YLYC&;#:>'Y0>1]1M7_P!02P,$%     @ $I,!3V /%?RW 0  T@,
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M"\>O_FRF,9L,I_OY!Y'E&Y=_ %!+ P04    "  2DP%/:=TJ2;D!  #2 P
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M$="Z8!Z\;=*:)<?I87Y!9'G&U6]02P,$%     @ $I,!3^(@7:/I 0  8 4
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MZVX)"#12;U.UY]-//P62#?-]AI9+M?@#4$L#!!0    ( !*3 4]IMWC%50,
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M[#-S@YN!H&W_.J'AB2S^ 5!+ P04    "  2DP%/+'\M";H#  ",$@  &0
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M5IF4QJ%\[Z"RW?FB4/NV.TW,>3U\'QDN6GT<O_V$YP]0Z[]02P,$%     @
M$I,!3^F-",%R @  [@@  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL
ME5;MCILP$'P5Q ,$;/,13B12252U4BM%5[7][21.0 >8VDYR??O:AN,(+'?7
M/\$VLS,[BS=V>N/B2>:,*>>Y*FNY<G.EF@?/DX><550N>,-J_>;$1465GHJS
M)QO!Z-$&5:6'?3_R*EK4[CJU:SNQ3OE%E47-=L*1EZJBXF_&2GY;N<A]67@L
MSKDR"]XZ;>B9_6#J9[,3>N;U+,>B8K4L>.T(=EJYG]##%L4FP")^%>PF!V/'
M6-ES_F0F7X\KUS<9L9(=E*&@^G%E&U:6ADGG\:<C=7M-$S@<O[!_MN:UF3V5
M;,/+W\51Y2MWZ3I'=J*74CWRVQ?6&0I=IW/_C5U9J>$F$ZUQX*6TO\[A(A6O
M.A:=2D6?VV=1V^>M?1-&71@<@+L W ?@Y,T T@60UP#T9D#0!02C *^U8FNS
MI8JN4\%OCF@_;T/-+D(/@:[^P2S:8MMWNCQ2KU[7)%RFWM40=9BLQ> [3'*/
MV0 8%-]CMA#F5<O3>?;)8C!9; G('4$"$Q"0@%B"8$@0^2,G$ ;!(@$H$DP(
M8C32:"&1A=06@J/E@HSJ!:#"9!'#N81@+B%@!L,$$4@0?;SD,4@03S/ HW)D
M+2:^,^K#(DM09#D1P9-=O)Q6,R:+F2^;@#()X&74"%F+208RB!!8!/EP2_KO
M[](,!,WIS+0^>G>C9AUF:">>*1F">Q9A(-%@A@+N6D0^O@D1W)-HVI2$X+%9
M !2%,SIPOR&HX:(9"KCCT'^T'()[#@%--W4+@*+QGXLW.$?,3> [%>>BELZ>
M*WTDV8/CQ+EBFM!?:.^YOGSTDY*=E!G&>BS:$[B=*-YTMPNOO^*L_P%02P,$
M%     @ $I,!3U'+8J+" P  -1,  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#4N>&ULE5AKCYLZ$/TKB.\%[+%YK))(W4=UK]1*JU[=]C.;.!M4P"EX-^V_
M+Z^-"#/>.OD0'CDSQX-]YA"O3KKYT1Z4,MZOJJS;M7\PYG@3ANWVH*J\#?11
MU=TO>]U4N>DNF^>P/38JWPU!51GR*(K#*B]J?[,:[CTVFY5^,651J\?&:U^J
M*F]^WZI2G]8^\]]N?"V>#Z:_$6Y6Q_Q9_:?,_\?'IKL*SUEV1:7JMM"UUZC]
MVO_(;A[$$# @OA7JU,[.O;Z4)ZU_]!?_[M9^U(](E6IK^A1Y=WA5=ZHL^TS=
M.'Y.2?TS9Q\X/W_+_FDHOBOF*6_5G2Z_%SMS6/NI[^W4/G\IS5=]^D=-!4G?
MFZK_K%Y5V<'[D70<6UVVP[>W?6F-KJ8LW5"J_-=X+.KA>)KROX71 7P*X.<
M)MX-@"D 7 /$%"!< ^04(!<!X5C[\##O<Y-O5HT^><VX'HYYO^S8C>RF:]O?
M'&9G^*U[GFUW]W4#<;H*7_M$$^9VQ/ +3':)N<,8?HFX_ROB 2/BZ P)NS+.
MM7"R%C[$PWR<(J$3 )D A@1BEB!ABSI'2#Q ZK&*. U@4:L3ZH% R2RPC%B0
M(Q9$R2F=0)())"H9Q')N1XR<C3,-8IHD)DEB1,+E8I'=C9AL1F*9^X2D2' =
M,:<3I&2"U'WQ9&2"#(] 1@LE9:C(C*9@$:W6")$P*9=RC=!\B8!9>"Q=@1'%
ML"4/0SS,NGP9+5G&B8+B)1''1#RPS"ZCI<VPMB%93L\$FA/))+#HB=&*9((@
M0H].("*P\M#"95BY"5H)6+D?() 6'EJ[#(L7)%\2C:#D@DA8>&@!,T+!4BQY
M$E10G 51-O]86&G5LQ2S F)-4766WL3HUL"(WI"@9Y@A%@9 \W"Z/7#<'M#2
MFS!SFL32'#C='#AN#JB=WW+<''@"MC;$+89..;I%)IS6/:=TO[1KCG7_(0HL
MZY?3NN>$[F6R),*Z?X>(%CXG+#L12R*)!6E1!J=USPG=+]\,[B?0_!4FLY9#
MZYX3ND\L+8K3(N97>#>G%<I=W)MCA5J>*=#Z!!?[ABOL&VB%@HM]PS7V#;1
MP<6^X1K[!LN;N8M]PS7V#;2,P<6^X0K[!EK%X&#?<(U] RUC<+'O"71)!+9W
M?*"%#"X&#J2!VTJBY0XNG@W8LVU:I3L"N'@V7.'9@NX)PL&S!6X),;--CZ![
M@G!Q[0ET\9>4<.UPMKO0;RA]R9OGHFZ])VV,KH;MA+W61G4IHZ ;]4'EN_-%
MJ?:F/TVZ\V;<R!DOC#Y.FU3A>:=L\P=02P,$%     @ $I,!3Z!%X>Z8 @
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ML-'T%A('R:J2K2B+@IT;)76BI X4O$*QFFR1)8KN@VC%XE"%21"[83(G3.:
MN5O!9)LT*0Y6Q-56E(6?[0MVHF 'RFZ%8C7WBRQQLCYK>/.'XC#;H*#%!= /
MT@_"+VTOO".3ZBZ9$W]F3()R# -55J/>P'E X2QU]T[UN7T)[$"R87KDT/S2
MEO\ 4$L#!!0    ( !*3 4_1.X2&J@(  %(*   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;)5678^;,!#\*XCW FN^HR12+U752JUTNJKMLR]Q$G2
MJ>TDUW]?VW"(P%)Q+P&;V?'LQ+OV^L;%BSPSIIS7JJSEQCTKU:Q\7^[/K*+2
MXPVK]9<C%Q55>BA.OFP$HP<;5)4^"8+$KVA1N]NUG7L4VS6_J+*HV:-PY*6J
MJ/C[P$I^V[C@ODT\%:>S,A/^=MW0$_O!U,_F4>B1W[,<BHK5LN"U(]AQXWZ$
MU8X$)L B?A7L)@?OCDGEF?,7,_AZV+B!4<1*ME>&@NK'E>U861HFK>-/1^KV
M:YK X?L;^V>;O$[FF4JVX^7OXJ#.&S=SG0,[TDNIGOCM"^L2BEVGR_X;N[)2
MPXT2O<:>E]+^.ON+5+SJ6+24BKZVSZ*VSUO[)8FZ,#R = &D#X#_!X1=0#@*
M\%ME-M5/5-'M6O";(]I_JZ%F4\ JU&;NS:3USG[3V4H]>]V&6;[VKX:HPSRT
M&#+ D'O$;HI(@A[B:P&]"H*J(#8^'*K(9PA"E""T!-$= 8S2:#&)Q=06DP:Y
MEXY2F:*2# :H.S$1*B9"Q(P<>V@Q\6"9#Y#EWMA8#):"%^-R8E1.C,@)1W+B
MR3HQ"0;+M&H0% 0#S7=B$E1,@HB)<((4)4B7;Y4,)<@6;)5LDFB43'8* HJ\
M!)>2HU)R1,K,7PL!7K[!<CM@I@/  D,Z4#I(EI!LW 5@X@B!9&Y_ -X*@"!R
M9EP%O!E ^ Y3\!(&K(8GIDRK,X3,F]@RA9$\]/(907@1 U;%,UT)\-*#Y!VV
MX,4'Z1);TFF;2+QP[ J"BF?W"E[*@-5R-D.!ER#DRTTA> V28($I'6AXKL2Y
M-SII=PA*=_MQ1O[@<#>WK>]4G(I:.L]<Z7N"/<V/G"NF&74/=YVSON#U@Y(=
ME7E-];MH;SGM0/&FN\'Y_35R^P]02P,$%     @ $I,!3]0,/= " @  "P8
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MR?\'D3H%4H>#F\^]3>^""%;)31#I/X/ BS-J[HQG(HYM)[T#5_JXVT-9<ZY
MJ_DK'4RCKZFYH% KLTWU7HQ_UK%0O)_N(3Q?AL4G4$L#!!0    ( !*3 4^P
M]95] @(  &P%   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;(U4[8Z;
M,!!\%<0#G/E,V@B0+JFJ5FJEZ*JVOQU8 CH;4]L)U[?OVB8<EW!1\R/8R^SL
MS&)O-@CYK!H [;UPUJG<;[3N-X2HL@%.U8/HH<,WM9"<:MS*(U&]!%K9),Y(
M% 0KPFG;^45F8WM99.*D6=O!7GKJQ#F5?[? Q)#[H7\)/+7'1IL *;*>'N$'
MZ)_]7N*.3"Q5RZ%3K>@\"77N/X:;W=K@+>!7"X.:K3WCY"#$L]E\K7(_,(*
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M3<Q>#A-A"+3HQF&'IHF;_P-02P,$%     @ $I,!3P(5,Q\I!   PQ0  !D
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M8O@*4YX$>5/X[W '9N#6B=FC%$RY7Z^\*2WXI&*L</HVCFWGQF%<V:43;9M
M)@*9"6'\7T(T$:(5 8_.7-3/5-,BDV+PY/AG]=3>B? 0F<,L;=.=G5LS:97I
MWHLD)AF^6Z$)<QPQ9(%9(4Z/B#28(=@8F%V031?$\:/E#A'9%H@V!2(G$'^(
M$:UBC)C483J'"7=/?K**,J*>%B@2Q=M6XDTK\8:5>&5EQ"2+3:*]GZZ</(+(
M?F'W@Y5DTTJR8665]Y@\G H)]WZX\K*!2LF#&;RX=?85^$'EM>V4=Q':7&!W
MS6HA-!C%P#>2C7EXYH)!K>UT9^9R_/S&0HM^>EGP_+P5_P!02P,$%     @
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MCEG;<;4309NNFW3[EG;U'U!+ P04    "  2DP%/(U5D.Z("  !>"P  &0
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M>P:NI@(G^#7PU+>=]0%2Y@-KX0?8G\-%.X\L+'4O0)I>2:2A*?!#<CJG'A\
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M-[HX'!KKS3MGZWA3HV/5,#]"LOP)RG]02P,$%     @ $I,!3Z(>'2X, @
MW@4  !D   !X;"]W;W)K<VAE971S+W-H965T-S N>&ULC53ICILP&'P5Q -@
M+N=8$:3FJ%JIE:*MMOWM)%\"6H.I[83MV]?7(D*LU?[!U\QXYK-QT3/^*BH
M&;PUM!6KL)*R>T)('"MHB(A8!ZU:.3/>$*F&_()$QX&<#*FA*(WC&6I(W89E
M8>;VO"S85=*ZA3T/Q+5I"/^W!LKZ59B$[Q//]:62>@*514<N\ OD2[?G:H0&
ME5/=0"MJU@8<SJOP2_*TPQIO +]KZ,6H'^@D!\9>]>#[:17&VA!0.$JM0%1S
M@PU0JH64C;].,QRVU,1Q_UW]J\FNLAR(@ VC?^J3K%;A(@Q.<"97*I]9_PU<
M'AP&+OP/N %5<.U$[7%D5)AO<+P*R1JGHJPTY,VV=6O:WJ[@I:/Y":DCI ,A
MR3\D9(Z0?9:0.T+^60)V!#PA()O=%'-+)"D+SOJ V^O0$7WKDB>LCNNH)\WI
MF#553Z%F;R5>S ITTT(.L[:8=(1)[Q&;1\0LOH=L'R%)DMQC=H\8O)@/&*2"
M#&E2;YK4"&1CISCV"V1>@<P(Y.,@DZQK"YD92&N#S.=1/JF(!Y6D4>KWDGN]
MY(]>LHD7"\&C7>)H>C8?8^Y\8*\/_. #+Q83(]A;E,E%VGA0JBB3TFT]J&42
M3:+O?#LN1R@;#(W^ _WR_23\4K<B.#"I?BES\<^,25"*<:0D*_78#@,*9ZF[
M<]7G]LFQ \DZ]YJBX4DO_P-02P,$%     @ $I,!3X\5)SF# @  ] D  !D
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M[7UI<^/(E>#GW5^!Z)''5 3)YJ6KVN,(E>IHV77(4I5[9QT;&R )2N@" 0X
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MD 9!OT]>(VE<%DW*2&$R(%S#W7V#/BNV4;YG09D1[@9)1^S0(53]2C23E>H
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ME$-QFQ+&0HY(N,F8$\%65<8"Y8!1\1_I7P7:$CMB0B,; 622%KQ,%QQ40&L
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MA, H0$"ZU7O4%E4.)C%70:7XHD[$1FZAKS0#D49#*RNQ4!I*AI;MA;/WABC
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M-83$ HNNDP[=!BP*OG?7: 6A*:>O#CK[U* )3QI7GP1>8*5'>M8$QPQAVQV
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M59%05U$BC3?-*7FOTH*"+Z8;SIF'E#;-V37IU"5G& DQY+Q8IPL50. Z<!C
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M0DW&=%G<<.'L+OMJ>*5/,*Y:6C*[PY0Y0_7-\4!WJ=/"=.:3D]*$6[ 3JU8
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M@+:* P?-$*4"^$U7NFTY&+U1IN"<YJ5'(4%IUTB!@]4>V+'4\/9EN<PY+A+
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M1S>D#N#SR)#?A[ Y&OA'S<*4+8]XL9&4CL[U.".W8M 1_'"3U+4J.M\;3TC
M<GM06XP(5G<$3SRE\51L'Y0!(ZEV"E,:'E0C%3<R!NP.I:E)/3!%6#N>YPEM
MXT-L.;6;@3:(",D*PYO9-><<+'XE4JQBZF9CNDP5A9Y$JCV+VMO.WDPZ&@)N
M*=><DY+(,@X5G&_&[S39VRO  6G?;-<KYW)^2PK%/^>.[ZEO&7_2R_NI:,\=
M\MO&N4ZK+W8B[T<J:B7=VCZ3P=@,Z%KZV;];5!+!(G8Y#$IR;<T41H(TV$3!
M;QPZI)WJAJ<V8M6Y:2-%DW']FXH&I.E)BJ$4Y0<T!]]C/TOV61OWKHFA(AF
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M6LYAP>2>1R,,Z>0/Z&,VC8WWH-+""56N/IOG,+<W63:J"3B]C>S+8J%F.S-
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M4%[RNEP8YC_V+W1EN7\U8[VMZ\]0]I>ZUMR7=]=X>A/\\C]02P,$%     @
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MZZU ;^7KK4!OY>L=@-Z!KW< >@>^W@'H'?AZ!Z!W6."L&QUV\_4.0._ USL
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M+G)E;'-02P$"% ,4    "  2DP%/)^B'#H(   "Q    $
M@ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !*3 4]KZFWE[@
M "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( !*3 4^97)PC$ 8  )PG   3              "  ;8"  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ $I,!3[Q.&ID\ P  G \  !@
M             ( !]P@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( !*3 4\<<98\?@0  *06   8              "  6D,  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  2DP%/;D+XE$\"  !1
M"   &               @ $=$0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ $I,!3S((HPCK!   G1@  !@              ( !HA,
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !*3 4\(_' F
MJP(  &@)   8              "  <,8  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    "  2DP%/_N4)BW@$   '%@  &
M@ &D&P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ $I,!
M3TB# O\R!0  I!P  !@              ( !4B   'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( !*3 4\-J O#L0$  -0#   8
M      "  ;HE  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M"  2DP%/IY!TCK !  #2 P  &               @ &A)P  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ $I,!3T! *JJU 0  T@,  !D
M             ( !ARD  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    "  2DP%/.-@.%K4!  #2 P  &0              @ %S*P  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !*3 4^_O/6^M $
M - #   9              "  5\M  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ $I,!3SLR\$:U 0  T@,  !D              ( !
M2B\  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  2DP%/
MD&O*E;\!   W!   &0              @ $V,0  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( !*3 4\B _Q6M@$  -(#   9
M      "  2PS  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ $I,!3\&ZUYRS 0  T@,  !D              ( !&34  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  2DP%/56LFN[<!  #2 P
M&0              @ $#-P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( !*3 4_S8A' M@$  -(#   9              "  ?$X  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ $I,!3Y*<-WFS
M 0  T@,  !D              ( !WCH  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    "  2DP%/O?,JEK0!  #2 P  &0
M@ '(/   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !*3
M 4^W?ZBCM $  -(#   9              "  ;,^  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ $I,!3S7# R^S 0  T@,  !D
M         ( !GD   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    "  2DP%/VI %<+0!  #2 P  &0              @ &(0@  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( !*3 4^\Y5N]M0$  -(#
M   9              "  7-$  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ $I,!3V]*,I>U 0  T@,  !D              ( !7T8
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  2DP%/5^RT
M-,,!   W!   &0              @ %+2   >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( !*3 4^2#-\3U $  )P$   9
M  "  45*  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M$I,!3_S8<TVW 0  T0,  !D              ( !4$P  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    "  2DP%/QF (AK<!  #2 P  &0
M            @ $^3@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( !*3 4^I:#*'Q $  #<$   9              "  2Q0  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ $I,!3Q6P&8## 0
M-P0  !D              ( !)U(  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    "  2DP%/=5D$RK,!  #2 P  &0              @ $A
M5   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !*3 4\#
MI\]OS0$  )P$   9              "  0M6  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ $I,!3[M((>*V 0  T@,  !D
M     ( !#U@  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !*3 4]IW2I)N0$  -(#   9              "
M <]A  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ $I,!
M3^(@7:/I 0  8 4  !D              ( !OV,  'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    "  2DP%/:;=XQ54#  !##P  &0
M        @ '?90  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( !*3 4^KL;Y_+P(  "X'   9              "  6MI  !X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ $I,!3RQ_+0FZ P  C!(
M !D              ( !T6L  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    "  2DP%/Z8T(P7("  #N"   &0              @ '";P
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( !*3 4]1RV*B
MP@,  #43   9              "  6MR  !X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ $I,!3Z!%X>Z8 @  X0@  !D
M ( !9'8  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  2
MDP%/4#<UNO\!  !U!0  &0              @ $S>0  >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( !*3 4_1.X2&J@(  %(*   9
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M970U,BYX;6Q02P$"% ,4    "  2DP%/J)H=G1X"  #V!0  &0
M    @ %9B   >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M !*3 4_,:-\9,@(  +@&   9              "  :Z*  !X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ $I,!3W)Q2?O' 0  %00  !D
M             ( !%XT  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    "  2DP%/D2W2FZX!  ## P  &0              @ $5CP  >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( !*3 4]N%9 [X0$
M !@%   9              "  ?J0  !X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ $I,!3[#UE7T" @  ; 4  !D              ( !
M$I,  'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  2DP%/
M7OA,XY4"  #!"0  &0              @ %+E0  >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( !*3 4_O*'5"Z@,  (H5   9
M      "  1>8  !X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ $I,!3WE)?WP# @  ?04  !D              ( !.)P  'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    "  2DP%/ A4S'RD$  ##%
M&0              @ %RG@  >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( !*3 4]9L1!6^ $  !0%   9              "  =*B  !X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ $I,!3VOR,./I
M 0  Z@0  !D              ( ! :4  'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    "  2DP%/M&5+Q"$"   8!@  &0
M@ $AIP  >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( !*3
M 4\&_[WZT0(  -X*   9              "  7FI  !X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ $I,!3R-59#NB @  7@L  !D
M         ( !@:P  'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4
M    "  2DP%/*04]D@$"  "!!0  &0              @ %:KP  >&PO=V]R
M:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( !*3 4^Y.#4)QP$  !4$
M   9              "  9*Q  !X;"]W;W)K<VAE971S+W-H965T-CDN>&UL
M4$L! A0#%     @ $I,!3Z(>'2X, @  W@4  !D              ( !D+,
M 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    "  2DP%/CQ4G
M.8,"  #T"0  &0              @ '3M0  >&PO=V]R:W-H965T<R]S:&5E
M=#<Q+GAM;%!+ 0(4 Q0    ( !*3 4_M[ZFGYV$  ,B* 0 4
M  "  8VX  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( !*3 4]%
M3=NM5P(  %P,   -              "  :8: 0!X;"]S='EL97,N>&UL4$L!
M A0#%     @ $I,!3Z0G"1A?!0  C2X   \              ( !*!T! 'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !*3 4^<E%[_40(  *HJ   :
M          "  ;0B 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( !*3 4]MVM,@" (  ,4I   3              "  3TE 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !0 %  XA4  '8G 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>194</ContextCount>
  <ElementCount>348</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005501 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Basis of Presentation and Principles of Consolidation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation</Role>
      <ShortName>Basis of Presentation and Principles of Consolidation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Contingent Consideration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ContingentConsideration</Role>
      <ShortName>Contingent Consideration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Derivative Instruments and Hedging Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities</Role>
      <ShortName>Derivative Instruments and Hedging Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Revenue recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognition</Role>
      <ShortName>Revenue recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - (Loss) earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LossEarningsPerShare</Role>
      <ShortName>(Loss) earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Share-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Defined benefit plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DefinedBenefitPlan</Role>
      <ShortName>Defined benefit plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Supplemental Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SupplementalInformation</Role>
      <ShortName>Supplemental Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Principles of Consolidation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies</Role>
      <ShortName>Basis of Presentation and Principles of Consolidation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Acquisitions</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Inventories</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/IntangibleAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Contingent Consideration (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ContingentConsiderationTables</Role>
      <ShortName>Contingent Consideration (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/ContingentConsideration</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Derivative Instruments and Hedging Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables</Role>
      <ShortName>Derivative Instruments and Hedging Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Debt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Revenue recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/RevenueRecognition</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - (Loss) earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LossEarningsPerShareTables</Role>
      <ShortName>(Loss) earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/LossEarningsPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Defined benefit plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DefinedBenefitPlanTables</Role>
      <ShortName>Defined benefit plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/DefinedBenefitPlan</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2317301 - Disclosure - Supplemental Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SupplementalInformationTables</Role>
      <ShortName>Supplemental Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/SupplementalInformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BusinessDetails</Role>
      <ShortName>Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Business</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Basis of Presentation and Principles of Consolidation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails</Role>
      <ShortName>Basis of Presentation and Principles of Consolidation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Acquisitions - Adapt Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails</Role>
      <ShortName>Acquisitions - Adapt Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Acquisitions - Adapt Total Purchase Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails</Role>
      <ShortName>Acquisitions - Adapt Total Purchase Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Acquisitions - Adapt Preliminary Allocation of Purchase Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails</Role>
      <ShortName>Acquisitions - Adapt Preliminary Allocation of Purchase Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Acquisitions - PaxVax Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails</Role>
      <ShortName>Acquisitions - PaxVax Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Acquisitions - PaxVax Preliminary Allocation of Purchase Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails</Role>
      <ShortName>Acquisitions - PaxVax Preliminary Allocation of Purchase Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2403407 - Disclosure - Acquisitions - Impact of Business Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails</Role>
      <ShortName>Acquisitions - Impact of Business Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/InventoriesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Intangible Assets - Schedule of Finite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Finite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ContingentConsiderationDetails</Role>
      <ShortName>Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/ContingentConsiderationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Derivative Instruments and Hedging Activities - Derivative Designated as Cash Flow Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Derivative Designated as Cash Flow Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Derivative Instruments and Hedging Activities - Fair Value by Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Fair Value by Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Derivative Instruments and Hedging Activities - Cash Flow Hedging on AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Cash Flow Hedging on AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Debt - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtScheduleDetails</Role>
      <ShortName>Debt - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Debt Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails</Role>
      <ShortName>Debt Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Revenue recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails</Role>
      <ShortName>Revenue recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Revenue recognition - Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails</Role>
      <ShortName>Revenue recognition - Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Revenue recognition - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails</Role>
      <ShortName>Revenue recognition - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2412401 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/IncomeTaxes</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - (Loss) earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LossEarningsPerShareDetails</Role>
      <ShortName>(Loss) earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/LossEarningsPerShareTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - Share-based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ShareBasedCompensationDetails</Role>
      <ShortName>Share-based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/ShareBasedCompensation</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Defined benefit plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails</Role>
      <ShortName>Defined benefit plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/DefinedBenefitPlanTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2416401 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - Supplemental Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SupplementalInformationDetails</Role>
      <ShortName>Supplemental Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/SupplementalInformationTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ebs-20190630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - ebs-20190630x10q.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - ebs-20190630x10q.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ebs-20190630x10q.htm">ebs-20190630x10q.htm</File>
    <File>ebs-201906030xex102.htm</File>
    <File>ebs-20190630.xsd</File>
    <File>ebs-20190630_cal.xml</File>
    <File>ebs-20190630_def.xml</File>
    <File>ebs-20190630_lab.xml</File>
    <File>ebs-20190630_pre.xml</File>
    <File>ebs-20190630xex101.htm</File>
    <File>ebs-20190630xex311.htm</File>
    <File>ebs-20190630xex312.htm</File>
    <File>ebs-20190630xex321.htm</File>
    <File>ebs-20190630xex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>chart-03d50f56d7cd54f29ca.jpg</File>
    <File>chart-1352e58451d95236ac3.jpg</File>
    <File>chart-8b90b56754be58a0a19.jpg</File>
    <File>chart-c40b459aee255b80b3c.jpg</File>
    <File>chart-fc671f5e2a225299909.jpg</File>
    <File>chart-fc88426c8115514eb1d.jpg</File>
    <File>emergentlogocmykregistered.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ebs-20190630x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 194,
   "dts": {
    "calculationLink": {
     "local": [
      "ebs-20190630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ebs-20190630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ebs-20190630x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ebs-20190630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ebs-20190630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml",
      "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ebs-20190630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 451,
   "entityCount": 1,
   "hidden": {
    "http://emergentbiosolutions.com/20190630": 3,
    "http://fasb.org/us-gaap/2018-01-31": 32,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 41
   },
   "keyCustom": 33,
   "keyStandard": 315,
   "memberCustom": 14,
   "memberStandard": 33,
   "nsprefix": "ebs",
   "nsuri": "http://emergentbiosolutions.com/20190630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://emergentbiosolutions.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Basis of Presentation and Principles of Consolidation",
     "role": "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation",
     "shortName": "Basis of Presentation and Principles of Consolidation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Acquisitions",
     "role": "http://emergentbiosolutions.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Inventories",
     "role": "http://emergentbiosolutions.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Property, Plant and Equipment",
     "role": "http://emergentbiosolutions.com/role/PropertyPlantAndEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Leases",
     "role": "http://emergentbiosolutions.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Intangible Assets",
     "role": "http://emergentbiosolutions.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Contingent Consideration",
     "role": "http://emergentbiosolutions.com/role/ContingentConsideration",
     "shortName": "Contingent Consideration",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Derivative Instruments and Hedging Activities",
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities",
     "shortName": "Derivative Instruments and Hedging Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Debt",
     "role": "http://emergentbiosolutions.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Revenue recognition",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognition",
     "shortName": "Revenue recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Income taxes",
     "role": "http://emergentbiosolutions.com/role/IncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - (Loss) earnings per share",
     "role": "http://emergentbiosolutions.com/role/LossEarningsPerShare",
     "shortName": "(Loss) earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Share-based compensation",
     "role": "http://emergentbiosolutions.com/role/ShareBasedCompensation",
     "shortName": "Share-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115100 - Disclosure - Defined benefit plan",
     "role": "http://emergentbiosolutions.com/role/DefinedBenefitPlan",
     "shortName": "Defined benefit plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116100 - Disclosure - Commitments and Contingencies",
     "role": "http://emergentbiosolutions.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117100 - Disclosure - Supplemental Information",
     "role": "http://emergentbiosolutions.com/role/SupplementalInformation",
     "shortName": "Supplemental Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Principles of Consolidation (Policies)",
     "role": "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies",
     "shortName": "Basis of Presentation and Principles of Consolidation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Acquisitions (Tables)",
     "role": "http://emergentbiosolutions.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Inventories (Tables)",
     "role": "http://emergentbiosolutions.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Property, Plant and Equipment (Tables)",
     "role": "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Leases (Tables)",
     "role": "http://emergentbiosolutions.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Intangible Assets (Tables)",
     "role": "http://emergentbiosolutions.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Contingent Consideration (Tables)",
     "role": "http://emergentbiosolutions.com/role/ContingentConsiderationTables",
     "shortName": "Contingent Consideration (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Derivative Instruments and Hedging Activities (Tables)",
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
     "shortName": "Derivative Instruments and Hedging Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Debt (Tables)",
     "role": "http://emergentbiosolutions.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Revenue recognition (Tables)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionTables",
     "shortName": "Revenue recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313301 - Disclosure - (Loss) earnings per share (Tables)",
     "role": "http://emergentbiosolutions.com/role/LossEarningsPerShareTables",
     "shortName": "(Loss) earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315301 - Disclosure - Defined benefit plan (Tables)",
     "role": "http://emergentbiosolutions.com/role/DefinedBenefitPlanTables",
     "shortName": "Defined benefit plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317301 - Disclosure - Supplemental Information (Tables)",
     "role": "http://emergentbiosolutions.com/role/SupplementalInformationTables",
     "shortName": "Supplemental Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401401 - Disclosure - Business (Details)",
     "role": "http://emergentbiosolutions.com/role/BusinessDetails",
     "shortName": "Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ebs:ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Basis of Presentation and Principles of Consolidation (Details)",
     "role": "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails",
     "shortName": "Basis of Presentation and Principles of Consolidation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Acquisitions - Adapt Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
     "shortName": "Acquisitions - Adapt Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember",
      "decimals": "-1",
      "lang": null,
      "name": "ebs:NumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - Acquisitions - Adapt Total Purchase Price (Details)",
     "role": "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails",
     "shortName": "Acquisitions - Adapt Total Purchase Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "D2018Q4Oct15-Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403404 - Disclosure - Acquisitions - Adapt Preliminary Allocation of Purchase Price (Details)",
     "role": "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
     "shortName": "Acquisitions - Adapt Preliminary Allocation of Purchase Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "I2018Q4Oct15_us-gaap_BusinessAcquisitionAxis_ebs_AdaptPharmaMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403405 - Disclosure - Acquisitions - PaxVax Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails",
     "shortName": "Acquisitions - PaxVax Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "D2018Q4Oct04-Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember",
      "decimals": "-1",
      "lang": null,
      "name": "ebs:NumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403406 - Disclosure - Acquisitions - PaxVax Preliminary Allocation of Purchase Price (Details)",
     "role": "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails",
     "shortName": "Acquisitions - PaxVax Preliminary Allocation of Purchase Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "I2018Q4Oct04_us-gaap_BusinessAcquisitionAxis_ebs_PaxVaxMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ebs:NumberOfBusinessAcquisitions",
      "reportCount": 1,
      "unitRef": "acquisition",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403407 - Disclosure - Acquisitions - Impact of Business Acquisitions (Details)",
     "role": "http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails",
     "shortName": "Acquisitions - Impact of Business Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_ebs_AdaptAndPaxVaxMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Inventories (Details)",
     "role": "http://emergentbiosolutions.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Leases - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive (Loss) Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ebs:ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406404 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "role": "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ebs:ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "lang": null,
      "name": "ebs:OperatingLeaseOtherLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Intangible Assets - Schedule of Finite-lived Intangible Assets (Details)",
     "role": "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
     "shortName": "Intangible Assets - Schedule of Finite-lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Intangible Assets - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails",
     "shortName": "Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Contingent Consideration (Details)",
     "role": "http://emergentbiosolutions.com/role/ContingentConsiderationDetails",
     "shortName": "Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails",
     "shortName": "Derivative Instruments and Hedging Activities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "instrument",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Derivative Instruments and Hedging Activities - Derivative Designated as Cash Flow Hedges (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
     "shortName": "Derivative Instruments and Hedging Activities - Derivative Designated as Cash Flow Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "instrument",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Derivative Instruments and Hedging Activities - Fair Value by Balance Sheet Location (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails",
     "shortName": "Derivative Instruments and Hedging Activities - Fair Value by Balance Sheet Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Derivative Instruments and Hedging Activities - Cash Flow Hedging on AOCI (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails",
     "shortName": "Derivative Instruments and Hedging Activities - Cash Flow Hedging on AOCI (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Debt - Schedule (Details)",
     "role": "http://emergentbiosolutions.com/role/DebtScheduleDetails",
     "shortName": "Debt - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "D2019Q2Jun01-Jun30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ebs:DebtInstrumentCovenantDebtServiceCoverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Debt Debt - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
     "shortName": "Debt Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "D2019Q2Jun01-Jun30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ebs:DebtInstrumentCovenantDebtServiceCoverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - Revenue recognition - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411403 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails",
     "shortName": "Revenue recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD_srt_StatementGeographicalAxis_country_US",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Revenue recognition - Contract Liabilities (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails",
     "shortName": "Revenue recognition - Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ebs:ScheduleofAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Revenue recognition - Accounts Receivable (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails",
     "shortName": "Revenue recognition - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ebs:ScheduleofAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412401 - Disclosure - Income taxes (Details)",
     "role": "http://emergentbiosolutions.com/role/IncomeTaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413402 - Disclosure - (Loss) earnings per share (Details)",
     "role": "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails",
     "shortName": "(Loss) earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414401 - Disclosure - Share-based compensation (Details)",
     "role": "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails",
     "shortName": "Share-based compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415402 - Disclosure - Defined benefit plan (Details)",
     "role": "http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails",
     "shortName": "Defined benefit plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD_srt_LitigationCaseAxis_ebs_ShareholderClassActionLawsuitMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416401 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD_srt_LitigationCaseAxis_ebs_ShareholderClassActionLawsuitMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417402 - Disclosure - Supplemental Information (Details)",
     "role": "http://emergentbiosolutions.com/role/SupplementalInformationDetails",
     "shortName": "Supplemental Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005501 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Business",
     "role": "http://emergentbiosolutions.com/role/Business",
     "shortName": "Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20190630x10q.htm",
      "contextRef": "I2018Q1Jan01",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - ebs-20190630x10q.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - ebs-20190630x10q.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 48,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. Government"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ebs_AdaptAndPaxVaxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adapt And PaxVax [Member]",
        "label": "Adapt And PaxVax [Member]",
        "terseLabel": "Adapt And PaxVax"
       }
      }
     },
     "localname": "AdaptAndPaxVaxMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_AdaptPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition on October 15, 2018.",
        "label": "Adapt Pharma [Member]",
        "terseLabel": "Adapt Pharma"
       }
      }
     },
     "localname": "AdaptPharmaMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended credit agreement dated October 15, 2018.",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expenses And Other Liabilities",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expenses And Other Liabilities",
        "negatedTerseLabel": "Accrued expenses and other liabilities, measurement period adjustment"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpensesAndOtherLiabilities",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities Noncurrent",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities Noncurrent",
        "negatedTerseLabel": "Deferred tax liability, net, measurement period adjustments"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Finite-lived Intangible Assets",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Finite-lived Intangible Assets",
        "terseLabel": "Acquired in-process research and development, measurement period adjustment"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinitelivedIntangibleAssets",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses and Other Assets",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses and Other Assets",
        "terseLabel": "Prepaid expenses and other assets, measurements period adjustments"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      },
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accrued expenses and other liabilities, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses and Other Liabilities",
        "negatedLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherLiabilities",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.",
        "label": "Cash Proceeds Excess Amount from Dispositions of Property or Casualty Events Subject to Certain Reinvestment Right",
        "terseLabel": "Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right"
       }
      }
     },
     "localname": "CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ChangeInFairValueOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value measurement of contingent value rights and contingent purchase considerations granted under purchase agreements.",
        "label": "Change In Fair Value Of Contingent Consideration",
        "terseLabel": "Change in fair value of contingent consideration, net"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentConsideration",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ChangeinContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in Contract With Customer, Liability [Roll Forward]",
        "label": "Change in Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Change in Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "localname": "ChangeinContractWithCustomerLiabilityRollForward",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_ContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue earned during the period arising from manufacturing sale under the terms of a contract.",
        "label": "Contract Manufacturing [Member]",
        "terseLabel": "Contract manufacturing",
        "verboseLabel": "Contract manufacturing"
       }
      }
     },
     "localname": "ContractManufacturingMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.",
        "label": "Contract with Customer, Liability, Additions",
        "terseLabel": "Deferral of revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ContractsAndGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants.",
        "label": "Contracts and Grants [Member]",
        "terseLabel": "Contracts and grants"
       }
      }
     },
     "localname": "ContractsAndGrantsMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ConvertibleSeniorNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2021 [Member]",
        "label": "Convertible Senior Notes Due 2021 [Member]",
        "terseLabel": "2.875% Convertible Senior Notes due 2021"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2021Member",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit agreement dated September 2017.",
        "label": "Credit Agreement [Member]",
        "terseLabel": "2017 Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_DebtInstrumentCovenantDebtServiceCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Debt Service Coverage Ratio",
        "label": "Debt Instrument, Covenant, Debt Service Coverage Ratio",
        "terseLabel": "Debt instrument, covenant, debt service coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDebtServiceCoverageRatio",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioAdjusted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, Adjusted",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, Adjusted",
        "terseLabel": "Debt instrument, covenant, net leverage ratio, adjusted"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioAdjusted",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period",
        "terseLabel": "Debt instrument, covenant, net leverage ratio adjustment period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioFour": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, Four",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, Four",
        "terseLabel": "Debt instrument, covenant, net leverage ratio thereafter"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioFour",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioOne": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, One",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, One",
        "terseLabel": "Debt instrument, covenant, net leverage ratio through June 30, 2019"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioOne",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio Rolling Period",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio Rolling Period",
        "terseLabel": "Debt instrument, covenant, net leverage ratio rolling period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioRollingPeriod",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioThree": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, Three",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, Three",
        "terseLabel": "Debt instrument, covenant, net leverage ratio from October 1, 2019 to September 29, 2020"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioThree",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioTwo": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, Two",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, Two",
        "terseLabel": "Debt instrument, covenant, net leverage ratio to September 30, 2019"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioTwo",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentRestrictedPaymentsLimitAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Restricted Payments Limit, Amount",
        "label": "Debt Instrument, Restricted Payments Limit, Amount",
        "terseLabel": "Debt instrument, restricted payments limit, amount"
       }
      }
     },
     "localname": "DebtInstrumentRestrictedPaymentsLimitAmount",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Fair Value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Fair Value",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Measurement Period Adjustment",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Measurement Period Adjustment",
        "terseLabel": "Measurement period adjustment"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMeasurementPeriodAdjustment",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ImpactOfBusinessAcquisitionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "3e9a79ca-9c5f-2a65-3fac-a5d12d315cc7",
        "label": "Impact of Business Acquisitions [Abstract]",
        "terseLabel": "Impact of Business Acquisitions [Abstract]"
       }
      }
     },
     "localname": "ImpactOfBusinessAcquisitionsAbstract",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_ImpactOfBusinessAcquisitionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of revenue and earnings of business acquisitions included in consolidated financial statements.",
        "label": "Impact of Business Acquisitions [Table Text Block]",
        "terseLabel": "Impact of Business Acquisitions"
       }
      }
     },
     "localname": "ImpactOfBusinessAcquisitionsTableTextBlock",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ebs_InProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of purchased research and development assets acquired in a business combination that have an indefinite life until completion or abandonment of the associated research and development efforts.",
        "label": "In Process Research And Development",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopment",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_LesseeOperatingLeaseTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period",
        "label": "Lessee, Operating Lease, Termination Period",
        "terseLabel": "Operating lease, termination period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_LockUpPeriodForAdjustmentOfFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The lock-up period considered for adjustment of fair value, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Lock-up Period for Adjustment of Fair Value",
        "terseLabel": "Lock-up period for adjustment of fair value"
       }
      }
     },
     "localname": "LockUpPeriodForAdjustmentOfFairValue",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_NumberOfBusinessAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Business Acquisitions",
        "label": "Number Of Business Acquisitions",
        "terseLabel": "Number of business acquisitions"
       }
      }
     },
     "localname": "NumberOfBusinessAcquisitions",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_NumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of persons employed by the entity",
        "label": "Number Of Employees",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "NumberOfEmployees",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_NumberOfLendingInstitutions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of lending institutions in which the entity has a credit facility.",
        "label": "Number Of Lending Institutions",
        "terseLabel": "Number of lending institutions"
       }
      }
     },
     "localname": "NumberOfLendingInstitutions",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_OperatingLeaseOtherLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Other Liability, Current",
        "label": "Operating Lease, Other Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseOtherLiabilityCurrent",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_OtherLongTermDebtFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Long Term Debt Facility [Member]",
        "label": "Other Long Term Debt Facility [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtFacilityMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_PaxVaxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition on October 4, 2018.",
        "label": "PaxVax [Member]",
        "terseLabel": "PaxVax"
       }
      }
     },
     "localname": "PaxVaxMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in the third year.",
        "label": "Percentage of Original Principal Amount Required to Repay During the Third Year",
        "terseLabel": "Percentage of original principal amount required to repay during the third year"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in the first two years.",
        "label": "Percentage of Original Principal Amount Required to Repay in First Two Years",
        "terseLabel": "Percentage of original principal amount required to repay in the first two years"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in remaining years.",
        "label": "Percentage of Original Principal Amount Required to Repay Remaining Years",
        "terseLabel": "Percentage of original principal amount required to repay remaining year"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_PresentValueDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure present value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.",
        "label": "Present Value, Discount Rate",
        "terseLabel": "Present value, discount rate"
       }
      }
     },
     "localname": "PresentValueDiscountRate",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_RaxibacumabMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Raxibacumab [Member]",
        "label": "Raxibacumab [Member]",
        "terseLabel": "Raxibacumab"
       }
      }
     },
     "localname": "RaxibacumabMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Leases Supplemental Balance Sheets [Table Text Block]",
        "label": "Schedule Of Leases Supplemental Balance Sheets [Table Text Block]",
        "terseLabel": "Schedule of Leases Supplemental Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfLeasesSupplementalBalanceSheetsTableTextBlock",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ebs_ScheduleofAccountsReceivableNetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Accounts Receivable, Net [Table Text Block]",
        "label": "Schedule of Accounts Receivable, Net [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Net"
       }
      }
     },
     "localname": "ScheduleofAccountsReceivableNetTableTextBlock",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ebs_ShareholderClassActionLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shareholder Class Action Lawsuit [Member]",
        "label": "Shareholder Class Action Lawsuit [Member]",
        "terseLabel": "Shareholder Class Action Lawsuit"
       }
      }
     },
     "localname": "ShareholderClassActionLawsuitMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term loan dated December 2013.",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Senior secured credit agreement - Term loan due 2023"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_VaxchoraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is a live attenuated cholera vaccine and the first vaccine approved by the FDA for the prevention of cholera infection",
        "label": "Vaxchora [Member]",
        "terseLabel": "Vaxchora"
       }
      }
     },
     "localname": "VaxchoraMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_VivotifMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is a live attenuated vaccine for oral administration to prevent typhoid fever.",
        "label": "Vivotif [Member]",
        "terseLabel": "Vivotif"
       }
      }
     },
     "localname": "VivotifMember",
     "nsuri": "http://emergentbiosolutions.com/20190630",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "invest_DerivativeNotionalAmount": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://xbrl.sec.gov/invest/2013-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r125",
      "r186",
      "r189",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]",
        "verboseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r126",
      "r186",
      "r190",
      "r320",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASC 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r17",
      "r187"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "totalLabel": "Total, net",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r154"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r57",
      "r61",
      "r62",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r73",
      "r90",
      "r282"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r90",
      "r139",
      "r148"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of acquisition-related intangible assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r124",
      "r300",
      "r310"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r52"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r204",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r255",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BilledContractReceivables": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.",
        "label": "Billed Contracts Receivable",
        "terseLabel": "Billed, net"
       }
      }
     },
     "localname": "BilledContractReceivables",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings, building improvements and leasehold improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Common stock issued for acquisition (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r232",
      "r233",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r232",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Consideration transferred, equity interests issued and issuable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r89",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "verboseLabel": "Contingent consideration liability increase"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r231",
      "r234",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of contingent purchase consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r231",
      "r235"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration, current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r231",
      "r235"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]",
        "terseLabel": "Measurement Period Adjustments"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in income that would have been recognized in previous periods if the adjustments to provisional amounts were recognized as of the acquisition date.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period",
        "negatedTotalLabel": "Total fair value of tangible assets acquired and liabilities assumed, measurement period adjustments"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      },
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r214",
      "r227"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "verboseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent",
        "negatedLabel": "Deferred tax liability, net of current"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquired intangible asset",
        "verboseLabel": "Acquired intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r226",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r226",
      "r227"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r226",
      "r227"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total fair value of tangible assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r226",
      "r227"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]",
        "terseLabel": "Estimated fair value of tangible assets acquired and liabilities assumed:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r32",
      "r92"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/SupplementalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/SupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r87",
      "r92",
      "r93"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/SupplementalInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://emergentbiosolutions.com/role/SupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r87",
      "r277"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months",
        "terseLabel": "Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income"
       }
      }
     },
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/SupplementalInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r158",
      "r304",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Notes 8 &amp; 16)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "$0.001 Par Value Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "negatedPeriodEndLabel": "Balance (in shares)",
        "negatedPeriodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200.0 shares authorized, 52.7 shares issued and 51.6 shares outstanding at 2019; 52.4 shares issued and 51.2 shares outstanding at 2018"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r65",
      "r67",
      "r68"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r243",
      "r245",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation and consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Rollforward of Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r179",
      "r180",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Contract with customer, liability, ending balance",
        "periodStartLabel": "Contract with customer, liability, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r179",
      "r180",
      "r187"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales and contract manufacturing"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Adoption of new revenue accounting standard (ASC 606), net of tax"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r301",
      "r302",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r97",
      "r171",
      "r172",
      "r173",
      "r174",
      "r280",
      "r281",
      "r283",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred Costs, Current",
        "terseLabel": "Deferred costs, current"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r35",
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedTerseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r96",
      "r219",
      "r220"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r215",
      "r218"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r195",
      "r198",
      "r199"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedTerseLabel": "Expected return on plan assets, net of expenses"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r193",
      "r196",
      "r199"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Total pension expense"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r192",
      "r194",
      "r197",
      "r199"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Net service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DefinedBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r90",
      "r122"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r53",
      "r54",
      "r257",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Asset Derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r53",
      "r54",
      "r257",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Liability Derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r256",
      "r258",
      "r262",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r253",
      "r256",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "auth_ref": [
      "r261",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "terseLabel": "Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DirectFinancingLeaseLeaseIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Direct Financing Lease, Lease Income [Abstract]",
        "terseLabel": "Operating leases:"
       }
      }
     },
     "localname": "DirectFinancingLeaseLeaseIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net (loss) income per common share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r72",
      "r104",
      "r112",
      "r114",
      "r115",
      "r116",
      "r119",
      "r306",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share - basic (in dollars per share)",
        "verboseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Shares used in computing (loss) income per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r72",
      "r104",
      "r112",
      "r114",
      "r115",
      "r116",
      "r119",
      "r306",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per share - diluted (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "(Loss) earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LossEarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r100",
      "r216",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective annual tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.",
        "label": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense",
        "terseLabel": "Discrete tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurocurrency"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsideration"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r273",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Milestone achievement - asset acquisition"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r255",
      "r260",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fixed rate on a U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to the Federal Funds effective rate with no additional spread over the Federal Funds effective rate on that variable-rate leg. Alternate captions include overnight index swap rate (OIS).",
        "label": "Federal Funds Effective Swap Rate [Member]",
        "terseLabel": "Federal Funds Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finance Lease, Cost [Abstract]",
        "terseLabel": "Operating lease cost:"
       }
      }
     },
     "localname": "FinanceLeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r287",
      "r290",
      "r294"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r287",
      "r290",
      "r294"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Amortization period of intangible asset"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r140",
      "r144",
      "r147",
      "r150",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r147",
      "r298"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r140",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, acquired during period"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r134",
      "r137"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Goodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "terseLabel": "Goodwill, cost"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r136",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Goodwill, measurement period adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r253",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails",
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "(Loss) income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net (loss) earnings"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r123",
      "r221"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r113",
      "r118"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive securities-equity awards (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r143",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "periodEndLabel": "Indefinite-lived intangible assets (excluding goodwill)",
        "periodStartLabel": "Indefinite-lived intangible assets (excluding goodwill)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r143",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit, from purchase accounting adjustments.",
        "label": "Indefinite-lived Intangible Assets, Purchase Accounting Adjustments",
        "terseLabel": "Indefinite-lived intangible assets, purchase accounting adjustments"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Indefinite-lived Intangible Assets [Roll Forward]",
        "terseLabel": "Indefinite-lived Intangible Assets [Roll Forward]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r138",
      "r145"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r70",
      "r121",
      "r279",
      "r282",
      "r307"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r23",
      "r130"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r50",
      "r129"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r25",
      "r26",
      "r130"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r24",
      "r130"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held.",
        "label": "Land and Land Improvements [Member]",
        "terseLabel": "Land and improvements"
       }
      }
     },
     "localname": "LandAndLandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Operating leases:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r303",
      "r314"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement, amount awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r168",
      "r302",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term debt, net of debt issuance costs",
        "terseLabel": "Debt, current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows provided by (used in) financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows provided by (used in) operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r63",
      "r66",
      "r71",
      "r91",
      "r118",
      "r305",
      "r317"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r103",
      "r105",
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-U.S. Government"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r249",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "terseLabel": "Number of Instruments"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesDerivativeDesignatedAsCashFlowHedgesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "(Loss) income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails",
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease, right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails",
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r292",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted Average Discount Rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r291",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted Average Remaining Lease Term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/Business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r255",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "negatedTerseLabel": "Derivatives"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "terseLabel": "Amount of Gain/(Loss) Recognized in OCI on Derivative"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesCashFlowHedgingOnAociDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "negatedLabel": "Derivatives"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r55",
      "r278"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translations, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r64",
      "r67",
      "r69",
      "r170"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income",
        "totalLabel": "Total other comprehensive (loss) income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income, net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r40"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesMember": {
     "auth_ref": [
      "r255",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other liabilities.",
        "label": "Other Liabilities [Member]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesFairValueByBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Contingent consideration payments"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForPreviousAcquisition": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash outflow representing an adjustment to the purchase price of a previous acquisition.",
        "label": "Payments for Previous Acquisition",
        "negatedTerseLabel": "Milestone payment from prior asset acquisition"
       }
      }
     },
     "localname": "PaymentsForPreviousAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchase of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r84",
      "r201"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.",
        "label": "Payments Related to Tax Withholding for Share-based Compensation",
        "negatedLabel": "Taxes paid on behalf of employees for equity activity"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r79",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Cash paid for acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Defined benefit plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DefinedBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding at both 2019 and 2018"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r83",
      "r98"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from revolving credit facility"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r82",
      "r212"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Issuances of stock under share-based benefit plans"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r153"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property Plant and Equipment Income Statement Disclosures [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r155",
      "r315"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r85",
      "r98"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedTerseLabel": "Principal payments on revolving credit facility"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfMediumTermNotes": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.",
        "label": "Repayments of Medium-term Notes",
        "negatedTerseLabel": "Principal payments on term loan facility"
       }
      }
     },
     "localname": "RepaymentsOfMediumTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r213",
      "r322"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r9",
      "r92",
      "r93",
      "r299",
      "r312"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/SupplementalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/SupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r9",
      "r92",
      "r93"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r175",
      "r313"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r181",
      "r185",
      "r186"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r102",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Senior secured credit agreement - Revolver loan due 2023"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsImpactOfBusinessAcquisitionsDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsPaxvaxPreliminaryAllocationOfPurchasePriceDetails",
      "http://emergentbiosolutions.com/role/ContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/SupplementalInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r256",
      "r262",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Derivative Instruments, Gain (Loss)"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r101",
      "r248",
      "r250",
      "r251",
      "r253",
      "r254",
      "r260",
      "r262",
      "r267",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Income per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LossEarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r140",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r140",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r149",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r149",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of Net Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DefinedBenefitPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r204",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75",
      "r128"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r202",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Compensation Award, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Third portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Compensation Award, Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Compensation Award, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of share-based compensation awards.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r47",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stock Issued or Granted During Period, Share-based Compensation [Abstract]",
        "terseLabel": "Stock issued or granted during period [Abstract]"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharebasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r170",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Employee equity plans activity (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r47",
      "r170",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptNarrativeDetails",
      "http://emergentbiosolutions.com/role/AcquisitionsAdaptTotalPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r175",
      "r203",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Employee equity plans activity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r127"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity including the portion attributable to noncontrolling interests, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance",
        "terseLabel": "Balance, as adjusted"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r46",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r46",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r46",
      "r176",
      "r177"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 1.2 common shares at both 2019 and 2018"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisOfPresentationAndPrinciplesOfConsolidationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledContractsReceivable": {
     "auth_ref": [
      "r48",
      "r297"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.",
        "label": "Unbilled Contracts Receivable",
        "terseLabel": "Unbilled"
       }
      }
     },
     "localname": "UnbilledContractsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule for share-based compensation.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule for share-based compensation.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r111",
      "r116"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average number of shares-diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r110",
      "r116"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares-basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://emergentbiosolutions.com/role/LossEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12053-110248"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=107668666&loc=SL79513924-113897"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e961-128460"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=SL65897772-128472"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109975725&loc=SL5629052-113961"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109976185&loc=SL5864739-113975"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=68054760&loc=d3e55302-109406"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r323": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r324": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r325": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r326": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r327": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r328": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r329": {
   "Article": "12",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "13",
   "Sentence": "Column B"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(c)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0001367644-19-000038-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001367644-19-000038-xbrl.zip
M4$L#!!0    ( !*3 4\EK96Q7CP  /]0   =    8VAA<G0M,#-D-3!F-39D
M-V-D-31F,CEC82YJ<&?MO E4$UNZ-ER("HH0$1!DB@H*BA@'!F5(C@,@HB!R
M,(I*VI'I("IRB!A21YG''$7E"$I$A@B(.<JD@"D@#$<1448!(22H(&-%(!2D
M4OG*OMWWNZN7W?U__UWKZ_O_J\/:6:3VKMKU[OV^S_L\NW8B?R_O!Y;N=71V
M!!04 $ !_P/D/< N_--_[_7M(O_=:RC(JP!U984-"NL5%58#\]05%-45Y+4
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MG;0L)LZJXN) LKP%FAH(H W_B7T![*5]Q/%BZN_4(+9?\M @-4IU'<1>PA:
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MW='7>P2M/[PJ?ND;3=.+JW<OJ/DE4_SBAZH_K0]:N])9.=]%>\V/ZS92_9C
M["LQ-/'+GB4*JR%CLCFSFU:2&D4)8*LS^1EJ" 6>&Q"EUJU S<1.$BI27?@E
MP[X-4^5+-_G.[;."BGT2,&N_N8TEI_((L0)%YLKWA^GK>VIX^F):C#FVLDD\
MT:^%_7:IX,1 EP64/$5$3"%4\^0,?_F%X9_EP!,2NI9,PO,HA\["%K&%>B/?
MEG^(F7!]7#C\B6EIG<@S0]+W/4/:R06/^"(-N-7)4 >^G5+@IYII@".G]!2M
MXX>KA5643)" 4/D\S80?8_CEEM'):7TO'B%9AZT.;#CHG[%*O&! $*!;G[G9
MW+)7-L8WO7&YM\M<6%(4\ZJHN*0LYC[W#>$7.5 2U#"1" '03[XKD:/]5!D7
M/ W&@KH\!>=^F<JQ]G%L*>J*O.QOCB)K(5PX_1#<EU70G(.D[X&IM<T$A@L2
MN+'HP4A89)@@PC+<J9:IGT)K-WHWQG &%V/O(8-+@IZ3?,EI,75T]D0VLC[H
MO4 D&%/-IF>YBDOO<1&I*(B%:2$IDE 8*Q0&+:23]CU+:ZCI6\KR0%X6(#[[
M(/'C)W)@$2T>=<M:,69AK\1?;E7>&5]%<?;EUA$1$Q]4BU!/*>'4)Q'Z!VL-
MK/M+ZHO$2I+CZ9('>(:_G2E>/CS8[YB921^H)B]&KDI):#A+M##UM%L# 3B&
MNL"1:8^Z]WGKM"W[W%K;D6&*G.FGGX)S)N*A@&^<$W;KCJ@5&%1JP001F B=
M92V@>XAH]0)EY"RHB6@+N8F/I^UM]R"L4.%(0B#-$PD/*/"C6A4-\=:*N3&C
MTT&JB-G1BAO[M9W$&3GW!4ATR^3."/?27Q7[AKB#W 8*[!'4HR>BU4S@S*J$
M.GI/"'4-\ME/!6-ZTD-8,UA$J(K%H3^:K9N-0*(7)@.T9+LU\ /I0/2+;(0J
M J\]0LV$8P21=][ ?EL'!'PXE(6':W2EAI_(4VQ_"TJT>/\H#.<MUWYE=F8L
M[I #OI1XBCI*E%HC,1(_V6_@.3P)"7[OK#,PJOZ9HEFY59SO3%Y3+;6B'PQ*
MPC3;IB$M>E%U6$?J ]1%EFVQ@BWTE%S-'BY"]/:TKRD3RQIB[Y<\;?N%$N;+
MO<U<CSK)<NR(8A6/&&%#U;VM(@'_"NU:>49%;CBK/HQXK=(]'SU/BR/KP.-)
M_8WW@NK"*@V)[^RTY8"R50&7WNS=R79LMW2Q#5+S=L@^,N)5V4V++@EZ&11+
M@:F"^ PM62+8SQ84_YPGY$825<]! = B>G,=38.\,J!/&_DD9@FAZG360OJ6
MD3IXZ!![,6]1SS#%H-(S%WEVE';8I'9W41F<RA^ZY--F=V[5"[%)5+$93!@B
MQ\.4+MJ 6J%T!]8$S2-O#^ 9OF.8%*)'$9=^8FP:%&VW720S:9A3NYJ'5/"]
MF"7AV;Y]EF^[IMB:?K>UK2\>[1HYY'#RQ=5ECLGK(I]P>?_*9]W?,B1B(FF1
M_5*I(*5]"<LM"AB 8J%YF.5+F%O/5K)@)Q$7H>XB@MJ(-DV-<2'X3$$ J(JM
M'BHW++GO)#82,O.X?C_KWLX2!A12=W4^"AW^BFC79RSL""D8\\,D#WZA;$(7
MX(GG.8X4M"2>NBS+@A8OT$=7B,U^@$G58$QJGR;B*=;V@'VJ],!YZ J<Y$1-
MA9L)K?F"B+E1;^MT84Q5DNL(?[-_&+LF2)7^VJ^[I*FMC&?<'B(+H1[EOL V
MH'84+2:1SJI2&<!Q2$VO]L#[&KM F%,[6 TMO41ZXM^AFY?"YZU=KGNGY5.%
ME" )F91%@\5^U-".TR;==FU37J:*DT>%+%1#14BK(5WUUI=E,%3%4DG'.[L%
M_4V!EL2%;CG,=D@=I8A8BX=8V?L?"!#M?6)BU.FW&P=AU\S X N792F/G/*]
M?>>FKB.I-7.Y5T5ZMJJNG1-N.$RK5:K#,4(\IGC+&99P7WJ_'(@1J%6:W4=,
MJKVU6HQNV&_E]RV'W]P)S!H*L[_19-Q:\B+ZGE_0N1O'W.Q?URWI]&B^8%Q$
M"?@/1;TC)"#P2I#]O8]+>[V.[S)_T512Z]X<="'(QL)CA]V6@CJ+K;LG-)_L
M*=2_7F%48+84)-['>[9AK&U!CXB2*'R!-G/KD$!A&NJJ."1+MR/ -:0XB@:Q
M7E!$O18"K:!?J>6MA)M'T\61]#G[7?U</LW %].".1&58+\US$D@39-4$+TJ
M3!?N3*Q<UR];BR?R;O:H@Z;"I-(H1[H!)Q&.2*@<6%Q1U4=&B@9(2D<:.9SH
M2U"\X<96U$WIFD7@5I>RED>5F_L+CIOQ,U:T5MH*'YXH.WHUQ^O]4_NIE#Z[
MP@U?-3Y"Q4148Z(**J;53\2 AI7.XF9)'DQ-X"W[T/@0M6QA+D<#*V"W"#N#
M1_Z&*]HKM47F <YP+9G89NZ:)X(6!91#,95.]A\[G<-S!6]^Y0=L710CL#B@
M5 4J0_WIQ"*W:EH<MA1)%2J338[O@LMJB>J,(_ N(3<.,Z<+:G&((2LB6:+>
MLO@-3".<.BGS#/S+;Y93HDH(&GX9UN+;R;D^[>:H[0,ZY_@[AE&04+;UX+.2
M(.@O:[%VP51$N]\^:*#Y*N3;,Q02+#81#M9 <6PEN^T7U)X$+X\A1I W(!QA
M:@)*4QV/+)"XC+D>]Q&2(HFN[6M.D-,#U;("Y_TVO>Z/60H.^OM870/U&0O*
M88?'9>+TJB23L5L#E)Z&?>(8?G-\6%DT(T38W&W4D$*OWP_2X)G8J%LC?MWS
MKR,3M;<[>,L#;),VMG2(5_U0H]S$C'OW@Z&ZU)[YAK@8UT&D>0)$17CH5H%7
MUPBV4>Q4ZZ9+9]49KNVL#,1Q %QF%Q16SDIDKF+\((;B@Z8IZO2R.FQU1;+"
MY7S_U*<JQ\F-+F^GTL-M<6Y;N*6YBN&,Q[H<@-WB('^9BJ2Z'!F1>AYA.,%M
MH;J.<<(DLX' 7E9-+Z6JO/1Y/VT9KD]ODA5IA)=^N,-(Z[MG^+ANSC!_VXU\
M\$^UV<?TSO+3>TKM*SZ@] J<#YUJCF(K5H(B5GS8H>?B !&QEJ:.,"GSCR#-
M Z%U$X:,,V)B!*:WX[&+R)>L1S>CBC\7YO<-D9>!2_>DU><_"("6TC/F^#M3
MZW@K.QNB*[>54]MONO^P8!60:'A'Z>MV[";>49TN;51)2O8C*E!\H*Z:-PWU
M%+@0/$N+IRDS-S%(9>GU8=G=8V6)/&74@:C)4+5ZP;71:P+W1]3M-6Z_U%CU
MNW\WB+H\7ES==%X=Q^A-X-F73"LZ?X!<]! ]+38VM)+=MZ!U9WDAUH\9WN)]
M<@ X(\NLM.30/5SASCIG3/-P*?O!\-Q$C-O5RE7Y0S\;&C_K9&S/05A\+^VX
M0HL]TV-&KFWFD,/#^P1KI 3^B%*1*R)BS,@ .Q92=8LU:LTRM$+<1"G]S;$V
M)A)FX:G\5!Q2XWC5^096+A-/#&S=P=_?G"NN:!S96C1FZ,^\C"ABB[2D%,86
MF, G*"*VHL&QT*Q>AGJ)V#J&IXI(FB4WQ?=B:L%HMBIZ(;#_C\H+< (_8UW+
MV*,E A7T>"@\6>W542@,9_*/;J;'\+T<H6P\CQ0FE;P&\V\>4+K-6(:8P<V2
M2XA;/^D:4<F.%-C?'$U;@FX_):0M1/P[AC'9I2;#*MO5S0^'RZC=C_/ D N6
M=1BGP+^L+"VC(._X\6&;J-ZZ3Z];*7GO_N\L*J(I>&0($!L06QP@W<!01'9(
MMZ%;WN+:^PO/$%5'K@A9T1E+TG&06,1PR:?'T]3H+OMC]K:PC[8]PHR__-PY
ME^Y5%?UUW(#<M-&$9%J66*$X!HEU!E$M"(N2 W_^/1PH 9H=/: TE_F.]NFR
M'%!/!JN/RH$AVK??XVE$*N1 1AWQWZ?\^Y1_G_+?/N6^\XR35(PWKN/"=7BP
M7P-?SC%[V))0L)B-/:;I4B=>RH&(>IPY%S9@9[Z=_)#RU:'R^/MK-NAA^X:V
M$!V[SLD5>,*AQ?(L&)[('7%"_:)<!Y$@@;B4X2,FU:D/E;(X0^^0A :F45NE
M>V%NR@GC&;<SN6LY^;WF45D?/MB7/(Q?GG$RVA&0=_TO4$L#!!0    ( !*3
M 4\D]>]+D5$  "ID   =    8VAA<G0M,3,U,F4U.#0U,60Y-3(S-F%C,RYJ
M<&?LO'E4$]N7-EP*"(H89A24J*@X(<H@"IB("(B($1%0$'(=$ $QURM(E)!2
M$,(@Q)DK"%% $!&C,BEB(H3A*B(R"RB95&:I4@@EJ52^\M?OVU^O_FYWO^OK
MM;K[CQ=6L5*54^?4WF?O9S_/J2J4'Y0B0'NGJ[LK,&,& ,S ?P%E'^",[_WG
M?GYU\I_M8X;R%:"C,6/MC-4J,Y8",W5FJ.C,4-8!1/PZU?ZI ?"_?F;,5%%5
MFZ6N,7N.)MZ@7!N8.4-%9::JBIJ:JBK^;2S^/:"JHZ:[9(/3+#VO0^I+3^E;
M7;AR5\-LVY,:@[VMT#+KPW_$S9YC:#1_@?'R%>8K5ZVVL=UHMVFSO?-V%U>W
M'>X[O??Y^/KM/^!_Y&CPL9#CH6&G(Z/.1-//GHN_F)#(2DI.N7KM^HV;&7_>
MRLS-R[]74'B_Z,'3TK+RBLIGSZMJ!77U#8U_O7[3UM[1V=7]H:=7+)%^_O)U
M8'!H&/[^8V)2-H7\G/YEUPQ Y9]-_UN[='"[9JJJJJBJ_[)KQLSH7PUT5-66
M;)BEZ^2E?NB4WE*K"QKZVZ[<?5(SV\QZ+V1P^(_6.8;+;,3+X5^F_<.R_S/#
MXOY_6?;/AOV_=O4"<U5FX).GH@.0 <5=)1"W$ZQ9QA?=HAKA?SB/"^O&D_F/
M,T9?2CE)00Z*#)XVDM? M(+)M12M,&PI3$Z:I,WI^1A6U5_Y("B@Z318-&SG
M\HVVKN#P#XK9DU>]Q=-+E, \#[S?'6";/?FH)6K%U%$"G^VIR-(0--<-F]VJ
M!([%0VY*8(]\M<+U#J&)C?Q!176=L2NM\B6@^!K$5@)+6O^^$X5;[GGR.K+X
M-0BY$Z;=W$83E$ BI9:,LMS0S9;8;'SL'8.*RWSH-8(/<'EDTC0%0)\I =9R
M)5"SC#RTB/C4"%M UE "WQ<1H<]\9!E+898GVZ8$!.9B(N;,[3BW4N6[%%N8
MH014+RN!_$CF7U3D*&JF!/Z*! 57E8#H*G$BG=VCJ03F<BZ"/^?QO0;_KPG_
MUX3_+A,L.)C&+7R(*P 1B<:MF+H,OM:#V-%[SAU(;QP:UI#P&U_(/D*-+(:>
M/ 3K#IH+,5D%])#:(!U%(49"CM1B)JT1>YM<(=RT2$)*_]JV,D^"^U/VJM""
M4/O@>R4)"0]T;\HJX.W5B[E3?M>^L:>D2J UE2I.50)JJDK@VH2BDCSZ30F$
MDA4'>39W")-3^)6N -\L T791-EQLBHX27C*[0A#G__]<6!E;LI_>CO*B03Y
M1.R2/^Y,*K+2'.44CN'CA43+W97 \!?X'OB\XS]J H!</JICC7GA4Z0ZJ 1*
MG1#\T_W8&\P\OR\M_\8W>V:XZ/^G-Y5E\CP%H@0F#G<CA_'P<B)_5I C6N0.
M_%Z*$O"S3%NC>)?_'S19J:*(Q6,JF?,]F8B8NRDR"35$A?-H\:0Q?QWX=X?/
MSUF9^__9'(_($A YU"(+0JRE0C;1:#+UI9YX7%"R=)'WP:KVR#0W:N>W G['
MJ,TB3>?W918K-+,] F"CY&JWXD',!/K&#M8\&':NO^30T43RIC><E0P5?-*O
M,\R0$JA%2JD;3\V9A>3)B:'$&5'<!4[P#'[HV*S&&F,#3@+#&G9HY&N>J/8I
M9&QOM]UR6OSHI84PF40<L2<DH:O$2L!PF+<*HER24N<,3T?5A@7I=:$^WX05
M+$'@:2EA]"6<(>:PF#JH&3)91&^L#7$#X\%%MFE4 6<N<]F055C546PQE/Y2
MXDG8U65+GBL<GE8UOFZJ!SL:1W0$+80O0[)R>G+PD5,VU$0JM(O?TR3C*ZXR
MR'(*?;A)]ILBUUL6%<#6.\!8AEL4B[HK[CFJP=<:IX7US=:R!J3DH3-L) [B
MPAF29<)Y/ .ZAX"C$450\__4/RPTW$M(RUD,O>RN+]'M//D(M940%@#,7'HT
M-B=+[DA_(;.!Q\<:Q>PYC)-=/#VZB82?S-1R$B<Q%^+QB0;!G+0)8GIF]"A<
M&)ICB-"XX><V%FE-I6)FP[W![,0RHN%!.K5>DQ8[-VCQ^PF+8PYI2XFYY&/4
M7JJW(M]&:!CFSQYMEU.P=^JUO8D9A^9QY+OH*K6\F1WH/EN'@.(,'I3-320M
MID-AQLP,V='*SI.6P>USC?QN7JY9]-JZC'B1/),Y ^LAK50D\T/Y/2'2#%3/
MJ,$OKUX)E(<T$'I_[(*$];1>H9@@&-=$O=K0:#E-(-]!!\5<%LD<>T<TJCX$
MXW%G7+WF3G_OR+1IN<1BS4[$YSZ]KY;<$[08/GS<^*FG>2OUB?HK8N]IV6Z8
M-98*OQ"#HTX@Y"!JP<?1Q9KL"35"Q+R$-:8)O=C#;XU2V-7YF1HI\OBA(\W>
M.V#R)=)LAD7&'HB=^I#A 4(_7C$MNFPIR;[\V2$=Y5%/X?'DLCY?8+I)0D8-
M"-L0;YB]#7&14C]4RJ;:+:H#8.%V10YJ! >2YB"Z4C$YS3%80M&EB!4$7ZBB
MG-A@B;B7TS2$?0>&3==%!%EJ6'QB78@L.5)?]>C&H?PAX^L5_/M;XZSL37.D
M6]R>#!-.Q5,S>4L0,SA/0D -3N/AV\">CSBM4-S$IY3RH:_^)E&M7)X6(+A:
MBWN1W4A)?CS(T8\:='2@%9.3(R8YFB@ '4L36QC59=YD:5WT)]=Q3 >G7?.I
MOEV+LR8>_4WVYA_SV?MVVX,X]\, ,/>J^V( >+WLO+H_X+_FZW@<N8(X6BYW
M1S@22CQI!@-$*#!83]:(RHK5E*Q(AN0-TX04RVJ[F*B"H7.W]9H-;\3\85EV
M5L\O?K?IDK9FV7E'YY 2>F#Y$HDE8>1<,.L^W4/"%U!,Z=<DQ'C40,J?0^?6
MDV='*1QJ.7K59+'B#X%O9[6*)#9@ZV-X=[9XW+#G@*=-KV%EM+C9S[,KMZU<
M+1$9JI1E>,YL= P^OV56BHAA!%/$E741E,9IR_.,*#%YP3!_#AIB)^ F&YK.
M[XX<.SGPJM^Q\OT$5?<3W:Y^P]"/%D6J),93L\[?M.AL+G5^N::#Y][7W^XD
M%&@X"B0A8Q?DJ]#YR T1/QXT(H<2+W#F\M8R7 Q#7@FUT!B84A.D!U>F7-M;
MG;&K[6@KPZYD9*/_O<_^7<6JTZ[)J_O6GNMZHEKE>WTJ\V+$28"4EGO^=#NJ
M!'(F_B<A=GB5Z\-O;Y+RUKZK\7$K.K9XQK<=^L.()3;GXEL.1.'VBEMO+6+.
MH3\N-K.RXJSKNQ&\Y+H\CO#RW'/# XKRG*,]=A73E;**\(Q@SGX9LV]8"5 ;
MO&KEM. 6CUZY9?C8%DY984M34XOF#\LU6]XJ@2=_[))NDA$/8*_?P#\S.A6%
M3V1*P*O6ISZ&&#XZC)\Q^GQ+86G1Z^;FUPY_\*O(96O!@>_=2F#F;TI >AT\
MOE\)M'SB2D_/4 *]-S!_*VI0\L+8I^.L0TJ &$TJQ#+;2<(8)4#. !&#TTJ@
M,5P>&#OGVS4ED'2%K]A+QJPX C[L,(*EY2F!.KX2J+^FV$42_F8?V$N0TRM_
MC<'O-23_F I7 A<V*@'T#WZ3P]@4_\?/:/R 'QD]PZ[LQR_ABQ!3.Z@$X%ZR
M9"=_^#/X%>].NA*L&^=.;\3IENZD$GC_&BL@_W-?ZT'XC0^O])A/0/&Q8TM\
M7.I4K^X&@!WNRVX#,Y9!:N!-6M\X;NDX;NDC$!F+:1E]$D,7EDV-BDJB(]\P
M2>A\59/B. VR;O5ZC<5OG%1U-1;'S=-8^OR4$G"F%/UVZL\6)(G7/OSG+M<U
M/4K@ 2.G_8-7=M!N</+JP6KT=O7'IU]>_@Q\>"98Z.GRY['Y<]519Y;'R+.W
MZ_1ZE4#) V;+B*W8K?</L/C4P.>!KU^^LFU+WG*CL#^O>_OA\NXL'H(;"_V@
M(45'=EML9VW*RCN'_C?W"/* QYU:42_(06J>6.V,HY0)O=0)5J_E)E69EHMI
MB4]KU.NHND/&_/BH$@=OG".>#WG>89-ZG!'^\,/'CZ$\_9M2WS81.^AY>V^@
MZVN5@VXC^]K^<E*['E^C>DEG\.P=@M0;F\V2ZD!RV66D%&IH:=!EOB<_Y<21
MM!F^T%0=.UT):(-'E( ^]H9:7CAJ#16^(CXI'+UUY,Z@J17R0O3)I+;J9-I9
MB85=;9=0@^$.90CZC=XSEP?2I2)CQMFG1F\J[9P_D$69PK)&5,_AE5 ?3ZD2
MCAI#'8YV0D#(2,)GV^!F,2S9->UH*%10](A!@.Q&3:"F74@W;"D@:U]SJ82[
MT67G=I>+^<G&G&3,C*!#3#9FIY=]BJEO':[*2.9:E.-A.?RUR;UUHB_;_P>E
M?4)N\A+<P_;M7O=PK&3L452V[Z(UGN_O=DP>$&_/\.HXW&H3071-F8:_5K%W
MMI4UVRXW]#6\['SW3R6 A^T5@A(PP/L;V]U2BO'%W?UK'HU,X_2;>A8MPX%B
M,1A!0,P+7P6&8W/88@J+JE-M(;9,-.24V]6W]!X1@PF.RT6T%*.KPYQ2N]J6
M'CW17)X5<D.<O8*H]BD\QR(1CW$<*:]YK0?#Z=)ZS+S-MNE)R*-P_WP[^T+\
M"FKV\L/8B#F>0NQ%6 =>=.-IO/F,.7#+6*JXY0*>*I718]?@IE>@MJ%@&Q*N
M'N=(>,"P;^7-HQ]3 K557>5PN+3A!I0;NQ14'>I=2])$J!!U;R=?O!:FI 1(
MUAKEF#S'GEO/Q\BTR8M*8*/BW/M=(3@0KM+ /%TX(0I0P*U>]X([@BV*_4I,
M,/*DSJ73CT\G=!7GIQ%V&!\KC#U]*N;L_2&!9[FAW51TQLX,.S^_FW$F65E9
M%P\\,K_I7N!SY<.\N*R7Y&K^U'LE8!RU)$'?:^O<_U":<*?L_RODRQH1!UEM
MB>9)9?@93\TE+0JC"&J,7PT9VD?]Z=8XA@/;44H]9WI=+Z_X OBY4B24KWZ&
MAY<O8OV%/H+MR%F/GT8E*X%.W[5*P&$VN<L=DX.#KK<HUQ1'.>.5V,70&UA7
M8_ @WPS=C%>!/]5BND=+E( Y66ZG!'J8B*42*+:LG125CU.?5J*WE<"H4 D$
MRT5\["%?L_M&#BY V9MQ,/?%T^[^#78(B_SY[E_@Z.D;>$A&J2BLC?X9-/XE
M?B!TL*JUYYSE7[B-L_2]7(!?VRFACNV:,>*KH(V=97V)91V1? TDR^MQE4M:
M?Z^LT9E?59ZMN^_JBN,GEZ;['#"C?[@_[U)^$383Q]LX'AZ(.R[M>:)XP#A\
MX,Z%#WAH64#\F_0K>(3^Q?IX-5P^@.!6+1-(+!5).1N40 ?-F_O]1ZK"DZ^(
M"0 'DT;DIP=9@H.;Z^:O<[@9*_BY(GKMNC6L(XDW:==%UJL.Y?G>/+7Z07R#
M>*1J=7&A9\>^G_L^;3I-O1& T(98]0L]!'\^4F43X'G15QH-W)),5V]V#4]O
MRDN.#+DF-P_\;:35)] RU,L[2O^V@?O]GMU^BI5X@O+ FAW@X+ C[KB+E3AO
MPWX;_-NC(S_"4K#7>-DZ)1Y0:!\TPC]5N'Q1 GM,=V!K\)ULB9O"" U5 LFD
M*"70S*-RSC"O*@&!D"S*)T]$F>+6U@:(026P/A+\FX-1/\M=B/ \1T<ED*L9
MAQ<RP[^J^<,JK]71[>.ZY$&^E(*Z_^!B$=]1>>E$&HZ'7 ZT5V=A/K.3M$'M
MT*V.?W)UXH[LZ[]<_>'"V A5V'V!-FY+4:.[[>TP#R]6.-=BIKR7SZ-<8E)?
MO#1](_EZ9G^GF6_FV:-7;MIL5TMR\7E%_%)C/EVD!$;Z\83:[DX=7@5U8^X#
M%\!13XB+_6DSC-E.!_W>/>]W3._\E\L0YG[5PX":U+7B@*OW^::@Y5Z%5^0&
M@:+'$XN"/7KWR<(*K5AE]Z4GSU+E 8/1^/34T7.V''2J6]!/?WQ]4Y38EY9Y
MI'1Y8E3([=6/XAK\'MZO>I!MZ]7N=?HSR_:GSXNPE;G\9,*W)5=C6S$4G-X0
MCFX 17<XWYF<B@%%MG ,![OBC(8;V,#>?[?!]1D8'I;0]I:?V]FH7A[6K"YB
M8W=E/M-IU SRWQW>JJ;O.ZORWG 5N^==EL1#"1"25/M_?_JXE<;KYC=]?\OI
MG8Z"V7]]D)/>'19^K<SBAT4 PES^U19D)8@:5,JZ%#?Y)RPOX?IJ(2)X91<T
M%UK>&'^X-02O2Q8F>[L^X='!ZC> MPSR7I;SVDN^S0FS;Y:\:NUQ>OK!V62-
MO0T;IJ+D%]@<$YQ(N-524)MS.'RO&YDF+YNV0&YP/O>XQERH^_U-3<B!8RH;
M:Q[\S+'*CDIX^WO9J>L&Q]W6%LWWV5=<O^]BV.X-MX]>_YRQ >W)B5W-6"\>
M';'[Z]3$LUO2I[O:B=>EB^86:^Z-KP_^4/7,T3EO[X'KR^UWERRH.GU]\9=Y
M!S8UC+G)"W/Y"6P$C$;U[;!$]D4.<GQB' MLQ?V!(VM<(LZG6B&<QFF99BN!
MIJI)LL2+L4\)W,G1&U("UB=H&8J=#.''EC68N7HM]>>/>A )J?T)=K2W0).5
M4Q074),(8>/(2II"BSB;#+4."=$7>1CQ$X[@6DK@;I[8'#/>XJ $,B+!NEP$
MCTDG1_-V[-@'H>7T]9_\YRQT-^$B_\= "CZU+0G?E4!1(4<\0ON6PYN-7URN
M$GA#(H=SY$N9.-RVGNF4DB$/0J^9M'#LEMS"#;XF:61'K$7W"W4=3XF="1<=
M%XC3B#NPM]#(D =.ZX^^+.W\*O>.?7K$L79PV:W )VZE^*[4;G2*!H^(J>G8
M/(83DBQ=Y6@ FP@R^@WAM>>6L^,F2@(GLEU\3KIRBHB:@8J4$0W'%^S2YL<_
MOER=1=8KO%#RRG2)>/V!B:(WW-FG?%7DOOO5U[IL?/KP3<)![]JJ*W=7]W]9
M)5]WO.WT&4_7::;4,78>&9HR2OO+Q\4M!:$N4MQ\TIIN&OKU;%38?I_D/3>.
MMTT-"WHWO<F->W&PJU0)V*SZYZ)"[=-1 O'1Y$.U[CA\"657/N/S9#8>AQ>D
M3];Y.%:=40*'6J87X062B%HR])3 NS?\]SX3Y="M9=RZWC7@7YD92L".,Q""
M[E1/I38+B B]Y!]01_LFYR</KY$?^OM.V B+)EN(3Q\^)@Y(4S5D=/0^CHCE
M4!;V@(9:[U4"7V&P[@Z]7)AH#[Z5<#,46_')Y-1-_GVY4^!UM<X!?#R@F*<$
MRMB8T:_9'0@.),>!H@OD)X4");  <6[,,84;Q^;R%D-N*8PMTD5J7#1<E-5D
MT%5M^?! >*9W$,Z_:RM2Q\ZD@H=.GHRH_H"U E>)&^R^+=Q<V%99^S#HP)]B
MO!(\S.G6NU O'CI]=$)*# T@[+V]^=[DP/$?[H$]/8$].>E>$SOA +6L8'IO
M2^++=+WU-8<??#\V&4P.8=6U%ML:3!J<_:/!?4UQ>=60G/&2(&_!W5!N_\Q)
M#.JS?]Z?'M\+?E81O1O84KU%"71/OO[*YU"0-5Q4/T#V1,$BV:$VR%DHIH&G
M__(](P#*P_0"=U,6H([O;4N<;$%D5]28ZKV2YDN9-EX'3"PV]E2S*JXZD;/,
M<WSJ0E&U5[<)MQ%6W7[F@K]"XA*/) LD3VR^_.E7Q!*LIMOO+@\**[M_>$6^
M*#-N7^;UAUGI ],ZC8Q35Y$H03F2E626=C,@@9L@\-D_1Q^>SPE->7"_[=2]
MO2\UGOTH?ZO(#8T,F4C[/\_6*'D&NM,RA3.A5QM+_AJ1]BLS*5GR6PCEWTK8
M%,R0+%8(H3W":6.2+BC.:^?_C';[&P3$RW*R"^R-Q=$IA6CS$QYU<M4/\#0!
MN4V<#0ZTX-Q;S-'$@]2;0A9T"3]M,4#7@@(Y7W27/V'S:WU/X%8(?O_&_YTO
M2A=6",<VR*,_8._]R O04W<^O(9JI\1I?)9;'$--_$DKF&+4BWR-V#<,TCQ/
M?'QJQXJ$0[_$_KE-ZQW.W9HI:[[0NP='&C^J"PZP#4)N(,RSQ_9#X7H+YQU*
MX:;0%J77?IF(O;'Z5JS&S@^7 NU(88^_%!0N;UZ6BW'C2%<P4UP@Z@5_7'7%
M6Z+Q]59F@Z-U8_ S!LE@K:&ZSI^^LAN'V"6;,*FFC_/-Z\\?_.'RO> +L9>6
M(OR^B[14"7Q(EA(5KI/V2L!R$[^C#X^D\DHL*9W?/A4 S7HAT3+Q?5].3.I?
MNM&XZQ:8+]2PH<YRV5#:4;+BZ7/M-XQ-V+Z"V9^_?_[01YSK<WXUN, /T^I1
M)+9Z&37@Z96T;[N+>F/_;/.PE3ZOR7.?;U(Q_QG)+9G>3.?7FAH=HE=DZ(-A
MIP?V7\HLT)0[J"WT__*J_6T>M6_SX94Q=@R?==NO/\^P[?W2_9EYE3GO%)CR
M+%VWJ'9\C=?KHA#M!O"XU/PBX\/0ET?LIUYW [(#-'V:>4'4Z)A/H-Z$GPQ/
M9.TQ3,"9<,#:R$C0+R&3?0.G0\)1G-0Z\\?,E$#">!SXL\=OHA+UY%X43GJ#
MXG\"J2:<*ZTTM8@6IW-^;"K^A5(DVK<0>(L+>(+\-QUX_?U(&WEZ8*>G$D@,
MHZ+]Q+_K</._SXQ03QIB%RXS"3Y*,\':E@<>,#$E03L< G?>)B*^!Q?JL9F-
M]YCM]/ :?W[B6)FGO>6B\(SIW:S0(X6"0V?S$2^UYIN<T$79U49VOOX&]]X?
MT?>ZM:+RZNP%W:M]W/VQX].NR,M:TDHQLC-#4PF$G3[:6?I<"I;][E6[[B##
MZAY+MFY3"M8J5 _(MC7U^>O;SS+L[K0MXE"/&?A*AF_O^5ZY</BFQUPCV1DK
M>F7SA9O!J[%.#X+;E>6I^7>Z[:R_]EV?6(W3K9OLX;O_]71KR2 S\6:*81KI
M%:C)@?SX/7)I=QI?E$LL<TMFF$!DJ5$JPZXH$-UL3TMB;(#XC4&+WY?/"(>N
MO;KIMT*PO\U&L]D>"@@*^.B_.^)1L/8GIRW5"<=2ME.;:4@PN9>%I97*SN/Y
M;P%;*X%;YY3 KJ=W;J/"^/7$RXM]?1K*<WO#JLXD1!6'RGJ[N!'W^X?L71KR
M5.USBD+RRE.&I\Y%7;Q6\FGRT?7>G$Q;A]3]QU@4^X3+U71F-^TK& 0)VX2;
MQ.],_Z*?RY@5_.S! 4//&Y\G8%OK@S[V?R8%_[F6-,=V8/<F=U>]8F/3MCV7
M\G._'.WU(Z<C68,7KL"6.@.H2\"E'P<M#LKMFZTSGX6=#=*]Y^CXPS'JQ(G!
M;7_4-7@G& 7MDVY>^=QUM>>*";S*<_[.)K(89_UAQ.F-+;TJ2F!N95T+%CRB
ML-KAE4-ER_+)-PDDY)W#>P,*'N"I.\BW#,; NL$0<&+;%RI"K\=)&9$K_DKG
MP,L^X@K5I0L'J,1+1AD*%]Q7 >"M2M2*,^:L!%Q[Y%M!\4WDEA)X^Y((O0'+
M"0J3D+$9>.L 28@2L)K$;FTZ*!T88;\T[^XN5/\J?R[=++F^.F=,"<1N4LQN
M^=E,A.T7"!7:S_TPTPU,ZJ3Z"'*6A;K;$7".%G4;AWXU/-N\@OA=PC00VL91
M0;K%4Z/61BPT1C1N@!"#B M(YM1%A ;2PBZ&Y4/--<]M],+/*C(>]>RGQE[]
M;)85PS%[G77DY\D^$^+3CO-'TD%=RK"[33F:48^Z>*?2\[9(PC[L_^W!P*V<
M-59%%^_M]2D2#Z3<'[;?4[RIUL=LUNB]E2Z\(F(W@RBX_LPMT6K=@KO)16GW
MKGQY=J(J9W7)IK:BI'3CS(('[VXO7UF[=^>W#=?<1VM35G)ODR[_\SH!@G.-
M>+82^#S,FP7V5',4!W@6W-%,?AH'V82KR-W%HA!%%JXB.[,DO5C:]!KPM?@-
M?]0+U^_#JBU?A?= ]%:U%&NX98X5MI&S>_&<["A%[_YC71C#"9*HE_A3E8GK
M:ID>@GNM0 FD=*+Y?I,T)3#K/2[\S&2-2N QYQ6HL$-]N37,:]3OP70!>A O
MS26^KN#66"/P\Q04K8B1D!7!/ZY-7\E-68/>)7<#N2DK_^4VX[]!='EMU0*K
M/H[]I#0K^@EDEC^V"J3QM8\+\8@6Y0OU^6'CNL-\=5Q:J:#K8260AGH^#,5,
M%?G8,B9>ERO]1J]$B:CJS,;,[4(UINZ!P#*F-IR0DQ7]8#_#%7&'N+46=_AC
M^J3UJ _$3E)/6MYY<U@)R ]R.8Y'Y"N9S1QMG@VB*4N!*VL(B<R5B!BJQ:LB
M!2+6*6@UTX9Y4H)67YCN4#OG2;B1KU6@[;OLC;=4J]3&!,TQX@S.7M*B9^WS
MGCQ0/%:!K&5WGSY3X',3,MXW1RZAU''C>#,Z2(N50,U!S !K)AR1[V)LA1O/
M\[3#.+AUP=1+_:JE$/656A?#P/!NT>!E1E"6H'\#+/W0ZR&NA--?PE1J&Y?A
M><\"2^D*DBL!U53D G1-=/*E/!Q[$YVCI;A.TF^&-&47$:+88SR-7$I+0JEW
MF2U$T^I3<B?4L:V<H$ZW$YSAS.<M9[AWE]'2374#MCC4D-8CM".P4;W%NGLE
M]+T1AC;\[GOMWI,Y[3)?9!=OL>+NNJALE5TP"X>:T&:W6FPY\@0"&WH)+,<#
M$#\0KH@79UO6^'-3/T,-E?G] 9ZQ4LIL)."5?4AJ9!\<DTO]A!BY=H\]M+#%
MF8HV-:R/:?KK5MDQM@9"$) U&:OD6QC:4*. K(;T;45NB'!AS%R$^(@"":\P
M R19''BLO2YH 3S 8JRZ-^B;:<B66A*0N-JFP-9JKT-'9E46C!C>[+UQ;\+O
MLHL5 )H)2\?3JMURT3\04/X;(QJA090&\J(H-K(&9/.#N4GG&J[(=S*"H"E4
M7],-9J7PCPN-42)DQ"JCJ(0:56":'-DAA I=\X*B*O+D9B-56\99U7X0U8F/
M(-,YG/M!_KO)^> 'H\!.'(BUF;A-,X^^["BGJF'-8 4U&9T!/9V>/F!IUNZH
M IN)&FO(O3N%KWRK+HXM^_&!80U;-@CUZ-8"F97#HPNB,8?:_D47$A[=4#VE
MV"\L+1Q%A4;L,57F+-24;+J;H[C*W(B+EB>0._)"<4V![T=RD0/FSB0K[)V]
ME_VA4N.6:XH<9IU^P.'5+!'E58LF0PVJX-\];E15\/(ATB=13V>N96R'.4FS
M.$I@ME$ZR0QU[5[1S?"4;*'*5S?M;K^S0["?'BVH\DF[;0PFH@O$>-U J+LO
MA4XO?[+8M/M?/]! ;6A!%X*X0O.!K+'FSSA<-<,1X-%.- */ZL8WS7(?QMS>
MAZ#4=(=(KP5=*S2$7W$'A;F5:,["8JQ^P3AV9Q<6,>TW(NH_19LV/LJ9YNS"
MS@P6_OP#;,$5'R\ 7?D=[S0'QS%&)>(WG1'U":1"(^/D-R:DEG\LH]/?K,(.
M<GXT*X%Q/(3F.#XG#V0I :$%IA\83>U&[>6U_VO=W8I?#"(;69@3L8*LN(CA
M^37$EY2#JYC_XFRL!!3UV@:WD4_$OG&-(I]'_C+;]!@IR>%ECT#4_'8JK$87
M4,L%_.F.S[3O'=CYZ76%2D"''U\&_EJY_ 6<E_]' >>_NS'J88%L@R*#'$K6
M"26M188@CU>X!&&XW3W.A]*'C!M3UJY[Q#UA0ZG\.!SO67E5LR\XP.M^4&"@
MZM'#RW.VF6BE3)_A,17%U:?@+''A:"L\("&,CD'#?9*!1JH:NAP>2.;IH-;5
MX>RGR(#$,$W<-S(^!SE)CUCWT-+R2,?D_@AQA%73GO;QJ"";%UNV-0Q_-[G_
MXBG:8O5FPX:&+P<2[=8V;+.^N.$L<S5/4V_^OH/E2XR1L.O#]]^11B7W0BV6
M96XJG5NYKOEQ6\W79W,-0^)OW]U\Z/1<B[G'C+T+?M[=O*?.NVCGWHOEEVX'
MI';:,'XH@7GX9,6=R>$\I=2:]6%.QFPJY>><7X];X9 <%PVVYJ.XDJIQS5,"
M3?[H*05.-1\%V;5A.LQ/0>;(+?D.7!<*=7@:3E*R+K)&!B)-<ENZ4+95<<]Q
M@^03*)U+GLU;0 ?]H3.5EC*+\1J"-C)0SU2#TC[+9H-28CQIZ<N7$#]Y4@GH
MNH-YJ9958 38"\J^*K)(OQXS<ZR>G=>'6E 3^ ;D<&Z/F>P,(H5KX8B3U2$P
MJXYH((51CHZC+30@UC\7VW4#RJK-/&HZTVB:=6ER7'^$M)2#Z998"K!Y;:)8
MDP/P+B7@A/%AH<*P.@#7Q[_$97,.E7.&H02FXU_Q)UP@#F;VW$T);/C)C.V9
MM$3ML[#9N&QWO0;]NEEBC%,5B^-X?GF#-0[\P3:F#BC*PR72EQ(&3E+4'."0
ML9=01"3!E/E.6$&]R% I8AR"*P6$GA^R2$5F%+G'L@;4X_(68^^IVOG53]M$
MG<S5(WP]E!R3BUAUM34%(%=@HI^I\3-3%21 Q)X?[A];\/S^ ?_0*3S1T3!D
MBCAZ2VY36,=./<="U[:8TD$GB!S_L(RM'KJQ?V$7SX%Q!CZ:28YW-!'16/U&
M-Z>\XMVZ>>L9NSH>1K*UAO2H_:&8,>N 769#?I4IZT'89<Z($EB$T\GP>CYR
M98"(]GSY.74(NP-9*G08>(8E?<.->\O$'726\'>N"!^D72 _K1S](;=RD]!Y
M,QDK(';M!_3XM&/.*NJ<GH_^6A$3JAW77,-QO1P8N&#>[2I>@47%=0W+D+\.
M]Q O<4HS4'T]644[_PBY]X?LLN(NZ@&--.18*/ 11+E*P)AIA!YN18U$<D^S
M6F^LF3_7,4+$U4#=WC,(CM;[AX?.0HW;8#"Y.D)$FX]<X$YRC?$R,*,PE+1Z
M!4%7&+@?%[,[^C)(GV,6ZJK,H\Q=W_1:E.YY2HKP4ZUW61R<%U*'.O\I"O\>
M<\*4;/_V"=V__TW^ZG;9,X;KBGNK<]Z5V$<=:E%_O5?G=L3*@C._T=T2K*I]
MUIXY(%BX)>/(\=/RA<?45S0]_O-!4-OMHGVR_2GSPZ)"Y3N]LS=_;S[M?5N\
MIF&O9X>7"V-H8LG_H(?=[E^"5UWQWSYKV8_E:N>_2W]"WX^R+4R:8A_)?>(V
M[-U6 2S/O1\P7!7Q,<?ST=TCIU<M^"ZJKLC<!30Z++W1-]]W<Z.+^9U-S]J6
M6JU9[WLE9?&6P%J;!.VH:)V\YRY-JJY_;"S6!J97+W%<<>3$\DL?-;J.:$19
M)07>TO4VC4ZZU=IZ=,V7TN+%A]]L/6>_0]-LS?EW%XMGS9 >3L^/^_VOX3?#
MS.#??,XO/@\,_^NG/'Z EXB:C,UPI1A,Q_3H%5/U_B$LYF)ZB#?44%R$$.O[
M%T-&ER)?Q.Y4,1YF&L$9";0RH38]/*B]0"=HZ!POXZQ6<_9GG<VZ]5]K+/.]
MMA)913@O//JX"HF6>_0A4[)LA \W2?WJP3EH,,2JX2:#AD8U%=-^-1;F$LL&
MZFSL_?2)QW0[<7<\0^\NPJ9V\FQ0*\1;2DG)6<Y_>G6@?B_=5. )O63'1YX]
M:=/$WJ.XC\].#GF^$CBYQ4U$KK-,(E?8-8(]%5-BNU22-LJ 6EZ-7PR:K_@3
MC1!1$JEE;$&VB5\B>?Y@_T8D&7*KPZSAV[[^K.3R$?JHHUOQ)[JS3]G&2BMD
M=]M6"Y'BC]SS)%/8;M2'!FM*S$?-8&\)JX&?S-%V#)5K#?.U'?V.@ ]".?,F
M8BS3>&1< -1DAXA>MJ0S5Q[/,8+24W-#>]^Q\NEL:G>9"8V5&7W1)LLB9E^6
MH?HNG\?&.-8>$L;SRUPK89)0=K><6#90:[DHG#BGVD-,[)F2TEB,!1+A1>HL
M1S^H24!:";WM7X4$YW,(O2,;,Z?2Q'#@Y%0*MUP1$A!5E;)I8DE^3_/9B%.R
M8/T9R.D"L&8^:39CEB(;9\GLGBS9?J@B64S69'[BE^TC+5/<8;ALX296;R"?
M!T->4NOCZ[#5"$440]1"F)\F.5KT\!I?;!7B!85LY>L>I/N/2!(&DB;3@D9V
MMUF6?%,"I_0C]I *T^.77<Z[4'MII>AW=?WAE?^:=OSW40^-#XW++ERFO]NM
ML4EZ[5H-L6Z>0[>(6FO9TRUJ25<"X7Q@2 D\;;P0Q<6K@B*G.E#NU(=](E:P
MZS2;%-%[%26.@;!Y+5&;H26A]ICXPCY?RLO98^MMJ$E!:ROAJ?KFD_)=+W%6
MKN>#>(F)\3S59V7PI7XSJ/&"$HA=X%SD^VZ^]N\[-I$NY5MQMFDL_JYA9@N%
MU+"1%>31S7)'I+M6J,W41%5;2:;TK!H__Y+QA ((5\W8,K?\P0S[S\9EQM4W
M@XRJX1)APKXP8E]5??W;/XY?=5DNRXNZ/VI\L6#X/(FLB%<"1X0]N$B7O5+@
M*'Z"D "6<FLX\:9ZB)V$NY#9P"E-O 65BD,N8HMJ0**@21Y!E-U!FAY6)MK(
MEW<SW*66ES;:\VNH6I28@<)$$I%A7 42LNR0+*D:#^;V&=68&B("F(+-&9%P
M+_6>?=D-'J5]2!634\%@H;8P[%QBQGU4]:I<3!Q3A\.FI.S:YKV]W_]"5!JK
M"NN%,TMR[L+J.PVG1V7"V39;YHWX9KFV<W90/[ 7TJ-EORNRR<?XE\*EB\P%
M5 +Y&,Z#Z!Y23ATW]?V?D_,96T+$'.- >KN$UDC4"?/J\=A8;$9G[8'-+Z'N
M);B$=:!^&C8N%[?G!22++C+5L'HBM(^(+*6AAD19(M0]*A>3+Y"6Q4LJ:X2L
M)Z'"V27\XP26/X4UP4]2 II,DY%SKD41HF;3$2<D7O*GXVGQN"8U=-HM[2%O
M/B.@(K/?JC)H>7ND2<GNECJKOO,QZW#J),N J/6T1'Z%_Q!'\RA2 U?]$(]U
M"UJT@X3(!:8E_9K$KX'V(>L5.&,M.9AH1#>U5-OOOQ][1Y[#M*"##9P*)9!N
M:T)-,O*=)G'$1)W7AZ"OPKJN3'[R-[XS691#)6)ST*U(5 &Z&*'D,WS;2S B
M:H<+_323>K*131IA5Q=I"VJ/\"6$I"O'P;)^-BE5PM9M.5N(1L #%YC+D>(]
M[/K?Z93&]<.55F'^.*N<<+"(=K;CA(^ \Q@&$LN%"%&RKC(WVZU>J#7&.! A
MRG:52/>%TPC\M-&)3W9UY](*KE=JYO$JS^8/I>8%C%1N] XW#DJ[/S+MFA$3
M4HAD4"L[Z)1X:JE?#;D'&ZB+YLRN-G9<8YD2419AA39QD<*@=(& MY 'KR@2
M<]7HAXGZX?YU07.16'$:I8&TKH-A"4W5NN<BEH+H'//NPM9(!\..;]'G8^KU
M:]:&Y"<QTPM_&L<".$F4;T,CNC#-XR0=F@9C,1(/\QOY.HR(4!%!%3%YY15Z
M9GUV$(V L.K]L,5P=UJU2]01,241 WZ]65!M\9 ZPEP/+Q=>G^+WF,Z'L&P)
M83[]FH!'[,"6=("BHG._OZ]>E4</EX4C)1(VNS>CD9Q*+54":<P9W#1, _'V
M1DY+E,"%_MGMC%B8$-2%F=.%$B,63S\L2(TRCYXGEMT5L[5#2>97Q^LT86*M
MK^[Q:=^JZ7>I^?+*,;F4TXNS(Z)&I(6U;#WB*2$F@;J.IZ0OB;7,53 K<07B
M=%9"N""<^^U$^1JA$>H'<>-X&QDNR!$1-=F4_-C#@TQ@;(%828X4]<3#L._+
M(Q+N_-YPD@'TKE!<$B-B$YC-S$6M#!VYO4<Q6+.\.A!.?26<9\D_+B<8#Y++
M.)? 8Y8I2J#\ Y(%IU, ^HLZ<AGI3A1N'\\<T8-/"F47X"WLE(>D#2/]BY%K
MN0P/W&U)OT&=4PFH&4VD05MK(R)T%U-260*A"@W;R*!!-PNAU=VU/%78J(Z8
M'#0?WETJYA@,D^=-D&</51542HPZ)SFLS,+D:MOB;&OGML+.X Q!9D&1ZN4;
MB497AX*6(U9D9#7IBKA%G<ZOY^.U^I@PC3KK,[$TIU#N@QI#4TE<S'1DNJ6!
M>K&7R1=Q9K<4;F6LD<12=B-G86=7V++>,L$X.A6=+0WO"Z#-[4-W0E_S&9X/
M C[0RQEV:5"C+!#I)J!Z-_B_L8GTH''G#LP::R:6CY\O)Q@?H(_O@@LO\(]E
M$5/.<5,.(6L@<Z].VT5A+8TYFU+%A8*6E$R:@#N/'E\S;5@D%N2C^ITN_7EY
MO<-!VBR_NU"3B-5 [@V0#-2TZ& =G-*5R %H0,0?M85C9(>15#%Q(=(DKDR?
MH*6!VN3C:2&BU:C34^A8%C12QUP6]T/$373< NDZ'Y'03)Q$;%WD 4@<VA-
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MFB8W(!$/WI'=!WS=A* AQ[ B.R.]-A;'UJ(R8FO45,4<X2V\3V0LA&5J?FZ
MI&3-H$'@J99/"?9H&/8ZI_#<.TV%8O+:2SV52U\)(C6[61[JB72K54B(9J3#
M>T04[3P6X_WS?47SK_C79 MH_"*ZD4GJ$=IVNL#U(G0'Z%CB:^W9&X>'N-GI
M,<&I(O8&<*PMWJ'J#NT&X6'=\^"RVKM)AP^*4N//TC^_$FE?\-OH%RA5>!I+
M8>42ON*Y&J\_#N+[B*V4J0S54_Z;&8UC#^,35*%<*/S6H/#44L3XO#C_(;9_
MDFT2!FCN?8"<V\=;TA*<VA5G"W[3EUW#.@CB"X*B0*$HNDY<3.V+DJHH^3>L
M6R^[H?VF6QB_^@H.USB>%ZIN"1_Y7R)O8EG)@%-* C->O>%FM8ZWN/EA?1@Q
MVT%T>.BS_H86*Y(-C>T&+;ZB(3HF7(J$) 6"8 W>AI8YDX-0-+$G0H9:8DR4
M?>U/?L"_=OI *1"ZHC8(_J9: #@(.&HECEBHM&/Y@_%J\9A;>UF/K)=C+SCA
M4$6ZC%C745<1G@6%:JA33]_Y>@:.%(;<C^MIS[IU51G)8) >#/\J;"V?FE Q
M%*W&4/AOT$>SXMK]I$S_0I1 *X\^-D8XEQ<4I38X,P^_A85J99' ,>,4/^.$
MEK*8:0@%9_(1CXSDJWL<VNX>K0E-6=X4\V+!.)$H5/V,@0=%*D_M:\>RF9#+
M:R&)*#F5F\$[[9&M!6E99Q@V^\:<.H9]@SW%L_LJ-%9Z8LB@;X?CH4[PKZ=5
MM%>)F=>F'U>G9:6&#<0->J73R3$E,;&84[LQON7'VJ)6YF"TP5%_%FS"^M#[
MTE^<.2P:I7S#L'\CTGC9]1 \VL&H_)9[VB=@_[%$Q;9<36%@!?' 8,OUM%'R
MV%\.9]JV_1D/E CM@'A#02AJG0_+/AE;#'=H20J)L=94.<5)X"E6B*) 7MXT
MJ83X*2>14S3F"3KF=:X=8Q9V*T[GTOD5C-W-S3+$N1I.&A$-U?6P+4!&+N)'
M.TZO2]A;;P3T $2CF'["B. CWB=H,"L<Q$OT'/69^?V"+O@YF"2CPH%S 4@Z
MC)#(F^!<8S5,TD9:=@V7<1:S%FD+B_V/# 4%J@PVDP[%_ T5=S6_;VS@TQ5&
MZ>\X4Q=8SA78:I6+WE%M$6N-P1I^WD78^(H>=%#-=X*CHF5(J)IA Y]&7R0Y
M!!AS&R8<'3-//[@3)]\Z&DU]<TQ*3UF MR_R%*7S1\*-1\#Q'LXEJDNZLH1L
M(2.O1%\IE"*B-;("2A^JW:I #@^C6Y.<3MT$1W:#&RJ]]K5H LTX^\CZHZ,Q
M(Q.SW_-/U)CX<8/8+&D.#CPP0&>'8.,4A*R N2#'N$7X&@M]_T%TN9QUP'1;
MF,0M%JX0QO-L)<?C'R 6L#LTK.44D]<@/G#(@PDGK\$QKOIES$ZP0;@2?:"F
M;_I3!796-<0F;,TC39'6%/[G)KIL1L67VZG"<\RX[ZD85F*U20NBA7V<"TH;
MH:JR;&S!(-N5_5S9W"IIA5/F7!$+4SWK,RVP,B' O1=8ANG9"^J*A5F.HC'+
MH6F&+7P&;Z= ]D.U9:6W8W0.G6MS.,MCMEOJ.7KK>5%E*C+C3I*<X%2U4K]T
M;B?30IU1A$36U.73?0&,=I0>2T!M2P^5?EG8A_H]>?VQXVN)6GG^[M":]OXJ
M2,E]+_!1+VUQ#AS9V%+WI*E]-[NKI?UQQ^.+'W[7.-='W/ONR>.VQV4[].^]
MQHM/YC#=\RL]JFZX[UE;YI_P1_&UUS\=L4-:V6]G/C!Y$L"%'83^II#HVX[3
MYX^OFHH0 !1)B-8? =C=LA=?<)C8["H5Y<*#H*X+6"%PU@H)B9VN \(3^$*J
MG+T=VL;3Z R*=>I)EA=CH4Z1(3X7NS5KUV]FW'[NC-3H"H=I*>>)#W.GKH&>
MFF D@"<F7@*:*%W2;/9V84M'0$6%M)"U8/ZTW$K(3IZTK]Z[YKOVQ^49UF55
MVWV4T6'6 U,?7KSO(GY]%;?^HX7[.\]Q9ZG"8$R0-6/:P.?@ .H+6^UM,EWY
M\RJ@V!<9<P3]K535S\]> _5V2$OHTZOH#6E/72-Z,FQI-[RK?WQ[A#;D-O)E
MVX!;P9'2=Y,H6ZBZ37S(+H<"T64/L.DS#L7QU+Q\'^1S4]5[\AHXPJA]+5AW
M-\F?N 3=Q*09=X#/41GOD0M ['Q6,_8N)40M+#%N251\B7[VM)'C_&Z&"#8T
MG/:S=HW:_:.%GK>8TWT<4-T$;-B>S%05XS*'1LS-E/0J'9AU^\"X"R#T>5!*
MO 9C^Y].M@^P71ME0%,Z<8G\69),]\B[U%C_5TMC@1F7WCQS8(_+A7-\N0Y=
MAND_3)";[B/IEB+B?$I]"/M#)(WU= /_7 T3"(/685^YM8 ?FN"+G*6)"GW9
M%?]"[:OC)1$5"?"QI/&]+241]1 CF;L)F:Z% _M2,-S+0!C:<;"U,$K]40GN
M(643;'(EI-NZ$]T9A"U-ID=D;UU4Y<K"7N $@7"SUZ'=3=_ 3U>_,XQ$M?8S
MZ"VKD[_N^\N#!VJ-@;*@LY#2B+&NBV1V+QMGX@D377V,UTQE0IKT(N!$WLP*
MA8OG EET>(<*+\_M,N,LR3ZP5H(YH.4L>S/K*S#\,N*F8=@@N^&3]<<0']!P
M 775Q:UO@V[%;>UH'+RJ#'\T$+T&K]/U$AW8+C"I3[F<[<*LZU7LPJA=47M=
M@2\U&W7J*#LT@-#N8WD]FEN"'#Q9'>:R-=Q7X7XYK2(\KM,N8F%M]IV&H@_)
M^6U$RWDFL@##B5!X%*SKYJP4.&LH1/2EJ(<#=B#!M9,_I[CWM D8=VD*:<XO
M@A/WIF*)>P?X:;SENNAK0_^>+4R*]KM6?8Q6=B,YX\RN\0B-?X\TN]-]6("?
M7WIROOD-Y-X%"[(:8.?H1^5BQL]P(NNDJIC2/>:7%;@7'.VZ>:1]4$#,.%<;
M=BK9S[/*L]>[>'GF(\5O0)E!'JX!IDPJOL(9728'AXU)IJMLGR2J%2>1(:\Q
MGH'/SA%8> @_53AWE+40CH&48MX2SDDIURE*C,\A;(*+M91+8ZL;X2@S;FE=
MP;2.M!PNU "]D1DB16[>-,_AF ZDS1H?!K4V+#!9LZ4 >(#[AF?\!1JK Z5&
MCJDZR!+R[)L]G9NEN>[KM5[7SNIT RM_XL3?38K; EJ/YZ7%.D?"I:I1LAEW
M0/: )(@%9V?$J$LS[T!CB?8@5_^XC]JB^]L!BX9CR#;84(4."QM/72<)DPP*
MDIK2Q97': P]&!=,%+88IBY $<;$7'1IT_W)RL4P.UE@!49HXDO22):A4#^5
M,)FYXA(8-6=!;8-E6NIR9 =X'EK!@W:.A)8?XAY%VQ/^'V_-G!W/1VU9'A"_
MJ).(A$'E(@J.V:2Q[#G7@3$\-:,D*$)EQN%IE9MA>I8F>$LSU684MA*W5U:D
M/F#NU,;UKYK(?-%)[) I#S7VUDY4VMADNMKC7IUWN:@L;"->^0ZO\1!_;ZN3
M?'+I[Y+P@=0PK*P $)S[]FGC^("/#6?3?MS$P,SZTH%;W_^A^EZ5MEI3]C_+
M93L7Z.#T3W[8%;)JC>K*CR'=?N/"%5@_-\&AQS76GFI 1,4AF_N1HYK1>,F8
MAXSM"H>*T*6-D'N)X,NR? U^M6XHSDGV\3F=VILY^>9(<;S8'Z+<G\SI?S,V
M^M7Q(G[5ZR^6X"PL@/S/.=O6H\W9H>E>DIJM9MR[]?%0W8$OK!6 8O9]\NR'
MU*O!^>OX]BJ<:CD^Y+]W[^UQUU=)MD_,W 1FAC+8.UXN"EE3\3;39P%\_@L@
MS[=Y/P[GLN#".X_:4)>K8[<"[R'7SB.9LGNW%T]1=S(EZV^5,)-YU__%3"Y)
M',"\OV%KR#CW7Y;DVRY$R?;)';75Y^U<QF]I7?<!GVO)L#19\^-&0MV3MR_>
M;._;I4GI7E<BQJI:>-TV?(;[,&,=M"@/R*N;_Q-"I^!JRL=GVV>7+XO>^'^^
MA\.YRID:P>"/@A5'<DYRSW.6 /'$G&CB5 >FVR\">-864-9=RN2I2?GI%-L(
MM71I8N-$]$%=YC6>N,);8<8=I!VQ&8L5U<EKQ7_^Z0"5?YO5BJYSP3J!:?97
MPOD'HLNA##,NN !GQAT*\$3X@&:+%/;DF#!XGG^>FN/(^<^;FG],_C'YQ^1_
MPV0I^9T9QP9,JUK054)P/^5O@#*2BOYN,)::<8//M7M-?P,@4XFL?&+&O<!L
MTRW1W:V%3VW"J8663V9+:BQOH"?(7JP(R+&/6R"T(V]A=OO^*HB!3FCP1:@;
M7!WL\/JCR0FP91K$F>4%?LW]R>LK)Z::Q0/3,;6-S>=NYCYNL=TI>['_URZB
M6?Y?4$L#!!0    ( !*3 4\-=Z3A*I4  %6L   =    8VAA<G0M.&(Y,&(U
M-C<U-&)E-3AA,&$Q.2YJ<&?LNWLX5.W_+SXZ"3')*<0DB1R:"A$RE? @)J<<
M,T])3DE"IIIF/97SL11*F"0D:2JGBDP8/)'S,<J843EGC<.TF#5K]GKV=__V
M[[N_G^?Y7K]K[^OZ7K\_-M?-6/=:]WV_[_5^OPYKAG!(.(;9;&ME8X41$<%@
M1-!OC' $8X'^]7_V]=<@_Z=CB @_8*0WBD2+Z*T5V8%9(RVR5EI$R,3@T'6N
M_[<3,/_C2V3-VG7K-XAN%!.70$^HW(Q9([)V[9IU:]>O7[<.[;V.]F/62:_?
MHK;OR 89Q].B.\)D]]^XD[]1_>BK>CFG;G"G_IE+-\7$Y16V*BII[-+4VJUM
M8'C R/B@B<4Q2ROKWVQLG5U<3[JY>WCZGO4[YQ\0&!0>$7DYBGSEZJWHF-BX
M^(3$]+OW,C*S[C_(?ESPI+"H^&G)L]?E%955U6_>OFMH9#8UM_SYL;6GMZ]_
M8'#H\S";,_[M^X^)R:EI[L+BTC+O%[2R^E=<(IBU_S/TOXU+&HUKS;IU:]>)
M_A67R)JHOTZ07K=>;=^&+4<<14^'R>S8?V.C[-$[^:_JQ=3UG4"Y,Y>ZQ>5W
M&K UN'^%]M\C^_\6V,W_K<C^9V#_;US#F$UK1=";MU8:0\ (\H68F[9 _4[&
MV .2 OJ#]K*8.9_ >)DU^WZ<%N]C*LBJVPP5-%/W<PD-1,D@9 >7$+\<*O[Y
M2]"[T>IG/EYMX4#)M)'ES] ]16<6B>JO/@R7KJH),5)VZ+B_ 3TFA+-X>#]5
M6HCY9D*"=OC#CZT1L6XAYMPMT%J(.<'7%E@]PK:E09=(\!8+Y$XW7PU@WP73
MA!BU[K\?1&#]^ _"'@+[(P#:8%>MK6=CA)A88@,!CK.&#^(1,73NWR8%MQG@
M1PB=X/;,LFHB!GXCQ,1I"#'U.PE3*KC7"H@B8:,0LZ"" [\QH)UQ O4"WE$A
MIE&3C4,LZ'U7M=8NC"/;LH28=;>%F"<1U#])T%E878CY,P)H3!=BQM)Q2ZEI
MGR6$F$VT:&!%BN$X^7]#^+\A_/\J!%)C**PRQU>FM@*OA!AFVE"HG2"+X,^(
M9F!FS<+':&D*R+Y*R&WLJWX]".7-'^5B&TU/R8][)AU/-9XO['G4%[EU]FQ&
MU(>L7[9EKP^7(@\-D2@:2#&",P!(,TUP=W[82(AQHL7(B@BHZ';($+YO(8 .
M:7P#W$W":MQGMVE#JO??'\?(.EK^ITT.),P)^&1R,$\9BF(+W,EKF01Y1 >V
M"TVX&EH_'S,L16?3Q(]P4OS9I'J&"AS.S6 EF(6.'R)9@O/1,)[-PL"'!BM/
MV8+VI>2'+CGNDU1)D)X 6SX=#DSYU41U NI_9YP#$FB5^%D:AX0A2XSA9KE\
MARG>,)YYRLX;.L1]U^CXBGO]QRNC1IS<% EK%LP_!!^M?CU8T;D&/@MJIN*7
MWKL1X[S!<7=HO'%QQD>2I$!6NFYC^."P>5H/X3P+ZXZT*<7-'>1&L8E-G3=:
M#B>>TO>!+,?I6/=.[JZ)%B+= R(TUFT$UUW=4/H,"N?$L)CSBD'9V+@ZJ1ES
MR4%#276.WF ";)RI(!]5G96I%-5!DB2,%5'5H F^)M)&JW#[0!H:Y-V FL9Q
MP^7'N;%E;&(T5:X.E,KU!7\Y@/+%I8&CN_K-]\*A7&HUFQ%-%>FMG=MCBMO4
M=.WYEV#DP*"A3HAZ SH[3Y+ZRQIJ&Z/!6ZQYCY/&B!\ZI4XA_8BF("/47(S:
M(\3($ *$F%NDM11#^3B^/X0=RTOBH%5 50*-&K$Q;E2\H'AI=R5^FS=%]BTI
M@;'93*-$9=>(%1C%Q":9Q(,Y6UK 7Q_JU*J_H:"/'S+EP8(<8"P3*&?,AG)-
MV7&S+'X@=*ZCMR5;<TZ1KT\Y!MV*!'WFB6"N$!._Q)*!=4!6/3V-@*68EI)#
MO5^!_LD&[^V:J'M(\8CX]6M-5<A>>:70I*5C8$A1!AU#C86\$/%31LWXS[_&
M:,VXSZ4\*\$3Q 1J&8]*H.Z!#O2RK3*"P?F&8+"%2<-0/.AD&0Y,4*3JD].:
MDT#3^JL7;HT3)(.H"N"+?-_QM,UM7 NW]"[*H5>#YWT'0BM"W2 W(6:]!*3(
MU>0I<_%SRR6>Y#8VJQ[=$F0S-,*A);PC)"V]/S#?3%U/XX4/PL%L0K+2^O;B
MZ,BT+0$^N_IJ#W)"XT8U>R+:Z*+!PS_O<(JJ7[_M,I1X8[C1%KE")O#V"2JI
M4L@'G)@0XV<?-4:?+>=[4/;2O*"6$&X6SX9KW0PD^*RI $D-^"VPE1 3S>>=
MAXZ 1KS;-6#R I1E)<C5'>N%53ABB 9LTKN,CS>Q+,L83>&H8*#KNF9V<T+,
M:Z/95WPGBI@@O4Z9VDR0-5>FK(,*P9HF9+W@Q1(]WG-#*1?''%6'HD#-#Z,&
M \4U@AR"GXK4B!=HF9549T;1ZZ'(< 2^[+1D./+%"#G4ZW479?>ZS.&3S[/+
MLIDB<X1R-UAV_\0XODF($:=(0BW\?91 P=TZ-=@#.E1&[0)$(EA)5P<;TF0^
MPYZ0#?N]7</5T,3BJCY$ECS1G%F'A5+&BK@3-^D4/["QZ5R;9Z\!:\MG4F#6
M\+<#GH,\TI0*8$YXJ0G+&'&R&H'A-G;UG ;7?PQ-5"'&7R##"X/6<Q7&4!1<
M'T"KTFQAC+@QS?$#5(UIZOK85;XUE]5RR-3N/43D'X3W@'$WBKNH8K!\K]ZY
M_JP37%:BX;S\1]_(HJE7).!('\;14O9?FMO**% /LA9<413/(_"(C "6P)8J
MZ[:J-OCW/2=$E_DH#QP78N[]A@*C"6&VBXI2QS3.C_2T?R7\G[K^?O;_924+
M(WQ;]++K=?LI4H)\<R-8L8?ASXI9_9D!TCG%J51<X'!'X3AVJQ=I>L!<;G#>
MX%K(T=6!@?JYD)]TM2J;G]NKS]W<K9)N%"F2MJQ!^K&(9K>H$'-W6O"2,?O=
M?!\P'?S,;4F(Z;YVXXUSZIND!-#;XZYCQ\6A;7<E$QN<RDB*1QR9Q+V%MJX[
M0'*RV9.O!SA]W[5&7.[V(5ZKSF'S\A<5),$.T^CRQ+?F.BJY9RX./:MX>CKX
M79_:K<C38M9R1VN=4BP_Y;B0K(:[!/%HS:<C)D!WQ5\TV<!JP<$O"I ==M"4
M$&/5^Q<52@#;@(5WC(>>.GP[1&.BGKZJ]I( 7>R &=/^W](X>.C^O!)ALKH9
M8&\@?D<I2HC9"=B0N%M(+<35 RC+0E[0N!"3T0<P;0 5PN3P7T3*#AU/0]S<
M%H,M<5R\N230+7D#)?'8*/1Z9\).''??J '0'9J,+F@3K0TI1'Y#TAF<G?14
MQE((82-Z5S_-CZ=^$6*Z3!@EQ,\,3FH!MX8'0+NY26X]SROTG#E9#9UKR$*,
M8W?%2%+2>X+M>VYH[)+@P@3Q]=MWQ]Z^J2S/YH[=#([V*$R1^^9ZR1)XL'D&
M,EHP1.XP7BK ]W_-QJ'(.0+ZHG)94IQQGWI/51'$KP'G-XT;$^->KAS05,GA
MO!QZUA=FO+I0=C1/8OAH3J:^0GRTR[E[](W-]O.[*@@E2)*J5A@+%Z8@^SM4
M3:#GG'ZIN$=9)KK03?+FHZ>#>2:YBBY$B=C\W4;$KQ6%6B->).>99UJ/&4G8
MN4>/$[4P_[[1%VO1,F,SOI6B66<&S-*HW8S5>[ 6?<GBG[H>86=^(1L?"#%:
M=U 1$P%\?@2CV]YGWLIP+%V8^(>>IYC_./._KN0*>A%:\1^7J4,DWB7:5L:R
M8;^.0*T4'@7&'J'"[#JI2D&04]R,%]A'VB)MJXK 1X]F$L_A-&$Y\!BBNQH,
M?%2K9_%.H(2V3%(?'T9#[NJ%.>):C_^0C8255Y10#<@:DD".7^-9"#'E(= ^
M(>;IAAC2CV\FB"2< CP)G5TOQ.PZQ$?%XN<J>"NZ]+5'Z>/$(G\XO59%B/&%
M_9'2SP+ZDI80DTY/(<SFH3PQW?I@N5_6D31Q!TF.D74\O/[?-R!W L9)"C$:
M)$0,3=2S?%X*.F@QVQ)XK/*/?1B Q "/=:X<2X-E"I!VT;$T))_GNII"RB+\
MW>'_=<:_:\##3E@6AQ!+>0UHV/<@%,5+7I20IB3_ 1]XI*XVQ+9C/\HLX2AM
ME=IJ<OU[O1 ;*2GT2)R"$/-L!:?:??R*>EK;_H_;CGH45,7_.;4U\\?O/W0"
MJC,6]VA(_]E]^&'A'=\[=[:JW\&.G*<.&["JW8680(,-4Q&L*B\@H/+IS"5=
M"JOROJCSWKBVD<4+PV+TI1V1D[UA*;9]^;M=8K2:(]45M"M#9Z>:#CPL<>I,
M%U_(H&E?]E_IW'3H:J)3L579;\TY,[8GB@]J]3SI*7%]4Y1A$O+B"N.R@G>[
M?,"S+I^AK_91(8'7?:/"3^]H!$*"KP6'A_GJ7!^B_W[30Z/B]L(:[YTA;^2:
MO_^N3TR@'##,9Y=S5-:1D_^PCNMX52QY\58([X/5'1YM;HTD;=5]QPAR".@A
M],'+#YM_[]O=1WZ^O]BSNG_*?O!)OIMTN]8U\4L3WW,OD!U46_4ZL_>GZ7%Z
M^G\/>Q&Y^[GJ[KX"ZQG#1R^7O:=.K_@20IVTMW45?#0F#G_4NM2Z_T?Y\2\J
MP ;$BM%CQ%N#W@A5 6HN9D>HFX!ID7RWE;=2C%N .FE*F2\"?$RC_@GP0A@;
M",N8KE+HUQ1::#OIHL"0$*.(WA,><$X@3OA6.D[D:[X$5E\778^TE'5;^084
MJ%G*GA#Y]XTT@9:::"/P$14_-U$L^VPN* "6=T..I,FX?^P[C!N<AZ7U$4<4
MR]=-HHET!$)?/;V>02UP^][Y#SW_Z[Q_U_XA!U<MW%90^*D_@CJC5<9Y//\@
M,9FTFCV=(<A:0A,SO3R9,9O3 $SW), >2P/H 8M;C-E\-+.GZZPGLM)^SNI&
MXM;Y=#Z"TMQK>RG.14$V8?ED+Z:YQBDCNVJOR>7=#_D[.G@#S=,6ARJN!(SW
M_2Q+:EQK$U#>?)YD>6@^P<PT_/23H !=V+IPQNUD5IY"1>_23+KNB[)=7 J"
M/\:/?"]X0;LBETS%O<N=WZ-1;F_DW,4\WGMD,L+MUP9"S.YQKOLGBZ86[+9S
M1GHM+JD*8@X9H<%96LURFO&\=-<9>^=",3-+I?M!]P*M4=[E//7,1F3;H+HB
M4G3]Z4PI]P=C+P]F;MC2-*YY\E;!_8^M$?EQ/$?RU;V1VATZV)-YNW*#TJ1C
MFMC!U8X0/48WDK1I#^U0\T..*1^+)5N[5[WI'FQ@G*L%/RVT%TV_@H"&7[R.
M+-P6I;FJ*>E3/G:E/H9U<1M>1L;3*U6.CB[2LX>G!YDU%=="(OUKN(:5/Y]7
MFYAGUFW-LJBIJ*P:6-X:>:_<:,OH\Y,HJ)]+,/0;5&=8]G[KL4K\-/^UV]M=
M2C0_:^SB?7'%O ,&%\F?#NR/L30IE;;I:K# L#<=>R53IM4I88'=ZLPD2L<U
MONDKL, 2\>YF4J+5N);*Q6V7\7OI&;_[>2G?8(YQ9;]H"7SHU<U$U6<NC2U8
M\7TY^UQ?;<D];K87RK'-,!E*/K8HFM(RG@'D_V\4S$K-OQ3,\>O_H6"\+^1R
M93Y<9:3 UN"@'3<M-A(7;X[MIA X!#EH5YM7[XM:9_9[T::[,_*CB@.&[>+*
M<7T59:8^M,,#!3TOZ"'LQ.6*$;K&_>UZ0^8'%BZ*.,_D[#468F[XXM(L>ACQ
M]"$W=RB$3T#SVMY\RY3Y6C1Q_1@C08T<;-H284, 3I9BR!9B$G!K"6.%#(E*
M>H*JEJ"N]@A7M(E04=S(KRDM"^=<+@:[/(*ILH+G&E"YWUB2,SL!. ?(>4'[
M6:=Z8'4)(2;/>G4_$*0$I%!PI>0D3S VBT.7"C+7 ;\<R#)7 ]M3:PI]R+>.
M5C-.\/1G3#0JO[TKRI#DW!YX/2V?^?'BP9@<:9M"\DC]\(\:.IEDR76+70[=
M0O8HZV76X7H-OVJ>&(#-?B7\\-Q3\\1CU/[IY%PDKO/"NXS*D@?4@$9QQ [9
M&D1ZY9H&R_8B8C/CN*$9%\$#,TNPP(E+FB,4!WKB9F>PJ2CCW4QOX<S+4-9"
M-Z*X:4TL\,04LO-C&1S$!1KFL"V75?%(5Q<E,I"-C[^JV51FQU[_O>_=]X%4
M Z_DM)NKG;.^; :TVW_6!F7[H>E%7B27\(&?=HM5=8V,M18D.C?Y\KC56+[Y
M"-36,OP+EGU$7IWQ@8K'Q_')9@<Y*0H?LD.9=,BB%GB"]/AH@NOR\"'AS(]/
MO3Z(",*FS,U !P9'\EK#55P2C'].+FAHEN/BXPSHFR=74]^S?[S!?'CW,\7_
MFGEQP8,;JB?ZRD*./Q QVJ+ORS3?!]*B4V_7[>8:Q<'&D8*3K*-=S>_+IJ[N
M&XBL>3D76#!%&(ZZ3!OV+&MMG@LM]KCRZZ[VOM0-F&Q$&1C+6$V[01'Y[P9
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M1N5#:X\,&$9T17PE^J3_, UN]['3>7_DO-J!JD$'_V =Y9H_%.4H;[9E=HA
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MQ34^__9[Y,6%PN1,'4GD-$B7!G]Z9;BVE3]?[]&?>99[KWR3E&.6[Z*XP3/
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MD@1KJ#@AAMW0PUA18I0 G'T0ZFRLL=$$<.4/5/>. K1S@*80PY1&I4!*IP+
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M0##-^EV7N0(DTS JTDU?WM!?*4EH6#VN=-8S]>E EX>DA=.#J-$@MS!WS^'
M@7+2ER^5J0\" PN'! \=*JHJXPO^:+%6B"YSEOUNAXUS\<<%N_)//K[WS'A*
M03N]G#(8QKM6J2/U B]FLO59!-@JI\/1]-S"<QE\'?W,Z9Y60Y!]@VR^^!W;
MO;^^^I<9]P;1KY.ND/&()783,"1JBTI(K>"Q87Y;/;"@1?9%/IBX(7<L2+LY
M1OQ,5)"==@666LU[&T-7MIXC\$11@T9D+A+3< MZJ.;CJ1 %1J3!-KEE0DO:
MBOP2P)<J1A[29[XG+K]10&RF<3SI1"&F]_D"^=^K6YU%KW'6'# >>@O80MUI
M#922[:RZ$44R;2PC+181G0:D:AU+*1:"Q^:J%,MWH$96&HK\>(Y>48U_$?F:
M'6A>RF%)0U>;(CHEH3@KD%<)#GHF<0J__L'UC\M_^0LO,DW;5B@H1M0A"5>H
MB4W'P?J0'SLIF*$X=9$BU05C2P(0(R@M*KP$QH,.:1P!OD7I^\^RL$=DK"V#
M&Y=RH?*0TH9WK[@*C9,[4D?G/?J&.X=3PXZ2LV*+'9[_*.6+F5KNG-=HYQ(N
M@R4%Y=]3YIY9=]CM*1/7KIUPV)R!#57F>[6:56BT9A>VM9^WW\AZ^/EMGTO?
MRKC3WM711+@9^LH_#=M"H7Q+<M('>4W+UZ!U-.S(-R4']5RARD-9302L82;4
M&.F+2Q%MP0Y[V7,U:-& 'UV&[#3ZTZ96@1TJ'R#3SM$Q98G,7*+)>,%V/177
M<4MS@V?3-3L7;'90N9N<**EM_#\3=NTV%GP[=E?YYU$;[[SD/:<M%-UD;+-,
M,N4+BIWSS$HJAM_U3[4KZIU?>O].]]56DR%/\M6,*U?"7/H]*675K6R'0%NN
M+5RYG:63;O^FNEU18XXE(L1\\QL@S&X ENIZZI[2,Y!_L2>IW$'XGGL:7_2O
M_R SPXX88Q&;3P34Y@@Q2XM_.1LS_O;_NG_->W(A;A+(T%/_ZZ,S3]="Z] S
M>E&C;$<()*S.@=5"C,O@'SH+7;[J.V]\N9$N^G0#PTF(&:L08A;2.X>)2 U%
M3XCI-QP3A\OIO&L-0LS*@3Q5X#.V 5A]_ ''\4^D+8376@HQKR?0/%^^EG8P
M*<3(M;(GLG"?AT]0=D?E"Q+I:*1R^P'3W/T([YJRJ7*(4X_B!=U0/<KNT"<>
M0QVG]WF>&GF7F;2&NZ^L]F I/FX9NZDS-'3# XX'Q2N4,E-&+)E6E>^)_+KA
M-]T>4_Z(6N2XI$UE\9OLA?$3;ZK3E:]]CP]22JE[*)H[*>M6MD>^K5!7/^.X
M=T'LA_ZVOFTOVP?R$W,T[E\_4],@N/"\W%!T&\7\E9*<MOUXH&/! ^?&\8 5
M1\Z75FGF4Z=Z5 !'ZM:W6\L%&8(O<RXMQ^4O,YXY>9Q]4OA'R?(5MV('G%.I
M9Y67L_3-LM; J^?*=E6JOB]K/.T?Z<>F0U9Z<TMM4Z%Z\Y0YVU[GOL@K:SW<
M]<IJ%P-YCE,F9^]\^3+$'&R^%A-XQZN,6,>8QR_*#O\_=H;NMJ=MRJ]"PRK7
M<_F[T_.9 >89/P?7F?[LY"O3)BY/>QP,V [W7$U<."6],7W%[0>O**;Z>>DS
M&]Y[NFA9Y9I$:+'![A(EV=U'WEYR=@TZ^:QOVJ$P\%W&,YN^$E/CQDPT%0YC
MH1WS<($U#Q4_+P%FFL";L#F0!KHS5O;15%&7/@XRA!CG4P=HJ  ]A9K4 .03
MBX>%T&PJC>-(ZB,2"JA-T!]G\;=1T5?3P46#*P_1Y%[(.D@0T.X#,^'J@F,<
M-#6.Z4X@GS01J"]MO"$_D[-17&SBIHS:CGT&W*/>-T6&-"+P-P^;'JG?KOJX
MB/Z0JA^0O2E[&HI=Z#S23[$_/39 W#!IK@ZY(.9I3*4?#Y\%>U86Q>1/#^[[
MXA7H-MP^.W Y.^-%ZCL@?BSQD(Z72?I49N=FU"88-\9/7ZRRUQW.VY!WR)GI
M5'@RP[M1(LM*ME@I/==]H*G58,;5.S%WDX;1<K)KT+VI$\G3MGNS(+=Z^" Q
M,?R^GWYSWP>3>]I]A2<S3Z5\^F[R,L.XX6[C6&!_F<-#5Q7;H1*+H=,!O;GG
MCY7T)#^SGMH3GKQM#I^\;7;3YH^I=>Z7U/&_UD6KF79H*U[8_L>C;++:_BV;
M[<U.9#6+#.U$X[6Z?"LY>5EN43YA0S&.&1]J6(:WKN5^G6 * E\8_ "1]V$<
M'>S:H#7(B"7W4!QSZ\^RBDDS?#X44M%N0I2R"0UCVQ]=-M31B;[;[/;2VZN<
M8PVK(9HT>^Y<CN<N1LG'L<L//R@1$\VQTZIX58W^BC)_IL+ \*ZDJ.>?=ZZJ
M\.@E5^0]<S-I@87D[(WY/9'SU2D[Y)RY.*Z<U\=RL_9O%5J<O8J5Q[==^N00
M%=W ^9[57>P0^2IR8'^J?.ZV%JQ3Y:8]^!W%)A!\ "\3DV\PD=A@+<UC<,5[
M.BY]*?-WG3G1XN<2EO[IY5LI@D)TJGGMC%6JC#CHW-37]'THFTQQP*^G/75L
M>W5?=X^^C U?5WZ_.U!2NER ;$2!1[,P5(@YF\7!(ZE@.]7VV,)'V4M$Z=@K
MZJDV[/VZS8I?Y7Y$?V+HCAY_SKW2MM!>WD[*:*)6HJ HCV+P4ADJ:=-A%'FZ
M1Q6?4V^'NYI)<&T#;7:#YE$&Q8I' ^W6']30LK>ZF$X<37Y<J!"Y,SM@"4GI
MOLC]U1!OT_0FK,-&?ERK0Z]%4?:+OZB6K4F@UL>F,N? +TBMSB*>H\GT4L;B
MH(&FI=+/JIU-2OWE?V;)MZ8;&+W.CSRI?/.5HLC;M73#U4!2ZG^C[LW#H>K_
M__'I;I'05$(1<V>)+*EL99N[A"0FA!!SEV2+2<C$,)60=4*X(R9D7R8Q=C,Q
MEEN2["'+C"W[C&4<LWY/[_?O][T^Z_7]_*[?=;VOW^^Z_&/FS#GG]7H]7X_E
M>5ZOYR&+D6<*?]U'17\KG.673J8@H#/3N(ZQ\B.P"'0E=X9Q1/F6<),6EED'
M$D0:S]2<#Q&"@RKBG0$?PML#.MH(&+T2M#*LW9,@\%H0 /L$*V0QVV&;!X*P
M>MLV7(%Y=IFWS<52R"HA,(XJ%\Y[NLV' *+>O*/8EAX0S']"L7S(,VTRU>6B
ML<Q0*!]2!N]BA%*^4RK9DR#$'.24+;O3PK)VP;]O<[#]W> 5%@HH740R'1:.
M2I34;*!_C7Y442?\=Z7GT/J>N^33;B+/37\M6FU__"MY9;]LWX+?.86$@AUN
M25_CI9=Y;ZP=4CS]Y_KF^$HT2%+YUKS&GEY]O1>N"5\<';G6Z4T3$R/8E*\Z
MTQV<V& X-\J&#[$8WEIO"T4PIGG&33 >!70J^4NLG;M-$_\V!ZA_1A_\#P<"
MUI\ @GL>)\FP_X2% ,/MVJ1S#'F>_D!83Q':WKF>?@EX,UT;=F0I2XZN-IX'
M,EJC.0W^@N$=_FETJ(X::H3HUU([/S=_U<EARP)F-!A8(HVT^585TB43.4Q%
MO0@ .\\IR;-BR=%MK9WKLH0$GI5XDN2&5+4:,N_/4R>C#,7S"]YY:P^?6Y0Y
MVMC?"*,:')@TP5_.ZK. V5;Z8!$>6@YSM:@K.:3L.V=[4\Q,(A24/_H7*1Q]
M.S>U4*?3M*.@M'-:L^PQ)J/5WB_.V2OA7,R+N_,J2B9623'VQ-?9^]),]V-5
M?38,B]CR',FA@EK=]\C#9S8S/?5_G]"GO\:+\V2A>S"W!QJ%<M"N%)(, ]J.
M$,PGU=NWDH_P(:YH]994&=FA+6!TOD.;=?"-0,)PZQ"SX@^RA5Y5POK5MIG$
M"3/I!(>9Q-B_ET,J&\1=!RI.91@??5C[0.-MX8V":[:2@0K[E>J(-1J.#5XK
MQ+&0ZM$2%Z+;7KNR:S'I7@?\7[^VL;(P61F[VN;9=\[)6&$5]C_0/+'_7O/\
M0/__0/-\)7O"IS[ A5T94,Y1<V;D8,]+V8\Z_AC-?8.E?3:'PZFP9W\V8ZM;
MS?PD.[]X/YUZ=+9[)Q>T:2[J+,D[X'T^ AFPG?P#>N "XN4Y0PDTZF5N6ETO
MX1/FI.-K7N4+G(%N(SS-\LALZDFSTR;7[)*L'<=/E6(C#-48[E JYR9#!>HD
M0W6,@OF%2GZXI1^PXV5-$V[)O+IA)*)DGNKGQ4B.)?9[V[1X_"UM>7I"C9Y5
MD.?-N_AX.- \=#>5]&:*ZVU5VT^4WFWZI"KS\1"3R8<XA%\?-&:AZXVS1D,/
M2O_&6KI2X=Y_9JI_[3[C5%Z!JK-[ D_0:Y3(C'H/H#K.F6I8T$P;B!\8[^C2
M7SYZ]GIZ'L]:;9ELE5Q92<WR];5CCO9;'EY(LW?TF:NE.SUY,NCJ-W@RJ_[X
M&5?'?-,$RI_*O3?3B*T#K>Y_D:0#'U85L1V_OS4XT;$KGIGRH:KBT*U@_6UF
M<9GD;0(TI2_5>.LM'Z)*Z>MY>.QMB]C\Q?;4@UFP*+K^M<)IK\&;A=1S6A^_
M]$ 6;K3?;!E QUWQ7&=?M"IS2BQ0G$1NI^W$;*[MY>CT<^RI4&%T*J6UO\VM
MW,/1-_=!>GQ3TRRK0ZM>V,6EN:A18E@J)2[]A>JW1?G8GV8Q5)4"Y'.&+Q(H
MSF93>'<ZET S)\GB0$7<WR0("/YUYZQRM81T1'8<Q3921;#++O+4:Q6K(IG@
M;WC5A8&X-/V3*ABK6 OUI':&H7'J=,63,!4IW5NE^]0/A[?VI0J=F$4<CBA3
M%BOJI$ O^%]^KW#\D:5?/:8RR1Y>2_Z?R2TP$*=>Z9X%W3A'E,#T[Q-?01EG
MXEJUV-;MLD?>A*D"Z_XO'!2$/GQVE?OB>S/Y^=43X)'B9Y^QA=&;E<HXX'J8
MQ/J7H]B_E_*W[PHL(6?A!WJ+HEC(V=K@WIDRHXYYDU(IBY:\,WIOE8UK:R2Z
ME(CHZLSR#$?\$DITJ"":)7,?'7.$^=H/9LH*+.PVL9HOL'_Z\^O;NGNY6MW'
M%;N4BE1&WJ_BIMM?:RB=='A]EK+W_@U*UK'?=A]$B"1V3J?COL3R@MOX$*PK
M'T(KW)#E0[(JL)/?07 MYD,";SM-J+%R.8(S^'60\'9A9\SJJI=_C&ED9F3<
M#WWL[KN&<9]("XG_GH3 1^E-GCEK<F)UIUWPV(,!EWO(C2%U-AO&AXB9OI'@
M;,7R>!U\2)OU++:+Q$(5AS:\YUH?-,/*D^D2L[,SI-GOH6%5V/^L"0B=B//J
M.TL27"Z.#XDA#.$!V?[<L-''S??B<1QEY,M&U9<=W*#(D'V*FX0.PU>=?$CK
M08:-*1\B;QG2RX=\.]$S1HI/3&(LM7BWF_,T,+B 84[;)UYC"6.85L-)@;TD
M,W7147R(I8;]LFV8+L<.I*Y<A@2O P&*TH5V+Y#E 0$N6QHDLU=\2'\O? )[
MB/P#Q RV$)[W)O%3K[$8Z\W.'[\* \5_XT+7"=\)$?#UZR2PW=\SJ9-<+<?A
MZ9)_['=@JE 1G&1U\%I,1700R*5V1/H)+&\^#3S2 LG5Q'UK!*5$Z!?XLG@:
M+^O"Y/\Q-;$-_-O4Q [OW['NKR59'PPU?^USV88^!2'N_!*,N1O.0GHB;]I_
M!H?R/Y !!5CB75,UY89/@?Y/1F#UAP#8A7,P7LLY+.M)Q%$KI$SHJW]I#:9=
M=$0[4@ PN@DDT\Q7;%ID1 ?5"WS4>T@#G'/O%B4JGP1KXX^&!8ZO9AI\:9.]
M$JW?Z73O:F+Y83%3W")/''!^YZE;WE2&UJ.N9N1Z.+KDE2U)IO0\YVBJ5:W(
MF5;4#FQ97)YJRS53'UE^H.;K.[^>DVIS](QLC)EV;NA>!I)GRL5R5_3 4=+6
MFM7],MI&2BRYC0[^2K%B[)%TR34,+_ :36F/S?.2_*'MW_G^UF)Z=WYFR?A/
MEL]<3O70,*LL/[EXW+/Z47>(3[Z7:+/T^\F^D3-W< 6O9L_EQ;5=,E+Z5.P7
M[_7UG%5SWXTXS_;WJ&,C"OMKQ\_<'.R94]T^\PEA^%5!7_R(=98/[O6L\M&;
M>:?O+EZ\9O-:YF-PW376XEH9;]\03Y77)LEM3Z%A93B[S*%2Z.N8"\.&XC]A
M8 RXA<(10 &M!!MO> ;W:5)H"QL>!AO4/+ZE=J<1-8VJ]! ?LK[],W@R4JNF
M(J-#TC0\RUME>#-S=S.\HJ>5#X&@IQV&PG9A3O4VZDQ-PM##2*""BH^9W*,O
M0FVR^805K5+30#"0"5MDV,_15%RH]QW:A48X-@^=:\\0J\XN^KYD*#V@JG6+
MZ&QN62>VX9O-/LOKPQYKE)XF !YP <SQ@;#?@8U;@'T@0WB!#Y'".!4#4C1[
M"C1J0F50_^9DI>(+>S/@-!4OQNO!BZ@%=EO"CWN&&?:B,$$,E=8)G7Z\'8-4
M)K>$]*2O%6 ,N&F&)P'L%+85-3)YHY)N&F4HBO$?,(0OC$Y&!2!>DG08[42V
M 5J(UM&"7U:#FP)!TS )P*3C-C!8[H45*V\TF\8=<<;\44?_(B/5SW'PRT'[
M6P\'D*$+CY/0-RM&!KT&%:*SE3>7K KG3U-GBN^>.[$>H."4[JO\H\K5RC+W
M8<KLL:\BME&8#P[&DIJ#!XKC;QMXM*?G.;Y>L,I>GEI2U7CA:GA_WN6AU0O7
M"\3CEF)CE $F]@7) -C-\&)M_$&?;)FE5Q/N4&'"Z.WK()&T(IZQW"DKYJUP
M87T'M=FH%X:R@+GEH&8RMV JTV7^>EW_W61QR:'P)]+Y&33<0>#Q(A]B7M.X
MK0[8\R!\2+; )SQ@#"#YD!2MC?D69 16G$SU\B1+&&KR(2WU_8V7IB:?IL(K
MMR,W)R,=AZ,#N]5;'XZC*4:,F@22@K<U&D<Q%$^CE-&<;5H,18ET F4,K7]E
M EH1W@HM1%,<ZP9](FJ&Q#;?^'J^[1(F5<:VM5B]S49LIWA<M(K!R6>*V5U+
M(<;@-&Y76#A<ZXB(^[S^UW!8Q][PI->NI\,6(YQN)EF:V=[,*3[5EZ95Y=-6
MW8]:QH?KAD:FT8<IVI)N$0EO7/<XOGS>8?&1V+_\#EJR>*3V^=?/Q]2RH2J-
M";+1N_]>DW,;_VN.$]BO.>Y$'<IU*_&L?USF=BH[MS'5,2\B*\]=KJV0(G^=
MF?;MAU.#R:*,MD>LR=1YL3]%?#E*?$CB;LKDUE<^V%&6:40\(X-WQ7R-Q>LC
M;]8K<TSB06+]X1UBQD9N9=D:$/2;"JJ>)"?C#7;J=II6O3>03C^XJT1E["*L
M@OF0B5QL4@[K2C+L&2FM/GQCID9=4;VAR]?)TQLF@&TATP6X^PU!U=JBW@(R
M?E$N3XP/>0K_>8FNR#O\*P,S:Q%89;\V.7HQBBO@"J?G_S+3LSO;[AO#3%]G
M/N2/8W#.J=Q9;H_\(R2=P $1^S+T&9P>^TMV*'N AA,[!64=P@CR(2^0$7S(
MCHVSSU&LQQQL4_I7Y;3T20X^;7X\ZO]\*N]1P]_0-BWI\-8]C;T<%6JH#-TC
M^#W2NP]S,<<S*.PFSFW.F%DB)!2"4[:()<$U7%></S\\UV)?ACD*]B45O@PM
M!,WKXQ2JG[:>E$W4!AIQ/.:MPM-6DQNILJ6Y2O4^6J!-D1]:R,=_V:Y%[GI6
MT'I1?V&*_N'M.<#S\D-*7URN@IVX7])SSQ(5S54<X7_*S)S*I]C)BDFF()1K
M(+J%^K>LO/ZK FN\BPS@22-$9$$'JN#'O!T);2AI(.C3:.#0LW>W;P-8B@C-
MJ63<L*-51H.AU5OU;3-4V\*RAWV^P^SY.KLM??!'N[/*'[5]I5JA-I:S"MSW
MC7K0>,MGBB\PMK!GTT"-#WW?VO31FC#QV$],N*1OSC-7>N!$VJEZTGF<*<ZI
MH8IN/(P;OHP5',5<JD4(63P\<G$+?8?[CG>"<Q^(]Z.W&1Y')U/W/<L'!&BH
MYR15EPZ&"H4/.4SL&K=O-=Q-&BC7+%/N;!2E&1SLZ[HRH$94C+U96Q<S;Y?@
MD5AZ^W+WL1G$<C=-Q,@Z[8_A1B35?#(\N*/#'#J*;.4)5-/+J[.4&H"_ZA,R
MI]6\FUGV,:N-YJ?2?.@X6X#PIZ&LJ=A:U!G]0(^/W5-K*YX!=7P(40T,B1)]
M++%(\H9O^EOIBXY)L8UBTSK*"99I!MS2I'A;-%N)^#C,W^08S$W SM.BQ2MG
MKN2T"H+V_,516Q>3%*5KUN]'DXNWKJZ1H+QOP:AV'[-A"D^ 89=!C>V!&M'(
M(NB.&X.<O86.BRR1E;:<GT$R<G1"%,:^!#U/=>-#X@(RQK#B:"%3 $?E'F&W
MD: ;6^B]$5LI<[$'"Z+#]-%("E[*4))S@/=E: LKBKE"9&C]8%7_I3E-Y4-V
MQT.;)TXRJF,]:2.KOK0F9YL.2<0+C)5BQ&:3\A#SI^//--WVTFI)VZ$T/^P4
M\B#V'OD81Z&&WDR'Q1H>\G0D@'8W/$L-,*"[.B)?U'?G%Q"^ ZG3+?LZ;G/?
MHS8GI9R\X$=\]?7<IL;U+^4#][<I#[TFE)H&]8,,5O&%X\:Y3@&LGN5H'S_&
M\*=)R4U8'%E2,^);F#JP,0V-:80&TK@:-G3\RT#L<8YZ(^!1;Y?HK?ABV.K;
MII./JL>HVM<T_])%N]Q/Z0](HM_XD H9M):*1X'->:;FP$\>>ZR7V3<'2O!K
M!S_FYPR@H&&9$^7IMK*SIQ6E,O5KQ@8?EK#Q=YRMKFDEVTX?+SZ8F]:XLV89
MMG3#5NK%P.D6,^[+?RYAXL;\VN(@WP5V%S=Z M2S_;9E8;I9OQQV6!OF-#BY
MW$#BX;6N'01G5_$0R0;4VS_ B<06_)4;2MR: "T/:0[&% )] $)&A>VPF!Z9
M/(47Z2EP-BC]B/ZHE-GK>K<W4\K^T8NK"9")F!'(B<+YXP)3*.!Z(X(/N12+
M8V][\R'M*JN$,5'>%80P]CM5@O?75CIGC6#_?(S7G%W",U0D< W<4SH$]7F5
MGCI;&.T%; ^1=W6!3#W/@'/WG8&OC1/XD&.Y/%%U45#;WYWF<4?Y$$;,G >A
MI&&5Q\1$J6)3X8]X]>JU_X/?Y*PUL+\_ZMAQW59?RF'C/O(A][JQMP8Q_K2K
M6E([OMFXEOOW3*_>5,6/20:C]EU(C![]<M;L1)9&=R@;F8FMF.?@>""95("R
M>V')DM![C>,>+_5D*Z2!-RU"Y@:;KF .)OVM]#X)>:OU9Q6R]5?VY :+_B\M
MYKA[(W<Z#0>O()T&"BQX76S3D0PS[O:8?AG/-RJ_FT=8_N@S1D9-7FQ'?Q5(
MQK;T\"&%ZKR;<'8,D>RQMJ/*T^!#0HS $P:9$0X3?JIFO1^R2E%0=$O[TZ>&
MN]MZ?9U7WC/_8/6UC'^&=OF$6SS*?EC4=M.]]-^>"0<X@(9B+Q_R&81R/_OD
M7A>0<C?@==@TD)RRW#\6<,AQY"];__XPJU^Y5=X[\LX-/F15>3U8B5G)<]]6
M7U_GL"N*-<?,TQ[7=W%ZAOB09^EX9D\+^8!7F.D(;_!@/@:OT3TRNQ3\^L*&
MMFF#H<M:;>W7B^W7R<?),U=(? AA107423FEB!$*[RKY.78ILH(/*1(G.&'_
M_0&$MH<K),WP$)(<Z-,HL7!4JWSM*;,'M;[I+K'JT8QQ=% ;=M1U2N!3R9@/
M?!K61A;@Z#0T]L&0-;@V#:_JWNIHZ>ZVU_55-8^#;;?B\U[8VZ6=[318Z?X0
M_R[Q[?ZGK]CQ:(EV_$&@OYVG! A,=>M2;M0#3NIM>I/2&*_T"=8%S1%-1*2A
M\!#&!I2&K/%89Z,S>>^!ANG?Z6I?L]U%RF:;9@GADY:#@YH-"TFHT8I!E3Y*
MW9V^P+<++:=;;"7(6N(SV<4QB'3$>YLE5WJCJM+7C_&/!Q4DDS/BK_:G%+78
M2L;E";9U%Q+W:];-3>^5'T'Q),'V<%39R.<=M.$7HK0F9IU.Y(/&W9KI321R
M"$W%1WGC=FVOZM"T6:QE_0"UMVK%Z&92W^2-).,/'TBU<(7,YMCW0!2# -K'
M%K--*50,\JB^('U]NNT( A:5S<!%!XSOLW#P.559W51?(]%O.NOY6$(W(=.[
M<"DH<MBHOYPH;0B.IW5U+;DJQM<2=A 8:\57,7-I!-$Q+S^.#H"B!U%T!5HR
M2KJ-W7NWH"_)1_41-#8^;D(^"F%>E!]E3Y\/UU>@#S=_0(Z/&"F04FADL3'/
M\Q8'R:7A#-!)[L8\8=3$<=P9N!;2'FXNYB*6$<Y$TJ,H! @@VK(]N5MSQ95*
M:,/N11.FU6@ BOFZAH%XJ6]$S;2?JHF#4_7IP]%:7 E$ X/P--!;#W;D%M!O
M/$#,G6JX@!D%.('"!HXQ.&(A0^NDR;E<J]$(Q<_S2L83MS>J3M<H.5MJ/$X@
MU$>*"CH2+URK^1@UN&!9DBJ;0%P<:3^4D?_:5?*1K;++VQ\GE*U1&2GX8AB/
M\+G)>ZJ @P.UW9^AIGR(415!O"]W0+:OJI;H6J!=)IZ6WU8B+7NZ;#.\N.,.
M2B8_X.49>-_O?2*L'YG*0KC)Y@)N.@CIP3B7?KH-S_0%'_+!,!?T!:.V?KL?
M43E]%A?JW+8R8NW\?#-'O7,1)@T9]%%S^.<DSSP<Y?U0SW;%IB&)T(&,F5R_
M&2;+AWQ?H,&X%[J1%;; $L.)=PW7BF1+ZX/(4'"\9",!5)-A'=CO\O#-341?
MXV5P_OYCG1*6==]TM_%1^T7WV5]5)'_[YS[%NR10-':>_[4A[VY0%'9ST!N9
M4/;?)$X^^8'TDP6ZF#M:V,T^^&7Z-G?[+-@41R0+34?])Q;IA?ZGCVR>\R$S
M1D8\,@V[N:1/T@'U*A?%%J!@%SZZU=2AOU2,CIL=&G^36YU)E0ICNEW]XHIB
MN)&0M#83V^>YKP/-=IUK4-GSZC3EV(^GY4?I8X*CZ M:#&P;*A(+;?1G6V.$
M>^=ZMP(8]B-:J/@)'<:^-]/D:%W]#;345'O%5(\(VK3ED$<P/%ZS1S 6=9QS
MA9$?#GWIXB.(OTDG1.@;Y[J8J7/D17]T; 0U(Z6!\,M %WWT,[N-%593XLF$
M59$*V+<QUY&CXL,TB7".*W5RKV=P&_,9X\ &M368EPW]Y*S1/'&^^EN5N0IH
M9]VI+KE4/>],%)4458#NHHSZ5M"<$+[Y\!&[FP5FC^H9V9*)A1,?T0%CN(]V
ML[?^NF:?)ANGS&-\/A2!V)>U>[0W\([MAO*14JJR7T+T79AR6K7O[1X1ZW.S
M.+W7/\GWLD]_Q2\IC_UHO'^SNB[I<(.&J8]>BS9W^7/B7^T]M"X,N2TFDB0#
M)$[]\B)B< _R4\1[HT!L\9*,9",W1ZM'&NU/4V_5<U)#4@DM;-P>3[A(5;QL
M!V5"JY+N/!'-V-TAHT_O7BW!I$NW!F\_;SQ7MM#7&0B+=JN'/=P8>)MDIO@,
M=(V?(,)9#R$R3P\LYMG9*CJ>.6>5I[7_JX;_?*.<-?,A3BWW@J*[5O>7UWBU
M237':Z\]2)X7;<,SXHH*'RE<M"'NS,T^N?S8Y]+Z>E?:Q$=6/Q/D;I YVV!,
M13S7P'.0=?J_)O;P>/A,*)+7>(<,AN&]*=S.(9"A/L0A>&__R>I3_UI67T]C
M)H!ZK6<:OET%YYH&I#,DF6NC>CQS.&C\)D"QMR7=Y]V".NF=85[B5MM0Y9WA
M%!M8_R%1ED3T?BD?X?O +57E94Y3M;OH2)>\:(?T%S_]5]=C>N%K.Z:<F/-D
MML2?Y"W)1,Y6)O;O>:T%/N3 A4FN6>'UXTYZ#I:Z4^&X<I$+_ZAD8#\GMA9#
M4@:,_F!4-TSA8Y$RO-]_NNAP"WG289UAD%H&]B5/!MW1*KFK3Q]9#-C3.EK)
MPE[!/<\Y6E0?Z"U&$&Z3ZT2%AF^IBXUYNTC0ZQ=T4?'J 676?,@-YXO<X99)
ML49/*O(IK,JEH5 Q#F/+@#/#X)(^JQ@UQL'M%AEYQAX7.;H]Q5P]FG2<'C=Q
M#O K0&/-@)3WAFEE/R5NH//A!P'7]J#@^P5GPFGC4 N&9720?P#U+YO7=6[7
M2N%!RN4^QOU53T:MDI)M_%\HV*5'::3 G_@HG)A/&XR[F7+-NNFJ]0UK+R]K
MIF==NY7EX0+K]YX6GS]KB<9.G #5XF_0RP</'M2#(<K$UF$ML$/H>2.@+@>C
M-T121(=/*T8U^K'5 =?I@:Q3#+&:%WU8*#I_J7T4&7$OC9*,1OQ!GR42**@8
MR<<-_F5H.4K-*Z^.2\F?TOL\6..#$>.+IENS@3=*2RB9)C>\+,_'O76RD-]^
MD;<OW;/@N,'R<K]Y5IG$Y?=_SA[/SU7Z>J+3#'ZZ7=3.L^2:,K.^T1&UY<Y\
M"(:(^A2>12W%+AJ7#$VVHW8.JY.7?I6N[/M9(OI_^)ZQK,-)#0!Q/!?+JG!?
M_H[?D2T FSP#WT**3M<KY9"#X+\)'ZR=V3*L73![UK$[X>U!PZS753=VN1#_
M/>/8)PW_QT0!C0'CO/1'L7>U8A>$MR]X\TQ'$-PH<'(M(_X;]Z_ N</H""\-
M4^685S4P#*-0@3[3^"/-?BCM;&'_2_J.KQ=4K7-/E+1_*CD]<_;W3<(7M&23
MY+$?#TJ&\DS4A?87V94<,"/[2-R;5\I?*4OM<L8-7%B/" 94A3VL2ARMVBQJ
M^PITXQ7-WH^^N-='2@L-./^S7(<G#GM&_NGSRQ0)@ZI&$DZ] TCQ(B>A?,C4
M5RB#T(^M.@O;E 89IJ48QJGLV5CN 7FOLA+*@K3S(50U+,]^CK3Q,:=V$K@5
MM@_LBAK0WP,:X9Q?J9NH*11+"@,'D>$"O!VW(BS %?B33"\&&ZRZP6&?Y7W]
M O^Y6XH/>4'D0W:0Z>RO;?\H , 6HQ?PS-+ $[%%&_5 7U;BR#&"'^*(A(.8
MBXIBP7:B+_&TV-[TYW,3&U1[2FR#64Y==1W=--*]IC:"TJ9YY"<3=[3B C4W
M<?^].Y33^T@2"147O(#KOV6_S';H.&S5:5UFF1L3D))QXW6Z\YE!0O[\!%U<
M0C2JW746"76)295,CRTQR=,Z59S?YQ]GX^GMUF]#P3Y [!S6/\>'N+Y LER'
MO#=(Y"OP__194[D0& 0B4!8?$OWK>07CPB3/=(N\_*N^>O[?<8?>1#1'REV(
M+FN=4_I"$TA40.]IP_3N_ARM\NG$E?6<JW_?NW+GMF?](U*N\L)H<%>I#^_[
MFP"V0L:MT[L=VP.C[7:=*G6M>EP5MV@1^+$W??#<;LW[*V);CYW3-LMV/!>R
MUW6\W5&+?$CZ=8)T7NDI\<BA4?&::B<E214/60_55^W6G_<E:)UUR(Z43?4[
M2K0Y:GQWWX7/WW-B(/]SDO#^MR3A]?]!DOC]VJO/5]U.OD[(?O:WW(]#^[<)
M/MQ<\DPET,-= 8/::OQ4HPD9VPDJ)IN47]4D0#=6.(";+UWBF1XG<./\R*SD
M&[19P(_.FVZ1Q%/8N+W W?E/HU]&!]O+J$*9,E^G*?5Q/+GA-8Q]^0_G!7]3
MA<8:W8(8+:FUP^.W5R1@8S7GO;YUBJRW:3X)AC6O1;@<1^Q5C J3!HRN(*,D
M)DX-8@2X&3EC3O (+:3D0IJN>ER@CZS;EZ42-,&LL>$#XU19D,)$7MG8CZ]:
M4B71\N?MWULYDSZG]#,#UHZUG\,D-KH*GC8Y/;IX+LDZQO&T_&#Z]2DF\<'T
MBK*C]>OW=;/NIXW;K;U8GZU\SZ,<C&NK::,8B6=AXAA-X(Y,A00%!P%,/U4
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MV\AXM]L=A<\CIJ$A8HT?';YW!2]VNHO-?F[S49A64<NY-BQ<*JN,M>!#ICZ
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M'^@$Y'XG=/NZ4$FA>J/]O@C82X+DZJI3O(EYPUC1_.<ZP)9^D \QH?/"GQ0
MOMNF]':<'[7[_!!6VFO]#4?K2:%YR3C@VFKOVO:<W>YRO&%@+HDW3\G2J&?L
MB]5<=EB^CI*%3PV]TD&O2I4L6>SC0]IT\(>TO*^JRD8Y8X^T37GWA\"B],T*
MO#Y,C"UX3GFC1$24GVRJ-,EBH1,N/5A-5@FZN^RN8Q8\]A-)+MF"40S="R3,
MZI]4F'Q>U7,8K6[#V,40XV64+ 5YYJ/O!J6WZ#EQW6_$B&@S KK,R4?&++SS
MO8XX:2=^N+Z+JX!M,:?F?9*1I2\^A1RHGTLH?A=@:]MXH'#?;\5/8]XI/WVW
M:WN2(^KDT+O&AW@V>*@&QI]B8@'[,"VL;,_-_M5YI4H@Q/^E3[G;ZYQ5J8S[
M@W__,#'!OM:,TRWI]*HPDRU-NM)Y%'<T2>F)[)/#OUUE7.V6^ONI?%S>-Y\[
MR HD_3+0BT7I_29G#*?GA2D+OQQ$Z+@(3Y^\--_W%%Y5_-]P\4]3Y'P#^W$X
MB+@$MB,=.T,+4V7"-W6\-'>MXWZ:_IZP7^[5I1//H;\G1&;=>Y5T/>F(B>"9
MF<2D[YT7VVFWA*?.C0^G^T*S.?''#*/6-2$-&>7,KT;N_NZ/N$-?_>NP$?4)
M#TT\[KO_WE#YZJQ0Y;G=\E/B\L^2+'7O)0^D7X<9[4B>_05'N_ZY3'#S%#>"
M#YGY@G6#LW4(+^"L\)^#O)#K!Z$"V<NA*EQ![#_S"C:_\@H2_\@KA#F#,Z69
MO/X MH^\3![!+A*!9\B_M["WX?2'?RHR_P2TGN$!,A/)*@O[W7X='OX3*_>'
M#(K&AQQ:FI >K'*0JZNTD+,:#)#:Y:T>J142JUU)&@KH5KE-&F[T57_7VZCH
MYY4>;D9%G_&9$+G/FC#0]@_RQU1\OU4YV(@0B%.M4KL\?WF@CT=Q&B#ZZ%W]
MT%"3T?S8[F-[EF1M_: O*B_Y)BCTXK/,]]60^C8SBM;>-0T$W,)65#7,^)09
M-;.TBS##PT5%GRL1=P)#\T3<[7 4%O'K:Z:U9_(B2SC(.W^R*7EA2.$PU3PD
MT?.WQ;-(U:L2$J8 *N]GD&Y3=\%+PY,(;CWK!RNE/&\ZT_W&Q_1M9,(M0J!"
MS(/KZ>\%SVAFFJZ(^.>6:B<NK.W1?EQQ95<*C?#RW(*AVJ^R]%P$A2&$.P9@
MKS \!M0?1,R(3\CV!BYQ]:[WKV2Q)KQ#S89:NNP:FE*/9Q/[RS6[+@GU$"AJ
MA&+A[6,&S<=^W]XC<TD C NZ=TP3@)K*M/0YL':3WIY8[.4BW=A+V.2ZV_0_
MT!)Y[-2T&Y%\O5]Q4*NKRXQH<6>:^+J*#QF5L!$J>1^Y_N?PH<N=8W>BY2/E
MD\PNRB=WRK]-,IM)>H0X]10>C)V:5-_11<0CF:AI/L0.$5'"FB/,>/-$-O:$
M#> E/X+.,@XK35Y\#SB2RQW_K_>^_0L>W"S]VL&*;X<!IPC+SHPUFLY+DBK&
M#M#..LW8COGZURBS'N/'$+VJTV'2IQJ@IJ?[.(K6I&->PS9,R1]QY$-R1HSF
M=@P?3-Q;DX^?P]+G$8 BDBOU PL\XH&.8L,?F:]C;S=DUS_A@A IRRL]_^/V
MCQ]=)\293+I)7[?^QK7.HV<I1S23NN1*_=I+5S\77P7ZIR1^E4=0XA9BW&AP
M"&8O-]=0&F/*<(\,,%\[.KX0;+":=[^^XX5FDXF!H@V#_)PH[6_>%X!_F;6G
M7^OB2@#7O ,&7>-84/6$NKI40IKN'E=7N_))1H,/.1@ =D(@']+;U,&'1*G3
M)OD0'4TL)1,^E8G=1/GQ(=0NH(8/Z>X.L5_>!K6+"#<6[D66 :*HN.4=]A6.
M_J^7'H@L2(3)UWW3AP<5M1D2J>8B#II2:\?1LFOV?9O=.C2=YZK$HC_[4/K>
M=-YV*T^,.%#N4UHP.%U;]TR>=9*DQM%!QI[C"!FJ]\&I/EWT56SL.6"_V;GA
M,6IW3?0[^@/>F4/[A7=?Q;5NG_7(MWFHH/-Q[Z&_!M_?@(9CJ5_QH.%CZ=2"
M@S[+<>)#YN9P@#^!(UJ*[?XW+=+:K(DB^Z!&C-J0!TAG.?[?2(8<31*@0Q=J
M"].AF[:MQ9BVVC%)N^BF,88GC/*[IWTTK!C.BV,_:[#?!>S[RU8) ;'=YI99
MO(6 ,:FNIDORU>;X2N1*!%N+-URO'KW5,S),ZXDBR3=/93IV76%DI;FCRCUD
M5.AAN<7?1>R-8]O"!!EAB52P3WQAASQ#B B1"6]=D4S<R\W6M!O?5@.%KN:]
M@1BH3&V#/C(*O\OP!!I%U6G!0W%":(&6<XN' .PER=2R4J']6\Y@?-TF614N
MI8VFEOC/+Z9GKGSU77,_MS-QT_ADPH5^O>FH3_@(?%409<6(BFJ'"T,E  E;
M<N^6^<JAQ=&)EXJD;UK' IU/85>@4"]=EP+8"&J%AN^*8<AFN*?IFAV^9]A@
M# ES!77E?PX!)3!4]+#->J9";,/B\ 'UULG86'RY?H &,$SB]<-J<,OQ;)E)
MP/TJ-Y=T$6U$3:BD<>&V0YMJ0E8XYZ&M!8[6NRX4B@!\9E^F9\731)!7Z(I1
M\_75X4C&7)U;/J!W)?U>[,UAM7L*)CH=>$ )OVS!UEB 0;76XF%56 I.< $F
MQCFGDT"2F71$+LJHQX+2%^I3%K"TU!.=JC+EK-.Z3J$W("H'-QN:$#2?S<=9
MO_6K!0KIQ:X=&FOSDSH$!;5:E![()WHQ*_!*^LC;9=#?9S""[OLWZ&&INF.9
MDSJ(IAX73U/.X6F>X(0&;H0/D:I[@+$$ZG6D\QY]9PQWKR>1M<.L32][KZ[\
M(AD*]"!';BC,8#%+G]Z(W:<)B]*-:AL'KUU>YE,$G%>/U$5&NC$RUQ+*MKK5
M"#Y:4&'%B#^36P][U?L[CXU[7O)=D43/Q)&/T]9&PYE8^JDRNN(?C* VE*!'
MV._<_"TV0IBSY]L9POW0(%IJV1-J"4%"&7 RJ:G)L*GO+VLT\ H4,7>J)1*_
M;3[S+W!<K(]/89;D.TY ,.'_]<366L;^1I[*0GZ$+0]/?^<I8B2 :UDBC"K'
M4R74@:&T]C##X?V]6S4?0RW[EV5D&88E^?BJ:KP'9L/#5W;=3[@B*CD0&4>F
M6\._HY@8H-*';C2MN*)(G_^$/#(!%[(H_JG;]I6@4!!^DM'6,@J<1T6'G>H/
MB 4-)D8EMBVI4X(C9XTQ&VY43E_V'^O))[9*'.I2'/L4>=QZOT'SWYR?N[PW
M>CKP]&L]WTUI[O$<9X9$.WEWL@,C*J'Q5VJR3;<."&?H_J_VKBVJB>O=1U$C
M(D1$[I>TBE#%&!40A9AHJ5!%C$B%"D)41"X14XMHA)#!"Q=!2=4*%351$4%M
MC H814B$ *FU&+G?)"3!JMQDIBKLDLGDC&>=AW/6L2__A_-PUO]A7F:O]>UO
M9G_[^_U^>\U\7_U0*O;HR$+L)G]?Q9A=3\*X*+&J: ._*8:=Q+88Q;G,SJ\,
MLR7.Q\>/ BJC0>" XH(X\XPVDI,'66#D>,@:C=5X&/SUGJQFNCW(?1_:>E!"
M9G+*E GFRA.Q;17I0<%5G2/[EW[H\PRI3'/>JOM]5)>UEI3[#[FF%+628*??
M,=#5D TN9!_=21W S"!<"=ZJ;/<2SX5Z@[3?I-ZIX92JXVU8<8@B6-(UU&&3
M^N!"V5L_FM-3\:"T)ZRX=.A!57Y!YR'/A,+QU-P=CGYE;M#>3S5)YN%:Q=1(
MT'$$OJ4CRNM8!V-&[\"=,P@I @0>@8<^_2I[;=@<82HF3W><NX7ZW*OJ&*GH
ML_H.:9>5QJ;L%,YK^1C9]^/0D.F7]^\_2JDEO)?\;X^+,:=!W-]A(Z$X38 '
M#JM!CNUGCS%SY#9\)W1A!7QYHAZRC<?F5""J>NHTWB+XY\GZEOJBB7KF28>7
M=$?8YT3%^WF>]M[0W.'".8-5^S8OR VZ0"B(/[=T]6VHQT.3^4;9J^K>K]+%
M94J@^#6>VE,B^Q16IDUXTQ%=GZ,VEYL7"%^/IG:,4JX5F%MMEG5^'*4R6W:W
MW]GWT7Q/$Z7C7%Q:3%Q:ROXI2#:ZNA4S;8->JW&^H"A$.$;"Q2*#.>Q^C.8)
M=];RK4":IL8K7FT)!V8?A&9QXS;8ADL5P2\..MIY]2VNCQ[RL3T\\77'[VH[
M?G-:RH&4E4WOFUPS+Z%2N!>;Y:RW1J/!G[>P)IPKXZ):GAV]!#25L$#Y!A>+
M5DZEM<.[2HW]0H&RBG0,#3QR(P+X*[$O8,?>/H%3/'TZ0LSY",U,SP4@Z]GF
M2(]R4O>'*1I6!76D%O8?+X-E>1I5OGH6"T_M"NP+YKQ!AV2V>B$,*CH7M'J;
M.U-E[=K3K,#JBPZ';J=SQH^\*6C[&TLXT>2TU?TWT6<H1 H:"Y[!S_!M&*L;
MP]\G;U<),-$*,CZ 2L@.J")M15V84TN)O+P5JOBX?4D2=3^EXNU2B3CS3T2Z
MLF..GYH5Q(F=-F')M1W%GW4ZT7!*'ALD,>_F\0Q7:5/@O]XWJ.?1_6!#R>CS
MV^(=0RXSL=9[S5>18[7:* _6V7Z%;=&#DH32A)Z/NMZ$U,O#SSBE45$;D@[>
MS> *_G.-.G'--T'&G.1Y$/JR^1_2D2L9WDX";E$J!1&H./J=O"47M1G(NS-P
M'=7^&UK$9/ ;@?>8Q7#TDA::YXWS\*/'[=YF8Q;<Y,AVK6^2N%W:[=5;D'8B
MY3M.)9_(@\ B?1!O32OFP9L*2C10GMSBHU^-_^8'R.$,GO\N'<4Y)6H^5,YV
MH+P:WUI=M/]1\4L\XA,GW4JMA>*2EY;FAO/5IVZMI;OA_OGBTMY(>/O?HXSQ
MF>TO$W<PV%!WN:+?#/-$$SKY*X!C(-BF7\.]J!3.!JH!,7/;2CH90+K^K/ #
M@Y@/W/'H<,JT32E]I*U%YHLJQ'2_X3[_L(</6BIR4LP#=&8)JZ%3<FG@R%4]
M@[<2<!"V[DTC9,'UKX7L=K>Z@5"O!RX+.V@;$'RO633HAD,T$@)(_KJ#!^DV
M[(+KF]E5UQW"LY;N;?9Z9#,6$4Q?84H0Z]?PZQCW52,2G9C3*)_*MZ,>18-T
M5)*14$?Y-3%(U^\(,OK>^F^M:&\0=/.8.LKNYR3PR_;('>G7U&H/2=_?T8?/
MJAS3CT3'PLD#C#I)#TDKS90MXUDA$UET=]X*1/QSI]H.*3W^\=N4)-*VW);Q
M-YO:YN>^7D*S[0F['9M^G>T0^RJL1RBXW=6?$%%R67@U+CG)]L;__4D</A_Q
M-Y%THHZ<(Z\@COCH=Z+F8'V:BP@)'"".-"$*K4@Q^%HFV"B%[+B]6F5.]1JM
MWD\<';"MA>)-"<#,5PR'ORP-DE:?1><DU9)5HX4-C"E8,^1H)&A^X4]KQDQX
M>V!;U"]\G 6&\<#IQ2E< RG#915.*JNMX+P&T3UI#IU '6G7D+.C%[WP^IL1
M7PHD R2SH8(>_CG85Z643>OP@C(/^]X0W7E:ME[;FZ8:&J\>"P?KX5(6.*FE
MYO6,*9@$-L.&9E(RG.I^E.^>*"/!V%7$K#:5>C+I505B(] R'*(2_@("1558
M3=*2G]B^A\[<C-@^%.)7\LISQKX,R(]\%VKH)_"[^Z7A(P:$4\\RPRC\WX4.
MAI_YIB@+N.M-^<K#HON!HY[P!T!Z$DUY07.^QNUO-!)<,._A?B*-JF=PH9#'
M(!WN5$3; Y:>SK5J5+O!RF,C23&7JUDZEOU+_]($(Z&27/&I?D8W![,4Y?4[
MT1DHK1T-+V'QIK1CLWA;"A5\,K@], K5LTQ2R',%<Q.QZ94@!;[E'-<0[9YE
M)$37G'VM:ZU3.\F0A7WBAKY?CG@]>"0E[SQ!>&6#1G7QU^<8%M7OB1&FFQ+?
MVRV O::@J?P_PEC3,%^L401O8W3/YBTWW*,[NI]F)*EZ0L=58(I6E26Z^Z91
M,FOX!]0-MFV0'/M4SR].-0='M=(&4:9L&@C2I0<\JQ=.A]L;+^A7#:4V7M )
MYH'DC>TT'_*)*^:_,+[&%[R(3C)<I2_BJT45I:,7$<=&T3Q>&CP182B0F?"?
MIQZN9^48"?>A7/ENBH=.).#9(YZZTGI*&#.+5=Y9[]<7I+M<>HQOS84:(OB9
M9>@Z<*:L/PI(=>[Y-,YUKN\KKG]=05@80UY+>*<<>J?X:TE ^F3N%L+@WV<W
MH,^9J82(KZYE,*;@*N:[9D@CQ#-2B*I'/O["4%9-1/+JY>6<1D&70$,Z)G-!
M(P$;9C6R[#\PLGLZGY#MT+AVOAO/ KD(K ([)9BC$C&5S>>RE=$NG=6';;/I
MUB K1*P0 \7F:OCE2?)K2-&?@ZTV9,AW2[K-QC<^- BKUUW%>AE61D+,Y9@G
M+$MY4HQ^.8]M*)79\9_BFTXDP"56&"+)I)L^*-?[H+[@YAWT$#)6E\:TB8H7
M6@"KTD1?IL*,,>?M3Z!0Z>);#K<5'!)^B35X]YE]@]#S?N5RZHL""G4D$C<[
MJ,UK3=JZC@_ZX,B C@]1$2UL\]# #J_'8/\2[S74K?<>/BR7MTK$;\JK*X61
M:;_$9@4&U,-DQ=A4'@4^G,UWX7G"<9DR9T"L<]CCZY-)L]0D$3?!A2=XGM<C
M"^*]:DP41>:568+B0;@PV5HHBN-P[/?VVCV]0OJ)L4?5/3R>CJ/!0=314%#M
M3LJO/JSW[L.>308^J<_62;/19'A B:T$,67 !3(9/MZHMD>6GM=(G+@>D0C]
M?,JME277@XJYK"TO'(R$D9ZH_'/3Q<?\/S6]F+X"<1^Y#4/C.D,F+51+/FHD
M.%!E5-X<@T0V&PR/"T A/#%.,]R4+0VZAJE<9AO.T^E<:JU-Q.$&%A%U0PJ.
MZT@6;U,[ZP6F$6H<^*4YE1X5B(4X1<PM5+2P4\/$9=NAS6MWQ@C7;'!_O]H=
M\6K)N'2V_WB5X+=EY!("9$.64C/YWF@PN(U[,Q6!ZLQ(O7[:$M5H3 SL$08.
MZ^=S6>/+@1Y)&T_"\Z\(I37+B#R_LXIM0(M\RX4"VXR$6(D5RKQ;P.B>&'#/
M]E(Y8<^%"P #UC]9E@A94FCK;[%[GO5"L=B<I.VHAU;:>3"283[,N?*VZ39(
M8U8'!RB^;G<,KO3-.AT+S3NP/CVN)-K^@S[R-UVNW^VT^'=SO;9/S3^>.)GF
MPJ3%O'[S6D,(VG-F\Y6I<A-((V7=_T[DY,WI8C?*3%MEE.^!HD%4&:> NJ0#
MC7(XS'R7M\02JQ55WKGIG@TE4K/[+24'S3U"'MT#"<DW0-HW[27(YNM)2;PI
M98XU+&;;ASQQ].M1(X%W<Z9*0J3-]4W5G!)LX:YI(/!]L18C87;E8Q)8+$$M
MGT\\D4WII&"V/"I8A[\Y9U@M+N.&UE5= T1M7WX)+!GGM="(5X:JL@2[C(29
M;XZ/5KHVW_&2STPHG'#X,7'!MP_+FZ\^3*+'Z]#OD<K24Y@;]K0?#N, ]_ 3
M\CAJCW^CO)(UBJ/6]""#A!<*K_03=+\9X&3SYX(%0<C8J+MVS I=;BC]R.D)
MC8 #+L.<.A<22,.GPL7LG KYW 3ZZBK$=2)B[\4$K<%7]_[[\O=0N=./)%K<
M(R6]>!6]F^A\<^6I<T^?/C=;;O\\8(KK;)< @M)N<*U+Z #KN' &*+Z&,EKI
M7\4/ZO[F.X$Q[5@#U2(J..5F@B0.\=#>N6IQ3\NR^:)%0G'9_JMW6?\6_?2!
M'0G2^>''0\H?952GH#J<N2CUBWEV>-CTJ7'@UC)J!3TF3XR$6=7A>E<T C@.
M]#N_[;\[-GK4)4\G[R7IH-''6A:9+8WV0#([:X,N5&_TKO%5;FEWU*EOWE*C
MJUIIGKMVQ90"Z2;X8_ZY&(YA0^NAV6^HG8QA,KE@)*;7[@KIE;\6&JE!SM!7
M\^O(][)KF=;\]B+1$TD7$YME*D8/W8-%C<RN<Q' JIAG GPTIG3?IT=2!CB]
M9EO:4J 9_#85LI&1,Y=KHEE36-M<DBA;#&<+O%F.Z&Y!2 U<V?: T9DZM2QW
M[;3%QXAKUYJ8=&W5Q#':-(<T!\D9SDPQA9 L7 8+LGB0EF'%M6TLLKF@@XC<
M5L6DZ@2Z72M.;/$S.-;3[1&WB\G%[$D;<<RR>,[!)M:&FL>M8Z-N8;FZ#MWW
MEZQC6$?E<*"\FUU/-L&(_+YP^O)*H!*#"079F4['E*(9:!!RUGP_T]Y?;XW]
MYB-;!"#]E\#LR6CZ]<&M+)Y?*^IWAXTM>/'QM(MZB&3/5G_5[BT?I6R"XL2B
M#Q[?SO#L/,MT%<HNT$AKEQ'W;2'^%:>M0#@CG\II30-&PO&DZF3$1RM1>E#\
MQKF@%![8#K370:0&:F3FJ!D@J5C0U3J>!7]3Z+((AY7WM4)WD%=:2SS)"[P:
M'WZ D144L2-Q)?*RP>F(<O!3C_<Z%U_$]E.CT^G>!C$>"F%H(*#HZ?QVD35&
MB.*9P[A"GS8L,JT^,.#,U!@)M:NJIR/)XYEMV!QN;N=FA)@Q2E_!S8]R>18
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MO+)$T4WL7+@?4VJW&$,!1]#,;B@YFZW/(1GMQJ\P:Z##+-UY7-ED#!>XU)7
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MTDIJTE?F I&J% QGAZP6PN@;1!?B:0Q5#ZKC J:\41CZ^W4PN&.CK'HUCG4
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MX1<7\,)PG.LU2;_U_V6;EZ@U9 H?[ ,_*X)3Z6BF)X8'7$.5D?J\V>___G5
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M^2 _L_<#ZEKH'1/S^B40[WC@_S,D\>Q O7$UIX[L5D0:<><";A_\1O90 KE
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MWJ2.(OAP<I PL^5D[85^%T*.792$:((>RX*MSUA,#F,KU\LS6C^40#5<@/H
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M[_6\^\MRK+OS=NUT@VPIQQ>'11W/QZHT;A=32.NQN@6&D$NZH/.3 B#%#Y5
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M/TN43E(7TNM-/9^_WZJ(SVRGV3G?UC.:?VRLP>K6,[]-68CWFVDAT9& ?_
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MN$!HIAS&TR\.1_<32TZHW\6^3$\.Y0+>V*C,M^CXRV^A)H8,-3R9;OMYZ<)
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M1\STT4[.A,=T)D-+'C%SW::Q7*!)WA\Q=.>(?K]6,-FX:#(=JS[D0PL.,Y*
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M_T;H9>N!T[[=TY,W]EA)'WWRE[:!"-6HA+IM+5T[Q!01A#&_%E?!&(S@ZI+
MF$/"-HM\"R\_ZO@1IT63\3=L.Y^[\M74F!FXP3/95OQRD]G;TO+W[RIU-HJT
MN4#D0JJ0K1/^C>N'7H>%^#H_T$\H/B5[MEZ7D1B>HTG>,2=>EEQ72AXT90Y4
M0*5/NCYN:,%I 89-^ PA!X,O30G^D.-Z8=83"\KRE[/*I#<'+%%BCF+[:6+Z
M*UF1V28YAW[9"UYUTQ]2N9WKJ&>X[;+/U$SA4.I[OX)D?$@R]>VZ.2FCX7+
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M4QGSEFD6Y-Y?UJNT<Q&EW6M[BDS]0P1/:S85.#MY#D;_:K/K+9':!0]ONW#
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M?!2Q(KP$ 4@]A 5.U'(!?B*Z)2"8[D-Y4Q  YN'M3G_3\HFS_GV.D?6A[^<
MP= W9V[%6\?HP@F?=;^,7Z?">;RBC_/G4QK9: MU^"0Y"A0WD"QZ*A9*5#?2
M_*;PE7CJ&ZS@@"_4"KUR6?5NA^_++:96L:!QYM]MF2HPV$6IC1&C1/QU><[=
MW@P_5WOXV><\]]#\-<$>[%S?.!>H/*2.>GYJIC)^KZ&$V[I=Z_7_H[TOCVHB
M[?J,*\IB9!<$HH*B(L2%10$3%141(0HJ"DC:1F63#HI A)!2=I"E%14%)(VB
MB"QAE4:6" G0BH+L6T-(4%:1*H18D$IEBG[/.^?,3+\SYYLY,]_\\?Y3YZ0J
M3SWUW.5W[^\\MVYM:0$SMD.B-1D^\3FWGO,J(KR^_/Z>U:=QVO%E&K7WW%QL
M4U;!0$=AL?VTU1=JO#E["@^V"X $A)))KZPEF?DJ'\X8,7B,+ ,$T^N\'DX;
MJW5K?DP/)E7FP$Z.%:WYHRF.]()9%P/:EBZ?Z 0>R1;!B[4907"_$)_8AX^<
M ]1A5D,- ;+RYH/WQA=$F3?S^\>[ OLN3_T0366E$(DBB_$??OWAFTL.^@9H
MC5+H3PHNRHD/']@0MLQ@:5[>,H/%8];:]^^/%_]JM6U#V&K5#V,ZLJ!'I#[G
M#<B)8.P25.:?_-91<$-AV?'6;\1F*<Y,W=]+]'"F.>S$,=W 7:MQ?FEO+VK9
M":X J5#CRFM&=HV](LH]<'!3Y%7N1O:C*Q6IC=OWMN1U1UK:$W?EF.<:<_N-
M&AIWTE\Z<H\<E\US+9P".7>T]M\']37!AB"!Z&"Z!\,VFFU-; 'GF:<>AA[I
MJLTS7'VZ3K![PB]KYLWXR+EMER?ES!_E[/W8=B]QXXV.S^))=$:*VV7WSTTG
M22%B_E?]Z=AB;P4_*>Z^-]I$%NV@-TEQ9UE)!K-=G-V<ORM?ARN%5"0=6$O^
M^EK(D;@-MXB&N>1Y4Y0 ]"K6L18RWRY6Q2N%_OZ.-";%,<F2=67H.@YXDC)/
MIO3[H\W3HF0LNVL:QO)!_YS_Q5\P5Z$"?]^]C]W$^A=M_9;^HS*]-.&3!#^3
MK=W]"GF+XOZ^$'WA+I;P/,66_@!SWKEYL%&*.\WG+B#E;%$(%S]O6J,CQ?VU
MJ*=O"4*/.-:,?]41S"5'[Y"QK'RQ(.\SO.&Y-K 2/7KO?@"R?EY39G&ZEMFH
MOZTMFDE#UY"DN&0;V%"*\]!^#DP4P7>IN>3_H9R=Z0C4-O)GO,@K.%^'2]F2
MLV0E R0;[$8=S RPZ2<Q8ME>\1@MHV/<8FM_&M"[XBXPGOX2-?9\BA&&L_B9
MDY"=D^@Z3"B@=R"'.IE:GF8U.WSJ.SQJ[K*[WG]WL%92."K%6<7-&5M,=MU?
M_3QUTCYE:@_>?,KCP1-^WSN]>S?U/K,</)]6_<G9_&[F\;#WE_/VYQ^>^5"$
MUWC4T02N<U4]P31R[:YW]XAZ?OQ<GM5(<D#NFP?K[Z<]^+)%<J+1HKDDF*YY
M_C4M]<K]X@_&?C=]+1L)=QK:F\"[IT[5#67&YI[=>\+R](8'FK)/C#-5GGDV
MU .G":"O^@*_?[V$?TN*$W=.SE/9$^&H J8<%[$[4 D2I+C@:N:^V8>8 /4;
M,M+W2W'Y]L>8[;,_82<$M<QT3#%YKP,!BMO_X5LJS(W_?7<$<?:_:U3_/Z]1
M-8G!?;Y=.W%@:MJ>'4_V 7HZT"[*D#6AC#J5)C8&ZF0S] ZQBIT:K<#+EI@V
M5J_W3*AL]+8T$%+A8]1#:'V_H.$C2^0\T=<CD>+ZI;CK[264DM\)#31$+2+\
M'WO4?@<Q:X(O?\)^&B]26U<GT?[A:=@T5W02SA%^=&ID*9.O$N%MK"2&;X'D
MCMBGGKE=DG=CBNK6"93<$%_0IX@#,_W!_!?IY\8#39T#7KK'7)TR'#JAYVV
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M[47/'V9X7^]-D=F/,N_>(DM[_PM02P,$%     @ $I,!3^&1)"T/90  AWT
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M=*GKO:L'G09T4):*3:#[X]=4P'(\LH.P [<Z;<<'1*7(P]2EDZAZI'*5&I7
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M&Y W<-0$/NFT+TZ6%,;Q:AI/VLPEH,Y(B.O/I,?)\&(HZ2>AF%8<;#E7K\P
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M=_K=BXXSNBD#V2M,+.:RB=:G2JHP7'"\UQ@U]J(^Z<,J=,8\>+)L,/A(D/F
MUO/R_HHLSQ/]3VO[EH_HG"K/\'.;%9[UF=\WGY<B''LQ[@NF$S7-X#GZY[YQ
M:G-W+'9#HRSY WU#O1%$9386,[6<F=ZW/6%_AFSW5M(?)DJL3>5,C22=]@R;
M7_>/4.-U1=3#;_ZV@N@QRS6T"HH0["MOU&(B7]%7X7ZP_2/VAQW]KQ>+PWEG
MTA%QPMQRBV@GZ:1J9#+(+,[G ZTGL)5XWG;ZEUED#7[,![K<P].Y5O1$W)+:
M>Q#BI8.++4R0Z5<ORP=RVGWX0/3)D/05=$ECW$ \BDWG*9\[&!8M ?(D.3B
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MN-I<V%G!$[9&!EF2)<PNC"5+>?+EG842S65W*_SVV15!#D[?9[Q+848+V35
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M.YIQ2#/[2,:!>^MW 0=(_W'L-I!%_@>/5>^'*1.^T-".OJQ T;QY1\<,NSE
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M.:L$]CL":,<,[U5'U) :BQE#'C%RAE.9;!)+*- 9.0(5"_C#XT++X<V3G*O
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MLCO"NK&0EB:/3)E%B*E?^"K2NJEQ3@GQ5>\_RP(0J32>M"'LA'#Y=3^027<
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MR%,&J2Q4JV2*$JG)(6F7,MV])L'XJU@KO#9CC#0SDAXX8MYC)4,X"E9Q?_U
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MU]MQ:-..#\\_6ZJJBN:)FZAF7K?-4SKN;BN5>$3[8MI"4E-R.^H!'M=X_5%
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M\IWS<W18"^2/D*EXG,?+FC=W@S6Q708SU3>5CSO<M'-\\[+^9=2%?Y7UL)\
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MLRCA*38BPU[B;;; )2J19V5\2N!!M*JE$-C#'00GXJH,AKU9#6FCJ,%.!E<
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MD$>)431O9@JJJC6M:E\2,X5834S\QD'%1&KR+" T$@D82NBXM%0!X)?-^3I
M3]&?'C-(<%RB,]<%TMFVY:,"8',@4;).NPQ#B9CC20UPJ;U$?VW::$'#9D[-
M; %+<EBL%26)#F9*G468(DA)L]S')DM.,D4)SJ#':%:I7PB8=.!3]:Y#/["5
MKPFG:B$*JS/V;M. R=YF%M^]>_HDC;,UE68,1"Y=3Y_ _9E;F8P[,V'68OA@
M(CGLHQ5-R,J"H 8E,\$3U$%$M_@U"H#A=NXTJ04EO8C=&CE(5JE;?YV3]%8!
MM3Y2+K(=)4$(>Q@0/(J1Q*^QDAH,G&_DD-BDQ#HT&/KVM<]$TL\T$D_H$<&!
MX]@'ESW%NQZI[D,3;FV[<N6Z^FI&_G[2'^9OWZHO/ES_GWP6;;1A.\$4I#$^
MJFXU8!P_:QU&.9-B36]0[_I)/LJQBZF.!S\%62GUGT,%]%#/A]EF[?;L6);V
MHKVL3=Z&&4%#IF3N*#@Q<W,,FXS>(  N.B"@)?$#K6+I#$8WH44%0.#R59,>
MJPU!5J8]%^LBC0SBB J\HZE7TV*P<KR @,=?OD!_!'5ZC\XI?RR8=AGRK @N
M$U/>C^'XTB@8R'2"94K'IM(VTG!(_BT$218U 25>1Q1^*P D\>UOX=W=P6&T
M37C2X5?/H<>= 8\G!^(YA[URS)[-/"N:IUZ=AG95;[7XW@T/C7PW^,XL_FX?
M+0#BW9KOCPM["*>%L(:V+,4^".CZ"'YB'RW,4DT-.G@\S]*Y\5AQT+D0>^=6
MKZVFI**D5&&9E*;SM$<-26X_3>$=-2(7C/M4?+$"0%&.(!YR==SE)28A>Y-O
MWQZY%SE3ETMC3G\^T-7J=?W)N3V!(8R!)@PJ[BT;I/52FETD0!I;^\1& 1 C
MT[)UTPT(YZQ&>;PM^E/4QG?;!I9OV,"/F'!].6WA4!C_#OXGG9N#^(T9'M7B
MCG1CTV?^"V3292YYRG'T<REGTTMYA_E/B:/Y0X[?4X@!P4$$MW$.:A:UNA/R
M;T=E$M6SB?*P!(0CA%/91!'HAJ(?;%BU'WMD8.&LKONG:MVMWG:]3W==NCKK
M[/@J]6?3RI>FQ)TO7\7?2Q=:FVQV5UNN\+Y:IJHQC_K#PSV1#D7'A97J'2J[
M/([_%+9]ML16JB.@HRH F]<=>^0>RR)17SKOL*WCD1#,(O71N.C( /V+W8LG
MX)2*C<W R6\_6JKR,68G,D^^4G.Y'#.A=.G(E61-+<J6MO(C6H6T5VFCSQ&*
MO^8%\0D9KO^)7CB4"1>2)8C?\O$*,(.)6#X9?8PZ/_U/=?(FOI$ ^,*S1/A<
M*N(,/=?7\,<6=@B ZQP%N.YR)_R@HV,(47JC&:N\_R,V4V[P#R/#WT5\C["P
M .P*#T*XWQ,<BQ_I,;"ZGT7BY6(EB3/Q+ S?Z9PDQ[ 9LVP^@E@[&-I,7JEO
MC47D_!6"E).-[)J_7.MV_GWR70"<*\,-_:);24"Q8%GKYLA. ?"2/+/T&(MO
MY9[@/[ZZ:[]^F "(&]%Y%=W6;ZG&+CN$_$\DNY&8< .?04?+1JH&=@6ZFU04
M?T7<'%&S04H^.1_G6WG*BP)@YWI)?M9<(G/%E+ZXDKEZE!?\DI\+K^&Y0M,1
MK&&R_!!O%^A;-B;",_4KM2X^&[1G\KQ)T$;C?;D>G_6*<S^PV1X.L4=#97QI
MK7/RET\_:&\Y9MS^_&0>P1>=S/FLIR%G=J"?P:YX'RMZ),Q']'*83F^,^=0Q
MJ90Y<UOM:K@=LDNA^XQLNNSIE?+D\3G0$A75<G[:K",P55DBBMLW5>N</&7O
M7"+BV/) P]R]*[FXF[@V\@.M"D.?@[2RFYC)J KAV3[0@YXORG\2J?A#"1-+
M"^H<M&M^BC.2N-;AD*1=MY\S-IKU2+^P@8-[2U.>OF81G@AOX5F#L^! I"J4
ML]_4OJ&OBBG_8TB_NG2H$AG)73"=,HIKF;NMJ@X*@&:BLC^Y:C]_B.#"Z4RR
MVD_P[H/U\1F-I9RT9J82#PV^(QQOX)0PDXTZ23D*B3R_LO9P5IZN\XL*3O-X
M?RD;%Y_ IBI 20P++H4W#R-!%W1)(V&K^ .WK/80M"&QL;3!'FXWG_P35XT9
M'.#F(G4RR.)!"B,JIHT=;\!6-C&.%/VTAXU[BXL_['&,LT0O/_&#<;XVXPRX
MD&4QH[=$L^5M0:C'DZM8F=,>$(I-G@DMQV/'.N.,'$TP\:KRW;!^@$LDJN]2
M0T>%)[Z55<.MB<$9+.)(0^7?G+],WMT/4X@%=)V &WVSS<VUO086>ZS6XJNC
MFT=WFSV3*K.6OM]1KK>V-!?D!9P/ZHH);!?#;/Z%*].[,&GN4A"=Z<^N,/)G
MEWD][J/$,-YGFRBTSFVLJ#T::2K28K1G"^%9GM)@=$FF7W=Y+'V@=*8@L33.
MS;7?<Y/Q&:V!EH/WGM<&]CVOJC ..-G,\O984>'GH<]U1J,J'4GQ1E@QJ B!
M309Q4] *.FY!%B3/RJS:\B[PBW@H5KU!4PK^J@=6"'(80R=9>K&80JTXN6GW
MUY"'8W=_D&Z$F+;L\&EW&QDC)J19,_.F $\<2XOC&8Z6>S?)HZHPK331R&ZL
M["5+Q3&,''[?Z;X&3<A$ +#RBPHQ)=,-2KU5]5AZOIP]+(.WW<<4\@_/\MS<
M6VY;'Q!1XBB<:+Q XR'*)C[+$@%ZVR3V',\R4D4 ?-^1!B5X-Y(7_!OT!0"]
ME=4)G]=%HDA""(<"QR-0#MU@T6#",K7NEP!@7^#)(#%R0@)QW,@=OY<M[<B+
M8<0?HNW<(,C1:]4!2N+6D@[U>HRE)<!BD#>7V,NS1\<;WU]@@35-5D8#\+8?
M#:@*L+<F^.'DO!V[4V;:HJ2_-,!'M80PH+N^C_'\@'C W"D>0GX8#JJ(Y"NR
MX83#JNA-Q%_29SOIDI!96A-J,ZS!VP>%2,Z4L<MWX.)5+<'PVZR^$JB2M?JY
MZA7A+'N_(;UK:N]@Z^AG]=>)S8L:K^\.F;.N]ZN)MLN8I5^A+H1S,B0.OMQ1
ML[X_5DGVB4L9>C9?)5M#YWB8CD.6.:-$__3.V2VO]M\-+N;2^6J66YI="^+H
MG)=($QW=3VKUN-E):5I44Y2NCCYXD2GWT;S9\X23ZYN 0.+AL+\^%'MD$W$O
M>H?= G4LZ!^I5D/:OZ=45GZ36&KT_Y]//"V4<#S46&D,VW5QV+508^;M[9DD
MDK&EG%?4QL5U2DBT/>O,HB7 6Z9,K<P@19Q$<URQ6B\A"#S&'M>S-&9?']DR
M,N$!JLP+X48[E5['&00K44C52VMURR*N,W1-5SX27 3 72\$*1F8WPNMIJ4#
MR]>;_R<=@82[9-0:)\QQJA$!KDUCET_#*M0LWUKMEE2?3+8/J6-T^MST>SFU
M]A,FE(2F\]KG=V]946CZON6HBWQHD<$/\B/YB)0VPTU"W#T%26_'+C^PL39Z
M'_(IDU!I3+=]:6_VJ84U9A'ZG:+;VS2VN^_R<AS6\_/3-PHQS0?EBNB\_5 :
M"Y<PI#P=J?CJE6OEJYO[/#^%!?GU$!Q99P/7MH450+DV#_AE#KWEW^QE180\
MSK;$L5LBXC<A"B*9< !RU'_UM)DCS.)6Y:^%*BA_/+=F'RY/:4EB?[7:58SW
M9NNGJ,HP+&19F[5PUP1 L']RQ9G)&DFN?W"0I"V_@*=!>51:1/#*Q4#[QZ@2
MUN*O?\:R'?_0SR@=PFBF![,EUP;9N*/EH8CC?\I%SXB9E%'>NW<Z54DJ#/G"
M+06,S+V!Z>VU'2_%],O;-:+9^OZC+\2GC$K?EV!&S@>^-S<)$CV>%[AL:RAM
MUE>B]&=RF>*?3@4IJ4)0I33=J/+UB0^U.EFF>XOP-\-)YCXI;)6LL,"#]W8Y
M2-@:=ERYWU\J:F1(4%7:7.)R%5Q^)JE?CA72(WZZZFK.PBI KJT6EI[;0%S\
MU329'Y4.ZB*E/P;21SS$XJ_=+R\93@A^5K ISB/H3U9MRH64H6UWU4SML!XD
M!HMS3XO]//,'^WEM8DB9M4Q<V;$&U7KM$JU31>[W*,?*S9M+#UZ^5Z3>DQ1
M1B70SU_&)WX^ZJO:("-'*M4Q2S;9F7ED2Z+<N2]^1ZJ5*F*/G-JN/F9V;,\]
M]T#[/?]A?B?]C_QNX/_RN[_A=Q>(C4[$<12JNI.?CI8G_G@3"#'_8;U^50T6
M31( 6A#_&7$F 4)(BLVPZ_+^9MI\^F<!L&J!1_.Q+,PB,P8]KO(<Q;VXA[A2
MR$!->&FNM*&9./[&@?L\.\@-D637<D(#<8_]&]1!WEP$2U(%?XTX(P#D\79.
MYP9?=1O+TO<__<"<7-D_F'VT]WBZI38Z,U3AD3W\ K.$\):#QF(.HNVX2[_>
M9IN>#_4+4N=H]+&''MZ=+-^5UQ]14FUK]\I?+3VXK^N1EB(R-B=#]>0]_AS5
M.1<::';15ECVAU.IG=S[TF-/IT^DRAT\$7*9\=3Y(1BF?<0L$5]MBP]HJ0MH
M(V:8NY@:MH<LA SN)QQ#H6)3 GNGO<SS3I^@'"RN.!:2>#=?D77*)YGB8DCO
M;;+XQ&@ZJ7'"X%?XF/!L.,>;>Z.N$@IA=XI#:BWYIE$=PR<QRD,C@5D6)O6L
M-Z7ZNQ:FIYEB[OR<"3O.KO;!+\1 #^O2K3JF-K45L86UQ\FG(SL$@/+%!BO"
MOK26.P&:!WLO5@?1)*=7CG0L7>M_79Y7GS>1ZQ6VPTZOWS3+E5LCE7 '@]N>
M/^2L'7M)\WO#_LB/ D#4:E]@/HJH,*W@J<*YF5=:T3VW<-;5KKK?V%&]4V^2
MXE@26/%%XLB(<NDSC8JLC9N_*U)J4\U];>=E^B(5>+O!\$;J^B'(M!%T""B<
MG#\[Y5JSDM=[A1FH,""F2.LW3OKN$$0T9M=$[6W?6IU74E(EU:SB=,B>1XS=
M2Y:=9VXVG/2M<XK^2-C;=,XO[CU8^]1%1B&'-:7E18DN22P3WZ77Z/W<B<MI
M&0O5<PP8\Z_M*W.6\RPL)_')295$44.T^/Q&'TOME/>$X\UCD^S0,RX*8LF-
MXZ<3KX2Q4LIC2BQ/G7E]6N4B3-63%][5]"ENPY-,'2.P%F]AS)>OG^;^?MZ8
MS,]%L)1&4!  ?=FL&\O<[OD.>&3?1ZOY;K@CN$GWC?)C@UT7M/X(<T@*T(B]
M+[*FU_R"^@8@'7L@\CUS/A1Q4B(_>RX*P=L7/ /L4[]3VGWO# .K**+WIGRV
M+/>4'G-ZH"ER;JKVO4Q2R+T+.8%.P<9/KJ'5WFGW%C'N:^CT3APIMYS3BST2
MMEWK9,Q8ZL,2Q2;[(WLQ=HKJ/5]1DW_62ZXBVJF@FJA,_(N#/W<-K&&$F?T(
MQK8P_^+1F_OD_^7\#_R0KTO[]M%7 ' -WR$A\=\\ARKUG_0<ZO_6%L2 4:7'
MY(LO'N[UBQ]?WETRZ9<^G.Y #,51%,N?[LCZPSO18W(LM=O\P@:S?)_T1IMM
ML.["[E(E-UQ\G]_'-HPT/5.C3:27K*?E=Y=0-=ER2E-7T__@W@?YZ4G!:DL&
MC^K-75JAD",J=8L!' FST Y9UD>+5^K>G2>*BX[]WGZ;T&H2G;]WSSGP*T%Q
M]2IO$T3BA!\$]<O!E1;'R(G&)26>15K<;$E-FM.KF@$%!WSU?N-+%V+U1[H6
M!K>]J4SUNN)=&Q?A[SL<6CF%W@ -K3;;L^]5(!JW/'#(=6A]#2FRN1SO?.K3
M7$=VL:/W(WQ<ZXF@KSY&Z:5?/3]_G3:U\'E6L)4AJ>*R=."N[OZ(LUB/2LX%
MSRWU]94<]0QHGQ/'YI=;P&7_4/_L:T-9]RF3+KBDZ3*O$JCZ9UC\@N1L@"U%
M" H__HI\O/=B+".+V$7 >,19.HZ^'MSIA=D79\U8O R)^"H&-5K4GO%$&5,L
MUY:<2%535#GK-O9<NM3"3-S*;_&&5*E>=Y9HX@,6;[BI-E(;?)/R8^)5V)G$
M1\2FWJ"QL6Q?!Y52]G-\\J/+'_:7ZWPFR#Z_5W#K@^8Q.0[TH)P=(A.S-Z=V
MJ$,JNXWXG-:(CJ=MY)F.1<S%NV3\<,:_7K4.-FP:<)5JO^ZCFB3_*&-J !QV
ML#0)MR!Q8UP^>1B1@U;WY]I?2]?UT+TY?"8\.JS>SQVG://,8_)EMI4JIWR
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M$TRF987/ZU=1#P^839<"NV$-N-]?'9(')P0EL]]XS&&5#@PF0H;ZE0#M[.I
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M<&H-]^:-O8=;]+8DW@CK(NL@M^D!IK#8FEZM0$K3"BB@"*IJJ^^B-K@52ZQ
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MB::)U70A601!F2 _?_!0+%ASQ69)!L#ABH4%RZ%;P?SH$2_ *2(CX44#IJ0
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M%M+'9\)+RL-]SFFS2YR-G GIJPX\?OLRIJ&!B_.8#(FCH%%B]FI5KY; 5;Q
M&IT>C!BGQ"!5;R,M=<.D[)I<=?>GJ4U*#LB$\C5F7!J4V;<.@?B?+F6MX030
MC%)2J4 +!O?IX"%48XQVV1.&FP18S^;.7?E_Y_KR]80S!PS0OS[X9X?U6EW_
M?%H[K)SJE?V]_8/:8?7S_I?]^O[>WD'E##<D\>>PX8VT MQ \/V:>J?#;O&0
M]M99:=%(TQ*2P6E/O!SQI:OW=%S3?!!Q-@ 3HPDE3\L*N)1LS1X\%)V75$=_
M(UZ=]'"_T2N(H@U&/YR J?TNU<,U,46_TMOG..DX;;0ZK<L;Q-@.S"YJ95K2
MBZ;=FT;V)K)R$VDZG1QE$0/9\7=8&[Q[[IFL4V:7H*E\:#]E7M?"E#0R[%6J
MZV%3$]#_:$&/7D]Y)F121<$C3/_X_;K$:D,LZWP6;^:*-F=0[4%/5G!>07%_
MN$;\< *R4<F:U@3 U1%PKR^T]I7&+B]K!+;Q!II-(WD3V;B)-!5H^T9H.S/)
MV*L^M2,\P][$H!QC[IN,S)I]O[I^IC<[.FM=ZVU-.H&76K/3:)X7\/1>:"K@
MJ8 G@">6.WRZTIHW9UJM>]-&/$I!U*EVV6U<M=IZ 5+OA:8"I'YFD-+EYK1[
MP:ZXPP< 5ILFGS$H7;=;]9M:E]7UW_7+UC6MW)]KC>Z%WNZ<WK3/DR!:@4DY
MIZG I)4PZ?7IN)L!2NOTG#:I@WGQ S<1$F(ST&AV]7:3_%'MLL#\=T-3@?D_
MLQ^:X\ERMZV!0\HN=)@;7Q @L:VS5ALN7W[;-*)_:[9NFTSKL&OMC]^U/TI$
M[G8!H.^!I@) ?V8 K9VUIA>B<P.D6EV[AMF]7)HM_+GW0E,!1S\S'&W %/[-
M]>K'T7FK7UYVV)G6/F^Q4ZWY6XG%$V2MTVG5&O2)<'5QG8D.GL""'5)E*< Q
M]/TP=0X7FA;YYZ;AS"9BWSII^K2;4:7U# 'Z-TQ9!BRK\WO+WWA&T,;0QW](
ME'Z;;JTQW B4QXA,ZSNHT76JY>*N;:5G[_#3)FC-#R<@&RCY]?JJU3[7FJQV
MH77T"-W+FO22"T@N(/EYD*PYP=!U)NR<VX(O\\GR[D9/=7+S 7K!*OP:P'G#
ME&5="GS=K#WEVQ9H6*#A\]!0]RR#7>!9Q[9M\9'_7@%QMI]KR^YY U#L" <W
M?/^.A3ZO/>%;^)X\XV)!0#9@UFY] V. M@%KK]2TIE;7"GM0V(,7V(-.@(?+
MLVZ9G7)C..).WH%_KD,Y GXMV27?H2(RKC?),^YGM+YRU6(76KO=Z!1!@4V@
M*8^P1^YA:SP6\+@U2F3FQ30^'CU=M=E\0_$LD_/D@Z\S:/S#]?6'$Y#5_O;K
M1A<<X%93+XQ 801>; 1^%?V^)R:L8PPYMS,R 4LLPL;R^]EK@M/<RQ.VU[$B
M5>%K/PMB&]W&?^O-PM/>")IR";+<N&._EID>^H&[MLEXUJYK1F2_ ;B]H[!Q
M-@IY=7-VSFZ:6.&S +4-H"F/H-858<#9^="R^6!MR^V98UHF5+\%I!5S\(U%
M@K9^KNJC()06(%J Z+-!M(E3K[$5_+UF<<D00C,@N8AE;H(N=FZ:W?9-IUO@
M6(%C+\6QWSB>-X);2$ZYO[;L^,R]P6FR\Q2_*W!L.8\N='8!6-9HGG=A@ALG
MC!:P5L#:"V'M5]<7XR'3RNS*LNU5E\CS HNSO<X3+KXK/Z\@(*/L*94MJEWI
M[49-*\*?A6EXL6FX*+,+=RS8+;?O?A;#,-WG/)F%=[>=(%M@1!?Z5N]T"1-Y
M@8H%*CX7%;GG3=@WX0W$)#>HE@'-.?-T-U\9WC--&>KC%986$C:[%?"=]_K#
M6W/EILQT.D]^2C%KW5@MK3=/691M'9U_4;A&A6OT["42S_(#BYU:WIVPL:)6
MQ_6$XPOGYP#EI=W/$SPOG$9NO%"_*#G_13\N!,?#C%G-]? 4]@#7T9P[Z-)[
M!I]-I"F/@%@7]]QAUR U*YS\^K8@EB(Y3[#U?L)>/YR ;*#@K-'N=!>L5!?^
M90&GSX93-QS8(#-8]<%S'W*SS626[CP!Z[M;5B@(R K@S[H7K'O1:-<+=/_1
M-.41W7\7'F>G979EZ/?NY.<(&2SN<P[,0A+&;31R#(4% =E@V47G5%8S93>=
M=/)180\*>_!<>] 6PF1MP$;AB+X0/X=!6-+I'%B$(BUU\R%%E=KO=+7FI?ZM
M<--_-$UYA&4LF>&[#M/7O 229;9_0G*>0B_ONW91AFN!JU5/_.%\^N$$9+1I
MK3Y;B:4P.^],];*L8#VT[KEC,6W O8=5R_CEQ7#-=#I/QNO=K1MDH]8WY4Y9
M!DJ6GOI2H&2!DL]%R:X[ FVSA"G66!(_:Y2;(GIMI_;E(L6D^F*BJLOE7'V;
M?'P=48<OI4D^4*D<?*H>'.Y7_^_3-&7T\Q\G.SW7G'S]Y61G&(SLK_\/4$L#
M!!0    ( !*3 4\M.SY"L0\  ,:W   0    96)S+3(P,3DP-C,P+GAS9.U=
M6W/;-A9^[Z_ ZF7;F54D^9+$F3H=V8Z[GG%LC^VTW:<.1$(2&A)@ 5"V]M<O
M )(2)8(@"<FQLM1,+S*)\YV#\P$'!Q>2/__R' 9@AAC'E)QV!F_Z'8"(1WU,
M)J>=+P_=X</YU57GEX\__/R/;O>/L_MK<$&].$1$@'.&H$ ^>,)B"G[W$?\*
MQHR&X'?*ON(9['83(:!_/'/_ _>F*(0 "L'P*!;HDK+P HUA'(C33DS^CF&
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MX02Q@3;]WNI$ UBJ:&4T+/I>/5'-H">N,1SA(#V9NR5>+=B5Q!96(\S$9BI
M3L>>60TJO0<G$Z:^;(K5R_O3$EMCMP*_DN'""J^9X54U:LDW*[>G68%NNO!;
M [&2RD(>:J:RW2O"14>[I:"E./:Y]\"0>YIH:F'&J1<PSB!7KVH*U482=,DZ
M2U#LF:?IW(,&ZJJO'/K RT&UGA''"&<'LP>W(\,YUS)^6AG5\GM#N<V@QAR5
MP-A[C^D$[,IF50YJSXEK][&CV?N/Z5QD&4/[_K/TA5MJ8 >SYP>F\X_E3/U?
M)PD_]]:^S)U>6/E^M_YZ-TJ\ ^"(ZVGH:4>P&'4TLVC$_]0?G50?>-&?./N,
MPA%B'?T9\M-.R3T<!,JW&1*/)306FNE?&8VCTX[Z1#+^@ 4*.T#,U<>/"24D
M#C_X-(287,D;JBX=D!2,$,/4?]0%_3A[&V*O61WNY)@70D,%UF[LGO7RKB]'
M?H9\+(9R'JF+KU7$7N;5ZI35(?MPB4Q?1ICHXG>,SC"7/U8Z^I5J[3!(5[LP
MF>A'<F07%FCH_Q5S_94&>5?6PT^/3*E'XV[%%+'< DKFEU?0Z^+KY$I(B1P]
MV'S=V:/DO,IIQ]/T[@8'%VB,F+3G$3[GZG]#B1<SIK?[7H*!&EI;XO_DT8O
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MX:,(@:1KNP>]1T^#TY)/6F;6+][5UM63U5;/?L1L[VIP:E[5<WM\/(O'JU3
M58M]*6K7W>!4[>@AM>]@<,Q;+3C;P'K&<FG=7MCE@?-I]G+;'/9N!BJ"83OA
MMX+M&]\;#NT-)W8;IINARN#8DJFM@,M@W&I*M8)=BZ^W$W\^64*\@[]7S3-2
M':ZD7(X6OR[B-,0PW'@M+HT40F+O]/1K_#)V5_A!![=DOL)I>6LIV;E;WC$Z
MGZ-C:\^>@S+HYW&RF%]]DM5#(TQ6EZ#^8_5Q=978"HN% TPSAJMU^']C>!N
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M4;WR$OXX]$2^#K(=AD6EIO?-Y(QI^+1H_%\GS00X/\_^R6+3!9YMH)5DFJC
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M_:[QI8.0UBB/XT^W1*[<A+ZQ.UQXN()\7W=J67+,,?3M+@Y7L=RR="G8Y'>
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M28E3,:?248&Y]=C3L"TP)1Z6J($[(CN1?'7M:A'1/S5MD&[,<U2PTRC6NQA
M<!4F^8_9+ LOC9<:VK#7F^3W<6W>Z2H]JG_"O,3&&:,@L!A8RATI,2:*BCZS
M62LZ8CJ3;MX]?C6]<7\?/^3S\?5>[_B+-@G#-!"B&6!&12>A)Q1OR&*H?FW4
MSOQK78NU*49U19=^N[K-B_TI8"\;)3S6:4).,NR@AP)K;GA)& "V_E:HLR#
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M+D$51:Q/M3PA7I6J>C==7;$:RT%M[?)^G'X93\;SQWW%9GNB(#'"$.BA$Y1
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M8O^]Y!IA<#XR')1UW*_H^A/9[P&^N\7=7J&]:)-H[03FE#.M&#!*>.3+B#B
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M08QK2C&B/F@K55($#DKWI'1X\/5MFSM:&\!Q"L&N,W,KRG?=.C&>Q\L1H##
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ME[0-TSF?>QDHD;$.6$0=YLY"9VS)*8.VSZMA!VY8M CC.9]J,"L8U$KKP)I
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M#"!HJ4L@?=C'#3"$O9NCW [ &HB:E-K^6%]5-H](L"92&06E%HP*#SVCM$1
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ME456 L!%:2-C-<0J0[UN!3I#<B#ZY+Y=31:C\?3FMSP??1T_;<&.UZI7CTH
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MW1/H'$2"8!OF)2RQTN$?)>=>TP&-UEZ,Y XP.[VVS#YD<_5EM@RJK+>I?/:
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MJ<WS!M:,FNN*PYCPSQ[KE8P1\_O]=#A9B'G1D>=O6<7K^]'WO-KX+L!>#(/
M23R; "=P$]!;\&(J57,O\UW#ZM]!8>D: R.IVE+TB.FN*6;DE%.0%".*=\+
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ME+G^U*3G !H0Y'@PH"1R'!\BQ$TB&P$W#J0N%I]D:+7BI$J<C#3-P)F:,'7
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MM=T7U7UYLJ9$'1=[!"0^IK9-XXC?>=$<EL$N9&BDMG-UV#,\AC^[Y45V&-?
MJ.@P/B^9LL/XT\L8C_BLWQ?;=Q4@;522]%&^%J72Z-$S =/-EO!K]7Q])VOV
M5_8XK6Z2??&-MG]0#4>,:)A@Z">0(,>& 2&>[;22ZH8@3FS1;JC%EL'-NQ-X
M%L=G<8!6CW"Q W@BM(WT1*VLKZ,KZG7IZ3/H^OD2KB'KS)U".$I!==2"D (O
M 1"X(,9Q'$,"_: S[]# E;J60IM1TR4,I]WS[>&J*&\5KCC51[&8YBW"KISN
M#5)W83WB^ 3F@FF(*(%C-5^Z8[ .%=3OUM/J+C.\B:KAA[NL9#W\</TN2YE8
M'(M"/Z8/C1J3^^PHR!B%R+.CR'=03%BJ% +/BUP<8^+;T!:JZC)BV+ J#EBM
M!JSD'$POQ6**N!B[<JKXA-C3HN0+JX=J$7[.8*&\4(;($74T$H]U**09UXH9
MVO,4I?R47]_4'ZY^J]K)Y,8F%"9V'+EV'+J)#8$#:6\S<1VI8U;3+,VFA?NF
MRY8<WIOBZLU]U5_LO&0/?<*6<)=497F-?5#9E]%.-XTAD1+SQ_8^U#=9.=2W
M]T<IX\BS 3]#Y#B)"V$00SCT;=?UB6AAN0Y;,_>T_>G@N&TQ6G?\ GO1^9DV
MDL>3D"7XG91W7%@-P.-YG NKPS@SK^*EXG/SJU8@/IUGD9)P 2Y>& =TL[A\
M^;=6;PHS;4W'['0P2NP@!JY-J>,FQ D\#T:D,QH 0J7NJYEH:KFQ0,=D5)S1
M*=-/(V1.%'YU*3(YOQR1+<T4KS%_57=&:-:HR-%$S=K$8>3YR(5.%+IQA'SD
M^.%@C0UH,M4[JC9F*>0I%+1JSKXEWZF$>5UU;Q+W0JP;2;(BVG\:(_P]^9/+
M-R$(@L"):1P&7N G)$:]G2C 4D>XY+\^[\A>_45N/%=@2VP(-TN4W*C=C=4<
MS6(+P<_X&)$1=>[6(2 3\!>Z6M&40??O&5^KRG;H*_O3Z^Q3=IOFA_XOOV3E
M+=A A_J![R7 #I'M!_S%K'[U*G#8!$9]ZJ#!N&')Z1%:'41KP-AMPW"4UD\/
M65I6?YXRO= 1!Y4)Q\PAF#@%$0K'DIG3ZW0*IU0:([,.J33GWF@2IIU'\4L'
MRVQ;)_DA/6R'C)#_S]O#MK@][L$%GNUYD0-C-K&"3A Y$? [ZR'P[%CNVD$]
M-M>=R6EC5DPQER!53BA;A-8 <5BR:42QA;E8.BA(WX@PZ@[ .O10NU?/;A\T
MP9J6-)-7;?$K43ZE=?8Q8VWZ4&\B"$'H0>0% $48. D 3@\#.XG4U%6[\;G3
MS!ZCQ4%JS"N5B->05YKF7'=>^8C_"ZN#O*+,\@5"53/+*;%9AY*:<T\FLYS.
MHW!FF5W6Q\+70<CMT'8P=IT0T#@@R ; HT[BAL2/["AQA&]85ONZP>R& 7IT
M!FVI1.9%8L;REFE,KJ-S377B:5:B@Q/ATV3='6P?KKC9)U>NN4F(8QL!)R!)
MC'T2X83T)ET2(9F$8Y(AP\G%Z=6#')U<.C&-0C'%F8T].=UY2MSB5P^/\30B
M0UKH78<8Z7'EZ0D[??Q(OC@Y+$:Q?*$Y0,9(^'"YS]L+XS<D\ ,'! G+'B+'
M33PO"+OK?P(G0;[4RKL>BX:EJ@-Y897#NN[=$:=5#$ OK/26YUIR6J:)=3%1
MFY]P.74;N#ZNH9] M#Z<<(W&N3;YS.<X?2.BIY?^=:B?9I]>?N!3*V-:]9!^
MO\NV;+[U);]E/_+AZC/[T^J*98_L[]K'KL&&!BQ]Q+$7^S$) Q@&-@IZ> $F
M4B>19P.U'E7-.F^LNG&'9S[5B4,7_!^.O1J_<' U*O/<<34FWKTCUI<AI)\?
MA?3C>$B74W>!$$P= '1&^0<:([2ZK3*,Z.==?.WL*BM+_H9C55=]>2O"'D!^
M' 6N2R$DQ*/$ZTV!()#:>U R8'@$Z#%96PYJ.!(EN>NJQ)SHFJ-ATF17'#N^
M<,O7(O7N+W$RNM@X@<)U:-<T%YXM-$[F0U13/I:\D+M^^,@:$7]JB/['?7['
MCX"U.ZV?Z[1NKJLXN:QB6/A,J.\'&$<NDS0'D0AZH>W8T \";"-@)X(=R"0$
M<_VL1VTUL)N7  ;@?=G" /WQ!3 +[0%,X'FD[\X1O75T\5D\+>;O&ZK[$F>Q
M-<N0&PH#C\ 080P)#:(H9I/OWGP00:$SW-J-&DY6>G07+ZI"NP8O^$25?KYE
M-S1FI%I->M58-KR],<Z:T%:')N+7H9KZW3J[!:*5M\D)5/SPA7T(?<^K38@H
M#7R/>! '$2%L;A@DG67@@R"1D4(=]I94P0N+PV1)$ ,J*85:J)Z8DQIB6:,
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M'R#H <</ (*)TZ.Q/<^3R6A,83"<T+QG,\"2-[Z_R*4QQB@74[(UL"TG=/R
M?/=ZX$\<])^M ;95%U8+W#I%?F$UV!?30T6.1^32=-36H:;&O2SF[0MR6GR$
MDC!F<,&GO_?\/>4[KC,LV:K83^SO^47!'_D9*I9]U7697][7+6H^_V7_B!&^
M;^;-3-.RJMY B@.7@ ![D1-&+@0V<'NP":%2%\PM!-&TDC.!^6G?*$O6#;]R
MDKY4Y,04_P<(FMR \'@PX#)B';VRCFZU=ZL45WQ5E"^G=DY:G9?6J9M\)'GL
MJ-5[.N_8829:(T/+PLUC'2//TB04J^JR<N/6W[/\^J;.=N@K W>=L;SX,BL_
M7#73E^K#?5W5Z8$C)?G^GA\,'A8%_K_RWFW)<1Q)$[[?I^#%KG65650-3R")
MO5@S$ !K<BVK(O_,J!X;JPN90F)$<%HA1I-29&8__0_P("D.HG DF;,V/969
M<9"[?PY\[@ <CJ;5UR&HQIX?4Y2X($QAEF89\ CHE4OB2.J]H)%4LKYENBT?
M^6ZY]!IC+)>(!: 9>D,NX/0&.)T%3FL"#RVM$<Z)%<UED>VJV'0=-*9:A)A!
M?2!PC.S6>02*L8TN)YU*=@)!LYA:X" (*0B#D(  9AC&_%FZ3H?0]2(;?"\F
MV3*M]\K^LNS89'M@D[I1^)?;9O?BIV+;?>%G.^POZ >S)&_>!1:YO-M(FB=Q
M-ZH9X&<YC_Q8-"QIFR+;JB HL2O4'JHM-]VV5"/]9;[??(UID:\_+;_S'T95
MQ09]>XMD@:"7I:&;NC#&#&L2>3[I%8M)A"1W@&RK8SNKYJ&Q>,Z=.E_MJZ9R
MY!?>^6;WW5E^75;K6IUXQ_"5\)[/G-PDO;_3*W_8W6^I^?6.S<&7].XN7^T.
M),XC**/XSBSGU*[1=W,T_3"\<S.6D^?!^F,:_'9'9ERL-9/N;@'P)E0M/."&
M7D (IIA@P!^4B ]1*D7\*0?Q-F>F94LQOWSGL\N)][K5W'CJK>X-K>1[%$=8
M3;\["V:1@)]#4SX%U_;+/.C8FG5B:;@A%%5+S-JDGV#D)VF*/423-(P]C-#A
M*)B2$,ODUFH21C@<+=H#MR<V3QM6='YQCEL4ZW*S65;U\;N2E*F(JQ@QVH=4
MCO[>%NU-LL7P+BP2U7IR,,Z#K31MN%"GIX*(*O-TQ+>(($P]&/@TB#T0H2SR
MJ-=+0R#U=+A'5,8T['.:IYGF'V%TU1C(!K#Z'#1)GG4&&@D>D@5SGDPD;<4%
M+E)#1?@MANVN6'?[+E\.6VCT&Z]'R-=MO0)_:[4Y_;R^>U/0_,@O=BV2S$^2
MF,9!G'F1BV@:@N,)%/"E]B3'T<@RTYT:<;(UZ>2=&6V=T^IH"%\R]>5J1_*3
M?)]A'%^*,>7\W"C'JR\\>#3 H2\\B%]Z\#TR;BT9^5$&$^ /,/>XSIT'SX]L
M\^NW&"9 7#2&D/QV]][E, RQS_XO]@&F*8(H"T(40D@RB&GL>T F*JC*L%[4
M=2O9+5@9+#':'0,G.2+E&LWC0NH9; 9X3A?->3"7MA6EV3%FZ)F7]U1(:1@F
M'J DC5$2X"B+0J][!".)7.S*=7TU*EIFABEUAAU\NL_0(XA*F(LQUV1@R]'9
M\ .[L^ Y&20'R,^*0^;!B'9,$WVM1Q\_4>[\PO+!YKSZ^N[T_AMM"F2.EY$Q
M]$B0 9H@! ' "78#W\4) , #R!<]MC0CS-[,/>C7'$^>:/@WI]5QLN)N(>0&
M9JI9Y.<Q10W;5-H<JXJ3\H;7F2Q"1). 9M3+4(! ZL,H(;T0&F&AQMN*'VUY
M<72<<'\U^D@^.B^+DR1+F8=(E8XNH6.7<QKA(N0B!]C,6$12^7-TH8*!-"^T
M+,3W<\HMKS5#WXIZX8=NF@91Y)(49T%$(''37J;KN5(7+/0D66:-+A8?E6)A
MF:FE2AYJ8$IRB74<)<\$92&TRS#OH2-".%JHSHQ_]&PY1T<&$!(N6W@IBI2/
MRV*[\#$E?DC\.$4Q0%$(489Z63'VI:[YJDD8F8V<OUJ]).E($3W!H@3KP.G1
MSV7,[!0DO ?+4#F"%HSSX!M-&UZ7(AA 1)1?3KKT=$]U1B2B+DT#ZJ;(\Q"F
M69)T<OP(DE2&6^0_W3*O_$_W5]?UG$_+ROG[<K//7S2^DN,6!>3$>,4N:'*<
M<@K/Y9>(K?#)&S@&N$0=NGGPB(;^I:E!)%G(M%XWSRTO-Y^6Q?K#%B^?BMUR
MT\D,*4(8LK0(>(&7Q$G@P8/,- JDBBOU)-DN/#HHYW#M?OFP=3K])&N)]. 4
M(YCQD)0CF]<@%@<0)Z*>0:"&ZG2, #P/2C)DR^NZ&H,(B5+53=6\-_/]E!0]
ME+@H]#!QW03&) 4^@+VD)$6^#$&I?+YE6NI54LEOE. 2(R#;2,G1SDN0)J*:
M=R 9(!@= .=!*UH6E.:&DV2VLUKM'_<;_AA6T[&=K]&J_(&W<7_.VWYSG?PL
M]J(X0)@E6<"%&?_#[^5G()"ZTF9.JNTLZ*AH]U+""U4=WHM/,A\R![A@;C0)
MUI)YTC7^\*:+ UO2-GL^TR1*HJ@-)4W&D9\'TUFPZW4R90DY45;\G.^6_%F:
MOOJY$X9=$D"89'&<$B\-"/" VPN#<1C+4*"B",M\UVMUN( @1VZJN(DQV0B0
MR='6&[0F(JOW@1E@)DTDYT%#ND:41D>7XA']1R:R:<*X0!1'<>I10G"0@ BA
M(,PZ08'GNXG2N;SXQX]7PL-U<AJE5(_B)4"3/'^W@Y<<JTA"9??(_0"(R#F[
M/'KS8!(= \Z=J*MB(=4 <%GG)&___+!]6W_XN=QLLK+B[>L6$,4A("%%*8B#
MS(U=2+U>"[:4E'WOP:ALR]S3J^O\U"O\LU-LSU3N<KV=3G%)?C+N$C'RFM(;
M<LQFP1'VVO.)(SI C;9\,P_>M&;=>UWVK*&H4%C0-I?Z4-?[?+U(_2AT/1>%
M819G%,5N$$2]-#>(TD7WV/RGYD%X%B"JG72M@91 H0D,VPE\1C?A*9TNV3]7
MN5!K/-N'Z:<@B1VI*\$ZC[FG;<7YXW4-5,37/Z_G[X+",,L0=K.0H,@GKIOA
M?G\["&(2+IYDYX^"$)G8]UH?V3DS=D;_&HS!C%X9N7G,#AT#WF3TFE@(QY=V
MR[-XSMNVQ==W?^1?CR^>?ZJ*[:IXVK#HU[+U]1U:ET_\S)DM,<+$"T,:Q7[@
M01I2G/25NF$,L-1+XA;5L%ZRTNK!K^5M\Z].E3_GVWWN+ _*.TTS2)8B.#^A
M+]B)W.CG*_:CS46^W?*;9+F<17^)9?XS<97<(N"H]$E[;J:W<U3<.6C.EP>M
M[ORG>NU'SC"441Y*0NR[;AY,/(:AKU.9L;!5SW94WFE#Z__:URQ7[](';Y%%
M,8Z!!PE@0<CGK7B"@[((95)US1.I:#DB='I<.<O:67:ZR>XY3^,ZT7WKV7M-
M=N_[[5:0QAN=5TYOFS.3I-N$?Z02]U$'Q#Q"SM0@7%Q 3. 3J5#5+OW)ON(J
MMJO<9DO@^) %+\C(MW73)&[A>S1- $Y3UR<PB%$6QWUW@Q#$4*KDU(9\RT&&
M/CYMRN]Y[G3/!3VQ[[)PLV()"/^G\J,15EPA$5<F]()"T'!:=9U6WV[1<-6]
M'G'UXOV?4[4/CT%G9767%[L]^^D)8H0<UI<"@"7/S8C=;5GX'G5;15.3EYLK
M?V<422,41Q#X<>2ER'-CA/WL$"#<6+*@Q+CX25G9"!-K@:]%Q&/A;HZ'&XU_
M0!H>0%J>A4VX;=8D;,1 ,0XVAZ4H!;,1VI8>\Z+_!4VHEZ:I3R,O UY,?(3[
M&UTAR:!4IWJY3[9,G'PB;J2O-4B"(\9^]G"1(S8.2:N(\Q-7Y><S=Q7&9:P7
MZ R0D1J*\^ 91=U+$^-(CAW.W5/@(IG\Z[N;Y;=% "'VO @'U VA[[._'[:7
M0>P%4KVWC BTS"7ME:G5BRM3[;L]<NQB!EPQTAD=5SDN>N\6V@MN.J12-P,'
MFE8(202Y 9XR"OP\Z,NL2:7%@6JF%"[P 4$H35 $LPP3E.*8'*1%:?RR%(YN
MUX(E"8KBE OA>LW^7RR#$P5U'C-,VPK!,C@Y5#3*X,*(N@@2B+((\6=)8YKU
MM:N /UG:E<$)SQT%$?)%<*KS9>K3.+D2.%'<YC$S= RX7 (GAX7$I186P%C<
M>J^S?8()C!(_@@E_:"A(V%+>(TD(24 R@(E4 P(M09:3YBZ;VRV_#>R!68!/
M+#T>#3FYM+@#C>DUCZ<SAF :8!TCZ,Z#?\R8\O8FB"E\%)Z^:*6C[?J=K/O8
MZS]A7$BRP,5N&F*7X(3@$,*(>%Z8NDDH_PB&$;$VM_U/GL-X=V$Z@^<P1# <
MS ;L>&,>4]6:=><?R[" HN(^/L]A((8A\GR(,76)U\L 'E^R2CWT)??9,G-2
MZ24OOA/TTZ;9L;ZP[3:G'6I!U.8Q=Q1U']ZAED+ Y YUN_WQ^K[E84)&*'8]
M@%E8]3WD)QA![/>*N8'<0YPCJ#/![O:+V79ZM^1_F]_QUG66N?WP$?UD<;=\
MLCQ%'V+-;75#_IL'(X]IL,*6O%&L37!_5E9Y<;_%^ZK*MZOO-]5R6_,ZJ7++
MTK/F7YNFK**M0.;IV^%T(8MI2 #T65KF8NC%(/9 KVR,/$\N>9I(2>M96*>[
ML^J4=W9'?6OU^X=3^50_;,S$F<9#2>_HWC#GQ++F?=<3VYRC<?,\L55WDF(P
M&F%4S#] C0&"1- :S2<F AE>U@_9IOSZ[_GZ/O]M66SY%]$=R^P_YZO-LJZ+
MNV+5J,OU(SY)D$L3G+D >1%.PS0\!-HL\OJSZALS2QJSRBF<;-_(+W (2U6>
MFXNTD@<1(WI)/QI-X!E; 8B;XG!;G,:8*X>;<_CNDMODO#;J:EYA1\H;BI'&
MCL?G'UPLV2T13VPB;R*$G##>_[=?;HJ[[\7V'M6-NL>BJI2Z+@II3!#V,7))
MG&;187_.A;@/'?I1PXP^"M%B!H'"D"_T \2(3K 5&$Y,<(XV\+8(K17S7(((
M :\8 \PZ=?[<;]A>"<ZW@;31JGR(("%^FOJ(N@$_8 $@Z41'P(5@L2MWRXVY
M4XV+ J7.+0ZZ"?/%#?\5IY0YO9@/)Y@J)!?UP?QGMKQ)*H7D<GA)%)*_EGJ0
M2*D;QT'LXB2B$?)BEQXV$"(/AD1F6NK(L3P;\?D9*/U\JSJ68EG26##*Y3^"
MQWM7L[BU-P#A<+&^-O#S8#(CEKPMVC>$CGKA_A_E+G^O*-'/TA &%'HT1C'R
M?1 PU! .0A($R)5[,-:<5,N5$:?7_%<G-[-U>Z\I@RQ&;]/@*T=V[S;+YVK.
MH^Y9&$*IJQ>Z;I@']5FPZ^)%#3/("=/BZB%?[S<YK^]\9J&UK+ZW1T>[FZ:W
MV4$\"@'VFO=PTR3UO1B'7M24:H=9@!&@4JQH2JCU>QVM=H7L)IDY5 5I< I
M)5FP4Y&G=@<EK[J#]QWCOR;%FXX%!1$<(D'33I@)!QHWZS4%VL%-E '[U^,^
MY563!!WE01)3G,41 0&(8$H#'[B^YV80)000*E4[JR[%,L=U[5'R_CW$I[QJ
M[T/+,9X&BF(4-PZ <IQV>$22*=4VRIHPCSL+T !EZ8,Z#XXR8$=I>K@IWUGK
M3USK0X5I@OW )8D;I\"+(AQ#BOGM I(A&H9$^"*HE@R;ZZ/3VVA]/40]ASMH
M;V :7 ,90'<>T\F,*>>ODNGB(W%OC(OZ5)7/Q3I?I]__K//UA^TUBW%+_JX
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MD)7;G-<#-<3(AP?CSJ+LBBY9GGI06HTK52&7XT>;,.MQXAV#LE?-00)H6J7
M]W$2H#U-@.=%=;K&G*$W(Q@)4UI5KO)\76?,RB]+_LH?^\IZSS/2O"NI3+TX
M0KZ/2 SX"Z>>ZP?XP*40N#++;P/B+"^W>PU;#JN7[9.8*J7C)J 5I*]Q496D
ML!> ?ND /2HX20GX9<2&R,P<W#,A-(,&O28UTUB9WV=<9"CBG2= E&0^27Q*
MP[!?;$,OSJB!HQD5L6,=S4RRJW@9=-.[B4;QMKZ+.->M0R-;AL*NF <]VC!,
M>8M0$CM-NCQTXWUGC]+UTX!&013 !,< 88KCM%<$1H@8.);1$3_>L<S[;S$>
MVWZ;IE,MIVC1ZEC^,$JO!Z5G?$@S *P\XYKPTJR9UXB!8@QL#DN5%?G'8IO7
MUW>XRM?%;D%3$F0@P(!&48;2+ A@W,E+/3>5NF.H+F74]7>5/Y>;Y^;MA$8[
MYVZY&J[^,XVI_ K<'IPZ"^]&J^8)[T:OZ9;;+^ 17&6K03H/#C-@Q\":6@<9
M44;ZG'?[^DS02WDP#'R:N3YV28I@% 8X[8]9>+TZ53CQ4!<VSF''IZI@\>!I
MN>D/.]BDVIKB*0VDQ7C*,KI*/'74B=/3I#QU%IX!GM*'=!X\9<".TO1@4^>I
MWYF<_2.;WX]_E#NV:@8I0%E"? ^@E$ ,@B@],&,$O%23J63%3<E5+"E[=#;E
M<FN I*1AEJ<I*] :(*I6KU\:-!O-IJ.J5Q )DI4JL/.C*V5+!@A+#QVEX]==
MN?K']5/S$ /]EE>K@JU %Y3P&])) )($9)1Q98R]7B[V _735R5IEA=__>MN
MS02KN8;=2Q3UR2.\M^T3.TU%GLZ1K!K<"B>RUI'6.I!M4.[4<P[Z37@<^QY<
MHJ>Q6E#/@]@,VC-T%FL *=FRN>YR\TUYL_S&;^D]E)LU6S)E977F868?\_Z*
M7I2B"(7 B_P$]R?#:1)X6*T(V;@:UDN2;_B;?$[308_E;[?YPW)SQQDR[VZ-
MM^5AO"YY][T_;9#=(;/F(T'"G-0Y>K5Y?5N'7=F\_'>B=N.7>3P@KPJP0%&?
M-9_-A)"MFWFF$- RKI+TS<2>>3;J<,OZG<.2A0=!&K@00^22R M<Y(/^XG6:
M0>HI<;@E7:P3.3[S'.%A?:Y$VK8\(\7<4[I$A[X;BC[W:.&QV\35N\?(DU"X
M&M*7>=RR!V=%YK9M?9_11T%8X3++Y[Q_Z9$_#?CX6&Z;Y<$" 13[(? #)M9%
M<>*Z;O^(;4J")%7+OS4$6B?H_O(?SZYWO+'(OOK>;D0H7UM1!E<N<;:-JO[U
ME:-ZS?%.HV"[_3#9)98SB GDO ;@GA4A&C'H_(46,UB9+V9<A"#.L)>"*$LR
M%"74CZ/TL.,!7&"@]EM%[%BUWZ>EBZ,6+%X&7HS^)L)<C@85"A3G6I5HI!I1
MV!7SH$@;ABE7'TIB)TJ9].XN7^VN[^BW5?,NZ&>6.UUON4[\__G%ZN?EIMV4
MJ'=5L6*9%?\&VJY??N'D)Q<^!ED"T\P-,L^+$QK1I'^C,*6>*]6W9PK]+!]V
MM28U^[B=40Y;#.3.JGN8E65'G*.O6J;.CXHW31"J@UG-]^5X>A)OBQ'ZW!TM
MQ_Q''_?V.-P@[EO<^+8)"R>Z7CE',]IO<F>__MK)+XP;*"QX9R"B3#D6YA%Z
M)D6@G,_,E MF6CI]RJNB7+_M+[K:[/GN^ZGU+2(+OBD#,?$S $"29&D*PT-I
M"+\C(+.&F)GJ(ZQ#BK[_;V$OWLT,5<%0.#.M[45)0Z'PRFF-=MYI*7WE'$Q_
M%8I;Z\<-H^-Z=B#"SG2(S2/XSA6<\H>@B1%#]B(.,$@SY 8Q=*, QUE\./C&
M41:%BZ?&S"^[9;4;(0Y?U$>&2E^K+LFJ(L'46>Z<V_R^V&XY/?*VAXW,$6/L
M90^.$#*-NFV2"/@#13%;04G8B?\-8HRXK29#AB3"XT2 +.4M'A$-71]#+\"1
M%P5'G6*_BP!T*WA8;5<;>?[O%;?$_CGO9'N1]_\?8A%1#_YW8!%A6XVRB!S"
MHBSR9?60K_>\SQA=5CR=X1EN7RY9K)A&I-CL>54E?VGU)O^V2S?\(#H+70]
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M$# V2UQZ#=X@=+)L80DU3<ZX!)@EUCB"(<0="MC-C4%43#C+(\IXB#RKVNR
M/)0;!@W>+.L:K;C8C\NO];XX/-"-4[:& @'QX@0B/T4Q/G!8P+XG^L*J"5EC
M',RV*CJ-CDZKI--I*?Z$J!%@AVEG"DSE&.@2G I/LQK!5?R5UK'Q57NP51]G
MD:=3!;!XA^!-HSC]@ZI&K2GMC#7-/:V/Q3;_L,L?ZT7H@XP- NJ!- 7 1R#,
M@DY@YH(HTMK7$A<SP=X65\YIM-/=X)) 4W&3RPZ0^AM=(AB.L]MU0$AFQTL>
MUIGN>BD8<FGG2Q4;84XZ),%?\MUND_.HV#Y,CKXN&8#KF[*IG_FTK';?%PBX
M%*9!' <!96J$+D[[';C,@PA)T911R>.MBNN#ME?.LGW"?=DJ[.S*KH'+$]=9
MDL[,.D*0X2;S@?(:^\L)_*VJ#CK"WQ8/?AJ$WPX3RB Y1(Y6/#(3OK1CVVL*
MM8B@**MFRZ+Z^W*SSS\6R]MBPS3*Z]_S)3\W75]O/^>K?55UY4SUG]ORMLZK
M9W[$\6'[M-^Q;S,\V6\U1MSDWW8I0_$?BPR0V(\!\((HH4GD!RCQ?3<.6#B@
M"$=2%=V3*&B9HU^JQ1_F.#'.Z:USECN'6^\TYCM_UKP@_$MQORWNBM62L<FI
MN4YC;^W\])$_Y>4$Y\N<9C0,Q*A_]B- +D(<77KUOMO9B#@8U92=UU?ON-IY
M-8C:,V2'6^@T)HZ<8-OPTD#TF710S"-(30M!.:-)*A?R2'Z[^["M=U6SL=8>
MV"-**$ X]'R4!5Z,F6 66@.<XI!X 92*6"J?;WL;>_60K_>,'GBH*;?WO[#/
M>'2XHLY14\7R'24XQ9C?-I*2F]=F0+3"ON\@-4">.KC.@_NT+"C-C3+)LE]&
MAL4N6W*JVWUOZ@&\T,,N23P<$Q"'!/EA&O>"0(2DME,5/MXR[[0:.;U*4H4\
M.J")T8MEO.3811(J.X7-;P 9(!$-].;!(3H&O*Y#UL5"C4&Z*H#( \CUTI3@
M-(.N3Q$$82_*=PE6YQ!! 6.SB%2ACQYT*DQB 35-+C%1Z*/))F<+?HQ@.$=&
MD35AD%.4\!!EE<_Y<[EY9LNSES*[(V87TRR&T(]2X">8^*F'#S*S /HR]*(G
MR?8J*=\69>74?+&:KYU5.XN6]U7>;,TZOSBM^GGE;,KEUEGO<\=W_4".AS3!
M%B.D\7"68Z:#7LX;CI*L2#'#48,X#9"5&7SGP5J&;"EMC$#QPL4;MAC_R&;E
M*T%I! F.(NJ#*/-(DA&<P$X0^YHO= ZL\?&3,Q;76X6M=" =IJB1T)3CI08F
MKI$$(1G#2[SZ< 3<U H.3X89?RS/(?FJ48V-."_X5:O*\'V;SQ06:@(T?2VA
MK@&EL<&BLZG>K(#]$,(L<'%&8X^$+B1AE/6"0E^N4E#AXRU3[ZM]7Z6M+170
M5';.C>,E1ZZ24(VP07YA:TL#O7FD=#H&#.Z.*V"AQB!_+!_[2RYI"-/(CP(8
M10"D0>+Q[NJ=.  2C;,Y"2'CLLF5PU53W.A2!U*%6RQAJ,4PHO"-P#1'>(3Y
M1@'1.;*.BAF#W*.,B\CRL5VEHG[EU.5* <"^3R-,:!#XB>][248/3 >(4.<L
M]4^WS#EL_,;]-LQ!-?'5CB)BEQ>']L%2VDT_**2P,E3$2GQA:!\SM74A?KTC
MT2X/OS V.:P/8[WUX;NFGUD>ZL$T_>I04__2U( 1YU7$/GV=K\^(HVE ?>)&
MD%*/N GR8MR)XU470CV2M(589ME.-PVBU8/P,M^.AIX<[9X#3H%^]1 49^'1
MD%0CXQ[1-]O$+2E?KW8EIV0/7'%:3O1H>0B+,^QL!+[I2=J,&:7A8261"I?;
MY[S:%;>;O#U?^*/<Y379Y[[K>YU4R);Y$44)\(@?9I'+HD342\U"3[@%A E9
MMM/D7Y,8_"_G1%.G.W9I=.W/53R);- $P )Y],C82F;5Y_ D'9XJ:;8)8"62
M[I$!5DS!]8$62L,O@W$N*3<(X_3L;]2:TLY@D]N8_?NR*GA1]&>6)33[OTD8
MXLP#:>(&B9\$ 0R]?I60I0&4>HI/^L,MLWVOC\,54CK4D8=+;-O5*E)RW"T%
MDI5-UM=@#&RN*N,VCTU5=?5+0^-'G2VZW5J7\F?:$,UHX!'J>ED&@UX0D#P(
M5OCX<1E#Z<A&!31YUK" EQ9O3'(\\Q800>Z01&]^["%KP !_*&$A_([<OBK;
M%PB[M,8/8II$/.%T,Q &:9QXV4&,Y\H]_2O[X9;9@^O#[\;FVY5D&Q9YF,08
MPRI"<GQQ5&6B\N#76 Q0A3)L\R *=?5?/W&FAX-PWY*< ;+<9/OMNJ9W=_EJ
M5SSG7[XNGS@]=9)1ED74I2!"'HQB)B_%!WK" 9:ZN&!"GF4JZ51T&AV;$"O9
M \0$I&(<,S::<K3S$LB#?@Y7L$M=)F$C =0&",HDYO/@+*,6O>YG81PM469+
MEW5^(B1(O10 1IR4,@%I&H.^7!>X<4JD%D^2'VV9K[@V"C0EBX\8(UF$1HY\
M#JA,1#(O@1C@$T7$YD$=JLJ71D:-3F'LQT.;31ACFI X!4D,*7 ]-PFZ(CC@
M42AV!J<KPS)%O*D<_ZC:@U<91#'Z& ,_.1Y1@FZ$@MB/ GUW==&<!\=H6S%8
M#:N*BD@%0/\JYL>\>023"RUV>W[J6/.GK7R0NB!)TRP$,$$$^[VTS(=0].1?
M1X9EUFE5XVV>-JUR3G&BG?AQM!:,P[PS)H)RO-.!=WWG='HY'\8'3_P,?RP0
MU<[NAT<B^X?S]:%8/3B[A]QA'\ZOK3XL:V?9EWC==5?_]$JY!C Z<Z1O M7I
MC_*-6%&:'6NR/=.W^?7=RQOXN-EMWJ5E595?^?W\Y1/[SN[[(L/$)32(_<BG
M;N1Y&<9NKP*$4.J9<*."+=-]IY=SVROFK#K-9/NBFP1;+.^<#&>YH-#DGHS%
M7C7]N')Z[ _*.O@2]I::HHOC.)"X6G''/+)9.Z:]Z8AN#3^UU7;3K_;+4Y4O
MU]?;TQ-0;Y$20*,((D 2X/J$QB0->_$XP5*GDL:$CK$>+T[N6=YR59VZT94W
MKG[N3_@KZ7T]<\"K+-E'PEQK#7_5=@-WOAS@?E%0,>6J_CQ\PLM\ QZ8!U.:
M-VMP(\ 8;EI)9?GX6.RX.EF>?\K9<&9+G7O^$+9'?0!H$KK4!;Z7N7T73.!%
ML=P1K$FYME/*@UK.79X[3P?%#&24JDAK))0C@&PJGSP"SW1U/ET&?KQT\GT4
M9;-)35_,@R*M6":22QI!3V0+]?CAUW?757%?;)>;3U6Q715/RTW[R,_G_)_[
MHN*O_'S.GY;?/VRSHJIW-U_+_\R75;V(FR/EB$**0P^3P$U!VNGDQPD6[EQG
M7Q/+9'HT@$_YLC/!>>IMZ-\VJSHK^.M:%;>#[X_QG;$[;HVS^UHZW[D]XGN0
M(SCQ\C;OO/PGQ],O7==K[QS4[]]%^WSBNL^]ZQHC'&:%\Y^S<YOX!O.\W*?8
MW>^A7=!Q)Q9;-H5S/I\>ECOGZ[)V;G.^;_.T+)HE"9]PASFZ;M:+=;W/VQ]G
MBY<+DU-OIUH;[#/[V>,Y<?I=[Q%M+:>8)C9C.-GS1X[8=+EY**HUUVL1HS D
M,(,4D2@-4Q2FM%^#^0@3BV%<09G91O)U8TM#&#MN34,6-B."BB=MQ'++3APK
MG).C_QI#FI ^-__9#.J6_3B_N'Z<IF.']+=0&XOJ&E[\$0.[CKE:L5T;9SOA
M_7/.K[TQS=J,PP,>)!E.?4R)CXCG1JC?-?"CF*3V0KND(K,-ZU5OA_5X+NLZ
M&['<HM?&BN,'$^ROR64]9C-Z6_3<O"+WRPDY^FK\)<[&PK:B^W[$D*UJJE:X
MUL)7J"79LG[X5)6K/%_7]-LJK^M6CXRA18KZJ:R+IHSN^H[]U%->[;Y?5^QW
M]LO-[CM]9L;47_:W_Y6O=C<E9M]ERGYF4^2931H^]3X7]P^[!0(H">.4T(B-
MX=CW0Y?VES?\-$.9<$NS&>AJ^WB3F<C">VNCDS=&]D&>#V!G?6(GIZBGSE(V
M6YQ59ZN3-\8Z=6LMIZ%5:R]CH:/!3L4MEN@!-@/X19JSS4!->PE&,T!Z\YS6
MOCZI: 8(>35 /IT,D-Y,I[73^7(<()VISJFMSN<?<(!(-)F;@;KCY#.K%ZS"
MO-P1R^G>'W]FB T7_O>NE]V7[NVKU^_)-<.L)Y0A/FI_\!4I,82Z=^J8J*(Z
M_,*5&%UI)DXC^/Q,;C6GT39]^C4K-,IY<H)X$O>R; V73)'E=O='OOO()EW%
MTLW/G#,^EQOV^_<L"2W*]2(,XP3#, @PC-.@N1F!>RU@$@O=?K<E>^Q:VU6G
M]96SS7?.IE.<+P,+MH)K5>>E9DQW\6AHQ2F7TY^I_:%9AXL/KF J.[W.3J.T
MTVGM?)J#*\03C:E=HI8X6'&-2(Q6@.M,S+4)_/0QU*IUY3C#5S?&\:]^R:OG
M8I7S+QVT640X!C%-L9^B(/$!#/VC B@(A9XVLR!VNLC6;$_6K<[-EX\A3I=(
MU9V@&LY&P=]8)&N^U:GK]/JVO#D=]+KA:Q07&(]<*JY0CUGG,)(*5]I SS52
MZ1MV,4@9PL[<&NQZFR]20 ,OH(D+"<U($L1,F4YV@%R,S:Z\1"3.:KVU>ZC*
M_?V#\W_WV]P)W.;%'&@ZUQ?R@ZG%EFD76%QB73E,V4G -KV<,@WZ"(NH8?#-
M+9V8%*T%DPRT<PT^6C9)+X[D$3,7<FZ^EHO0HS%.*$:0ID% 8\]'?0^4('"1
M<#V5.8GS"CGER;N9MD*.D!],A1S3+K :<IBRDX!M.N28!GV4D#,$OKF0PZ1H
MA1P9:'^4D"-EDW3(D4?,8,AAXR5?\'Z),(IAY&=A2 $)P[Z),P@BE)H..D(R
M9Q5VFO/QP]N@;=1Y&8M\R+_JN\;I4<Q!QJ*1<=_8C4=<W8D@-QZ3C$,_3E0:
M=('!N,3EZ$4F*8!_F-@D9Y5\=%) S5Q\RM@H7< TB%S@NAGV,PC<Q <HZH7C
M)!-JH&-8Y*RBT^XAK_+E'9-CF@K%X#<5?(PC;S7V<&VGP=MTY#&.^RB!9Q!_
M<W&'B]$*.U+H_BA11\XHZ:"C@)FYF(/6_[6O=_EZ$:4A<,,DHI1Z$<!A&J5]
M<\V NJE0,V +8N<4>ZZ<9:>V:2H4]X*I\&/% 59#$)H<>].AR(H/1@E'%WUA
M+B3UHK3"DC32/TIHDC=,.CPI8F<Z1/&?Z*KX8)J$'O*(2],H@D&,7)_TB@ @
M?@W?DO@YA:PN8C475>Q4BLM[QVP(L^08BZ',.2INJ61<WB=V0ILEWXQ1."[N
M(].A[@B:@9"GX($?*_2I&*@8 I6QE ^%GW/VMV+%HNZGY7?^A?IC\5CLVDM?
M"YK%F(+$2S*2QC!- T+ZQG<!\C/AB^LF98X=]*J#MLY3IZZSX?I>=??253E5
M$WK9X#8>ZIH1[:BHTVOJ?&P!1U,"KAJYQ@/>4+A2=X!\A!H$1R@LF8%W;K'(
MD%5G Y!)U-3>O_G0]1;B[TE\84.6:7+LFAX2D&(7Q%D0@C##KA="U"D09B +
MU%_ T1)K.?:T^BB_Z6 2W^'H,C&TF@&FU[-YVN;*Z5"?ZD$'<0S?H4.+CIC'
M<PXV#!M\\\8@=J*\F!5L*;#*/^;+.L=EO4.W3)GE:K>(44;<D.7^B8])@"%Q
MB><B'(0DI5X"A!H\:PNQS'G7C.U8OK*]=S9<-6?%=/O?<KRGCI\8RXT"G1RG
M=2HYC4Y\@X&QV5^]7B,_PGT.G@&ZTD9T'N2D;T9I>*2I$T_3FN7Z[L\Z1W6=
M\T2PVA7_:M<Z*/*\-(@HS<(D)6X<A"[II;MA(O74EBF9EFGI5!?>UJGIO?1+
M>??+GG'4DFLKV*'4.-;RG#46S%H4]KD'F*GI-'HVJ\V#IM-QV@!\@A1GP@'S
M8SPC5@T0H#G45/BPSP/IMZ=\6^>+((C=*"29YV8I"3P8NPGJ)?IQ$JMRH*P<
MR[QW6!LQVFL3LDVQO.5][XI<@_&DT91G.9M :C'; =).L^F8[!5$@NRE"NS\
M&$O9D@&6TD-'^&'4/B-<)!D-DSC&'@JR(,C<!(>'SR>4'\F4N^5&C(?$/U6*
M=0X*",^8&_XK3OG.4E#R55-QF,0(Q@Y"<G1RLL8;^:G1WO@!HI ':!ZTH*#W
MZT= %2V7GO(W_-7EF_S;+F4&_&.1>;X7^C1F])*F$ >I%Q&2A) $D1="5ZAO
MI:X,RTF(R(@WBYDD&UB$2YD;G+\:K1RNEM/H-?(^T!ET1,A#$<^948FJ%>>(
M10L5D5*0+ZN'?+W?Y-=WC<SZR_[I:9,W)\B;=+GA.<Z7ASS?U:\TP<0+<98
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MS;/I.!LOK_357S@I1MLD6TIUD\Z^+D5;S'ZY3=.'  L4OV:3^:S^I)K6Q2\
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MVV6*K8X93 .^#?\##J;3E?Z^!]70TU%(Z)"#@1)&*RZ!E<37W*"5WSGFE'S
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M$NSR;_2V$NSJ0,(M-<X[Z3$B'DDCP[RP7H=9V*=>Z+LL0QDA@U3R>5,_+NV
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MH._;^;8^8/Y2?$F_5<=[55ZC@) ORJ,OEI_:9(),%=D(F59,D6 7([$QBK7
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M&CH9Y<H<T 7)[L]$3T7T1/_V*EG@U<W';'E;M^I'/E^%U.[P:^^ID4AJ$-6
M"JT]H5(H:U#=98^B4F\,:$%H37%%%ZCV-754\E[=O P@65_PTT59%G]4H4#I
M0_C-?-L5VU.:2;RQ51Y3CAAR@,$JPW%M;$$I9=15J\OE5P]0GV>]6CZ*^3FH
M+1U?39]OP?>]U=RTB41;ZAB3BEH1S#+KN-6D1L (<]%G+?%DZPCFL\YNQ?U]
M/E_>5,NRZZP<59J]W7?5X8A6PBP/':+4"1+L08J@!W7,+H6,1_E6!^\TZ6AN
M:P7I$PVKI^^[NKDJ\]M\FDZNRWPZRA_2R>H1\4_9?R[RT.,OQ:?L(?W^8>KS
M<C;_\D=178O=97Y%MYOPI7.9.>F"K6HL!IKJM?B("Q,3X3IX2SW.2.L;^]ZH
M9Q?5&]-?[K(O=WDYKKK:&OO>-IUP18B57CIEF29:$>WJ&1\I8V,(.* 4*L,@
M8#3\O7'P4U8=FX3.MCO[O6PV@<%ZM=YH9)Q%RD+ 5#WW(Q9,CPCN#2A=RS"X
M%P7]J?%ZZ>SNNBQ&63:>N6^CZAFM9==\P,;FLX=B]9KK[.HFE'K(RNI!I5!G
MD4[FW]UCD&_V>?'UG]EH_J4PX;>A_Y^R?/J8S99VQ*?\]F[;S=V>OCE15 G"
MM0T&,P8<H6# U(>!2'L5\_+B@/+-=,'>X6GG1(*_!*5*OC&M4JQE\X_98U:&
MT?FITNRG8A(:NEWETMA!V!-:2@@)5HHD&!O)-5YZHTPMHA0\YE1_0*ENNB!@
M]VBW2JCJT\]9^9B/LF6"E[J#1W%I5R,),YQRIPW2"@M$)4%/@BE,H@Z*!Y0>
MIS\>M81TIW/2U72;J^2H^HFF#D/L!)#6>2LP#_*MQ<$*F*B;W1=^PM 5R)UR
M)FR<HS@3ZB<$.FZ$,THZC;'C$*GZ^ 1CH&),_B$]'7@^SAP/<K><"2W$S33+
M%I(*(LFX9,@3XJ@EI(['I)@I'<6;"SX Z!;F3IGCB\4NQU?S!A*I,0,4 &^0
MEQ2$55?5L2+8B*@W2(;T;.'Y>',"RIW21HW_N9C-L[A]5MU(PC2A@ CFG(.,
M&J*K1]W6@CF@HRX-7[A_OE.D>Z!05:*%+?OKQL)8$00J:('3C$G,%4"V%I32
M**?GD!Y6/#>E3D:\%6I]RL)/^2@0^SK]7GTP^YC?Y_.5FZL1G_:VD#@?X*,"
M"F\UEUIC:_5F5X!\C.]Q2*\S=D^B-F$^3]S-\OVX($45P+%\>7[<*!JB>2,)
ML50;0*N'(2CQ!D BZVA9XJG',62[8$]WYT@_\:VG3*Z?1W?9>#&YF"2N!&&G
MP^"NMC;00Z4 !\0:AX2$TJ-&5R;Z&.*G)'%EQ%9^(^Z8PDY@ +A@:]F0!>#'
MR+3<6,$-DK@>!VA?:T%L$E<;K"+/. __T]PLESI?2X7DCY#$M;%>#R=Q/0[,
M\U#DM"2N5'O.M,&(8P&L#+MZM)%,&!:U:1D>36)4VR2)ZW%HGK@A:2/_ID#>
M46X58\B$/F/OS::CS/%&3Q*\5[4?JZO#^3>/0[.OZ:&;W+T><\#"/UK8\+40
M2J7L6E;,A8QZH^]"F=,%L.?9DAZ?Q!4@Z0"V0"(O"*26 %8OPI@J&C/1#) N
M;9HAT6">AR)Q25PY)$1YC[CTS$#!K0.REE!A>-%7&X]3<=,DKL<A>FH\:*?Y
M&UF85;&BC'$$N$$:4+T1(0@1Y1,=.BE.T>21^1N/@_=$AES-[[+R8S&]K4RH
M2L1&UNN!6@DT7#IG #!<!!.>6<)<W77,:<SEP<&O+I',:!?:]Y=)P5/*O#:0
M*^,@YPH!0]?R$<A%3(S;X,-.VC1,3D6TMRNFSRB^AR;/BR6(<4TI1M2'N9$J
M*0+G:TFDPQ>=4?P$?;Z^)'HZE.<@Q?IN?D-NK$LGQO/JI14H#/"0(ZJ4JAW0
MQ O1S^,4<D61:79;'3=]>==,.0W8_M:=E3Y\/DVG5?3W;#[[O9B.5IW^/=M_
M1G6@;D(%M0A9@YS@&$(,%4*;02)$/PG*WSN9VH;Y''/14W\;3D=/%9(PQSID
M@P%/N2'*&F\V3DB">=2,]([B(=N8BDX&M?=S^Z4A]_Z/ZX$ R!B,!'2:6P4@
M)&[Y #630'K4:!O7C81U8,35S0;N)J\D[ZN68"^,!@HB;@-3F97&VUI:;&7,
MQ?R!6I<Q*B\Z0[;GT7H3YJBQSJ;AA_GU))V>;=2:XOXAF\Y6W)F./V7SO%R^
M^'+44#ZBE80(!HBAD'"MH;8$ L>L(-)BQ[SQC1C?#1;70825 $M_R'4P&LJ-
M)&MES8Y[(?W4)A.DC4?46 ^TQ%B!8)R(&B7I+^T!LT[X4YQ%%6>>2,X=M-?_
M? )M6#*J:[;<. (]IUP$0X\RSARDDC6Z^]/9/O&5=C;WA6<']HB[ZR5A'QS,
M366%<Q81I0@(GZSE#;^XL)"_3ICP=K/8&MX]^B!>]=E]>\BJ"/< T:*<7DVK
MS]1LELWW.\2;-Y,80DW @H, IK304H+L&@GD$(]9DX;KYCH/ 5O3POGX^'NV
MOIF3C]:?'CWM;6\B$4X IYS0VCI.!$3>LAH!ZVB_IS7%/)U<( %;@?[,MM"9
M'2+]FT)!\Y(Y KS#F%LB!1!D9:F&O[IFID'7KI- K&>$FIW@1=G;0J*$\01H
M)I"CS@KFL <U!L*P2PMF[8(=.[TL;2+?\]Q0YH]I]0#8DYMX%O#Z]VQ\FT]O
M5?4V6#[/S^H];=C#(UVL)[>:0(,X\DA1ZZ2682FQ1J[4:8/]R_[_]JZTMXV<
M27_?'[/+^_BR ,]!@$P2))EW/A**W;;UKBQY=>387[^DU"U?.KK5ISL##":)
M+5*LIQX6BV2QJE2@U6"P*F-AZG0;!/<2QRV"AH)YRC!QB!5H00UJO9X<GMGI
MA%>O?)3.U#-,VY3R*?K9XD?^BX]SM;B:]GW>,SR[E:+41%2TI11Z3 4$5.3G
M_E3''[TIN[4Z_RCTPCX#<THR9:SSGF%O@816YC@Q9O'('GMUPJCZ%NLBW72W
MQS\@SQ^3Z?S]8K72OW*Q/F>S+1]6=].'LT]$+NDP*,B9DD@9I1W4FG*_O]EC
MI%ZXU3B86Y5%97C;M%JZ(NV!T9Y]D7*T3;"6ZNA(L/@?58H;$)V*0D9 V.BN
MZ]LEPJ(=V#M[<OW<(3O[EO+@YU.,(X5:((J$ )X8R^E^ED;P1G:?TX".7[Z]
M;@#5KACS;A[=_EU"F&VD6E)F4MGI9?)$JP"9P$P8((S 2!MN"62YG-QC/[HG
ME5VOA<UAWS/'SBYZ)]L%+9ES"$%A*)8*"0 =+&15BHYLM]"(ULLQZ2)\N^/2
M+HU5NHZ<KXY7)3_Y^> )Q=$ ,PB0,UIA@( O9+,<U<H@_F:X4U7/K]A3']D^
M]XF?IZO_N6 W6#0+7#'''&:($:4B>M&3)(6D*0-VIW>^(USG&@2_>YJ9Q7Q[
M4O,U?G^)= /'FP65DO*)5#Z:1">1QRGI]%Y2H7Z#8_SJ2C_*I-KX=KW,;;,U
M_I@\E%[GGC=(U8@X-HH9*CSWRG(K"M= "$M'%K3;C**/K'.UD.WU0/2,F7Y?
MZIEZC7X#H]9I2*V$6 'H&7 .%UA1R$;W]FL(2V5;VNF*R=N0^!1,LLSN4IQ\
MDBVYL>F@[^D!2[8__<MN%LOL<W8UFZQ6TYOISLG].OEY@M;-?4F@!DI'N931
ME38V*@^[O3VPR(_N47XGC%L,1%V#N,]Z%".[3A4+U=75YGXS2T'''\V[N$PM
M=FBXFYLLX9]]6BR3N.>>?[?SE7%?F9(+*@9EW =J:@5'J$"8@5H97D=R#EA_
M0@Q$><.,3GG\H,U6T]MY$EP]MQ.K?X)57H86."B($X8(P!"/5M')E#\R:5XA
MS&VIH['!8-5BL(JBB$ /L<1IJF!AG,LOAQ0VS(PLJK<31C46K%)--QW?^Q?&
MZ/PMV^$& 0!!D1.("QDWL)8*8V$AG<!NM'OZUEAP^-*_'NS]D:IL+,FK)D$K
M@;D4TA#)+4! (K&74&E6)W?R (E55\UG67,1JMWM-!Y=HGSHC_/K[&ECB=;!
M(X8,132E-*+8&RU%8?:)I+[._<B;8%-5];]:_9J&^"U?ML7=.C+6 8NHP]Q9
MZ(PM)&70UCE=&<EFLMZ:UR#X;_FRC5G!8-SPZBB:0)0Q(4 A*:9@=/F]FU!Z
ME<NV:OB^M<LV[CV,1AU:993S &..?2&=X6)TB<";4'2YR[9JR/[>EVTXSE/B
M)=#0.:U!=#F<++"RBM<Y=QU57$J32V5;VNF*R1\V:9I]O'DZ_1[EC/[GHPH.
M\+5$ZT"CK)X1Y @RC- XA6T>NZ&HTZY4R<.W:!M;Y<BB;3U4X]\JN_K/V\7W
M_YK.X[>M$_MP_O?$._R$=[N?/H'IPR(I=3([6JCX3(N@#$NISRRE3G*<]NQ%
M.(:BC-I2.;?&O4&XG%_-8C_,RR(_F2[_-9EM,OU+3V8I0_.7NRQ[C)7]YY[H
MQ:D^54HXHH& S (6'30273)@%*,<(Z1*[<C;P6JORB<W@*M#2M6_#ONP^W=D
M3TYSSETDM?>E 5+EA'4I@9+3# JF/(]("TH$99;_#B_\FN;D8J#*>\M'=$ Z
MY'S$W7M&H2!0.X2 9=II@9T?V1OH(5"FRAE>->V\Y3,\!8E@S!BKB(+ >*R1
MR"65V(WM75@S2J\4,%\)W[=VAL<\L9H2:B17/L7<:LF2='%&2D[H:)];U%%T
MN3.\:LB^M: ,JC3FZ<2<4>P(]<097!AM(52=\XT![C\'N/HUHI>W&+4!L$&0
M>LVL@@H;0REZ!,SC.B<? [18==5<-FJC&JKCB=H0'CH>/08+O--> 6^5S.5F
M@J&1G=/65_\%41O5(.Z*6H>L]YFE\%B3P"' 2AB,55SP-6<1-%](B 6O$ZTQ
MP"NH 2Z&#6FF3^Z=71"/-PIQNV,H4G&W0[@G2B/*Z5Y*YT86QE%?V278<Q&R
MG;X5W!4C.+L(OOIL0,(:J0R! ECBXQX9&I?+Q#WR8OQLJ:K<0\_R:D#:*4W>
M3R??4B'Q:5:2*Z\:! RQE) *Y;UP\2\2@F)><:UDG3." >[UVB),75R[/Z-\
MO"1\7RF*YT"[X'&<'ML]B@*(V[AEP;J050!=)\?> )_$#]!%:E(]W5-Q/^14
M:++XX=8$EV+D\>9!,\4119A")R2%5C(C'DUWK8.L :Z&#;'@*+<: WH@%"N,
M]J_+:;;O(L3U@D6YHY4'4 GJ,'(F1T 0;^K$RPYP'>V%:I>"/<P@G0^3Y7*R
M>]#]3SC.\] 'R7RZFH$.,TVHPA2K/(. 8A#H4EO>P6#5XK-M@3&10FNCC5(6
MX?A'@1/'V/P&M\.-,ZJQ9]O5=/.68V6PERAN: 22!BGH%84*%9(R(?])%E25
M$55"8:J!_Y9#89CWU%C-HZ#1F^ *,5"\X>*&HY&=;#6C]$K/V2KA^]9"8:QC
M+CT*0 R3)*/U5A72 >-&RYXZBBX7"E,-V=_[.1MC@AF93#^5G@JLR?XEH8BX
M_5-.H(6ELBWM=,7D@[D ORYT]C0EVM_3]=UT_O5'-ON>_1FG_-TI#E_88U!.
M2,"M@H29J)NXU/!BV1%4F']B]R_ATHER*^WI9I@G(CT7E![>.0A.Q0PT0(C$
M=90P0*&$Z5!->&RE%Z4F7#M8/18M/BA?M8K3I[L(EE@ E72.(>4M(CRN";O#
M/LFX$2/+Y-0)7XZ6H&Y4%5VMD&>&_VZ^KQ;R\<9/YY/YU70R^[1831,;]B?-
M#7"VZC<%H+1 QB@JE'%$:::M0=$;AP(1+\ __F#;U&Y98P.9 84?<43:;'FS
M6-ZGZ^L&YD#U[PH@.2@B*I2!%#NJ>-J: HN1<8ZS6KNB 498#G 6M*ZS3OW-
M72+HKY.?/?J2^S%4\A5/M K820:=E@H;(3UBS.WKNGLK6:D#K,YD+6-'3C4+
MPB29$),B[6&P( K 0EIJRB5N?CL^7R-Z/U@/KQ%X^YJ]?5^,-S^)-0!" **8
MP=IY:H7F#$'@9;3@W.A26YEV9-WGS=\//QWSIM/CZ7P3EZ6/#]ERJ]53!TOE
M.PFIW! QU!MEE"<,$@A4@82B;F0)51OAQ*(CL+MR6MW]PVSQ*\N^9,OOTQ0Z
M&:'4DU5VG8JB9/-5'A?Y4V?S[&:Z3E4?GOXF+]5XBHZ-?$& E'@$$!'040@Y
M=(+K CW#[,@BI%NA:A^*Z'C56D_FM]-OLUT\9']KUA^+Q?6/Z6P6-Q0OQU1I
M%:O43[  8<*ULE93!)W%4#@BI8U$(<2K7IW38X,OYZ.>;1T<PH98Z)EQ $1'
M#47!<]DID&YDX2\M\>+U57/#N/=J#083ZMF/=0#11 OB*3!>1661N/$@6TU9
M1""&I:+PV\%#W:<J4?^W5?4VU>1!(WX @-,- ]((*\\Q,(1M(Z&=$+G$U G=
M:6#F]VSY;3$HJU":#XL60>_*RU57_[N91EWYZ7RZSMY'(_ *HK^SZ>U=>F4?
M536YS?Y:93>;V?OIS2G?MDZW 1.&,8  (40(]E)RPG*D&-:DSHW: #W:CLC9
MG4)Z7<L>CY)/2/I[KG,&&RDHL00B9QCQUG.^TR(3!/)2]QAMWP^]BQJX.:ZX
M<V\5JG44@,:8"2DA,TH0YC6P+D=$<FI&=HS;$EN.WN6TH(+NPGI/#EW_^G/R
M[\72I(BG,T\3*O84I,$<(!EW"=)#!+%#U!1X6(M'5M>B+;*\VJ^UJ82!D/)1
MA@^3^_./&2[H+3@OL6/:D'358T'$QM,<%R5)K7(7 R1G:ZRIQLX&--$=0S\M
M%U=9*H>\RN*7WL6EQF;?L]GBH532M%+M Z#482! ](/C0D2<@=(6LHL(^V_%
MPGKL>,7$YO$?B'5\.EO?EWA(<4EW@5F.G#/>*H&14,8XG&_.F*&^5BZV 6Y<
MA[=X7ZJ)@7#T\V(V\XOEC\GR5 6@\IT$H;@DF$)IO++(2@"X*%# :FR%@-HE
M2C567JZ%@7#1_;R:;:ZG\]MBUW@Y(U]U%0!GA"@EM$Y5) 01"H,]Z$AT6E7[
M(5M.%]=?UI/END]V7D28:IRLJX>!,//3)CHFDU6FKJY21:04DWK][\UJO0T5
MO9RE)[N-'I5 5CE/>,1*6,J8ACE2%IM:*<0&N++WS]4FM3$0WK9J41,<SF.$
M#>20>1>1]P4B3N@Z04"58]1W%M7-KT?.T;I:Z/[UQ8DKD?(GZ^<ZB;,36PK2
M@RN7BM)9:OQ^=J8@_''9RJY/U1N&_T(2KI;K)P2,_WI)OOBC\#F.+CMR/O[L
M]T%2HU+(MX[#) (PJ!PJQ@R8'-E%3!O*7-2'M74J'#W_>_&)@'UZQPD<5B).
M#V:%1<6FS&J$1O*D]D)=O=3T19BUJ>L_(ZGO-_<GM?WL,\$;[0 !A$",E%)2
M*EN<*#JB[4CN%2[6V*(9W%K5^>3G>9T__4SP"D,+(;)6*P<I85X5QX'.(CF2
MA*2-Z+P&;EWYF"<6LC*G[66:!RWCOH]1A8&!2$N&X^ZOD#S:SI$]=&C126@1
M]?[Y5BH\L4SS )V#2!!LX_J+)58Z_J.0W&LZDE6I'3*49MK%>/?/M-6';%TB
M2*]<!P$ID5(A.48TY(Q3Z/?1 ]X*5^=,?(#6K2>VU4!\ 'S[8[E87;B*;IL&
M2HDT6B$+4V4UXB'>+Q31K0 CBYQHF@;E678)VMWR:W9HV$6,.#S+L=/-@W,6
M,@BCV8;&$F@@LWO)!0(CNRWIA&>-(CX 6Z:NKC;WF]FV>N.3=S.76;<CG05+
MG55&&,XD=!3AZ% 4"XA'0'63N4?N>#C/;M/XOHZ#CBVJ80#D_'"RM,_IAL%9
M;Z#VQ%#%)0#IZ4QQD.>EP'4.+ZM7FUJL)[.1LJTZUETQJ[@2*A?/=>#3P7(#
MJ17<.H.!E1Z9_46B1U37.1P;8,JQ;J[0ZN/<-7_.^?O//A<4-,(:9A34%CJ?
MRK/E!X,<4(SK.%T#=.YK:?,(,R[!L6M.7!K]5*I]2!/+Q9TUU-PAHCS7T!:R
M*^]'^O*V20XUB6_7W"JV$W:SC./^M WC*4&I0\T"EM93:IS6#G#IC?:2%)(:
MZCH-2'J;3&H UJX)5((L(?(<(<FH,]!2S@BC3.\E( Z-RSUN@Q@5(>SU.7[/
M.?/[>6@/@7+0&>.BM0?,0&)9GOHG;G>YZC&-8K4G.]72+5?J,1C'N70, LPD
MP(0:"$".$19.U#$# _96&^9/K:?WE^IB>&&KU7A:NK<@G,0<Q.V 3H&]6'A+
M?(X+092.+/U]UQQM2P\=KW??X^\6RVFOR;QW8_A5,0_PT58!Q$UOG/HX%<R6
M0$@0-;S-OTR8] #VF"GFP*C+)4H\WBQ PJ6 7$J@#+/2$>A((2V$I-,,B5UD
M0VM$\Z^>2C0&<%_SM^^D4,U/8Q@7=J48C-L$SH!D&EB]PUT;;FFI/7C+LGZ>
M_/AS$M>VZ626BDQ\V3P\S%+Q\6S]\28E(5A^STZ_Z:O03T#*B+A* 1-W600"
M**&T.1[62CLRG[,19AR;YBW@W=TSO5R&OQ?+_]EGO*C,N..M@^*"&^>-@TH#
M&NV=<*Z0FU-3IYCK /W&5GG6&,J=LRNYMZOHZR:WNCJ[CK<.WDG#&70" D(L
M50K"_:S"6-8)%!S@R6JK[&H,Y<[9=3I"X>G'@L).<> =D X3)0E6"A62..#K
MA#$/\,"U5;Y4A[,O9[;G<]?F?5F#.1%":F-2&!&GWME\8^*<L+94RNKVSU3S
M\9O-,G'UHD/44UT$E0[GI-:8:J$1Y(9 MD/!8Z/HR )X&^'#B3/2!J'N=)Z_
MSR:K'B?W[NM+S.?G'PS(.BR]I A(@[TQWG.#@*!:<4BA*K7]:DNBU2K+\HI$
M\]O=N,M,W-,-@\=0.2=A]%)3=6U&4F5:("$4! LWMOS"EZI[T2*F73EFNT'O
M:E)F5?ESN%D@"#IN%2*4.RL18C15,Y90 06QYG6,_0"WD8VRIQ%$>[#IJ:S4
M8IY"A3[>;'^2UY;J^VSR4I,/4\%&Z Q@ AG@.2/4 F4PB8XW(+C'TBI/&6(6
MJY(/^0XV"5SY*(T%+@IIL9$66)A+Z:"@:M1FOK2*7T=V-X%FAZ\%]L/]G.ID
M?+SY:[6[KBS_?J5,#R%N4*%.E90]$1%"C@DH -W6^Q@7F^K3X 2OFH.Y#YJ]
MFT?XL]7Z?"7)$ZT"QAPP8CT$7EL,)0="%7(B+D86Q- JG>I!VYTKFLM^;IE.
MGPG".R(X-U!AC[$'PI"]#-;Y;E^:=/%:J5EZ7 ID#[[E8*K\7>I,$L\H0(Y3
MC2R-NP!BX.[DE>)T^MKC=?9NT[$=KLU65\OIPZYB[.F4BB=:Q9T*<I!YZZ.L
M$D%&"=*%K(J0D3D!ERKZX-ZO"4"'D1710LP@5AQI@A1PFD!CBC''#;$<&PD:
MT-[!-(C5<!Q.&D2FH>; "Y4>N%*/',6L&#<P8XE7N5!71](@5L-L6&D0(:*4
M2HXUT41X9(WT(A^[LH:/I/;7Q1H[F@:Q&FX#2X,HI"""*,E@'' T:LH7:YV2
MCHXD5J@1G=? K=MK@)=KV/L2&1#/M R< ,$IP=80!(F0%%JWYS@5(^%)&[Y
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MO [6:0SV\Q0[;+I.#4%=7V]7D4/[IO*- W'$: DP]4Q B)&U5A6""%_KW>N
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M@A*V(_]%^E\Z6?KO__A_4$L#!!0    ( !*3 4_$'UDZGGD" !QI'0 4
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M:;;/@7\?](,T8(+C=L!Q,^ 6;'>2.DZPG6"[TV*[K1]^N&P348?=IQ4$JJZ
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M!D'8^HX"GWRZR:*73#VKO#1>VB*X- %Z[AKG/I 58KH-?>7U%1_K=_XY"I*
M,UK;DVM#5J6X#,Y-SYV/A[D/#4?3<F[RH4/X<]$C/P3/'^'-T2CNL"3_V&,^
MR!WX&_#[Z=?LAY\OPK <VZ**;&'55BWL4%=V=%U'GJI1P[;5,[C)K]TH)>E+
M'R1K/PC918\%C[WT(R;H/W\9^MTN:,*+^RA-H\%'-'S^A<N "[\?/(8?.\!\
M+/[E 03#11+\BWW$RC#]!1Z>#/VP?&9V]<$?!/V7CQXHRA_P$NFW*.T%'<F*
MHA_GB1\F%PE(FX?I)W6B?A1__'>$%%,O+C[ED[L'D0LO^O[UZLYUI-L[>N?>
M2K>N_?WFZNX*_J1?'<G]7_O/].MOKF1??_ER=7M[=?WUUP]\9EM8N+FI=9O+
M+/NO?M*#R:51>"XYE_:E1)"JF%M;W*ZQZD7Q0"I7D_\$:@^C,).A\ ).XUU9
M5Q2,%4*8AM#%TX\+S^^D%[:K8LT#HE>H81J.;7JZY1@Z<FW9L36-GDFASVV(
M+@L^.E$G4TK<P#R3"O5VPQXFC)NI=3=,?CTH-*P;HXO?QTB<6/&G.C1V@0)I
M;6+"!*BI]CJ4TT[M">4-??:05K07A-Q6RS[77Q$"+?C]\4O2:,@?^<P?F?KW
M?29U6+]?7/W3&3K+/L/4.^7G!F#=@6V72%_9DW03#?QP>K9/03?MP9^PMOLH
M!@E[ >#J^\.$?2S_J+,+7T8V'9#$:1?(B+\>S$:9"]FTRW_$XZO%;/)7Z/_Y
M2SEF^I(\YYJJ5=?JSZZ]N;PA.U*PX_>+J0+T?IF /L=5';3USP4^ZU_%&4I(
M#OX:1J>AL26Y>/;IW1<__B%=A^S])'VVP7EJ_?F2?KGW.S\>XV@4=B]R1M@*
M4&9YH T*- [\OO0]##I1ETE?;AO89QDI**MC*>BHCJ.:FF89!D:Z+"-7 RFH
MN#JAEHT=W"0%?Q^!Q\#B_LL-&T9QVBX0I0?.DRD8_H!U<,  K%'_WN_WH_0^
M>C[[]%__;NJ*]DN;")M%7)UVR3S:W0WB=J;G&^3N[]_IS9U[\_EOTHW[[?KF
M3OKV_>;V._UZ)]U=<_OF#HP8"<O2]8V$U7?=]]*U)]W]V:V;/F.SA]IW_#(V
M964!MRR6' 7G; /<$;SJH1\]?>P%75 !OQ2"WVA4(VV #\(> #B=O>.__AUK
MZ)>UI,7NI>6B5:ZPO+=<539D>TH S$,I[3'IGZ7 DO)0A<3 A.CN&2RVJ0\;
MY,>OLV;B4R](V04WB1B(XZ?8'YXMTB2Z/M8DKNO8CJE9U#)M2AS==@@AG@(_
M#1O4B]VD2;YEZ'#SD-)R>N1CEQ>4PL!>UW]Y8>!C@V__EU'()!F=2_R>1>ID
M?7/@B(2:6.HQ+G7OC/P9LTC?E%C3F\7:]<V^,?BNK7L=5]8]<8F*76RIR#:Q
MJBB*00BW[BT+FX0@M3'& 2C( Z(;,>^5;9CWQV;,W]W0K[=7F<DNK'EAS6_#
MFM\A)H]-F;<C;MO:K'1@TK%,+CV8AS@:Y$!*HS8J_Y#%/<??;R;87P_!$F6"
M63<*C2+P3#K\OR;8V-%@$"0\\2X]!'TFY:FSCZND W2-C%6E176=8$U5==VU
M9")3#[L\'6!2K&)J3K@O;I9Q]^"M7_-\W6HI@?J:-D4I".$+6<:ROO6TP%+(
M63\KL#+5K2X\?[V//WS:]@2YZSQXE)*XP]/;+'Z$*_WH,>H,7G[$[#%(X"[6
MO?S'\/%,\OOIXD'%]$HUR?5D'N4GR,C?]P%>>,(0WW8:LIW:W2_NS6\N&&O6
MU?7M]>?OW%J[E:Z^VI>[6_.VA6_VS(]!"O-IA,$[]QG$J/05A*04/4@W&?7R
M9A:2GTBW0];AQ55="69PE2:2W<LB<N]//GFH&Y>@Q$ULJ@HBQ#2,;:<2%:4]
M7XCG7%-(<R[Q=)RTI2P*4QY;%"95+)=B9-FZ;#G4\!!6P/GV=,.S5:*[LQ;%
M5=B)8O"YL_+!;.>\G>^1MZ/NDN'1S ]/^*W#./K)7\#CHP[K^T\^+QU:P14_
M33_B5"G70!7E&J[I6:KBRD!C2-<-5]<U3KDVL1U/MALH]\Y_OBHJ:#L9]2XT
MC+%R@4W$VRPL3Y1O&L?;;51S0MV"=LVD@03NX#7X@['TEU$<)-T@JR$&==NJ
M1M]TTA/B+)M[_.B'P;^RSTUU&2<K=(Z6;*\N;RYO+Z5B&T:\IW0Z(;FDK]'E
M>D5#)ZLZ9%S5$UF.BQS;,0P5(:3:JHH<0@T7J;)CJ5B>51VTVXU9DA2_/H-1
MCN>H#04AZ5L</; L\N/W)2<.?@J[9B_LFNU6].UW1'\_&5.IRC-L0G7/TU3-
MDH$S7<]2*.:,J5 9:=BQEF%,,H<Q;T<!&"C GH(73V5]@O%:&4^KG"E75CQ#
MD15')ZXBJP:R+(LSGD$=P]4<I97Q;/CS.KZ+GL(Y;/>;'W"'(+D?Q8\;X+S3
M19@Q1ICN6=A6;$1U4]4P4HCB90BS5=LBIJRW(BSST:YC,$]^!F'G50&;+W[\
MTO?#[F&@]&U*%^<C5*\XT$,R-52'Z*:.91D!*CW@/17)AN/HEM*N^KY%@)C^
M_Q<,Y\??/A%DZ O+#O==;F[?&2R@RM,#WV+@D& (]KO[S#JC%&QXZ?H!7#"6
MB,# T1,"<)3$6:K5S=YZY0*:R!YM8T]F>[;PW0H5"H99VZIC(E,U3:(A4]=L
MA1@V-K@8LZF-*9JL4."V XV9OT!P;;PZH45B$P5MO2YA*=B_7Z4\Q*SM%O4\
M1#6LNLB3J8(=5Y4M"X"/,;$UU[8F=HM^CH"!O_6B\ W*0UH0H,GX0B9H3[#P
MRCVCJ[#V(EF]O;QXD5(&?J]RX?^=2'>LSX:<-J2<.,ZEJ[#3'_%%2IQC)P7C
M >6S!W[\&(3Y]/Q1&I5?Y"HH^R;/))O&)4@M55=T3#1%UK:>\I:U]K0V67)K
M[?Y7UF_;ZKX%.PVLF@!HH"I-DH:C.!GQ*H\TDF!$%D#'Y-W]>V[E\=)%VDD/
M*9.W>2A.&3]W0=K/*F28W^E)'=X*:$\,WK<%2^QG(O#V90#T]FYOO( W!4I9
M3)61"GON]/SP$;X(I2=X7J_&AGOE9&XM ["4S:96?C]Q= \9EFZH%E4MRR"R
MHW";S38=3%1C(O)62+<73.XS#IUCL_'"8\!!UE+N7/KFQ](??G_$I/] EPAA
M7J M9;U_#B-VLUVJ7A9I5?3-T&0%>S)X.I1[-Z:E&A[\)D@QJ:L3HXZT0FCD
M,F,.QESK=H^1\;:@KT6J9=DR+<NV%60JX%\B&3N8@UZQ/5G3D-;$+VXAE;BH
M6B'@R859&>OD%N7?HOA'SE%2^<05XVFO#!E,.Q;_&"5I\/ RK^)V1U&#L1]Q
M%79YB0*3[E^D3H\!J :\Q\E3CV4E0=S8BL>>QD?I'7XO]?PDVQS1E?Q^'Z[R
M_7S<?/OG*.#&&]AL]ZP8  \=VV\R+];)]YD55ES-^"OQPRT[?IGO,Y.ZV9%@
MV=!AS#HLT^682-E&[41Z!\\#$I"2$:BMI!?QVM]R)TO:\].IR4M/_N0LLPT>
MV<W%&MZ?2W[8E=Z1?(WW0$AP_?X?L (^/AL*-_%9%,_A6QN3;!+9)/TDE4PD
M=?V7Y%):Y/[.V9BY).[&G4YVLPMC_-Z5PAUZM1O&,%5;TV0+Z3JA5*66J2 0
M!3(RX0,UR6S(W![%,8 XWS/*A7+JIZ/D+7?&C('P-Y9L/>ZQ#CY6)+4E7S'>
M=?LV&WYV!LJOT<:B2(<N[#,9".)O$*0I"$S6!S$81R&W7?HO$@,[YD6ZXF8>
ML#;/M#A^ZDM\^]JT*JB>4??K;T9]7MFA%OLZ1OV\3N[VXF[;<C^?SUB<L^2]
M$-:%L#:KV+1N:IZ'=-/550LI+A>R+A?6.O&0;5*M::/!F!@X+12R6PAK(:R%
ML-ZZL X2R9?Z?@PFM-_I@+".?2YQN7R+N5G;^*T$C'#1>"&!.<"?A67,Y6\G
M&L#*7\ZY%0^/RS:6\N\?X^@I[967+\&H9]G<NNPA"+/=Y5EN_JQM;F?26>.7
M[3,XRZSTLY89G/'=@)ERP>3^@I2^1MW!N)3>V1E HY"]_[C-M%'+'M>C3,!H
MEZJ*=:)@63=EC.37)6"4Q0D8TIYDF9.;D?%RU_:DO<\;1&\P(I49H#B6J2-7
M<U17M1%67),:A!J>96JFKDY&SJH.!K$-S/P8Q2^K1&^RNS/^[Q1W\T#.YV:Y
M(>UW1?#:=6P+#,T9.W)_UEFJT*W1+IVF@?V#P39PK:Q7);V/"UX5XU^;S!/I
MA-%^["Q^VV;T[1\L-HSSY12SJHT5,U8LA=HZLES;L&Q"$74IH297T;KB*0W;
MJ3/@6J,$#,ID3@QUXPWX]JH3ZO)%7(>Q-6=[EN+<[CJ[?.WA<?NJBW:;7=E#
M!\.&A)Y>Y?$=#]N*AZFN6Z9)L&<3GDHRD>HB3"VO(8-4@O:W#+)V&2/8K? [
M@33RPYR@T+D4-,>R@H>FG$.6:0!K+XRR1,$HR0-*L-BLPWI3W\(HSM[5?^$O
M?PK@U?!:*61//%H5LY]!DEF/H1]V.$F"3<E;X/#!2>J'73_N)A+?*15TI[(4
MR3A[_<Y_WQQ+VE'J8-H>/#+Z63W8F?18OU^2F/0.""<+.>;MP.8' )=(^&P\
M6/TWEJR2BL&HEHNQ3%M%-L$64DQ/5S6=>)ZGN1AII@(FH-I@ZW'@O%K:+9F@
M69"Q6(JFWSHK4^42VM[Y5^ HSE7)_N9\IL-"QR4C:)9(V-6NDO%K_S+JO^0F
M/]'*LR!V/(7S6379E?PA:*SG /B7]5]V#Y8)(>9E>5_0D]-2#$14M=O)=3!%
MBH%X_R_'PA1GK>M,4U8T775H0_E/5A2;5?!EYZ4FUZ,T4]A N)-2[2H3:C+@
MBFAG$C^R,ONZ.$X3-$,' -5/_G1V <(R ;,9WJ--'@$2C@;=*"U&GGU2\:56
MBJ5R>9\D@&4_.]5SPM[;&=#S&N",#SIYP7"2E3=&%5QFNX.6/E7U^2WW1DT/
M79A7QE-6=?:S%U<)M$=V<1\S_\>%_P!3^^CWG_R7A*=Q>O'DL:2.:UL&464'
M$:0B%U'3LG2%;W-TJ*8@Q._Q)P#5"L/7;1I='EK3%/2%=8/1H*6M; V<[4<K
MND5'8,D*HMNH/\HSM%=A9]-M9=]RD6!.LF=NOV=G>4X<;+D6 RS,TAYTCG=G
M)TYBM3WWJL_)V9H+MLR]Y;$>+:<N^*_3!]EC9@A[3/?\WR]G4B_F2N[?$PW9
MADZ);!(0;R923=.$KVR'&*!M*:(;L=*6FM*G;WZ<2E>7DC=VMJ_"7,O6U:;_
M::F@UEOL5-G<WMYF@&7O!BNCZ&#Y<01B(.8"( ,>^*=?H\NU@NB'3>MMI&TA
MU7-<CVBNXZJJ:QB>;KNVB:E)=*3(WN8P-4W)5RD#U7&YAS2[132\!>#//E7"
M(NMVE.VJV$.XM\J*34!^6BZ V\%60H<Z#:I]%AD;(YV]['ZS$P8%92_K1 4/
M1D<J5K&!L>IB@AW'=727V)N$LAUQ8Y4'T>&O).H'W:P>P_+[P+=,NNTQ)CAV
MBF,7XT=P[-X0RFY4JJ;KQ#,4FZB*:KNJI5@R-0T%N>#(JEC9 <=6^I7'D*Z'
M+*==P;M3VG8AIC3!N_M"*#OA7== 8'!IFF8" 6@V-K%N4$.VP=6V#$>S=LZ[
M/+D7LQZ,XYOOWGV.DN0]#^-% R:8>8*9%Z-.%\R\+X2R$V:FFJ)JV'; )+-4
MBAQJFYYJRXZG$]X>1-X],_M)3_+ZT9-0Q).\NQA3AN#=?2&4G? N<3P;68IA
M>(JL$A-1F1*"+&JZFFP2!^^>=[.RHH17'669ZE[4[[(X^6_)_><H2%\$0T\P
M]&+TF8*A]X50=F-9$\-V5 /KGFZK"D&&Z^E4HRJQB&[91-LDE+]&*7!J&DDM
MG"T"T8NMZ87HPNB0.'B;R2M$7<6A1-5DQU9=;%%'5S5'E0&"AD(4LN7D%3G9
MY-7N ,]/U0C]QTQ4_'<B.4'2&>7GQ_,F!33T^R])D-D)E6SAPB>O7^=C;E@R
MZHMXW%RALQB?Y*""Z=L4.CK%"C'!6;)=3;5MQ90510-Q[5DV)53>8)2Y4>C(
M)RMT=@?XLT^_\PTJ =@H//C'I0A\T2\_<R'4CY(1KQ2E]]$HE;[X\0^62C=!
M\F,/L?.6DF4QTF0A60I8V12DKF%B0Y:1JIJZX6J6JED:P::A +BV+%F4E27+
M3O;=;D>8[ [669@CC:-^D@F2;W'485TN.X2DF) 4BS&RCJ38X=;WLLA9'ZY2
MKW\8V^#%6K>_5E%ZW52?ZF"D4XLJ"E55W99-Q7,]C:@4.YJEHPWFA1=-J2B]
MOKJ4KK,]LZ^HNSZ2?ARG:J>Y-K)LL&:)(RO@,JN&K"%7L9!KRQ0#48J:Z6V%
MLG<&^+-/G]FCW\^MM:Q!LC#7IN+4"W$A'U0-UU;CU!AYNF&:EHP<U= L^.W*
MNDVP8KFF0S:HQ)H%!CU9B;$[R)]]XM$?B>_$CF(A+*;BRPO1(!]4C=A6A86B
MFXZJ&QJU/=7PB*5;MFPXFJW+GFQM,E\KDEJ3LF)G@#_[]#VL'<=XZ_?SG@-Y
M14O]W!X>,?J>L/ST[<P4$:)E2K0LQ)IV4"5LVQ0MFHQL#X$+C9"I6AJE3G;L
MA&?!-[)BJ2)UM271LCO GWURV(.?);R_#_EY+RP,HK@F4O80!6\I/A9C1HB/
M<2[/0;JK844CEJ6JGF(:&@A9XAG@\Q';WK;X6#T_==AH> O GWWZ$H0,+)('
M!H9(+=&]AZ!_T[3V0HP(L5'""KM8=F3#4DQ^+JGE&DBC'L(6^'\.E?4-=D]I
M%!OJR8J-W0'^[-.K<R)'+C 6XT((C!)6"B:Z82+-,76BJJYK:+;G>=AT%.)8
MLK?!+2B- D,[68&Q.\"??7*?>\%](,K_I^3$8A2L(R=V7RU!5NM:>="5(6*M
M)U)4(':CO;Y'"W$]1W-!R%F&ZAJJ89NN9Q*L&@:6/;31MF>WL"H_%=[K;/N5
MA4C0F_>8O?*@C:E&MDT]T"?%B[XIOBL>-/?,G2VT<-^XX&A>P8%WH"8;ZT"]
M1*/6B0[43=.?;N9[]AH2G^5RO!I%S.W5C(?+-*3^XM[\YGZ]DZRKZ]OKS]_O
MKJZ_WDI77^WI-JAMU+02(:U/^PX;!*_I2?V-WMQEG7&OOM*O]A7]#&OTKF^^
M4+[@C3']*RV#U[?>OOWF9HO[>GWG2C?N;_3&N?KZFP0K_2O\>?'Y^OI_^.?;
M.WH'F/]Z=WO \FZAY+CK!8GTSY$? Y/U7XIC#:4HK/J29QGT[+SLJ#/*>TH\
M,2D(034.N7;,3L0!M<ABQCLMPH7^J,OXP05/?MR]Z,,$@_P8H[(E!3_^"%;
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M5?F!=L/L\?-Q"N, $/PDO.P8NZ!*7)P7Y,(1T@EBT!K\Z)<.T.UFC8B]4J-
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M'L^R83)^3J;@MM*^[$E5M]NZ_9X4'<R2NLE7I]I =;&B[=;*E8Y,58"P@0P
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MC.3Y$*T4(VW">MT;T*13 SK*WV.2OY-YWECB4?YN+']9(W]!:K!R@"@IG3?
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MCA#'B&5"4J$<#F\ILQ=E&":^IE KVF[O5J;M.AT(XOVD"418B/IM%&B1<J-
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M[%T^>W_U.?O>645UU[TP?UB,MI<6F!$3(B9$R1:I.%+Q3B0;!Z*1;(YS: Q
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MZ\1_K[_*T$N%Z>LD_][+;V=)$<E,LE$_N<TG]:.;\=QK]J\VWH8&.3:#R_7
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M+0HCC]Z ?!QRWXX2EU].YL&YXR&'E7KLHK:]31.?:L^"OZC_)_G9J4_IJSJ
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MH8PV%GQ?QUNR\JANVZI-Z3XNO!#CTHT2_0J/B]<_C\?]L&&G[2AHP3I_U$_
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M:Q\G!#/:\ZV)[=!D&D6UKANZ-D*NA3S3LQV?,&*%N')Y^3[=AZZ[E4S3HNE
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M01]8^/%3LHF.Y)B]I8KPU^C'WZ,?ASS#]S+X[=  N$L!N@SSPI#X=S'#&97
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M*,V7C$_1;%3B1+&Q\CKUY)-GYHWW$Y8'('4,<G TD-Y2B9,QB!%5U,J8C %
M_RWW&:;?+S<;I%_%&.IR^6VQEP4A)+F4/U/6N5^X*9EQ<CXHI@2)E^1]^2:0
M6H.H4S!Y)6H5IQ>@5+QP*"7K6*D2TCJ!F58B"[A>>E$?8KAF(&_O3I1( WP8
MID^PO.E#GL)@P9SNQ!> ]4.ECL@SEID?@!!'_9=<GN(5HTW2PI5;S&CEA(N!
M2&E5CG@&6"K)JXA>BJ52-$I:;8C^'H@D #JI/\A%ENLE7=H7,*..&L2%(0GB
M0NJ-^3B;=(KO))-E(-] *H(@OY :2M1)Y.9*A4<YQ(L+2S&JIMT!,QW6$6X$
M2NXT.Z)-1P%K 0/H9$DAJ\^&>Z10R;I2I,C-_:% #-2X0SV)<_ 9QJ+O^XQ,
M*HF/Y6K-:YS%])MZN.3!06=27!45 G V%ANT\$2J]@L:O(*RYTAII=*_ED\/
M>A91O-;<ADOJC=2G3E.+H!+=I:H[!<>'>!A+M7KF+*P0P^HX"3@BEF(^DD?3
M\*C)8#QSM%6,O8#(Z2IUI(8MA7MI'2Q9)W76/:=OQE$F;::QM+E&R2B6X%(?
MCD>#%.906%M3O5X2KZ030,+AI =_3#(Y4WG\!TM=6BY/TNPMS8)Q<YR/,/EL
MDY'.Z25=J;R,U8(K4PQN@#V66DEE5$Y&)?X78"V7?)+'R[;]I+%U-M9LT[?Z
M\5.RB>7@F+VE1Q/70,4=1:85=!D-[,J/?\%7&TV2W*>R7N%'+%64DO#W;<)M
MYEQS4!U="P++-IG/'!?S('#L$)FX%&.^[SBLZ5R[41ZJV]X2^32701E>%_&P
M#0G5X,!5/BZT>-(+XNH9% 0 5+!/G]/]BJK5ZVP\5'3>F%:N?/:37,).])!^
MCPM_3.%UJ:%(*I0R0:N P608#3L26*>9&'EI7C?H"(11(PRB"97R*0"Z<Z$
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M3*J*2(?Y.)L4P>5%J<7'3-=:7*NZS&0G+N8?GK%JPQH=FHE) ^;Y@4>H<+Q
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M)<)7^6;M>Q;XYKW+<@VDVWO/TC#/0\0R'=?U?&:'/K5LMQHRMIQF2V'NA6$
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MQT9QG\,9RSNJ7^]XZCOGPM:J7[0*I@<"/A:JP<=#*!3"(1@SWV&^C0)+@4_
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MGIS%(XDE< E,-WV 52K>7D).904 >(UAXGDO!F3J%B7:HT&%=/)7N#B/06L
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MX?6->R.NW<_&W3U\\046Y.Z$IO_S9!A-0$6)NQ=2JI?^$<#$0BTH5!X%<B-
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M^&OCWNEV3>L_J@=4]Z@'5$_[I9C@[)6K7B7+Y:I%597^R_=,R;0<\LSBP",
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MA"$6,C70]T/F6:;=R"*T T)\R_9-!V.$Y"F1X' I)3ZR" KYZS7RU[UGH0/
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M,YBX/KY=<GQKZ%+CFEC>4FK<:*/*^)$?]=_%PR3-C#SN3&0"5YF7%3UFL3*
MC4OC/LZ>C$$*[^M.8E@N0@^D!,$A"9NS=_N?3P$;XG!LQ=RN6^&:PK&0)3R,
M D]:O(P&-IA0PK=MQ^/6PH'OYW3X*+E*6I=K:M0(Q8_P%E6+0;FAXH?\G_+N
MS\"2U0^MQ2:8IBX&HY'J.)W[<Q,\0*39$%LL5(=1.<PC06AS2_B$^7; D6\I
M;'$I)TQX;\269NF6_6.+U6KDT\?ZN+5N"+KAM_A[.H"Y:_WP7>D=[XB-.2JE
MR2(UL E+6%@$MN>&1+A4,!+R0FFB5% ?MZLT53\5! MK.'M-:QA''?L*:?WI
M3#CYF!AV4Q8U&Q4UJ.N'2)Y5$<\5)I6]QQ6+.M3&PG';U3WVQJ)FNRRJU9 =
MJR'DRK;8GPV1#M7TY E6J9G<I+)T5:EV8 U66NU8CFF<U64R ^0+!X?8L1BS
MB2L$)X7:86+*T4*MX3>H'?*2.B1I:D\UZ+8@6T6U_B26--M>4@G2?INS8>5C
MXMA->=2NHZA]%4;#O="Q:.B*D'E.P:..S85M+411OT'O."4>U8K'CA4/E9BE
MH>AU05'$\E11DJ,?1IX.DJY1Q5^=K]9AHSI".T341%@$IF-[1)B.$\+_E-;!
M1!!85OM:1U%VN_&8]NVH=AT=V]*15DB.  6.B=DW96]BUX<TON6%)C&QCQS"
M'>J8IB@4EM#W3&<A >/]"LNIL;?697:LR]RGXVB@ ITUE&DWR7)$8W7#3>J!
M_45,WZ:.Q6T6,H&*D!876R'QMU!86H D&."YELXX0T8\)G[;E,,LTJ@2@@DA
M@6\C%-B.R3S3\@N3P.>.%RPD):W7&=K@,&1?V=I%<3QB74RR3(9BC(HD7)G,
M-$CEZ&70KI3V%[(+PS3'*<GSB>K@T$GSO76$/58 .F%-X.=U0.7437(%X@ZQ
M0M]T64!]&=SJ<GD2[)#0M3A;*.35!*J2/'>F$6!TA?>A$"R2\.%&3<[O^"^:
MS4].SUC'OPZN^=<BB-C$\X0M?$$08X+YBG\IP@*_?N*YFG_;T3=:YM]C8M/E
MC'DN>LOO0'-299'-%;1FHC63S9'-K)T4+K>P:8<6"8@G'$$1#V0(J>\$%"PH
M;TG+TUX,>-8MNE#%0E+:33KL%""W6,"F13V%7%E:3]%ZBM93YKB9U]QL"QKX
M@6DSZENV92/!,2NXF82.AQ8R7;;AYI:T%K-5-^0Q,>UY:RU 7I>=18_+^9ZJ
MO.',CXY^&-UT(J-WWW,JO%+TE6]3U6YV=KSX$1G5ZU;Q/2G7VRW:(1Y>.4X=
M/\BX;<HJ\PZH@8AQT\7"+2Q>;'*+O7H<7TN0W1UC471E[NQL_2T4LA>>T8=@
M!X&;!PB/.P+$8\6]#9$.(UPKS8!FW+,)%[8-?Y@(,Y.4SKW09.+5%*U7H:X=
M3=FRS2NV5Z@[2$1KNRAJ8Q9OK$:XMO?X&^N:OD+2>.62+"WIVBSAJ2XK;JSF
M^ZZ.ZV6!J?4E%S?=E;4]U1>*D*E_^UGU\%'T&%\^9''TQV74@[%]B@;/T4L.
M0_AK/YN9:W,8\U48?WH/*;R[ZM:7N)M,GC:IQ+FJJFWP)?CV6W!S;WC7MW>W
MGW^_O[Z]N3.N;\25T1;![W&6J^J-WMS>!W?&_:TA;F_\X.8N\.5?,-]KW[V'
M#^'UC7LCKMW/QMT]?/$%%N3NA*;_\V083;K)..Y>R#[*\):!K,M]8<0_.O%H
M;.1]57EUV#5&<59]4IU>\U^V7H8: ;:K.;L9MM?@U "K%BKVME-R=U9-?%_-
MW<W)0!4,7$(&9<KN75E,I$CN-MRJF,C>!%SK.EN;XOD JR7?#F'/1N.B8")Q
M5,%$Z\(8]V-#]JR*AB^&PAC5)7V<&I&1KRD;\[.\5Y:\)^A7^; %6E"_X5]_
M,9Z3<7\J"?8UX0V5<%J7,K$9$K[C$=ODS#,#&P2>%_(PQ$Q@BLWI.53\D'\"
M'0<6\K;W.1Y*.I"A_?\_>V_>W+B1Y(%^%42_\9ON"$J#P@U[UQ$X[9YUMWI:
M\LS;OR8@LBC!!@$.0+9:^^E?9E7AX"51%$GQJ#ELD<111^8OC\HCG4Q9IX)U
MFK8LSUYDZ]<LWT(*0#[E7[0*_,?/\8JN!+!H?=3B'T"1AHU\]_.PF);/:?#[
MVAHEXZNF#)G//TTRH+EV 2\5(-:K_J1 4B4FK^WY%*GFB@<+-H#/*'Z^TFK"
M&H;/TR.GV'?UM?,_OQ.$.IIFDW0,QD@]RN[8>LH#K !<5 QXFW)\Y%+JOU2P
M0/FJERGOTP_P8&"JI!)/*>N"&36K#44NB!AW4U"C?EB=*P(#9\W2WX;#_O(\
MB[5I^X;I.*%'#,LQ#-NU3,WWU-A6-=<SC5!W%LN@ >Y>#6<KB(A@%K\HR^(!
MEB-(L.8Y+,,,WPGC%\B(F*]EO#FSN<MU3]O-FKJ8?%-K3F_%>\ P!TLH;::E
MKMJA'6NZ&<<>L1Q7-UT="$4G?D1\S5X,J]Z84+96=NHY*A-0L#-BLPZ/V'H
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M=X4NI&EFL%!SZD6ZT)8]9\Y)%)9EGK._L>S_^OM5SU[OH7Q)/D]',([^S*R
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M^8&\-1>D9CV/&R_3NG<!&R-V!DLYI\'>P/YW#D4[1 J;'=(^LY<5G?0$^V;
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MEX/NEDPX0HN+#&?NFEU'V3\1VK-6C/W'F^B3HETJ.Z'&K04"OUE]HM4R8#:
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M41Z,&XE=<']Y;;)>4U-W[CG X)0IYIW:9.Q9]9W*%):Q;-['_?YW9=(4A'W
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M>U!M-G)B2$*3>O,Z5MO)J\W207RVBJ*NRUIFIT>JQT21 +"F*6./):GM@]3
M)-G$ RLI36J*ZY@AIZ\J;L_#NB5JW>/< _BB3/H3993DTR'\,2UA9.?)M>>M
M-1-GLX,\J30?,*4>$T&"TJS+\A"2TO93'N+2/7F]1J;K'3V9:IL<-AT9E4H?
M[1EJF[HAJT.<'*4>$T&^^]EPI8=64MI>Q#@Q976(4Z794Z)3_?35S6U6ASA:
M;V^E)/E N8/;)]5Y<JU,H7M*.S>(K!5Q=I1^3 3[[F<BF\5)2MO/J80A*>W
M*.V$J.NX.B&? 6U)S? IS=#2-G*:2<WPF"G]F @6(]9DYHRDM+U0FBHI[< H
M[82HRSV#SA"RMD%)O]%\2J4;]@R#(#1#W^A<4&K+ATRJF\Q5V$=XQ0MJ(>W>
M]:6IFQ'H1M.11"J)=+.H\5<<5DD:E2KZYH=0I]]-0]91.%OUU-#UC;(DI'IZ
MR*1Z0I)?US=L:2U%OR32O;GQS,U 5-*H5$]?:QEM<E1[7.KIP=5NF*?6>\HN
M) Y<>6R4>\!S;22)OD_-_( 71&[^Z<_[G.8J]_CTY[I3<^" YWU.<Y6"6FZ^
M!/$3GJO<X].?ZUD*ZG-)"KX:TS*9P& 4^GU,\XI6/QXHQ1\*DKVIJG+JL'8H
MFWP"<SWU^<F]/)WY'92*(?=2"E*YR1)\Y5Z>WEQ/?7YG(T@WM,_5HS/0@Z*:
M*,5PM@TNJ^#5+V3W!AFKR[HWJ.IFA1EDK.X!D^HQ4>2[GQWS<I-V[)+2)*6]
M-._&E"6Y#HS23HFZSC-L]@R(],QU1%>3+;Y.CE2/B2*!!G57UDR2I+8/4C-U
M:8X<&*6=$'7IYZDDGHW3]2NM:%+V[YF?=4"_T:P8CV@^.4_&/6_%V9)U$$Z/
M4H^)(%D1^DU,-TEIDM)>JMBX&Y5\DY0FU6;9[N#X:.N\-3M"U,TJ"$G5[H!)
M]9@HDOFI9!]:26G[H#1+JG8'1FDG1%W'I=J=C2/SFF9P^5U/N:,Y+9.,.323
MP2C-TVJ"B9_?Z'FRWGEKOK:,%ST]2CTF@F2>)AG%)REM'Y1&9"C @5':"5&7
MO<GAX/&' IP!D9ZWBDAT:Z-8/:DC'C*I'A-%(K;*<V]):7MRCDI*.RQ*.R'J
MLLE9ZHAGXV7U1@5,Z_^225KDF*N?YI,DOTMO,ZHD544GLK_K,SHC;W<B9K+8
M\>0T%>S-@OHV7BLIJXZ TH^)H-_]O&%D]#-K( E5$NJ6"95L>-XE*56J_^<6
M&W$&M"45TZ<44VVS' "IF)XRI1\30;_[V9;B_E0)];@(42.RX,6!4=H)4==Q
M*9:;N8-UZ^C<P3?%),F48J&SRGGRVWF'46BFNIDV+;7E R;53>9ZH!WJB:EO
M%N<C6]1+(MT7D;K6:PPZ2:-2Q]Z8]*Q-8L>//W;C#(CTO!53PW(V2HN0BNDA
MD^H)R7S-45\3(".%OB32?52+MR\M2:3'0Z2GI)EN@H['KYF^:6=NV7)^ORWG
M#[J'J-S\M]W\$YOW.<U5[O'IS_6@>I'*/9:"6FZ^!'&YQW*/Y1Y+0?VV;H0]
MNE#>_U94U0<ES?O%B"K#LAC5D6E%+B/2SO#@[[V]W:+GQ^11G%^+#Y(!3LDA
MOEF4D#QND93V4J%J;U:V_YBP\FS1\83H]+@21,Z MLY<]=2-[=:4/"8\E;KG
M*6L$IBV+3$M*VXONZ9*-XB*/"2O/%AU/B$Z/2_>4466G/U=Y6"TW7QYDGO!<
MY1Z?_ES/\K#Z7/=8"FJY^><R[W.:J]SCTY_K60KJ<XDJNYK RM1!9>]%@;,/
M/QXHU1\*FKVING+JT'8HFWP"<SWU^<F]/)WY'92:(?=2"E*YR1)\Y5Z>WEQ/
M?7YG(TC/IBWEQWQ"2UI-Z@+DDJ[WIU0<3,BM>VG*B%L9<7N"<9!DHSS&8R)@
M2;(G1K+.1F L2?8(2/:$R/2X(G?/@+;.7(4EKJQ8('78DU0(R$;-H?Y_]KZ\
MJ6TLW?NKJ/KMF4ZJ% :ST[DS50Z0-#-)R 5ZNNZ?LG1LJR-+'BTXGD__/MM9
M),M "!@PNLL, 5LZR[,OO^<Y$7!'LNM&LG<;KMK1[#.@V36BT^=EQ+Z8F+1;
M..9[J2I?)J-U$^BO,W+O-C2Y&T"_SH3^G.@9C^1@J[=U%RW;#:'OB'7%Q/HP
MXK8CU,Y.7SL[_0705F>:7F>:;G:F:4?HSUK;;]YM[&NG[3M"736A]CI"?5:$
MND9FZ?;+'/M^MSCT]MZSBT-?9F60>!E%HZ4\N@M'O]0"DX.[:9JNON3E,<!S
MHO.N1KHCV>='LOMW$L8=R3X#DETC,NW"UD^,MEZX"=L[V-CK;-C.AEU#@V!S
MX[ S"#J2?4XDV]OO1G2L*\VN$9T^+R.V&]&Q_GM]'@A@W>4_[N6OV;Y?TEZ[
M.U[_O3XI)+'NCCM%W5U^)\2[.^[NN+OC3E&_F!$=KSYF1?%:S^@8J&&6*_VO
M,OBFBB=*_T^%YM<T3[C;U;IU><)U3+KL[=X)EZ:KR>@H[;MA/+N4]-K2[!K1
MZ?-*[[T VGKAMN?N=H?CV=F>ZV@1[.[="1:@D[4=I7UW:=GFX9UH[3D)RQ<K
M'M>(4)^7\?E2@L*G)O[KO1JH5 WC\G4W'NHEV^1=VTAGDJ^CH=3;O5,)?F>2
M=Y3VO2;Y5N].D%K/25:^6.FX1G3ZO"SR%T!;+]ST[.W?#4NSLSU?'@<\)T('
MV_-N8YTZ6=M1VG?;GG?#?7A.LO+%2L<UHM/G97N^E&CP9U5ZKQ*G3+CCLQOP
MA+>GW[PHJP:)^B%0Y:4VK+P-O_IPT,4_:*O^_!"G>*-5?]UIWNG05NWN'-YI
M]O>/']QWJ?CG0'^=-; J*?4$B>&!Q,]SE3(__6/W/F#RV^3**BZ_\U0[/N_X
M_':>_N[AW5+UMSV29V\G=)9!%R?HM-'SUT:=;_SB?./M.Y:A=<YQYQQW1G-G
M-"\[CIW=.R5B.^>XX_..SY\1GV-'_EW 'SKG^&5+C,XY?N D^M_* -C)_)[^
MTR[GER@NIDF #X=S4&\&219^?>O-XJ@<P^,W__+VE]K'@6R"DA<N']HY:'SF
M)WJ0QA+;@D<TKK"'=^@<PY]54<;#.?\J3H$B@1)VIM^#078WDWTKQ/_E/\YX
MO8,LB>B>O3?>YZST)BI(8>G#*FF<;_TT]178?__ >81P "JO'<?F=YW&=V]W
MJRFYZ3_'N7[X-!@!:>0J^/HF&,+:?@V263 O8 E_&^>UO;K+N(PGJO ^JYEW
MGDV"M,$'-YW*9NNAW)TD/JDHKB8W$\7FYL[A_K#ME$X^G9Q_./E\Z;T[/;LX
M^_C[Y>G9YPOO]//1AE<_OF>Q2U*%+;O\U/_<_P!;_7SYRX5W?'IQ]/O%!6S4
MZW\^AO_O?_R_B],+[^R]]_[T<__ST6G_HW=T]OGX]%)_YOSDXO>/E_21LR\G
MYWT^I34ZH%=5&E117*K(]X))5J5EX<'SX6U)G*6%[ZEOH9J67C$.<N4%:>1-
M5:[_Q9]O&@++Q,AC"^FZ<OXQD7S[@S_<&;;RWY<\BZJP]"Z"1!4MHX+O5^32
M=F%_\63D%7GX]Y]"N,'RS<'@<'.PN[>_NS-0NP?!9M [W/AS.OK)"Y+RQL_(
MZF1AVP<(M,D7M+W9X]?]#=YW?QM:O"[GF;7;-7SF:!SWI6F63X*D9IWU-GG)
M9&!XH4H2^>O??]K\B?X-MQ/J?]]"0316.PGR49SR\H*JS/0OV*REW_#A'>YN
M[.QO;^WV-K<.#C;W=@__HAT H*DDF!;J5_W#VZ;Y]9,I,S3UR3L_+2]"%';Z
MR]N?%HP_^=/V\K_M7O.U _NW6]<^+L96-S?WU&#8.0U/O.BS?W[4_^Q]#HH@
M\2ZF>3"_ER:<8!!&*T)U[R[_SI=_1@/O:[KL1^J?VV0 *=".#)XT&?2/^I^V
MP,*\'\[?Q/_MKOQI7_D1_"(/@.D_!6DUA!^J'%9VO\P_&*J.^9\\);R+L\MQ
M'GR[%^;?V\7_[:[\:5^Y9OZ"(@(?X.OE4KU_?<CV.;KNBQ;OW2-"SR%\O+C=
M60 W'_ZGBG,58;CH+"RS 1B"6YN] _QWF*6I"LLX2[U97(X]L!*]HVP""Y[_
M(M\L8OIS-O3Z43 MO5P555+"R>#W86-Q&N8J*'#$A#<5^[) ^Q)_@<\+JSR'
MT_'^4P5Y">]&2IRK /-D;Z*@5!BHBK.HV/BQNWE:I-=N:*T7O5W"Y4;*WK[>
MLUS_,,OI_O41K&I9Y3A7' $MXF_>!#XP+CP%)Q9Y_ZQ2Y6UO^DC_AZM>%S'C
M-(\G00Z/]Z)*>65&)W25)=5$$8OI(XQ4$H-&@C7+9RX^7\!7T'3K#M4]5#C3
M$ 66<U1/]&P.5KVN#>^B&A0EZ/PX2(#BX#^0QO"(#)W5)7:NKE1:P0\.I5U_
MW[3M56_L,0[3FP$W>I,@,ES[^\4'#PQBU&A>DJ%)J/()'B@H/#5!C1=JURN
M_\-_%7%1XA^N@J0BO>=%6:$VO&/F]KF7#4#8!ZAP"WDV++ZXZ?&TM&&%=US
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M(!HN40"/*>_AW+6/B((ZR8J2[0==%.,[/7J2%O.="DNC)FRO#^):@[-#-LX
M0[%@DQ0JF7L!V3ETQ5@KJL0.0FL]RT..ID0*[@1-++#]V3JBY!P94KFGT)E,
M,8A"U9FZAC0)4G1/;6SLWLV0:UM->_?(+;V'L_E7NH>6=MDFZ5T0]Y[;L/L7
M#KL_ZWW_Z-T]BYKQT]3[%,"E4;>YB(LLR"-V8< ]PIII-\."GP".#3@2PO$
M<^T+-?A>-<4?83?!:)2K$?([X@OL;KH0#@N=O>PP!KR4-\&4*J*69W=,_.98
MA8J<M>T>HU=L>'T0+O8;D8X-4=P719H1F9@6K62D209"B+P\#O28.![))P[%
M4Q:5_,$PRZ<9%2+"6Z99@77O_4="05H Y7L$_ Z*JY-'C&& 28 5_;5+*$Q
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MBPS<LIE O8_)*J:%".E1ID?7;6@$IQ*\JG6_XU,LZDO \LMRIP2B*GQC?*)
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MVM.T"4LU+D6A [N2/;./;.3S7'_+&IZ43AW%E.O6?TED2'E=GZ')]WUF<\,
M:;&BJ=;P.TUG*6IOK&04Y)%)R^!VXH'IKBLHH<I)]?&\ !8.4CWGUZE]LYGQ
M%H%5"V8_GVJ6QV-\)\M6V !H+<>R*+[)4 E,OI[#!)( ;G'5S87(DR1B&GD6
MZMV8"+50N2_%2E+IYU 2H]93^TR#?W0BA%!67+O9\9@(LH/Y,,MM68G&OE"P
M%9G&:VHRQS7NID9>I%:&A?;RN/CJ*5AQ9=D3CD@W1W")RFB^UBKD<D%8ZBK2
MYD$>*ZS3T:G6?^)6X'Y>'9_]\S7FSC*R=D722J;#N;BZOG!D@*L4:C46Z+.Q
M?ZQK>3AX9.B0Y):61E2EEU@\'A-;<4-2%C^LUA@KQ*Z'0PA!M<;'[&'!OI&8
M,NJ&01G,F;IZ34QK%*<1+K3B-1L.W]#+I$<M$C-)VB9:$D=ZN]B-W+)AO]V.
M4ZBL!-N41^ZQIV1>;ZYGP_MWG"7U_.9[%=$TB_<99N2/\VK$.N,H*R;PI=!,
MS-$Y5$[$-\FI.63'KVD\N1(A"RJ7=BP)(I.VH*KI"*26?=W[;NY^<>,%NOV@
MHN&A5[6=#F67))"PNA8[T!,,SB -#O.@$GS\ =Y5$LP*WXU;\5<P,@MJE>ZK
ME-H _.A:2Y1:S)-&JW '&%S?7&X.CKHJ$BR _)IF,P<Y^DK[!P8NJ]T-*!:B
MJ4O!DDD;.17HMW!0N*YS3A59&)6'Q6H?V:'B7QN7^"-SG@Z>\Y@GHK=UFO/T
M^/9=4X^XOM%WT/[;IC%]K\/).J+MB/8ZHD4=KFTGK];T[/I['8UV-/IX-%J/
M9E#&NJ/.QZ3.Y5?W(JC3"98X. SMS0,MZ L=N7;"='7D.@NX?#%192F&:*6'
M-,KO.H+LY.<*"=(F->MM*44SR=G194>7J]3KPPHGJSA-E5B,)#FPQ"V9)*AL
M:P&8J&[M<[HQCQOQ.UKN:'FELV(#GKNJ96M'?QW]K6Z+43!!F 6&VC/(CI(B
MJ)6Y='39T>7JMEBEP^ J8V E3$YBA2AL2:,]6;)EK.=IQ:48'9%V1+JZ+0X9
M-!&CH'%I@IY17(RR?*1T;<=4#WJW U0Z,NW(='5;+*J"T"V8/.M>?4N=_\W$
MN68MM-M="^TS;*'M)&0G(1\@HB2X9E3..R'4$\*YXI_JX!2=%N]H=*5M]]P'
MJ>+_5KGJB*\COE6.)OFS2FV[FY:.1:SKS,/X*B:HIS"/<5R(T]+VM@V$I:/6
MCEH?;(N)[3IAV#PJX]1@P!47O3N*O%E ODB=]UM2_GT.S7V?SF><U];H?#[Y
M?5F3FK0(2?.)U!Y.<5QJ$&97\2A.N)>?VEP74)D<0/,F"*';G*+;3*;@I@18
M4>9-LZDT7_L$JRC3C?6 H *.-L:.)40;-3W61N1L>!<@A9(@1T"$)=7J^+Z3
MWPU^RS4]>DZ[ 2Y:Y04U7+I-BF:)NEW"7:!M[J7VAT $Z<M"ESOB0=?<%<\0
MZ=@I4B1V^)2>?R6-D3(B:BZMET5)9")#?+%!N=Z%:\':E[1$+@R+N&:(HL ,
M\.W3>):9\D7SS;FA@5^V[KTG[8,/$(H-UNS]6>5Q$4D!J,\P;8R30%AR@9=6
MDX'*!82)+_M*-:&8-("H-*]A$UAD?EEG1>X:HJ:A8EZ4:L+)>V[1UP"/--,0
M1WZU$\*R_G==S.I@G#8;[=QI%I9*&F 4&GDBP>$^V+_4UE9^>VBL/Y09Z4E;
M%3Y:Z)'B'A_G@ @Q;^)-@*4(9HB^+NUK091-2SM\DAG2%_10+60)&":/1UF.
M+3LF_P(6'B$JFOX_"P :9;-T%N01IVP( CRU3*0++7P-!UYC8/UVAJS1T&(+
MH$[KSG"?:##?UF9OT_>^P"G&-(+V;!!, E(J=&G8?AS,Z&2_L%F#"&I:2>&]
M]!&()R*;^@B)@5H"<9;Q!(?:1KJQ_S?NPJ./X-=.X(Q9(.L',%F?*\17A)_E
MCT"-K_#V\(V@TF4 1?^H_WK#ZT\RJS@;7:#P"=*A.#."@"\XQJ)[D]VQ.P8Y
M9@G&-=$M+"&;==UC75WN S)EH*?B^300$+@'H:F0OH9*\<R\.8_2FVL9:_K)
M&)V%:+SP$,,,;$+D/EABI*)E6(;N@ GL'^]"C1W%KYCBC2TN%@+WG:.U-HG3
M>%)-0%,/6!;7T8 )1G-:&\>"R:<PB"/J;@=5@M]#?37*@TE'V!UAKVZ+P<.#
MDS6@R%*@M8DJQUF$\GR.=A<;_9I]LAE;8_4FY-LQ#P^I#Y*PXBC+,'.P+,P,
MZ3@=!PG/!L*Y /0#7$3"OYO@<'K!H8G3/VDBZ&TK !X"1ZAC]X[=[VN+X#<'
M5/>R<K8''\?QQ-OQ3>H +IQ :<*XF#F:&D"E#W;FFW_%X==!$'ZED$Q5@D.-
M8L:9%.F M6!S!,B87$.VC -"U+4Q210:8-?:B'"GDCL>7:&M2;3+6B['<$9>
M>L<VV#0*IHQW4V$@G=4>3;G3$\9=K4FV9S#*%0<3<&B@M[OY%V" &-Z;#=_@
M!%7S. Q*#!'.-2MC@<GD0=Q#W1Z$5$ZN6AU&"TZ.W#^>#A;&B#3OSEJBL=O.
M^O6XI8"G<NJQDSKIX>[!I".RJI2$5>W=A$\/CS:CO1H'U_%NQ[NKXUU!QN>\
M6"LXF[%>V=SU0,/80#E"JUW%4878TBJ54:^P.O,E>"3P4,0@85D^"M+XO]RC
MTM%Y1^>KI'.Q(Y'.6?PS$9M4",IR0[:BICHB[8CTL8B49SF6G*HT!LLPRQWK
MQ\88OE0#,'=T,NA"Y5>8K9,B#U71J9!U)'!H7>"N(^[5$C?Z"$TX'P8%-W.+
M;1E0D.=8.S"QH]\;4-JEPH$10,OCK)ABR4HGJCMJ7KG/VX#2YAPC@3X379MZ
M;XT(WT@M2D3'0*YA#91,L*^CQW>TW='VJFE;JE+>'%'C&KAP9U499D@9YZI0
M5.)RFG+7+,=J"+$8T>:QW 4'M8.YH4<(Q:F,UQ;\-@Q5!CG'-@UB&T_C@5]1
M[4@N;ZE-X!A6#!)CQF/H3W4<TG'(JCGD%*QO1"VBVJU@3EJ@'UW%!>;8WV58
M1/?J]$O_W6L]"0LG].IQ*W.9[H;EK,@88@+IFDFIMC:Q03'9^4O 0DK&M\5<
MHB*U8.93MJ+2U@+R]R+,[-OA$ZWE*UV[1\=0*_9\"Z2FN!@KSI6QTG%B,E+<
M: (TIVF:77$E(RH&*7'AKQ7U[_T5K"\GC"F^<>&].OIT\9H8#=X.#,(/Q&2;
M\#*5^HLG'8$'3GC]DPQ^;!;^/W2WR>/7M-H!!ERD[-:":YEEJ\9-"3C/J>!"
MY2*F$E$I(9T%&#$.L%9A V[3ZU<C3/UL;?9Z7(GZKHI&JO2.,I[PA)G4;"A_
M#Z@^E5>"ES_"@5&YHA20*98F&T&CRN5*IE&2K(2'CK"\></K>__$S!)0!1;"
MPA\FD[@LN2CPF%)#)=@[9I)E&11?E>F2$>%-Q=[PIWQ$4U@B^9IY):6C2NPK
M@0W^W-O80FS:)'$32',P8@K<W#;\,\^J$=8/;\%.\9BJ5,^%S-'KM5-N1QGX
MO5*SCQH@CT<CI5-8;F^&'7$,3@;VNX3.ZK#515U1:MK)/^L(J)X)IB]9QH'!
MM8Y&6-A?*O=LX5EK/:I]I\.9>(8X$S\NC!]/]EH+4)MMW)^"00(>FEU-\5=;
M?\$DM3>,"W2E4)[XIC>%RDDP[<W-+K"X/OAF"<L;[OI+<(8@CL/#ORK=.F4D
MT0X(H80J^FVGB!:B=G8A-FO"^H*O*N714/T)[!D;ZRZ#;[!^6-\YZ%$U=*3Y
M5KLTU\9JZ_:UN++'P'TL7.\:.=6NA%WOCGGC1+Z1NX[ $W/\"GN=X#_:CUM
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MOY9Y]XIT7QY,Y]ZKB\O7G%R,OVE@.>QP20*<,(T'04N5N)M>OOH6JJF ; E
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M*BC&?.+>NBPNB2(=73S''.,Q0/E 2S> IV:T?/P"T/@=[<62*LGG/H2.K<K
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M%R@1TS3[RM5@P!HVO(8^K-;-#='@6#$JJ)^ >3*<CE@+@^ C;P4P;4HH2E%
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MSY1+DM*-:$KOK@<'>F:1P^-0'"ICEJ4/G9F)4E+_J08#?:\P;U>^&)&D$Q2
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M"9^-(;(IW-(IX#5=6'A^:H0I)3-/B0&U;O64V<TR>L<$WN<8$+UJR-L(<QH
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M>Q,>5U%,3329[$1Z&@-/LPK^Q"Q0OR&)9-N%>PP%CO;[\3 )K3#8*H MI-:
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M%7IC=G+.U]XX/\?E!CM?ID,62)T80(/#/[>G:-[/6  C<CJEVA8 OI\&P&B
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M738"'Z>S,5$$;XW 5\9AHTA_7CC45NN\5@0U16VR-PPXE+84L>I9.^X)^4+
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MOIQP$?%R.X1W+=1LD?>=^^N^_>;YAYO-U36X84TIB7)XM>-F:LH"ZG[9N63
M.=%$**A",I7J;-6+*L:2TW-Y7Y3;Y&;TBNPLM?&".A"-ZQ-,NX'PI=J;!XUQ
M^/J(<3AB'#[J'EFN-T1S+'A76K/)6B3D45,!GCS9E3< /QY6-'%M>7]\Q!B&
MM\[OE1PO8GNSB7S:]L?'#?3]R#XA$0+Y\=)&$P8IEK8&TK&0+D)]F-!0BB>0
MGBHOH8U'&H7U$,4-!0M4J:=.39W39\EL/68"L6:=^B#23.);!JT?E+6DMO&*
M&A<D*8U$R*!/XZJCJYR_"#(9:_SOUZ9LF<J>:$-H,CJI1;V/%A?D6%5NC%+A
M9:FZ084T3Y(. T$7F?2 S]_AZ4=FC;<9FU9JXMKQ;T[F[]>^X[B4R[3W0U.R
MBRHOU_'V,L!V%.6^/O:BYKI%.J)3(_&\:5V#U@+S_K0]]:3U?>5:XJ5$LX)@
M*>D6CHW$[[PT9T_\T8&&P \?I3/6'"#ZDP1EW;A^"N*!D.B0)S=9/Y%''TS&
M32>"S]RXQT["069_2,+!>"LLEY0WPB9UYG0XX5O( _FA\0?U"T?)/VJ5NW3,
M2J,W]6,0<P\=<VYH8%I3*RCT103<_SY:!P[!'^Y#"+Y\\].3U[<9"_@;BO(N
M@-G57^P"<4FJ9\M'2NG*Q9*Q9C_(0GYL$:K9A[_A=>-YW0K<M]PF22<.8>5=
MP8T$P_-W*VM*"-1,!V6%3\;&:",![%9Y%6AL5#\B8\P)$AQ!4T+=/':*KJ.-
M>6>U*H1L-]1*MTZ: )-KVZY(VBK\>%"KQVQ+N="#GJZ7M=^^7-Y)O4#B'5BO
M!!S(YA&^K,=6WB'UW1+Y5>SV?/7ZR2MBB C\+'D'#*Z&F_[K-*Z/W<*AC_+A
M@P=_9_TO_29U-&+XHVV89Z&()TKC4!K3/^N\; JWI"J(\@3)BW3</4X/=N;\
M=;?<YS_[Z:<S1NE1GHN;>/-P>4Z8FYMX<RO0OJG=ZOY#WD<23# \M+T(9:=<
MGHJH3;\,A2\$M97(CH=1,VM02D5AP(_9DEL%"2Y5=MQ%&I+(DT^G_%,7"/73
M80DT@(:_.K)NO9D:+6J7$ESCU#O[/Y(->Y.V6=31LJUS4(T\*ILWYVW^UD>=
MIR?/O0D\R&;^QW*>+_IU/O>_KK?^[UU99;-')V^P9']]]N.S7S,68I]Z)\XZ
M=BY]*DYID\4]?/#PH8]W$]/1OF5P=TMVT$S/V*KA$G(IK%"UPWN9V;KL!#*'
M=BKO0.B:&^K+]=^P8*#1J*)@XAVCN\3?DT>'Y1[Q-S>B6=T%T@P=[M.FAO0
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MR;1&LJG?@G0@>8M)2(DO>@$2M4;A! U0'DE4F7@TQPXU'(4'X7%-YL?\V#>
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M!,LJ*'(2U"96>8;R.6&"\!*$$0S#"0E1Z0>3AX2&\>\("^BTO@!MPY;ZC+M
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M\  DULN?(Y<_N'=[2Z4OWRBGF;W#M_@.O\F2%IR<%FD<9M,RM3VHE@JMCAC
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M".W089^4QYY]9X?7F>@K=I:)>[N^\ZPG",(GA_UZUO7<\+QK]FWGJ=RR^RP
MC3V [O5-]XK?"^S_LK(H#,(K&KAEWW^Z-L$U^_AN4))J2D%0I+R0+2IB+2]4
M+J6<4BA)2JY4O:S(9Y^N,R;^YV^-?HQZ=FR7G?<83:,L9H6_7X7L,3PW'?N[
M6^X@&)@_.X!KNC)OZ+;;8[X=SKXA>V[7MK YVW3@%L'JXX< &GT[)!#_\M-E
M5A2OH.7!'8.N[>"U@ U,'Y]TGN#!#GL0]MAUAAJ>F,E^)V&PSA!OV(@=T[5
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M&)AW*!? '?;OF$_[,Y%..JB":><MV &8?0I&6V &$+ 0NIX?]L".\RK$?!J
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M-8?$"RD-X_(!+;55YPDME)ZRP<)R8?6=%E]0DB:UW3#),F+KS?;61F)A=)B
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M7R:,2<;/VAM_)9D\BHZ0G[G!XP?^LMI6QW.&P1$PX>F+WEVV7<R4%E6F7\^
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M_; VJ G4<TO !R5@\H@(V)MR70:U('3*-$5MI*; E=M0XR +O8/N59>;"Y[
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M//&7BL3%&B'_+A5<#JM"621AW_+9=A-DNPGR'F=/-<H.N*' #MHWHQVX1$G
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MI/T)]J9*)[_&M[_I+.CZ*=!_ZT#JDVY,AW!/GG;#Z>"3_P%02P,$%     @
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M4A(WXII"\22R^?A9D9@&1D_%6K#,WPDDE/)18WQ[LQ$.\+ZEDIFELCC[;;;
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MD%X5LS98UWS0]B!I(W>=Q50RMK+VJ^K[9*PQ@6K=TBS'3VW8Z79HS*VRX8X
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M!]S8% BACNMK\7"'2"=P\,X?W*>@PKD_&*\I_ WO_/D9;E$4?3E_)-*U*.K
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MWTUSE9.X6H1JOO/?*=<H5MR8]+>$JK["IR8RP*Z8C=/\X]'[&39F0&1@47.
M]!.VVEH85XD,IGB&&W9DP 2R:VVD92'\/, CE QXYY#XCRBZ]FB%;CF &]86
MG>W_%\>RD'2#7((L:@XJ%E$TJ25]WU85=#*/S"5B&/X").:DO3G($;,$AG
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M;NYW]E;%:C(BCTC-G]@7/&<R1F?:.*(J,-KH1!FVUZZ=G6AIC73/7;K8 JE
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MZ+D_O15Q\#\MM<RS 2Z8J&[0@< 6"%.)BQ;:D[U\W1AX4?&W%TS)%P^XY5&
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M:(&<4Z<LF[<T71RF!@.O8T^OIH##X28;5V6#?[)<%YB_-,1C$D;,/;C[:_"
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M9C(Y8V$N:G!G4$L! A0#%     @ $I,!3R3U[TN140  *F0  !T
M     ( !F3P  &-H87)T+3$S-3)E-3@T-3%D.34R,S9A8S,N:G!G4$L! A0#
M%     @ $I,!3PUWI.$JE0  5:P  !T              ( !98X  &-H87)T
M+3AB.3!B-38W-31B934X83!A,3DN:G!G4$L! A0#%     @ $I,!3P5XD!00
M80  MG@  !T              ( !RB,! &-H87)T+6,T,&(T-3EA964R-35B
M.#!B,V,N:G!G4$L! A0#%     @ $I,!3^&1)"T/90  AWT  !T
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M+3(P,3DP-C,P7V1E9BYX;6Q02P$"% ,4    "  2DP%/* 5Y(1VY   C@PD
M%               @ &WZ ( 96)S+3(P,3DP-C,P7VQA8BYX;6Q02P$"% ,4
M    "  2DP%/] /3M.1Y  " *@8 %               @ $&H@, 96)S+3(P
M,3DP-C,P7W!R92YX;6Q02P$"% ,4    "  2DP%/Q!]9.IYY @ <:1T %
M            @ $<' 0 96)S+3(P,3DP-C,P>#$P<2YH=&U02P$"% ,4
M"  2DP%/I="=+FP3  !@MP  %@              @ 'LE08 96)S+3(P,3DP
M-C,P>&5X,3 Q+FAT;5!+ 0(4 Q0    ( !*3 4]%#?AVC0<  '@L   6
M          "  8RI!@!E8G,M,C Q.3 V,S!X97@S,3$N:'1M4$L! A0#%
M  @ $I,!3_$HJ!R#!P  62P  !8              ( !3;$& &5B<RTR,#$Y
M,#8S,'AE>#,Q,BYH=&U02P$"% ,4    "  2DP%/YQYF-74$   0$P  %@
M            @ $$N08 96)S+3(P,3DP-C,P>&5X,S(Q+FAT;5!+ 0(4 Q0
M   ( !*3 4^W%J+R6 0  .D1   6              "  :V]!@!E8G,M,C Q
M.3 V,S!X97@S,C(N:'1M4$L! A0#%     @ $I,!3QVU^_*<6P  BV<  !X
M             ( !.<(& &5M97)G96YT;&]G;V-M>6MR96=I<W1E<F5D+FIP
79U!+!08     $P 3 "\%   1'@<    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
